

**Funding Opportunities Monthly Edition
June 2022 Due Dates**

Introduction

This funding opportunity packet contains information on funding opportunities with deadlines in June 2022. The opportunities are organized in the following order:

1. [National Institutes of Health \(NIH\)](#)
2. [National Science Foundation \(NSF\)](#)
3. [Other Federal](#)
4. [Non Federal](#)

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
109720	International Bioethics Research Training Program (D43 Clinical Trial Optional)	Fogarty International Center/NIH/DHHS	PAR-22-116	07-Jun-2022	1,150,000 USD
	<p>Contact Name: Barbara Sina, Ph.D.</p> <p>Contact Telephone: 301-402-9467</p> <p>Contact Email: sinab@mail.nih.gov</p> <p>Sponsor Website:</p> <p>Program URL: Link to program URL</p> <p>Deadline Dates (ALL): 07-Jun-2022 , 06-Jun-2023 , 06-Jun-2024</p> <p>Synopsis: The overall goal of this initiative is to support the mentored training of a sustainable critical mass of bioethics scholars in low and middle-income country (LMIC) research intensive institutions with the capabilities to conduct original empirical or conceptual ethics research that addresses challenging issues in health research and research policy in these countries as well as provide research ethics leadership to their institutions, governments and international research organizations. FIC will support LMIC-U.S. collaborative institutional bioethics doctoral and postdoctoral research training programs that incorporate mentored research, advanced theoretical didactic courses and ethics career skills training components to prepare multiple individuals for positions of ethics scholarship and leadership in health research institutions in LMICs. This Funding Opportunity Announcement (FOA) allows appointment of Trainees (D43) proposing to serve as the lead investigator of an independent clinical trial; or proposing a separate ancillary clinical trial; or proposing to gain research experience in a clinical trial led by another investigator, as part of their research and career development.</p>				
107618	Notice of Special Interest (NOSI): RNA Modifications in Cancer Biology	National Cancer Institute/NIH/DHHS	NOT-CA-22-003	22-Apr-2022	Not Specified
	<p>Contact Name: Stefan Maas, Ph.D.</p> <p>Contact Telephone: 240-276-6230</p> <p>Contact Email: stefan.maas@nih.gov</p> <p>Sponsor Website:</p> <p>Program URL: Link to program URL</p> <p>Deadline Dates (ALL): 22-Apr-2022 , 07-May-2022 , 16-Jun-2022 , 24-Jun-2022 , 07-Sep-2022 , 22-Sep-2022 , 16-Oct-2022 , 20-Oct-2022 , 07-Jan-2023 , 16-Feb-2023 , 07-May-2023</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

Synopsis | The purpose of this Notice of Special Interest (NOSI) is to stimulate research on the role of RNA modifications in the area of cancer biology. Despite the recognition that RNA modifications and editing exert substantial impact on gene expression and function, there are a lack of mechanistic insights into the dynamic regulation of RNA modifications and how their de-regulation drives cancer formation. A better understanding of the extent, diversity and crosstalk between different types of RNA modification, and the elucidation of the molecular players that read and interpret the modification code are needed to reveal the mechanisms of RNA modifications that underly cancer formation and the cancer phenotype.

107760	Notice of Special Interest (NOSI): Research on Interprofessional Teamwork and Coordination During Cancer Diagnosis and Treatment	National Cancer Institute/NIH/DHHS	NOT-CA-22-014	26-Apr-2022	Not Specified
--------	--	------------------------------------	---------------	-------------	---------------

Contact Name	Sallie J. Weaver, PhD, MHS
Contact Telephone	240-276-6254
Contact Email	sallie.weaver@nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	26-Apr-2022 , 07-May-2022 , 25-May-2022 , 26-May-2022 , 05-Jun-2022 , 07-Jun-2022 , 16-Jun-2022 , 24-Jun-2022 , 26-Aug-2022 , 07-Sep-2022 , 25-Sep-2022 , 27-Sep-2022 , 05-Oct-2022 , 07-Oct-2022 , 16-Oct-2022 , 20-Oct-2022 , 08-Nov-2022 , 28-Dec-2022 , 07-Jan-2023 , 25-Jan-2023 , 26-Jan-2023 , 05-Feb-2023 , 16-Feb-2023 , 07-Mar-2023 , 26-Apr-2023 , 07-May-2023 , 25-May-2023 , 26-May-2023 , 05-Jun-2023 , 07-Jun-2023 , 16-Jun-2023 , 26-Aug-2023 , 07-Sep-2023 , 25-Sep-2023 , 26-Sep-2023 , 05-Oct-2023 , 09-Oct-2023 , 16-Oct-2023 , 05-Nov-2023 , 28-Dec-2023 , 07-Jan-2024 , 25-Jan-2024 , 05-Feb-2024 , 16-Feb-2024 , 07-Mar-2024 , 07-May-2024 , 25-May-2024 , 05-Jun-2024 , 07-Jun-2024 , 16-Jun-2024 , 07-Sep-2024 , 25-Sep-2024 , 05-Oct-2024 , 08-Oct-2024
Synopsis	This Notice of Special Interest (NOSI) highlights the NCI Healthcare Delivery Research Program's interest in receiving applications focused on understanding and improving interprofessional teamwork and coordination during cancer diagnosis and treatment.

108323	Notice of Special Interest (NOSI): Disparities Affecting Healthcare Utilization and Health Outcomes Among Childhood Cancer Survivors	National Cancer Institute/NIH/DHHS	NOT-CA-22-029	26-Apr-2022	Not Specified
--------	--	------------------------------------	---------------	-------------	---------------

Contact Name	Veronica Chollette, RN, MS
Contact Telephone	240-276-6969

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

Contact Email	cholletv@mail.nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	26-Apr-2022 , 07-May-2022 , 25-May-2022 , 26-May-2022 , 05-Jun-2022 , 07-Jun-2022 , 16-Jun-2022 , 24-Jun-2022 , 26-Aug-2022 , 07-Sep-2022 , 25-Sep-2022 , 27-Sep-2022 , 05-Oct-2022 , 07-Oct-2022 , 16-Oct-2022 , 22-Oct-2022 , 08-Nov-2022 , 28-Dec-2022 , 07-Jan-2023 , 25-Jan-2023 , 26-Jan-2023 , 05-Feb-2023 , 16-Feb-2023 , 07-Mar-2023 , 26-Apr-2023 , 07-May-2023 , 25-May-2023 , 26-May-2023 , 05-Jun-2023 , 07-Jun-2023 , 16-Jun-2023 , 26-Aug-2023 , 07-Sep-2023 , 25-Sep-2023 , 26-Sep-2023 , 05-Oct-2023 , 09-Oct-2023 , 16-Oct-2023 , 05-Nov-2023 , 28-Dec-2023 , 07-Jan-2024 , 25-Jan-2024 , 05-Feb-2024 , 16-Feb-2024 , 07-Mar-2024 , 07-May-2024 , 25-May-2024 , 05-Jun-2024 , 07-Jun-2024 , 16-Jun-2024 , 25-Sep-2024 , 08-Oct-2024
Synopsis	The purpose of this Notice is to highlight the interest of the National Cancer Institute (NCI) Division of Cancer Control and Population Sciences (DCCPS) in receiving applications to understand and address the full spectrum of factors that contribute to disparities in survivorship care, healthcare utilization, and health outcomes among childhood cancer survivors. Studies that focus on factors that extend beyond the individual (e.g., survivor, caregiver, clinician) to include an examination or intervention that involves healthcare teams, healthcare system, community, payer, and/or policy-level factors that contribute to disparities in health outcomes and result in inequitable survivorship care are strongly encouraged.

106733	Notice of Special Interest (NOSI): Dietary Effects on Nutrient Sensing Pathways in Tumor Etiology and Prevention	National Cancer Institute/NIH/DHHS	NOT-CA-21-121	26-Apr-2022	Not Specified
--------	--	------------------------------------	---------------	-------------	---------------

Contact Name	Phillip J. Daschner, MSc
Contact Telephone	240-276-6227
Contact Email	pd93u@nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	26-Apr-2022 , 07-May-2022 , 26-May-2022 , 05-Jun-2022 , 12-Jun-2022 , 21-Jun-2022 , 25-Jun-2022 , 20-Jul-2022 , 26-Aug-2022 , 07-Sep-2022 , 27-Sep-2022 , 05-Oct-2022 , 12-Oct-2022 , 25-Oct-2022 , 28-Dec-2022 , 07-Jan-2023 , 26-Jan-2023 , 05-Feb-2023 , 12-Feb-2023 , 25-Feb-2023 , 26-Apr-2023 , 07-May-2023 , 26-May-2023 , 05-Jun-2023 , 12-Jun-2023 , 25-Jun-2023 , 07-Sep-2023 , 26-Sep-2023 , 05-Oct-2023 , 12-Oct-2023 , 25-Oct-2023 , 28-Dec-2023 , 07-Jan-2024 , 05-Feb-2024 , 12-Feb-2024 , 25-Feb-2024 , 07-May-2024 , 05-Jun-2024 , 12-Jun-2024 , 25-Jun-2024 , 07-Sep-2024

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Synopsis	This Notice of Special Interest (NOSI) seeks to support new and ongoing basic research that provides a deeper understanding of the biology and molecular mechanisms that determine the outcome of key diet/nutrient/cell interactions during early tumor development. Specifically, studies that examine the tumor preventive or tumor-promoting effects of dietary modulation of nutrient sensor signaling pathways during early tumor formation (initiation and malignant progression from early lesions) in preclinical cell, organoid, and animal models, with the goal of identifying and testing potential molecular intervention targets.			
101162	Notice of Special Interest (NOSI): Tailoring Follow-up Care for Survivors Using Risk-Stratified Pathways	National Cancer Institute/NIH/DHHS	NOT-CA-21-019	07-May-2022	Not Specified
	Contact Name	Michelle Mollica, PhD, MPH, RN, OCN			
	Contact Telephone	240-276-7621			
	Contact Email	michelle.mollica@nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	07-May-2022 , 05-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 07-Jan-2023 , 05-Feb-2023			
	Synopsis	The purpose of this Notice is to highlight the NCI Division of Cancer Control and Population Sciences' interest in receiving applications focused on identifying important factors for defining risk-stratified survivorship care or developing and testing approaches to improve the clinical management and outcomes for adult cancer survivors using risk-stratified survivorship care pathways. Risk-stratified survivorship care describes a personalized approach to care in which cancer survivors are triaged or stratified to distinct care pathways based on the complexity of their needs and the types of providers their care requires.			
102278	Notice of Special Interest (NOSI): Translation of Quantitative ImagingTools and Methods for the Academic Industrial Partnership	National Cancer Institute/NIH/DHHS	NOT-CA-21-032	07-May-2022	Not Specified
	Contact Name	Robert J. Nordstrom, Ph.D.			
	Contact Telephone	240-276-5934			
	Contact Email	nordstrr@mail.nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Deadline Dates (ALL)	07-May-2022 , 05-Jun-2022 , 07-Sep-2022			
	Synopsis	This NOSI highlights the NCI Cancer Imaging Program's interest in receiving investigator-initiated grant applications focused on the translation of mature well-developed and optimized quantitative imaging (QI) tools and methods for prediction and/or measurement of response to cancer therapies, or for planning and translating radiation therapy treatment strategies in clinical trials and workflow.			
100707	National Cancer Institute's Investigator-Initiated Early Phase Clinical Trials for Cancer Treatment and Diagnosis (R01 Clinical Trial Required)	National Cancer Institute/NIH/DHHS	PAR-21-033	07-May-2022	2,499,995 USD
	Contact Name	Lori A. Henderson, Ph.D.			
	Contact Telephone	240-276-5930			
	Contact Email	hendersonlori@mail.nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	07-May-2022 , 05-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 07-May-2023 , 05-Jun-2023 , 07-Sep-2023 , 05-Oct-2023 , 07-Jan-2024			
	Synopsis	The purpose of this Funding Opportunity Announcement (FOA) is to seek research projects that implement early phase (Phase 0, I, and II) investigator-initiated clinical trials focused on cancer-targeted diagnostic and therapeutic interventions of direct relevance to the research mission of the National Cancer Institute's (NCI) Division of Cancer Treatment and Diagnosis (DCTD) and the Office of HIV and AIDS Malignancies (OHAM, Office of the Director). Applicants are strongly encouraged to consult the NCI DCTD website and/or the OHAM website to learn more about the various program goals, research priorities, and strategies developed to fight cancer. Applications submitted to this FOA must include studies that meet the National Institutes of Health (NIH) definition of a clinical trial (see NOT-OD-15-015 for details) and provide specific clinical trial information as described in this FOA. This FOA does not accept phase III clinical trials in any area of cancer research; therefore, applications that propose phase III clinical trials will be deemed non-responsive and will not be reviewed.			
100708	Cancer Prevention and Control Clinical Trials Grant Program (R01 Clinical Trial Required)	National Cancer Institute/NIH/DHHS	PAR-21-035	07-May-2022	Not Specified
	Contact Name	Brandy Heckman-Stoddard, Ph.D., M.P.H.			
	Contact Telephone	240-276-7048			
	Contact Email	heckmanbm@mail.nih.gov			
	Sponsor Website				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2022 , 05-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 07-May-2023 , 05-Jun-2023 , 07-Sep-2023 , 05-Oct-2023 , 07-Jan-2024</p> <p>Synopsis Through this Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI) invites applications for support of investigator-initiated clinical trials related to the programmatic interests of the NCI Division of Cancer Prevention and/or the NCI Division of Cancer Control and Population Sciences that have the potential to reduce the burden of cancer through improvements in early detection, screening, prevention and interception, healthcare delivery, quality of life, and/or survivorship related to cancer; with such attributes, the proposed studies should also have the potential to improve clinical practice and/or public health. Applications submitted to this FOA must include studies that meet the National Institutes of Health (NIH) definition of a clinical trial (see NOT-OD-15-015 for details) and provide specific clinical trial information as described in this FOA and the application instructions. This FOA does not and will not support clinical trials for studies of cancer diagnosis and/or oncologic therapy in patients.</p>				
092626	RFA-CA-20-031 -- Strengthening Institutional Capacity to Conduct Global Cancer Research in Low- and Middle-Income Countries (D43 Clinical Trial Not Allowed)	National Cancer Institute/NIH/DHHS	RFA-CA-20-031	07-May-2022	1,250,000 USD
	<p>Contact Name Sudha Sivaram, DrPH, MPH</p> <p>Contact Telephone 240-276-5804</p> <p>Contact Email nciglobaltraining@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2022 , 05-Jun-2022 , 07-Sep-2022</p> <p>Synopsis The purpose of this Funding Opportunity Announcement (FOA) is to establish an institutional program for mentored training in global cancer research. This program will support research training led by the United States (U.S.)-based cancer research-intensive institutions working in collaboration with institutions in low and middle-income countries (LMICs). These training programs will be built upon the US institutions' pre-existing training infrastructure and research collaborations with LMICs and will leverage these resources to expand the global cancer research workforce both in the US and in LMICs. The overarching goal of this initiative is to build capacity to conduct innovative and collaborative global research projects that will contribute to the advancement of basic, clinical, translational, and population-based cancer research in LMICs. This FOA does not allow appointed trainees to lead an independent clinical trial but does allow them to obtain research experience in a clinical trial led by a mentor or co-mentor.</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
083680	Stimulating Innovations in Behavioral Intervention Research for Cancer Prevention and Control (R21 Clinical Trial Optional)	National Cancer Institute/NIH/DHHS	PAR-19-309	07-May-2022	275,000 USD
	<p>Contact Name Tanya Agurs-Collins, Ph.D</p> <p>Contact Telephone 240-276-6956</p> <p>Contact Email collinsta@mail.nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2022 , 16-Jun-2022 , 07-Sep-2022</p> <p>Synopsis The purpose of this Funding Opportunity Announcement (FOA) is to provide support for the development of innovative interventions that improve cancer-related health behaviors across diverse racial/ethnic populations. Specifically, this FOA is intended to stimulate research aimed at 1) testing new theories and conceptual frameworks; 2) developing and evaluating novel strategies to improve cancer-related health behaviors; 3) investigating multi-level and multi-behavioral approaches; and 4) utilizing innovative research designs, methodologies, and technologies. The cancer-related health behaviors to be targeted are diet, obesity, physical activity and sedentary behavior, smoking, sleep and circadian dysfunction, alcohol use, and/or adherence to cancer-related medical regimens. Research can involve several stages of the cancer continuum and any phase of the translational spectrum.</p>				
101459	Notice of Special Interest (NOSI): Leveraging Population-based Cancer Registry Data to Study Health Disparities	National Cancer Institute/NIH/DHHS	NOT-CA-21-020	07-May-2022	Not Specified
	<p>Contact Name Kathy Cronin, Ph.D.</p> <p>Contact Telephone 240-276-6836</p> <p>Contact Email cronink@mail.nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2022 , 05-Jun-2022 , 16-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 16-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 16-Feb-2023 , 07-May-2023</p> <p>Synopsis The National Cancer Institute (NCI) is issuing this Notice of Special Interest (NOSI) to encourage applications that efficiently use the existing cancer registry infrastructure by augmenting existing data with additional information not routinely collected by registries to study observed health disparities such as those that exist by race, ethnicity, socioeconomic status,</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>income, insurance status, age, education level, or geographic area. The Surveillance, Epidemiology, and End Results (SEER) Program and the National Program of Cancer Registries (NPCR) are uniquely positioned to support research to assess health disparities in the United States (US) population because they contain information on all cases diagnosed within geographically defined areas. The goal of these hypothesis-driven studies should be to understand why disparities in cancer treatment and outcomes persist by identifying factors contributing to disparities and their relative importance.</p>				
105645	Integration of Imaging and Fluid-Based Tumor Monitoring in Cancer Therapy (R01 Clinical Trial Optional)	National Cancer Institute/NIH/DHHS	PAR-21-290	07-May-2022	499,999 USD
	<p>Contact Name Shane Woodward Contact Telephone 240-276-6624 Contact Email woodwars@mail.nih.gov Sponsor Website Program URL Link to program URL Deadline Dates (ALL) 07-May-2022 , 05-Jun-2022 , 05-Jul-2022 , 07-Sep-2022 , 05-Oct-2022 , 05-Nov-2022 , 07-Jan-2023 , 05-Feb-2023 , 05-Mar-2023 , 07-May-2023 , 05-Jun-2023 , 05-Jul-2023 , 07-Sep-2023 , 05-Oct-2023 , 05-Nov-2023 , 07-Jan-2024 , 05-Feb-2024 , 05-Mar-2024 , 07-May-2024 , 05-Jun-2024 , 05-Jul-2024 , 07-Sep-2024 Synopsis National Cancer Institute (NCI) invites applications for research projects that integrate imaging and fluid-based tumor monitoring (liquid biopsy) assays during cancer therapy in patients to determine the optimal use of those modalities in the characterization of therapy response and/or emergence of resistance. This FOA will use the NIH Research Project (R01) award mechanism.</p>				
103489	Notice of Special Interest (NOSI): Telehealth in Cancer Care	National Cancer Institute/NIH/DHHS	NOT-CA-21-043	07-May-2022	Not Specified
	<p>Contact Name Gurvaneet Randhawa, M.D., M.P.H. Contact Telephone 240-276-6940 Contact Email Gurvaneet.Randhawa@nih.gov Sponsor Website Program URL Link to program URL</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Deadline Dates (ALL)	07-May-2022 , 05-Jun-2022 , 16-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 16-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 16-Feb-2023 , 07-May-2023 , 05-Jun-2023 , 16-Jun-2023 , 07-Sep-2023 , 05-Oct-2023 , 16-Oct-2023 , 07-Jan-2024 , 05-Feb-2024 , 16-Feb-2024			
	Synopsis	The purpose of this Notice of Special Interest (NOSI) is to highlight the interest of the NCI's Division of Cancer Control and Population Sciences in receiving investigator-initiated applications for conducting research on the use of telehealth in cancer-related care. Studies focused on populations that experience inequities in access to care and have worse cancer outcomes compared to the general population are strongly encouraged. This NOSI for R01 and R21 applications is a companion announcement to the RFA titled "Centers on Telehealth Research and Cancer-Related Care" (RFA-CA-21-029).			
107784	Notice of Special Interest (NOSI): Administrative Supplements to Support Collaborations with the NCI-supported Drug Resistance and Sensitivity Network (DRSN)	National Cancer Institute/NIH/DHHS	NOT-CA-22-020	07-May-2022	Not Specified
	Contact Name	Kim Witherspoon			
	Contact Telephone	240-276-6141			
	Contact Email	kw265c@nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	07-May-2022 , 05-Jun-2022 , 16-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 16-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 16-Feb-2023 , 07-May-2023 , 05-Jun-2023 , 16-Jun-2023 , 07-Sep-2023 , 05-Oct-2023 , 16-Oct-2023 , 07-Jan-2024 , 05-Feb-2024 , 16-Feb-2024 , 07-May-2024 , 05-Jun-2024 , 16-Jun-2024 , 07-Sep-2024			
	Synopsis	With planned use of funds available from the Cancer Moonshot Initiative, and pursuant to NIH's interest in accelerating cancer research, the National Cancer Institute (NCI) invites, through PA-20-272 in conjunction with this Notice of Special Interest (NOSI), the submission of request for administrative supplement to active NCI-funded grants and cooperative agreements for new interdisciplinary collaborations between outside (non-DSRN-supported) investigators and DSRN U54-supported investigators to perform research within the scientific scope(s) of their active parent grant(s) and/or cooperative agreement award(s).			
104859	Notice of Special Interest (NOSI): New Information Technology-Enabled Care Delivery Models to Improve Depression Care in Cancer	National Cancer Institute/NIH/DHHS	NOT-CA-21-085	07-May-2022	Not Specified
	Contact Name	Gurvaneet S. Randhawa, M.D., M.P.H.			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Telephone 240-276-6940</p> <p>Contact Email Gurvaneet.Randhawa@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2022 , 05-Jun-2022 , 16-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 16-Oct-2022 , 08-Nov-2022 , 07-Jan-2023 , 05-Feb-2023 , 16-Feb-2023 , 07-Mar-2023 , 07-May-2023 , 05-Jun-2023 , 16-Jun-2023 , 07-Sep-2023 , 05-Oct-2023 , 16-Oct-2023 , 05-Nov-2023 , 07-Jan-2024 , 05-Feb-2024 , 16-Feb-2024 , 07-Mar-2024</p> <p>Synopsis This Notice of Special Interest (NOSI) highlights interest of the National Cancer Institute (NCI)'s Division of Cancer Control and Population Sciences in receiving investigator-initiated applications for conducting research on the design and implementation of new information technology (IT)-enabled care delivery models to improve depression-related care in cancer.</p>				
106036	Notice of Special Interest (NOSI): Advancing the Development of Tumor Site-Activated Small Molecules	National Cancer Institute/NIH/DHHS	NOT-CA-21-101	07-May-2022	Not Specified
	<p>Contact Name Sharad K. Verma, PhD</p> <p>Contact Telephone 202-657-3694</p> <p>Contact Email sharad.verma@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2022 , 26-May-2022 , 05-Jun-2022 , 21-Jun-2022 , 25-Jun-2022 , 20-Jul-2022 , 07-Sep-2022 , 27-Sep-2022 , 05-Oct-2022 , 25-Oct-2022 , 07-Jan-2023 , 26-Jan-2023 , 05-Feb-2023 , 25-Feb-2023 , 07-May-2023 , 26-May-2023 , 05-Jun-2023 , 25-Jun-2023 , 07-Sep-2023 , 26-Sep-2023 , 05-Oct-2023 , 25-Oct-2023 , 07-Jan-2024 , 05-Feb-2024 , 25-Feb-2024 , 07-May-2024 , 16-Jun-2024 , 07-Sep-2024</p> <p>Synopsis This Notice of Special Interest (NOSI) seeks to highlight the interest of NCI's Division of Cancer Treatment and Diagnosis (DCTD) to support investigation of the development of novel therapies for cancer-applied research encompassing chemistry and biology disciplines to support the discovery and testing of novel therapeutics offering improved safety and efficacy profiles for eventual translation to the clinic.</p>				
086964	NCI Small Grants Program for Cancer Research for Years 2020, 2021, and 2022 (NCI Omnibus R03 Clinical Trial Optional)	National Cancer Institute/NIH/DHHS	PAR-20-052	07-May-2022	100,000 USD

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2022 , 24-Jun-2022 , 07-Sep-2022 , 20-Oct-2022 , 07-Jan-2023</p> <p>Synopsis This funding opportunity announcement (FOA) supports small research projects on cancer that can be carried out in a short period of time with limited resources. The R03 grant mechanism supports different types of projects including pilot and feasibility studies; secondary analysis of existing data; small, self-contained research projects; development of research methodology; and development of new research technology.</p>				
109999	RFA-CA-22-024 -- Sustained Support for Informatics Technologies for Cancer Research and Management (U24 Clinical Trial Optional)	National Cancer Institute/NIH/DHHS	RFA-CA-22-024	15-May-2022 [Optional][LOI/Pre-App]	Not Specified
	<p>Contact Name Juli Klemm, Ph.D.</p> <p>Contact Telephone 202-853-7889</p> <p>Contact Email juli.klemm@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 15-May-2022 [Optional][LOI/Pre-App], 14-Jun-2022 , 18-Oct-2022 [Optional][LOI/Pre-App], 17-Nov-2022</p> <p>Synopsis The purpose of this Funding Opportunity Announcement (FOA) is to invite Cooperative Agreement (U24) applications for the continued development and sustainment of high value informatics research resources to improve the acquisition, management, analysis, and dissemination of data and knowledge across the cancer research continuum including cancer biology, cancer treatment and diagnosis, early cancer detection, risk assessment and prevention, cancer control and epidemiology, and/or cancer health disparities. As a component of the NCI's Informatics Technology for Cancer Research (ITCR) Program, this FOA focuses on sustaining operations and improving the user experience and availability of existing, widely-adopted informatics tools and resources. This is in contrast to early-stage and advanced development efforts to generate these tools and resources that are supported by companion ITCR FOAs. The central mission of ITCR is to promote research-driven informatics technology across the development lifecycle to address priority needs in cancer research. In order to be successful, the proposed sustainment plan must provide clear justification for why the research resource should be maintained and how it has benefitted and will continue to benefit the cancer research field. In addition, mechanisms for</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
					assessing and maximizing the value of the resource to researchers and supporting collaboration and deep engagement between the resource and the targeted research community should be described.
109997	RFA-CA-22-023 -- Advanced Development of Informatics Technologies for Cancer Research and Management (U24 Clinical Trial Optional)	National Cancer Institute/NIH/DHHS	RFA-CA-22-023	15-May-2022 [Optional][LOI/Pre-App]	3,000,000 USD
	Contact Name	Juli Klemm, Ph.D.			
	Contact Telephone	202-853-7889			
	Contact Email	juli.klemm@nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	15-May-2022 [Optional][LOI/Pre-App], 14-Jun-2022 , 18-Oct-2022 [Optional][LOI/Pre-App], 17-Nov-2022			
	Synopsis	<p>The purpose of this Funding Opportunity Announcement (FOA) is to invite Cooperative Agreement (U24) applications for advanced development and enhancement of emerging informatics technologies to improve the acquisition, analysis, visualization, and interpretation of data across the cancer research continuum including cancer biology, cancer treatment and diagnosis, early cancer detection, risk assessment and prevention, cancer control and epidemiology, and cancer health disparities. As a component of the NCI's Informatics Technology for Cancer Research (ITCR) Program, this FOA focuses on emerging informatics technology, defined as one that has passed the initial prototyping and pilot development stage, has demonstrated potential to have a significant and broader impact, has compelling reasons for further improvement and enhancement, and has not been widely adopted in the cancer research field. To be successful, proposed development plans must have a clear rationale on why the proposed technology is needed and how it will benefit the cancer research field. In addition, mechanisms to solicit feedback from users and collaborators throughout the development process must be included. Potential applicants who are interested in early-stage development or informatics resource sustainment should consult the companion FOAs listed above.</p>			
109996	RFA-CA-22-022 -- Early-Stage Development of Informatics Technologies for Cancer Research and Management (U01 Clinical Trial Optional)	National Cancer Institute/NIH/DHHS	RFA-CA-22-022	15-May-2022 [Optional][LOI/Pre-App]	900,000 USD
	Contact Name	Juli Klemm, Ph.D.			
	Contact Telephone	202-853-7889			
	Contact Email	juli.klemm@nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Deadline Dates (ALL) 15-May-2022 [Optional][LOI/Pre-App], 14-Jun-2022 , 18-Oct-2022 [Optional][LOI/Pre-App], 17-Nov-2022</p> <p>Synopsis The purpose of this Funding Opportunity Announcement (FOA) is to invite Cooperative Agreement (U01) applications for the development of enabling informatics technologies to improve the acquisition, management, analysis, and dissemination of data and knowledge across the cancer research continuum including cancer biology, cancer treatment and diagnosis, early cancer detection, risk assessment and prevention, cancer control and epidemiology, and/or cancer health disparities. As a component of the NCI's Informatics Technology for Cancer Research (ITCR) Program, this FOA focuses on early-stage development from prototyping to hardening and adaptation. Early-stage development is defined for the purpose of this FOA as initial tool development or the significant modification of existing tools for new applications. The central mission of ITCR is to promote research-driven informatics technology across the development lifecycle to address priority needs in cancer research. In order to be successful, proposed development plans must have a clear rationale on why the proposed technology is needed and how it will benefit the cancer research field. In addition, mechanisms to solicit feedback from users and collaborators throughout the development process must be included.</p>				
109889	<p>RFA-CA-22-021 -- Development of Innovative Informatics Methods and Algorithms for Cancer Research and Management (R21 Clinical Trial Optional)</p>	National Cancer Institute/NIH/DHHS	RFA-CA-22-021	15-May-2022 [Optional][LOI/Pre-App]	275,000 USD
	<p>Contact Name Juli Klemm, Ph.D.</p> <p>Contact Telephone 202-853-7889</p> <p>Contact Email juli.klemm@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 15-May-2022 [Optional][LOI/Pre-App], 14-Jun-2022 , 18-Oct-2022 [Optional][LOI/Pre-App], 17-Nov-2022</p> <p>Synopsis The purpose of this Funding Opportunity Announcement (FOA) is to invite exploratory/developmental research grant applications (R21) for innovative informatics methods and algorithms to improve the acquisition, analysis, visualization, or interpretation of data across the cancer research continuum including cancer biology, cancer treatment and diagnosis, early cancer detection, risk assessment and prevention, cancer control and epidemiology, and/or cancer health disparities. As a component of the NCI's Informatics Technology for Cancer Research (ITCR) Program, the emphasis of this FOA is on supporting the development of novel informatics capabilities that involve a high degree of innovation that have the potential to accelerate or enhance research. To be successful, there must be a clear rationale for how the proposed informatics method or algorithm is novel and how it will benefit the cancer research field. Projects with a significant level of data generation and/or data analysis will not be considered responsive to this funding opportunity.</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount														
085330	Linking the Provider Recommendation to Adolescent HPV Vaccine Uptake (R01 Clinical Trial Optional)	National Cancer Institute/NIH/DHHS	PAR-19-360	05-Jun-2022	Not Specified														
	<table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 20%; padding-right: 5px;">Contact Name</td> <td>Sarah Kobrin, Ph.D., MPH</td> </tr> <tr> <td style="padding-right: 5px;">Contact Telephone</td> <td>240-276-6931</td> </tr> <tr> <td style="padding-right: 5px;">Contact Email</td> <td>kobrins@mail.nih.gov</td> </tr> <tr> <td style="padding-right: 5px;">Sponsor Website</td> <td></td> </tr> <tr> <td style="padding-right: 5px;">Program URL</td> <td>Link to program URL</td> </tr> <tr> <td style="padding-right: 5px;">Deadline Dates (ALL)</td> <td>05-Jun-2022</td> </tr> <tr> <td style="padding-right: 5px;">Synopsis</td> <td>This Funding Opportunity Announcement (FOA) encourages research on how the healthcare delivery system enhances or inhibits the effectiveness of a provider's recommendation of the adolescent human papillomavirus (HPV) vaccine. Characteristics of the provider, parent/patient, and clinical setting, can all affect whether a provider makes a recommendation, and whether that recommendation results in uptake of the HPV vaccine. This research requires expertise in cancer prevention, adult and childhood behavior, immunization promotion, and healthcare delivery.</td> </tr> </table>					Contact Name	Sarah Kobrin, Ph.D., MPH	Contact Telephone	240-276-6931	Contact Email	kobrins@mail.nih.gov	Sponsor Website		Program URL	Link to program URL	Deadline Dates (ALL)	05-Jun-2022	Synopsis	This Funding Opportunity Announcement (FOA) encourages research on how the healthcare delivery system enhances or inhibits the effectiveness of a provider's recommendation of the adolescent human papillomavirus (HPV) vaccine. Characteristics of the provider, parent/patient, and clinical setting, can all affect whether a provider makes a recommendation, and whether that recommendation results in uptake of the HPV vaccine. This research requires expertise in cancer prevention, adult and childhood behavior, immunization promotion, and healthcare delivery.
Contact Name	Sarah Kobrin, Ph.D., MPH																		
Contact Telephone	240-276-6931																		
Contact Email	kobrins@mail.nih.gov																		
Sponsor Website																			
Program URL	Link to program URL																		
Deadline Dates (ALL)	05-Jun-2022																		
Synopsis	This Funding Opportunity Announcement (FOA) encourages research on how the healthcare delivery system enhances or inhibits the effectiveness of a provider's recommendation of the adolescent human papillomavirus (HPV) vaccine. Characteristics of the provider, parent/patient, and clinical setting, can all affect whether a provider makes a recommendation, and whether that recommendation results in uptake of the HPV vaccine. This research requires expertise in cancer prevention, adult and childhood behavior, immunization promotion, and healthcare delivery.																		
085257	Intervening with Cancer Caregivers to Improve Patient Health Outcomes and Optimize Health Care Utilization (R01 Clinical Trial Optional)	National Cancer Institute/NIH/DHHS	PAR-19-352	05-Jun-2022	Not Specified														
	<table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 20%; padding-right: 5px;">Contact Name</td> <td>Michelle Mollica, PhD, MPH, RN, OCN</td> </tr> <tr> <td style="padding-right: 5px;">Contact Telephone</td> <td>240-276-7621</td> </tr> <tr> <td style="padding-right: 5px;">Contact Email</td> <td>michelle.mollica@nih.gov</td> </tr> <tr> <td style="padding-right: 5px;">Sponsor Website</td> <td></td> </tr> <tr> <td style="padding-right: 5px;">Program URL</td> <td>Link to program URL</td> </tr> <tr> <td style="padding-right: 5px;">Deadline Dates (ALL)</td> <td>05-Jun-2022</td> </tr> <tr> <td style="padding-right: 5px;">Synopsis</td> <td>This Funding Opportunity Announcement (FOA) invites applications for intervention research designed to support caregivers of adult cancer patients. Interventions supported by this FOA are intended to provide caregivers with care training, promote coping skills, and ultimately help them manage care. Outcomes of such interventions are expected to (1) optimize patient health care utilization, (2) improve caregiver well-being, and (3) improve patient physical health and psychosocial outcomes.</td> </tr> </table>					Contact Name	Michelle Mollica, PhD, MPH, RN, OCN	Contact Telephone	240-276-7621	Contact Email	michelle.mollica@nih.gov	Sponsor Website		Program URL	Link to program URL	Deadline Dates (ALL)	05-Jun-2022	Synopsis	This Funding Opportunity Announcement (FOA) invites applications for intervention research designed to support caregivers of adult cancer patients. Interventions supported by this FOA are intended to provide caregivers with care training, promote coping skills, and ultimately help them manage care. Outcomes of such interventions are expected to (1) optimize patient health care utilization, (2) improve caregiver well-being, and (3) improve patient physical health and psychosocial outcomes.
Contact Name	Michelle Mollica, PhD, MPH, RN, OCN																		
Contact Telephone	240-276-7621																		
Contact Email	michelle.mollica@nih.gov																		
Sponsor Website																			
Program URL	Link to program URL																		
Deadline Dates (ALL)	05-Jun-2022																		
Synopsis	This Funding Opportunity Announcement (FOA) invites applications for intervention research designed to support caregivers of adult cancer patients. Interventions supported by this FOA are intended to provide caregivers with care training, promote coping skills, and ultimately help them manage care. Outcomes of such interventions are expected to (1) optimize patient health care utilization, (2) improve caregiver well-being, and (3) improve patient physical health and psychosocial outcomes.																		
086149	Perception and Cognition Research to Inform Cancer Image Interpretation (R01 Clinical Trial Optional)	National Cancer Institute/NIH/DHHS	PAR-19-387	05-Jun-2022	Not Specified														
	<table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 20%; padding-right: 5px;">Contact Name</td> <td>Todd S. Horowitz, Ph.D.</td> </tr> </table>					Contact Name	Todd S. Horowitz, Ph.D.												
Contact Name	Todd S. Horowitz, Ph.D.																		

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Telephone 240-276-6963</p> <p>Contact Email todd.horowitz@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 05-Jun-2022 , 05-Oct-2022</p> <p>Synopsis The purpose of this Funding Opportunity Announcement (FOA) is to facilitate research on the perceptual and cognitive processes underlying the performance of cancer image observers in radiology and pathology, in order to improve the accuracy of cancer detection and diagnosis.</p>				
097239	Secondary Analysis and Integration of Existing Data to Elucidate the Genetic Architecture of Cancer Risk and Related Outcomes (R01 Clinical Trial Not Allowed)	National Cancer Institute/NIH/DHHS	PAR-20-276	05-Jun-2022	1,750,000 USD
	<p>Contact Name Melissa Rotunno, Ph.D.</p> <p>Contact Telephone 240-276-7245</p> <p>Contact Email rotunnom@mail.nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 05-Jun-2022</p> <p>Synopsis Through this funding opportunity announcement (FOA), the National Cancer Institute (NCI) along with the National Human Genome Research Institute (NHGRI) and National Institute of Dental and Craniofacial Research (NIDCR) encourages submission of applications proposing to conduct secondary data analysis and integration of existing datasets and database resources, with the ultimate aim to elucidate the genetic architecture of cancer risk and related outcomes (e.g., risk prediction or reduction, survival, or response to treatment, etc.). The goal of this initiative is to address key scientific questions relevant to cancer genomic and epidemiology by supporting the analysis of existing genetic or genomic datasets, in combination with other omics and environmental, clinical, behavioral, lifestyle, and molecular profiles data. Applicants are encouraged to leverage existing genetic data and perform innovative analyses of the existing data.</p>				
087228	Co-infection and Cancer (R01 Clinical Trial Not Allowed)	National Cancer Institute/NIH/DHHS	PAR-20-062	05-Jun-2022	Not Specified
	Contact Name Tram Kim Lam, Ph.D., MPH				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Telephone 240-276-6967</p> <p>Contact Email lamt@mail.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 05-Jun-2022 , 05-Oct-2022</p> <p>Synopsis The purpose of this Funding Opportunity Announcement (FOA) is to enhance mechanistic and epidemiologic investigations addressing the roles of co-infection. Co-infection is defined as the occurrence of infections by two or more infectious (pathogenic or non-pathogenic) agents – either concurrently or sequentially – and includes both acute and chronic infections by viruses, bacteria, parasites, and/or other microorganisms. Preference will be given to investigations of co-infections with known oncogenic agents (excluding human immunodeficiency virus [HIV]) and of co-infections that engender novel opportunities for prevention and treatment</p>				
099622	Tobacco Control Policies to Promote Health Equity (R01 Clinical Trial Optional)	National Cancer Institute/NIH/DHHS	PAR-20-302	05-Jun-2022	Not Specified
	<p>Contact Name Bob Vollinger, DrPH, MSPH</p> <p>Contact Telephone 240-276-6919</p> <p>Contact Email Bob.Vollinger@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 05-Jun-2022 , 05-Oct-2022 , 05-Feb-2023 , 05-Jun-2023</p> <p>Synopsis The purpose of this Funding Opportunity Announcement (FOA) is to support observational or intervention research focused on reducing disparities in tobacco use and secondhand smoke (SHS) exposure in the U.S. Specifically, this FOA aims to stimulate scientific inquiry focused on innovative state and local level tobacco prevention and control policies. The long-term goal of this FOA is to reduce disparities in tobacco-related cancers, and in doing so, to promote health equity among all populations. Applicants submitting applications related to health economics are encouraged to consult NOT-OD-16-025 to ensure that the research projects align with NIH mission priorities in health economics research.</p>				
103024	Academic-Industrial Partnerships for Translation of Technologies for Diagnosis and Treatment (R01 - Clinical Trial Optional)	National Cancer Institute/NIH/DHHS	PAR-21-206	05-Jun-2022	2,495,000 USD
	Contact Name Miguel Ossandon MS				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Telephone 240-276-5714</p> <p>Contact Email ossandom@mail.nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 05-Jun-2022 , 05-Oct-2022 , 05-Feb-2023 , 05-Jun-2023 , 05-Oct-2023</p> <p>Synopsis The purpose of this Funding Opportunity Announcement (FOA) is to stimulate efforts to translate scientific discoveries and engineering developments into methods or tools that address problems in basic research to understand disease, or in applied research to assess risk, detect, prevent, diagnose, treat, and/or manage disease. The rationale is to deliver new capabilities to meet evolving requirements for technologies and methods relevant to the advance of research and delivery of care in pre-clinical, clinical and non-clinical settings, domestic or foreign, for conditions and diseases within the missions of participating institutes. This FOA specifies a partnership structure that is expected to help bridge gaps in knowledge and experience by engaging the strengths of academic, industrial, and other investigators. The partners on each application should establish an inter-disciplinary, multi-institutional research team to work in strategic alliance to implement a coherent strategy to develop and translate a solution to their chosen problem. They are expected to plan, design, and validate that the solution will be suitable for end users. Each partnership should include at least one academic and one industrial organization. Each partnership should plan to transition a technology, method, assay, device, and/or system from a demonstration of possibility to a status useful in the chosen setting. Funding may be requested to enhance, adapt, optimize, validate, and otherwise translate technologies that address problems in biology, pathology, risk assessment, diagnosis, treatment, and/or monitoring of disease status. This FOA defines "innovation" as likelihood to deliver a new capability to end users. This FOA will support clinical trials that test functionality or validate performance in the chosen setting. This FOA is not intended to support straight clinical trials that lack translation as the primary motivation. Applications that propose phase III clinical trials in any area of cancer research are not sought by and will not be supported through this FOA. This FOA does not propose to support commercial production or basic research projects.</p>				
106546	Clinical Characterization of Cancer Therapy-induced Adverse Sequelae and Mechanism-based Interventional Strategies (R01 Clinical Trial Optional)	National Cancer Institute/NIH/DHHS	PAR-21-329	05-Jun-2022	Not Specified
	<p>Contact Name Kelly Filipski PhD, MPH</p> <p>Contact Telephone 240-276-6841</p> <p>Contact Email Filipskikk@mail.nih.gov</p> <p>Sponsor Website </p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 05-Jun-2022 , 05-Oct-2022 , 05-Feb-2023 , 05-Jun-2023 , 05-Oct-2023 , 05-Feb-2024 , 05-Jun-2024 , 05-Oct-2024</p> <p>Synopsis The purpose of this Funding Opportunity Announcement (FOA) is to support collaborative research projects designed to address adverse sequelae of cancer therapies that persist and become chronic comorbidities or develop as delayed posttreatment effects. This FOA supports basic, translational, and/or clinical research projects that seek to identify the mechanisms of therapy-induced adverse sequelae, clinically characterize the adverse sequelae, or translate the mechanistic understanding into therapeutic approaches to prevent or minimize the development of long-term sequelae. Research projects should focus on 1) mechanistic studies with translational endpoints; and/or 2) longitudinal clinical phenotyping to identify and validate clinical endpoints (biomarkers, imaging, patient-reported outcomes, or combined elements) for future use in clinical trials that will evaluate the efficacy of interventions designed to prevent or reduce specific adverse sequelae.</p>				
090364	<p>Research Projects to Enhance Applicability of Mammalian Models for Translational Research (R01 Clinical Trial Not Allowed)</p>	National Cancer Institute/NIH/DHHS	PAR-20-131	05-Jun-2022	1,350,000 USD
	<p>Contact Name Joanna Watson, Ph.D.</p> <p>Contact Telephone 240-276-6230</p> <p>Contact Email Joanna.Watson@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 05-Jun-2022 , 05-Oct-2022 , 05-Feb-2023</p> <p>Synopsis The purpose of this Funding Opportunity Announcement (FOA) is to invite applications for projects to expand, improve, or transform the utility of mammalian cancer and tumor models for translational research. With this FOA, the NCI intends to encourage submission of projects devoted to demonstrating that mammalian models or their derivatives used for translational research are robust representations of human biology, are appropriate to test questions of clinical importance, and provide reliable information for patients' benefit. These practical goals contrast with the goals of many mechanistic, NCI-supported R01 projects that use mammals, or develop and use mammalian cancer models, transplantation tumor models, or models derived from mammalian or human tissues or cells for hypothesis-testing, non-clinical research. Among many other possible endeavors, applicants in response to this FOA could propose demonstrations of how to overcome translational deficiencies of mammalian oncology models, define new uses of mammalian models or their genetics for unexplored translational challenges, advance standard practices for use of translational models, test approaches to validate and credential models, or challenge current practices for how models are used translationally.</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
107221	Modulating Human Microbiome Function to Enhance Immune Responses Against Cancer (R01 Clinical Trial Not Allowed)	National Cancer Institute/NIH/DHHS	PAR-22-061	05-Jun-2022	Not Specified
	<p>Contact Name Phillip J. Daschner, M.Sc.</p> <p>Contact Telephone 240-276-6227</p> <p>Contact Email PD93u@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 05-Jun-2022 , 05-Oct-2022 , 05-Feb-2023 , 05-Jun-2023 , 05-Oct-2023 , 05-Feb-2024 , 05-Jun-2024 , 05-Oct-2024</p> <p>Synopsis The purpose of this Funding Opportunity Announcement (FOA) is to support basic research that elucidates mechanisms by which the human microbiome inhibits or enhances anti-tumor immune responses, and to identify potential novel molecular targets for cancer prevention strategies. Applications should be focused on delineating how host interactions with specific microbes (or consortia) or their metabolites target immune responses that enhance or prevent inflammation-associated or sporadic tumor formation. Concentration, timing, and duration of administered beneficial microbes may alter its effectiveness and thus those parameters should be rigorously addressed in the application.</p>				
108548	Epidemiologic Research on Emerging Risk Factors and Liver Cancer Susceptibility (R01 Clinical Trial Not Allowed)	National Cancer Institute/NIH/DHHS	PAR-22-083	05-Jun-2022	Not Specified
	<p>Contact Name Tram Kim Lam, Ph.D., MPH</p> <p>Contact Telephone 240-276-6967</p> <p>Contact Email Tram.Lam@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 05-Jun-2022 , 05-Oct-2022 , 05-Feb-2023 , 05-Jun-2023 , 05-Oct-2023 , 05-Feb-2024 , 05-Jun-2024 , 05-Oct-2024 , 05-Feb-2025</p> <p>Synopsis The purpose of this Funding Opportunity Announcement (FOA) is to promote epidemiologic research investigating novel and innovative hypotheses on emerging risk factors (biological, environmental, and social) and their interplay with established risk factors (e.g., viral hepatitis) associated with the development of liver cancer (hepatocellular carcinoma and other histological subtypes) in the United States.</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
108551	Cancer Tissue Engineering Collaborative: Enabling Biomimetic Tissue-Engineered Technologies for Cancer Research (R01 Clinical Trial Optional)	National Cancer Institute/NIH/DHHS	PAR-22-099	05-Jun-2022	2,000,000 USD
	<p>Contact Name Steven Becker, Ph.D.</p> <p>Contact Telephone 240-276-6210</p> <p>Contact Email steven.becker@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 05-Jun-2022 , 05-Oct-2022 , 05-Feb-2023 , 05-Jun-2023 , 05-Oct-2023 , 05-Feb-2024 , 05-Jun-2024 , 05-Oct-2024 , 05-Feb-2025</p> <p>Synopsis This Funding Opportunity Announcement (FOA) will support the development and characterization of state-of-the-art biomimetic tissue-engineered technologies for cancer research. Collaborative, multidisciplinary projects that engage the fields of regenerative medicine, tissue engineering, biomaterials, and bioengineering with cancer biology will be essential for generating novel experimental models that mimic cancer pathophysiology in the context of a testable cancer research hypothesis. The projects supported by this FOA will collectively participate in the Cancer Tissue Engineering Collaborative (TEC) Research Program. The Cancer TEC Program will (1) catalyze the advancement of innovative, well characterized in vitro and ex vivo systems available for cancer research, (2) expand the breadth of these systems to several cancer types, and (3) promote the exploration of cancer phenomena with biomimetic tissue-engineered systems.</p>				
106282	Mechanisms that Impact Cancer Risk after Bariatric Surgery (R01 Clinical Trial Optional)	National Cancer Institute/NIH/DHHS	PAR-21-331	05-Jun-2022	2,500,000 USD
	<p>Contact Name Edward R. Sauter, M.D., Ph.D.</p> <p>Contact Telephone 240-276-7657</p> <p>Contact Email edward.sauter@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 05-Jun-2022 , 05-Jul-2022 , 05-Oct-2022 , 05-Nov-2022 , 05-Feb-2023 , 05-Mar-2023 , 05-Jun-2023 , 05-Jul-2023 , 05-Oct-2023 , 05-Nov-2023 , 05-Feb-2024 , 05-Mar-2024 , 05-Jun-2024 , 05-Jul-2024</p> <p>Synopsis Through this Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI) invites applications for support of investigator-initiated studies addressing mechanisms by which bariatric surgery impacts cancer risk, and seeks to draw in</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		talented scientists who study bariatric surgery to investigate its effects on cancer, rather than shorter term outcomes such as weight loss and diabetes.			
106261	Basic Research in Cancer Health Disparities (R01 Clinical Trial Not Allowed)	National Cancer Institute/NIH/DHHS	PAR-21-322	05-Jun-2022	Not Specified
	Contact Name	Anu Sharman, Ph.D.			
	Contact Telephone	240-276-6250			
	Contact Email	sharmananu@nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	05-Jun-2022 , 05-Jul-2022 , 05-Oct-2022 , 05-Nov-2022 , 05-Feb-2023 , 05-Mar-2023 , 05-Jun-2023 , 05-Jul-2023 , 05-Oct-2023 , 05-Nov-2023 , 05-Feb-2024 , 05-Mar-2024 , 05-Jun-2024 , 05-Jul-2024			
	Synopsis	National Cancer Institute (NCI) invites applications from investigators interested in conducting basic, mechanistic research into the biological/genetic causes of cancer health disparities. These research project grants (R01) will support innovative studies designed to investigate biological/genetic bases of cancer disparities, such as (1) mechanistic studies of biological factors associated with cancer disparities, including those related to basic research in cancer biology or cancer prevention strategies, (2) the development and testing of new methodologies and models, and (3) secondary data analyses. This FOA is also designed to aid and facilitate the growth of a nationwide cohort of scientists with a high level of basic research expertise in cancer health disparities research who can expand available resources and tools, such as biospecimens, patient derived models, and methods that are necessary to conduct basic research in cancer health disparities. This FOA will use the NIH Research Project (R01) award mechanism.			
086487	Fundamental Mechanisms of Affective and Decisional Processes in Cancer Control (R01 Clinical Trial Optional)	National Cancer Institute/NIH/DHHS	PAR-20-034	05-Jun-2022	Not Specified
	Contact Name	Rebecca A Ferrer, Ph.D.			
	Contact Telephone	240-276-6963			
	Contact Email	ferrerra@mail.nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	05-Jun-2022 , 05-Oct-2022			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Synopsis	The purpose of this Funding Opportunity Announcement (FOA) is to encourage projects to generate fundamental knowledge of affective processes. Basic affective science projects should have key consequences for single (e.g., cancer screening) and multiple (e.g., adherence to oral chemotherapy regimen) event decisions and behaviors across the cancer prevention and control continuum. The FOA is expected to encourage collaboration among cancer control researchers and those from scientific disciplines not traditionally connected to cancer control applications (e.g., affective and cognitive neuroscience, decision science, consumer science) to elucidate perplexing and understudied problems in affective and decision sciences with downstream implications for cancer prevention and control.			
087000	Program to Assess the Rigor and Reproducibility of Extracellular Vesicle-Derived Analytes for Cancer Detection (R01 Clinical Trial Not Allowed)	National Cancer Institute/NIH/DHHS	PAR-20-053	05-Jun-2022	Not Specified
	Contact Name	Sudhir Srivastava, Ph.D., M.P.H.			
	Contact Telephone	240-276-7028			
	Contact Email	srivasts@mail.nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	05-Jun-2022 , 05-Oct-2022			
	Synopsis	This Funding Opportunity Announcement (FOA) encourages research projects that focus on innovative research in the isolation and characterization of extracellular vesicles (EVs) and their cargo for discovery of predictive biomarkers for risk assessment, detection, diagnosis and prognosis of early cancer. This FOA will promote rigor and reproducibility research in both the isolation of EVs as well as the computational analysis of the cargo carried in these vesicles.			
109909	Systematic Testing of Radionuclides in Preclinical Experiments (STRIPE) (R01 Clinical Trial Not Allowed)	National Cancer Institute/NIH/DHHS	PAR-22-139	05-Jun-2022	2,500,000 USD
	Contact Name	Michael Graham Espey, Ph.D.			
	Contact Telephone	240-276-7619			
	Contact Email	SP@nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	05-Jun-2022 , 05-Oct-2022 , 05-Feb-2023 , 05-Jun-2023 , 05-Oct-2023 , 05-Feb-2024 , 05-Jun-2024 , 05-Oct-2024 , 05-Feb-2025			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Synopsis	The purpose of this Funding Opportunity Announcement (FOA) is to solicit R01 research projects utilizing state-of-the-art cancer biology methods and model systems to study effects of different types of radiation used in radionuclide-based therapeutics (e.g., radiopharmaceutical therapy) on normal tissue, tumor cells and the tumor microenvironment.			
092676	New Informatics Tools and Methods to Enhance U.S. Cancer Surveillance Research (U01 Clinical Trial Optional)	National Cancer Institute/NIH/DHHS	PAR-20-170	06-Jun-2022	Not Specified
	Contact Name	Angela B. Mariotto, PhD			
	Contact Telephone	240-276-6698			
	Contact Email	mariotta@mail.nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	06-Jun-2022 , 18-Nov-2022 , 06-Jun-2023			
	Synopsis	<p>The goal of this Funding Opportunity Announcement (FOA) is to advance surveillance science by supporting the development of new and innovative tools and methods for more efficient, detailed, timely, and accurate data collection by cancer registries. Specifically, the FOA solicits applications for projects to develop, adapt, apply, scale-up, and validate tools and methods to improve the collection and integration of cancer registry data to expand the data items collected. Applications proposed must be based on partnership with at a minimum of two U.S. population-based central cancer registries. Tools and methods proposed for development are expected to enhance the registry core infrastructure and, in so doing, expand the usefulness of registry-collected data to support high-quality cancer research. The scientific scope of this FOA includes but is not limited to Development, validation, evaluation of scalable tools/methods to facilitate automatic/unsupervised extraction and consolidation of specific data from various types of unstructured medical records as for example, pathology reports, diagnostic imaging, laboratory, hospital discharge forms and clinical visits; Supplementation of cancer registries with new or more detailed data items, from existing data sources or from linkages with novel data sources, e.g. electronic medical records (EMR) Funds will be made available through the U01 cooperative agreement award mechanism.</p>			
109682	RFA-CA-22-015 -- Cancer Control Research in Persistent Poverty Areas (U54 Clinical Trial Optional)	National Cancer Institute/NIH/DHHS	RFA-CA-22-015	06-Jun-2022 [Optional][LOI/Pre-App]	7,500,000 USD
	Contact Name	Shobha Srinivasan, Ph.D.			
	Contact Telephone	240-276-6938			
	Contact Email	ss688k@nih.gov			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 06-Jun-2022 [Optional][LOI/Pre-App], 06-Jul-2022</p> <p>Synopsis Through this Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI) invites applications for Cancer Control Research in Persistent Poverty Areas (Persistent Poverty Initiative). The goal is to provide resources to support the time and effort of transdisciplinary teams, in collaboration with institutions, clinics, and communities/tribes, to develop a cancer prevention and control research program and provide support to early-career investigators that focuses on and serves populations living in persistent poverty areas. For this purpose, NCI will support several U54 Specialized Centers. The long-term goal of this initiative is to build capacity in persistent poverty areas to foster cancer prevention and control research and promote the implementation of programs and practices in institutions/clinics/communities/tribes to alleviate the effects of persistent poverty.</p>				
106892	Exploratory Grants in Cancer Control (R21 Clinical Trial Optional)	National Cancer Institute/NIH/DHHS	PAR-21-341	07-Jun-2022	275,000 USD
	<p>Contact Name Mukesh Verma, Ph.D.</p> <p>Contact Telephone 240-276-6889</p> <p>Contact Email vermam@mail.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-Jun-2022 , 07-Oct-2022 , 07-Jun-2023 , 09-Oct-2023 , 07-Jun-2024 , 08-Oct-2024</p> <p>Synopsis Through this funding opportunity announcement (FOA), the National Cancer Institute (NCI) encourages the submission of exploratory/developmental research grant (R21) applications that focus on different aspects of cancer control by modifying behavior, screening, and understanding etiologic factors contributing to the development of cancer, and developing ways to control cancer. The overarching goal is to provide support to promote the early and conceptual stages of research efforts on novel scientific ideas that have the potential to substantially advance population-based cancer research, such as the development of novel techniques, agents, methodologies, models, or applications that could have a major impact on a field of cancer research (e.g. epidemiologic, biomedical, behavioral, health care delivery or clinical).</p>				
106117	NCI Research Specialist (Clinician Scientist) Award (R50 Clinical Trial Not Allowed)	National Cancer Institute/NIH/DHHS	PAR-21-306	07-Jun-2022	Not Specified
	Contact Name Deborah Jaffe, Ph.D.				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Telephone 240-276-6169</p> <p>Contact Email jaffed@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-Jun-2022 , 06-Oct-2022 , 07-Feb-2023 , 06-Jun-2023 , 06-Oct-2023</p> <p>Synopsis Through this Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI) invites applications for the Research Specialist Award (R50) specifically for clinician scientists supporting NCI-funded clinical trials research. The Research Specialist Award is designed to encourage the development of stable research career opportunities for exceptional clinician scientists who want to continue to participate in the NCI clinical trials networks through leadership in the 1) development of national clinical trials, 2) implementation of NCI clinical trials in their institutions, and 3) national service to the NCI clinical trials networks through participation in the scientific review committees, monitoring committees and other activities, but not serve as principal investigators of research project grants. These clinician scientists are vital to sustaining the NCI-funded clinical trials enterprise. The Research Specialist Award is intended to provide salary support and sufficient autonomy so that individuals are not solely dependent on NCI grants held by others or other sources of support for cancer research career continuity.</p>				
107027	<p>Integrating Biospecimen Science Approaches into Clinical Assay Development (U01 Clinical Trial Not Allowed)</p>	National Cancer Institute/NIH/DHHS	PAR-22-049	07-Jun-2022	1,250,000 USD
	<p>Contact Name Abhi Rao, Ph.D.</p> <p>Contact Telephone 240-276-5715</p> <p>Contact Email abhi.rao@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-Jun-2022 , 13-Sep-2022 , 11-Jan-2023 , 07-Jun-2023 , 13-Sep-2023 , 11-Jan-2024 , 07-Jun-2024 , 13-Sep-2024</p> <p>Synopsis This Funding Opportunity Announcement (FOA) will support extramural research to investigate and mitigate challenges facing clinical assay development and subsequent analytical validation due to preanalytical variability in tumor tissue biopsies, blood biospecimens utilized as “liquid biopsies, or other biospecimens as described in this FOA. Extramural research funded under this FOA may include investigations of preanalytical variability associated with the procurement and study of small biopsies (core biopsies, small excision samples), blood utilized for liquid biopsies, tissue swabs, tissue secretions, pleural and esophageal aspirates, feces, or bodily fluids like sweat, urine, CSF, breast milk and saliva. Investigator-designed experiments will explore how different biospecimen preanalytical conditions affect emerging and clinically relevant</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>biomarkers quantified by a variety of testing platforms. The results from this research program will improve the understanding of how analytical quantification of clinically relevant biomarkers is affected by variation in biospecimen collection, processing, and storage procedures. The overall goal is to expedite biomarker clinical assay development through evidence-based standardization of biopsy handling practices.</p>				
084969	Innovative Approaches to Studying Cancer Communication in the New Information Ecosystem (R21 Clinical Trial Optional)	National Cancer Institute/NIH/DHHS	PAR-19-350	08-Jun-2022	275,000 USD
	<p>Contact Name Kelly D. Blake, ScD Contact Telephone 240-281-5934 Contact Email kelly.blake@nih.gov Sponsor Website Program URL Link to program URL Deadline Dates (ALL) 08-Jun-2022</p> <p>Synopsis Through this Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI) announces its interest in supporting meritorious research projects in three distinct domains related to cancer communication: 1) the utility and application of new cancer communication surveillance approaches; 2) the development and testing of rapid cancer communication interventions using innovative methods and designs; and 3) the development and testing of multilevel cancer communication models emphasizing bidirectional influence between levels. For such projects, applicants should apply communication science approaches to the investigation of behavioral targets and health outcomes related to cancer prevention and control. Applications should utilize one or more innovative communication research methodologies.</p>				
084968	Innovative Approaches to Studying Cancer Communication in the New Information Ecosystem (R01 Clinical Trial Optional)	National Cancer Institute/NIH/DHHS	PAR-19-348	08-Jun-2022	Not Specified
	<p>Contact Name Kelly D. Blake, ScD Contact Telephone 240-281-5934 Contact Email kelly.blake@nih.gov Sponsor Website Program URL Link to program URL Deadline Dates (ALL) 08-Jun-2022</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Synopsis	Through this Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI) announces its interest in supporting meritorious research projects in three distinct domains related to cancer communication: 1) the utility and application of new cancer communication surveillance approaches; 2) the development and testing of rapid cancer communication interventions using innovative methods and designs; and 3) the development and testing of multilevel cancer communication models emphasizing bidirectional influence between levels. For such projects, applicants should apply communication science approaches to the investigation of behavioral targets and health outcomes related to cancer prevention and control. Applications should utilize one or more innovative communication research methodologies.			
084813	Leveraging Cognitive Neuroscience to Improve Assessment of Cancer Treatment-Related Cognitive Impairment (R21 Clinical Trial Optional)	National Cancer Institute/NIH/DHHS	PAR-19-339	08-Jun-2022	275,000 USD
	Contact Name	Todd S Horowitz, Ph.D			
	Contact Telephone	240-276-6963			
	Contact Email	todd.horowitz@mail.nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	08-Jun-2022			
	Synopsis	This FOA encourages the integration of cognitive neuroscience approaches to improve traditional assessment of acute and chronic cognitive changes following cancer treatment for non-central nervous system malignancies.			
084812	Leveraging Cognitive Neuroscience to Improve Assessment of Cancer Treatment-Related Cognitive Impairment (R01 Clinical Trial Optional)	National Cancer Institute/NIH/DHHS	PAR-19-340	08-Jun-2022	Not Specified
	Contact Name	Todd S Horowitz, Ph.D			
	Contact Telephone	240-276-6963			
	Contact Email	todd.horowitz@mail.nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	08-Jun-2022			
	Synopsis	This FOA encourages the integration of cognitive neuroscience approaches to improve traditional assessment of acute and chronic cognitive changes following cancer treatment for non-central nervous system malignancies.			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
106440	Pancreatic Cancer Detection Consortium: Research Units (U01 Clinical Trial Optional)	National Cancer Institute/NIH/DHHS	PAR-21-334	10-Jun-2022	3,000,000 USD
	<p>Contact Name Sudhir Srivastava, Ph.D., M.P.H.</p> <p>Contact Telephone 240-276-7028</p> <p>Contact Email srivasts@mail.nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 10-Jun-2022 , 11-Oct-2022 , 10-Feb-2023 , 13-Jun-2023 , 11-Oct-2023 , 11-Jun-2024</p> <p>Synopsis Through this Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI) is soliciting applications for the Research Units (RUs), one of the two scientific components of the Pancreatic Cancer Detection Consortium (PCDC), to conduct research on early detection of pancreatic ductal adenocarcinoma (PDAC) and characterization of its precursor lesions to identify those patients who are at high risk of progression to cancer. The PCDC will continue to address one of the four research priorities identified in the NCI's 2014 Scientific Framework for Pancreatic Ductal Adenocarcinoma (PDAC). The PCDC will support research for the development and testing of new molecular and imaging biomarkers for detecting PDAC early and for identifying those patients at high risk of PDAC (because of genetic factors or presence of precursor lesions) who could be candidates for early intervention. The PCDC-RUs will consist of multi-disciplinary teams and will undertake studies to: identify and test biomarkers measurable in bodily fluids for early detection of PDAC and/or its precursor lesions; develop molecular- and/or imaging-based markers of pancreatic cysts and determine which ones are likely to progress to cancer; develop molecular- and/or imaging-based approaches for screening populations at high risk of PDAC; use machine learning and computational approaches towards biomarker discovery and/or validation; and conduct biomarker validation studies. The PCDC-RUs will also collect longitudinal biospecimens for building a biorepository. Each PCDC-RU is expected to participate in collaborative activities with other PCDC-RUs and share ideas, biospecimens, and data within the Consortium. The other scientific component of the PCDC will be the Management and Data Coordination Unit (MDCU; see companion PAR-21-335). The PCDC-MDCU will provide support toward study design, protocol development, statistical analysis, coordination, harmonization, data management and stewardship for the trans-PCDC collaborative projects, including biorepository building effort. The PCDC-MDCU will also support the coordination and organization of Consortium-wide calls, meetings and workshops.</p>				
106441	Pancreatic Cancer Detection Consortium: Management and Data Coordination Unit (U24 Clinical Trial Not Allowed)	National Cancer Institute/NIH/DHHS	PAR-21-335	10-Jun-2022	2,500,000 USD
	<p>Contact Name Sudhir Srivastava, Ph.D., M.P.H.</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Telephone 240-276-7028</p> <p>Contact Email srivasts@mail.nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 10-Jun-2022 , 11-Oct-2022 , 10-Feb-2023 , 13-Jun-2023 , 11-Oct-2023 , 11-Jun-2024</p> <p>Synopsis Through this Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI) is soliciting applications for the establishment of the Management and Data Coordination Unit (MDCU), one of the two scientific components of the Pancreatic Cancer Detection Consortium (PCDC). The PCDC will continue to address one of the four research priorities identified in the National Cancer Institute's 2014 Scientific Framework for Pancreatic Ductal Adenocarcinoma and conduct research on early detection of pancreatic ductal adenocarcinoma (PDAC) and characterization of its precursor lesions to identify those patients who are at high risk of progression to cancer. The PCDC-MDCU will provide support toward collaborative efforts such as: study design, protocol development, statistical analysis, coordination and data management. Other PCDC-MDCU activities include: coordination and support toward biorepository building; and organizational and logistics support for PCDC activities. The other scientific component of the PCDC will be the Research Units (PCDC-Rus; see companion PAR-21-334). The PCDC-RUs will conduct research for the development and testing of new molecular and imaging biomarkers for early detection of PDAC and/or for identifying those patients at high risk of PDAC (because of genetic factors and/or family history or presence of precursor lesions) who could be candidates for early intervention.</p>				
106319	<p>Utilizing the PLCO Biospecimens Resource to Bridge Gaps in Cancer Etiology and Early Detection Research (U01 Clinical Trial Not Allowed)</p>	National Cancer Institute/NIH/DHHS	PAR-21-330	10-Jun-2022	Not Specified
	<p>Contact Name Claire Zhu, Ph.D.</p> <p>Contact Telephone 240-276-7013</p> <p>Contact Email zhucla@mail.nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 10-Jun-2022 , 11-Oct-2022 , 10-Feb-2023 , 13-Jun-2023 , 11-Oct-2023 , 13-Feb-2024 , 11-Jun-2024 , 11-Oct-2024</p> <p>Synopsis Through this Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI) encourages the submission of applications that propose to advance research in cancer etiology and early detection biomarkers, utilizing the advantages of the unique biorepository resources of the NCI-sponsored Prostate, Lung, Colorectal, and Ovarian Cancer (PLCO) Screening Trial. The PLCO Biorepository offers high-quality, prospectively collected, serial pre-diagnostic blood samples from the PLCO screened arm participants, and a onetime collection of buccal cells from both the screened and the control arm participants.</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

Available data associated with the biospecimens includes demographic, diet, lifestyle, smoking, screening results, and other clinical data. This FOA supports a wide range of cancer research including, but not limited to, biochemical and genetic analyses of cancer risk, as well as discovery and validation of early detection biomarkers. The proposed research project must involve use of PLCO biospecimens and may include other resources; additionally, it should also take advantage of the unique characteristics of the PLCO biospecimens. Research on non-cancer outcomes, especially those related to aging (e.g., Alzheimer's, depression, hip fracture, osteoporosis and rheumatoid arthritis) may also be supported. Research projects that do not involve the use of PLCO biospecimens will not be supported under this FOA.

100261	Assay Validation of High Quality Markers for Clinical Studies in Cancer (UH2/UH3 Clinical Trial Not Allowed)	National Cancer Institute/NIH/DHHS	PAR-20-313	11-Jun-2022	1,025,000 USD
--------	--	------------------------------------	------------	-------------	---------------

Contact Name	Tracy G. Lively, Ph.D.
Contact Telephone	240-276-5944
Contact Email	livelyt@mail.nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	11-Jun-2022 , 11-Oct-2022 , 14-Feb-2023 , 10-Jul-2023 , 10-Oct-2023

Synopsis

Through this Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI) invites applications to support the validation of molecular/cellular/imaging markers (referred to as "markers" or "biomarkers") and assays for cancer detection, diagnosis, prognosis, monitoring, and prediction of response or resistance to treatment, as well as markers for cancer prevention and control. This FOA will support investigator-initiated research for both analytical, and clinical validation of assays to be used in cancer treatment, control, or prevention trials supported by the NCI. This FOA will also support the validation of pharmacodynamic markers and markers of toxicity. Applicants should have assays that work on human samples and whose importance is well justified for development into clinical assays. As chemotherapies and/or radiation therapies are increasingly combined with immunotherapies to enhance durability of anti-cancer responses, assays for measuring multiple markers, including immune markers, can be developed and validated simultaneously. The UH2 phase of this FOA supports analytical validation of assays for these molecular/cellular/imaging markers, which must be achieved within 2 years before assays may undergo clinical validation. The UH3 phase of this FOA supports clinical validation of analytically validated assays for up to 3 years using well-annotated biospecimens from retrospective or prospective clinical trials or studies. This FOA may be used to validate existing assays for use in other cancer clinical trials, observational studies, or population studies. Efforts to harmonize clinical laboratory tests, including investigation into the performance and reproducibility of assays across multiple clinical laboratories, are also appropriate for this funding opportunity. Projects proposed for this FOA will require multi-disciplinary interaction and collaboration among scientific investigators, oncologists, statisticians, and

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		<p>clinical laboratory scientists. This FOA is not intended to support early-stage development of technology or the conduct of clinical trials but is intended for validation of assays to the point where they could be integrated into clinical trials/studies as investigational assays. Investigators responding to this FOA must address both UH2 and UH3 phases. Milestones to be accomplished in the UH2 phase for transition to the UH3 phase must be proposed by the investigators.</p>			
100262	Assay Validation of High Quality Markers for Clinical Studies in Cancer (UH3 Clinical Trials Not Allowed)	National Cancer Institute/NIH/DHHS	PAR-20-314	11-Jun-2022	750,000 USD
	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email</p> <p>Sponsor Website</p> <p>Program URL</p> <p>Deadline Dates (ALL)</p> <p>Synopsis</p>	<p>Tracy G. Lively, Ph.D.</p> <p>240-276-5944</p> <p>livelyt@mail.nih.gov</p> <p></p> <p>Link to program URL</p> <p>11-Jun-2022 , 11-Oct-2022 , 14-Feb-2023 , 10-Jul-2023 , 10-Oct-2023</p> <p>The purpose of this Funding Opportunity Announcement (FOA) is to accelerate the adoption and validation of molecular/cellular/imaging markers (referred to as "markers" or "biomarkers") and assays for cancer detection, diagnosis, prognosis, monitoring, and prediction of response or resistance to treatment, as well as markers for cancer prevention and control. This FOA will also support the validation of pharmacodynamic markers and markers of toxicity. Applicants to this FOA must have an assay(s) whose performance has been analytically validated in specimens similar to those for the intended clinical use of the marker(s) and assay(s). As chemotherapies and/or radiation therapies are increasingly combined with immunotherapies to enhance the durability of anti-cancer responses, assays for measuring multiple markers, including immune markers, can be developed and validated simultaneously. The UH3 mechanism will support the clinical validation of established assays for up to 3 years using specimens from retrospective or prospective clinical trials or studies. This FOA may be used to validate existing assays for use in other trials, observational studies, or population studies. Efforts to harmonize clinical laboratory tests, including investigation into the performance and reproducibility of assays across multiple clinical laboratories, are also appropriate for this funding opportunity. Projects proposed for this FOA will require multi-disciplinary interaction and collaboration among scientific investigators, oncologists, statisticians, and clinical laboratory scientists. This FOA is not intended to support early-stage development of technology or the conduct of clinical trials but is intended for validation of assays to the point where they could be integrated into clinical trials/studies as investigational assays.</p>			
106356	NCI Transition Career Development Award to Promote Diversity (K22 Independent Clinical Trial Not Allowed)	National Cancer Institute/NIH/DHHS	PAR-21-301	12-Jun-2022	Not Specified
	Contact Name	Mulualem E. Tilahun, D.V.M., Ph.D			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Telephone 240-276-7360</p> <p>Contact Email mulualem.tilahun@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 12-Jun-2022 , 12-Oct-2022 , 12-Feb-2023 , 12-Jun-2023 , 12-Oct-2023 , 12-Feb-2024 , 12-Jun-2024</p> <p>Synopsis The purpose of the NCI Transition Career Development Award to Promote Diversity (K22) is to assist postdoctoral fellows or individuals in equivalent positions to transition to positions of assistant professor or equivalent and initiate a successful biomedical career as an independent research scientist. This Funding Opportunity Announcement (FOA) is a continuation of the NCI Transition Career Development Award to Promote Diversity (K22) to enhance the diversity in the NCI-funded cancer research workforce by supporting eligible individuals from diverse backgrounds, including groups that have been shown to be nationally underrepresented in the biomedical, behavioral, social and clinical sciences. This award will provide "protected time" through salary and research support for 3 years beginning at the time when the candidate starts a tenure-track faculty position. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or a separate ancillary clinical trial. Applicants to this FOA are permitted to propose research experience in a clinical trial led by another investigator. Applicants proposing a clinical trial or a separate ancillary clinical trial as lead investigator, should apply to the companion FOA (PAR-21-302).</p>				
106354	<p>NCI Mentored Clinical Scientist Research Career Development Award to Promote Diversity (K08 Clinical Trial Required)</p>	National Cancer Institute/NIH/DHHS	PAR-21-299	12-Jun-2022	Not Specified
	<p>Contact Name Mulualem E. Tilahun, D.V.M., Ph.D</p> <p>Contact Telephone 240-276-7360</p> <p>Contact Email mulualem.tilahun@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 12-Jun-2022 , 12-Oct-2022 , 12-Feb-2023 , 12-Jun-2023 , 12-Oct-2023 , 12-Feb-2024 , 12-Jun-2024</p> <p>Synopsis The purpose of the NCI Mentored Clinical Scientist Career Development Award (K08) program is to prepare individuals for careers that have a significant impact on the health-related research needs of the nation. This program represents the continuation of a long-standing NIH program that provides support and protected time to individuals with a clinical doctoral degree or a health professional doctoral degree for an intensive, supervised research career development experience in the fields of biomedical and behavioral research, including translational research. This NCI-sponsored K08 award is specifically designed to enhance the diversity in the NCI-funded cancer research workforce by supporting eligible clinical scientists from</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

diverse backgrounds, including groups that have been shown to be nationally underrepresented in health-related sciences and for those who are committed to a career in basic biomedical, behavioral or translational cancer research, including research on cancer health disparities. The expectation is that through this sustained period of research career development and training, awardees will develop enhanced research capabilities for cancer research careers and be better prepared to compete for research project grants (e.g. R03, R21, or R01) funding. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary clinical trial, as part of their research and career development. Applicants not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must apply to companion FOA (PAR-21-300).

106355	NCI Mentored Clinical Scientist Research Career Development Award to Promote Diversity (K08 - Independent Clinical Trial Not Allowed)	National Cancer Institute/NIH/DHHS	PAR-21-300	12-Jun-2022	Not Specified
--------	---	------------------------------------	------------	-------------	---------------

Contact Name	Muluaem E. Tilahun, D.V.M., Ph.D
Contact Telephone	240-276-7360
Contact Email	muluaem.tilahun@nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	12-Jun-2022 , 12-Oct-2022 , 12-Feb-2023 , 12-Jun-2023 , 12-Oct-2023 , 12-Feb-2024 , 12-Jun-2024
Synopsis	<p>The purpose of the NCI Mentored Clinical Scientist Career Development Award (K08) program is to prepare individuals for careers that have a significant impact on the health-related research needs of the nation. This program represents the continuation of a long-standing NIH program that provides support and protected time to individuals with a clinical doctoral degree or a health professional doctoral degree for an intensive, supervised research career development experience in the fields of biomedical and behavioral research, including translational research. This NCI-sponsored K08 award is specifically designed to enhance the diversity in the NCI-funded cancer research workforce by supporting eligible clinical scientists from diverse backgrounds, including groups that have been shown to be nationally underrepresented in health-related sciences and for those who are committed to a career in basic biomedical, behavioral or translational cancer research, including research on cancer health disparities. The expectation is that through this sustained period of research career development and training, awardees will develop enhanced research capabilities for cancer research careers and be better prepared to compete for research project grants (e.g. R03, R21, or R01) funding. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or a separate ancillary clinical trial. Applicants to this FOA are permitted to propose research</p>

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		experience in a clinical trial led by a mentor or co-mentor. Applicants proposing a clinical trial or a separate ancillary clinical trial as lead investigator, should apply to the companion FOA (PAR-21-299).			
106228	NCI Mentored Research Scientist Development Award to Promote Diversity (K01 Independent Clinical Trial Not Allowed)	National Cancer Institute/NIH/DHHS	PAR-21-295	12-Jun-2022	Not Specified
	Contact Name	Muluaem E. Tilahun, D.V.M., Ph.D			
	Contact Telephone	240-276-7360			
	Contact Email	muluaem.tilahun@nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	12-Jun-2022 , 12-Oct-2022 , 12-Feb-2023 , 12-Jun-2023 , 12-Oct-2023 , 12-Feb-2024 , 12-Jun-2024 , 12-Oct-2024			
	Synopsis	This Funding Opportunity Announcement (FOA) is a continuation of the NCI Mentored Research Scientist Development Award to Promote Diversity (K01) to enhance the diversity in the NCI-funded cancer research workforce by supporting eligible individuals from diverse backgrounds, including groups that have been shown to be nationally underrepresented in the biomedical, behavioral, social and clinical sciences. This FOA provides salary and research support for a sustained period of "protected time" for intensive research career development under the guidance of an experienced mentor. This FOA is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or a separate ancillary clinical trial. Applicants to this FOA are permitted to propose research experience in a clinical trial led by a mentor or co-mentor. Applicants proposing a clinical trial or a separate ancillary clinical trial as lead investigator, should apply to the companion FOA.			
106230	NCI Mentored Research Scientist Development Award to Promote Diversity (K01 Clinical Trial Required)	National Cancer Institute/NIH/DHHS	PAR-21-296	12-Jun-2022	Not Specified
	Contact Name	Muluaem E. Tilahun, D.V.M., Ph.D			
	Contact Telephone	240-276-7360			
	Contact Email	muluaem.tilahun@nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	12-Jun-2022 , 12-Oct-2022 , 12-Feb-2023 , 12-Jun-2023 , 12-Oct-2023 , 12-Feb-2024 , 12-Jun-2024 , 12-Oct-2024			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Synopsis	<p>This Funding Opportunity Announcement (FOA) is a continuation of the NCI Mentored Research Scientist Development Award to Promote Diversity (K01) to enhance the diversity in the NCI-funded cancer research workforce by supporting eligible individuals from diverse backgrounds, including groups that have been shown to be nationally underrepresented in the biomedical, behavioral, social and clinical sciences. This FOA provides salary and research support for a sustained period of "protected time" for intensive research career development under the guidance of an experienced mentor. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary clinical trial, as part of their research and career development. Applicants not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must apply to the companion FOA.</p>			
106358	NCI Transition Career Development Award to Promote Diversity (K22 Clinical Trial Required)	National Cancer Institute/NIH/DHHS	PAR-21-302	12-Jun-2022	Not Specified
	Contact Name	Muluaem E. Tilahun, D.V.M., Ph.D			
	Contact Telephone	240-276-7360			
	Contact Email	muluaem.tilahun@nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	12-Jun-2022 , 12-Oct-2022 , 12-Feb-2023 , 12-Jun-2023 , 12-Oct-2023 , 12-Feb-2024 , 12-Jun-2024			
	Synopsis	<p>The purpose of the NCI Transition Career Development Award to Promote Diversity (K22) is to assist postdoctoral fellows or individuals in equivalent positions to transition to positions of assistant professor or equivalent and initiate a successful biomedical career as an independent research scientist. This Funding Opportunity Announcement (FOA) is a continuation of the NCI Transition Career Development Award to Promote Diversity (K22) to enhance the diversity in the NCI-funded cancer research workforce by supporting eligible individuals from diverse backgrounds, including groups that have been shown to be nationally underrepresented in the biomedical, behavioral, social and clinical sciences. This award will provide "protected time" through salary and research support for 3 years beginning at the time when the candidate starts a tenure-track faculty position. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary clinical trial, as part of their research and career development. Applicants not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must apply to companion FOA (PAR-21-301).</p>			
102792	The NCI Transition Career Development Award (K22 Independent Basic Experimental Studies with Humans Required)	National Cancer Institute/NIH/DHHS	PAR-21-318	12-Jun-2022	450,000 USD

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Name Sonia B. Jakowlew, Ph.D.</p> <p>Contact Telephone 240-276-5630</p> <p>Contact Email jakowles@mail.nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 12-Jun-2022 , 12-Oct-2022 , 12-Feb-2023 , 12-Jun-2023 , 12-Oct-2023 , 12-Feb-2024</p> <p>Synopsis This Funding Opportunity Announcement (FOA) represents the continuation of an NCI program to facilitate the transition of investigators in mentored, non-independent cancer research positions to independent faculty cancer research positions. This goal is achieved by providing protected time through salary and research support for the initial 3 years of the first independent tenure-track faculty position, or its equivalent, beginning at the time when the candidate starts a tenure-track faculty position. This FOA is designed specifically for basic science experimental studies involving humans, referred to in NOT-OD-18-212 as "prospective basic science studies involving human participants." These studies fall within the NIH definition of a clinical trial and also meet the definition of basic research. Types of studies that should submit under this FOA include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental aspects of phenomena without specific application towards processes or products in mind. Applicants planning studies with specific application toward processes or products in mind should submit under the "Independent Clinical Trial Required" companion FOA (PAR-21-111). Applicants not planning an independent clinical trial, a clinical trial feasibility study, or a separate ancillary clinical trial or independent basic experimental study with humans, must apply to the "Independent Clinical Trial Not Allowed" companion FOA (PAR-21-128).</p>				
102781	The NCI Transition Career Development Award (K22 - Independent Clinical Trial Required)	National Cancer Institute/NIH/DHHS	PAR-21-128	12-Jun-2022	450,000 USD
	<p>Contact Name Sonia B. Jakowlew, Ph.D.</p> <p>Contact Telephone 240-276-5630</p> <p>Contact Email jakowles@mail.nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 12-Jun-2022 , 12-Oct-2022 , 12-Feb-2023 , 12-Jun-2023 , 12-Oct-2023 , 12-Feb-2024</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Synopsis	<p>This Funding Opportunity Announcement (FOA) represents the continuation of an NCI program to facilitate the transition of investigators in mentored, non-independent cancer research positions to independent faculty cancer research positions. This goal is achieved by providing protected time through salary and research support for the initial 3 years of the first independent tenure-track faculty position, or its equivalent, beginning at the time when the candidate starts a tenure-track faculty position. This FOA is designed specifically for candidates proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary study to a clinical trial. Applicants proposing a clinical trial, a clinical trial feasibility study, or an ancillary study to an ongoing clinical trial as lead investigator, should apply to the companion FOAs (PAR-21-111 or PAR-21-318).</p>			
109178	RFA-RM-22-008 -- NIH Faculty Institutional Recruitment for Sustainable Transformation (FIRST) Program: FIRST Cohort (U54 Clinical Trial Optional)	National Cancer Institute/NIH/DHHS	RFA-RM-22-008	12-Jun-2022 [Optional][LOI/Pre-App]	10,245,000 USD
	Contact Name	Jessica M. Calzola, Ph.D.			
	Contact Telephone	240-276-7474			
	Contact Email	FIRSTNIH@nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	12-Jun-2022 [Optional][LOI/Pre-App], 12-Jul-2022			
	Synopsis	<p>The purpose of the FIRST Cohort is to transform culture at NIH-funded extramural institutions by building a self-reinforcing community of scientists committed to diversity and inclusive excellence (defined below). Implementing and sustaining cultures of inclusive excellence within the program has the potential to be transformational for biomedical research at the recipient institutions and beyond. This community will be built through recruitment of individuals who: are competitive for an advertised research tenure-track or equivalent faculty position (positions must be at the Assistant Professor (or equivalent) level), meet the criteria for NIH-defined Early Stage Investigators, and have demonstrated a strong commitment to promoting diversity and inclusive excellence.</p>			
102778	The NCI Transition Career Development Award (K22 - Independent Clinical Trial Required)	National Cancer Institute/NIH/DHHS	PAR-21-111	12-Jun-2022	450,000 USD
	Contact Name	Sonia B. Jakowlew, Ph.D.			
	Contact Telephone	240-276-5630			
	Contact Email	jakowles@mail.nih.gov			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 12-Jun-2022 , 12-Oct-2022 , 12-Feb-2023 , 12-Jun-2023 , 12-Oct-2023 , 12-Feb-2024</p> <p>Synopsis This Funding Opportunity Announcement (FOA) represents the continuation of an NCI program to facilitate the transition of investigators in mentored, non-independent cancer research positions to independent faculty cancer research positions. This goal is achieved by providing protected time through salary and research support for the initial 3 years of the first independent tenure-track faculty position, or its equivalent, beginning at the time when the candidate starts a tenure-track faculty position. This FOA is designed specifically for candidates proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary clinical trial, as part of their research and career development. Applicants not planning an independent clinical trial, a clinical trial feasibility study, or a separate ancillary clinical trial must apply to the "Independent Clinical Trial Not Allowed companion FOA (PAR-21-128).</p>				
102905	Exploratory Grant Award to Promote Workforce Diversity in Basic Cancer Research (R21 Clinical Trial Not Allowed)	National Cancer Institute/NIH/DHHS	PAR-21-061	14-Jun-2022	275,000 USD
	<p>Contact Name Mauricio Rangel-Gomez, Ph.D.</p> <p>Contact Telephone 240-620-0534</p> <p>Contact Email Mauricio.Rangel-Gomez@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 14-Jun-2022 , 17-Nov-2022 , 14-Jun-2023 , 17-Nov-2023</p> <p>Synopsis This Funding Opportunity Announcement (FOA) is a continuation of an NCI program to enhance the diversity of the pool of the cancer research workforce by recruiting and supporting eligible New Investigators and Early Stage Investigators from diverse backgrounds, including from groups that have been shown to be nationally underrepresented in the biomedical, behavioral, clinical and social sciences. This FOA will fund investigators to develop a larger research project grant application.</p>				
108550	Epidemiologic Research on Emerging Risk Factors and Liver Cancer Susceptibility (R21 Clinical Trial Not Allowed)	National Cancer Institute/NIH/DHHS	PAR-22-084	16-Jun-2022	275,000 USD
	<p>Contact Name Tram Kim Lam, Ph.D., MPH</p> <p>Contact Telephone 240-276-6967</p> <p>Contact Email Tram.Lam@nih.gov</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 16-Jun-2022 , 16-Oct-2022 , 16-Feb-2023 , 16-Jun-2023 , 16-Oct-2023 , 16-Feb-2024 , 16-Jun-2024 , 16-Oct-2024 , 16-Feb-2025</p> <p>Synopsis The purpose of this Funding Opportunity Announcement (FOA) is to promote epidemiologic research investigating novel and innovative hypotheses on emerging risk factors (biological, environmental, and social) and their interplay with established risk factors (e.g., viral hepatitis) associated with the development of liver cancer (hepatocellular carcinoma and other histological subtypes) in the United States.</p>				
087229	Co-infection and Cancer (R21 Clinical Trial Not Allowed)	National Cancer Institute/NIH/DHHS	PAR-20-061	16-Jun-2022	275,000 USD
	<p>Contact Name Tram Kim Lam, Ph.D., MPH</p> <p>Contact Telephone 240-276-6967</p> <p>Contact Email lamt@mail.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 16-Jun-2022 , 16-Oct-2022</p> <p>Synopsis The purpose of this Funding Opportunity Announcement (FOA) is to enhance mechanistic and epidemiologic investigations addressing the roles of co-infection. Co-infection is defined as the occurrence of infections by two or more infectious (pathogenic or non-pathogenic) agents – either concurrently or sequentially – and includes both acute and chronic infections by viruses, bacteria, parasites, and/or other microorganisms. Preference will be given to investigations of co-infections with known oncogenic agents (excluding human immunodeficiency virus [HIV]) and of co-infections that engender novel opportunities for prevention and treatment.</p>				
085337	Linking the Provider Recommendation to Adolescent HPV Vaccine Uptake (R21 Clinical Trial Optional)	National Cancer Institute/NIH/DHHS	PAR-19-358	16-Jun-2022	275,000 USD
	<p>Contact Name Sarah Kobrin, Ph.D., MPH</p> <p>Contact Telephone 240-276-6931</p> <p>Contact Email kobrins@mail.nih.gov</p> <p>Sponsor Website</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 16-Jun-2022</p> <p>Synopsis This Funding Opportunity Announcement (FOA) encourages research on how the healthcare delivery system enhances or inhibits the effectiveness of a provider's recommendation of the adolescent human papillomavirus (HPV) vaccine. Characteristics of the provider, parent/patient, and clinical setting, can all affect whether a provider makes a recommendation, and whether that recommendation results in uptake of the HPV vaccine. This research requires expertise in cancer prevention, adult and childhood behavior, immunization promotion, and healthcare delivery.</p>				
085343	Linking the Provider Recommendation to Adolescent HPV Vaccine Uptake (R03 Clinical Trial Optional)	National Cancer Institute/NIH/DHHS	PAR-19-359	16-Jun-2022	100,000 USD
	<p>Contact Name Sarah Kobrin, Ph.D., MPH</p> <p>Contact Telephone 240-276-6931</p> <p>Contact Email kobrins@mail.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 16-Jun-2022</p> <p>Synopsis This Funding Opportunity Announcement (FOA) encourages research on how the healthcare delivery system enhances or inhibits the effectiveness of a provider's recommendation of the adolescent human papillomavirus (HPV) vaccine. Characteristics of the provider, parent/patient, and clinical setting, can all affect whether a provider makes a recommendation and whether that recommendation results in uptake of the HPV vaccine. This research requires expertise in cancer prevention, adult and childhood behavior, immunization promotion, and healthcare delivery.</p>				
099631	Tobacco Control Policies to Promote Health Equity (R21 Clinical Trial Optional)	National Cancer Institute/NIH/DHHS	PAR-20-303	16-Jun-2022	275,000 USD
	<p>Contact Name Bob Vollinger, DrPH, MSPH</p> <p>Contact Telephone 240-276-6919</p> <p>Contact Email Bob.Vollinger@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 16-Jun-2022 , 16-Oct-2022 , 16-Feb-2023 , 16-Jun-2023</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Synopsis	<p>The purpose of this Funding Opportunity Announcement (FOA) is to support observational or intervention research focused on reducing disparities in tobacco use and secondhand smoke (SHS) exposure in the U.S. Specifically, this FOA aims to stimulate scientific inquiry focused on innovative state and local level tobacco prevention and control policies. The long-term goal of this FOA is to reduce disparities in tobacco-related cancers, and in doing so, to promote health equity among all populations. Applicants submitting applications related to health economics are encouraged to consult NOT-OD-16-025 to ensure that the research projects align with NIH mission priorities in health economics research.</p>			
106264	Basic Research in Cancer Health Disparities (R21 Clinical Trial Not Allowed)	National Cancer Institute/NIH/DHHS	PAR-21-323	16-Jun-2022	400,000 USD
	Contact Name	Anu Sharman, Ph.D.			
	Contact Telephone	240-276-6250			
	Contact Email	sharmananu@nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	16-Jun-2022 , 16-Jul-2022 , 16-Oct-2022 , 16-Nov-2022 , 16-Feb-2023 , 16-Mar-2023 , 16-Jun-2023 , 16-Jul-2023 , 16-Oct-2023 , 16-Nov-2023 , 16-Feb-2024 , 16-Mar-2024 , 16-Jun-2024 , 16-Jul-2024			
	Synopsis	<p>National Cancer Institute (NCI) invites applications from investigators interested in conducting basic, mechanistic research into the biological/genetic causes of cancer health disparities. These research project grants (R01) will support innovative studies designed to investigate biological/genetic bases of cancer disparities, such as (1) mechanistic studies of biological factors associated with cancer disparities, including those related to basic research in cancer biology or cancer prevention strategies, (2) the development and testing of new methodologies and models, and (3) secondary data analyses. This FOA is also designed to aid and facilitate the growth of a nationwide cohort of scientists with a high level of basic research expertise in cancer health disparities research who can expand available resources and tools, such as biospecimens, patient derived models, and methods that are necessary to conduct basic research in cancer health disparities.</p>			
106265	Basic Research in Cancer Health Disparities (R03 Clinical Trial Not Allowed)	National Cancer Institute/NIH/DHHS	PAR-21-324	16-Jun-2022	100,000 USD
	Contact Name	Anu Sharman, Ph.D.			
	Contact Telephone	240-276-6250			
	Contact Email	sharmananu@nih.gov			
	Sponsor Website				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 16-Jun-2022 , 16-Jul-2022 , 16-Oct-2022 , 16-Nov-2022 , 16-Feb-2023 , 16-Mar-2023 , 16-Jun-2023 , 16-Jul-2023 , 16-Oct-2023 , 16-Nov-2023 , 16-Feb-2024 , 16-Mar-2024 , 16-Jun-2024 , 16-Jul-2024</p> <p>Synopsis This Funding Opportunity Announcement (FOA) encourages grant applications from investigators interested in conducting basic, mechanistic research into the biological/genetic causes of cancer health disparities. These small research grants (R03) will support projects on cancer health disparities that can be carried out in a short period of time with limited resources. The projects should propose innovative studies designed to investigate biological/genetic bases of cancer disparities, such as (1) mechanistic studies of biological factors associated with cancer disparities, including those related to basic research in cancer biology or cancer prevention strategies, (2) the development and testing of new methodologies and models, and (3) secondary data analyses.</p>				
106283	Mechanisms that Impact Cancer Risk after Bariatric Surgery (R21 Clinical Trial Not Allowed)	National Cancer Institute/NIH/DHHS	PAR-21-332	16-Jun-2022	550,000 USD
	<p>Contact Name Edward R. Sauter, M.D., Ph.D.</p> <p>Contact Telephone 240-276-7657</p> <p>Contact Email edward.sauter@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 16-Jun-2022 , 16-Jul-2022 , 16-Oct-2022 , 16-Nov-2022 , 16-Feb-2023 , 16-Mar-2023 , 16-Jun-2023 , 16-Jul-2023 , 16-Oct-2023 , 16-Nov-2023 , 16-Feb-2024 , 16-Mar-2024 , 16-Jun-2024 , 16-Jul-2024</p> <p>Synopsis Through this Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI) invites applications for support of investigator-initiated studies addressing mechanisms by which bariatric surgery impacts cancer risk, and seeks to draw in talented scientists who study bariatric surgery to investigate its effects on cancer, rather than shorter term outcomes such as weight loss and diabetes.</p>				
085275	Intervening with Cancer Caregivers to Improve Patient Health Outcomes and Optimize Health Care Utilization (R21 Clinical Trial Optional)	National Cancer Institute/NIH/DHHS	PAR-19-355	16-Jun-2022	275,000 USD
	<p>Contact Name Michelle Mollica, PhD, MPH, RN, OCN</p> <p>Contact Telephone 240-276-7621</p> <p>Contact Email michelle.mollica@nih.gov</p> <p>Sponsor Website</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 16-Jun-2022</p> <p>Synopsis This Funding Opportunity Announcement (FOA) invites applications for intervention research designed to support caregivers of adult cancer patients. Interventions supported by this FOA are intended to provide caregivers with care training, promote coping skills, and ultimately help them manage care. Outcomes of such interventions are expected to (1) optimize patient health care utilization, (2) improve caregiver well-being, and (3) improve patient physical health and psychosocial outcomes</p>				
086150	Perception and Cognition Research to Inform Cancer Image Interpretation (R21 Clinical Trial Optional)	National Cancer Institute/NIH/DHHS	PAR-19-389	16-Jun-2022	400,000 USD
	<p>Contact Name Todd S. Horowitz, Ph.D.</p> <p>Contact Telephone 240-276-6963</p> <p>Contact Email todd.horowitz@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 16-Jun-2022 , 16-Oct-2022</p> <p>Synopsis The purpose of this Funding Opportunity Announcement (FOA) is to facilitate research on the perceptual and cognitive processes underlying the performance of cancer image observers in radiology and pathology, in order to improve the accuracy of cancer detection and diagnosis.</p>				
097241	Secondary Analysis and Integration of Existing Data to Elucidate the Genetic Architecture of Cancer Risk and Related Outcomes (R21 Clinical Trials Not Allowed)	National Cancer Institute/NIH/DHHS	PAR-20-277	16-Jun-2022	400,000 USD
	<p>Contact Name Melissa Rotunno, Ph.D.</p> <p>Contact Telephone 240-276-7245</p> <p>Contact Email rotunnom@mail.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 16-Jun-2022</p> <p>Synopsis Through this funding opportunity announcement (FOA), the National Cancer Institute (NCI) along with the National Human Genome Research Institute (NHGRI) and National Institute of Dental and Craniofacial Research (NIDCR) encourages</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>submission of applications proposing to conduct secondary data analysis and integration of existing datasets and database resources, with the ultimate aim to elucidate the genetic architecture of cancer risk and related outcomes (e.g., risk prediction or reduction, survival, or response to treatment, etc.). The goal of this initiative is to address key scientific questions relevant to cancer genomic and epidemiology by supporting the analysis of existing genetic or genomic datasets, in combination with other omics and environmental, clinical, behavioral, lifestyle, and molecular profiles data. Applicants are encouraged to leverage existing genetic data and perform innovative analyses of the existing data.</p>				
108359	Exploratory/Developmental Bioengineering Research Grants (EBRG) (R21 Clinical Trial Optional)	National Cancer Institute/NIH/DHHS	PAR-22-091	16-Jun-2022	275,000 USD
	Contact Name	Miguel R. Ossandon, Ph.D.			
	Contact Telephone	240-276-5714			
	Contact Email	ossandom@mail.nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	16-Jun-2022 , 16-Oct-2022 , 16-Feb-2023 , 16-Jun-2023 , 16-Oct-2023 , 16-Feb-2024 , 16-Jun-2024 , 16-Oct-2024			
	Synopsis	<p>The purpose of this engineering-oriented funding opportunity announcement (FOA) is to encourage submissions of exploratory/developmental Bioengineering Research Grant (EBRG) applications to demonstrate feasibility and potential utility of new capabilities or improvements in quality, speed, efficacy, operability, costs, and/or accessibility of solutions to problems in basic biomedical, pre-clinical, or clinical research, clinical care delivery, or accessibility. This FOA will support clinical trials that test functionality or validate performance in the chosen setting. Applications that propose phase III clinical trials in any area of cancer research are not sought by and will not be supported through this FOA</p>			
107222	Modulating Human Microbiome Function to Enhance Immune Responses Against Cancer (R21 Clinical Trial Not Allowed)	National Cancer Institute/NIH/DHHS	PAR-22-062	16-Jun-2022	275,000 USD
	Contact Name	Phillip J. Daschner, M.Sc.			
	Contact Telephone	240-276-6227			
	Contact Email	PD93u@nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	16-Jun-2022 , 16-Oct-2022 , 16-Feb-2023 , 16-Jun-2023 , 16-Oct-2023 , 16-Feb-2024 , 16-Jun-2024 , 16-Oct-2024			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Synopsis	The purpose of this Funding Opportunity Announcement (FOA) is to support basic research that elucidates mechanisms by which the human microbiome inhibits or enhances anti-tumor immune responses, and to identify potential novel molecular targets for cancer prevention strategies. Applications should be focused on delineating how host interactions with specific microbes (or consortia) or their metabolites target immune responses that enhance or prevent inflammation-associated or sporadic tumor formation. Concentration, timing, and duration of administered beneficial microbes may alter their effectiveness and thus those parameters should be rigorously addressed in the application.			
109910	Systematic Testing of Radionuclides in Preclinical Experiments (STRIPE) (R21 Clinical Trial Not Allowed)	National Cancer Institute/NIH/DHHS	PAR-22-140	16-Jun-2022	275,000 USD
	Contact Name	Michael Graham Espey, Ph.D.			
	Contact Telephone	240-276-7619			
	Contact Email	SP@nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	16-Jun-2022 , 16-Oct-2022 , 16-Feb-2023 , 16-Jun-2023 , 16-Oct-2023 , 16-Feb-2024 , 16-Jun-2024 , 16-Oct-2024 , 16-Feb-2025			
	Synopsis	The purpose of this Funding Opportunity Announcement (FOA) is to solicit R21 research projects utilizing state-of-the-art cancer biology methods and model systems to study effects of different types of radiation used in radionuclide-based therapeutics (e.g., radiopharmaceutical therapy) on normal tissue, tumor cells and the tumor microenvironment.			
098641	NCI Clinical and Translational Exploratory/Developmental Studies (R21 Clinical Trial Optional)	National Cancer Institute/NIH/DHHS	PAR-20-292	21-Jun-2022	275,000 USD
	Contact Name	William C. Timmer, Ph.D			
	Contact Telephone	240-276-6130			
	Contact Email	william.timmer@nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	21-Jun-2022 , 21-Jun-2022 , 20-Jul-2022			
	Synopsis	This Funding Opportunity Announcement (FOA) supports preclinical and early phase clinical research, as well as correlative studies, directly related to advancements in cancer treatment, diagnosis, prevention, symptom management, or reduction			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

of cancer health disparities. This includes (but is not limited to) development and testing of the following: new molecular agents or biologics for cancer treatment; management strategies for cancer-related symptoms or treatment-related toxicity; cancer screening or diagnostic tools, such as imaging techniques; cancer preventive agents or approaches; predictive and prognostic biomarkers for patient selection or stratification; clinically relevant in vivo or in vitro tumor models (including genetically engineered mouse models, patient-derived xenograft models, organoids, and cell lines); and strategies to address therapeutic outcome disparities among diverse racial/ethnic populations. In addition to novel agents, new treatment strategies may involve repurposed agents or novel combinations of interventions (including radiation), based on established mechanisms of action. Comparative oncology studies in dogs investigating strategies for treatment and diagnosis of human disease are supported as well. This FOA does not support research that focuses on basic cancer biology (such as studies of cancer-related pathways or molecular mechanisms), late-stage clinical trials, risk assessment studies, epidemiological studies, or studies of behavioral interventions. These applications will be deemed not responsive to this FOA and will not be reviewed (see below for a more detailed description of studies that are not responsive for this FOA). The R21 mechanism is intended to encourage exploratory and developmental research projects by providing support for the early and conceptual stages of these projects. These studies may involve considerable risk but may lead to breakthroughs in particular areas, or to the development of novel techniques, agents, methodologies, models, or applications that could have a major impact on cancer research (preclinical or clinical).

091405	Investigator Initiated Clinical Trials of Complementary and Integrative Interventions Delivered Remotely or via mHealth (R01 Clinical Trial Required)	National Center for Complementary and Integrative Health/NIH/DHHS	PAR-20-154	07-May-2022	Not Specified
--------	---	---	------------	-------------	---------------

Contact Name	Lanay Mudd, Ph.D
Contact Telephone	301-594-9346
Contact Email	lanay.mudd@mail.nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	07-May-2022 , 05-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 07-May-2023
Synopsis	This Funding Opportunity Announcement (FOA) encourages applications for investigator-initiated fully remotely delivered and conducted clinical trials to assess the efficacy or effectiveness of complementary and integrative health interventions in NCCIH designated areas of high research priority. Applications submitted under this FOA are expected to propose a remotely delivered and conducted clinical trial with no in-person contact between research staff and study participants and may utilize mHealth tools or technologies. To justify the proposed remotely delivered efficacy or effectiveness clinical trial, applications must have sufficient preliminary data that includes: demonstration of feasibility of remote recruitment and

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

accrual of participants; demonstration of participant adherence to the intervention as well as retention of participants throughout the study; completion of final data collection from any related studies; demonstration of the safety of the intervention; and evidence that the intervention has promise of clinical benefit. Applicants are encouraged to contact the appropriate NCCIH Scientific/Research contact for the area of science for which they are planning to develop an application prior to submitting to this FOA.

102903	Notice of Special Interest (NOSI): Fundamental Science Research on Complementary and Integrative Health Approaches	National Center for Complementary and Integrative Health/NIH/DHHS	NOT-AT-21-006	07-May-2022	Not Specified
--------	--	---	---------------	-------------	---------------

Contact Name	Wen Chen, M.M.Sc., Ph.D.
Contact Telephone	301-451-3989
Contact Email	chenw@mail.nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	07-May-2022 , 05-Jun-2022 , 16-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 16-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 16-Feb-2023 , 07-May-2023 , 05-Jun-2023 , 16-Jun-2023 , 07-Sep-2023 , 05-Oct-2023 , 16-Oct-2023 , 07-Jan-2024 , 05-Feb-2024 , 16-Feb-2024 , 07-May-2024 , 05-Jun-2024 , 16-Jun-2024 , 07-Sep-2024
Synopsis	The purpose of this Notice of Special Interest (NOSI) is to describe NCCIH priorities in innovative basic and mechanistic research or technology/method development research relevant to complementary and integrative health approaches.

107999	Notice of Special Interest (NOSI): NCCIH High Priority Pain Research	National Center for Complementary and Integrative Health/NIH/DHHS	NOT-AT-22-007	07-May-2022	Not Specified
--------	--	---	---------------	-------------	---------------

Contact Name	Inna Belfer, Ph.D.
Contact Telephone	301-435-1573
Contact Email	inna.belfer@nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	07-May-2022 , 05-Jun-2022 , 16-Jun-2022 , 20-Jun-2022 , 25-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 16-Oct-2022 , 19-Oct-2022 , 25-Oct-2022

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p style="text-align: center;">Synopsis The National Center for Complementary and Integrative Health (NCCIH) is inviting applications to focus on the following pain related research topic areas in response to this NOTICE.</p>				
107544	Notice of Special Interest (NOSI): Administrative Supplements on High Priority Topic Areas for NCCIH Grants	National Center for Complementary and Integrative Health/NIH/DHHS	NOT-AT-22-002	01-Jun-2022	100,000 USD
	<p style="text-align: center;">Contact Name</p> <p style="text-align: center;">Contact Telephone</p> <p style="text-align: center;">Contact Email</p> <p style="text-align: center;">Sponsor Website</p> <p style="text-align: center;">Program URL Link to program URL</p> <p style="text-align: center;">Deadline Dates (ALL) 01-Jun-2022</p> <p style="text-align: center;">Synopsis The National Center for Complementary and Integrative Health (NCCIH) announces the availability of funds for one-year Administrative Supplements to promote or support high priority topic areas in NCCIH grants by expanding ongoing basic, translational, technological, or clinical studies in the context of complementary and integrative approaches. Active awards with project end dates in FY 2023 or later are eligible. The award may not be in a terminal no-cost extension or going into a no-cost extension in FY 2022.</p>				
094929	Clinical Coordinating Center for NCCIH Multi-Site Investigator-Initiated Clinical Trials of Natural Products (Collaborative UG3/UH3 Clinical Trial Required)	National Center for Complementary and Integrative Health/NIH/DHHS	PAR-20-215	01-Jun-2022	Not Specified
	<p style="text-align: center;">Contact Name Wendy Weber, N.D., Ph.D, M.P.H.</p> <p style="text-align: center;">Contact Telephone 301-402-1272</p> <p style="text-align: center;">Contact Email weberwj@mail.nih.gov</p> <p style="text-align: center;">Sponsor Website</p> <p style="text-align: center;">Program URL Link to program URL</p> <p style="text-align: center;">Deadline Dates (ALL) 01-Jun-2022 , 07-Sep-2022 , 01-Feb-2023 , 07-May-2023</p> <p style="text-align: center;">Synopsis This Funding Opportunity Announcement (FOA) encourages cooperative agreement applications for investigator-initiated, multi-site, clinical trials (Phase III and beyond) to study the effects of natural products in NCCIH designated areas of high research priority. Applicants should describe plans for a Clinical Coordinating Center to develop and implement the</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

proposed multi-site clinical trial. The objective of the Clinical Coordinating Center is to provide the design scientific rationale and a comprehensive scientific and operational plan for the clinical trial. The Clinical Coordinating Center is expected to be responsible for project management, participant recruitment and retention strategies, performance milestones, scientific conduct, and dissemination of results. Clinical Coordinating Center applications submitted under this FOA will utilize a two-phase, milestone-driven, cooperative agreement (UG3/UH3) funding mechanism. In addition, an accompanying Data Coordinating Center application, submitted under PAR-20-219, proposing a data analysis and data management plan for the clinical project is required. Both a Clinical Coordinating Center application and a corresponding Data Coordinating Center (DCC) application need to be submitted simultaneously for consideration by NCCIH.

094930	NCCIH Natural Product Mid Phase Clinical Trial Cooperative Agreement (U01 Clinical Trial Required)	National Center for Complementary and Integrative Health/NIH/DHHS	PAR-20-216	01-Jun-2022	1,750,000 USD
--------	--	---	------------	-------------	---------------

Contact Name	Wendy Weber, N.D., Ph.D, M.P.H.
Contact Telephone	301-402-1272
Contact Email	weberwj@mail.nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	01-Jun-2022 , 07-Sep-2022 , 01-Feb-2023 , 07-May-2023

Synopsis

This Funding Opportunity Announcement (FOA) invites cooperative agreement applications for investigator-initiated mid-phase clinical trials of natural products. All applications submitted under this FOA must be supported by sufficient preliminary data of bioavailability and documentation that the natural product produces a replicable and measurable impact on a biological signature (i.e., measure of the mechanism of action). Only in cases when it is not possible/practical to measure a biological signature in the patient population of interest or when there is a fundamental understanding of the product's mechanism of action will this preliminary data requirement be waived. Applications submitted to this FOA should propose a mid-phase clinical trial to do the following: determine the optimal dose or formulation of a given natural product for use in a future multi-site clinical trial; or determine which patient phenotypes will be responders versus non-responders to the natural product to inform inclusion/exclusion criteria of a future efficacy study. Clinical trials submitted under this FOA are expected to be hypothesis based, milestone-driven, and directly related to the research priorities and mission of NCCIH. This FOA will not support single-site or multi-site efficacy or effectiveness trials, nor will it support trials to test natural products for the treatment or prevention of cancer. Applicants are encouraged to contact the appropriate NCCIH Scientific/Research contact for the area of science for which they are planning to develop an application prior to submitting to this FOA.

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount														
094934	Natural Product Multi-Site Clinical Trial Data Coordinating Center (Collaborative U24 Clinical Trial Required)	National Center for Complementary and Integrative Health/NIH/DHHS	PAR-20-219	01-Jun-2022	Not Specified														
	<table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 20%; vertical-align: top;">Contact Name</td> <td>Wendy Weber, N.D., Ph.D, M.P.H.</td> </tr> <tr> <td style="vertical-align: top;">Contact Telephone</td> <td>301-402-1272</td> </tr> <tr> <td style="vertical-align: top;">Contact Email</td> <td>weberwj@mail.nih.gov</td> </tr> <tr> <td style="vertical-align: top;">Sponsor Website</td> <td></td> </tr> <tr> <td style="vertical-align: top;">Program URL</td> <td>Link to program URL</td> </tr> <tr> <td style="vertical-align: top;">Deadline Dates (ALL)</td> <td>01-Jun-2022 , 07-Sep-2022 , 01-Feb-2023 , 07-May-2023</td> </tr> <tr> <td style="vertical-align: top;">Synopsis</td> <td>This Funding Opportunity Announcement (FOA), utilizing the U24 grant funding mechanism, encourages applications for a collaborating Data Coordinating Center (DCC) application that accompanies an investigator-initiated multi-site clinical trial (Phase III and beyond) application submitted under PAR-20-215 The DCC application must be specific to the collaborating Clinical Coordinating Center (CCC) application. The objective of the DCC application is to propose a comprehensive plan that provides overall project coordination, and administrative, data management, and biostatistical support for the proposed clinical trial. Both a DCC application and a corresponding CCC application need to be submitted simultaneously for consideration by NCCIH. Trials for which this FOA applies must be relevant to the research mission of the NCCIH and considered a high priority by the Center. For additional information about the mission, strategic vision, and research priorities of the NCCIH, applicants are encouraged to consult the NCCIH website: (http://www.nccih.nih.gov). Applicants are strongly encouraged to contact the appropriate Scientific/Research contact for the area of science for which they are planning to develop an application prior to submitting to this FOA.</td> </tr> </table>					Contact Name	Wendy Weber, N.D., Ph.D, M.P.H.	Contact Telephone	301-402-1272	Contact Email	weberwj@mail.nih.gov	Sponsor Website		Program URL	Link to program URL	Deadline Dates (ALL)	01-Jun-2022 , 07-Sep-2022 , 01-Feb-2023 , 07-May-2023	Synopsis	This Funding Opportunity Announcement (FOA), utilizing the U24 grant funding mechanism, encourages applications for a collaborating Data Coordinating Center (DCC) application that accompanies an investigator-initiated multi-site clinical trial (Phase III and beyond) application submitted under PAR-20-215 The DCC application must be specific to the collaborating Clinical Coordinating Center (CCC) application. The objective of the DCC application is to propose a comprehensive plan that provides overall project coordination, and administrative, data management, and biostatistical support for the proposed clinical trial. Both a DCC application and a corresponding CCC application need to be submitted simultaneously for consideration by NCCIH. Trials for which this FOA applies must be relevant to the research mission of the NCCIH and considered a high priority by the Center. For additional information about the mission, strategic vision, and research priorities of the NCCIH, applicants are encouraged to consult the NCCIH website: (http://www.nccih.nih.gov). Applicants are strongly encouraged to contact the appropriate Scientific/Research contact for the area of science for which they are planning to develop an application prior to submitting to this FOA.
Contact Name	Wendy Weber, N.D., Ph.D, M.P.H.																		
Contact Telephone	301-402-1272																		
Contact Email	weberwj@mail.nih.gov																		
Sponsor Website																			
Program URL	Link to program URL																		
Deadline Dates (ALL)	01-Jun-2022 , 07-Sep-2022 , 01-Feb-2023 , 07-May-2023																		
Synopsis	This Funding Opportunity Announcement (FOA), utilizing the U24 grant funding mechanism, encourages applications for a collaborating Data Coordinating Center (DCC) application that accompanies an investigator-initiated multi-site clinical trial (Phase III and beyond) application submitted under PAR-20-215 The DCC application must be specific to the collaborating Clinical Coordinating Center (CCC) application. The objective of the DCC application is to propose a comprehensive plan that provides overall project coordination, and administrative, data management, and biostatistical support for the proposed clinical trial. Both a DCC application and a corresponding CCC application need to be submitted simultaneously for consideration by NCCIH. Trials for which this FOA applies must be relevant to the research mission of the NCCIH and considered a high priority by the Center. For additional information about the mission, strategic vision, and research priorities of the NCCIH, applicants are encouraged to consult the NCCIH website: (http://www.nccih.nih.gov). Applicants are strongly encouraged to contact the appropriate Scientific/Research contact for the area of science for which they are planning to develop an application prior to submitting to this FOA.																		
104713	Clinical Coordinating Center for NCCIH Multi-Site Investigator-Initiated Clinical Trials of Mind and Body Interventions (Collaborative UG3/UH3 Clinical Trial Required)	National Center for Complementary and Integrative Health/NIH/DHHS	PAR-21-243	20-Jun-2022	Not Specified														
	<table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 20%; vertical-align: top;">Contact Name</td> <td>Lanay Mudd, Ph.D.</td> </tr> <tr> <td style="vertical-align: top;">Contact Telephone</td> <td>301-594-9346</td> </tr> <tr> <td style="vertical-align: top;">Contact Email</td> <td>lanay.mudd@nih.gov</td> </tr> <tr> <td style="vertical-align: top;">Sponsor Website</td> <td></td> </tr> <tr> <td style="vertical-align: top;">Program URL</td> <td>Link to program URL</td> </tr> </table>					Contact Name	Lanay Mudd, Ph.D.	Contact Telephone	301-594-9346	Contact Email	lanay.mudd@nih.gov	Sponsor Website		Program URL	Link to program URL				
Contact Name	Lanay Mudd, Ph.D.																		
Contact Telephone	301-594-9346																		
Contact Email	lanay.mudd@nih.gov																		
Sponsor Website																			
Program URL	Link to program URL																		

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Deadline Dates (ALL)	20-Jun-2022 , 22-Jul-2022 , 19-Oct-2022 , 14-Nov-2022 , 21-Feb-2023 , 10-Mar-2023 , 20-Jun-2023 , 22-Jul-2023 , 20-Oct-2023 , 14-Nov-2023 , 20-Feb-2024 , 11-Mar-2024			
	Synopsis	<p>This Funding Opportunity Announcement (FOA) encourages applications for investigator-initiated multi-site clinical trials (e.g. efficacy, effectiveness or pragmatic trials) to study the effects of complementary and integrative health approaches with physical and/or psychological therapeutic inputs (often called mind and body interventions) in NCCIH designated areas of high research priority. Clinical Coordinating Centers should develop and implement the proposed fully powered multi-site clinical trial. The objective of a Clinical Coordinating Center application is to present the scientific rationale and a comprehensive scientific and operational plan for the clinical trial. Clinical Coordinating Center applications are expected to describe plans for project management, participant recruitment and retention strategies, performance milestones, scientific conduct, and dissemination of results. Clinical Coordinating Center applications submitted under this FOA will utilize a two-phase, milestone-driven cooperative agreement (UG3/UH3) funding mechanism. In addition, an accompanying Data Coordinating Center application (U24), submitted under PAR-21-242 proposing a data analysis and data management plan for the clinical project is required. Both a Clinical Coordinating Center application and a corresponding Data Coordinating Center (DCC) application need to be submitted simultaneously for consideration by NCCIH. For additional information about the mission, strategic vision, and research priorities of the NCCIH, applicants are encouraged to consult the NCCIH website: (https://nccih.nih.gov/about/plans). Applicants are encouraged to contact the appropriate the Scientific/Research contact for the area of science for which they are planning to develop an application prior to submitting to this FOA.</p>			
104706	Feasibility Clinical Trials of Mind and Body Interventions for NCCIH High Priority Research Topics (R34 Clinical Trial Required)	National Center for Complementary and Integrative Health/NIH/DHHS	PAR-21-240	20-Jun-2022	450,000 USD
	Contact Name	Peter Murray, Ph.D.			
	Contact Telephone	301-496-4054			
	Contact Email	peter.murray@nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	20-Jun-2022 , 22-Jul-2022 , 19-Oct-2022 , 14-Nov-2022 , 21-Feb-2023 , 10-Mar-2023 , 20-Jun-2023 , 22-Jul-2023 , 20-Oct-2023 , 14-Nov-2023 , 20-Feb-2024 , 11-Mar-2024			
	Synopsis	<p>The goal of this funding opportunity is to support early phase clinical trials of complementary and integrative health approaches with physical and/or psychological therapeutic inputs (often called mind and body interventions) for conditions that have been identified by NCCIH as high priority research topics. This funding opportunity is intended to support feasibility clinical trials, which will provide data that are critical for the planning and design of a subsequent clinical efficacy</p>			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

or effectiveness study, or a pragmatic trial. The data collected should be used to fill gaps in scientific knowledge necessary to develop a competitive full-scale clinical trial, including, but not limited to the following: examining feasibility and acceptability of interventions lacking published data; adapting an intervention to a specific population; refining the intervention to determine the most appropriate frequency or duration; determining feasibility of recruitment, retention and data collection procedures; refining and assessing the feasibility of protocolized multimodal interventions; or examining acceptability and adherence of control conditions. This FOA will not support randomized clinical trials that test or determine efficacy or effectiveness; nor will this FOA support repetition of feasibility or acceptability research that has been previously conducted in the same or similar patient population with the same or similar intervention. Applications that propose solely to write a protocol or manual of operations or to develop infrastructure for a clinical trial are not appropriate for this announcement. Applications must propose to conduct a feasibility clinical trial. The subsequent larger trial should have the potential to make a significant impact on public health.

104712	Data Coordinating Center for NCCIH Multi-Site Investigator-Initiated Clinical Trials of Mind and Body Interventions (Collaborative U24 Clinical Trial Required)	National Center for Complementary and Integrative Health/NIH/DHHS	PAR-21-242	20-Jun-2022	Not Specified
--------	---	---	------------	-------------	---------------

Contact Name	Lanay Mudd, Ph.D.
Contact Telephone	301-594-9346
Contact Email	lanay.mudd@nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	20-Jun-2022 , 22-Jul-2022 , 19-Oct-2022 , 14-Nov-2022 , 21-Feb-2023 , 10-Mar-2023 , 20-Jun-2023 , 22-Jul-2023 , 20-Oct-2023 , 14-Nov-2023 , 20-Feb-2024 , 11-Mar-2024
Synopsis	This Funding Opportunity Announcement (FOA), utilizing the U24 grant funding mechanism, encourages applications for a collaborating Data Coordinating Center (DCC) application that accompanies an investigator-initiated multi-site clinical trial (Phase III and beyond) application submitted under PAR-21-243. The DCC application must be specific to the companion Clinical Coordinating Center (CCC) application. The objective of the DCC application is to propose a comprehensive plan that provides overall project coordination, and administrative, data management, and biostatistical support for the proposed clinical trial. Both a DCC application and a corresponding CCC application need to be submitted simultaneously for consideration by NCCIH. Trials for which this FOA applies must be relevant to the research mission of NCCIH and considered a high priority by the Center. For additional information about the mission, strategic vision, and research priorities of NCCIH, applicants are encouraged to consult NCCIH website: (http://www.nccih.nih.gov). Applicants are encouraged to contact the

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

appropriate the Scientific/Research contact for the area of science for which they are planning to develop an application prior to submitting to this FOA

104709	NCCIH Multi-Site Feasibility Clinical Trials of Mind and Body Interventions (R01 Clinical Trial Required)	National Center for Complementary and Integrative Health/NIH/DHHS	PAR-21-241	20-Jun-2022	Not Specified
--------	---	---	------------	-------------	---------------

Contact Name	Della White, Ph.D.
Contact Telephone	301-827-6538
Contact Email	della.white@nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	20-Jun-2022 , 22-Jul-2022 , 19-Oct-2022 , 14-Nov-2022 , 21-Feb-2023 , 10-Mar-2023 , 20-Jun-2023 , 22-Jul-2023 , 20-Oct-2023 , 14-Nov-2023 , 20-Feb-2024 , 11-Mar-2024
Synopsis	<p>This Funding Opportunity Announcement (FOA) invites applications for investigator-initiated clinical trials of complementary and integrative health approaches with physical and/or psychological therapeutic inputs (often called mind and body interventions) in NCCIH-designated areas of high research priority. Applications submitted under this FOA are expected to propose a multi-site feasibility clinical trial to assess whether the intervention can be delivered with fidelity across sites; demonstrate feasibility of recruitment, accrual, and randomization of participants across sites; demonstrate participant adherence to the intervention, as well as retention of participants throughout the study across sites; and/or demonstrate feasibility of data collection across sites in preparation for a future fully powered, multi-site efficacy/ effectiveness trial. The need for multi-site feasibility trials is expected to be justified by sufficient preliminary data from previous single site feasibility or acceptability trial(s) or the published literature. This FOA will not support clinical trials that determine efficacy or effectiveness. The data collected should be used to fill gaps in scientific knowledge and be necessary to develop a competitive fully powered multi-site clinical trial that has the potential to make a significant impact on public health Prior to submitting to this FOA, applicants are encouraged to contact the appropriate NCCIH Scientific/Research contact person for the science area of the planned application.</p>

108854	Notice of Special Interest (NOSI): Addressing Accessibility Inequities with COVID Home-Based Testing for Individuals with Visual Impairment	National Eye Institute/NIH/DHHS	NOT-EY-22-010	05-Apr-2022	Not Specified
--------	---	---------------------------------	---------------	-------------	---------------

Contact Name	Sangeeta Bhargava, Ph.D
Contact Telephone	301-435-8175

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Email sangeeta.bhargava@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 05-Apr-2022 , 07-May-2022 , 05-Jun-2022 , 16-Jun-2022 , 25-Jun-2022 , 05-Sep-2022 , 07-Sep-2022 , 05-Oct-2022 , 16-Oct-2022 , 25-Oct-2022 , 05-Jan-2023 , 07-Jan-2023 , 05-Feb-2023 , 16-Feb-2023 , 25-Feb-2023 , 05-Apr-2023 , 07-May-2023 , 05-Jun-2023 , 16-Jun-2023 , 25-Jun-2023 , 05-Sep-2023 , 07-Sep-2023 , 05-Oct-2023 , 16-Oct-2023 , 25-Oct-2023 , 05-Jan-2024 , 07-Jan-2024 , 05-Feb-2024 , 16-Feb-2024 , 25-Feb-2024</p> <p>Synopsis The National Eye Institute (NEI) is issuing this Notice of Special Interest (NOSI) to support research addressing the urgent need to provide accessible home-based COVID testing to people who are visually impaired.</p>				
101324	<p>Notice of Special Interest (NOSI): NEI Anterior Segment Initiative (ASI): Identification and Development of New Biomarkers and Effective Methods to Diagnose Dry Eye Disease.</p>	National Eye Institute/NIH/DHHS	NOT-EY-21-007	05-Apr-2022	Not Specified
	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 05-Apr-2022 , 07-May-2022 , 05-Jun-2022 , 16-Jun-2022 , 05-Sep-2022 , 07-Sep-2022 , 05-Oct-2022 , 16-Oct-2022 , 05-Jan-2023 , 07-Jan-2023 , 05-Feb-2023 , 16-Feb-2023 , 05-Apr-2023 , 07-May-2023</p> <p>Synopsis The purpose of this Notice of Special Interest (NOSI) is to inform potential applicants of the special interest of the NEI in research to identify new biomarkers and develop effective methods that can be used for the early diagnosis of dry eye disease (DED) and its subtypes, prognosis of disease progression, and monitoring of treatment response.</p>				
109824	<p>NEI Research Grant for Vision-Related Secondary Data Analysis (R21 Clinical Trial Not Allowed)</p>	National Eye Institute/NIH/DHHS	PAR-22-141	07-May-2022	275,000 USD
	<p>Contact Name Donald Everett, M.A.</p> <p>Contact Telephone 301-435-8181</p> <p>Contact Email everettd@mail.nih.gov</p> <p>Sponsor Website</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2022 , 16-Jun-2022 , 07-Sep-2022 , 16-Oct-2022 , 07-Jan-2023 , 16-Feb-2023 , 07-May-2023 , 16-Jun-2023 , 07-Sep-2023 , 16-Oct-2023 , 07-Jan-2024 , 16-Feb-2024 , 07-May-2024 , 16-Jun-2024 , 07-Sep-2024 , 16-Oct-2024 , 07-Jan-2025 , 16-Feb-2025 , 07-May-2025</p> <p>Synopsis This FOA encourages applications from institutions/organizations that propose to conduct vision-related secondary data analyses utilizing existing database resources. Applications may be related to, but must be distinct from, the specific aims of the original data collection. The NEI supports an extensive portfolio of clinical trials and large-scale epidemiologic research projects wherein numerous data collection activities are required to meet each project's specific aims. The resultant wealth of data generated by these studies often provides unique, cost-effective opportunities to investigate additional research questions or develop new analytical approaches secondary to a project's originally-intended purpose. Data are not limited to those collected under NEI support, but such data are of the highest programmatic interest. The purpose of this FOA is for secondary data analysis using existing data sets from vision-related clinical trials, epidemiologic, and other clinical research studies. This FOA may be used to develop new statistical methodologies or test hypotheses using existing data, but this FOA must not be used to support the collection of new data.</p>				
100970	NEI Institutional Mentored Physician Scientist Award (K12 Clinical Trial Optional)	National Eye Institute/NIH/DHHS	PAR-21-073	09-Jun-2022	Not Specified
	<p>Contact Name Neeraj Agarwal, Ph.D.</p> <p>Contact Telephone 301-451-2020</p> <p>Contact Email agarwalnee@nei.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 09-Jun-2022 , 09-Jun-2023</p> <p>Synopsis The purpose of this Funding Opportunity Announcement (FOA) is to encourage institutions to propose creative and innovative institutional research career development programs which prepare clinically trained vision scientists for independent research careers. This initiative is intended to expand and strengthen the community of clinician investigators engaged in clinical research. Such an increase in the number of well-trained clinical researchers is necessary to achieve a pool of scientists with contemporary, multidisciplinary expertise able to leverage recent advances in ocular genetics, artificial intelligence, computational modelling, ocular therapeutics, bioengineering, and bio-behavioral research in order to enhance patient treatment and to increase scientific momentum in these fields. This Funding Opportunity Announcement (FOA) allows appointment of Scholars proposing a separate ancillary study to an existing trial or proposing to gain research</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>experience in a clinical trial led by another investigator, as part of their research and career development. For this career development program scholars are limited to clinical trials that are mechanistic and/or minimal risk. The existing clinical trial must be a NIH-defined clinical trial that fulfills the NIH requirement for either a mechanistic or minimal risk trial. A mechanistic trial is designed to understand a biological or behavioral process, the pathophysiology of a disease, or the mechanism of action of an intervention. A minimal risk trial is one in which the probability and magnitude of harm or discomfort anticipated in the research are not greater in and of themselves than those ordinarily encountered in daily life or during the performance of routine physical or psychological examinations or tests. For this career development program, scholars are limited to clinical trials that are mechanistic and/or minimal risk. Applicants are strongly advised to consult with NEI program staff prior to submitting an application with human subjects to determine the appropriate funding opportunity.</p>				
109530	NEI Clinical Research Study Planning Grant Program (R34 Clinical Trial Not Allowed)	National Eye Institute/NIH/DHHS	PAR-22-128	16-Jun-2022	300,000 USD
	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email</p> <p>Sponsor Website</p> <p>Program URL</p> <p>Deadline Dates (ALL)</p> <p>Synopsis</p>	<p>Donald Everett, MA</p> <p>301-435-8181</p> <p>everettd@mail.nih.gov</p> <p></p> <p>Link to program URL</p> <p>16-Jun-2022 , 07-Sep-2022 , 16-Oct-2022 , 07-Jan-2023 , 16-Feb-2023 , 07-May-2023 , 16-Jun-2023 , 07-Sep-2023 , 16-Oct-2023 , 07-Jan-2024 , 16-Feb-2024 , 07-May-2024 , 16-Jun-2024 , 07-Sep-2024 , 16-Oct-2024 , 07-Jan-2025 , 16-Feb-2025 , 07-May-2025</p> <p>The NEI supports large-scale clinical vision research projects, including randomized clinical trials and epidemiologic studies on eye/vision conditions. At the time of submission, applications requesting support for these activities are expected to provide detailed information regarding the study rationale, design, analytic techniques, protocols and procedures, facilities and environment, organizational structure, and collaborative arrangements. This information is best conveyed in a Manual of Procedures (MOP), the development of which represents a costly and time-consuming activity. This clinical research planning grant funding opportunity supports applicants in their planning efforts to conduct collaborative clinical research. The grant may be used to support the development of a MOP, as well as to conduct preliminary studies to refine study procedures or document recruitment potential. The grant must not be used to generate data on the effects of a proposed intervention. This NEI FOA is applicable to both epidemiologic and clinical trial research studies.</p>			
109678	NEI Regenerative Medicine Clinical Trial Planning Grant (R34 - Clinical Trials Not Allowed)	National Eye Institute/NIH/DHHS	PAR-22-135	16-Jun-2022	300,000 USD

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Name Donald Everett, MA</p> <p>Contact Telephone 301-435-8181</p> <p>Contact Email everettd@mail.nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 16-Jun-2022 , 07-Sep-2022 , 16-Oct-2022 , 07-Jan-2023 , 16-Feb-2023 , 07-May-2023 , 16-Jun-2023 , 07-Sep-2023 , 16-Oct-2023 , 07-Jan-2024 , 16-Feb-2024 , 07-May-2024 , 16-Jun-2024 , 07-Sep-2024 , 16-Oct-2024 , 07-Jan-2025 , 16-Feb-2025 , 07-May-2025</p> <p>Synopsis The National Eye Institute (NEI) supports regenerative medicine clinical trials. Before a research team undertakes a clinical trial, it is critical to have clear delineation and documentation of the trial’s rationale, design, analytic techniques, protocols, and procedures in a Manual of Procedures (MOP). Additionally, there are other elements essential to the launching of a trial, such as obtaining regulatory authorizations or approvals and establishing agreements with requisite partners including cell manufacturing and production facilities, assay or cell analysis centers, and data coordinating centers. These activities are often costly and time-consuming, and they may involve collection of preliminary data to assess feasibility. The Regenerative Medicine Clinical Trial Planning Grant may be used by applicants to support the preparation of a clinical trial MOP and procedures necessary for implementing a clinical trial to evaluate interventions (or new treatments) that restore vision in humans through regeneration of cells.</p>				
093741	RFA-HL-21-013 -- Disease Modifying Therapies for Chronic Lung Disease (R61/R33 Clinical Trial Required)	National Heart, Lung, and Blood Institute/NIH/DHHS	RFA-HL-21-013	02-May-2022 [Optional][LOI/Pre-App]	1,000,000 USD
	<p>Contact Name Antonello Punturieri, MD, PhD</p> <p>Contact Telephone 301-435-0233</p> <p>Contact Email punturiera@nhlbi.nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 02-May-2022 [Optional][LOI/Pre-App], 01-Jun-2022</p> <p>Synopsis The purpose of this Funding Opportunity Announcement (FOA) is to support multiple Protocol Leadership Groups (PLGs) that will conduct phase II trials within the NHLBI Pulmonary Trials Cooperative (PTC) clinical trials network. The PTC will include multiple Protocol Leadership Groups (PLGs) and a single Network Management Core (NEMO) and will conduct multiple</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount														
	simultaneous phase II clinical trials that test innovative disease modifying therapies (DMT) for chronic lung diseases. A companion FOA (RFA-HL-21-012) seeks applications for the Network Management Core (NEMO).																		
108728	Notice of Special Interest (NOSI): Research on Barriers To Care and Risk of HIV-Associated Comorbidities Among Vulnerable Population Groups	National Heart, Lung, and Blood Institute/NIH/DHHS	NOT-HL-22-010	07-May-2022	Not Specified														
	<table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 20%; padding-right: 10px;">Contact Name</td> <td>Sean Altekruise D.V.M., Ph.D.</td> </tr> <tr> <td style="padding-right: 10px;">Contact Telephone</td> <td>301-435-1290</td> </tr> <tr> <td style="padding-right: 10px;">Contact Email</td> <td>altekruise@nhlbi.nih.gov</td> </tr> <tr> <td style="padding-right: 10px;">Sponsor Website</td> <td></td> </tr> <tr> <td style="padding-right: 10px;">Program URL</td> <td>Link to program URL</td> </tr> <tr> <td style="padding-right: 10px;">Deadline Dates (ALL)</td> <td>07-May-2022 , 05-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 07-May-2023 , 05-Jun-2023 , 07-Sep-2023 , 05-Oct-2023 , 07-Jan-2024 , 05-Feb-2024 , 07-May-2024 , 05-Jun-2024 , 07-Sep-2024 , 05-Oct-2024 , 07-Jan-2025 , 05-Feb-2025 , 07-May-2025</td> </tr> <tr> <td style="padding-right: 10px;">Synopsis</td> <td>The purpose of this Notice is to inform potential applicants to the National Heart, Lung, and Blood Institute (NHLBI) of an area of special interest in supporting analysis of barriers to care and risk of HIV-associated comorbidities among disproportionately vulnerable and affected population groups of people living with or at risk for HIV infection.</td> </tr> </table>					Contact Name	Sean Altekruise D.V.M., Ph.D.	Contact Telephone	301-435-1290	Contact Email	altekruise@nhlbi.nih.gov	Sponsor Website		Program URL	Link to program URL	Deadline Dates (ALL)	07-May-2022 , 05-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 07-May-2023 , 05-Jun-2023 , 07-Sep-2023 , 05-Oct-2023 , 07-Jan-2024 , 05-Feb-2024 , 07-May-2024 , 05-Jun-2024 , 07-Sep-2024 , 05-Oct-2024 , 07-Jan-2025 , 05-Feb-2025 , 07-May-2025	Synopsis	The purpose of this Notice is to inform potential applicants to the National Heart, Lung, and Blood Institute (NHLBI) of an area of special interest in supporting analysis of barriers to care and risk of HIV-associated comorbidities among disproportionately vulnerable and affected population groups of people living with or at risk for HIV infection.
Contact Name	Sean Altekruise D.V.M., Ph.D.																		
Contact Telephone	301-435-1290																		
Contact Email	altekruise@nhlbi.nih.gov																		
Sponsor Website																			
Program URL	Link to program URL																		
Deadline Dates (ALL)	07-May-2022 , 05-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 07-May-2023 , 05-Jun-2023 , 07-Sep-2023 , 05-Oct-2023 , 07-Jan-2024 , 05-Feb-2024 , 07-May-2024 , 05-Jun-2024 , 07-Sep-2024 , 05-Oct-2024 , 07-Jan-2025 , 05-Feb-2025 , 07-May-2025																		
Synopsis	The purpose of this Notice is to inform potential applicants to the National Heart, Lung, and Blood Institute (NHLBI) of an area of special interest in supporting analysis of barriers to care and risk of HIV-associated comorbidities among disproportionately vulnerable and affected population groups of people living with or at risk for HIV infection.																		
108068	Notice of Special Interest (NOSI): Diagnostics and Disease Management Tools for Use in Underserved Populations	National Heart, Lung, and Blood Institute/NIH/DHHS	NOT-HL-22-006	07-May-2022	Not Specified														
	<table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 20%; padding-right: 10px;">Contact Name</td> <td>Bishow Adhikari, Ph.D.</td> </tr> <tr> <td style="padding-right: 10px;">Contact Telephone</td> <td>301-594-2791</td> </tr> <tr> <td style="padding-right: 10px;">Contact Email</td> <td>adhikarb@nhlbi.nih.gov</td> </tr> <tr> <td style="padding-right: 10px;">Sponsor Website</td> <td></td> </tr> <tr> <td style="padding-right: 10px;">Program URL</td> <td>Link to program URL</td> </tr> <tr> <td style="padding-right: 10px;">Deadline Dates (ALL)</td> <td>07-May-2022 , 05-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 07-May-2023 , 05-Jun-2023 , 07-Sep-2023 , 05-Oct-2023 , 07-Jan-2024 , 05-Feb-2024 , 07-May-2024 , 05-Jun-2024 , 07-Sep-2024 , 05-Oct-2024 , 05-Feb-2025 , 05-Jun-2025</td> </tr> <tr> <td style="padding-right: 10px;">Synopsis</td> <td>The purpose of this NOSI is to stimulate research focused on the development of transformative diagnostics and disease management tools for heart, lung, blood, or sleep (HLBS) disorders that are designed to meet the needs of the underserved populations. Underserved populations, for the purpose of this NOSI, can include racial and ethnic minorities, immigrants, the</td> </tr> </table>					Contact Name	Bishow Adhikari, Ph.D.	Contact Telephone	301-594-2791	Contact Email	adhikarb@nhlbi.nih.gov	Sponsor Website		Program URL	Link to program URL	Deadline Dates (ALL)	07-May-2022 , 05-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 07-May-2023 , 05-Jun-2023 , 07-Sep-2023 , 05-Oct-2023 , 07-Jan-2024 , 05-Feb-2024 , 07-May-2024 , 05-Jun-2024 , 07-Sep-2024 , 05-Oct-2024 , 05-Feb-2025 , 05-Jun-2025	Synopsis	The purpose of this NOSI is to stimulate research focused on the development of transformative diagnostics and disease management tools for heart, lung, blood, or sleep (HLBS) disorders that are designed to meet the needs of the underserved populations. Underserved populations, for the purpose of this NOSI, can include racial and ethnic minorities, immigrants, the
Contact Name	Bishow Adhikari, Ph.D.																		
Contact Telephone	301-594-2791																		
Contact Email	adhikarb@nhlbi.nih.gov																		
Sponsor Website																			
Program URL	Link to program URL																		
Deadline Dates (ALL)	07-May-2022 , 05-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 07-May-2023 , 05-Jun-2023 , 07-Sep-2023 , 05-Oct-2023 , 07-Jan-2024 , 05-Feb-2024 , 07-May-2024 , 05-Jun-2024 , 07-Sep-2024 , 05-Oct-2024 , 05-Feb-2025 , 05-Jun-2025																		
Synopsis	The purpose of this NOSI is to stimulate research focused on the development of transformative diagnostics and disease management tools for heart, lung, blood, or sleep (HLBS) disorders that are designed to meet the needs of the underserved populations. Underserved populations, for the purpose of this NOSI, can include racial and ethnic minorities, immigrants, the																		

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
100825	Notice of Special Interest (NOSI): Integrative Omics Analysis of NHLBI TOPMed Data (Parent R01 Clinical Trial Not Allowed)	National Heart, Lung, and Blood Institute/NIH/DHHS	NOT-HL-20-823	07-May-2022	Not Specified
	Contact Name Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL)	Weiniu Gan, Ph.D. 301-435-0202 ganw2@mail.nih.gov Link to program URL 07-May-2022 , 05-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 07-May-2023			
	Synopsis	<p>The symptom-based diagnosis and treatment of heart, lung, blood, and sleep (HLBS) diseases has vastly improved in recent years, yet an understanding of the molecular mechanisms underlying many of these diseases has remained elusive. Furthermore, in most cases the impact of genetic variation on severity of disease and treatment outcomes remains unknown. Therefore, the NHLBI has recently created the Trans Omics for Precision Medicine (TOPMed) program, which aims to utilize high throughput omics to characterize a variety of HLBS diseases. TOPMed is well on its way to collecting whole genome sequence from over 130,000 well-phenotyped individuals and is currently generating high-throughput expression and other “omics” data (e.g. RNA, DNA methylation, metabolites, and proteins) from many of these individuals to complement whole genome sequence information. Having produced an unprecedented volume of high-throughput data, TOPMed now seeks to turn its attention to effectively leveraging this resource through novel systems biology analyses to uncover disease pathobiology. Although lower costs and technological improvements in sequencing technology have vastly expanded our ability to generate large volumes of omics data, the ability to analyze such large datasets to extract biologically meaningful insights from them remains challenging. Systems level models incorporating trans-omics analyses will be an important step in uncovering the underlying biological networks, gene-gene and gene-environment interactions influencing disease and treatment outcomes. Thus, advanced analyses that incorporate genotype and phenotype datasets from thousands to tens of thousands of individuals are required to move TOPMed to the next phase of discovery.</p>			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

106202	Notice of Special Interest (NOSI): Promoting Cardiovascular and Cardiometabolic Health in Early Stages of the Lifecourse: Pre-adolescence Through Adolescence to Young Adulthood	National Heart, Lung, and Blood Institute/NIH/DHHS	NOT-HL-21-015	07-May-2022	Not Specified
--------	--	--	---------------	-------------	---------------

Contact Name	Alison G.M. Brown, PhD, MS, RDN
Contact Telephone	301-435-0583
Contact Email	Alison.brown@nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	07-May-2022 , 05-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 07-May-2023 , 05-Jun-2023 , 07-Sep-2023 , 05-Oct-2023 , 07-Jan-2024 , 05-Feb-2024 , 07-May-2024 , 05-Jun-2024 , 07-Sep-2024 , 05-Oct-2024 , 07-Jan-2025 , 05-Feb-2025 , 07-May-2025 , 05-Jun-2025 , 07-Sep-2025 , 05-Oct-2025 , 07-Jan-2026 , 05-Feb-2026 , 07-May-2026 , 05-Jun-2026
Synopsis	This Notice of Special Interest (NOSI) calls for research to understand and promote cardiovascular and cardiometabolic health during transitional phases across the lifecourse, from pre-adolescence (6-10 years) through adolescence (11-18 years) to young adulthood (19-39 years). This initiative would support research to: 1) understand the mechanisms and the pathogenesis of cardiometabolic health and cardiovascular disease (CVD) risk in vulnerable groups throughout transitional phases from pre-adolescence into adolescence and adolescence into young adulthood, and 2) develop precision prevention interventions (at the individual and populations levels) to address cardiovascular and cardiometabolic risk across these transitional phases.

108064	Notice of Special Interest (NOSI): Promoting Fundamental Research on Mitochondrial Involvement in Lung Diseases and Sleep Disorders	National Heart, Lung, and Blood Institute/NIH/DHHS	NOT-HL-22-003	07-May-2022	Not Specified
--------	---	--	---------------	-------------	---------------

Contact Name	Jining Lu
Contact Telephone	301-827-2807
Contact Email	jining.lu@nih.gov
Sponsor Website	
Program URL	Link to program URL

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Deadline Dates (ALL)	07-May-2022 , 05-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 07-May-2023 , 05-Jun-2023 , 07-Sep-2023 , 05-Oct-2023 , 07-Jan-2024 , 05-Feb-2024 , 07-May-2024 , 05-Jun-2024 , 07-Sep-2024 , 05-Oct-2024 , 07-Jan-2025 , 05-Feb-2025			
	Synopsis	The purpose of this NOSI is to stimulate research focused on cell-type-specific signatures of mitochondrial behavior in healthy and diseased lungs. Multidisciplinary collaboration among experts in recently developed technologies, such as iPSC cell and lung progenitor/organoid culture systems, advanced single cell-and “-omic” technologies, and lung cell biology is encouraged. We encourage investigators to Utilization of lung cells from human donors and animal models with respiratory diseases and/or well-defined congenital mitochondrial diseases is also encouraged.			
107093	Notice of Special Interest (NOSI): DEA2Health: Innovative Data Evaluation and Analysis to Health	National Heart, Lung, and Blood Institute/NIH/DHHS	NOT-HL-22-001	07-May-2022	Not Specified
	Contact Name	Lucy L. Hsu, M.P.H.			
	Contact Telephone	301-402-3276			
	Contact Email	lucy.hsu@nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	07-May-2022 , 05-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 07-May-2023 , 05-Jun-2023 , 07-Sep-2023 , 05-Oct-2023 , 07-Jan-2024 , 05-Feb-2024 , 07-May-2024 , 05-Jun-2024 , 07-Sep-2024 , 05-Oct-2024 , 07-Jan-2025			
	Synopsis	The purpose of this Notice of Special Interest (NOSI) is to stimulate research and advancement of methodologies in data science in heart, lung, blood, or sleep (HLBS) biomedical research, and ultimately translate new insights into decision-making to improve health.			
100447	Notice of Special Interest (NOSI): Use of Predictive Analytics to Accelerate Late-Stage Implementation Research to Address Heart, Lung, Blood, and Sleep Disorders	National Heart, Lung, and Blood Institute/NIH/DHHS	NOT-HL-20-815	07-May-2022	Not Specified
	Contact Name	Rebecca A. Roper, MS, MPH			
	Contact Telephone	301-496-1051			
	Contact Email	Rebecca.Roper@nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Deadline Dates (ALL)	07-May-2022 , 05-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 07-May-2023 , 05-Jun-2023 , 07-Sep-2023 , 05-Oct-2023 , 07-Jan-2024			
	Synopsis	<p>NHLBI is issuing this Notice of Special Interest (NOSI) to leverage existing data resources using Predictive Analytics Implementation Research (PAIR) that utilizes complex and innovative methodologies and modeling techniques to rely on integration of existing data to inform the designs (and often test) implementation strategies for heart, lung, blood, and sleep (HLBS) conditions. NHLBI also encourages applications which focus on the development of advance modeling techniques and data reporting, which would be publicly available and could be used to inform subsequent implementation strategies to address HLBS conditions.</p>			
105201	Notice of Special Interest (NOSI): Integrative Omics Analysis of NHLBI TOPMed Data (Parent R01 Clinical Trial Not Allowed)	National Heart, Lung, and Blood Institute/NIH/DHHS	NOT-HL-21-017	07-May-2022	Not Specified
	Contact Name	James Luo, Ph.D.			
	Contact Telephone	301-435-0533			
	Contact Email	luoja@nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	07-May-2022 , 05-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 07-May-2023			
	Synopsis	<p>The symptom-based diagnosis and treatment of heart, lung, blood, and sleep (HLBS) diseases has vastly improved in recent years, yet an understanding of the molecular mechanisms underlying many of these diseases has remained elusive. Furthermore, in most cases the impact of genetic variation on severity of disease and treatment outcomes remains unknown. Therefore, the NHLBI has recently created the Trans Omics for Precision Medicine (TOPMed) program, which aims to utilize high throughput omics to characterize a variety of HLBS diseases. TOPMed is well on its way to collecting whole genome sequence from over 130,000 well-phenotyped individuals and is currently generating high-throughput expression and other “omics” data (e.g. RNA, DNA methylation, metabolites, and proteins) from many of these individuals to complement whole genome sequence information. Having produced an unprecedented volume of high-throughput data, TOPMed now seeks to turn its attention to effectively leveraging this resource through novel systems biology analyses to uncover disease pathobiology. Although lower costs and technological improvements in sequencing technology have vastly expanded our ability to generate large volumes of omics data, the ability to analyze such large datasets to extract biologically meaningful insights from them remains challenging. Systems level models incorporating trans-omics analyses will be an important step in uncovering the underlying biological networks, gene-gene and gene-environment interactions influencing disease and treatment outcomes. Thus, advanced analyses that incorporate genotype and phenotype datasets from thousands to tens of thousands of individuals are required to move TOPMed to the next phase of discovery.</p>			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
099803	Notice of Special Interest (NOSI): Palliative Care in Heart, Lung, Blood, and Sleep Diseases	National Heart, Lung, and Blood Institute/NIH/DHHS	NOT-HL-20-737	07-May-2022	Not Specified
	<p>Contact Name Lora Reineck, MD, MS</p> <p>Contact Telephone 301-435-0222</p> <p>Contact Email lora.reineck@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2022 , 05-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 07-May-2023 , 05-Jun-2023</p> <p>Synopsis Providing care that is consistent with a patient’s values, preferences, and goals is a cornerstone of palliative care, an interdisciplinary patient-centered approach that aims to improve quality of life for persons with advanced illness and their families. Palliative care focuses on several objectives including relief of symptoms and suffering, communication of prognosis and treatment options in the context of patients’ goals, and coordination of care within and across healthcare settings. Palliative care is not synonymous with hospice or end-of-life care. Rather, palliative care addresses the spectrum of care for serious illness from diagnosis through terminal stages of diseases. Moreover, palliative care does not necessarily entail withholding or curbing treatment. Relief of symptoms, enhancing quality of life, and many other specific aspects of goal-concordant care may, in fact, involve optimal medical or surgical treatment of diseases. The expected outcome of integrating palliative care into the management of the patient’s disease is a better quality of life, a realistic understanding of risks and benefits of treatment and interventions, and medical treatment decisions that align with the patient’s goals, preferences, and values. Many heart, lung, blood, and sleep (HLBS) diseases, including heart failure, chronic obstructive pulmonary disease (COPD), pulmonary fibrosis, pulmonary hypertension, cystic fibrosis, myelodysplastic syndromes, and aplastic anemia are life-limiting, non-curable illnesses. These and other HLBS diseases may benefit from care focused on improvement of symptoms and quality of life, in addition to care focused on slowing or halting progression of diseases. Integration of palliative care into cardiology, pulmonary, hematology, and critical care practice is recommended by multiple professional societies. Additionally, symptoms of HLBS diseases such as cough, shortness of breath, and fatigue may be especially burdensome, even in diseases that are not life-limiting. Research to improve burdensome symptoms has the potential to greatly improve the quality of life for all patients with HLBS diseases, not just those with life-limiting disease.</p>				
106714	Notice of Special Interest (NOSI): Resilience and Vulnerability following Acute Heart, Lung, Blood, and Sleep Insults in People with HIV (R01, Clinical Trial Not Allowed)	National Heart, Lung, and Blood Institute/NIH/DHHS	NOT-HL-22-002	07-May-2022	Not Specified
	<p>Contact Name Shimian Zou, PhD</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Telephone 301-827-8301</p> <p>Contact Email shimian.zou@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2022 , 05-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 07-May-2023 , 05-Jun-2023 , 07-Sep-2023 , 05-Oct-2023 , 07-Jan-2024</p> <p>Synopsis This NOSI encourages the submission of research project applications focused on understanding the long-term manifestations of acute HLBS illnesses with an emphasis on host response, viral pathways, and mechanisms that contribute to long-term manifestations in the context of HIV. Proposals considered responsive to the NOSI may address questions across the spectrum of basic science to population science.</p>				
107287	<p>Notice of Special Interest (NOSI): Heart, Lung, Blood and Sleep Focused Ancillary Studies to Large Ongoing Clinical Studies (Revised)</p>	National Heart, Lung, and Blood Institute/NIH/DHHS	NOT-HL-21-030	07-May-2022	Not Specified
	<p>Contact Name Jue Chen, Ph.D.</p> <p>Contact Telephone 301-435-0550</p> <p>Contact Email jue.chen@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2022 , 05-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 07-May-2023</p> <p>Synopsis This Notice of Special Interest (NOSI) seeks to expand the breadth of scientific research on the clinical course, prevention and treatment of diseases within the mission of the National Heart, Lung, and Blood Institute (NHLBI) by leveraging ongoing clinical research studies through ancillary studies. The purpose of this NOSI is to invite research project applications to conduct focused ancillary studies to large ongoing clinical trials (including late-stage T4 implementation clinical trials), observational studies, and registries. This NOSI also serves as a replacement for NOT-HL-20-755 (expired as of November 6, 2021).</p>				
100811	<p>NHLBI Clinical Trial Pilot Studies (R34 Clinical Trial Optional)</p>	National Heart, Lung, and Blood Institute/NIH/DHHS	PAR-21-079	07-May-2022	450,000 USD
	Contact Name Patrice Desvigne-Nickens, MD				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Telephone 301-435-0504</p> <p>Contact Email gweinmann@nih.gov</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2022 , 16-Jun-2022 , 07-Sep-2022 , 16-Oct-2022 , 07-Jan-2023 , 16-Feb-2023 , 07-May-2023 , 16-Jun-2023 , 07-Sep-2023 , 16-Oct-2023 , 07-Jan-2024</p> <p>Synopsis This Funding Opportunity Announcement (FOA) supports studies that are both necessary and sufficient to inform the planning of a Phase II-IV clinical trial within NHLBI's mission. The NHLBI expects that applications to this FOA will describe the planned clinical trial and in so doing demonstrate that the proposed (R34) research is scientifically necessary to design or plan the subsequent trial. Furthermore, this FOA will support research projects that are designed to provide results that will be sufficient to inform the future trial without further studies. The planned Phase II, III, or IV trial must be primarily intended to test the efficacy, safety, clinical management, or implementation of intervention(s) in the prevention and/or treatment of heart, lung, blood, and sleep disorders. In contrast to the study start up or preparation phase of NHLBI funding opportunities for clinical trials (as described at https://www.nhlbi.nih.gov/grants-and-training/funding-opportunities-and-contacts/clinical-trials-optimization), the R34 mechanism is intended to provide new information that answers a scientific or operational question(s) which may be pragmatic in nature and, therefore, informs the final development of a Phase II-IV clinical trial. Regardless of the results of the R34, support of the proposed future clinical trial will require a new application.</p>				
106072	<p>Notice of Special Interest (NOSI): Bold New Bioengineering Research for Heart, Lung, Blood and Sleep Disorders and Diseases (Reissue)</p>	National Heart, Lung, and Blood Institute/NIH/DHHS	NOT-HL-21-024	07-May-2022	Not Specified
	<p>Contact Name Narasimhan Danthi, Ph.D.</p> <p>Contact Telephone 301-435-5170</p> <p>Contact Email ndanthi@mail.nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2022 , 16-Jun-2022 , 07-Sep-2022 , 16-Oct-2022 , 07-Jan-2023 , 16-Feb-2023 , 07-May-2023 , 16-Jun-2023 , 07-Sep-2023 , 16-Oct-2023 , 07-Jan-2024 , 16-Feb-2024 , 07-May-2024 , 16-Jun-2024 , 07-Sep-2024 , 16-Oct-2024 , 07-Jan-2025</p> <p>Synopsis This Notice of Special Interest is a reissue of NOT-HL-20-796. The purpose of this NOSI is to advise potential applicants to the National Heart, Lung and Blood Institute (NHLBI) of an area of special interest to support early phases of innovative bioengineering projects which are expected to transition their research into future follow-on funding, technologies, or</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

commercial products. Please note that this R21 program does not overlap with projects which are expected to transition their research into future follow-on funding, technologies, or commercial products. Please note that this R21 program does not overlap with the NHLBI Catalyze Program, and it does focus on new investigator-initiated ideas that will feed into the Catalyze pipeline.

084638	Clinical Coordinating Center for Multi-Site Investigator-Initiated Clinical Trials (Collaborative UG3/UH3 Clinical Trial Required)	National Heart, Lung, and Blood Institute/NIH/DHHS	PAR-19-329	11-May-2022	Not Specified
--------	--	--	------------	-------------	---------------

Contact Name | Nancy DiFronzo, PhD
 Contact Telephone | 301-435-0065
 Contact Email | difronzon@nhlbi.nih.gov
 Sponsor Website |
 Program URL | [Link to program URL](#)
 Deadline Dates (ALL) | 11-May-2022 , 10-Jun-2022 , 08-Sep-2022

Synopsis | This Funding Opportunity Announcement (FOA) supports applications to develop and implement a Clinical Coordinating Center (CCC) for investigator-initiated multi-site clinical trials including efficacy, comparative effectiveness, pragmatic and/or implementation research clinical trials. These trials may include ones that test different therapeutic, behavioral, and/or prevention strategies. Trials for which this FOA applies must be relevant to the research mission of the NHLBI and meet the NIH definition of a clinical trial (see NOT-OD-15-015) . For additional information about the mission, strategic vision, and research priorities of the NHLBI, applicants are encouraged to consult the NHLBI website. This FOA will utilize a bi-phasic, milestone-driven cooperative agreement mechanism of award and runs in parallel with a companion FOA that encourages applications for a collaborating Data Coordinating Center (DCC) (PAR-19-330). The objective of the CCC application is to present the scientific rationale for the clinical trial and a comprehensive scientific and operational plan that describes it. The application should address project management, subject recruitment and retention, performance milestones, scientific conduct of the trial, and dissemination of results. Both a CCC application and a collaborating DCC application must be submitted on the same application due date for consideration by NHLBI.

084646	Data Coordinating Center for Multi-Site Investigator-Initiated Clinical Trials (Collaborative U24 Clinical Trial Required)	National Heart, Lung, and Blood Institute/NIH/DHHS	PAR-19-330	11-May-2022	Not Specified
--------	--	--	------------	-------------	---------------

Contact Name | Nancy DiFronzo, PhD
 Contact Telephone | 301-435-0065
 Contact Email | difronzon@nhlbi.nih.gov

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 11-May-2022 , 10-Jun-2022 , 08-Sep-2022</p> <p>Synopsis This Funding Opportunity Announcement (FOA) supports applications for a collaborating Data Coordinating Center (DCC) for investigator-initiated multi-site clinical trials including efficacy, comparative effectiveness, pragmatic and/or implementation research clinical trials. These trials may include ones that test different therapeutic, behavioral, and/or prevention strategies. Trials for which this FOA applies must be relevant to the research mission of the NHLBI and meet the NIH definition of a clinical trial (see NOT-OD-15-015). For additional information about the mission, strategic vision, and research priorities of the NHLBI, applicants are encouraged to consult the NHLBI website. This FOA will utilize a cooperative agreement mechanism of award and runs in parallel with a companion FOA (PAR-19-329) that encourages applications for a collaborating Clinical Coordinating Center (CCC). The objective of the DCC application is to present a comprehensive plan to provide overall project coordination, administration, data management, and biostatistical support for the clinical trial proposed in the collaborating CCC application. Both a DCC application and a collaborating CCC application must be submitted on the same application due date for consideration by NHLBI.</p>				
084637	Single-Site Investigator-Initiated Clinical Trials (R61/R33 Clinical Trial Required)	National Heart, Lung, and Blood Institute/NIH/DHHS	PAR-19-328	11-May-2022	Not Specified
	<p>Contact Name Nahed El Kassar, MD</p> <p>Contact Telephone 301-435-0065</p> <p>Contact Email nahed.elkassar@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 11-May-2022 , 10-Jun-2022 , 08-Sep-2022</p> <p>Synopsis This Funding Opportunity Announcement (FOA) supports applications to develop and implement investigator-initiated single site clinical trials including efficacy, comparative effectiveness, pragmatic and/or implementation research clinical trials. These trials may include ones that test different therapeutic, behavioral, and/or prevention strategies. Trials for which this FOA applies must be relevant to the research mission of the NHLBI and meet the NIH definition of a clinical trial (see NOT-OD-15-015). For additional information about the mission, strategic vision, and research priorities of the NHLBI, applicants are encouraged to consult the NHLBI website. This FOA will utilize a bi-phasic, milestone-driven mechanism of award. The objective of the application is to present the scientific rationale for the clinical trial and a comprehensive scientific and operational plan that describes it. The application should address project management, subject recruitment and retention,</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		performance milestones, scientific conduct of the trial, and dissemination of results. The multiple PD/PI model is strongly encouraged but not required. Applicants are encouraged to include a PD/PI with expertise in biostatistics, clinical trial design, and coordination.			
101704	NHLBI Early Phase Clinical Trials for Therapeutics and/or Diagnostics (R61/R33 Clinical Trial Required)	National Heart, Lung, and Blood Institute/NIH/DHHS	PAR-21-119	04-Jun-2022	Not Specified
	Contact Name	Traci Heath Mondoro, Ph.D.			
	Contact Telephone	301-435-0065			
	Contact Email	xxxx@mail.nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	04-Jun-2022 , 07-Sep-2022 , 02-Oct-2022 , 07-Jan-2023 , 04-Jun-2023 , 07-Sep-2023 , 02-Oct-2023 , 07-Jan-2024			
	Synopsis	The objective of this funding opportunity is to support investigator-initiated, Phase I clinical trials for diagnostic and therapeutic interventions for heart, lung, blood, and sleep (HLBS) disorders in adults and children. In addition to supporting clinical trial start-up and implementation activities, this FOA will provide support for final stage preclinical activities needed for the implementation of the proposed trial. All the activities proposed in the R61 phase must be directly related to the therapeutic/diagnostic in preparation for the clinical trial. The proposed trial can be single or multisite. This FOA will utilize a bi-phasic, milestone-driven mechanism of award where the first phase can be used to finalize required pre-trial activities such as stability, shipping studies, and site training.			
101703	NHLBI Early Phase Clinical Trials for Therapeutics and/or Diagnostics (R33 Clinical Trial Required)	National Heart, Lung, and Blood Institute/NIH/DHHS	PAR-21-118	04-Jun-2022	4,545,000 USD
	Contact Name	Traci Heath Mondoro, Ph.D.			
	Contact Telephone	301-435-0050			
	Contact Email	mondorot@nhlbi.nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	04-Jun-2022 , 07-Sep-2022 , 02-Oct-2022 , 07-Jan-2023 , 04-Jun-2023 , 07-Sep-2023 , 02-Oct-2023 , 07-Jan-2024			
	Synopsis	The objective of this funding opportunity is to support investigator-initiated, phase I clinical trials for diagnostic and therapeutic interventions for heart, lung, blood, and sleep (HLBS) disorders in adults and children. The proposed trial can be			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

single or multisite. Applicants applying for funding under this FOA should be ready to initiate the clinical trial within the first quarter of the project period. Discussion, submission, and attainment of applicable regulatory (FDA, DSMB, IRB) approvals, and establishment of drug (and placebo, if applicable) supplies, and any necessary third-party agreements should be established by the time of award. If time and support for these and other pre-clinical and/or trial readiness activities are desired, applicants should consider the companion FOA, PAR-21-119, which utilizes an R61/R33 phased approach.

106893	NHLBI Career Transition Award for Intramural Postdoctoral Fellows and Research Trainees (K22 Independent Clinical Trial Not Allowed)	National Heart, Lung, and Blood Institute/NIH/DHHS	PAR-22-034	12-Jun-2022	Not Specified
--------	--	--	------------	-------------	---------------

Contact Name	Shawn Bediako, Ph.D.
Contact Telephone	301-827-5163
Contact Email	direducation@nhlbi.nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	12-Jun-2022 , 12-Oct-2022 , 12-Feb-2023 , 12-Jun-2023 , 12-Oct-2023 , 12-Feb-2024 , 12-Jun-2024
Synopsis	The purpose of the NHLBI Career Transition Award (K22) program is to provide highly qualified postdoctoral fellows and other doctoral-level researchers currently in training in the NHLBI Division of Intramural Research with the opportunity to transition their research programs to extramural institutions as junior investigators. To achieve these objectives, the NHLBI Career Transition Award will support two phases of research: a mentored intramural phase (up to two years) and an extramural phase (three years), for a total of five years of combined support. Transition from the intramural phase of support to the extramural phase is not automatic. Approval of the transition will be based on the success of the awardee's research program during the mentored phase as determined by an NHLBI progress review, which will include an evaluation of a research plan to be carried out at the extramural institution. This Funding Opportunity Announcement (FOA) is designed specifically for candidates proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary study to a clinical trial. Applicants to this FOA are permitted to propose research experience in a clinical trial led by a mentor or co-mentor. Those proposing a clinical trial or an ancillary clinical trial as lead investigator, should apply to the companion FOA, PAR-22-040 "NHLBI Career Transition Award for Intramural Postdoctoral Fellows and Research Trainees (K22- Clinical Trial Required)".

106898	NHLBI Career Transition Award for Intramural Postdoctoral Fellows and Research Trainees (K22 Clinical Trial Required)	National Heart, Lung, and Blood Institute/NIH/DHHS	PAR-22-040	12-Jun-2022	Not Specified
--------	---	--	------------	-------------	---------------

Contact Name	Shawn Bediako, Ph.D.
Contact Telephone	301-827-5163

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

Contact Email	direducation@nhlbi.nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	12-Jun-2022 , 12-Oct-2022 , 12-Feb-2023 , 12-Jun-2023 , 12-Oct-2023 , 12-Feb-2024 , 12-Jun-2024
Synopsis	The purpose of the NHLBI Career Transition Award (K22) program is to provide highly qualified postdoctoral fellows and other doctoral-level researchers currently in training in the NHLBI Division of Intramural Research with the opportunity to transition their research programs to extramural institutions as junior investigators. To achieve these objectives, the NHLBI Career Transition Award will support two phases of research: a mentored intramural phase (up to two years) and an extramural phase (three years), for a total of five years of combined support. Transition from the intramural phase of support to the extramural phase is not automatic. Approval of the transition will be based on the success of the awardee's research program during the mentored phase as determined by an NHLBI progress review, which will include an evaluation of a research plan to be carried out at the extramural institution. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary study to an existing trial, as part of their research and career development. Applicants not proposing to serve as lead investigator of an independent clinical trial must apply to the companion FOA (PAR-22-034).

109308	RFA-HL-23-018 -- Maximizing the Scientific Value of the NHLBI Biologic Biospecimen Repository: Scientific Opportunities for Exploratory Research (R21)	National Heart, Lung, and Blood Institute/NIH/DHHS	RFA-HL-23-018	21-Jun-2022	150,000 USD
--------	--	--	---------------	-------------	-------------

Contact Name	Margaret Ochocinska, PhD
Contact Telephone	301-827-8285
Contact Email	ochocinm@mail.nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	21-Jun-2022 , 09-Aug-2022 , 19-Oct-2022 , 07-Dec-2022 , 20-Jun-2023 , 09-Aug-2023 , 19-Oct-2023 , 07-Dec-2023 , 20-Jun-2024 , 09-Aug-2024 , 21-Oct-2024 , 10-Dec-2024
Synopsis	This Funding Opportunity Announcement (FOA) will support meritorious exploratory research relevant to the NHLBI mission (http://www.nhlbi.nih.gov/about/org/mission) using the existing biospecimen collections that are stored in the NHLBI Biologic Specimen Repository (Biorepository), thereby maximizing the scientific value of the stored collections and providing researchers with an opportunity to generate preliminary data for subsequent research proposals.

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
101174	Notice of Special Interest (NOSI): Advancing Genomic Technology Development for Research and Clinical Application	National Human Genome Research Institute/NIH/DHHS	NOT-HG-21-018	05-Apr-2022	Not Specified
	<p>Contact Name Michael W. Smith, Ph.D.</p> <p>Contact Telephone 301-480-3413</p> <p>Contact Email smithmw@mail.nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 05-Apr-2022 , 07-May-2022 , 05-Jun-2022 , 16-Jun-2022 , 05-Sep-2022 , 07-Sep-2022 , 05-Oct-2022 , 16-Oct-2022 , 05-Jan-2023 , 07-Jan-2023 , 05-Feb-2023 , 16-Feb-2023 , 05-Apr-2023 , 07-May-2023 , 05-Jun-2023 , 16-Jun-2023 , 05-Sep-2023 , 07-Sep-2023 , 05-Oct-2023 , 16-Oct-2023 , 05-Jan-2024 , 07-Jan-2024</p> <p>Synopsis The National Human Genome Research Institute (NHGRI) is issuing this Notice of Special Interest (NOSI) to encourage applications focused on developing novel laboratory-focused tools and technologies that enable new lines of scientific inquiry and clinical applications in human genomics.</p>				
108325	Notice of Special Interest (NOSI): Development and Implementation of Clinical Informatics Tools to Enhance Patients' Use of Genomic Information	National Human Genome Research Institute/NIH/DHHS	NOT-HG-22-011	05-Apr-2022	Not Specified
	<p>Contact Name Ken Wiley, Jr., Ph.D.</p> <p>Contact Telephone 301-435-5540</p> <p>Contact Email ken.wiley@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 05-Apr-2022 , 07-May-2022 , 25-May-2022 , 05-Jun-2022 , 16-Jun-2022 , 01-Aug-2022 , 07-Sep-2022 , 25-Sep-2022 , 05-Oct-2022 , 16-Oct-2022 , 07-Jan-2023 , 25-Jan-2023 , 05-Feb-2023 , 16-Feb-2023 , 13-Mar-2023 , 07-May-2023 , 25-May-2023 , 05-Jun-2023 , 16-Jun-2023 , 07-Sep-2023 , 25-Sep-2023 , 05-Oct-2023 , 16-Oct-2023 , 07-Jan-2024 , 25-Jan-2024 , 05-Feb-2024 , 16-Feb-2024 , 07-May-2024 , 25-May-2024 , 05-Jun-2024 , 16-Jun-2024 , 07-Sep-2024</p> <p>Synopsis The National Human Genome Research Institute (NHGRI) is issuing a Notice of Special Interest (NOSI) to encourage applications to develop and implement patient-facing genomic-based clinical informatics tools that facilitate or enhance patient-provider electronic communication, patient tracking and registry functions, patient self-management and support, provider electronic prescribing, test tracking, referral tracking, and health care decision-making.</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount														
107786	Notice of Special Interest (NOSI): Methods Development for Genomic Studies of Genetic Variation, Function, and Disease	National Human Genome Research Institute/NIH/DHHS	NOT-HG-22-007	05-Apr-2022	Not Specified														
	<table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 20%; padding: 5px;">Contact Name</td> <td style="padding: 5px;">Lisa D. Brooks, Ph.D.</td> </tr> <tr> <td style="padding: 5px;">Contact Telephone</td> <td style="padding: 5px;">301-547-1387</td> </tr> <tr> <td style="padding: 5px;">Contact Email</td> <td style="padding: 5px;">lisa.brooks@nih.gov</td> </tr> <tr> <td style="padding: 5px;">Sponsor Website</td> <td style="padding: 5px;"></td> </tr> <tr> <td style="padding: 5px;">Program URL</td> <td style="padding: 5px;">Link to program URL</td> </tr> <tr> <td style="padding: 5px;">Deadline Dates (ALL)</td> <td style="padding: 5px;">05-Apr-2022 , 07-May-2022 , 05-Jun-2022 , 16-Jun-2022 , 05-Sep-2022 , 07-Sep-2022 , 05-Oct-2022 , 16-Oct-2022 , 05-Jan-2023 , 07-Jan-2023 , 05-Feb-2023 , 16-Feb-2023 , 05-Apr-2023 , 07-May-2023 , 05-Jun-2023 , 16-Jun-2023 , 05-Sep-2023 , 07-Sep-2023 , 05-Oct-2023 , 16-Oct-2023 , 05-Jan-2024 , 07-Jan-2024 , 05-Feb-2024 , 16-Feb-2024 , 05-Apr-2024 , 07-May-2024 , 05-Jun-2024 , 16-Jun-2024 , 05-Sep-2024 , 07-Sep-2024 , 05-Oct-2024</td> </tr> <tr> <td style="padding: 5px;">Synopsis</td> <td style="padding: 5px;">The National Human Genome Research Institute (NHGRI) is issuing this Notice of Special Interest (NOSI) to encourage applications that develop novel computational or experimental approaches for genomic studies of how genetic variants relate to genomic function, phenotype, and disease.</td> </tr> </table>					Contact Name	Lisa D. Brooks, Ph.D.	Contact Telephone	301-547-1387	Contact Email	lisa.brooks@nih.gov	Sponsor Website		Program URL	Link to program URL	Deadline Dates (ALL)	05-Apr-2022 , 07-May-2022 , 05-Jun-2022 , 16-Jun-2022 , 05-Sep-2022 , 07-Sep-2022 , 05-Oct-2022 , 16-Oct-2022 , 05-Jan-2023 , 07-Jan-2023 , 05-Feb-2023 , 16-Feb-2023 , 05-Apr-2023 , 07-May-2023 , 05-Jun-2023 , 16-Jun-2023 , 05-Sep-2023 , 07-Sep-2023 , 05-Oct-2023 , 16-Oct-2023 , 05-Jan-2024 , 07-Jan-2024 , 05-Feb-2024 , 16-Feb-2024 , 05-Apr-2024 , 07-May-2024 , 05-Jun-2024 , 16-Jun-2024 , 05-Sep-2024 , 07-Sep-2024 , 05-Oct-2024	Synopsis	The National Human Genome Research Institute (NHGRI) is issuing this Notice of Special Interest (NOSI) to encourage applications that develop novel computational or experimental approaches for genomic studies of how genetic variants relate to genomic function, phenotype, and disease.
Contact Name	Lisa D. Brooks, Ph.D.																		
Contact Telephone	301-547-1387																		
Contact Email	lisa.brooks@nih.gov																		
Sponsor Website																			
Program URL	Link to program URL																		
Deadline Dates (ALL)	05-Apr-2022 , 07-May-2022 , 05-Jun-2022 , 16-Jun-2022 , 05-Sep-2022 , 07-Sep-2022 , 05-Oct-2022 , 16-Oct-2022 , 05-Jan-2023 , 07-Jan-2023 , 05-Feb-2023 , 16-Feb-2023 , 05-Apr-2023 , 07-May-2023 , 05-Jun-2023 , 16-Jun-2023 , 05-Sep-2023 , 07-Sep-2023 , 05-Oct-2023 , 16-Oct-2023 , 05-Jan-2024 , 07-Jan-2024 , 05-Feb-2024 , 16-Feb-2024 , 05-Apr-2024 , 07-May-2024 , 05-Jun-2024 , 16-Jun-2024 , 05-Sep-2024 , 07-Sep-2024 , 05-Oct-2024																		
Synopsis	The National Human Genome Research Institute (NHGRI) is issuing this Notice of Special Interest (NOSI) to encourage applications that develop novel computational or experimental approaches for genomic studies of how genetic variants relate to genomic function, phenotype, and disease.																		
101030	Notice of Special Interest (NOSI): High-throughput Molecular and Cellular Phenotyping	National Human Genome Research Institute/NIH/DHHS	NOT-HG-21-004	07-May-2022	Not Specified														
	<table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 20%; padding: 5px;">Contact Name</td> <td style="padding: 5px;">Colin Fletcher, Ph.D.</td> </tr> <tr> <td style="padding: 5px;">Contact Telephone</td> <td style="padding: 5px;">301-496-7531</td> </tr> <tr> <td style="padding: 5px;">Contact Email</td> <td style="padding: 5px;">fletcher2@mail.nih.gov</td> </tr> <tr> <td style="padding: 5px;">Sponsor Website</td> <td style="padding: 5px;"></td> </tr> <tr> <td style="padding: 5px;">Program URL</td> <td style="padding: 5px;">Link to program URL</td> </tr> <tr> <td style="padding: 5px;">Deadline Dates (ALL)</td> <td style="padding: 5px;">07-May-2022 , 05-Jun-2022 , 05-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 05-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 05-Feb-2023 , 07-May-2023 , 05-Jun-2023 , 05-Jun-2023 , 07-Sep-2023 , 05-Oct-2023 , 05-Oct-2023 , 07-Jan-2024</td> </tr> <tr> <td style="padding: 5px;">Synopsis</td> <td style="padding: 5px;">The National Human Genome Research Institute (NHGRI) is issuing this Notice of Special Interest (NOSI) to encourage applications focused on developing novel methods to perform high-throughput molecular and cellular phenotyping in order to elucidate the functional consequences of DNA variation.</td> </tr> </table>					Contact Name	Colin Fletcher, Ph.D.	Contact Telephone	301-496-7531	Contact Email	fletcher2@mail.nih.gov	Sponsor Website		Program URL	Link to program URL	Deadline Dates (ALL)	07-May-2022 , 05-Jun-2022 , 05-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 05-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 05-Feb-2023 , 07-May-2023 , 05-Jun-2023 , 05-Jun-2023 , 07-Sep-2023 , 05-Oct-2023 , 05-Oct-2023 , 07-Jan-2024	Synopsis	The National Human Genome Research Institute (NHGRI) is issuing this Notice of Special Interest (NOSI) to encourage applications focused on developing novel methods to perform high-throughput molecular and cellular phenotyping in order to elucidate the functional consequences of DNA variation.
Contact Name	Colin Fletcher, Ph.D.																		
Contact Telephone	301-496-7531																		
Contact Email	fletcher2@mail.nih.gov																		
Sponsor Website																			
Program URL	Link to program URL																		
Deadline Dates (ALL)	07-May-2022 , 05-Jun-2022 , 05-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 05-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 05-Feb-2023 , 07-May-2023 , 05-Jun-2023 , 05-Jun-2023 , 07-Sep-2023 , 05-Oct-2023 , 05-Oct-2023 , 07-Jan-2024																		
Synopsis	The National Human Genome Research Institute (NHGRI) is issuing this Notice of Special Interest (NOSI) to encourage applications focused on developing novel methods to perform high-throughput molecular and cellular phenotyping in order to elucidate the functional consequences of DNA variation.																		
108514	RFA-HG-22-004 -- Genome Research Experiences to Attract Talented Undergraduates into Genomic Fields to Enhance Diversity (R25 Clinical Trial Not Allowed)	National Human Genome Research Institute/NIH/DHHS	RFA-HG-22-004	01-Jun-2022 [Optional][LOI/Pre-App]	1,750,000 USD														

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

Contact Name Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL)	Tina Gatlin, Ph.D. 301-480-2280 gatlincl@nih.gov Link to program URL 01-Jun-2022 [Optional][LOI/Pre-App], 01-Jul-2022 , 01-Jun-2023 [Optional][LOI/Pre-App], 01-Jul-2023 Synopsis The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The overarching goal of this R25 program is to support educational activities that encourage individuals from diverse backgrounds, including those from groups underrepresented in the biomedical and behavioral sciences, to pursue further studies or careers in research. The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The overarching goal of this NHGRI R25 program is to support educational activities that encourage undergraduates from diverse backgrounds, including those from groups underrepresented in the biomedical workforce, to pursue further training and careers in the scientific, medical, ethical, social and/or legal areas of genomics research. To accomplish the stated over-arching goal, this FOA will support creative educational activities with a primary focus on: Research Experiences Courses for Skills Development This Genome Research Experiences to Attract Talented Undergraduates into the Genomic Field to Promote Diversity (GREAT) Program will support collaborative institutional partnerships that provide research education programs for undergraduates enrolled at minority-serving institutions (MSIs) or Institutional Development Award (IDeA)-eligible institutions. A partnership will include a MSI or IDeA-eligible institution, and one or more research-intensive institutions or organizations with a suitable research base for graduate-level training in scientific areas of interest to NHGRI.
--	---

109305	RFA-AI-22-010 -- Partnerships for Rapid Diagnostics and Phenotypic Antibacterial Susceptibility Testing for Bacteremia or Hospital Acquired Pneumonia (R01 Clinical Trial Not Allowed)	National Institute of Allergy and Infectious Diseases/NIH/DHHS	RFA-AI-22-010	02-May-2022 [Optional][LOI/Pre-App]	Not Specified
--------	--	--	---------------	-------------------------------------	---------------

Contact Name Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL)	Michael R. Schaefer, Ph.D. 240-627-3364 mschaefer@niaid.nih.gov Link to program URL 02-May-2022 [Optional][LOI/Pre-App], 01-Jun-2022
--	---

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Synopsis	The purpose of this Funding Opportunity Announcement (FOA) is to support research projects focused on development and/or production of medical diagnostics that permit rapid differential species identification, and corresponding phenotypic antibacterial susceptibility profiles for bacteremia or hospital acquired pneumonia. The primary goal of such diagnostics is to facilitate antibacterial stewardship, thereby reducing selective pressure and improving patient outcomes.			
108053	RFA-AI-21-079 -- Asthma and Allergic Diseases Cooperative Research Centers (U19 Clinical Trial Optional)	National Institute of Allergy and Infectious Diseases/NIH/DHHS	RFA-AI-21-079	04-May-2022 [Optional][LOI/Pre-App]	4,500,000 USD
	Contact Name	Gang Dong, M.D., Ph.D.			
	Contact Telephone	240-627-3508			
	Contact Email	gdong@mail.nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	04-May-2022 [Optional][LOI/Pre-App], 03-Jun-2022			
	Synopsis	The purpose of this Funding Opportunity Announcement (FOA) is to invite applications from single institutions or consortia of institutions to participate in the Asthma and Allergic Diseases Cooperative Research Centers (AADCRC) program. The program will support centers that integrate clinical and translational research to conduct studies on the mechanisms underlying the onset and progression of diseases of interest, including asthma, rhinitis (allergic and non-allergic), chronic rhinosinusitis, atopic dermatitis, food allergy, and drug allergy. The overarching goal of the program is to improve the understanding of the pathogenesis of these conditions and to provide a rational foundation for new, effective treatments and prevention strategies.			
107638	Notice of Special Interest (NOSI): Accelerating Malaria Vaccine Discovery	National Institute of Allergy and Infectious Diseases/NIH/DHHS	NOT-AI-22-014	07-May-2022	Not Specified
	Contact Name	Annie Mo, Ph.D.			
	Contact Telephone	240-627-3320			
	Contact Email	moa@niaid.nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	07-May-2022 , 05-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 07-May-2023 , 05-Jun-2023 , 07-Sep-2023 , 05-Oct-2023 , 07-Jan-2024 , 05-Feb-2024 , 07-May-2024 , 05-Jun-2024 , 07-Sep-2024 , 05-Oct-2024 , 07-Jan-2025			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Synopsis	The purpose of this Notice of Special Interest (NOSI) is to inform potential applicants about an area of special interest to NIAID on early phase translational research that will generate new malaria vaccine candidates with desirable features suitable for further downstream development and clinical evaluation. This NOSI encourages studies that will lead to discovery of new vaccine candidates that prevent infection, ameliorate disease, and/or interrupt transmission caused by human malaria parasites, especially Plasmodium falciparum and Plasmodium vivax.			
094378	NIAID Physician-Scientist Pathway to Independence Award (K99/R00 Clinical Trial Required)	National Institute of Allergy and Infectious Diseases/NIH/DHHS	PAR-20-209	07-May-2022	Not Specified
	Contact Name	Deborah Philip, Ph.D.			
	Contact Telephone	301-761-7776			
	Contact Email	AITrainingHelpDesk@niaid.nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	07-May-2022 , 12-Jun-2022 , 07-Sep-2022 , 12-Oct-2022 , 07-Jan-2023 , 12-Feb-2023 , 07-May-2023			
	Synopsis	The purpose of the NIAID Physician-Scientist Pathway to Independence Award (K99/R00) program is to increase and maintain a strong cohort of new and talented independent physician-scientists. This program is designed to facilitate a timely transition of outstanding postdoctoral researchers with a clinical doctorate degree from mentored, postdoctoral research positions to independent, tenure-track or equivalent faculty positions. The program will provide independent NIAID research support during this transition to help awardees launch competitive, independent research careers in biomedical fields and thereby help to address the national physician-scientist workforce shortage. This Funding Opportunity Announcement (FOA) is designed specifically for candidates proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary clinical trial, as part of their research and career development. Those not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must apply to companion FOA (PAR-20-210).			
094380	NIAID Physician-Scientist Pathway to Independence Award (K99/R00 Independent Clinical Trial Not Allowed)	National Institute of Allergy and Infectious Diseases/NIH/DHHS	PAR-20-210	07-May-2022	Not Specified
	Contact Name	Shawn Drew Gaillard, Ph.D.			
	Contact Telephone	301-761-7776			
	Contact Email	AITrainingHelpDesk@niaid.nih.gov			
	Sponsor Website				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2022 , 12-Jun-2022 , 07-Sep-2022 , 12-Oct-2022 , 07-Jan-2023</p> <p>Synopsis The purpose of the NIAID Physician-Scientist Pathway to Independence Award (K99/R00) program is to increase and maintain a strong cohort of new and talented independent physician-scientists. This program is designed to facilitate a timely transition of outstanding postdoctoral researchers with a clinical doctorate degree from mentored, postdoctoral research positions to independent, tenure-track or equivalent faculty positions. The program will provide independent NIAID research support during this transition to help awardees launch competitive, independent research careers in biomedical fields and thereby help to address the national physician-scientist workforce shortage. This Funding Opportunity Announcement (FOA) is designed specifically for candidates proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary study to a clinical trial. Under this FOA candidates are permitted to propose a research experience in a clinical trial led by a mentor or co-mentor. Those proposing a clinical trial or an ancillary study to an ongoing clinical trial as lead investigator, should apply to the companion FOA (PAR-20-209).</p>				
107851	Notice of Special Interest (NOSI): Advancing Research Needed to Develop a Universal Influenza Vaccine	National Institute of Allergy and Infectious Diseases/NIH/DHHS	NOT-AI-22-013	07-May-2022	Not Specified
	<p>Contact Name Jennifer L. Gordon, Ph.D.</p> <p>Contact Telephone 301-761-6805</p> <p>Contact Email Jennifer.gordon2@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2022 , 05-Jun-2022 , 16-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 16-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 16-Feb-2023 , 07-May-2023 , 05-Jun-2023 , 16-Jun-2023 , 07-Sep-2023 , 05-Oct-2023 , 16-Oct-2023 , 07-Jan-2024 , 05-Feb-2024 , 16-Feb-2024 , 07-May-2024 , 05-Jun-2024 , 16-Jun-2024 , 07-Sep-2024 , 05-Oct-2024 , 16-Oct-2024 , 07-Jan-2025</p> <p>Synopsis The purpose of this Notice of Special Interest (NOSI) is to support research that contributes to the areas of interest outlined in “A Universal Influenza Vaccine: The Strategic Plan for the National Institute of Allergy and Infectious Diseases.”</p>				
102961	Notice of Special Interest (NOSI): Investigations on Inborn Errors of Immunity/Primary Immunodeficiencies	National Institute of Allergy and Infectious Diseases/NIH/DHHS	NOT-AI-21-032	07-May-2022	Not Specified
	<p>Contact Name Frosso Voulgaropoulou, PhD</p> <p>Contact Telephone 240-627-3205</p> <p>Contact Email fvoulgaropoulou@niaid.nih.gov</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2022 , 05-Jun-2022 , 16-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 16-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 16-Feb-2023 , 07-May-2023 , 05-Jun-2023 , 16-Jun-2023 , 07-Sep-2023 , 05-Oct-2023 , 16-Oct-2023 , 07-Jan-2024 , 05-Feb-2024 , 16-Feb-2024 , 07-May-2024</p> <p>Synopsis This Notice of Special Interest (NOSI) is to support the discovery and characterization of Inborn Errors of Immunity, also referred to as Primary Immunodeficiencies, to understand the causes and mechanisms of disease, to enable early detection and molecular diagnosis, and to support the development of strategies to treat and eventually cure these disorders.</p>				
105630	Notice of Special Interest (NOSI): Understanding the Immune Functions of DEAD/H-box Helicases	National Institute of Allergy and Infectious Diseases/NIH/DHHS	NOT-AI-21-066	07-May-2022	Not Specified
	<p>Contact Name Qian “Joy” Liu, M.D., M.Sc.</p> <p>Contact Telephone 301-761-6621</p> <p>Contact Email liujoy@niaid.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2022 , 05-Jun-2022 , 16-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 16-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 16-Feb-2023 , 07-May-2023 , 05-Jun-2023 , 16-Jun-2023 , 07-Sep-2023 , 05-Oct-2023 , 16-Oct-2023 , 07-Jan-2024 , 05-Feb-2024 , 16-Feb-2024 , 07-May-2024 , 05-Jun-2024 , 16-Jun-2024 , 07-Sep-2024</p> <p>Synopsis This Notice of Special Interest (NOSI) supports research aimed at gaining a comprehensive understanding of the expression, function, and regulation of DEAD/H-box helicases in immune homeostasis, activation, and/or function. Knowledge obtained from such studies may be applied to the design of improved vaccines and immunotherapies to combat pathogenic infections or treat/prevent immune-mediated diseases.</p>				
099832	Limited Competition: Exploratory and Developmental Research Grant Program for NIAID K01/K08/K23 Recipients (R21 Clinical Trial Not Allowed)	National Institute of Allergy and Infectious Diseases/NIH/DHHS	PAR-20-291	07-May-2022	275,000 USD
	<p>Contact Name Timothy A. Gondré-Lewis, Ph.D.</p> <p>Contact Telephone 240-627-3566</p> <p>Contact Email tglewis@mail.nih.gov</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	07-May-2022 , 16-Jun-2022 , 07-Sep-2022 , 16-Oct-2022 , 07-Jan-2023 , 16-Feb-2023 , 07-May-2023 , 16-Jun-2023 , 07-Sep-2023			
	Synopsis	The National Institute of Allergy and Infectious Diseases (NIAID) announces a program that provides NIAID-supported K01, K08, and K23 recipients with the opportunity to apply for Exploratory and Developmental Research Grant (R21) support at some point during the final two years of their K award. Through the use of this mechanism, NIAID seeks to enhance the capability of its K01, K08, and K23 award recipients to conduct research as they complete their transition to fully independent investigator status (e.g., R01 support). The R21 grant mechanism supports different types of projects, including pilot and feasibility studies; secondary analysis of existing data; small, self-contained research projects; development of research methodology; and development of new research technology. The R21 is, therefore, intended to support research projects that may provide preliminary data to support a subsequent R01, or equivalent, application.			
099831	Limited Competition: Small Research Grant Program for NIAID K01/K08/K23 Recipients (R03 Clinical Trial Not Allowed)	National Institute of Allergy and Infectious Diseases/NIH/DHHS	PAR-20-290	07-May-2022	100,000 USD
	Contact Name	Stacy E. Ferguson, Ph.D.			
	Contact Telephone	240-627-3504			
	Contact Email	fergusont@niaid.nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	07-May-2022 , 16-Jun-2022 , 07-Sep-2022 , 16-Oct-2022 , 07-Jan-2023 , 16-Feb-2023 , 07-May-2023 , 16-Jun-2023 , 07-Sep-2023			
	Synopsis	The National Institute of Allergy and Infectious Diseases (NIAID) announces a program that provides NIAID-supported K01, K08, and K23 recipients with the opportunity to apply for Small Research Grant (R03) support at some point during the final two years of their K award. Through the use of this mechanism, NIAID seeks to enhance the capability of its K01, K08, and K23 award recipients to conduct research as they complete their transition to fully independent investigator status (e.g., R01 support). The R03 grant mechanism supports different types of projects, including pilot and feasibility studies; secondary analysis of existing data; small, self-contained research projects; development of research methodology; and development of new research technology. The R03 is, therefore, intended to support research projects that can be carried out in a short period of time with limited resources and that may provide preliminary data to support a subsequent R01, or equivalent, application.			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
107589	Notice of Special Interest (NOSI): Molecular and Genetic Characterization of Inborn Errors of Immunity	National Institute of Allergy and Infectious Diseases/NIH/DHHS	NOT-AI-21-082	07-May-2022	Not Specified
	<p>Contact Name: Frosso Voulgaropoulou, PhD</p> <p>Contact Telephone: 240-627-3205</p> <p>Contact Email: fvoulgaropoulou@niaid.nih.gov</p> <p>Sponsor Website:</p> <p>Program URL: Link to program URL</p> <p>Deadline Dates (ALL): 07-May-2022 , 05-Jun-2022 , 16-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 16-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 16-Feb-2023 , 07-May-2023 , 05-Jun-2023 , 16-Jun-2023 , 07-Sep-2023 , 05-Oct-2023 , 16-Oct-2023 , 07-Jan-2024 , 05-Feb-2024 , 16-Feb-2024 , 07-May-2024 , 05-Jun-2024 , 16-Jun-2024 , 07-Sep-2024 , 05-Oct-2024 , 16-Oct-2024 , 07-Jan-2025</p> <p>Synopsis: The purpose of this Notice of Special Interest (NOSI) is to advance the experimental validation and functional characterization of genetic variants in coding or non-coding genomic regions that result in inborn errors of immunity/primary immunodeficiency diseases and to elucidate the molecular, cellular, and immunological mechanisms of these disorders. Understanding the genetic basis of primary immunodeficiency disorders is essential for their diagnosis, prognosis, and the development of precision therapeutics.</p>				
108513	NIAID Career Transition Award (K22 Independent Clinical Trial Not Allowed)	National Institute of Allergy and Infectious Diseases/NIH/DHHS	PAR-22-075	07-May-2022	Not Specified
	<p>Contact Name:</p> <p>Contact Telephone:</p> <p>Contact Email: AITrainingHelpDesk@niaid.nih.gov</p> <p>Sponsor Website:</p> <p>Program URL: Link to program URL</p> <p>Deadline Dates (ALL): 07-May-2022 , 12-Jun-2022 , 07-Sep-2022 , 12-Oct-2022 , 07-Jan-2023 , 12-Feb-2023 , 07-May-2023 , 12-Jun-2023 , 07-Sep-2023 , 12-Oct-2023 , 07-Jan-2024 , 12-Feb-2024 , 07-May-2024 , 12-Jun-2024 , 07-Sep-2024 , 12-Oct-2024 , 07-Jan-2025</p> <p>Synopsis: The purpose of the NIAID Career Transition Award program is to assist postdoctoral fellows' transition to positions of assistant professor or equivalent and initiate a successful biomedical career as an independent research scientist. This Funding Opportunity Announcement (FOA) is designed specifically for candidates proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary study to a clinical trial. Under this FOA candidates are permitted to propose a research experience in a clinical trial led by another investigator.</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
102013	Notice of Special Interest (NOSI): Complement in Basic Immunology (CIBI)	National Institute of Allergy and Infectious Diseases/NIH/DHHS	NOT-AI-21-008	07-May-2022	Not Specified
	<p>Contact Name Cheryl Lapham, Ph.D.</p> <p>Contact Telephone 240-627-3490</p> <p>Contact Email clapham@niaid.nih.gov</p> <p>Sponsor Website </p> <p>Program URL </p> <p>Deadline Dates (ALL) 07-May-2022 , 05-Jun-2022 , 16-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 16-Oct-2022 , 07-Jan-2023</p> <p>Synopsis The main objective of this program is to support studies that accelerate our understanding of the roles of complement components and/or receptors in the initiation, magnitude, maintenance, and quality of immune responses against infectious agents, or of the roles played by complement in the development of immune-mediated pathogenic responses following infection. The results of such studies will inform the development of adjuvants and vaccine candidates or therapeutics that target complement components.</p>				
105735	Notice of Special Interest (NOSI): Using the Collaborative Cross (CC) Mouse Model for Immunoregulatory and Infectious Disease Research	National Institute of Allergy and Infectious Diseases/NIH/DHHS	NOT-AI-21-071	07-May-2022	Not Specified
	<p>Contact Name Qian "Joy" Liu, M.D., M.Sc.</p> <p>Contact Telephone 301-761-6621</p> <p>Contact Email liujoy@niaid.nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2022 , 05-Jun-2022 , 16-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 16-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 16-Feb-2023 , 07-May-2023 , 05-Jun-2023 , 16-Jun-2023 , 07-Sep-2023 , 05-Oct-2023 , 16-Oct-2023 , 07-Jan-2024 , 05-Feb-2024 , 16-Feb-2024 , 07-May-2024 , 05-Jun-2024 , 16-Jun-2024 , 07-Sep-2024</p> <p>Synopsis The National Institute of Allergy and Immunology (NIAID) is issuing this Notice of Special Interest (NOSI) to highlight interest in receiving grant applications focusing on the following area(s): Use mouse lines from the Collaborative Cross (CC) and recombinant inbred intercrosses of CC lines (CC-RIX) to more faithfully reproduce human immune responses and to advance understanding of the host genetics involved in immune regulation and function Screen CC mouse lines to identify and</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		characterize lines suitable for specific studies and disease models within the mission of NIAID (e.g., fundamental immunology, immune-mediated diseases, infectious diseases).			
106991	Notice of Special Interest (NOSI): Leveraging Microbial Exposure for Improving Mouse Models of Human Immunity	National Institute of Allergy and Infectious Diseases/NIH/DHHS	NOT-AI-21-072	07-May-2022	Not Specified
	Contact Name	Qian “Joy” Liu, M.D., M.Sc.			
	Contact Telephone	301-761-6621			
	Contact Email	niaidmousemodelnosi@nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	07-May-2022 , 05-Jun-2022 , 16-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 16-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 16-Feb-2023 , 07-May-2023 , 05-Jun-2023 , 16-Jun-2023 , 07-Sep-2023 , 05-Oct-2023 , 16-Oct-2023 , 07-Jan-2024 , 05-Feb-2024 , 16-Feb-2024 , 07-May-2024 , 05-Jun-2024 , 16-Jun-2024 , 07-Sep-2024 , 05-Oct-2024 , 16-Oct-2024 , 07-Jan-2025			
	Synopsis	This Notice of Special Interest (NOSI) solicits research on immunologic characterization of mice with diverse microbial exposures (commonly referred to as “dirty mice”) to determine their usefulness as research tools to advance understanding of human immune function in homeostasis and in response to infectious or immune-mediated diseases.			
109413	RFA-AI-22-012 -- Immune Drivers of Autoimmune Disease (IDAD) (U01 Clinical Trial Not Allowed)	National Institute of Allergy and Infectious Diseases/NIH/DHHS	RFA-AI-22-012	01-Jun-2022 [Optional][LOI/Pre-App]	3,750,000 USD
	Contact Name	Thomas R. Esch, Ph.D.			
	Contact Telephone	240-627-3565			
	Contact Email	tesch@niaid.nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	01-Jun-2022 [Optional][LOI/Pre-App], 01-Jul-2022			
	Synopsis	This Funding Opportunity Announcement (FOA) invites applications to participate in the Immune Drivers of Autoimmune Disease (IDAD) cooperative research program, which will focus on defining the immunologic states and dynamics that drive autoimmune disease. The main objective of this program is to enhance our understanding of the immunologic processes, events, and changes that underlie the clinical manifestations of autoimmune diseases, including disease flare, remission, and			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		progression of established disease, as well as the progression from a state of elevated risk to clinical diagnosis of autoimmune disease.			
102837	RFA-AI-21-035-- Exploratory Data Science Methods and Algorithm Development in Infectious and Immune-mediated Diseases (R21 Clinical Trial Not Allowed)	National Institute of Allergy and Infectious Diseases/NIH/DHHS	RFA-AI-21-035	01-Jun-2022 [Optional][LOI/Pre-App]	275,000 USD
	Contact Name	Steve Tsang, PhD			
	Contact Telephone	240-627-3330			
	Contact Email	AI-DSFOAinquiries@nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	01-Jun-2022 [Optional][LOI/Pre-App], 01-Jul-2022 , 18-Jan-2023 [Optional][LOI/Pre-App], 17-Feb-2023 , 06-Jun-2023 [Optional][LOI/Pre-App], 06-Jul-2023			
	Synopsis	The purpose of this Funding Opportunity Announcement (FOA) is to support exploratory research focused on developing innovative methods and algorithms in biomedical computing, informatics, and data science addressing priority needs across the infectious or immune-mediated disease research continuum aligned with the research mission of NIAID. This includes infectious diseases, emerging infections, or immune-mediated diseases that include allergy, autoimmunity, or immune reactions associated with transplantation. As a part of the trans-NIAID Data Science program, this R21 FOA encourages applications focused on the development of novel computational, mathematical, and statistical algorithms and methods, including artificial intelligence and machine learning approaches, that can considerably improve acquisition, management, analysis, visualization, and dissemination of relevant data and/or knowledge. This contrasts with early-stage development (U01) and enhancement/sustainment (U24) efforts to generate these tools and resources that are supported by the companion FOAs.			
102836	RFA-AI-21-020 -- Early-Stage Development of Data Science Technologies for Infectious and Immune-mediated Diseases (U01 Clinical Trial Not Allowed)	National Institute of Allergy and Infectious Diseases/NIH/DHHS	RFA-AI-21-020	01-Jun-2022 [Optional][LOI/Pre-App]	900,000 USD
	Contact Name	Steve Tsang, PhD			
	Contact Telephone	240-627-3330			
	Contact Email	AI-DSFOAinquiries@nih.gov			
	Sponsor Website				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 01-Jun-2022 [Optional][LOI/Pre-App], 01-Jul-2022 , 18-Jan-2023 [Optional][LOI/Pre-App], 17-Feb-2023 , 06-Jun-2023 [Optional][LOI/Pre-App], 06-Jul-2023</p> <p>Synopsis The purpose of this Funding Opportunity Announcement (FOA) is to solicit applications for the development of enabling data science technologies to improve the acquisition, management, analysis, visualization, and dissemination of data and knowledge for immune-mediated and infectious diseases including disease mechanism, risk prediction, epidemiology, detection and diagnosis, treatment and vaccines across the allergy, immune-mediated, and infectious-disease research continuum, aligned with the research mission of NIAID. This includes infectious diseases, emerging infections, or immune-mediated diseases that include allergy, autoimmunity, or immune reactions associated with transplantation. As a part of the trans-NIAID data science program, this FOA focuses on early-stage development from prototyping to hardening and adaptation. Early-stage development is defined for the purpose of this FOA as initial tool development or the significant modification of existing tools for new applications. This contrasts with exploratory (R21) and enhancement/sustainment (U24) efforts to generate these tools and resources that are supported by the companion FOAs.</p>				
109336	Notice of Special Interest (NOSI): <u>ptimizing Vascularized Composite Allograft Survival</u>	National Institute of Allergy and Infectious Diseases/NIH/DHHS	NOT-AI-22-023	05-Jun-2022	Not Specified
	<p>Contact Name Patricia Kehn, Ph.D.</p> <p>Contact Telephone 240-627-3547</p> <p>Contact Email pkeh@NIAID.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 05-Jun-2022 , 16-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 16-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 16-Feb-2023 , 07-May-2023 , 05-Jun-2023 , 16-Jun-2023 , 07-Sep-2023 , 05-Oct-2023 , 16-Oct-2023 , 07-Jan-2024 , 05-Feb-2024 , 16-Feb-2024 , 07-May-2024 , 05-Jun-2024 , 16-Jun-2024 , 07-Sep-2024 , 05-Oct-2024 , 16-Oct-2024 , 07-Jan-2025 , 05-Feb-2025 , 16-Feb-2025 , 07-May-2025 , 05-Jun-2025 , 16-Jun-2025 , 07-Sep-2025 , 05-Oct-2025 , 16-Oct-2025 , 07-Jan-2026 , 05-Feb-2026 , 16-Feb-2026 , 07-May-2026</p> <p>Synopsis The National Institute of Allergy and Infectious Diseases (NIAID) is interested in supporting preclinical studies utilizing animal models or human tissue specimens that focus on 1) optimizing treatment and graft monitoring to reduce incidence of acute rejection and maximize graft survival after vascularized composite allotransplantation (VCA) and 2) minimizing immunosuppression required for long-term VCA acceptance.</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount														
109533	RFA-AI-22-016 -- Improved Drug Susceptibility Testing (DST) for Tuberculosis (R01 Clinical Trial Not Allowed)	National Institute of Allergy and Infectious Diseases/NIH/DHHS	RFA-AI-22-016	08-Jun-2022 [Optional][LOI/Pre-App]	2,500,000 USD														
	<table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 20%; padding-right: 5px;">Contact Name</td> <td>Karen A. Lacourciere, Ph.D.</td> </tr> <tr> <td style="padding-right: 5px;">Contact Telephone</td> <td>240-627-3297</td> </tr> <tr> <td style="padding-right: 5px;">Contact Email</td> <td>lacourcierek@mail.nih.gov</td> </tr> <tr> <td style="padding-right: 5px;">Sponsor Website</td> <td></td> </tr> <tr> <td style="padding-right: 5px;">Program URL</td> <td>Link to program URL</td> </tr> <tr> <td style="padding-right: 5px;">Deadline Dates (ALL)</td> <td>08-Jun-2022 [Optional][LOI/Pre-App], 08-Jul-2022</td> </tr> <tr> <td style="padding-right: 5px;">Synopsis</td> <td>The purpose of this Funding Opportunity Announcement (FOA) is to support the development of new diagnostic technologies for tuberculosis (TB) drug susceptibility testing (DST), including point of care (POC) DST and companion diagnostics for new TB drugs.</td> </tr> </table>					Contact Name	Karen A. Lacourciere, Ph.D.	Contact Telephone	240-627-3297	Contact Email	lacourcierek@mail.nih.gov	Sponsor Website		Program URL	Link to program URL	Deadline Dates (ALL)	08-Jun-2022 [Optional][LOI/Pre-App], 08-Jul-2022	Synopsis	The purpose of this Funding Opportunity Announcement (FOA) is to support the development of new diagnostic technologies for tuberculosis (TB) drug susceptibility testing (DST), including point of care (POC) DST and companion diagnostics for new TB drugs.
Contact Name	Karen A. Lacourciere, Ph.D.																		
Contact Telephone	240-627-3297																		
Contact Email	lacourcierek@mail.nih.gov																		
Sponsor Website																			
Program URL	Link to program URL																		
Deadline Dates (ALL)	08-Jun-2022 [Optional][LOI/Pre-App], 08-Jul-2022																		
Synopsis	The purpose of this Funding Opportunity Announcement (FOA) is to support the development of new diagnostic technologies for tuberculosis (TB) drug susceptibility testing (DST), including point of care (POC) DST and companion diagnostics for new TB drugs.																		
106576	Notice of Special Interest (NOSI): Promoting Pain Research Within the NIAMS Mission Areas	National Institute of Arthritis and Musculoskeletal and Skin Diseases/NIH/DHHS	NOT-AR-22-007	12-Apr-2022	Not Specified														
	<table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 20%; padding-right: 5px;">Contact Name</td> <td>Leslie K. Derr, Ph.D.</td> </tr> <tr> <td style="padding-right: 5px;">Contact Telephone</td> <td>301-402-4735</td> </tr> <tr> <td style="padding-right: 5px;">Contact Email</td> <td>leslie.derr@nih.gov</td> </tr> <tr> <td style="padding-right: 5px;">Sponsor Website</td> <td></td> </tr> <tr> <td style="padding-right: 5px;">Program URL</td> <td>Link to program URL</td> </tr> <tr> <td style="padding-right: 5px;">Deadline Dates (ALL)</td> <td>12-Apr-2022 , 05-Jun-2022 , 16-Jun-2022 , 01-Jul-2022 , 12-Jul-2022 , 20-Jul-2022 , 12-Aug-2022 , 05-Oct-2022 , 16-Oct-2022 , 25-Oct-2022 , 01-Nov-2022 , 12-Nov-2022 , 18-Nov-2022 , 12-Dec-2022 , 22-Jun-2025</td> </tr> <tr> <td style="padding-right: 5px;">Synopsis</td> <td>The purpose of this announcement is to notify the research community that the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) is interested in receiving grant applications focused on pain within the NIAMS mission areas.</td> </tr> </table>					Contact Name	Leslie K. Derr, Ph.D.	Contact Telephone	301-402-4735	Contact Email	leslie.derr@nih.gov	Sponsor Website		Program URL	Link to program URL	Deadline Dates (ALL)	12-Apr-2022 , 05-Jun-2022 , 16-Jun-2022 , 01-Jul-2022 , 12-Jul-2022 , 20-Jul-2022 , 12-Aug-2022 , 05-Oct-2022 , 16-Oct-2022 , 25-Oct-2022 , 01-Nov-2022 , 12-Nov-2022 , 18-Nov-2022 , 12-Dec-2022 , 22-Jun-2025	Synopsis	The purpose of this announcement is to notify the research community that the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) is interested in receiving grant applications focused on pain within the NIAMS mission areas.
Contact Name	Leslie K. Derr, Ph.D.																		
Contact Telephone	301-402-4735																		
Contact Email	leslie.derr@nih.gov																		
Sponsor Website																			
Program URL	Link to program URL																		
Deadline Dates (ALL)	12-Apr-2022 , 05-Jun-2022 , 16-Jun-2022 , 01-Jul-2022 , 12-Jul-2022 , 20-Jul-2022 , 12-Aug-2022 , 05-Oct-2022 , 16-Oct-2022 , 25-Oct-2022 , 01-Nov-2022 , 12-Nov-2022 , 18-Nov-2022 , 12-Dec-2022 , 22-Jun-2025																		
Synopsis	The purpose of this announcement is to notify the research community that the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) is interested in receiving grant applications focused on pain within the NIAMS mission areas.																		
107713	Notice of Special Interest (NOSI): Promoting Research Opportunities on HIV/AIDS in NIAMS	National Institute of Arthritis and Musculoskeletal and Skin Diseases/NIH/DHHS	NOT-AR-20-005	07-May-2022	Not Specified														
	<table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 20%; padding-right: 5px;">Contact Name</td> <td>Heiyoung Park, Ph.D.</td> </tr> </table>					Contact Name	Heiyoung Park, Ph.D.												
Contact Name	Heiyoung Park, Ph.D.																		

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Telephone 301-594-5032</p> <p>Contact Email parkh1@mail.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2022 , 05-Jun-2022 , 16-Jun-2022 , 20-Jul-2022 , 07-Sep-2022 , 05-Oct-2022 , 16-Oct-2022 , 18-Nov-2022 , 07-Jan-2023</p> <p>Synopsis The purpose of this announcement is to inform potential applicants to the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) of an area of special interest in HIV/AIDS-associated comorbidities that are within the NIAMS mission.</p>				
108115	Notice of Special Interest (NOSI): Promoting Research on COVID-19 and Rheumatic, Musculoskeletal and Skin Diseases	National Institute of Arthritis and Musculoskeletal and Skin Diseases/NIH/DHHS	NOT-AR-22-012	07-May-2022	Not Specified
	<p>Contact Name Marie Mancini, Ph.D.</p> <p>Contact Telephone 301-594-5032</p> <p>Contact Email mancinim2@mail.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2022 , 05-Jun-2022 , 16-Jun-2022 , 01-Jul-2022 , 20-Jul-2022 , 07-Sep-2022 , 05-Oct-2022 , 16-Oct-2022 , 04-Nov-2022 , 18-Nov-2022 , 07-Jan-2023</p> <p>Synopsis The purpose of this Notice is to announce to potential applicants to the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) an interest in research on the impact of COVID-19 as related to diseases and conditions within the NIAMS mission.</p>				
109528	Limited Competition: Small Grant Program for NIAMS K01, K08, K23, and K25 Recipients (R03) (Clinical Trials Not Allowed)	National Institute of Arthritis and Musculoskeletal and Skin Diseases/NIH/DHHS	PAR-22-119	20-Jun-2022	100,000 USD
	<p>Contact Name Su-Yau Mao, Ph.D.</p> <p>Contact Telephone 301-594-5032</p> <p>Contact Email maos2@mail.nih.gov</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	20-Jun-2022 , 19-Oct-2022 , 21-Feb-2023 , 19-Jun-2023 , 19-Oct-2023 , 20-Feb-2024 , 19-Jun-2024 , 21-Oct-2024 , 19-Feb-2025			
	Synopsis	<p>The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) announces a program that provides NIAMS-supported K01, K08, K23, and K25 recipients the opportunity to apply for Small Grant (R03) support at an appropriate point during the second to fourth year of their K award. Through the use of this mechanism, which allows up to \$100,000 direct costs for the entire project period of up to two years, the NIAMS is seeking to enhance the capability of its scientists to conduct research as they complete their transition to fully independent investigator status. The R03 grant mechanism supports different types of projects, including pilot and feasibility studies; secondary analysis of existing data; small, self-contained research projects; development of research methodology; and development of new research technology. The R03 is, therefore, intended to support research projects that can be carried out in a short period of time with limited resources and that provide support, in addition to the career development award, for a subsequent R01, or equivalent, application. Clinical trials of any phase will not be supported by this FOA.</p>			
100387	Mechanistic Ancillary Studies to Ongoing Clinical Projects (R21 Clinical Trial Not Allowed)	National Institute of Arthritis and Musculoskeletal and Skin Diseases/NIH/DHHS	PAR-21-054	20-Jun-2022 [Optional][LOI/Pre-App]	400,000 USD
	Contact Name	Heiyoung Park, Ph.D.			
	Contact Telephone	301-594-5032			
	Contact Email	parkh1@mail.nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	20-Jun-2022 [Optional][LOI/Pre-App], 20-Jul-2022 , 18-Oct-2022 [Optional][LOI/Pre-App], 18-Nov-2022			
	Synopsis	<p>This Funding Opportunity Announcement (FOA) solicits applications that propose to conduct time-sensitive mechanistic ancillary studies related to the NIAMS mission in conjunction with privately or publicly funded, ongoing clinical projects. The ongoing “parent” clinical project can be an interventional clinical trial, or a clinical study such as an observational study that will be actively collecting patient samples or clinical data. The “parent” project(s) should provide a cohort of well-characterized patients, infrastructure, data, and biological samples for the ancillary study. Applications submitted in response to this FOA will undergo an accelerated review and award process. The objective of this FOA is to provide a flexible mechanism to leverage established resources and maximize the return on existing investments in parent projects. Successful</p>			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		ancillary studies will enhance the scientific content and value of the parent projects, improve the research community's understanding of a disease or organ system in the NIAMS portfolio, and thus may identify novel targets for diagnosis, treatment, and prevention of disease.			
100388	Mechanistic Ancillary Studies to Ongoing Clinical Projects (R01 Clinical Trial Not Allowed)	National Institute of Arthritis and Musculoskeletal and Skin Diseases/NIH/DHHS	PAR-21-055	20-Jun-2022 [Optional][LOI/Pre-App]	1,200,000 USD
	Contact Name	Heiyoung Park, Ph.D.			
	Contact Telephone	301-594-5032			
	Contact Email	parkh1@mail.nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	20-Jun-2022 [Optional][LOI/Pre-App], 20-Jul-2022 , 18-Oct-2022 [Optional][LOI/Pre-App], 18-Nov-2022			
	Synopsis	<p>This Funding Opportunity Announcement (FOA) solicits applications that propose to conduct time-sensitive mechanistic ancillary studies related to the NIAMS mission in conjunction with privately or publicly funded, ongoing clinical projects. The ongoing "parent" clinical project can be an interventional clinical trial, or a clinical study such as an observational study that will be actively collecting patient samples or clinical data. The "parent" project(s) should provide a cohort of well-characterized patients, infrastructure, data, and biological samples for the ancillary study. Applications submitted in response to this FOA will undergo an accelerated review and award process. The objective of this FOA is to provide a flexible mechanism to leverage established resources and maximize the return on existing investments in parent projects. Successful ancillary studies will enhance the scientific content and value of the parent projects, improve the research community's understanding of a disease or organ system in the NIAMS portfolio, and thus may identify novel targets for diagnosis, treatment, and prevention of disease.</p>			
109946	Notice of Special Interest (NOSI): Technological Innovations for Advancing Clinical SPECT Imaging	National Institute of Biomedical Imaging and Bioengineering/NIH/DHHS	NOT-EB-22-006	05-Jun-2022	Not Specified
	Contact Name	I. George Zubal, Ph.D.			
	Contact Telephone	301-827-5168			
	Contact Email	igeorge.zubal@nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Deadline Dates (ALL) 05-Jun-2022 , 12-Jun-2022 , 16-Jun-2022 , 08-Aug-2022 , 12-Aug-2022 , 05-Sep-2022 , 07-Sep-2022 , 05-Oct-2022 , 12-Oct-2022 , 16-Oct-2022 , 08-Dec-2022 , 12-Dec-2022 , 05-Jan-2023 , 07-Jan-2023 , 05-Feb-2023 , 12-Feb-2023 , 16-Feb-2023 , 05-Apr-2023 , 08-Apr-2023 , 12-Apr-2023 , 07-May-2023 , 05-Jun-2023 , 12-Jun-2023 , 16-Jun-2023 , 08-Aug-2023 , 12-Aug-2023 , 05-Sep-2023 , 07-Sep-2023 , 05-Oct-2023 , 12-Oct-2023 , 16-Oct-2023 , 08-Dec-2023 , 12-Dec-2023 , 05-Jan-2024 , 07-Jan-2024 , 05-Feb-2024 , 12-Feb-2024 , 16-Feb-2024 , 05-Apr-2024 , 08-Apr-2024 , 07-May-2024</p> <p>Synopsis The purpose of this Notice is to inform potential applicants to the National Institute of Biomedical Imaging and Bioengineering (NIBIB) of an area of special interest in developing nuclear medicine imaging technologies to achieve more cost-efficient clinical Single-Photon Emission Computerized Tomography (SPECT) applications.</p>				
108116	Notice of Special Interest (NOSI): Clone Program	National Institute of Child Health and Human Development/NIH/DHHS	NOT-HD-21-053	05-Apr-2022	Not Specified
	<p>Contact Name Monica Longo, MD, PhD</p> <p>Contact Telephone 240-204-4605</p> <p>Contact Email monica.longo@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 05-Apr-2022 , 07-May-2022 , 05-Jun-2022 , 16-Jun-2022 , 05-Sep-2022 , 07-Sep-2022 , 05-Oct-2022 , 16-Oct-2022 , 05-Jan-2023 , 07-Jan-2023 , 05-Feb-2023 , 16-Feb-2023 , 05-Apr-2023 , 07-May-2023 , 05-Jun-2023 , 16-Jun-2023 , 05-Sep-2023 , 07-Sep-2023 , 05-Oct-2023 , 16-Oct-2023 , 05-Jan-2024 , 07-Jan-2024 , 05-Feb-2024 , 16-Feb-2024 , 05-Apr-2024 , 07-May-2024</p> <p>Synopsis The purpose of this Notice of Special Interest (NOSI) is to stimulate adaptation of non-invasive monitoring technologies for use in fetal assessment. The aim of the initiative is to improve accuracy in fetal assessment, leading to improved clinical decision making and, ultimately, improved maternal and fetal outcomes. Research encouraged and supported by this NOSI should focus on direct assessment of fetal status through non-invasive measurement of fetal blood pH, oxygenation, or other direct measures.</p>				
105294	Notice of Special Interest (NOSI): High Priority Areas in Placental Research for Healthy Pregnancies	National Institute of Child Health and Human Development/NIH/DHHS	NOT-HD-21-040	11-Apr-2022	Not Specified
	<p>Contact Name John V. Ilekis, PhD</p> <p>Contact Telephone 301-435-6895</p> <p>Contact Email ilekisj@nih.gov</p> <p>Sponsor Website</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 11-Apr-2022 , 07-May-2022 , 05-Jun-2022 , 16-Jun-2022 , 10-Aug-2022 , 07-Sep-2022</p> <p>Synopsis Although the placenta is a short-lived organ limited to pregnancy, its importance is often underappreciated in being a crucial organ for the propagation of our species and future health of our progeny. Perturbations in any one of its many functions may result in many common adverse pregnancy outcomes. These include early pregnancy loss, preeclampsia, fetal growth restriction, stillbirth, and preterm birth. In addition, a poorly functioning placenta can lead to aberrant programming of the fetus that can impact the health of the individual later in adult life. This includes an increased incidence of adult diseases such as obesity, cardiovascular disease, and diabetes. Thus, a more comprehensive understanding of the placenta is necessary to help address a number of major gaps in knowledge.</p>				
087240	Archiving and Documenting Child Health and Human Development Data Sets (R03 Clinical Trial Not Allowed)	National Institute of Child Health and Human Development/NIH/DHHS	PAR-20-064	07-May-2022	100,000 USD
	<p>Contact Name Regina Bures, Ph.D.</p> <p>Contact Telephone 301-496-9485</p> <p>Contact Email regina.bures@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2022 , 16-Jun-2022 , 07-Sep-2022 , 16-Oct-2022 , 07-Jan-2023</p> <p>Synopsis The purpose of this funding opportunity announcement (FOA) is to support the archiving and documentation of existing data sets within the scientific mission of the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) in order to enable secondary analysis of these data by the scientific community. The highest priority is to archive original data collected with NICHD funding.</p>				
104366	Notice of Special Interest (NOSI): Reduction of Sudden Unexpected Infant Death and Sudden Infant Death Syndrome	National Institute of Child Health and Human Development/NIH/DHHS	NOT-HD-21-032	07-May-2022	Not Specified
	<p>Contact Name Marion Koso-Thomas M.D, MPH</p> <p>Contact Telephone 301-435-6873</p> <p>Contact Email kosomari@mail.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Deadline Dates (ALL)	07-May-2022 , 05-Jun-2022 , 16-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 16-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 16-Feb-2023 , 07-May-2023			
	Synopsis	Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) invites basic science, clinical researchers, behavioral scientists and implementation science experts either as individual or as multi-disciplinary teams, to submit research projects that will identify risk-reduction strategies that address infant mortality domestically , as well as efforts to understand the root causes of sudden infant death syndrome and sudden unexpected infant death.			
100064	Notice of Special Interest (NOSI): Small Grants for Secondary Analyses of Existing Data Sets and Stored Biospecimens	National Institute of Child Health and Human Development/NIH/DHHS	NOT-HD-20-022	07-May-2022	Not Specified
	Contact Name	Regina Bures, PhD			
	Contact Telephone	301-496-9485			
	Contact Email	regina.bures@nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	07-May-2022 , 16-Jun-2022 , 07-Sep-2022 , 16-Oct-2022 , 07-Jan-2023 , 16-Feb-2023 , 07-May-2023			
	Synopsis	This Notice of Special Interest (NOSI) encourages applications that propose to conduct secondary analyses using publicly available NICHD-funded data sets or stored biospecimens. The goal of this program is to facilitate innovative yet cost-effective research utilizing data and biospecimens collected with NICHD resources.			
101700	Notice of Special Interest (NOSI): Biophysical and Biomechanical Aspects of Embryonic Development (R21)	National Institute of Child Health and Human Development/NIH/DHHS	NOT-HD-21-004	07-May-2022	Not Specified
	Contact Name	Mahua Mukhopadhyay, PhD			
	Contact Telephone	301-435-6886			
	Contact Email	mukhopam@mail.nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	07-May-2022 , 16-Jun-2022 , 07-Sep-2022 , 16-Oct-2022			
	Synopsis	The Notice of Scientific Interest (NOSI) is intended to encourage innovative and high risk/impact research in the area of physics/mechanics of embryonic development to be explored in model organisms. The research proposed under this program can explore approaches and concepts new to the area of developmental tissue mechanics, research and			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		development of new technologies, or initial research and development of data upon which significant future research may be built. The focus of this NOSI is to promote research aimed at generating new and critical information about tissue mechanics relevant to vertebrate development and understanding the basis for developmental disorders.			
085590	Small Research Grants for Analyses of Gabriella Miller Kids First Pediatric Research Data (R03 Clinical Trial Not Allowed)	National Institute of Child Health and Human Development/NIH/DHHS	PAR-19-375	07-May-2022	200,000 USD
	Contact Name	James N. Coulombe, Ph.D.			
	Contact Telephone	301-451-1390			
	Contact Email	CoulombeJ@mail.nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	07-May-2022 , 16-Jun-2022 , 07-Sep-2022 , 16-Oct-2022 , 07-Jan-2023			
	Synopsis	<p>The NIH Common Fund has established the Gabriella Miller Kids First Pediatric Research Program (Kids First) to develop a pediatric research data resource populated by genome sequence and phenotype data that will be of high value for the communities of investigators who study the genetics of childhood cancers and/or structural birth defects. The goal of the Gabriella Miller Kids First Pediatric Data Resource is to build a collection of curated genomic and phenotypic data from childhood cancer and birth defects cohorts and provide a central portal where data and analysis tools will be readily accessible to the research community. Access to these data will promote comprehensive and cross-cutting research and collaboration leading to more refined diagnostic capabilities and ultimately more targeted therapies. This FOA is intended to support meritorious small research projects focused on the development and analyses of childhood cancer and/or structural birth defects datasets that are part of the Kids First Data Resource or could be included in the Kids First Data Resource. Development of statistical methodology appropriate for analyzing genome-wide data relevant to childhood cancer and/or structural birth defects may also be proposed.</p>			
103657	NICHD Small Research Grant Program (R03 Basic Experimental Studies with Humans Required)	National Institute of Child Health and Human Development/NIH/DHHS	PA-21-231	07-May-2022	100,000 USD
	Contact Name				
	Contact Telephone				
	Contact Email	NICHDReferral@mail.nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Deadline Dates (ALL) 07-May-2022 , 16-Jun-2022 , 07-Sep-2022 , 16-Oct-2022 , 07-Jan-2023 , 16-Feb-2023 , 07-May-2023 , 16-Jun-2023 , 07-Sep-2023 , 16-Oct-2023 , 07-Jan-2024 , 16-Feb-2024 , 07-May-2024</p> <p>Synopsis The NICHD Small Research Grant Program (Clinical Trial Required) supports clinical trials that fall within the NICHD mission. This funding opportunity announcement is for basic science experimental studies involving humans, referred to in NOT-OD-18-212 as “prospective basic science studies involving human participants.” These studies fall within the NIH definition of a clinical trial and also meet the definition of basic research. Types of studies that should submit under this FOA include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental aspects of phenomena without specific application towards processes or products in mind. Studies conducted with specific applications toward processes or products in mind should submit under the appropriate ‘Clinical Trials Required’ FOA.</p>				
103808	Notice of Special Interest (NOSI): Reproductive Health, Pregnancy, and Parenting among Women with Disabilities	National Institute of Child Health and Human Development/NIH/DHHS	NOT-HD-21-025	07-May-2022	Not Specified
	<p>Contact Name Rosalind King, Ph.D.</p> <p>Contact Telephone 301-435-6986</p> <p>Contact Email kingros@mail.nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2022 , 05-Jun-2022 , 16-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 16-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 16-Feb-2023 , 07-May-2023 , 05-Jun-2023 , 16-Jun-2023 , 07-Sep-2023 , 05-Oct-2023 , 16-Oct-2023 , 07-Jan-2024 , 05-Feb-2024 , 16-Feb-2024 , 07-May-2024</p> <p>Synopsis The purpose of this Notice of Special Interest (NOSI) is to encourage and support research studies in women with disabilities (WWD) in any of three interconnected areas of high priority to NICHD: Gynecologic care and preconception health for women and adolescent girls with disabilities Pregnancy in WWD Postpartum and parenting needs of WWD It is not expected or required that all areas will be addressed in one application.</p>				
103656	NICHD Small Research Grant Program (R03 Clinical Trial Required)	National Institute of Child Health and Human Development/NIH/DHHS	PA-21-221	07-May-2022	100,000 USD
	<p>Contact Name </p> <p>Contact Telephone </p> <p>Contact Email NICHDReferral@mail.nih.gov</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2022 , 16-Jun-2022 , 07-Sep-2022 , 16-Oct-2022 , 07-Jan-2023 , 16-Feb-2023 , 07-May-2023 , 16-Jun-2023 , 07-Sep-2023 , 16-Oct-2023 , 07-Jan-2024 , 16-Feb-2024 , 07-May-2024</p> <p>Synopsis The NICHD Small Research Grant Program (R03 Clinical Trial Required) supports clinical trials that fall within the NICHD mission. The R03 activity code supports small research projects that can be carried out in a short period of time with limited resources. The R03 program may be used for different types of projects including pilot and feasibility studies; secondary analysis of existing data; small, self-contained research projects; development of research methodology; and development of new research technology.</p>				
103810	Notice of Special Interest (NOSI): Research on the Impact of the Covid 19 Pandemic and Risks for Abuse and Injury Among Vulnerable Children and Youth	National Institute of Child Health and Human Development/NIH/DHHS	NOT-HD-21-026	07-May-2022	Not Specified
	<p>Contact Name Valerie Maholmes, Ph.D., CAS</p> <p>Contact Telephone 301-496-1514</p> <p>Contact Email maholmev@mail.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2022 , 05-Jun-2022 , 16-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 16-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 16-Feb-2023 , 07-May-2023 , 05-Jun-2023 , 16-Jun-2023 , 07-Sep-2023 , 05-Oct-2023 , 16-Oct-2023 , 07-Jan-2024 , 05-Feb-2024 , 16-Feb-2024 , 07-May-2024</p> <p>Synopsis Pre-existing disparities and apparent challenges in resources for treatment and care of children experiencing abuse call for more data and research resources to identify, substantiate and improve care and ultimately outcomes for vulnerable children and youth during and following the current crisis. It is anticipated that research stemming from this NOSI will help to provide greater recognition of the need for better resources and support for vulnerable children. More touchpoints for communication, identification and screening for risks of child trauma, and injury will help inform processes for screening, identification, treatment and care in new and emerging disaster related contexts in the future.</p>				
105045	Notice of Special Interest (NOSI): Promoting Vaccine Access, Acceptance and Uptake among Children, Adolescents, Pregnant and Lactating Women, and Persons with Disabilities	National Institute of Child Health and Human Development/NIH/DHHS	NOT-HD-21-038	07-May-2022	Not Specified

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Name Regina M. Bures, Ph.D.</p> <p>Contact Telephone 301-496-9485</p> <p>Contact Email regina.bures@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2022 , 16-Jun-2022 , 07-Sep-2022 , 16-Oct-2022 , 07-Jan-2023 , 16-Feb-2023 , 07-May-2023 , 16-Jun-2023 , 07-Sep-2023 , 16-Oct-2023 , 07-Jan-2024 , 16-Feb-2024 , 07-May-2024 , 16-Jun-2024 , 07-Sep-2024</p> <p>Synopsis This NOSI encourages applications that address dimensions of access, acceptance and uptake of CDC-recommended vaccines among infants, children, adolescents, pregnant and lactating women, and persons with disabilities, especially among populations who are underserved or experience health disparities.</p>				

107427	RFA-RM-22-006 -- Expert-Driven Small Projects to Strengthen Gabriella Miller Kids First Discovery (R03 Clinical Trial Not Allowed)	National Institute of Child Health and Human Development/NIH/DHHS	RFA-RM-22-006	10-May-2022 [Optional][LOI/Pre-App]	200,000 USD
--------	--	---	---------------	-------------------------------------	-------------

	<p>Contact Name James Coulombe, Ph.D.</p> <p>Contact Telephone 301- 451-1390</p> <p>Contact Email CoulombeJ@mail.nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 10-May-2022 [Optional][LOI/Pre-App], 10-Jun-2022</p> <p>Synopsis The NIH Common Fund has established the Gabriella Miller Kids First Pediatric Research Program (Kids First) with the vision of alleviating suffering from childhood cancer and structural birth defects by fostering collaborative research to uncover the etiology of these diseases and supporting data sharing within the pediatric research community. Kids First has established and continues to develop a Data Resource including a large collection of curated genomic and phenotypic data from childhood cancer and structural birth defects cohorts and a central portal where these data and analysis tools are accessible to the research community. This FOA is intended to engage experts in a variety of activities that will enhance the utility of childhood cancer and/or structural birth defects genomic datasets generated by the Kids First program and/or associated phenotypic datasets and resources. These activities should strengthen future analyses of Kids First datasets by the broader researcher community with the ultimate goal of improving diagnostic capabilities and therapies for children and their families affected by these conditions. This FOA is a Common Fund initiative (Common Fund) through the NIH Office of the Director, Office of Strategic Coordination (https://dpcpsi.nih.gov/). All NIH Institutes and Centers participate in Common</p>				
--	--	--	--	--	--

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
Fund initiatives. The FOA will be administered by a trans-NIH team led by the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)					
107317	Innovative Screening Approaches and Therapies for Screenable Disorders in Newborns (R01 - Clinical Trial Optional)	National Institute of Child Health and Human Development/NIH/DHHS	PAR-21-353	05-Jun-2022	Not Specified
	Contact Name	Mollie Minear, Ph.D.			
	Contact Telephone	301-827-9442			
	Contact Email	mollie.minear@nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	05-Jun-2022 , 05-Oct-2022 , 05-Feb-2023 , 05-Jun-2023 , 05-Oct-2023 , 05-Feb-2024 , 05-Jun-2024 , 05-Oct-2024			
	Synopsis	This FOA encourages research relevant to the development of novel screening approaches and/or therapeutic interventions for potentially fatal or disabling conditions that have been identified through newborn screening, as well as for "high priority" genetic conditions where screening may be possible in the near future. Having an accurate screening test, as well as demonstrating the benefits of early intervention or treatment, are important criteria for including a condition on a newborn screening panel. This FOA defines a "high priority" condition as one where screening is not currently recommended, but infants with the condition would significantly benefit from early identification and treatment.			
099263	Notice of Special Interest (NOSI): Emerging Viral Infections and their Impact on the Male and Female Reproductive Tract	National Institute of Child Health and Human Development/NIH/DHHS	NOT-HD-20-021	05-Jun-2022	Not Specified
	Contact Name	Stuart B. Moss, PhD			
	Contact Telephone	301-435-6979			
	Contact Email	mossstua@mail.nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	05-Jun-2022 , 16-Jun-2022 , 05-Oct-2022 , 16-Oct-2022 , 05-Feb-2023 , 16-Feb-2023 , 05-Jun-2023 , 16-Jun-2023			
	Synopsis	The purpose of this Notice is to invite applications proposing cutting-edge research on emerging viral infections that are thought to primarily impact non-reproductive sites, at least at initial presentation, but may also affect the male and/or female reproductive tract. The recent global outbreak of the novel coronavirus, SARS-CoV-2, is not an anomaly and will most likely not be the last virus occurrence. Today, infectious diseases are emerging and reemerging more quickly than ever			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

before. In the last four-five years alone, two viral infections, one caused by the Zika virus (ZIKV) and the other caused by a SARS-CoV-2 (Covid19), have spread world-wide, resulting in death, severe disease with yet, unknown, long-term morbidities., or severe birth defects to the new-born. Both ZIKV and SARS-CoV-2 infections may affect male and/or female reproductive systems in addition to other non-reproductive sites. Therefore, it becomes essential to investigate possible effects of emerging viruses on reproductive tissues and cells to better understand potential impacts on fertility that may be sex specific.

107319	Innovative Screening Approaches and Therapies for Screenable Disorders in Newborns (R21 - Clinical Trial Optional)	National Institute of Child Health and Human Development/NIH/DHHS	PAR-21-355	16-Jun-2022	275,000 USD
--------	--	---	------------	-------------	-------------

Contact Name	Mollie Minear, Ph.D.
Contact Telephone	301-827-9442
Contact Email	mollie.minear@nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	16-Jun-2022 , 16-Oct-2022 , 16-Feb-2023 , 16-Jun-2023 , 16-Oct-2023 , 16-Feb-2024 , 16-Jun-2024 , 16-Oct-2024
Synopsis	This FOA encourages research relevant to the development of novel screening approaches and/or therapeutic interventions for potentially fatal or disabling conditions that have been identified through newborn screening, as well as for "high priority" genetic conditions where screening may be possible in the near future. Having an accurate screening test, as well as demonstrating the benefits of early intervention or treatment, are important criteria for including a condition on a newborn screening panel. This FOA defines a "high priority" condition as one where screening is not currently recommended, but infants with the condition would significantly benefit from early identification and treatment.

107320	Innovative Screening Approaches and Therapies for Screenable Disorders in Newborns (R03 - Clinical Trial Optional)	National Institute of Child Health and Human Development/NIH/DHHS	PAR-21-354	16-Jun-2022	100,000 USD
--------	--	---	------------	-------------	-------------

Contact Name	Mollie Minear, Ph.D.
Contact Telephone	301-827-9442
Contact Email	mollie.minear@nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	16-Jun-2022 , 16-Oct-2022 , 16-Feb-2023 , 16-Jun-2023 , 16-Oct-2023 , 16-Feb-2024 , 16-Jun-2024 , 16-Oct-2024

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Synopsis	This FOA encourages research relevant to the development of novel screening approaches and/or therapeutic interventions for potentially fatal or disabling conditions that have been identified through newborn screening, as well as for "high priority" genetic conditions where screening may be possible in the near future. Having an accurate screening test, as well as demonstrating the benefits of early intervention or treatment, are important criteria for including a condition on a newborn screening panel. This FOA defines a "high priority" condition as one where screening is not currently recommended, but infants with the condition would significantly benefit from early identification and treatment.			
087243	Small Research Grants for Establishing Basic Science-Clinical Collaborations to Understand Structural Birth Defects (R03 Clinical Trial Not Allowed)	National Institute of Child Health and Human Development/NIH/DHHS	PAR-20-065	16-Jun-2022	150,000 USD
	Contact Name	Reiko Toyama, PhD			
	Contact Telephone	301-435-2723			
	Contact Email	toyamar@mail.nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	16-Jun-2022 , 16-Oct-2022			
	Synopsis	The purpose of this funding opportunity announcement (FOA) is to promote initial establishment of basic science-clinical collaborations by providing small grants to teams of basic scientists, physician scientists, and/or clinicians. These interdisciplinary teams may include but are not limited to the following: developmental biologists, cell biologists, geneticists, genomicists, physician-scientists including individuals with DVM/VMD degrees, clinicians, epidemiologists, biostatisticians, and/or bioinformaticists. Applications must include at least one scientist with expertise from the basic science side of the spectrum as well as one from the clinical side. The multiple PD/PI model is strongly encouraged but not required. The goal is to facilitate the gathering of preliminary data to support future, larger research grant applications that will combine expertise and integrate basic, translational, and/or clinical approaches to understanding the developmental biology, genetics, and/or environmental basis of structural birth defects.			
109646	RFA-HD-23-007 -- CAPSTONE Centers for Multidisciplinary Research in Child Abuse and Neglect (P50) (Clinical Trial Optional)	National Institute of Child Health and Human Development/NIH/DHHS	RFA-HD-23-007	27-Jun-2022 [Optional][LOI/Pre-App]	5,500,000 USD
	Contact Name	Valerie Maholmes, Ph.D., CAS			
	Contact Telephone	301-496-1514			
	Contact Email	maholmev@mail.nih.gov			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 27-Jun-2022 [Optional][LOI/Pre-App], 27-Jul-2022</p> <p>Synopsis This Request for Applications (RFA) is being re-issued to continue to stimulate collaborative research on all forms of child abuse and neglect and to foster dissemination and outreach efforts that bridge research, clinical practice and policy. This funding opportunity announcement (FOA) will use the specialized research center mechanism (P50) to call for multidisciplinary centers to serve as the CAPSTONE for research on child abuse and neglect and to serve as a national resource for the field. The Center(s) will conduct innovative and high quality research including: 1) trials testing the efficacy and effectiveness of clinical interventions; 2) longitudinal prospective studies examining the long term effects of specific and understudied types of maltreatment including abusive head trauma, medical child abuse and neglect, chronic sexual abuse; 3) studies examining the neurobiology of abuse and neglect and implications for health outcomes; and 4) studies testing the development of screening tools and clinical assessment measures for early identification and treatment of specific types of abuse and neglect to decrease morbidity and mortality and to identify potential comorbidities. The Centers are also required to propose a dissemination and outreach core which will provide opportunities for students and faculty at all levels, to be exposed to cutting edge educational tools and technologies, research, and expertise within the field of child maltreatment. A central goal of this core will be to engage the scientific and lay professional communities in participatory activities such as technical assistance, evidence-based practice, participation in grand rounds, conferences and seminars, or webinars based on information emanating from the other cores. The format for the community engagement activities will be tailored to the expertise of the Center and the needs of the community.</p>				
109857	<p>RFA-HD-23-011 -- National Centers for Translational Research in Reproduction and Infertility (NCTRI) (P50) (Clinical Trial Optional)</p>	National Institute of Child Health and Human Development/NIH/DHHS	RFA-HD-23-011	28-Jun-2022 [Optional][LOI/Pre-App]	5,500,000 USD
	<p>Contact Name Ravi Ravindranath, DVM, Ph.D.</p> <p>Contact Telephone 301-435-6889</p> <p>Contact Email ravindr@nctri.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 28-Jun-2022 [Optional][LOI/Pre-App], 28-Jul-2022</p> <p>Synopsis The Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), through the Fertility and Infertility (FI) Branch, provides funding for a limited number of research centers in the reproductive sciences. These centers provide an arena for multidisciplinary interactions among basic and clinical scientists interested in establishing high quality</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
<p>translational research programs in these scientific areas. The purpose of this FOA is to announce the re-competition of the National Centers for Translational Research in Reproduction and Infertility (NCTRI). The NCTRI will be administered through the Specialized Research Center (P50) award mechanism. These centers will form a national network that facilitates and accelerates bidirectional knowledge transfer between the laboratory and clinic with the ultimate goal of improving human reproductive health through research excellence and innovation.</p>					
081268	Clinical Research to Improve the Oral Health of Older Adults (R01 Clinical Trial Not Allowed)	National Institute of Dental and Craniofacial Research/NIH/DHHS	PAR-19-239	07-May-2022	Not Specified
	<p>Contact Name Darien Weatherspoon, DDS, MPH</p> <p>Contact Telephone 301-594-5394</p> <p>Contact Email darien.weatherspoon@mail.nih</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2022 , 05-Jun-2022 , 07-Sep-2022</p> <p>Synopsis The purpose of this Funding Opportunity Announcement (FOA) is to stimulate research to address gaps in our knowledge related to the risk factors, access to care barriers, oral health promotion and disease prevention strategies, and clinical management of dental, oral, and craniofacial (DOC) diseases more commonly experienced by older adults. This FOA defines "older adults" as those individuals age 65 years and older.</p>				
083076	Mechanistic Studies of Gene-Environment Interplay in Dental, Oral, Craniofacial, and Other Diseases and Conditions (R01 Clinical Trial Not Allowed)	National Institute of Dental and Craniofacial Research/NIH/DHHS	PAR-19-292	07-May-2022	Not Specified
	<p>Contact Name Kathryn Stein, Ph.D.</p> <p>Contact Telephone 301-827-4653</p> <p>Contact Email kathryn.stein@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2022 , 05-Jun-2022 , 07-Sep-2022</p> <p>Synopsis This Funding Opportunity Announcement (FOA) is intended to foster research towards a better understanding of the biological mechanisms of gene-environment interplay in human diseases and conditions. Through this FOA, the NIDCR,</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		<p>NIEHS, and NICHD solicit applications that use animal models, in vitro systems, or ex vivo approaches to conduct mechanistic investigation of the interplay of genes/gene networks and environmental factors in dental, oral, craniofacial (DOC), and other diseases and conditions.</p>			
102596	NIDCR Clinical Trial Planning and Implementation Cooperative Agreement (UG3/UH3 Clinical Trial Required)	National Institute of Dental and Craniofacial Research/NIH/DHHS	PAR-21-160	07-May-2022	Not Specified
	Contact Name	Dena Fischer, DDS, MSD, MS			
	Contact Telephone	301-594-4876			
	Contact Email	dena.fischer@nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	07-May-2022 , 07-Jun-2022 , 07-Sep-2022 , 04-Oct-2022 , 07-Jan-2023 , 07-Feb-2023 , 07-May-2023 , 06-Jun-2023 , 07-Sep-2023 , 03-Oct-2023 , 07-Jan-2024 , 06-Feb-2024 , 07-May-2024			
	Synopsis	<p>This Funding Opportunity Announcement (FOA) will support UG3/UH3 phased, cooperative agreement research applications to plan and implement clinical trials within the mission of the National Institute of Dental and Craniofacial Research (NIDCR). Studies appropriate for this FOA are those testing diagnostic, prevention or treatment approaches to test a drug, biologic, device, or procedure for dental, oral, or craniofacial diseases or conditions, including trials for any phase of testing for a Food and Drug Administration (FDA)-regulated product. Awards made under this FOA will initially support a one-year milestone-driven UG3 planning phase, with possible transition to a UH3 clinical trial implementation phase of up to five years. The UH3 phase of the award will support the conduct of one investigator-initiated clinical trial. The UG3 planning phase permits both operational and scientific planning activities. Operational planning activities include, at minimum, finalizing the protocol and preparing other documents to implement the clinical trial (e.g., data collection instruments, Manual of Procedures, data management plan). Allowable scientific planning activities include small-scale data collection to assess the feasibility and/or acceptability of a planned intervention and associated study procedures (e.g., acceptability of mode of intervention delivery; feasibility of proposed data collection procedures; preliminary testing of intervention training and fidelity monitoring procedures) and assessment of the subject population to determine recruitment potential for the future trial. The UG3 phase cannot be used to test for intervention safety or efficacy. If the application proposes a clinical trial with an investigational drug, biologic or device, the investigators must have submitted the appropriate investigational application to the FDA prior to the UH3 phase.</p>			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
108355	NIDCR Dual Degree Dentist Scientist Pathway to Independence Award (K99/R00 Basic Experimental Studies Involving Humans Required)	National Institute of Dental and Craniofacial Research/NIH/DHHS	PAR-22-043	07-May-2022	Not Specified
	<p>Contact Name Leslie A. Frieden, PhD</p> <p>Contact Telephone 301-496-4263</p> <p>Contact Email leslie.frieden@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2022 , 12-Jun-2022 , 07-Sep-2022 , 12-Oct-2022 , 07-Jan-2023 , 12-Feb-2023 , 07-May-2023 , 12-Jun-2023 , 07-Sep-2023 , 12-Oct-2023 , 07-Jan-2024 , 12-Feb-2024 , 07-May-2024 , 12-Oct-2024 , 07-Jan-2025</p> <p>Synopsis The purpose of the NIDCR Dual Degree Dentist Scientist Pathway to Independence Award (K99/R00) program is to develop and maintain a strong cohort of independently funded dentist scientists dedicated to improving dental, oral and craniofacial health. This program is designed to facilitate a timely transition of outstanding dual degree dentist scientists from mentored, postdoctoral research positions to independent, tenure-track or equivalent faculty positions by providing support for two years of mentored training and three to five years of independent research. An option for five years of independent (R00) support is available to accommodate clinical training in a dental specialty program at no more than 3 person-months effort (25% full-time professional effort) in any year of the R00 phase. This Funding Opportunity Announcement is for basic science experimental studies involving humans, referred to in NOT-OD-18-212 as “prospective basic science studies involving human participants.” These studies fall within the NIH definition of a clinical trial and also meet the definition of basic research. Types of studies that should be submitted under this FOA include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental aspects of phenomena without specific application towards processes or products in mind. Applicants not planning an independent clinical trial or basic experimental study with humans, or proposing to gain research experience in a clinical trial or basic experimental study with humans led by another investigator, must apply to the 'Independent Clinical Trial Not Allowed' companion FOA. The proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) based on their scientific missions.</p>				
108353	NIDCR Dual Degree Dentist Scientist Pathway to Independence Award (K99/R00 Clinical Trial Not Allowed)	National Institute of Dental and Craniofacial Research/NIH/DHHS	PAR-22-041	07-May-2022	Not Specified
	Contact Name Leslie A. Frieden, PhD				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Telephone 301-496-4263</p> <p>Contact Email leslie.frieden@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2022 , 12-Jun-2022 , 07-Sep-2022 , 12-Oct-2022 , 07-Jan-2023 , 12-Feb-2023 , 07-May-2023 , 12-Jun-2023 , 07-Sep-2023 , 12-Oct-2023 , 07-Jan-2024 , 12-Feb-2024 , 07-May-2024 , 12-Oct-2024 , 07-Jan-2025</p> <p>Synopsis The purpose of the NIDCR Dual Degree Dentist Scientist Pathway to Independence Award (K99/R00) program is to develop and maintain a strong cohort of independently funded dentist scientists dedicated to improving dental, oral and craniofacial health. This program is designed to facilitate a timely transition of outstanding dual degree dentist scientists from mentored, postdoctoral research positions to independent, tenure-track or equivalent faculty positions by providing support for two years of mentored training and three to five years of independent research. An option for five years of independent (R00) support is available to accommodate clinical training in a dental specialty program at no more than 3 person-months (25% full-time professional effort) in any year of the R00 phase. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary study to a clinical trial. Applicants to this FOA are permitted to propose research experience in a clinical trial led by a mentor or co-mentor. Applicants proposing a clinical trial or an ancillary study to an ongoing clinical trial as lead investigator, should apply to the companion FOA (PAR-22-042). Applicants proposing basic experimental studies in humans referred to in NOT-OD-18-212 as "prospective basic science studies involving human participants" should apply to the companion Basic Experimental Studies with Humans FOA (PAR-22-043).</p>				
108354	<p>NIDCR Dual Degree Dentist Scientist Pathway to Independence Award (K99/R00 Clinical Trial Required)</p>	National Institute of Dental and Craniofacial Research/NIH/DHHS	PAR-22-042	07-May-2022	Not Specified
	<p>Contact Name Leslie A. Frieden, PhD</p> <p>Contact Telephone 301-496-4263</p> <p>Contact Email leslie.frieden@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2022 , 12-Jun-2022 , 07-Sep-2022 , 12-Oct-2022 , 07-Jan-2023 , 12-Feb-2023 , 07-May-2023 , 12-Jun-2023 , 07-Sep-2023 , 12-Oct-2023 , 07-Jan-2024 , 12-Feb-2024 , 07-May-2024 , 12-Oct-2024 , 07-Jan-2025</p> <p>Synopsis The purpose of the NIDCR Dual Degree Dentist Scientist Pathway to Independence Award (K99/R00) program is to develop and maintain a strong cohort of independently funded dentist scientists dedicated to improving dental, oral and craniofacial</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

health. This program is designed to facilitate a timely transition of outstanding dual degree dentist scientists from mentored, postdoctoral research positions to independent, tenure-track or equivalent faculty positions by providing support for two years of mentored training and three to five years of independent research. An option for five years of independent (R00) support is available to accommodate clinical training in a dental specialty program at no more than 3 person-months effort (25% full-time professional effort) in any year of the R00 phase. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary study to an existing trial, as part of their research and career development. Applicants not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must apply to companion FOA (PAR-22-041).

096097	Enabling Technologies to Accelerate Development of Oral Biodevices (R01 Clinical Trial Not Allowed)	National Institute of Dental and Craniofacial Research/NIH/DHHS	PAR-20-233	07-May-2022	Not Specified
--------	---	---	------------	-------------	---------------

<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email</p> <p>Sponsor Website</p> <p>Program URL</p> <p>Deadline Dates (ALL)</p> <p>Synopsis</p>	<p>Orlando Lopez, PhD</p> <p>301-402-4243</p> <p>orlando.lopez@nih.gov</p> <p></p> <p>Link to program URL</p> <p>07-May-2022 , 05-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 07-May-2023</p> <p>This Funding Opportunity Announcement (FOA) invites applications that propose transformative engineering solutions to technical challenges associated with new development, substantial optimization of existing technologies and clinical translation of intraoral biodevices. Proposed technologies are expected to advance development of oral biodevices for clinical use, including but not limited to: precision medicine-based detection, diagnosis and treatment of oral and overall health conditions, and measurement of patient functional status and clinical outcome assessment. Areas of interest in this FOA include engineering approaches that allow integration of electronic, physical, and biological systems into functional biodevices that are safe and effective for detection, diagnosis and treatment of oral and systemic disease. Products of this research will be functional biodevices and integrated approaches thoroughly characterized to demonstrate preclinical safety and effective performance in support of specific intended clinical applications. To streamline the development of oral biodevices that advance precision medicine-based approaches in clinical practice, this FOA encourages interdisciplinary collaborations across engineering, multifunctional sensors, pharmacology, chemistry, medicine, and dentistry, as well as between academia and industry.</p>
---	--

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
108402	NIDCR Dentist Scientist Career Transition Award for Intramural Investigators (K22 Clinical Trial Not Allowed)	National Institute of Dental and Craniofacial Research/NIH/DHHS	PAR-22-044	07-May-2022	Not Specified
	<p>Contact Name Leslie A. Frieden, PhD</p> <p>Contact Telephone 301-496-4263</p> <p>Contact Email leslie.frieden@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2022 , 12-Jun-2022 , 07-Sep-2022 , 12-Oct-2022 , 07-Jan-2023 , 12-Feb-2023 , 07-May-2023 , 12-Jun-2023 , 07-Sep-2023 , 12-Oct-2023 , 07-Jan-2024 , 12-Feb-2024 , 07-May-2024 , 12-Oct-2024 , 07-Jan-2025</p> <p>Synopsis The purpose of the NIDCR Dentist Scientist Career Transition Award for Intramural Investigators (K22) program is to facilitate transition of highly qualified dentists from NIH Intramural postdoctoral research positions to extramural academic tenure-track or equivalent faculty positions at eligible institutions. The award will provide support for two years of mentored postdoctoral research training in the NIH Intramural Research Program, and three years of independent research funding at the extramural institution. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary study to a clinical trial. Applicants to this FOA are permitted to propose research experience in a clinical trial led by a mentor or co-mentor. Applicants proposing a clinical trial or an ancillary study to an ongoing clinical trial as lead investigator, should apply to the companion FOA (PAR-22-045).</p>				
087123	NIDCR Prospective Observational or Biomarker Validation Study Cooperative Agreement (U01 Clinical Trial Not Allowed)	National Institute of Dental and Craniofacial Research/NIH/DHHS	PAR-20-060	07-May-2022	Not Specified
	<p>Contact Name Dena Fischer, DDS, MSD, MS</p> <p>Contact Telephone 301-594-4876</p> <p>Contact Email dena.fischer@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2022 , 05-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 07-Jan-2023</p> <p>Synopsis This Funding Opportunity Announcement (FOA) will support, through the cooperative agreement mechanism, investigator-initiated observational studies or biomarker validation studies that require prospective collection of data/biospecimens or continued analysis of data/biospecimens collected as part of a previous NIDCR award.</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount														
087114	Improving Oral Health and Reducing Disparities in Adolescents (R01 Clinical Trial Not Allowed)	National Institute of Dental and Craniofacial Research/NIH/DHHS	PAR-20-058	07-May-2022	Not Specified														
	<table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 20%; padding-right: 5px;">Contact Name</td> <td>Darien Weatherspoon, DDS, MPH</td> </tr> <tr> <td style="padding-right: 5px;">Contact Telephone</td> <td>301-594-5394</td> </tr> <tr> <td style="padding-right: 5px;">Contact Email</td> <td>darien.weatherspoon@nih.gov</td> </tr> <tr> <td style="padding-right: 5px;">Sponsor Website</td> <td></td> </tr> <tr> <td style="padding-right: 5px;">Program URL</td> <td>Link to program URL</td> </tr> <tr> <td style="padding-right: 5px;">Deadline Dates (ALL)</td> <td>07-May-2022 , 05-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 07-Jan-2023</td> </tr> <tr> <td style="padding-right: 5px;">Synopsis</td> <td>The purpose of this Funding Opportunity Announcement (FOA) is to stimulate research to improve the oral health of adolescents in the United States, and to reduce observed oral health disparities and inequities in this population. This FOA defines “adolescents” as those individuals between the ages of 10 and 19.</td> </tr> </table>					Contact Name	Darien Weatherspoon, DDS, MPH	Contact Telephone	301-594-5394	Contact Email	darien.weatherspoon@nih.gov	Sponsor Website		Program URL	Link to program URL	Deadline Dates (ALL)	07-May-2022 , 05-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 07-Jan-2023	Synopsis	The purpose of this Funding Opportunity Announcement (FOA) is to stimulate research to improve the oral health of adolescents in the United States, and to reduce observed oral health disparities and inequities in this population. This FOA defines “adolescents” as those individuals between the ages of 10 and 19.
Contact Name	Darien Weatherspoon, DDS, MPH																		
Contact Telephone	301-594-5394																		
Contact Email	darien.weatherspoon@nih.gov																		
Sponsor Website																			
Program URL	Link to program URL																		
Deadline Dates (ALL)	07-May-2022 , 05-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 07-Jan-2023																		
Synopsis	The purpose of this Funding Opportunity Announcement (FOA) is to stimulate research to improve the oral health of adolescents in the United States, and to reduce observed oral health disparities and inequities in this population. This FOA defines “adolescents” as those individuals between the ages of 10 and 19.																		
100184	National Dental Practice-Based Research Network Clinical Trial or Observational Study Planning and Implementation Cooperative Agreement (UG3/UH3 Clinical Trial Optional)	National Institute of Dental and Craniofacial Research/NIH/DHHS	PAR-20-306	07-May-2022	Not Specified														
	<table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 20%; padding-right: 5px;">Contact Name</td> <td>Dena Fischer, DDS, MSD, MS</td> </tr> <tr> <td style="padding-right: 5px;">Contact Telephone</td> <td>301-594-4876</td> </tr> <tr> <td style="padding-right: 5px;">Contact Email</td> <td>dena.fischer@nih.gov</td> </tr> <tr> <td style="padding-right: 5px;">Sponsor Website</td> <td></td> </tr> <tr> <td style="padding-right: 5px;">Program URL</td> <td>Link to program URL</td> </tr> <tr> <td style="padding-right: 5px;">Deadline Dates (ALL)</td> <td>07-May-2022 , 09-Jun-2022 , 07-Jul-2022 , 07-Sep-2022 , 07-Oct-2022 , 07-Jan-2023 , 09-Feb-2023 , 07-May-2023 , 09-Jun-2023 , 07-Sep-2023</td> </tr> <tr> <td style="padding-right: 5px;">Synopsis</td> <td>The National Institute of Dental and Craniofacial Research (NIDCR) is continuing support for research conducted within a dental Practice-Based Research Network (PBRN). The National Dental PBRN Administrative and Resource Center and National Coordinating Center support the infrastructure for and implementation of multiple observational studies and clinical trials. This Funding Opportunity Announcement (FOA) is soliciting applications for clinical trials and large clinical observational studies to be conducted in the National Dental PBRN through a milestone-driven UG3/UH3 cooperative agreement mechanism. Each UG3/UH3 award will support an individual project which will utilize the National Dental PBRN infrastructure and resources for study planning and implementation. This FOA supports a UG3 clinical study planning phase and potential transition to a UH3 implementation phase. Progression to the UH3 phase is based on an administrative review</td> </tr> </table>					Contact Name	Dena Fischer, DDS, MSD, MS	Contact Telephone	301-594-4876	Contact Email	dena.fischer@nih.gov	Sponsor Website		Program URL	Link to program URL	Deadline Dates (ALL)	07-May-2022 , 09-Jun-2022 , 07-Jul-2022 , 07-Sep-2022 , 07-Oct-2022 , 07-Jan-2023 , 09-Feb-2023 , 07-May-2023 , 09-Jun-2023 , 07-Sep-2023	Synopsis	The National Institute of Dental and Craniofacial Research (NIDCR) is continuing support for research conducted within a dental Practice-Based Research Network (PBRN). The National Dental PBRN Administrative and Resource Center and National Coordinating Center support the infrastructure for and implementation of multiple observational studies and clinical trials. This Funding Opportunity Announcement (FOA) is soliciting applications for clinical trials and large clinical observational studies to be conducted in the National Dental PBRN through a milestone-driven UG3/UH3 cooperative agreement mechanism. Each UG3/UH3 award will support an individual project which will utilize the National Dental PBRN infrastructure and resources for study planning and implementation. This FOA supports a UG3 clinical study planning phase and potential transition to a UH3 implementation phase. Progression to the UH3 phase is based on an administrative review
Contact Name	Dena Fischer, DDS, MSD, MS																		
Contact Telephone	301-594-4876																		
Contact Email	dena.fischer@nih.gov																		
Sponsor Website																			
Program URL	Link to program URL																		
Deadline Dates (ALL)	07-May-2022 , 09-Jun-2022 , 07-Jul-2022 , 07-Sep-2022 , 07-Oct-2022 , 07-Jan-2023 , 09-Feb-2023 , 07-May-2023 , 09-Jun-2023 , 07-Sep-2023																		
Synopsis	The National Institute of Dental and Craniofacial Research (NIDCR) is continuing support for research conducted within a dental Practice-Based Research Network (PBRN). The National Dental PBRN Administrative and Resource Center and National Coordinating Center support the infrastructure for and implementation of multiple observational studies and clinical trials. This Funding Opportunity Announcement (FOA) is soliciting applications for clinical trials and large clinical observational studies to be conducted in the National Dental PBRN through a milestone-driven UG3/UH3 cooperative agreement mechanism. Each UG3/UH3 award will support an individual project which will utilize the National Dental PBRN infrastructure and resources for study planning and implementation. This FOA supports a UG3 clinical study planning phase and potential transition to a UH3 implementation phase. Progression to the UH3 phase is based on an administrative review																		

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

and is dependent on success in meeting UG3 milestones, consideration of the dental PBRN as an appropriate venue for conduct of the research, NIDCR program priorities, and availability of funds. The main goals of the dental PBRN are to streamline the implementation of national oral health research studies in dental practices on topics of importance to practitioners and their patients, to provide evidence useful in daily patient care, and to facilitate the translation of research findings into clinical practice. This FOA encourages applications proposing research studies that align with the goals of the dental PBRN.

108427	NIDCR Dentist Scientist Career Transition Award for Intramural Investigators (K22 Basic Experimental Studies Involving Humans Required)	National Institute of Dental and Craniofacial Research/NIH/DHHS	PAR-22-046	07-May-2022	Not Specified
--------	---	---	------------	-------------	---------------

Contact Name	Leslie A. Frieden, PhD
Contact Telephone	301-496-4263
Contact Email	leslie.frieden@nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	07-May-2022 , 12-Jun-2022 , 07-Sep-2022 , 12-Oct-2022 , 07-Jan-2023 , 12-Feb-2023 , 07-May-2023 , 12-Jun-2023 , 07-Sep-2023 , 12-Oct-2023 , 07-Jan-2024 , 12-Feb-2024 , 07-May-2024 , 12-Oct-2024 , 07-Jan-2025
Synopsis	<p>The purpose of the NIDCR Dentist Scientist Career Transition Award for Intramural Investigators (K22) program is to facilitate transition of highly qualified dentists from NIH Intramural postdoctoral research positions to extramural academic tenure-track or equivalent faculty positions at eligible institutions. The award will provide support for two years of mentored postdoctoral research training in the NIH Intramural Research Program, and three years of independent research funding at the extramural institution. This Funding Opportunity Announcement is for basic science experimental studies involving humans, referred to in NOT-OD-18-212 as “prospective basic science studies involving human participants.” These studies fall within the NIH definition of a clinical trial and also meet the definition of basic research. Types of studies that should be submitted under this FOA include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental aspects of phenomena without specific application towards processes or products in mind. Applicants not planning an independent clinical trial or basic experimental study with humans, or proposing to gain research experience in a clinical trial or basic experimental study with humans led by another investigator, must apply to the 'Independent Clinical Trial Not Allowed' companion FOA. The proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) based on their scientific missions.</p>

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
108403	NIDCR Dentist Scientist Career Transition Award for Intramural Investigators (K22 Clinical Trial Required)	National Institute of Dental and Craniofacial Research/NIH/DHHS	PAR-22-045	07-May-2022	Not Specified
	<p>Contact Name Leslie A. Frieden, PhD</p> <p>Contact Telephone 301-496-4263</p> <p>Contact Email leslie.frieden@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2022 , 12-Jun-2022 , 07-Sep-2022 , 12-Oct-2022 , 07-Jan-2023 , 12-Feb-2023 , 07-May-2023 , 12-Jun-2023 , 07-Sep-2023 , 12-Oct-2023 , 07-Jan-2024 , 12-Feb-2024 , 07-May-2024 , 12-Oct-2024 , 07-Jan-2025</p> <p>Synopsis The purpose of the NIDCR Dentist Scientist Career Transition Award for Intramural Investigators (K22) program is to provide highly qualified dentists in NIH Intramural postdoctoral fellowship positions with opportunity to transition from mentored research experiences in the NIH Intramural program to extramural institutions as new investigators with independent research funding. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary clinical trial to an existing trial, as part of their research and career development. Applicants not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must apply to companion FOA (PAR-22-044).</p>				
083077	Development of Novel and Robust Systems for Mechanistic Studies of Gene-Environment Interplay in Dental, Oral, Craniofacial, and Other Diseases and Conditions (R21 Clinical Trial Not Allowed)	National Institute of Dental and Craniofacial Research/NIH/DHHS	PAR-19-293	07-May-2022	275,000 USD
	<p>Contact Name Kathryn Stein, Ph.D.</p> <p>Contact Telephone 301-827-4653</p> <p>Contact Email kathryn.stein@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2022 , 16-Jun-2022 , 07-Sep-2022</p> <p>Synopsis This Funding Opportunity Announcement (FOA) is intended to foster research towards a better understanding of the biological mechanisms of gene-environment interplay in human diseases and conditions. Through this FOA, the NIDCR, NIEHS , and NICHD solicit applications to develop novel and robust experimental systems that offer approaches</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		complementary to human epidemiologic or in vivo studies to facilitate mechanistic investigation of gene-environment interplay in dental, oral, craniofacial, and other diseases and conditions.			
081272	Clinical Research to Improve the Oral Health of Older Adults (R21 Clinical Trial Not Allowed)	National Institute of Dental and Craniofacial Research/NIH/DHHS	PAR-19-240	07-May-2022	275,000 USD
	Contact Name	Darién Weatherspoon, DDS, MPH			
	Contact Telephone	301-594-5394			
	Contact Email	darien.weatherspoon@mail.nih			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	07-May-2022 , 16-Jun-2022 , 07-Sep-2022			
	Synopsis	The purpose of this Funding Opportunity Announcement (FOA) is to encourage exploratory or developmental research to address risk factors, access to care barriers, oral health promotion and disease prevention strategies, and clinical management of dental, oral, and craniofacial (DOC) diseases more commonly experienced by older adults. This FOA defines “older adults” as those individuals age 65 years and older.			
087115	Improving Oral Health and Reducing Disparities in Adolescents (R21 Clinical Trial Not Allowed)	National Institute of Dental and Craniofacial Research/NIH/DHHS	PAR-20-059	07-May-2022	275,000 USD
	Contact Name	Darién Weatherspoon, DDS, MPH			
	Contact Telephone	301-594-5394			
	Contact Email	darien.weatherspoon@nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	07-May-2022 , 16-Jun-2022 , 07-Sep-2022 , 16-Oct-2022 , 07-Jan-2023			
	Synopsis	The purpose of this Funding Opportunity Announcement (FOA) is to encourage exploratory or developmental research to improve the oral health of adolescents in the United States, and to reduce observed oral health disparities and inequities in this population. This FOA defines “adolescents” as those individuals between the ages of 10 and 19.			
101831	Notice of Special Interest (NOSI): NIDCR Support for Research on the Physiological Involvement of Oral Cavity in Coronavirus Disease 2019 (COVID-19)	National Institute of Dental and Craniofacial Research/NIH/DHHS	NOT-DE-21-001	07-May-2022	Not Specified

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Name Amanda Melillo, Ph.D.</p> <p>Contact Telephone 301-529-7217</p> <p>Contact Email amanda.melillo@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2022 , 05-Jun-2022 , 16-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 16-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 16-Feb-2023 , 07-May-2023</p> <p>Synopsis The National Institute of Dental and Craniofacial Research (NIDCR) is issuing this Notice of Special Interest (NOSI) to encourage research studies focused on the physiological involvement of oral cavity and oral manifestations related to SARS-CoV-2 and/or Coronavirus Disease 2019 (COVID-19). Globally, the death toll for COVID-19 caused by the coronavirus SARS-CoV-2 has surpassed 1.9 million, and in the United States, more than 375,000 individuals have succumbed to the disease as of January 2021. Synergizing with a myriad of initiatives across NIH and responding to a palpable sense of public health urgency, NIDCR is positioned to address COVID-19 research knowledge gaps unique to our mission, as well as to facilitate broad and rapid dissemination of research findings. Outcomes from this NOSI are expected to strengthen the knowledge base of COVID-19 disease mechanisms and presentations in the oral cavity.</p>				
086959	NIDCR Research Grants for Analyses of Existing Genomics Data (R01 Clinical Trial Not Allowed)	National Institute of Dental and Craniofacial Research/NIH/DHHS	PAR-20-045	07-May-2022	Not Specified
	<p>Contact Name Lu Wang, Ph.D.</p> <p>Contact Telephone 301-594-4846</p> <p>Contact Email wanglu@nidcr.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2022 , 05-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 07-Jan-2023</p> <p>Synopsis The purpose of this FOA is to announce support for meritorious research projects that address research questions relevant to human dental, oral, or craniofacial (DOC) conditions or traits through analysis of existing and publicly available genomics data using statistical and computational approaches. Data analysis for each project can be performed using existing and/or novel methods to be developed in the same project, including machine learning-based methods (ML). In addition to analysis of existing data, experimental or in silico work is required to validate data analysis results, or to validate a newly developed</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

analytic method. Work that tackles causal mechanisms of action for onset and progression of disease for identified candidate causal genetic variants is highly encouraged.

108981	NIDCR Mentored Career Development Award to Promote Diversity (K01 Independent Basic Experimental Studies with Humans Required)	National Institute of Dental and Craniofacial Research/NIH/DHHS	PAR-22-052	07-May-2022	Not Specified
--------	--	---	------------	-------------	---------------

Contact Name	Leslie A. Frieden, Ph.D.
Contact Telephone	301-496-4263
Contact Email	leslie.frieden@nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	07-May-2022 , 12-Jun-2022 , 07-Sep-2022 , 12-Oct-2022 , 07-Jan-2023 , 12-Feb-2023 , 07-May-2023 , 12-Jun-2023 , 07-Sep-2023 , 12-Oct-2023 , 07-Jan-2024 , 12-Feb-2024 , 07-May-2024 , 12-Jun-2024 , 07-Sep-2024 , 12-Oct-2024 , 07-Jan-2025
Synopsis	The purpose of the NIDCR Mentored Career Development Award to Promote Diversity is to support postdoctoral fellows and early career faculty from diverse backgrounds, including those from groups underrepresented in the biomedical, behavioral, and social sciences, to ensure a well-trained dental, oral, and craniofacial research workforce. This FOA provides salary and research support for a sustained period of “protected time” for intensive research career development under the guidance of an experienced mentor. This Funding Opportunity Announcement is for basic science experimental studies involving humans, referred to in NOT-OD-18-212 as “prospective basic science studies involving human participants.” These studies fall within the NIH definition of a clinical trial and also meet the definition of basic research. Types of studies that should be submitted under this FOA include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental aspects of phenomena without specific application towards processes or products in mind. Applicants not planning an independent clinical trial or basic experimental study with humans, or proposing to gain research experience in a clinical trial or basic experimental study with humans led by another investigator, must apply to the 'Independent Clinical Trial Not Allowed' companion FOA.

108979	NIDCR Mentored Career Development Award to Promote Diversity (K01 Clinical Trial Required)	National Institute of Dental and Craniofacial Research/NIH/DHHS	PAR-22-051	07-May-2022	Not Specified
--------	--	---	------------	-------------	---------------

Contact Name	Leslie A. Frieden, Ph.D.
Contact Telephone	301-496-4263

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Email leslie.frieden@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2022 , 12-Jun-2022 , 07-Sep-2022 , 12-Oct-2022 , 07-Jan-2023 , 12-Feb-2023 , 07-May-2023 , 12-Jun-2023 , 07-Sep-2023 , 12-Oct-2023 , 07-Jan-2024 , 12-Feb-2024 , 07-May-2024 , 12-Jun-2024 , 07-Sep-2024 , 12-Oct-2024 , 07-Jan-2025</p> <p>Synopsis The purpose of the NIDCR Mentored Career Development Award to Promote Diversity is to support postdoctoral fellows and early career faculty from diverse backgrounds, including those from groups underrepresented in the biomedical, behavioral, and social sciences, to ensure a well-trained dental, oral, and craniofacial research workforce. This FOA provides salary and research support for a sustained period of “protected time” for intensive research career development under the guidance of an experienced mentor. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary study to an existing trial, as part of their research and career development. Applicants not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must apply to companion FOA (PAR-22-050).</p>				
108980	NIDCR Mentored Career Development Award to Promote Diversity (K01 Independent Clinical Trial Not Allowed)	National Institute of Dental and Craniofacial Research/NIH/DHHS	PAR-22-050	07-May-2022	Not Specified
	<p>Contact Name Leslie A. Frieden, Ph.D.</p> <p>Contact Telephone 301-496-4263</p> <p>Contact Email leslie.frieden@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2022 , 12-Jun-2022 , 07-Sep-2022 , 12-Oct-2022 , 07-Jan-2023 , 12-Feb-2023 , 07-May-2023 , 12-Jun-2023 , 07-Sep-2023 , 12-Oct-2023 , 07-Jan-2024 , 12-Feb-2024 , 07-May-2024 , 12-Jun-2024 , 07-Sep-2024 , 12-Oct-2024 , 07-Jan-2025</p> <p>Synopsis The purpose of the NIDCR Mentored Career Development Award to Promote Diversity is to support postdoctoral fellows and early career faculty from diverse backgrounds, including those from groups underrepresented in the biomedical, behavioral, and social sciences, to ensure a well-trained dental, oral, and craniofacial research workforce. This FOA provides salary and research support for a sustained period of “protected time” for intensive research career development under the guidance of an experienced mentor. This Funding Opportunity Announcement (FOA) is designed specifically for candidates proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary study to a clinical trial. Applicants to this FOA are permitted to propose research experience in a clinical trial led by a mentor or co-</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		mentor. Those proposing a clinical trial or an ancillary clinical trial as lead investigator, should apply to the companion FOA (PAR-22-051).			
107548	Notice of Special Interest (NOSI): Basic and Translational Oral Health Research Related to HIV/AIDS	National Institute of Dental and Craniofacial Research/NIH/DHHS	NOT-DE-21-019	07-May-2022	Not Specified
	Contact Name	Hiroko Iida, DDS, MPH			
	Contact Telephone	301-594-7404			
	Contact Email	hiroko.iida@nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	07-May-2022 , 05-Jun-2022 , 16-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 16-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 16-Feb-2023 , 07-May-2023			
	Synopsis	The National Institute of Dental and Craniofacial Research (NIDCR) is issuing this Notice of Special Interest (NOSI) to encourage basic and translational research into mechanisms of HIV transmission, persistence, and pathogenesis in the oral cavity and its associated co-morbidities.			
096105	Enabling Technologies to Accelerate Development of Oral Biodevices (R21 Clinical Trial Not Allowed)	National Institute of Dental and Craniofacial Research/NIH/DHHS	PAR-20-232	07-May-2022	Not Specified
	Contact Name	Orlando Lopez, PhD			
	Contact Telephone	301-402-4243			
	Contact Email	orlando.lopez@nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	07-May-2022 , 16-Jun-2022 , 07-Sep-2022 , 16-Oct-2022 , 07-Jan-2023 , 16-Feb-2023 , 07-May-2023			
	Synopsis	This Funding Opportunity Announcement (FOA) invites exploratory/developmental applications that propose transformative engineering solutions to technical challenges associated with meaningful development, substantial optimization of existing technologies and clinical translation of intraoral biodevices. Proposed technologies are expected to advance development of oral biodevices to clinical use, including but not limited to: precision medicine-based detection, diagnosis and treatment of oral and overall health conditions, and measurement of patient functional status and clinical outcome assessment. Areas of interest in this FOA include engineering approaches that allow integration of electronic, physical, and biological systems			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

essential to the development of functional biodevices that are safe and effective for detection, diagnosis and treatment of oral and systemic disease. Products of this research will be proof-of-concept prototype biodevices, dedicated biosensors and associated core technologies that enable development of safe and effective intra-oral biodevices intended for specific clinical applications. To streamline the development of oral biodevices that advance precision medicine-based approaches in clinical practice, this FOA encourages interdisciplinary collaborations across engineering, multifunctional sensors, pharmacology, chemistry, medicine, and dentistry, as well as between academia and industry.

100931	NIDCR Small Grant Program for New Investigators (R03 Clinical Trial Not Allowed)	National Institute of Dental and Craniofacial Research/NIH/DHHS	PAR-21-084	07-May-2022	200,000 USD
--------	--	---	------------	-------------	-------------

	Contact Name	Preethi Chander, PhD
	Contact Telephone	301-827-4620
	Contact Email	preethi.chander@nih.gov
	Sponsor Website	
	Program URL	Link to program URL
	Deadline Dates (ALL)	07-May-2022 , 16-Jun-2022 , 07-Sep-2022 , 16-Oct-2022 , 07-Jan-2023 , 16-Feb-2023 , 07-May-2023 , 16-Jun-2023 , 07-Sep-2023 , 16-Oct-2023 , 07-Jan-2024
	Synopsis	This NIDCR Small Grant Program for New Investigators supports basic and clinical research conducted by scientists who are in the early stages of establishing an independent research career in oral, dental and craniofacial research. This R03 program supports pilot or feasibility studies and developmental research projects with the intention of obtaining sufficient preliminary data for a subsequent investigator- initiated Research Project Grant (R01) or equivalent application.

106245	NIDCR Behavioral and Social Intervention Clinical Trial Planning and Implementation Cooperative Agreement (UG3/UH3 Clinical Trial Required)	National Institute of Dental and Craniofacial Research/NIH/DHHS	PAR-21-317	07-May-2022	Not Specified
--------	---	---	------------	-------------	---------------

	Contact Name	Melissa W. Riddle, PhD
	Contact Telephone	301-451-3888
	Contact Email	riddleme@mail.nih.gov
	Sponsor Website	
	Program URL	Link to program URL

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Deadline Dates (ALL)	07-May-2022 , 07-Jun-2022 , 07-Jul-2022 , 07-Sep-2022 , 04-Oct-2022 , 04-Nov-2022 , 07-Jan-2023 , 07-Feb-2023 , 07-Mar-2023 , 07-May-2023 , 06-Jun-2023 , 06-Jul-2023 , 07-Sep-2023 , 03-Oct-2023 , 03-Nov-2023 , 07-Jan-2024 , 06-Feb-2024 , 06-Mar-2024 , 07-May-2024			
	Synopsis	<p>The purpose of this Funding Opportunity Announcement (FOA) is to encourage UG3/UH3 phased cooperative agreement research applications to plan and implement behavioral and social intervention clinical trials. Studies appropriate for this FOA include clinical trials to develop and test behavior change interventions related to dental, oral, or craniofacial conditions. Applications for NIDCR support of clinical trials research are expected to identify research proposals using the NIH Stage Model framework, described in detail here and incorporate an experimental medicine approach. Awards made under this FOA will initially support a milestone-driven UG3 planning phase for up to 2 years, with possible transition to a UH3 clinical trial implementation phase (UH3) of up to five years. The UG3 phase for behavioral and social intervention clinical trials will permit both scientific and operational planning activities. Scientific planning activities include small-scale data collection to assess the feasibility and/or acceptability of a planned behavioral or social intervention and associated study procedures (e.g., acceptability of study content or mode of delivery; feasibility of proposed data collection procedures; preliminary testing of intervention training and fidelity monitoring procedures). Operational planning activities include, at a minimum, development of: the final clinical protocol; the intervention manual or equivalent; the data management system and other tools for data and quality management, safety and operational oversight plans; recruitment and retention strategies; and other essential documents. The UH3 phase will support the conduct of investigator-initiated intervention research at all stages, from early mechanistic research and intervention development (e.g., Stages 0/ I) through implementation and health services research (Stages IV/V). This FOA may also support basic behavioral experimental studies with humans that are considered clinical trials based on the NIH's revised clinical trial definition (please see Clinical Trial Requirements for Grants and Contracts for guidance).</p>			
086963	NIDCR Small Research Grants for Analyses of Existing Genomics Data (R03 Clinical Trial Not Allowed)	National Institute of Dental and Craniofacial Research/NIH/DHHS	PAR-20-046	07-May-2022	200,000 USD
	Contact Name	Lu Wang, Ph.D.			
	Contact Telephone	301-594-4846			
	Contact Email	wanglu@nidcr.nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	07-May-2022 , 16-Jun-2022 , 07-Sep-2022 , 16-Oct-2022 , 07-Jan-2023			
	Synopsis	The purpose of this FOA is to announce support for meritorious research projects that address research questions relevant to human dental, oral, or craniofacial (DOC) conditions or traits through analysis of existing and publicly available genomics			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>data using statistical and computational approaches. Data analysis for each project can be performed using existing and/or novel methods to be developed in the same project, including machine learning-based methods (ML).</p>				
109089	RFA-DE-23-005 -- In utero Treatments of Congenital Dental and Craniofacial Disorders Using Precision Medicine Approaches (R21 Clinical Trial Not Allowed)	National Institute of Dental and Craniofacial Research/NIH/DHHS	RFA-DE-23-005	14-May-2022 [Optional][LOI/Pre-App]	275,000 USD
	<p>Contact Name Lu Wang, PhD Contact Telephone 301-594-4846 Contact Email wanglu@mail.nih.gov Sponsor Website Program URL Link to program URL Deadline Dates (ALL) 14-May-2022 [Optional][LOI/Pre-App], 14-Jun-2022 Synopsis This FOA is intended to foster innovative research to directly enable precision medicine approach- and animal model-based development of in utero treatments for congenital dental and craniofacial diseases and conditions. The FOA looks to support projects that will demonstrate the feasibilities of treatment targets, treatment modalities, treatment delivery modalities, and gestational treatment time windows, as well as projects that will establish experimental systems and methods for the development of in utero treatments, all designed in the context of specific congenital dental and craniofacial diseases and conditions. The long-term goal is to lay the groundwork for therapies and cures in humans for congenital dental and craniofacial diseases and conditions as well as other diseases and conditions that share the same disease etiologies.</p>				
109088	RFA-DE-23-004 -- In utero Treatments of Congenital Dental and Craniofacial Disorders Using Precision Medicine Approaches (R01 Clinical Trial Not Allowed)	National Institute of Dental and Craniofacial Research/NIH/DHHS	RFA-DE-23-004	14-May-2022 [Optional][LOI/Pre-App]	Not Specified
	<p>Contact Name Lu Wang, PhD Contact Telephone 301-594-4846 Contact Email wanglu@mail.nih.gov Sponsor Website Program URL Link to program URL Deadline Dates (ALL) 14-May-2022 [Optional][LOI/Pre-App], 14-Jun-2022</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Synopsis	This FOA is intended to support research to accelerate the development of treatments for congenital dental and craniofacial diseases and conditions. The FOA invites applications for projects that will use precision medicine approaches in animal models to develop in utero treatments for congenital dental and craniofacial diseases and conditions. It is anticipated that successful treatments can arrest, ameliorate, or cure the diseases or conditions of interest. The long-term goal is to lay the groundwork for delivery of in utero therapies and cures in humans affected by congenital dental and craniofacial diseases and conditions as well as other diseases and conditions that share similar disease etiologies.			
108878	RFA-DE-23-001 -- NIDCR Dental Specialty and PhD Program (K12 Clinical Trial Not Allowed)	National Institute of Dental and Craniofacial Research/NIH/DHHS	RFA-DE-23-001	07-Jun-2022 [Optional][LOI/Pre-App]	Not Specified
	Contact Name	Leslie Frieden, Ph.D.			
	Contact Telephone	301-496-4263			
	Contact Email	leslie.frieden@nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	07-Jun-2022 [Optional][LOI/Pre-App], 07-Jul-2022			
	Synopsis	The purpose of the NIDCR Dental Specialty and PhD Program (DSPP) is to develop outstanding dentist scientists through structured programs that provide advanced clinical training in an approved dental specialty, research career development activities, and mentored research training leading to a PhD in biomedical or behavioral science. The programs are expected to accelerate the process of early career dentist scientists achieving competencies in both clinical and research areas, and to facilitate their transition to independent and productive research careers dedicated to improving dental, oral, and craniofacial health.			
109617	RFA-DE-23-003 -- Advancing HIV/AIDS Research at the Intersection of Oral and Mental Health (R21 Clinical Trial Not Allowed)	National Institute of Dental and Craniofacial Research/NIH/DHHS	RFA-DE-23-003	25-Jun-2022 [Optional][LOI/Pre-App]	275,000 USD
	Contact Name	Hiroko Iida, DDS, MPH			
	Contact Telephone	301-594-7404			
	Contact Email	hiroko.iida@nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	25-Jun-2022 [Optional][LOI/Pre-App], 25-Jul-2022			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

Synopsis | The purpose of this Funding Opportunity Announcement (FOA) is to support interdisciplinary research to better understand the underlying mechanisms and interplay of biological, psychosocial, behavioral, and social structural factors contributing to oral health, mental health and co-occurring disorders in people living with HIV.

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

109616	RFA-DE-23-002 -- Advancing HIV/AIDS Research at the Intersection of Oral and Mental Health (R01 Clinical Trial Not Allowed)	National Institute of Dental and Craniofacial Research/NIH/DHHS	RFA-DE-23-002	25-Jun-2022 [Optional][LOI/Pre-App]	Not Specified
--------	---	---	---------------	-------------------------------------	---------------

	Contact Name	Hiroko Iida, DDS, MPH
	Contact Telephone	301-594-7404
	Contact Email	hiroko.iida@nih.gov
	Sponsor Website	
	Program URL	Link to program URL
	Deadline Dates (ALL)	25-Jun-2022 [Optional][LOI/Pre-App], 25-Jul-2022
	Synopsis	The purpose of this Funding Opportunity Announcement (FOA) is to support interdisciplinary research to better understand the underlying mechanisms and interplay of biological, psychosocial, behavioral, and social structural factors contributing to oral health, mental health and co-occurring disorders in people living with HIV.

107686	RFA-DK-21-030 -- New Investigator Gateway Awards for Collaborative T1D Research (R03 Clinical Trial Not Allowed)	National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS	RFA-DK-21-030	01-May-2022 [Optional][LOI/Pre-App]	200,000 USD
--------	--	---	---------------	-------------------------------------	-------------

	Contact Name	Kristin M. Abraham, Ph.D
	Contact Telephone	301-451-8048
	Contact Email	abrahamk@mail.nih.gov
	Sponsor Website	
	Program URL	Link to program URL
	Deadline Dates (ALL)	01-May-2022 [Optional][LOI/Pre-App], 01-Jun-2022 , 20-Feb-2023 [Optional][LOI/Pre-App], 20-Mar-2023

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Synopsis The New Investigator Gateway Award in T1D Research is designed to ensure that a robust pipeline of talented new investigators will continue to embark on successful careers in T1D research. In addition to providing support for preliminary research, the Gateway program provides an opportunity for new Program Directors/Principal Investigators (PD/PIs) to pursue their studies within the intellectual environment of a select number of large, ongoing collaborative research programs. Embedding awardees within an established scientific framework in each of these consortia will provide unique opportunities for New and Early Stage Investigators to increase their understanding of key questions in the field, to network, and to establish unique and potentially long-lasting collaborations that will propel their careers forward. It is anticipated that the Gateway award will provide the support needed to enhance the success of future R01 submissions from New Investigators interested in pursuing careers in T1D research.</p>				
101372	NIDDK High Risk Multi-Center Clinical Study Cooperative Agreement (U01 Clinical Trial Required)	National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS	PAR-21-102	07-May-2022	Not Specified
	<p>Contact Name Tracy Rankin, Ph.D., M.P.H.</p> <p>Contact Telephone 301-594-4748</p> <p>Contact Email rankint@mail.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2022 , 05-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 07-May-2023 , 05-Jun-2023 , 07-Sep-2023 , 05-Oct-2023 , 07-Jan-2024</p> <p>Synopsis This FOA invites applications for investigator-initiated, high-risk multi-center clinical trials involving more than one clinical center. Proposed trials should be hypothesis-driven, have the potential to change clinical practice and/or public health, and focus on a disease relevant to the mission of NIDDK. Planning activities must be completed prior to submission and are not permitted under this FOA. Applicants who require a planning phase may first apply for an implementation planning cooperative agreement (U34; see PAR-21-101). Consultation with NIDDK Scientific/Research staff is strongly encouraged prior to the submission of either a U34 or U01 application.</p>				
101373	NIDDK High Risk Multi-Center Clinical Study Cooperative Agreement (U01 Clinical Trial Not Allowed)	National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS	PAR-21-103	07-May-2022	Not Specified
	<p>Contact Name Tracy Rankin, Ph.D., M.P.H.</p> <p>Contact Telephone 301-594-4748</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Email rankint@mail.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2022 , 05-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 07-May-2023 , 05-Jun-2023 , 07-Sep-2023 , 05-Oct-2023 , 07-Jan-2024</p> <p>Synopsis This FOA invites applications for investigator-initiated, high-risk multi-center observational studies involving more than one clinical center. Proposed studies should be hypothesis-driven and focus on a disease relevant to the mission of NIDDK. Planning activities must be completed prior to submission and are not permitted under this FOA. Applicants who require a planning phase may first apply for an implementation planning cooperative agreement (U34; see PAR-21-101). Consultation with NIDDK Scientific/Research staff is strongly encouraged prior to the submission of either a U34 or U01 application.</p>				
105892	Notice of Special Interest (NOSI): Advancing Research in Gastrointestinal Dysfunction in People with Neurodevelopmental Disorders	National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS	NOT-DK-21-024	07-May-2022	Not Specified
	<p>Contact Name Terez Shea-Donohue, Ph.D.</p> <p>Contact Telephone 301 825-2314</p> <p>Contact Email terez.shea-donohue@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2022 , 05-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 07-May-2023 , 05-Jun-2023 , 07-Sep-2023 , 05-Oct-2023 , 07-Jan-2024 , 05-Feb-2024 , 07-May-2024 , 05-Jun-2024 , 07-Sep-2024</p> <p>Synopsis The National Institute of Diabetes and Digestive and Kidney Diseases is issuing this Notice to highlight interest in receiving grant applications focused in the following area(s) to support basic, translational, and/or clinical research on the causes, diagnosis, prevention, or treatment of gastrointestinal dysfunction in people with neurodevelopmental disorders. Interdisciplinary science in this area plays a pivotal role and projects are encouraged to include close collaboration between scientists with expertise in neurodevelopmental disorders and scientists with expertise in neurogastroenterology.</p>				
091518	Small R01s for Clinical Trials Targeting Diseases within the Mission of NIDDK (R01 Clinical Trial Required)	National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS	PAS-20-160	07-May-2022	600,000 USD
	Contact Name Susan Mendley, M.D.				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

Contact Telephone	301- 827-1861
Contact Email	susan.mendley@nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	07-May-2022 , 05-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 07-May-2023
Synopsis	This Funding Opportunity Announcement encourages the submission of pilot and feasibility clinical trials conducted in humans that will lay the foundation for larger clinical trials related to the prevention and/or treatment of diseases and conditions within the mission of NIDDK. The program will support small, short-term clinical trials in humans to acquire preliminary data regarding the effects of the intervention, as well as feasibility data related to recruitment and retention, and study conduct. Applications for clinical trials submitted under this FOA should have clearly described aims and objectives, and have a high likelihood that the trial findings will lead to more definitive, hypothesis-driven trials to improve understanding, diagnosis, prevention or treatment of the diseases studied and have the potential to impact clinical practice and/or public health. Preliminary data regarding intervention efficacy are not required.

090534	Catalytic Tool and Technology Development in Kidney, Urologic, and Hematologic Diseases (R21 Clinical Trial Not Allowed)	National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS	PAR-20-140	07-May-2022	275,000 USD
--------	--	---	------------	-------------	-------------

Contact Name	Daniel Gossett, Ph.D.
Contact Telephone	301-594-7723
Contact Email	daniel.gossett@nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	07-May-2022 , 16-Jun-2022 , 07-Sep-2022 , 16-Oct-2022 , 07-Jan-2023 , 16-Feb-2023 , 07-May-2023
Synopsis	The purpose of this Funding Opportunity Announcement is to promote development of innovative, enabling tools and technologies in the areas of kidney, urologic, and hematologic diseases.

085472	Limited Competition: Small Grant Program for NIDDK K01/K08/K23/K25 Recipients (R03 Clinical Trial Optional)	National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS	PAR-19-365	07-May-2022	150,000 USD
--------	---	---	------------	-------------	-------------

Contact Name	Lisa M. Spain, Ph.D.
--------------	----------------------

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Telephone 301-451-9871</p> <p>Contact Email SpainL@niddk.nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2022 , 16-Jun-2022 , 07-Sep-2022</p> <p>Synopsis National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) invites applications to provide NIDDK-supported K01, K08, K23, and K25 recipients the opportunity to apply for Small Grant (R03) support at some point during the final two years of their K award. Through the use of this mechanism, the NIDDK is seeking to enhance the capability of its K01, K08, K23, and K25 award recipients to conduct research as they complete their transition to fully independent investigator status. The R03 grant mechanism supports different types of projects, including pilot and feasibility studies; secondary analysis of existing data; small, self-contained research projects; development of research methodology; and development of new research technology. The R03 is, therefore, intended to support research projects that can be carried out in a short period of time with limited resources and that may provide preliminary data to support a subsequent R01, or equivalent, application. This program will use the NIH Small Research Grant (R03) award mechanism.</p>				
109856	<p>RFA-DK-22-004 -- NIDDK Partnerships with Professional Societies to Enhance Scientific Workforce Diversity and Promote Scientific Leadership (R25 - Clinical Trial Not Allowed)</p>	National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS	RFA-DK-22-004	21-May-2022 [Optional][LOI/Pre-App]	675,000 USD
	<p>Contact Name Katrina Serrano, Ph.D.</p> <p>Contact Telephone 301-480-7855</p> <p>Contact Email katrina.serrano@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 21-May-2022 [Optional][LOI/Pre-App], 21-Jun-2022</p> <p>Synopsis The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The overarching goal of this R25 program is to support educational activities that encourage individuals from diverse backgrounds, including those from groups underrepresented in the biomedical and behavioral sciences, to pursue further studies or careers in research. To accomplish the stated over-arching goal, this FOA will support creative educational activities with a primary focus on: Courses for Skills Development Mentoring Activities This R25 program encourages professional societies supporting the NIDDK mission areas to develop educational programs aimed at recruiting talented junior faculty from diverse backgrounds, including those from groups underrepresented in biomedical, behavioral, clinical,</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

and social sciences research. Professional societies should propose an educational program that includes a diversity recruitment plan that would enhance the diversity of the the candidate pool for available positions in the organization's scientific workforce, including recruitment of individuals from groups historically underrepresented in the organization's programs and leadership.

101487	RFA-DK-20-032 -- Pilot and Feasibility Studies to Facilitate the Use of Diabetes Self-Management Education and Support to Improve Diabetes Care (R34 Clinical Trial Required)	National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS	RFA-DK-20-032	22-May-2022 [Optional][LOI/Pre-App]	600,000 USD
--------	---	---	---------------	-------------------------------------	-------------

Contact Name	Henry B. Burch, M.D
Contact Telephone	301-827-0827
Contact Email	henry.burch@nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	22-May-2022 [Optional][LOI/Pre-App], 22-Jun-2022 , 22-May-2023 [Optional][LOI/Pre-App], 22-Jun-2023
Synopsis	The purpose of this funding opportunity announcement (FOA) is to test an innovative and pragmatic approach to address barriers to and facilitate greater use of diabetes self-management education and support (DSMES) by people living with diabetes mellitus. Research applications should engage key stakeholders in cultivating a practical and sustainable strategy with the potential for dissemination. The pilot trial of the proposed strategy should be designed to generate preliminary data in support of a future, full-scale trial to study broader dissemination and implementation to expand the use of DSMES.

107664	High Impact, Interdisciplinary Science in NIDDK Research Areas (RC2 Clinical Trial Optional)	National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS	PAR-22-069	01-Jun-2022	Not Specified
--------	--	---	------------	-------------	---------------

Contact Name	Norann Zaghoul, Ph.D.
Contact Telephone	301-435-6677
Contact Email	norann.zaghoul@nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	01-Jun-2022 , 02-Nov-2022 , 01-Jun-2023 , 02-Nov-2023 , 30-May-2024 , 30-Oct-2024

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Synopsis	The purpose of the High Impact, Interdisciplinary Science grants program is to support high impact ideas that may lay the foundation for new fields of investigation within the mission of NIDDK. The interdisciplinary approach encouraged by this FOA is envisioned to generate a research resource and/or foster discovery-based or hypothesis-generating science that can have a significant impact on the broader scientific community. This FOA seeks novel approaches in areas that address specific knowledge gaps, scientific opportunities, new technologies, data generation, or research methods that will advance the area in significant ways designed to accelerate scientific progress in the understanding, treatment, and prevention of diseases within the mission of the NIDDK.			
108051	Stimulating Hematology Investigation: New Endeavors (SHINE) (R01 Clinical Trial Not Allowed)	National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS	PAS-22-096	05-Jun-2022	Not Specified
	Contact Name	Shilpa Hattangadi, M.D.			
	Contact Telephone	301-594-7726			
	Contact Email	shilpam.hattangadi@nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	05-Jun-2022 , 05-Oct-2022 , 05-Feb-2023 , 05-Jun-2023 , 05-Oct-2023 , 05-Feb-2024 , 05-Jun-2024 , 05-Oct-2024			
	Synopsis	The Stimulating Hematology Investigation: New Endeavors (SHINE) program is intended to promote innovative, high-quality nonmalignant hematology research relevant to the missions of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institute of Aging (NIA), and the National Heart, Lung, and Blood Institute (NHLBI). Investigator-initiated research project grant applications (R01s) in specific areas of basic and early translational hematology research are invited to this program that supports growth in the nonmalignant hematology research domain. Specific emerging topics that are at the leading edge of the field will change over time and will be updated regularly through the NIH Guide to Grants and Contracts and hyperlinked to this FOA.			
107685	Stimulating Urology Interdisciplinary Team Opportunity Research (SUITOR) (R01 Clinical Trial Optional)	National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS	PAS-22-074	05-Jun-2022	Not Specified
	Contact Name	Julie Barthold, MD			
	Contact Telephone	301-594-9655			
	Contact Email	julia.barthold@nih.gov			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 05-Jun-2022 , 05-Oct-2022 , 05-Feb-2023 , 05-Jun-2023 , 05-Oct-2023 , 05-Feb-2024 , 05-Jun-2024 , 05-Oct-2024 , 05-Feb-2025</p> <p>Synopsis The Stimulating Urology Interdisciplinary Team Opportunity Research (SUITOR) program is intended to promote innovative, high quality, interdisciplinary research relevant to the mission of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). The NIDDK invites investigator-initiated research project grant applications (R01s) in specific areas of basic, translational, or clinical research in specific benign urologic conditions and diseases where needs and opportunities for progress are particularly timely. As such, research topics of interest will change over time to take advantage of emerging opportunities. The research topic area previously supported by the SUITOR program, urinary incontinence, will now transition to neurourology, as described below.</p>				
084473	NIDDK Central Repositories Non-renewable Sample Access (X01 Clinical Trial Not Allowed)	National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS	PAR-19-319	28-Jun-2022	Not Specified
	<p>Contact Name Lisa M. Spain, Ph.D</p> <p>Contact Telephone 301-451-9871</p> <p>Contact Email SpainL@niddk.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 28-Jun-2022</p> <p>Synopsis National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) invites investigators to apply for access to non-renewable samples from one or more of these studies. Information about the samples available can be found at www.niddkrepository.org. Applicants must provide information from the NIDDK Central Repositories documenting sample availability. This FOA will utilize the NIH X01 Resource Access Award mechanism.</p>				
084593	RFA-ES-19-011 -- Mechanism for Time-Sensitive Research Opportunities in Environmental Health Sciences (R21 Clinical Trial Not Allowed)	National Institute of Environmental Health Sciences/NIH/DHHS	RFA-ES-19-011	02-May-2022	275,000 USD
	<p>Contact Name Martha I. Barnes, MS</p> <p>Contact Telephone 919-541-3335</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Email barnes@niehs.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 02-May-2022 , 01-Jun-2022 , 01-Jul-2022 , 01-Aug-2022 , 01-Sep-2022 , 03-Oct-2022</p> <p>Synopsis This funding opportunity announcement (FOA) is intended to support novel environmental health research in which an unpredictable event or policy change provides a limited window of opportunity to collect human biological samples or environmental exposure data. The primary motivation of the FOA is to understand the consequences of natural and human-made disasters, emerging environmental public health threats, and policy changes in the U.S. and abroad. A distinguishing feature of an appropriate study is the need for rapid review and funding, substantially shorter than the typical NIH grant review/award cycle, for the research question to be addressed and swiftly implemented. The shortened timeframe will be achieved by more frequent application due dates and expediting peer review, council concurrence and award issuance. The entire cycle, from submission to award, is expected to be within 3-4 months.</p>				
108560	RFA-ES-22-002 -- Revolutionizing Innovative, Visionary Environmental Health Research (RIVER) (R35 Clinical Trial Optional)	National Institute of Environmental Health Sciences/NIH/DHHS	RFA-ES-22-002	10-May-2022 [Optional][LOI/Pre-App]	6,000,000 USD
	<p>Contact Name Jennifer B. Collins</p> <p>Contact Telephone 984-287-3247</p> <p>Contact Email collins6@niehs.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 10-May-2022 [Optional][LOI/Pre-App], 09-Jun-2022</p> <p>Synopsis The NIEHS Revolutionizing Innovative, Visionary Environmental health Research (RIVER) program is intended to provide support for outstanding investigators in the Environmental Health Sciences, giving them intellectual and administrative freedom, as well as sustained support to pursue their research in novel directions in order to achieve greater impacts. The program seeks to identify individuals with a potential for continued innovative and impactful research and combine their existing investigator-initiated research into a single award to support the majority of their independent environmental health sciences research program.</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
110095	Notice of Special Interest (NOSI): Promoting Health, Safety, and Recovery Training for COVID-19 Essential Workers and their Communities	National Institute of Environmental Health Sciences/NIH/DHHS	NOT-ES-22-005	06-Jun-2022	400,000 USD
	<p>Contact Name Sharon D. Beard, MS</p> <p>Contact Telephone 984-287-3237</p> <p>Contact Email beard1@niehs.nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 06-Jun-2022</p> <p>Synopsis The purpose of this supplement is to provide support for successful applicants to develop partnerships with local worker centers and community organizations specifically targeting under served and disadvantaged communities with higher than average COVID-19 transmission rates.</p>				
102788	Transition to Independent Environmental Health Research (TIEHR) Career Award (K01 Clinical Trial Not Allowed)	National Institute of Environmental Health Sciences/NIH/DHHS	PAR-21-172	12-Jun-2022	375,000 USD
	<p>Contact Name Carol Shreffler, PhD</p> <p>Contact Telephone 984-287-3322</p> <p>Contact Email shreffl1@niehs.nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 12-Jun-2022 , 12-Oct-2022 , 12-Feb-2023 , 12-Jun-2023 , 12-Oct-2023 , 12-Feb-2024</p> <p>Synopsis The Transition to Independent Environmental Health (TIEHR) Career Award is a 3-year bridge scholar development program for newly independent faculty who intend to pursue research careers in environmental health sciences. At the conclusion of the career development period the candidates are expected to demonstrate they can successfully compete for research funding in the environmental health sciences. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary study to a clinical trial. Applicants to this FOA are permitted to propose a research experience in a clinical trial led by a mentor or co-mentor. Applicants proposing a clinical trial or an ancillary study to an ongoing clinical trial as lead investigator, should apply to the companion FOA PAR-21-171. Applicants proposing basic science experimental studies</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		involving humans, referred to in NOT-OD-18-212 as “prospective basic science studies involving human participants”, should apply to the companion FOA PAR-21-170)			
102785	Transition to Independent Environmental Health Research (TIEHR) Career Award (K01 Independent Basic Experimental Studies with Humans Required)	National Institute of Environmental Health Sciences/NIH/DHHS	PAR-21-170	12-Jun-2022	375,000 USD
	<p>Contact Name Carol Shreffler, PhD</p> <p>Contact Telephone 984-287-3322</p> <p>Contact Email shreffl1@niehs.nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 12-Jun-2022 , 12-Oct-2022 , 12-Feb-2023 , 12-Jun-2023 , 12-Oct-2023 , 12-Feb-2024</p> <p>Synopsis The Transition to Independent Environmental Health (TIEHR) Career Award is a 3-year bridge scholar development program for newly independent faculty who intend to pursue research careers in environmental health sciences. At the conclusion of the career development period the candidates are expected to demonstrate they can successfully compete for research funding in the environmental health sciences. Note: This Parent Funding Opportunity Announcement is for basic science experimental studies involving humans, referred to in NOT-OD-18-212 as “prospective basic science studies involving human participants.” These studies fall within the NIH definition of a clinical trial and also meet the definition of basic research. Types of studies that should submit under this FOA include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental aspects of phenomena without specific application towards processes or products in mind. Studies conducted with specific applications toward processes or products in mind should submit under the companion ‘Independent Clinical Trial Required’ PAR 18-261.</p>				
102787	Transition to Independent Environmental Health Research (TIEHR) Career Award (K01 Clinical Trial Required)	National Institute of Environmental Health Sciences/NIH/DHHS	PAR-21-171	12-Jun-2022	375,000 USD
	<p>Contact Name Carol Shreffler, PhD</p> <p>Contact Telephone 984-287-3322</p> <p>Contact Email shreffl1@niehs.nih.gov</p> <p>Sponsor Website </p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 12-Jun-2022 , 12-Oct-2022 , 12-Feb-2023 , 12-Jun-2023 , 12-Oct-2023 , 12-Feb-2024</p> <p>Synopsis The Transition to Independent Environmental Health (TIEHR) Career Award is a 3-year bridge scholar development program for newly independent faculty who intend to pursue research careers in environmental health sciences. At the conclusion of the career development period the candidates are expected to demonstrate they can successfully compete for research funding in the environmental health sciences. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary clinical trial trial, as part of their research and career development. Applicants proposing basic science experimental studies involving humans, referred to in NOT-OD-18-212 as "prospective basic science studies involving human participants", must apply to companion FOA, PAR-21-170. Applicants not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must apply to companion FOA, PAR-21-172.</p>				
108741	Notice of Special Interest (NOSI): Inclusion of Economic Factors and Outcomes in Infectious Disease Modeling Studies	National Institute of General Medical Sciences/NIH/DHHS	NOT-GM-22-021	08-Apr-2022	Not Specified
	<p>Contact Name Veerasamy (Ravi) Ravichandran, Ph.D.</p> <p>Contact Telephone</p> <p>Contact Email Veerasamy.ravichandra@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 08-Apr-2022 , 07-May-2022 , 17-May-2022 , 27-May-2022 , 05-Jun-2022 , 12-Jun-2022 , 25-Jun-2022 , 08-Aug-2022 , 07-Sep-2022 , 03-Oct-2022 , 05-Oct-2022 , 12-Oct-2022 , 25-Oct-2022 , 08-Dec-2022 , 07-Jan-2023 , 27-Jan-2023 , 05-Feb-2023 , 12-Feb-2023 , 25-Feb-2023 , 08-Apr-2023 , 07-May-2023 , 05-Jun-2023 , 12-Jun-2023 , 25-Jun-2023 , 08-Aug-2023 , 07-Sep-2023 , 05-Oct-2023 , 12-Oct-2023 , 25-Oct-2023 , 08-Dec-2023 , 07-Jan-2024 , 05-Feb-2024 , 12-Feb-2024 , 25-Feb-2024 , 08-Apr-2024 , 07-May-2024 , 05-Jun-2024 , 12-Jun-2024 , 08-Aug-2024 , 07-Sep-2024 , 05-Oct-2024 , 12-Oct-2024 , 08-Dec-2024 , 07-Jan-2025</p> <p>Synopsis The National Institute of General Medical Sciences (NIGMS) is issuing this Notice to highlight interest in receiving grant applications focused on infectious disease modeling research that incorporates economic factors. The Institute is particularly interested in mathematical and computational modeling studies of infectious disease spread and evolution, and of the effects of possible intervention strategies, that include consideration of economic influences and feedback.</p>				
107585	NIGMS National and Regional Resources (R24 - Clinical Trial Not Allowed)	National Institute of General Medical Sciences/NIH/DHHS	PAR-22-065	14-Jun-2022	Not Specified

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Name Christina Liu, Ph.D., PE</p> <p>Contact Telephone </p> <p>Contact Email christina.liu@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 14-Jun-2022 , 14-Jun-2023 , 14-Jun-2024</p> <p>Synopsis This Funding Opportunity Announcement (FOA) encourages applications for support of resources that will provide access to state-of-the-art equipment, technologies, research tools, materials, organisms, software, and/or services to a substantial regional (multi-state) or national user base. Only those resources with technical capabilities that fall within the NIGMS-supported program areas are eligible for awards. The resources should already be established or may be formed through consolidation of existing local or regional facilities. The intent is to provide resource access to investigators without regard to the specific biomedical focus of their research, while not duplicating or replacing resources supported by sources such as other NIH Institutes and Centers (ICs) or host institutions. The resource is expected to be maintained or upgraded to current best practices, make its capabilities and availability known to the biomedical research community through outreach activities, and provide user training and support. The FOA does not support major new research and development efforts and stand-alone data resources and databases are not eligible.</p>				
099764	<p>Modules for Enhancing Biomedical Research Workforce Training (R25 Clinical Trial Not Allowed)</p>	National Institute of General Medical Sciences/NIH/DHHS	PAR-20-296	20-Jun-2022	250,000 USD
	<p>Contact Name Patrick H. Brown, Ph.D.</p> <p>Contact Telephone </p> <p>Contact Email patrick.brown@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 20-Jun-2022 , 19-Jun-2023</p> <p>Synopsis The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The overarching goal of this R25 program is to support educational activities that complement and/or enhance the training of a workforce to meet the nation’s biomedical, behavioral and clinical research needs. To accomplish the stated over-arching goal, this FOA will support creative educational activities with a primary focus on: Curriculum or Methods Development Specifically, this FOA will support the development of training modules designed to be freely available, at no cost to the</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	broader community to enhance training of the biomedical research workforce. Responsive topics will be indicated through Notices of Special Interest (NOSIs) released annually by NIGMS.				
109436	Notice of Special Interest (NOSI): Training Modules to Address Resiliency and Wellness, and Structural Racism and Discrimination in Research Training Environments	National Institute of General Medical Sciences/NIH/DHHS	NOT-GM-22-016	20-Jun-2022	Not Specified
	<p>Contact Name: Patrick H. Brown, Ph.D.</p> <p>Contact Telephone:</p> <p>Contact Email: patrick.brown@nih.gov</p> <p>Sponsor Website:</p> <p>Program URL: Link to program URL</p> <p>Deadline Dates (ALL): 20-Jun-2022</p> <p>Synopsis: The purpose of this Notice is to inform applicants of the topic areas for the June 20, 2022 due date of the NIGMS funding opportunity announcement (FOA) PAR-20-296 "Modules for Enhancing Biomedical Research Workforce Training (R25 - Clinical Trial Not Allowed)".</p>				
107450	Notice of Special Interest (NOSI): Secondary Analysis of Posttraumatic Psychopathology Data	National Institute of Mental Health/NIH/DHHS	NOT-MH-22-045	08-Apr-2022	Not Specified
	<p>Contact Name: Susan Borja, Ph.D.</p> <p>Contact Telephone: 310-443-1252</p> <p>Contact Email: susan.borja@nih.gov</p> <p>Sponsor Website:</p> <p>Program URL: Link to program URL</p> <p>Deadline Dates (ALL): 08-Apr-2022 , 15-Apr-2022 , 07-May-2022 , 05-Jun-2022 , 12-Jun-2022 , 16-Jun-2022 , 25-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 12-Oct-2022 , 16-Oct-2022 , 25-Oct-2022 , 08-Dec-2022 , 15-Dec-2022 , 07-Jan-2023 , 05-Feb-2023 , 12-Feb-2023 , 16-Feb-2023 , 25-Feb-2023 , 08-Apr-2023 , 14-Apr-2023 , 07-May-2023 , 05-Jun-2023 , 12-Jun-2023 , 16-Jun-2023 , 25-Jun-2023 , 08-Aug-2023 , 07-Sep-2023 , 05-Oct-2023 , 12-Oct-2023 , 16-Oct-2023 , 25-Oct-2023 , 15-Dec-2023 , 07-Jan-2024 , 05-Feb-2024 , 12-Feb-2024 , 16-Feb-2024 , 25-Feb-2024 , 07-May-2024 , 05-Jun-2024 , 12-Jun-2024 , 16-Jun-2024 , 07-Sep-2024</p> <p>Synopsis: NIMH is issuing this Notice of Special Interest (NOSI) to highlight interest in research to analyze existing and accumulating data to aid in refining phenotypes of posttraumatic psychopathology(ies), markers of onset and change, and risk detection.</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		NIMH is also interested in research using available data to identify potential prevention and treatment targets and to advance and refine measurement and validation of potential novel targets for future development in experimental therapeutics research.			
108843	Notice of Special Interest (NOSI): NIMH Priorities on Research on Aggression and Violence Against Others	National Institute of Mental Health/NIH/DHHS	NOT-MH-22-095	08-Apr-2022	Not Specified
	Contact Name				
	Contact Telephone				
	Contact Email	NIMHResearchOnAggres@mail.nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	08-Apr-2022 , 07-May-2022 , 24-May-2022 , 05-Jun-2022 , 12-Jun-2022 , 15-Jun-2022 , 16-Jun-2022 , 22-Jun-2022 , 25-Jun-2022 , 08-Aug-2022 , 07-Sep-2022 , 05-Oct-2022 , 12-Oct-2022 , 14-Oct-2022 , 16-Oct-2022 , 25-Oct-2022 , 15-Nov-2022 , 08-Dec-2022 , 07-Jan-2023 , 05-Feb-2023 , 12-Feb-2023 , 16-Feb-2023 , 22-Feb-2023 , 25-Feb-2023 , 08-Apr-2023 , 07-May-2023 , 05-Jun-2023 , 12-Jun-2023 , 15-Jun-2023 , 16-Jun-2023 , 25-Jun-2023 , 08-Aug-2023 , 07-Sep-2023 , 05-Oct-2023 , 12-Oct-2023 , 15-Oct-2023 , 16-Oct-2023 , 17-Oct-2023 , 25-Oct-2023 , 15-Nov-2023 , 08-Dec-2023 , 07-Jan-2024 , 05-Feb-2024 , 12-Feb-2024 , 16-Feb-2024 , 25-Feb-2024 , 08-Apr-2024 , 07-May-2024 , 05-Jun-2024 , 12-Jun-2024 , 16-Jun-2024 , 08-Aug-2024 , 07-Sep-2024 , 05-Oct-2024 , 12-Oct-2024 , 16-Oct-2024 , 08-Dec-2024 , 07-Jan-2025			
	Synopsis	NIMH is issuing this Notice of Special Interest (NOSI) to outline priorities for research on the etiology, risks for, and prevention of interpersonal aggression and violence against others.			
102539	Notice of Special Interest (NOSI): Advancing Health Communication Research on HIV Prevention, Treatment and Cure	National Institute of Mental Health/NIH/DHHS	NOT-MH-21-105	08-Apr-2022	Not Specified
	Contact Name	Collene Lawhorn, Ph.D.			
	Contact Telephone	301-828-7186			
	Contact Email	collene.lawhorn@nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	08-Apr-2022 , 07-May-2022 , 25-May-2022 , 05-Jun-2022 , 12-Jun-2022 , 16-Jun-2022 , 25-Jun-2022 , 08-Aug-2022 , 07-Sep-2022 , 25-Sep-2022 , 05-Oct-2022 , 12-Oct-2022 , 16-Oct-2022 , 25-Oct-2022 , 08-Dec-2022 , 07-Jan-2023 , 25-Jan-2023 , 05-Feb-2023 , 12-Feb-2023 , 16-Feb-2023 , 25-Feb-2023 , 08-Apr-2023 , 07-May-2023 , 25-May-2023 , 05-Jun-2023 , 12-Jun-			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Synopsis</p>	<p>2023 , 16-Jun-2023 , 25-Jun-2023 , 08-Aug-2023 , 07-Sep-2023 , 25-Sep-2023 , 05-Oct-2023 , 12-Oct-2023 , 16-Oct-2023 , 25-Oct-2023 , 08-Dec-2023 , 07-Jan-2024 , 25-Jan-2024 , 05-Feb-2024 , 12-Feb-2024 , 16-Feb-2024 , 25-Feb-2024 , 08-Apr-2024</p> <p>The National Institute of Mental Health is issuing this Notice to highlight interest in research applications to optimize health communication strategies that advance HIV prevention, treatment and cure.</p>			
083168	Clinical Studies of Mental Illness (Collaborative R01 Clinical Trial Optional)	National Institute of Mental Health/NIH/DHHS	PAR-19-297	07-May-2022	Not Specified
	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email</p> <p>Sponsor Website</p> <p>Program URL</p> <p>Deadline Dates (ALL)</p> <p>Synopsis</p>	<p>Anjené Addington</p> <p>301-443-6653</p> <p>anjene.addington@nih.gov</p> <p></p> <p>Link to program URL</p> <p>07-May-2022 , 05-Jun-2022 , 07-Sep-2022</p> <p>This Funding Opportunity Announcement (FOA) seeks to support collaborative clinical studies, not involving treatment development, efficacy, or effectiveness trials. Primary areas of focus include mental health genetics, biomarker studies, and studies of mental illnesses (e.g., psychopathology, neurodevelopmental trajectories of psychopathology) also when associated with HIV/AIDS. Applicants should apply to this FOA when two or more sites are needed to complete the study. Accordingly, the collaborating studies share a specific protocol across the sites and are organized as such in order to increase sample size, accelerate recruitment, or increase sample diversity and representation. In studies with a large number of sites, it is expected that one site will be submitted as a coordinating R01 for data management and/or other centralized administration. For a linked set of collaborative R01s, each application has its own Program Director/Principal Investigator (PD/PI). The collaborative R01 program provides a mechanism for cross-R01 coordination, quality control, database management, statistical analysis, and reporting.</p>			
104058	NIMH Exploratory/Developmental Research Grant (R21 Clinical Trial Not Allowed)	National Institute of Mental Health/NIH/DHHS	PA-21-235	07-May-2022	275,000 USD
	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email</p> <p>Sponsor Website</p> <p>Program URL</p>	<p>Susan Koester, Ph.D.</p> <p>301-443-3563</p> <p>koesters@mail.nih.gov</p> <p></p> <p>Link to program URL</p>			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Deadline Dates (ALL)	07-May-2022 , 16-Jun-2022 , 07-Sep-2022 , 16-Oct-2022 , 07-Jan-2023 , 16-Feb-2023 , 07-May-2023 , 16-Jun-2023 , 07-Sep-2023 , 16-Oct-2023 , 07-Jan-2024 , 16-Feb-2024 , 07-May-2024			
	Synopsis	The NIMH Exploratory/Developmental Grant program supports exploratory and high-risk research projects that fall within the NIMH mission by providing support for the early and conceptual stages of these projects. These studies may involve considerable risk but may lead to a breakthrough or to the development of novel techniques, agents, methods, measures, models, or strategies, or to the generation of pilot or feasibility data. The preliminary work from these studies could lead to a major impact on biomedical, behavioral, or clinical mental health research, or on the delivery of mental health care.			
102537	Notice of Special Interest (NOSI): Reducing Suicide Risk in Young People in Low- and Middle-Income Countries and Low-Resource Settings	National Institute of Mental Health/NIH/DHHS	NOT-MH-21-090	07-May-2022	Not Specified
	Contact Name	Andrea Horvath Marques, MD, MPH, PhD			
	Contact Telephone	301-646-7320			
	Contact Email	andrea.horvathmarques@nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	07-May-2022 , 05-Jun-2022 , 16-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 16-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 16-Feb-2023 , 07-May-2023 , 05-Jun-2023 , 16-Jun-2023 , 07-Sep-2023 , 05-Oct-2023 , 16-Oct-2023 , 07-Jan-2024 , 05-Feb-2024 , 16-Feb-2024 , 07-May-2024			
	Synopsis	The National Institute of Mental Health is issuing this Notice of Special Interest (NOSI) to highlight interest in developing and implementing prevention strategies to reduce suicide risk (suicide ideation and behavior, including acts of self-harm/suicide) and promote resilience among young people, age 10-24 years, in low-and middle-income countries (LMICs)and low-resources settings. NIMH welcomes applicants from LMICs and strongly encourages applicants from the United States or upper middle-income countries to partner with sites in LMICs.			
103802	RFA-MH-21-175 -- BRAIN Initiative: Development and Validation of Novel Tools to Probe Cell-Specific and Circuit-Specific Processes in the Brain (R01 Clinical Trial Not Allowed)	National Institute of Mental Health/NIH/DHHS	RFA-MH-21-175	08-May-2022 [Optional][LOI/Pre-App]	Not Specified
	Contact Name	Douglas S. Kim, Ph.D.			
	Contact Telephone	301-827-6463			
	Contact Email	douglas.kim@nih.gov			
	Sponsor Website				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 08-May-2022 [Optional][LOI/Pre-App], 07-Jun-2022 , 08-May-2023 [Optional][LOI/Pre-App], 07-Jun-2023</p> <p>Synopsis The purpose of this Brain Research through Advancing Innovative Neurotechnologies® (BRAIN) Initiative is to encourage research that will develop and validate novel tools to facilitate the detailed analysis of complex circuits and provide insights into cellular interactions that underlie brain function. The new tools and technologies should inform and/or exploit cell-type and/or circuit-level specificity. Plans for validating the utility of the tool/technology will be an essential feature of a successful application. The development of new genetic and non-genetic tools for delivering genes, proteins and chemicals to cells of interest or approaches that are expected to target specific cell types and/or circuits in the nervous system with greater precision and sensitivity than currently established methods are encouraged. Tools that can be used in a number of species/model organisms rather than those restricted to a single species are highly desired. Applications that provide approaches that break through existing technical barriers to substantially improve current capabilities are highly encouraged.</p>				
108512	<p>RFA-MH-22-111 -- Scalable and Systematic Neurobiology of Psychiatric and Neurodevelopmental Disorder Risk Genes: Assay and Data Generation Centers (RM1 Clinical Trial Not Allowed)</p>	National Institute of Mental Health/NIH/DHHS	RFA-MH-22-111	11-May-2022 [Optional][LOI/Pre-App]	Not Specified
	<p>Contact Name Alexander Arguello, Ph.D.</p> <p>Contact Telephone 301-827-3547</p> <p>Contact Email alexander.arguello@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 11-May-2022 [Optional][LOI/Pre-App], 10-Jun-2022</p> <p>Synopsis This Funding Opportunity Announcement (FOA) is one of two to establish the Scalable and Systematic Neurobiology of Psychiatric and Neurodevelopmental Disorder Risk Genes (SSPsyGene) Consortium. The long-term goal of SSPsyGene is to systematically characterize phenotypes, across biological scales of organization (molecular, cellular, circuit, systems/organismal), for neurodevelopmental and psychiatric disorder (NPDs) risk genes. This resource will be made available for broad use by the biomedical community. The program will leverage scalable technologies to functionally characterize at ~100-250 null alleles from genes with an increased burden of loss-of-function mutations in NPDs. It will also optimize novel assays for cellular and physiological phenotypes, assess the scale limitations of such methods for allelic series of patient variants across large numbers of risk genes, and develop common data formats. This specific FOA seeks applications for Assay and Data Generation Centers (ADGC). The ADGCs will be responsible for developing and carrying out</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		<p>high-throughput assays to characterize the function of a set of NPD risk genes, to be selected by the SSPsyGene Consortium, in the central nervous system using relevant experimental systems (e.g., cellular, ex vivo, model organism). ADGCs will work in collaboration with a central Data Resource and Administrative Coordination Center (DRACC), as described in the companion funding announcement, RFA-MH-22-110, to form the SSPsyGene Consortium. The consortium will develop methods and standards to create a harmonized cross-modality and cross-species phenotypic data set to systematically characterize the function of NPD risk genes. ADGCs selected for funding will collaborate closely with other funded ADGCs and the DRACC to achieve the goals of the SSPsyGene Consortium.</p>			
108509	RFA-MH-22-110 -- Scalable and Systematic Neurobiology of Psychiatric and Neurodevelopmental Disorder Risk Genes: Data Resource and Administrative Coordination Center (U24 Clinical Trial Not Allowed)	National Institute of Mental Health/NIH/DHHS	RFA-MH-22-110	11-May-2022 [Optional][LOI/Pre-App]	Not Specified
	Contact Name Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL)	Alexander Arguello, Ph.D. 301-827-3547 alexander.arguello@nih.gov Link to program URL 11-May-2022 [Optional][LOI/Pre-App], 10-Jun-2022			
	Synopsis	<p>This Funding Opportunity Announcement (FOA) is one of two to establish the Scalable and Systematic Neurobiology of Psychiatric and Neurodevelopmental Disorder Risk Genes (SSPsyGene) Consortium. The long-term goal of SSPsyGene is to systematically characterize phenotypes, across biological scales of organization (molecular, cellular, circuit, systems/organismal), for neurodevelopmental and psychiatric disorder (NPDs) risk genes. This resource will be made available for broad use by the biomedical community. The program will leverage scalable technologies to functionally characterize ~100-250 null alleles from genes with an increased burden of loss-of-function mutations in NPDs. It will also optimize novel assays for cellular and physiological phenotypes, assess the scale limitations of such methods for allelic series of patient variants across large numbers of risk genes, and develop common data formats. This specific FOA seeks applications for a Data Resource and Administrative Coordination Center (DRACC) that will be responsible for (1) establishing a rigorous approach to prioritize NPD risk genes for functional characterization across the consortium, (2) providing administrative and logistical coordination among all funded groups in the consortium, (3) establishing a data processing pipeline, and (4) building and maintaining a knowledge base that adheres to Findability, Accessibility, Interoperability, and Reuse (FAIR) principles. The DRACC will work in a hub and spoke model in collaboration with the Assay and Data Generation Centers (ADGCs), as described in the companion funding announcement RFA-MH-22-111 to achieve the goals of the SSPsyGene Consortium.</p>			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
092121	RFA-MH-20-525 -- NIMH Biobehavioral Research Awards for Innovative New Scientists (NIMH BRAINS) (R01 Clinical Trial Optional)	National Institute of Mental Health/NIH/DHHS	RFA-MH-20-525	21-May-2022 [Optional][LOI/Pre-App]	2,500,000 USD
	<p>Contact Name Eric R. Murphy, Ph.D.</p> <p>Contact Telephone 301-443-9230 ?</p> <p>Contact Email eric.murphy@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 21-May-2022 [Optional][LOI/Pre-App], 20-Jun-2022</p> <p>Synopsis The NIMH Biobehavioral Research Awards for Innovative New Scientists (BRAINS) award is intended to support the research and research career advancement of outstanding, exceptionally productive scientists who are in the early, formative stages of their careers and who plan to make a long-term career commitment to research in specific mission areas of the NIMH. This award seeks to assist these individuals in launching an innovative clinical, translational, basic, or services research program that holds the potential to profoundly transform the understanding, diagnosis, treatment, or prevention of mental disorders. The NIMH BRAINS program will focus on the research priorities and gap areas identified in the NIMH Strategic Plan.</p>				
106865	RFA-MH-22-120 -- Pilot Practice-based Research for Primary Care Suicide Prevention (R34 Clinical Trial Optional)	National Institute of Mental Health/NIH/DHHS	RFA-MH-22-120	22-May-2022 [Optional][LOI/Pre-App]	450,000 USD
	<p>Contact Name Stephen O'Connor, Ph.D.</p> <p>Contact Telephone 301-480-8366</p> <p>Contact Email stephen.o'connor2@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 22-May-2022 [Optional][LOI/Pre-App], 21-Jun-2022 , 22-Jan-2023 [Optional][LOI/Pre-App], 21-Feb-2023</p> <p>Synopsis This Funding Opportunity Announcement (FOA) encourages primary care practice-based research focused on rigorous evaluations of factors that impact or account for the effectiveness of existing suicide prevention practices and/or pilot clinical trials aimed at optimizing and pilot testing patient-, provider-, or systems-level suicide prevention strategies. Applications of interest include those that refine and test scalable strategies for use in primary care across different</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

intercepts in the chain-of-care, including strategies for identifying individuals at risk, assessing and stratifying risk, providing brief interventions, promoting initial and ongoing engagement in indicated services, continued outcome monitoring and follow-up, and tracking patient outcomes. For purposes of this FOA, primary care is defined as pediatric practice, family practice, obstetrics/gynecology, internal medicine, and geriatric practice. Primary care practices range in size, resources and patient health needs; proposed strategies should meet the practice needs to be feasible, scalable, sustainable, and practice-ready. NIMH encourages prevention approaches that incorporate the use of mHealth (the use of mobile and wireless devices [cell phones, tablets, etc.]) and other design features that can facilitate scalability and sustainability, and deployment-focused research approaches that take into account the perspectives of key stakeholders (e.g., patients, providers, administrators) and system-level factors such as setting resources, workforce capacity, and training needs. This FOA also encourages studies that examine suicide prevention strategies that have broad reach, including potential for addressing risk among individuals who experience mental health service disparities (e.g., racial/ethnic minority groups; sexual and gender minorities, individuals living in rural areas, socioeconomically disadvantaged persons), and studies that explore how the proposed strategies can reduce health disparities and promote health equity.

107426	RFA-MH-22-150 -- Using Just-in-Time Adaptive Interventions to Optimize Established Adolescent Mental Health Treatments (R61/R33 Clinical Trial Required)	National Institute of Mental Health/NIH/DHHS	RFA-MH-22-150	23-May-2022 [Optional][LOI/Pre-App]	Not Specified
--------	--	--	---------------	-------------------------------------	---------------

Contact Name	Mary Rooney, Ph.D.
Contact Telephone	301-827-1325
Contact Email	mary.rooney@nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	23-May-2022 [Optional][LOI/Pre-App], 22-Jun-2022 , 23-Jan-2023 [Optional][LOI/Pre-App], 22-Feb-2023
Synopsis	NIMH seeks applications for pilot research to develop and test just-in-time adaptive intervention (JITAI) augmentations to enhance the effectiveness and clinical potency of established adolescent mental health treatments. An emphasis is placed on studies that are informed by developmental science and grounded in an empirical model of behavior change. Support will be provided for up to two years (R61 phase) for milestone-driven testing, refinement, and/or validation of the intervention's impact on empirically supported, measurable target mechanisms and the possibility (contingent on meeting the R61 milestones) of up to 3 additional years of support (R33 phase) to replicate the target engagement findings in a larger sample and examine the relationship between the target mechanisms and clinical outcomes.

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
082860	Building in vivo Preclinical Assays of Circuit Engagement for Application in Therapeutic Development (R01 Clinical Trial Not Allowed)	National Institute of Mental Health/NIH/DHHS	PAR-19-289	05-Jun-2022	Not Specified
	<p>Contact Name Lois Winsky, Ph.D.</p> <p>Contact Telephone 301-443-5288</p> <p>Contact Email lwinsky@mail.nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 05-Jun-2022</p> <p>Synopsis The overall goal of this Funding Opportunity Announcement (FOA) is to identify, in animals, in vivo neurophysiological and behavioral measures for use as assays in the early screening phase of treatment development. The FOA will support efforts to optimize and evaluate measures of neurophysiological and behavioral processes that may serve as surrogate markers of neural processes of clinical interest based on available knowledge of the neurobiology of mental illnesses. The screening assays thus developed from this FOA are expected to build upon systems neurobiology and clinical neuroscience to enhance the scientific value of preclinical animal data contributing to a therapeutic development pipeline by assessing the impact of therapeutic targets and treatment candidates on neurobiological mechanisms of clinical relevance to mental illnesses. The objectives of the FOA will be accomplished by supporting basic and translational neuroscientists who are committed to improving the efficiency and scientific value of the therapeutic development pipeline by advancing the discovery of in vivophysiological and behavioral measures reflecting circuit engagement as tools for early phase target validation and therapeutic screening for mental illness treatment development. The efforts supported by this initiative focus on measures in animals as a first step in generating translational assay measures that are adaptable across early therapeutic screens in animals to evaluation in humans. As such, this FOA may be considered a prequel to build a suite of assays that are evaluated in future projects for coherence of assay performance between the preclinical species and healthy humans. In summary, this FOA will support efforts to improve the tool kit of assays available for early phase testing of novel therapeutic agents by incorporating measures proximal to neural systems that impact mental health.</p>				
105700	Utilizing Invasive Recording and Stimulating Opportunities in Humans to Advance Neural Circuitry Understanding of Mental Health Disorders (R01 Clinical Trial Optional)	National Institute of Mental Health/NIH/DHHS	PAR-21-289	05-Jun-2022	Not Specified
	<p>Contact Name David McMullen, M.D.</p> <p>Contact Telephone 301-451-0180</p> <p>Contact Email david.mcmullen@nih.gov</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 05-Jun-2022 , 05-Oct-2022 , 05-Feb-2023 , 05-Jun-2023 , 05-Oct-2023 , 05-Feb-2024 , 05-Jun-2024</p> <p>Synopsis The purpose of this Funding Opportunity Announcement (FOA) is to encourage applications to pursue invasive neural recording studies focused on mental health-relevant questions. Invasive neural recordings provide an unparalleled window into the human brain to explore the neural circuitry and neural dynamics underlying complex moods, emotions, cognitive functions, and behaviors with high spatial and temporal resolution. Additionally, the ability to stimulate, via the same electrodes, allows for direct causal tests by modulating network dynamics. This FOA aims to target a gap in the scientific knowledge of neural circuit function related to mental health disorders. Researchers should target specific questions suited to invasive recording modalities that have high translational potential. Development of new therapies is outside the scope of this FOA, though development of novel tools/methods to enable relevant mental health studies is encouraged. This FOA uses the R01 grant mechanism, encouraging longer-term projects, whereas its companion R21 FOA, PAR-21-288, seeks grant applications encouraging shorter, higher-risk studies.</p>				
107489	Basic Neurodevelopmental Biology of Circuits and Behavior (R01 Clinical Trial Not Allowed)	National Institute of Mental Health/NIH/DHHS	PAR-22-066	05-Jun-2022	2,500,000 USD
	<p>Contact Name Andrew Breeden, Ph.D.</p> <p>Contact Telephone 301-451-3185</p> <p>Contact Email neurodevelopmentpar@mail.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 05-Jun-2022 , 05-Oct-2022 , 05-Feb-2023 , 05-Jun-2023 , 05-Oct-2023 , 05-Feb-2024 , 05-Jun-2024 , 05-Oct-2025</p> <p>Synopsis This Funding Opportunity Announcement (FOA) encourages research projects focused on the dynamic and mechanistic links between the maturation of brain circuits and behaviors across development in rodents and non-human primates. The goal is to build a foundation for understanding how interactions within and among brain regions change over pre- and post-natal development, allowing for the emergence of cognitive, affective and social behaviors. To this end, projects supported will focus on neurodevelopmental trajectories and investigate questions using in vivo neural measures in awake, behaving animals. This FOA uses the R01 grant mechanism, whereas its companion FOA, PAR-22-067, seeks shorter, higher-risk R21 grant applications.</p>				
105881	Implementing and Sustaining Evidence-Based Mental Health Practices in Low-Resource Settings to Achieve Equity in Outcomes (R34 Clinical Trial Required)	National Institute of Mental Health/NIH/DHHS	PAR-21-283	05-Jun-2022	450,000 USD

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Name Denise Pintello, Ph.D.</p> <p>Contact Telephone 301-451-1481</p> <p>Contact Email denise.pintello@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 05-Jun-2022 , 05-Oct-2022 , 05-Feb-2023 , 05-Jun-2023 , 05-Oct-2023 , 05-Feb-2024 , 05-Jun-2024</p> <p>Synopsis This Funding Opportunity Announcement (FOA) supports pilot work for subsequent studies testing the effectiveness of strategies to deliver evidence-based mental health services, treatment interventions, and/or preventive interventions (EBPs) in low-resourced mental health specialty and non-specialty settings within the United States. The FOA targets settings where EBPs are not currently delivered or delivered with fidelity, such that there are disparities in mental health and related functional outcomes (e.g., employment, educational attainment, stable housing, integration in the community, treatment of comorbid substance use disorders) for the population(s) served. Implementation strategies should identify and use innovative approaches to remediate barriers to provision, receipt, and/or benefit from EBPs and generate new information about factors integral to achieving equity in mental health outcomes for underserved populations. Research generating new information about factors causing/reducing disparities is strongly encouraged, including due consideration for the needs of individuals across the life span. Applications proposing definitive tests of an implementation strategy should respond to the companion R01 announcement PAR-21-284.</p>				
108834	Notice of Special Interest (NOSI): Neuro-Glia Mechanisms Governing Complex Behaviors (R01 Clinical Trial Optional)	National Institute of Mental Health/NIH/DHHS	NOT-MH-22-090	05-Jun-2022	Not Specified
	<p>Contact Name Michele Ferrante, Ph.D.</p> <p>Contact Telephone 301-435-6782</p> <p>Contact Email michele.ferrante@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 05-Jun-2022 , 16-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 16-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 16-Feb-2023 , 07-May-2023 , 05-Jun-2023 , 16-Jun-2023 , 07-Sep-2023 , 05-Oct-2023 , 16-Oct-2023 , 07-Jan-2024 , 05-Feb-2024 , 16-Feb-2024 , 07-May-2024 , 05-Jun-2024 , 16-Jun-2024 , 07-Sep-2024 , 05-Oct-2024 , 16-Oct-2024 , 07-Jan-2025 , 05-Feb-2025 , 16-Feb-2025 , 07-May-2025</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Synopsis	This Notice of Special Interest (NOSI) encourages projects to experimentally test mechanistic hypotheses on the role of neuro-glia activity coupling in modulating complex behaviors.			
097908	Cellular and Molecular Biology of Complex Brain Disorders (R01 Clinical Trial Not Allowed)	National Institute of Mental Health/NIH/DHHS	PAR-20-263	05-Jun-2022	Not Specified
	Contact Name	David Panchision			
	Contact Telephone	301-443-5288			
	Contact Email	panchisiond@mail.nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	05-Jun-2022 , 05-Oct-2022 , 05-Feb-2023 , 05-Jun-2023			
	Synopsis	<p>This Funding Opportunity Announcement (FOA) encourages research on the biology of high confidence risk factors associated with complex brain disorders, with a focus on the intracellular, transcellular and circuit substrates of neural function. For the purposes of this FOA, the term “complex” can refer to a multifactorial contribution to risk (e.g., polygenic and/or environmental) and/or highly distributed functional features of the brain disorder. Studies may be either hypothesis-generating (unbiased discovery) or hypothesis-testing in design and may utilize in vivo, in situ or in vitro experimental paradigms, e.g., model organisms or human cell-based assays. While behavioral paradigms and outcome measures can be incorporated into the research design to facilitate the characterization of intracellular, transcellular and circuit mechanisms, these are neither required nor expected. Studies should not attempt to “model” disorders but instead should aim to elucidate the neurobiological impact of individual or combined risk factor(s), such as the affected molecular and cellular components and their relationships within defined biological process(es). This can include the fundamental biology of these factors, components and processes. The resulting paradigms, component pathways and biological processes should be disseminated with sufficient detail to enrich common and/or federated data resources (e.g., those contributing to the Gene Ontology, Synaptic Gene Ontology, FAIR Data Informatics) in order to bridge the gap between disease risk factors, biological mechanism and therapeutic target identification. The present announcement (R01 activity code) can be used for applications to further develop lines of inquiry where feasibility or proof-of-concept has been established.</p>			
105829	Initiation of a Mental Health Family Navigator Model to Promote Early Access, Engagement and Coordination of Needed Mental Health Services for Children and Adolescents (R01 Clinical Trial Required)	National Institute of Mental Health/NIH/DHHS	PAR-21-291	05-Jun-2022	2,500,000 USD
	Contact Name	Denise Pintello, Ph.D., M.S.W.			
	Contact Telephone	301-451-1481			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Email dpintell@mail.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 05-Jun-2022 , 05-Oct-2022 , 05-Feb-2023 , 05-Jun-2023 , 05-Oct-2023 , 05-Feb-2024 , 05-Jun-2024</p> <p>Synopsis The purpose of this Funding Opportunity Announcement (FOA) is to encourage research applications to develop and test the effectiveness and implementation of family navigator models designed to promote early access, engagement, coordination and optimization of mental health treatment and services for children and adolescents who are experiencing early symptoms of mental health problems. For the purposes of this FOA, NIMH defines a family navigator model as a health care professional or paraprofessional whose role is to deploy a set of strategies designed to rapidly engage youth and families in needed treatment and services, work closely with the family and other involved treatment and service providers to optimize care, and through the use of technology – to monitor the trajectory of mental health symptoms and outcomes over time. Applicants are required to develop and test the navigator model’s ability to promote early access, engagement, coordination and optimization of mental health treatment and services for children and adolescents as soon as symptoms are detected. Applicants are also required to identify and test components of navigator models that drive improvements in mental health care; detect and interrogate tailoring variables that optimize the ‘personalized match’ between the unique mental health needs of youth to the appropriate level of intensity and frequency of mental health services; and utilize emerging novel technologies to track and monitor the trajectory of clinical, functional and behavioral progress toward achieving intended services outcomes. This FOA is published in parallel to a companion R34 FOA, PAR-21-292 supporting pilot studies in preparation for the larger-scale studies described here.</p>				
105794	<p>Effectiveness of Implementing Sustainable Evidence-Based Mental Health Practices in Low-Resource Settings to Achieve Mental Health Equity for Traditionally Underserved Populations (R01 Clinical Trial Optional)</p>	National Institute of Mental Health/NIH/DHHS	PAR-21-284	05-Jun-2022	Not Specified
	<p>Contact Name Denise Pintello, Ph.D.</p> <p>Contact Telephone 301-451-1481</p> <p>Contact Email denise.pintello@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 05-Jun-2022 , 05-Oct-2022 , 05-Feb-2023 , 05-Jun-2023 , 05-Oct-2023 , 05-Feb-2024 , 05-Jun-2024</p> <p>Synopsis This Funding Opportunity Announcement (FOA) encourages studies that develop and test the effectiveness of strategies for implementation and sustainable delivery of evidence-based mental health treatments and services to improve mental health</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>outcomes for underserved populations in low-resourced settings in the United States. Studies should identify and use innovative approaches to remediate barriers to provision, receipt, and/or benefit from evidence-based practices (EBPs) and generate new information about factors integral to achieving equity in mental health outcomes for underserved populations. Research generating new information about factors causing/reducing disparities are strongly encouraged, including due consideration of the needs of individuals across the life span. This FOA is published in parallel to a companion R34, PAR-21-283, that supports pilot studies in preparation for the larger-scale studies described here.</p>				
106066	Innovative Mental Health Services Research Not Involving Clinical Trials (R01 Clinical Trials Not Allowed)	National Institute of Mental Health/NIH/DHHS	PAR-21-316	05-Jun-2022	Not Specified
	Contact Name	Michael C. Freed, Ph.D., EMT			
	Contact Telephone	301-443-3747			
	Contact Email	michael.freed@nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	05-Jun-2022 , 05-Oct-2022 , 05-Feb-2023 , 05-Jun-2023 , 05-Oct-2023 , 05-Feb-2024 , 05-Jun-2024			
	Synopsis	<p>The purpose of this Funding Opportunity Announcement (FOA) is to encourage innovative research that will inform and support the delivery of high-quality, continuously improving mental health services to benefit the greatest number of individuals with, or at risk for developing, a mental illness. This announcement invites applications for non-clinical trial R01-level projects that address NIMH strategic priorities that strengthen the public health impact of NIMH-supported research as described in Goal 4 of the NIMH Strategic Plan. Proposed research should seek to: Identify mutable factors that impact access, continuity, utilization, quality, value, and outcomes, including disparities in outcomes, or scalability of mental health services, which may serve as targets in future service delivery intervention development; Develop and test new research tools, technologies, measures, or methods and statistical approaches to study these issues; Integrate and analyze large data sets to understand factors affecting mental health services outcomes using advanced computational and predictive analytic approaches; Wherever possible, leverage existing infrastructure and partnerships to accomplish these goals.</p>			
103213	Effectiveness Trials for Post-Acute Interventions and Services to Optimize Longer-term Outcomes (R01 Clinical Trial Required)	National Institute of Mental Health/NIH/DHHS	PAR-21-210	05-Jun-2022	Not Specified
	Contact Name	Adam Haim, Ph.D.			
	Contact Telephone	301-435-3593			
	Contact Email	haima@mail.nih.gov			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	05-Jun-2022 , 05-Oct-2022 , 05-Feb-2023 , 05-Jun-2023 , 05-Oct-2023 , 05-Feb-2024			
	Synopsis	<p>NIMH seeks applications for research projects to evaluate the effectiveness of therapeutic and service delivery interventions for the post-acute management of mental health conditions affecting youth, adults, and older adults. This Funding Opportunity Announcement (FOA) encourages clinical trials to establish the effectiveness and test hypotheses regarding moderators, mediators, and mechanisms of action of post-acute phase therapeutic and services interventions that are matched to the stage of illness in terms of both their focus (e.g., consolidating and maintaining gains from initial treatment, managing residual symptoms/impairment, preventing relapse, promoting adherence and appropriate service use) and intensity/burden for promoting optimal longer-term outcomes. This FOA is intended to support trials that are statistically powered to provide a definitive answer regarding the effectiveness of the post-acute phase intervention. Support for pilot effectiveness trials designed to evaluate the initial feasibility, tolerability, acceptability, safety and preliminary indications of post-acute phase intervention approaches is provided via the R34, PAR-21-211.</p>			
106895	Neuromodulation/Neurostimulation Device Development for Mental Health Applications (R01 Clinical Trial Not Allowed)	National Institute of Mental Health/NIH/DHHS	PAR-22-039	05-Jun-2022	Not Specified
	Contact Name	David McMullen, M.D.			
	Contact Telephone	301-451-0180			
	Contact Email	david.mcmullen@nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	05-Jun-2022 , 05-Oct-2022 , 05-Feb-2023 , 05-Jun-2023 , 05-Oct-2023 , 05-Feb-2024 , 05-Jun-2024 , 05-Oct-2024			
	Synopsis	<p>The purpose of this funding opportunity announcement (FOA) is to encourage applications seeking to develop the next generation of brain stimulation devices for treating mental health disorders. Applications are encouraged that will either 1) develop novel brain stimulation devices or 2) significantly enhance, by means of hardware/software improvements, the effectiveness of brain stimulation devices that are currently U.S. Food and Drug Administration (FDA)-approved or cleared.</p> <p>Novel devices should move beyond existing electrical/magnetic stimulation and develop new stimulation techniques capable of increased spatiotemporal precision as well as multi-focal, closed-loop approaches. Applications seeking to develop new capabilities should focus on significant enhancement of the spatial resolution, depth of delivery, and/or precision of the device. Incremental changes to existing devices (e.g., software updates) are not within the scope of this announcement. Applications should be submitted by multi-disciplinary teams with diverse expertise including systems neuroscience,</p>			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
106926	Neuromodulation/Neurostimulation Device Development for Mental Health Applications (R01 Clinical Trial Not Allowed)	National Institute of Mental Health/NIH/DHHS	PAR-22-039	05-Jun-2022	Not Specified

engineering, clinical, and regulatory affairs. Applications submitting in response to this FOA should promote the development or significant enhancement of novel tools (hardware/software) for brain stimulation in humans. Although the application should focus on the engineering development and bench top testing of the tool, animal and limited human testing necessary to demonstrate initial proof of concept is allowable. Applications to this FOA are not expected to be hypothesis-driven, but should propose design-directed, developmental, or discovery-driven technology research using integrative approaches.

Contact Name	David McMullen, M.D.
Contact Telephone	301-451-0180
Contact Email	david.mcmullen@nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	05-Jun-2022 , 05-Oct-2022 , 05-Feb-2023 , 05-Jun-2023 , 05-Oct-2023 , 05-Feb-2024 , 05-Jun-2024 , 05-Oct-2024
Synopsis	<p>The purpose of this funding opportunity announcement (FOA) is to encourage applications seeking to develop the next generation of brain stimulation devices for treating mental health disorders. Applications are encouraged that will either 1) develop novel brain stimulation devices or 2) significantly enhance, by means of hardware/software improvements, the effectiveness of brain stimulation devices that are currently U.S. Food and Drug Administration (FDA)-approved or cleared. Novel devices should move beyond existing electrical/magnetic stimulation and develop new stimulation techniques capable of increased spatiotemporal precision as well as multi-focal, closed-loop approaches. Applications seeking to develop new capabilities should focus on significant enhancement of the spatial resolution, depth of delivery, and/or precision of the device. Incremental changes to existing devices (e.g., software updates) are not within the scope of this announcement. Applications should be submitted by multi-disciplinary teams with diverse expertise including systems neuroscience, engineering, clinical, and regulatory affairs. Applications submitting in response to this FOA should promote the development or significant enhancement of novel tools (hardware/software) for brain stimulation in humans. Although the application should focus on the engineering development and bench top testing of the tool, animal and limited human testing necessary to demonstrate initial proof of concept is allowable. Applications to this FOA are not expected to be hypothesis-driven, but should propose design-directed, developmental, or discovery-driven technology research using integrative approaches.</p>

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
106498	Mood and Psychosis Symptoms during the Menopause Transition (R01 Clinical Trial Optional)	National Institute of Mental Health/NIH/DHHS	PAR-22-035	05-Jun-2022	Not Specified
	<p>Contact Name Laura M. Rowland, Ph.D.</p> <p>Contact Telephone 301-480-8335</p> <p>Contact Email laura.rowland@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 05-Jun-2022 , 05-Oct-2022 , 05-Feb-2023 , 05-Jun-2023 , 05-Oct-2023 , 05-Feb-2024 , 05-Jun-2024 , 05-Oct-2024</p> <p>Synopsis The purpose of this Funding Opportunity Announcement (FOA) is to encourage applications that will advance mechanistic and translational research on the onset and worsening of mood and psychotic disorders during the menopausal transition (or perimenopause). In particular, NIMH seeks research that will advance understanding of the underlying neurobiological and behavioral mechanisms of mood disruption and psychosis during the menopausal transition and that will identify novel targets for future mental health interventions or prevention efforts This FOA uses the R01 grant mechanism, while the companion FOA (PAR-22-036) uses the R21 mechanism. Investigators proposing high risk/high reward projects, projects that lack preliminary data, or studies that utilize existing data may wish to apply using the R21 mechanism, while applicants with preliminary data who seek longer-term funding may wish to apply using the R01 mechanism.</p>				
102908	Understanding and Modifying Temporal Dynamics of Coordinated Neural Activity (R01 Clinical Trial Optional)	National Institute of Mental Health/NIH/DHHS	PAR-21-175	05-Jun-2022	Not Specified
	<p>Contact Name Andrew Rossi, Ph.D.</p> <p>Contact Telephone 301-443-1576</p> <p>Contact Email andrew.rossi@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 05-Jun-2022 , 05-Oct-2022 , 05-Feb-2023 , 05-Jun-2023 , 05-Oct-2023 , 05-Feb-2024</p> <p>Synopsis A growing body of evidence suggests that optimal cognitive, affective, and social processes are associated with highly coordinated neural activity. These findings indicate that oscillatory rhythms, their co-modulation across frequency bands, spike-phase correlations, spike population dynamics, and other patterns might be useful drivers of therapeutic development for the treatment of cognitive, social, or affective symptoms in neuropsychiatric disorders. This Funding Opportunity Announcement (FOA) supports projects that test whether modifying electrophysiological patterns during behavior can</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

improve cognitive, affective, or social processing. Applications must use experimental designs that incorporate active manipulations to address at least one, and ideally more, of the following topics: (1) in animals or humans, determine which parameters of neural coordination, when manipulated in isolation, improve particular aspects of cognitive, affective, or social processing; (2) in animals or humans, determine how particular abnormalities at the genomic, molecular, or cellular levels affect the systems-level coordination of electrophysiological patterns during behavior; (3) determine whether in vivo, systems-level electrophysiological changes in behaving animals predict analogous electrophysiological and cognitive improvements in healthy persons or clinical populations; and (4) use biologically-realistic computational models that include systems-level aspects to understand the function and mechanisms by which oscillatory and other electrophysiological patterns unfold across the brain to impact cognitive, affective, or social processing. This FOA uses the R01 grant mechanism, whereas its companion FOA, PAR-21-176, seeks shorter, higher-risk R21 grant applications.

109334	RFA-RM-22-013 -- Somatic Mosaicism across Human Tissues (SMaHT) Program: Genome Characterization Centers (UM1 Clinical Trial Not Allowed)	National Institute of Mental Health/NIH/DHHS	RFA-RM-22-013	08-Jun-2022	Not Specified
--------	---	--	---------------	-------------	---------------

Contact Name | Amy C. Lossie, Ph.D.
 Contact Telephone | 301-827-6092
 Contact Email | SMaHT@mail.nih.gov
 Sponsor Website |
 Program URL | [Link to program URL](#)
 Deadline Dates (ALL) | 08-Jun-2022 , 08-Jul-2022

Synopsis | This funding opportunity announcement invites applications to establish the Genome Characterization Centers (GCCs) for the Somatic Mosaicism across Human Tissues (SMaHT) Network. The purpose of the SMaHT Network is to enable discovery of new biology and disease mechanisms mediated by genomic variation in somatic tissues. The GCCs will be responsible for generating state of the art, high throughput genomic data characterizing somatic variants in a set of 10-15 human tissues from 150+ donors. The GCCs will work closely with the SMaHT Data Analysis Center to build the framework for a comprehensive catalog of variants. This Funding Opportunity Announcement (FOA) is developed as a Common Fund initiative (<http://commonfund.nih.gov/>) through the NIH Office of the NIH Director, Office of Strategic Coordination (<https://dpcpsi.nih.gov/>). All NIH Institutes and Centers participate in Common Fund initiatives. The FOA will be administered by the National Institute of Drug Abuse (NIDA) on behalf of the NIH.

109327	RFA-RM-22-012 -- Somatic Mosaicism across Human Tissues (SMaHT) Program: Tissue Procurement Center (U24 Clinical Trial Not Allowed)	National Institute of Mental Health/NIH/DHHS	RFA-RM-22-012	08-Jun-2022	Not Specified
--------	---	--	---------------	-------------	---------------

Contact Name | Geetha Senthil, Ph.D.

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Telephone 301-402-0754</p> <p>Contact Email SMaHT@mail.nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 08-Jun-2022 , 08-Jul-2022</p> <p>Synopsis This Funding Opportunity Announcement (FOA) invites applications to establish the Tissue Procurement Center for the Somatic Mosaicism across Human Tissues (SMaHT) Network. The purpose of the SMaHT Network is to enable discovery of new biology and disease mechanisms mediated by genomic variation in somatic tissues. The goal of the Tissue Procurement Center is to collect, process, store, and rapidly distribute to the Network at least 15 high quality, well characterized, human tissues recovered from a minimum of 150 individuals recruited from a diverse pool of donors. This Funding Opportunity Announcement (FOA) is developed as a Common Fund initiative (http://commonfund.nih.gov/) through the NIH Office of the NIH Director, Office of Strategic Coordination (https://dpcpsi.nih.gov/). All NIH Institutes and Centers participate in Common Fund initiatives. The FOA will be administered by the National Institute of Mental Health (NIMH) on behalf of the NIH.</p>				
105330	NIMH Career Transition Award for Tenure-Track Intramural Investigators (K22 No Independent Clinical Trials)	National Institute of Mental Health/NIH/DHHS	PAR-21-239	12-Jun-2022	Not Specified
	<p>Contact Name Ashlee Van't Veer, PhD</p> <p>Contact Telephone 301-443-3107</p> <p>Contact Email dnbbstrainingbranch@mail.nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 12-Jun-2022 , 12-Oct-2022 , 12-Feb-2023 , 12-Jun-2023 , 12-Oct-2023 , 12-Feb-2024 , 12-Jun-2024</p> <p>Synopsis The primary goal of the NIMH Career Transition Award for Tenure-Track Intramural Investigators (K22) Program (hereafter abbreviated as the NIMH Career Transition K22 Program) is to provide support for career intramural investigators at NIMH who aim to transition from the Division of Intramural Research Programs (IRP) to an independent research faculty position in the extramural community. Applicants should have a demonstrated record of meritorious research in mental health-related fields. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary clinical trial.</p>				
102818	Mentored Career Transition Award for Intramural Fellows (K22 Clinical Trials Required)	National Institute of Mental Health/NIH/DHHS	PA-21-195	12-Jun-2022	Not Specified

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Name Ashlee Van't Veer</p> <p>Contact Telephone 301-443-3107</p> <p>Contact Email dnbbstrainingbranch@mail.nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 12-Jun-2022 , 12-Oct-2022 , 12-Feb-2023 , 12-Jun-2023 , 12-Oct-2023 , 12-Feb-2024</p> <p>Synopsis The Mentored Career Transition Award for NIMH Intramural Fellows (K22) is a two-phase, mentored career development award program that is intended to facilitate a timely transition of qualified postdoctoral fellows in the NIMH Division of Intramural Programs (DIRP) from intramural postdoctoral research positions to extramural, academic tenure-track or equivalent faculty positions at eligible U.S. institutions. Both the intramural and extramural phases will be mentored, and the award will provide research support during the extramural phase to help awardees launch competitive, independent research programs. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary clinical trial, as part of their research and career development. Applicants not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must apply to companion FOA, PA-21-194.</p>				
102817	Mentored Career Transition Award for Intramural Fellows (K22 Clinical Trials Not Allowed)	National Institute of Mental Health/NIH/DHHS	PA-21-194	12-Jun-2022	Not Specified
	<p>Contact Name Ashlee Van't Veer</p> <p>Contact Telephone 301-443-3107</p> <p>Contact Email dnbbstrainingbranch@mail.nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 12-Jun-2022 , 12-Oct-2022 , 12-Feb-2023 , 12-Jun-2023 , 12-Oct-2023 , 12-Feb-2024</p> <p>Synopsis The Mentored Career Transition Award for NIMH Intramural Fellows (K22) is a two-phase, mentored career development award program that is intended to facilitate a timely transition of qualified postdoctoral fellows in the NIMH Division of Intramural Programs (DIRP) from intramural postdoctoral research positions to extramural, academic tenure-track or equivalent faculty positions at eligible U.S. institutions. Both the intramural and extramural phases will be mentored, and the award will provide research support during the extramural phase to help awardees launch competitive, independent research programs. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing research</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		<p>that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary clinical trial. Applicants to this FOA are permitted to propose research experience in a clinical trial led by a mentor or co-mentor. Applicants proposing a clinical trial or an ancillary clinical trial as lead investigator should apply to the companion FOA, PA-21-195.</p>			
100747	RFA-MH-21-110 -- Service-Ready Tools for Identification, Prevention, and Treatment of Individuals at Risk for Suicide (R01 Clinical Trial Optional)	National Institute of Mental Health/NIH/DHHS	RFA-MH-21-110	15-Jun-2022	Not Specified
	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email</p> <p>Sponsor Website</p> <p>Program URL</p> <p>Deadline Dates (ALL)</p> <p>Synopsis</p>	<p>Stephen O'Connor, Ph.D.</p> <p>301-480-8366</p> <p>stephen.o'connor2@nih.gov</p> <p></p> <p>Link to program URL</p> <p>15-Jun-2022</p> <p>NIMH seeks applications for research projects to evaluate the effectiveness of service-ready tools and technologies that can be used to advance training, quality monitoring, and quality improvement efforts and ultimately improve the availability of evidence-based suicide prevention services. Specifically, this initiative encourages research on the effectiveness-implementation continuum aimed at (1) developing and testing the effectiveness of optimized, service-ready suicide prevention tools for identification, prevention, and treatment of individuals at risk for suicide; and (2) testing strategies to improve adoption, implementation fidelity, and sustained use of these tools, guided by an implementation science framework. Given the focus on practice-ready accessible resources and products that could be readily integrated into practice, NIMH encourages the use of technology and other design features that make the tools scalable and robust against implementation drift, and a deployment-focused approach that takes into account the perspectives of key stakeholders (e.g., service users, providers, administrators) and system-level factors, such as workforce capacity that influence potential integration of tools into clinical workflows. This Funding Opportunity Announcement (FOA) is intended to support effectiveness research of service-ready tools and technologies for suicide prevention that are statistically powered to provide a definitive answer regarding the study tool's effectiveness. Support for pilot effectiveness research to evaluate the initial feasibility, tolerability, acceptability, safety, and preliminary indications of effectiveness of service-ready tools and technologies for suicide prevention is provided via the R34 in RFA-MH-21-111. Support for SBIR studies focused on service-ready tools and technologies or suicide prevention is provided via the R43/R44 in RFA-MH-21-112.</p>			
100751	RFA-MH-21-112 -- Service-Ready Tools for Identification, Prevention, and Treatment of Individuals at Risk for Suicide (R43/R44 Clinical Trial Optional)	National Institute of Mental Health/NIH/DHHS	RFA-MH-21-112	15-Jun-2022	Not Specified

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Name Stephen O'Connor, Ph.D.</p> <p>Contact Telephone 301-480-8366</p> <p>Contact Email stephen.o'connor2@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 15-Jun-2022</p> <p>Synopsis This SBIR Funding Opportunity Announcement (FOA) is intended to support small businesses to develop and test service-ready, commercially viable tools and technologies for suicide prevention, including technologies that can be used to advance training, quality monitoring, and quality improvement efforts and ultimately improve the availability of evidence-based suicide prevention services. Specifically, this initiative encourages research on the effectiveness-implementation continuum aimed at (1) developing and testing the effectiveness of optimized, service-ready suicide prevention tools for identification, prevention, and treatment of individuals at risk for suicide; and (2) testing strategies to improve adoption, implementation fidelity, and sustained use of these tools, guided by an implementation science framework. Given the focus on practice-ready accessible resources and products that could be readily integrated into practice, NIMH encourages the use of technology and other design features that make the tools scalable and robust against implementation drift, and a deployment-focused approach that takes into account the perspectives of key stakeholders (e.g., service users, providers, administrators) and system-level factors, such as workforce capacity that influence potential integration of tools into clinical workflows.</p>				
100749	RFA-MH-21-111 -- Service-Ready Tools for Identification, Prevention, and Treatment of Individuals at Risk for Suicide (R34 Clinical Trial Optional)	National Institute of Mental Health/NIH/DHHS	RFA-MH-21-111	15-Jun-2022	450,000 USD
	<p>Contact Name Stephen O'Connor, Ph.D.</p> <p>Contact Telephone 301-480-8366</p> <p>Contact Email stephen.o'connor2@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 15-Jun-2022</p> <p>Synopsis NIMH seeks applications for pilot effectiveness projects to evaluate the preliminary effectiveness of service-ready tools and technologies that can be used to advance training, quality monitoring, and quality improvement efforts and ultimately improve the availability of evidence-based suicide prevention services. Specifically, this initiative encourages research on the</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

effectiveness-implementation continuum aimed at (1) developing and testing the effectiveness of optimized, service-ready suicide prevention tools for identification, prevention, and treatment of individuals at risk for suicide; and (2) testing strategies to improve adoption, implementation fidelity, and sustained use of these tools, guided by an implementation science framework. Given the focus on practice-ready accessible resources and products that could be readily integrated into practice, NIMH encourages the use of technology and other design features that make the tools scalable and robust against implementation drift, and a deployment-focused approach that takes into account the perspectives of key stakeholders (e.g., service users, providers, administrators) and system-level factors, such as workforce capacity that influence potential integration of tools into clinical workflows. This Funding Opportunity Announcement (FOA) supports pilot effectiveness research to evaluate the feasibility, tolerability, acceptability, safety and preliminary indications of effectiveness of service-ready tools and technologies for suicide prevention and inform the design of definitive effectiveness trials. Support for fully-powered, definitive effectiveness studies focused on service-ready tools and technologies or suicide prevention is provided via the R01 in RFA-MH-21-110. Support for SBIR studies focused on service-ready tools and technologies or suicide prevention is provided via the R43/R44 in RFA-MH-21-112.

102507	Pilot Effectiveness Trials for Treatment, Preventive and Services Interventions (R34 Clinical Trial Required)	National Institute of Mental Health/NIH/DHHS	PAR-21-131	15-Jun-2022	450,000 USD
--------	---	--	------------	-------------	-------------

Contact Name	Joel Sherrill, Ph.D.
Contact Telephone	301-443-2477
Contact Email	jsherril@mail.nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	15-Jun-2022 , 14-Oct-2022 , 15-Feb-2023 , 15-Jun-2023 , 17-Oct-2023 , 15-Feb-2024

Synopsis NIMH solicits clinical trial applications through a series of Funding Opportunity Announcements (FOAs) that cover the intervention development pipeline, from first-in-human, early testing of new interventions, confirmatory efficacy trials, through to effectiveness trials. The purpose of this FOA is to encourage pilot research consistent with NIMH's priorities for: 1) effectiveness research on preventive and therapeutic interventions with previously demonstrated efficacy, for use with broader target populations or for use in community practice settings, and 2) research on the development and preliminary testing of innovative services interventions. Consistent with the NIMH experimental therapeutics approach, this FOA is intended to support pilot studies of intervention effectiveness or service delivery approaches that explicitly address whether the intervention engages the target(s)/mechanism(s) presumed to underlie the intervention effects (i.e., the mechanism(s) that accounts for changes in clinical/functional outcomes, changes in provider behavior, improved access or continuity of services, etc.). In this pilot effectiveness phase of research, NIMH places highest priority on intervention and service delivery

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

approaches that can be justified in terms of their potential to substantially impact practice and public health. This FOA supports pilot studies and provides resources for evaluating the feasibility, tolerability, acceptability and safety and preliminary effectiveness of approaches to improve mental health/functional outcomes, to modify risk factors, or to improve service delivery, and for obtaining the preliminary data needed as a pre-requisite to a larger-scale effectiveness trial (e.g., comparative effectiveness study, pragmatic trial). Support for fully-powered effectiveness studies is provided through separate FOAs that utilize the R01 mechanism for single-site effectiveness trials (PAR-21-130; "Clinical Trials to Test the Effectiveness of Treatment, Preventive, and Services Interventions (R01).") and collaborative R01 mechanism for multi-site effectiveness trials (PAR-21-129;"Clinical Trials to Test the Effectiveness of Treatment, Prevention, and Services Interventions (Collaborative R01 Clinical Trial Required)"). Applicants pursuing other stages of the clinical trial pipeline should consider one of the companion FOAs.

102505	Clinical Trials to Test the Effectiveness of Treatment, Preventive, and Services Interventions (Collaborative R01 Clinical Trial Required)	National Institute of Mental Health/NIH/DHHS	PAR-21-129	15-Jun-2022	Not Specified
--------	--	--	------------	-------------	---------------

Contact Name	Joel Sherrill, Ph.D.
Contact Telephone	301-443-2477
Contact Email	jsherril@mail.nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	15-Jun-2022 , 14-Oct-2022 , 15-Feb-2023 , 15-Jun-2023 , 17-Oct-2023 , 15-Feb-2024
Synopsis	NIMH solicits clinical trial applications through a series of Funding Opportunity Announcements (FOAs) that cover the intervention development pipeline, from first-in-human, early testing of new interventions, confirmatory efficacy trials, through to effectiveness trials. This FOA seeks to support clinical trials to establish the effectiveness of interventions and to test hypotheses regarding moderators, mediators, and mechanisms of action of these interventions. This FOA supports clinical trials designed to test the therapeutic value of treatment and preventive interventions for which there is already evidence of efficacy, for use in community and practice settings. Applications might include research to evaluate the effectiveness or increase the clinical impact of pharmacologic, somatic, psychosocial (e.g., psychotherapeutic, behavioral), device-based, rehabilitative and combination interventions to prevent or treat mental illness. This FOA also supports clinical trials to test patient-, provider-, organizational-, or systems-level services interventions to improve access, continuity, quality, equity, and/or value of services. The intervention research covered under this announcement is explicitly focused on practice-relevant questions. This FOA supports trials that require participation of two or more collaborative sites for completion of the study. Accordingly, the collaborating studies share a specific protocol across the sites and are organized as such in order to increase sample size, accelerate recruitment, or increase sample diversity and representation. Each site has

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
102506	Clinical Trials to Test the Effectiveness of Treatment, Preventive, and Services Interventions (R01 Clinical Trial Required)	National Institute of Mental Health/NIH/DHHS	PAR-21-130	15-Jun-2022	Not Specified

its own Program Director/Principal Investigator (PD/PI) and the program provides a mechanism for cross-site coordination, quality control, database management, statistical analysis, and reporting. Support for fully-powered effectiveness studies via a single R01 grant is provided through a separate FOA, PAR-21-130, "Clinical Trials to Test the Effectiveness of Treatment, Preventive, and Services Interventions (R01)." This FOA is designed for applicants seeking funding for multi-site collaborative clinical trials to establish the effectiveness of interventions. Applicants pursuing other stages of the clinical trial pipeline should consider one of the companion FOAs.

Contact Name	Joel Sherrill, Ph.D.
Contact Telephone	301-443-2477
Contact Email	jsherril@mail.nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	15-Jun-2022 , 14-Oct-2022 , 15-Feb-2023 , 15-Jun-2023 , 17-Oct-2023 , 15-Feb-2024
Synopsis	<p>NIMH solicits clinical trial applications through a series of Funding Opportunity Announcements (FOAs) that cover the intervention development pipeline, from first-in-human, early testing of new interventions, confirmatory efficacy trials, through to effectiveness trials. This FOA seeks to support clinical trials to establish the effectiveness of interventions and to test hypotheses regarding moderators, mediators, and mechanisms of action of these interventions. This FOA supports clinical trials designed to test the therapeutic value of treatment and preventive interventions for which there is already evidence of efficacy, for use in community and practice settings. Applications might include research to evaluate the effectiveness or increase the clinical impact of pharmacologic, somatic, psychosocial (e.g., psychotherapeutic, behavioral), device-based, rehabilitative and combination interventions to prevent or treat mental illness. This FOA also supports clinical trials to test patient-, provider-, organizational-, or systems-level services interventions to improve access, continuity, quality, equity, and/or value of services. The intervention research covered under this announcement is explicitly focused on practice-relevant questions. This FOA uses the R01 grant mechanism to support trials that are adequately powered and of sufficient scope to test effectiveness and examine mediators and moderators of response. Support for multi-site trials that require participation of two or more collaborative sites for completion of the study (e.g., in order to increase sample size, accelerate recruitment, or increase sample diversity and representation) is provided through a separate FOA, PAR-21-129 "Clinical Trials to Test the Effectiveness of Treatment, Preventive, and Services Interventions (Collaborative R01)." This FOA is designed for applicants seeking funding for single-site clinical trials to establish the effectiveness of interventions. Applicants pursuing other stages of the clinical trial pipeline should consider one of the companion FOAs.</p>

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount														
102530	Early Stage Testing of Pharmacologic or Device-based Interventions for the Treatment of Mental Disorders (R61/R33 Clinical Trial Required)	National Institute of Mental Health/NIH/DHHS	PAR-21-137	15-Jun-2022	Not Specified														
	<table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 20%; padding-right: 5px;">Contact Name</td> <td>Margaret Grabb, Ph.D.</td> </tr> <tr> <td style="padding-right: 5px;">Contact Telephone</td> <td>301-443-3563</td> </tr> <tr> <td style="padding-right: 5px;">Contact Email</td> <td>mgrabb@mail.nih.gov</td> </tr> <tr> <td style="padding-right: 5px;">Sponsor Website</td> <td></td> </tr> <tr> <td style="padding-right: 5px;">Program URL</td> <td>Link to program URL</td> </tr> <tr> <td style="padding-right: 5px;">Deadline Dates (ALL)</td> <td>15-Jun-2022 , 14-Oct-2022 , 15-Feb-2023 , 15-Jun-2023 , 17-Oct-2023 , 15-Feb-2024</td> </tr> <tr> <td style="padding-right: 5px;">Synopsis</td> <td>NIMH solicits clinical trial applications through a series of Funding Opportunity Announcements (FOAs) that cover the intervention development pipeline, from first-in-human, early testing of new interventions, confirmatory efficacy trials, through to effectiveness trials. The purpose of this FOA is to support the early stage testing of pharmacologic interventions with novel mechanisms of action or device-based interventions for the treatment of symptoms or domains of altered functions in individuals with mental illness (e.g., schizophrenia, depression, autism, obsessive compulsive disorder, anxiety, bipolar disorder). Early intervention studies are also encouraged where symptoms of a disorder have been identified in subjects (a prodromal phase) prior to full diagnostic criteria being met. Ultimately, this FOA is intended to support early stage testing of pharmacologic or device-based interventions using a protocol design where the presumed mechanism of action of the intervention is adequately tested, to provide meaningful information where target modulation yields a well-controlled, dose-dependent neurophysiological/clinical/behavioral effect. The R61/R33 FOAs are intended to support biphasic high-risk applications. Support for a single phased award that does not need the developmental (R61) phase is available in the companion R33, PAR-21-136 . Applicants pursuing other stages of the clinical trial pipeline should consider one of the companion FOAs.</td> </tr> </table>					Contact Name	Margaret Grabb, Ph.D.	Contact Telephone	301-443-3563	Contact Email	mgrabb@mail.nih.gov	Sponsor Website		Program URL	Link to program URL	Deadline Dates (ALL)	15-Jun-2022 , 14-Oct-2022 , 15-Feb-2023 , 15-Jun-2023 , 17-Oct-2023 , 15-Feb-2024	Synopsis	NIMH solicits clinical trial applications through a series of Funding Opportunity Announcements (FOAs) that cover the intervention development pipeline, from first-in-human, early testing of new interventions, confirmatory efficacy trials, through to effectiveness trials. The purpose of this FOA is to support the early stage testing of pharmacologic interventions with novel mechanisms of action or device-based interventions for the treatment of symptoms or domains of altered functions in individuals with mental illness (e.g., schizophrenia, depression, autism, obsessive compulsive disorder, anxiety, bipolar disorder). Early intervention studies are also encouraged where symptoms of a disorder have been identified in subjects (a prodromal phase) prior to full diagnostic criteria being met. Ultimately, this FOA is intended to support early stage testing of pharmacologic or device-based interventions using a protocol design where the presumed mechanism of action of the intervention is adequately tested, to provide meaningful information where target modulation yields a well-controlled, dose-dependent neurophysiological/clinical/behavioral effect. The R61/R33 FOAs are intended to support biphasic high-risk applications. Support for a single phased award that does not need the developmental (R61) phase is available in the companion R33, PAR-21-136 . Applicants pursuing other stages of the clinical trial pipeline should consider one of the companion FOAs.
Contact Name	Margaret Grabb, Ph.D.																		
Contact Telephone	301-443-3563																		
Contact Email	mgrabb@mail.nih.gov																		
Sponsor Website																			
Program URL	Link to program URL																		
Deadline Dates (ALL)	15-Jun-2022 , 14-Oct-2022 , 15-Feb-2023 , 15-Jun-2023 , 17-Oct-2023 , 15-Feb-2024																		
Synopsis	NIMH solicits clinical trial applications through a series of Funding Opportunity Announcements (FOAs) that cover the intervention development pipeline, from first-in-human, early testing of new interventions, confirmatory efficacy trials, through to effectiveness trials. The purpose of this FOA is to support the early stage testing of pharmacologic interventions with novel mechanisms of action or device-based interventions for the treatment of symptoms or domains of altered functions in individuals with mental illness (e.g., schizophrenia, depression, autism, obsessive compulsive disorder, anxiety, bipolar disorder). Early intervention studies are also encouraged where symptoms of a disorder have been identified in subjects (a prodromal phase) prior to full diagnostic criteria being met. Ultimately, this FOA is intended to support early stage testing of pharmacologic or device-based interventions using a protocol design where the presumed mechanism of action of the intervention is adequately tested, to provide meaningful information where target modulation yields a well-controlled, dose-dependent neurophysiological/clinical/behavioral effect. The R61/R33 FOAs are intended to support biphasic high-risk applications. Support for a single phased award that does not need the developmental (R61) phase is available in the companion R33, PAR-21-136 . Applicants pursuing other stages of the clinical trial pipeline should consider one of the companion FOAs.																		
102508	Confirmatory Efficacy Clinical Trials of Non-Pharmacological Interventions for Mental Disorders (R01 Clinical Trial Required)	National Institute of Mental Health/NIH/DHHS	PAR-21-132	15-Jun-2022	Not Specified														
	<table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 20%; padding-right: 5px;">Contact Name</td> <td>Adam Haim, Ph.D.</td> </tr> <tr> <td style="padding-right: 5px;">Contact Telephone</td> <td>301-435-3593</td> </tr> <tr> <td style="padding-right: 5px;">Contact Email</td> <td>haima@mail.nih.gov</td> </tr> <tr> <td style="padding-right: 5px;">Sponsor Website</td> <td></td> </tr> <tr> <td style="padding-right: 5px;">Program URL</td> <td>Link to program URL</td> </tr> <tr> <td style="padding-right: 5px;">Deadline Dates (ALL)</td> <td>15-Jun-2022 , 14-Oct-2022 , 15-Feb-2023 , 15-Jun-2023 , 17-Oct-2023 , 15-Feb-2024</td> </tr> </table>					Contact Name	Adam Haim, Ph.D.	Contact Telephone	301-435-3593	Contact Email	haima@mail.nih.gov	Sponsor Website		Program URL	Link to program URL	Deadline Dates (ALL)	15-Jun-2022 , 14-Oct-2022 , 15-Feb-2023 , 15-Jun-2023 , 17-Oct-2023 , 15-Feb-2024		
Contact Name	Adam Haim, Ph.D.																		
Contact Telephone	301-435-3593																		
Contact Email	haima@mail.nih.gov																		
Sponsor Website																			
Program URL	Link to program URL																		
Deadline Dates (ALL)	15-Jun-2022 , 14-Oct-2022 , 15-Feb-2023 , 15-Jun-2023 , 17-Oct-2023 , 15-Feb-2024																		

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

Synopsis NIMH solicits clinical trial applications through a series of Funding Opportunity Announcements (FOAs) that cover the intervention development pipeline, from first-inhuman, early testing of new interventions, confirmatory efficacy trials, through to effectiveness trials. The purpose of this FOA is to support confirmatory efficacy testing of non-pharmacological therapeutic and preventive interventions for mental disorders in adults and children through an experimental therapeutics approach. Under this FOA, trials must be designed so that results, whether positive or negative, will provide information of high scientific utility and will support "go/no-go" decisions about further development, effectiveness testing, or dissemination of the intervention. Interventions to be studied include, but are not limited to behavioral, cognitive, interpersonal, and device-based (both invasive/surgically implanted as well as noninvasive/transcranial) approaches, or a combination thereof. Interventions appropriate for efficacy testing must be based on a compelling scientific rationale, previous demonstration that the intervention engages and alters the hypothesized mechanism of action, a preliminary efficacy signal, and must address an unmet therapeutic need. Support will be provided for a trial of the intervention's efficacy that includes measurement of the hypothesized mechanism of action and the relationship between change in the mechanism and change in functional or clinical effects. Ultimately, this FOA is intended to support a sufficiently-powered efficacy trial to determine the intervention's potential for significant clinical benefit. Applicants pursuing other stages of the clinical trial pipeline should consider one of the companion FOAs

102528	Early Stage Testing of Pharmacologic or Device-based Interventions for the Treatment of Mental Disorders (R33- Clinical Trial Required)	National Institute of Mental Health/NIH/DHHS	PAR-21-136	15-Jun-2022	Not Specified
--------	---	--	------------	-------------	---------------

Contact Name | Margaret Grabb, Ph.D.
 Contact Telephone | 301-443-3563
 Contact Email | mgrabb@mail.nih.gov
 Sponsor Website |
 Program URL | [Link to program URL](#)
 Deadline Dates (ALL) | 15-Jun-2022 , 14-Oct-2022 , 15-Feb-2023 , 15-Jun-2023 , 17-Oct-2023 , 15-Feb-2024

Synopsis NIMH solicits clinical trial applications through a series of Funding Opportunity Announcements (FOAs) that cover the intervention development pipeline, from first-in human, early testing of new interventions, confirmatory efficacy trials, through to effectiveness trials. The purpose of this FOA is to support the early stage testing of pharmacologic interventions with novel mechanisms of action or device-based interventions, for the treatment of symptoms or domains of altered functions in individuals with mental illness (e.g., schizophrenia, depression, autism, obsessive compulsive disorder, anxiety, bipolar disorder). Early intervention studies are also encouraged where symptoms of a disorder have been identified in subjects (a prodromal phase), prior to full diagnostic criteria being met. Ultimately, this FOA is intended to support early stage testing of pharmacologic or device-based interventions using a protocol design where the presumed mechanism of

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

action of the intervention is adequately tested, to provide meaningful information where target modulation yields a well-controlled, dose-dependent neurophysiological/clinical/behavioral effect. Pediatric, adult and geriatric focused interventions are appropriate for this FOA. This R33 FOA supports single-phased clinical trial awards. Applicants proposing high risk projects are encouraged to apply to the companion FOA, PAR-21-137or PAR-21-133.

102511	Development of Psychosocial Therapeutic and Preventive Interventions for Mental Disorders (R33 Clinical Trial Required)	National Institute of Mental Health/NIH/DHHS	PAR-21-134	15-Jun-2022	Not Specified
--------	---	--	------------	-------------	---------------

Contact Name	Alexander Talkovsky, Ph.D.
Contact Telephone	301-827-7614
Contact Email	alexander.talkovsky@nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	15-Jun-2022 , 14-Oct-2022 , 15-Feb-2023 , 15-Jun-2023 , 17-Oct-2023 , 15-Feb-2024
Synopsis	<p>NIMH solicits clinical trial applications through a series of Funding Opportunity Announcements (FOAs) that cover the intervention development pipeline, from first-in-human, early testing of new interventions, confirmatory efficacy trials, through to effectiveness trials. The purpose of this FOA is to encourage pilot research developing and testing innovative psychosocial intervention approaches in which the target and/or intervention strategy is novel. Consistent with NIMH’s experimental therapeutics approach, this FOA is intended to speed the translation of emergent research on mechanisms and processes underlying mental disorders into promising novel psychosocial preventative or therapeutic interventions. Targets may include, but are not limited to, potentially modifiable behavioral, cognitive, affective and/or interpersonal factors or processes, neural circuits or neural activity subserving specific behaviors or cognitive processes, and/or other neurobiological mechanisms. Novel psychosocial intervention strategies might include in-person or technology-assisted delivery, provided the target and/or the intervention strategy is novel. They may also be standalone interventions or augmentations of efficacious interventions for which there is an empirical rationale by which the augmentation (and corresponding target) is expected to substantially enhance outcomes. Support will be provided for up to 3 years for studies to replicate previous target engagement findings, and to relate change in the intervention target/mechanism to clinical benefit. Ultimately, trials must be designed so that results, whether positive or negative, will provide information of high scientific utility and will support “go/no-go” decisions about further development and/or testing of the intervention. This FOA is designed for applicants seeking to fund pilot stages of research. Applicants pursuing other stages of the clinical trial pipeline should consider one of the companion FOAs.</p>

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
102513	Development of Psychosocial Therapeutic and Preventive Interventions for Mental Disorders (R61/R33 Clinical Trial Required)	National Institute of Mental Health/NIH/DHHS	PAR-21-135	15-Jun-2022	Not Specified
	<p>Contact Name Alexander Talkovsky, Ph.D.</p> <p>Contact Telephone 301-827-7614</p> <p>Contact Email alexander.talkovsky@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 15-Jun-2022 , 14-Oct-2022 , 15-Feb-2023 , 15-Jun-2023 , 17-Oct-2023 , 15-Feb-2024</p> <p>Synopsis NIMH solicits clinical trial applications through a series of Funding Opportunity Announcements (FOAs) that cover the intervention development pipeline, from first-in-human, early testing of new interventions, confirmatory efficacy trials, through to effectiveness trials. The purpose of this FOA is to encourage pilot research developing and testing innovative psychosocial intervention approaches in which the target and/or intervention strategy is novel. Consistent with NIMH's experimental therapeutics approach, this FOA is intended to speed the translation of emergent research on mechanisms and processes underlying mental disorders into promising novel psychosocial preventative or therapeutic interventions. Targets may include, but are not limited to, potentially modifiable behavioral, cognitive, affective and/or interpersonal factors or processes, neural circuits or neural activity subserving specific behaviors or cognitive processes, and/or other neurobiological mechanisms. Novel psychosocial interventions may be standalone interventions or augmentations to efficacious interventions for which there is an empirical rationale by which the augmentation (and corresponding target) is expected to substantially enhance outcomes. Support will be provided for up to two years (R61 phase) for preliminary milestone-driven testing of a novel intervention's impact on a target process or mechanism associated mental disorder risk, causation, or maintenance (target engagement). Up to 3 years of additional support (R33 phase) will be provided for studies with findings that meet the "go/no-go" milestones embedded in the R61 phase. The R33 phase is intended to support the replication of target engagement and to test whether engaging the intervention target/mechanism mediates changes in clinical outcomes. Ultimately, trials must be designed so that results, whether positive or negative, will provide information of high scientific utility and will support "go/no-go" decisions about further development and/or testing of the intervention. Applicants pursuing other stages of the clinical trial pipeline should consider one of the companion FOAs.</p>				
102509	First in Human and Early Stage Clinical Trials of Novel Investigational Drugs or Devices for Psychiatric Disorders (U01 Clinical Trial Required)	National Institute of Mental Health/NIH/DHHS	PAR-21-133	15-Jun-2022	Not Specified
	<p>Contact Name Margaret Grabb, Ph.D.</p> <p>Contact Telephone 301-443-3563</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

	Contact Email	mgrabb@mail.nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	15-Jun-2022 , 14-Oct-2022 , 15-Feb-2023 , 15-Jun-2023 , 17-Oct-2023 , 15-Feb-2024			
	Synopsis	<p>NIMH solicits clinical trial applications through a series of Funding Opportunity Announcements (FOAs) that cover the intervention development pipeline, from first-in-human, early testing of new interventions, confirmatory efficacy trials, through to effectiveness trials. The purpose of this FOA is to encourage cooperative agreement applications to support early stage clinical trials of novel mechanism of action investigational drugs or novel neuromodulatory devices for the treatment of psychiatric disorders in areas of unmet medical need. The FOA will support milestone-driven early stage trials in pediatric and adult populations. First in human (FIH) and Phase Ib studies of novel agents must assess target engagement (brain exposure), pharmacological effects, safety, and tolerability to assess feasibility for Phase II/proof of concept (PoC) studies in psychiatric disorders. Phase II/PoC studies must evaluate the drug's impact on clinically relevant physiological systems (functional measures) and clinical indicators of effect. The FOA also supports FIH and early feasibility studies (EFS) of novel devices to evaluate target engagement, safety, tolerability, and efficacy. The overall objective is to facilitate rapid collection of data to "de-risk" novel mechanism of action investigational drugs, novel drugs for use in pediatric populations with psychiatric disorders, and devices or combination treatments in order to attract private or other public funding (when appropriate) for further clinical development as FDA-approved treatments. A key aspect of this FOA is the formation of collaborative partnerships between the biomedical researchers and biotechnology or industry researchers to facilitate psychiatric drug or device development. This FOA is designed for applicants seeking funding for cooperative agreements supporting early stage clinical trials as outlined above. Applicants pursuing other stages of the clinical trial pipeline or funding for clinical research not involving cooperative agreements should consider one of the companion FOAs.</p>			

105830	Pilot Studies to Test the Initiation of a Mental Health Family Navigator Model to Promote Early Access, Engagement and Coordination of Needed Mental Health Services for Children and Adolescents (R34 Clinical Trial Required)	National Institute of Mental Health/NIH/DHHS	PAR-21-292	16-Jun-2022	450,000 USD
--------	---	--	------------	-------------	-------------

	Contact Name	Denise Pintello, Ph.D., M.S.W.			
	Contact Telephone	301-451-1481			
	Contact Email	dpintell@mail.nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	16-Jun-2022 , 16-Oct-2022 , 16-Feb-2023 , 16-Jun-2023 , 16-Oct-2023 , 16-Feb-2024 , 16-Jun-2024			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

Synopsis The purpose of this Funding Opportunity Announcement (FOA) is to encourage research applications to develop and pilot test the effectiveness and implementation of existing family navigator models designed to promote early access, engagement, coordination and optimization of mental health treatment and services for children and adolescents who are experiencing early symptoms of mental health problems. For the purposes of this FOA, NIMH defines a family navigator model as a health care professional or paraprofessional whose role is to deploy a set of strategies designed to rapidly engage youth and families in needed treatment and services, work closely with the family and other involved treatment and service providers to optimize care, and through the use of technology – to monitor the trajectory of mental health symptoms and outcomes over time. Applicants are required to develop and pilot test the navigator model’s ability to promote early access, engagement, coordination and optimization of mental health treatment and services for children and adolescents as soon as symptoms are detected. Applicants are also required to identify and pilot test components of navigator models that drive improvements in mental health care; detect and interrogate tailoring variables that optimize the ‘personalized match’ between the unique mental health needs of youth to the appropriate level of intensity and frequency of mental health services; and utilize emerging novel technologies to track and monitor the trajectory of clinical, functional and behavioral progress toward achieving intended services outcomes. This FOA is published in parallel to a companion R01 FOA, PAR-21-291 which uses the R01 funding mechanism.

103214	Pilot Effectiveness Trials for Post-Acute Interventions and Services to Optimize Longer-term Outcomes (R34 Clinical Trial Required)	National Institute of Mental Health/NIH/DHHS	PAR-21-211	16-Jun-2022	450,000 USD
--------	---	--	------------	-------------	-------------

Contact Name Adam Haim, Ph.D.
 Contact Telephone 301-435-3593
 Contact Email haima@mail.nih.gov
 Sponsor Website
 Program URL [Link to program URL](#)
 Deadline Dates (ALL) 16-Jun-2022 , 16-Oct-2022 , 16-Feb-2023 , 16-Jun-2023 , 16-Oct-2023 , 16-Feb-2024

Synopsis NIMH seeks applications for pilot projects to evaluate the preliminary effectiveness of therapeutic and service delivery interventions for the post-acute management of mental health conditions that are matched to the stage of illness in terms of both their focus (e.g., consolidating and maintaining gains from initial treatment, managing residual symptoms/impairment, preventing relapse, promoting adherence and appropriate service use) and intensity/burden. In this pilot phase of effectiveness research, the trial should be designed to evaluate the feasibility, tolerability, acceptability, safety, and potential effectiveness of the approach; to address whether the intervention engages the target(s)/mechanisms(s) that is/are presumed to underlie the intervention effects; and to obtain preliminary data needed as a pre-requisite to a larger-scale effectiveness trial (e.g., comparative effectiveness study, practical trial) designed to

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		<p>definitely test the effectiveness of interventions to improve post-acute outcomes. This FOA supports pilot research to evaluate the feasibility, tolerability, acceptability, safety and preliminary indications of effectiveness of post-acute phase intervention approaches and inform the design of definitive effectiveness trials. Support for fully-powered, definitive effectiveness studies focused on post-acute phase interventions is provided via the R01, PAR-21-210.</p>			
108811	Innovative Pilot Mental Health Services Research Not Involving Clinical Trials (R34 Clinical Trial Not Allowed)	National Institute of Mental Health/NIH/DHHS	PAR-22-082	16-Jun-2022	450,000 USD
	Contact Name	Christine M. Ulbricht, Ph.D.			
	Contact Telephone	301-480-6928			
	Contact Email	christine.ulbricht@nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	16-Jun-2022 , 16-Oct-2022 , 16-Feb-2023 , 16-Jun-2023 , 16-Oct-2023 , 16-Feb-2024 , 16-Jun-2024 , 16-Oct-2024 , 16-Feb-2025			
	Synopsis	<p>The purpose of this Funding Opportunity Announcement (FOA) is to encourage innovative pilot research that will inform and support the delivery of high-quality, continuously improving mental health services to benefit the greatest number of individuals with, or at risk for developing, a mental illness. This announcement invites applications for non-clinical trial pilot projects that address NIMH strategic priorities to strengthen the public health impact of NIMH-supported research as described in Goal 4 of the NIMH Strategic Plan. Proposed research should seek to: Identify mutable factors that impact access, continuity, utilization, quality, value, and outcomes, including disparities in outcomes, or scalability of mental health services, which may serve as targets in future service delivery intervention development; Develop and test new research tools, technologies, measures, or methods and statistical approaches to study these issues; Test the feasibility of integrating and analyzing large data sets to understand factors affecting mental health services outcomes using advanced computational and predictive analytic approaches; Wherever possible, leverage existing infrastructure and partnerships to accomplish these goals.</p>			
107491	Basic Neurodevelopmental Biology of Circuits and Behavior (R21 Clinical Trial Not Allowed)	National Institute of Mental Health/NIH/DHHS	PAR-22-067	16-Jun-2022	275,000 USD
	Contact Name	Andrew Breeden, Ph.D.			
	Contact Telephone	301-451-3185			
	Contact Email	neurodevelopmentpar@mail.nih.gov			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 16-Jun-2022 , 16-Oct-2022 , 16-Feb-2023 , 16-Jun-2023 , 16-Oct-2023 , 16-Feb-2024 , 16-Jun-2024 , 16-Oct-2025</p> <p>Synopsis This Funding Opportunity Announcement (FOA) encourages research projects focused on the dynamic and mechanistic links between the maturation of brain circuits and behaviors across development in rodents and non-human primates. The goal is to build a foundation for understanding how interactions within and among brain regions change over pre- and post-natal development, allowing for the emergence of cognitive, affective and social behaviors. To this end, projects supported will focus on neurodevelopmental trajectories and investigate questions using in vivo neural measures in awake, behaving animals. This FOA seeks shorter, higher-risk R21 grant applications, whereas its companion funding opportunity PAR-22-066 seeks R01 grant applications.</p>				
097912	<p>Cellular and Molecular Biology of Complex Brain Disorders (R21 Clinical Trial Not Allowed)</p>	National Institute of Mental Health/NIH/DHHS	PAR-20-264	16-Jun-2022	275,000 USD
	<p>Contact Name David Panchision</p> <p>Contact Telephone 301-443-5288</p> <p>Contact Email panchisiond@mail.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 16-Jun-2022 , 16-Oct-2022 , 16-Feb-2023 , 16-Jun-2023</p> <p>Synopsis This Funding Opportunity Announcement (FOA) encourages research on the biology of high confidence risk factors associated with complex brain disorders, with a focus on the intracellular, transcellular and circuit substrates of neural function. For the purposes of this FOA, the term “complex” can refer to a multifactorial contribution to risk (e.g., polygenic and/or environmental) and/or highly distributed functional features of the brain disorder. Studies may be either hypothesis-generating (unbiased discovery) or hypothesis-testing in design and may utilize in vivo, in situ, or in vitro experimental paradigms, e.g., model organisms or human cell-based assays. While behavioral paradigms and outcome measures can be incorporated into the research design to facilitate the characterization of intracellular, transcellular and circuit mechanisms, these are neither required nor expected. Studies should not attempt to “model” disorders but instead should aim to elucidate the neurobiological impact of individual or combined risk factor(s), such as the affected molecular and cellular components and their relationships within defined biological process(es). This can include the fundamental biology of these factors, components and processes. The resulting paradigms, component pathways and biological processes should be disseminated with sufficient detail to enrich common and/or federated data resources (e.g., those contributing to the Gene</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		<p>Ontology, Synaptic Gene Ontology, FAIR Data Informatics) in order to bridge the gap between disease risk factors, biological mechanism and therapeutic target identification. The present announcement (R21 activity code) can be used for applications to develop early stage, high-risk, exploratory approaches or establish proof-of-concept where there is little or no preliminary data.</p>			
102910	Understanding and Modifying Temporal Dynamics of Coordinated Neural Activity (R21 Clinical Trial Optional)	National Institute of Mental Health/NIH/DHHS	PAR-21-176	16-Jun-2022	275,000 USD
	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email</p> <p>Sponsor Website</p> <p>Program URL</p> <p>Deadline Dates (ALL)</p>	<p>Andrew Rossi, Ph.D.</p> <p>301-443-1576</p> <p>andrew.rossi@nih.gov</p> <p></p> <p>Link to program URL</p> <p>16-Jun-2022 , 16-Oct-2022 , 16-Feb-2023 , 16-Jun-2023 , 16-Oct-2023 , 16-Feb-2024</p>			
	Synopsis	<p>A growing body of evidence suggests that optimal cognitive, affective, and social processes are associated with highly coordinated neural activity. These findings indicate that oscillatory rhythms, their co-modulation across frequency bands, spike-phase correlations, spike population dynamics, and other patterns might be useful drivers of therapeutic development for treatment of cognitive, social, or affective symptoms in neuropsychiatric disorders. This Funding Opportunity Announcement (FOA) supports projects that test whether modifying electrophysiological patterns during behavior can improve cognitive, affective, or social processing. Applications must use experimental designs that incorporate active manipulations to address at least one, and ideally more, of the following topics: (1) in animals or humans, determine which parameters of neural coordination, when manipulated in isolation, improve particular aspects of cognitive, affective, or social processing; (2) in animals or humans, determine how particular abnormalities at the genomic, molecular, or cellular levels affect the systems-level coordination of electrophysiological patterns during behavior; (3) determine whether in vivo, systems-level electrophysiological changes in behaving animals predict analogous electrophysiological and cognitive improvements in healthy persons or clinical populations; and (4) use biologically-realistic computational models that include systems-level aspects to understand the function and mechanisms by which oscillatory and other electrophysiological patterns unfold across the brain to impact cognitive, affective, or social processing. This FOA uses the R21 exploratory grant mechanism, whereas its companion FOA, PAR-21-175, seeks R01 grant applications for larger research applications that have an established premise.</p>			
106896	Neuromodulation/Neurostimulation Device Development for Mental Health Applications (R21 Clinical Trial Not Allowed)	National Institute of Mental Health/NIH/DHHS	PAR-22-038	16-Jun-2022	275,000 USD

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Name David McMullen, M.D.</p> <p>Contact Telephone 301-451-0180</p> <p>Contact Email david.mcmullen@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 16-Jun-2022 , 16-Oct-2022 , 16-Feb-2023 , 16-Jun-2023 , 16-Oct-2023 , 16-Feb-2024 , 16-Jun-2024 , 16-Oct-2024</p> <p>Synopsis The purpose of this funding opportunity announcement (FOA) is to encourage applications seeking to develop the next generation of brain stimulation devices for treating mental health disorders. Applications are sought that will either 1) develop novel brain stimulation devices or 2) significantly enhance, by means of hardware/software improvements, the effectiveness of brain stimulation devices that are currently U.S. Food and Drug Administration (FDA)-approved or cleared. Novel devices should move beyond existing electrical/magnetic stimulation and develop new stimulation techniques capable of increased spatiotemporal precision as well as multi-focal, closed-loop approaches. Applications seeking to develop new capabilities should focus on significant enhancement of the spatial resolution, depth of delivery, and/or precision of the device. Incremental changes to existing devices (e.g., software updates) are not within the scope of this announcement. Applications should be submitted by multi-disciplinary teams with diverse expertise including systems neuroscience, engineering, clinical, and regulatory affairs. Applications submitted in response to this FOA should promote the development or significant enhancement of novel tools (hardware/software) for brain stimulation in humans. Although the application should focus on the engineering development and bench top testing of the tool, animals and limited human testing necessary to demonstrate initial proof of concept is allowable. Applications to this FOA are not expected to be hypothesis-driven, but should propose design-directed, developmental, or discovery-driven technology research using integrative approaches. Applications that seek to study scientific or clinical hypotheses that simply utilize devices are outside the scope of this FOA. This FOA uses the R21 grant mechanism, encouraging shorter, higher-risk applications, whereas its companion funding opportunity, PAR-22-039, seeks R01 grant applications.</p>				
106499	Mood and Psychosis Symptoms during the Menopause Transition (R21 Clinical Trial Optional)	National Institute of Mental Health/NIH/DHHS	PAR-22-036	16-Jun-2022	275,000 USD
	<p>Contact Name Laura M. Rowland, Ph.D.</p> <p>Contact Telephone 301-480-8335</p> <p>Contact Email laura.rowland@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Deadline Dates (ALL) 16-Jun-2022 , 16-Oct-2022 , 16-Feb-2023 , 16-Jun-2023 , 16-Oct-2023 , 16-Feb-2024 , 16-Jun-2024 , 16-Oct-2024</p> <p>Synopsis The purpose of this Funding Opportunity Announcement (FOA) is to encourage applications that will advance mechanistic and translational research on the onset and worsening of mood and psychotic disorders during the menopausal transition (or perimenopause). In particular, NIMH seeks research that will advance understanding of the underlying neurobiological and behavioral mechanisms of mood disruption and psychosis during the menopausal transition and that will identify novel targets for future mental health interventions or prevention efforts. This FOA uses the R21 mechanism, while the companion FOA (PAR-22-035) uses the R01 grant mechanism. Investigators proposing high risk/high reward projects, projects that lack preliminary data, or studies that utilize existing data may wish to apply using the R21 mechanism, while applicants with preliminary data who seek longer-term funding may wish to apply using the R01 mechanism.</p>				
105701	<p>Utilizing Invasive Recording and Stimulating Opportunities in Humans to Advance Neural Circuitry Understanding of Mental Health Disorders (R21 Clinical Trial Optional)</p>	National Institute of Mental Health/NIH/DHHS	PAR-21-288	16-Jun-2022	275,000 USD
	<p>Contact Name David McMullen, M.D.</p> <p>Contact Telephone 301-451-0180</p> <p>Contact Email david.mcmullen@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 16-Jun-2022 , 16-Oct-2022 , 16-Feb-2023 , 16-Jun-2023 , 16-Oct-2023 , 16-Feb-2024 , 16-Jun-2024</p> <p>Synopsis The purpose of this Funding Opportunity Announcement (FOA) is to encourage applications to pursue invasive neural recording studies focused on mental health-relevant questions. Invasive neural recordings provide an unparalleled window into the human brain to explore the neural circuitry and neural dynamics underlying complex moods, emotions, cognitive functions, and behaviors with high spatial and temporal resolution. Additionally, the ability to stimulate, via the same electrodes, allows for direct causal tests by modulating network dynamics. This FOA aims to target a gap in the scientific knowledge of neural circuit function related to mental health disorders. Researchers should target specific questions suited to invasive recording modalities that have high translational potential. Development of new therapies is outside the scope of this FOA, though development of novel tools/methods to enable relevant mental health studies is encouraged. This FOA uses the R21 grant mechanism, encouraging shorter, higher-risk applications, whereas its companion funding opportunity, PAR-21-289, seeks R01 grant applications.</p>				
106927	<p>Neuromodulation/Neurostimulation Device Development for Mental Health Applications (R21 Clinical Trial Not Allowed)</p>	National Institute of Mental Health/NIH/DHHS	PAR-22-038	16-Jun-2022	275,000 USD

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		<p>Contact Name David McMullen, M.D.</p> <p>Contact Telephone 301-451-0180</p> <p>Contact Email david.mcmullen@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 16-Jun-2022 , 16-Oct-2022 , 16-Feb-2023 , 16-Jun-2023 , 16-Oct-2023 , 16-Feb-2024 , 16-Jun-2024 , 16-Oct-2024</p> <p>Synopsis The purpose of this funding opportunity announcement (FOA) is to encourage applications seeking to develop the next generation of brain stimulation devices for treating mental health disorders. Applications are sought that will either 1) develop novel brain stimulation devices or 2) significantly enhance, by means of hardware/software improvements, the effectiveness of brain stimulation devices that are currently U.S. Food and Drug Administration (FDA)-approved or cleared. Novel devices should move beyond existing electrical/magnetic stimulation and develop new stimulation techniques capable of increased spatiotemporal precision as well as multi-focal, closed-loop approaches. Applications seeking to develop new capabilities should focus on significant enhancement of the spatial resolution, depth of delivery, and/or precision of the device. Incremental changes to existing devices (e.g., software updates) are not within the scope of this announcement. Applications should be submitted by multi-disciplinary teams with diverse expertise including systems neuroscience, engineering, clinical, and regulatory affairs. Applications submitted in response to this FOA should promote the development or significant enhancement of novel tools (hardware/software) for brain stimulation in humans. Although the application should focus on the engineering development and bench top testing of the tool, animals and limited human testing necessary to demonstrate initial proof of concept is allowable. Applications to this FOA are not expected to be hypothesis-driven, but should propose design-directed, developmental, or discovery-driven technology research using integrative approaches. Applications that seek to study scientific or clinical hypotheses that simply utilize devices are outside the scope of this FOA. This FOA uses the R21 grant mechanism, encouraging shorter, higher-risk applications, whereas its companion funding opportunity, PAR-22-039, seeks R01 grant applications.</p>			
108301	RFA-NS-22-034 -- HEAL Initiative: Discovery and Validation of Novel Targets for Safe and Effective Pain Treatment (R01 Clinical Trial Not Allowed)	National Institute of Neurological Disorders and Stroke/NIH/DHHS	RFA-NS-22-034	07-Apr-2022	Not Specified
		<p>Contact Name Michael L. Oshinsky, PhD</p> <p>Contact Telephone 301-496-9964</p> <p>Contact Email michael.oshinsky@nih.gov</p> <p>Sponsor Website </p>			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-Apr-2022 , 02-Jun-2022 , 08-Aug-2022 , 04-Oct-2022 , 07-Dec-2022 , 02-Feb-2023 , 07-Apr-2023 , 02-Jun-2023 , 07-Aug-2023 , 04-Oct-2023 , 07-Dec-2023 , 02-Feb-2024 , 09-Apr-2024 , 04-Jun-2024 , 07-Aug-2024 , 02-Oct-2024 , 06-Dec-2024</p> <p>Synopsis The purpose of this Funding Opportunity Announcement (FOA) is to promote the discovery and validation of novel therapeutic targets to facilitate the development of pain therapeutics. Specifically, the focus of this FOA is on the basic science discovery of targets in the peripheral nervous system, central nervous system, immune system or other tissues in the body that can be used to develop treatments that have minimal side effects and little to no abuse/addiction liability. Research supported by this FOA must include rigorous validation studies to demonstrate the robustness of the target as a pain treatment target. This will lower the risk of adopting the target in translational projects to develop small molecules, biologics, natural substances, or devices that interact with this target for new pain treatments. Translational research to develop new medical devices is not the focus of this FOA. Basic science studies of pain and related systems in the body are responsive to this FOA and are encouraged in the context of novel pain therapeutic target discovery. This FOA is not specific for any one or group of pain conditions. Projects to identify novel targets for acute pain, chronic pain, migraine, other headache disorders, osteoarthritis, diabetic neuropathy, chemotherapy-induced neuropathy, sickle-cell pain, post stroke pain, orofacial pain, etc. will be considered. Projects to identify novel targets for a combination of chronic overlapping pain conditions or for specific pathological conditions will be considered. Projects that seek to identify novel targets in specific populations such as women, children, older adults or other underrepresented groups will also be responsive to this FOA.</p>				
106266	<p>NINDS Alzheimer’s Disease and Alzheimer’s Disease-Related Dementias (AD/ADRD) Advanced Postdoctoral Career Transition Award to Promote Diversity (K99/R00 Independent Clinical Trial Not Allowed)</p>	National Institute of Neurological Disorders and Stroke/NIH/DHHS	PAR-22-022	07-May-2022	Not Specified
	<p>Contact Name Amelie Gubitz, Ph.D.</p> <p>Contact Telephone 301-451-7966</p> <p>Contact Email gubitza@ninds.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2022 , 12-Jun-2022 , 07-Sep-2022 , 12-Oct-2022 , 07-Jan-2023 , 12-Feb-2023 , 07-May-2023 , 12-Jun-2023 , 07-Sep-2023 , 12-Oct-2023 , 07-Jan-2024 , 12-Feb-2024 , 07-May-2024 , 12-Jun-2024</p> <p>Synopsis The purpose of the NINDS Alzheimer’s Disease and Alzheimer’s Disease-Related Dementias (AD/ADRD) Advanced Postdoctoral Career Transition Award to Promote Diversity (K99/R00) program is to support a cohort of new and talented, independent investigators from diverse backgrounds (e.g. see NOT-OD-20-031, Notice of NIH’s Interest in Diversity)</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

conducting AD/ADRD research. The program is designed to facilitate a timely transition of eligible postdoctoral researchers from their mentored, postdoctoral research positions to independent, tenure-track or equivalent faculty positions. The program will provide independent NIH research support during this transition in order to help awardees establish independent research programs in the AD/ADRD field. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary study to a clinical trial. Applicants to this FOA are permitted to propose research experiences in a clinical trial led by a mentor or co-mentor.

086932	NINDS Postdoctoral Mentored Career Development Award (K01 - Clinical Trial Required)	National Institute of Neurological Disorders and Stroke/NIH/DHHS	PAR-20-050	07-May-2022	Not Specified
--------	--	--	------------	-------------	---------------

Contact Name	Stephen Korn, PhD
Contact Telephone	
Contact Email	korns@mail.nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	07-May-2022 , 12-Jun-2022 , 07-Sep-2022 , 12-Oct-2022 , 07-Jan-2023
Synopsis	<p>The purpose of the NINDS Postdoctoral Mentored Career Development Award is to support the ability of outstanding, mentored postdoctoral researchers to develop a potentially impactful research project with a comprehensive career development plan that will enable them to launch an independent research program. Candidates are encouraged to apply for support from this NINDS K01 any time between the second through fourth year of cumulative mentored postdoctoral research experience, and may be supported by this NINDS K01 within the first 6 years of cumulative postdoctoral research experience. Because the completion of a strong, well-planned, thorough career development plan, in addition to development of an impactful research project, is a critical aspect of this K01, applications are strongly encouraged early in the postdoctoral eligibility window. By the end of the proposed K01 award period, the candidate should be poised to begin an independent research career with a well-developed, impactful research project and the expertise required to become a leader in the field. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing to serve as the lead investigator of an independent small clinical trial as part of their research and career development. Applicants not planning an independent small clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must apply to companion FOA (PAR-20-049).</p>

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
104258	NINDS Efficacy Clinical Trials (UG3/UH3 Clinical Trial Required)		National Institute of Neurological Disorders and Stroke/NIH/DHHS	PAR-21-237 07-May-2022	Not Specified
	<p>Contact Name Jeremy Brown, MD</p> <p>Contact Telephone 301-496-9135</p> <p>Contact Email Jeremy.brown@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2022 , 09-Jun-2022 , 07-Sep-2022 , 11-Oct-2022 , 07-Jan-2023 , 09-Feb-2023 , 07-May-2023 , 09-Jun-2023 , 07-Sep-2023 , 10-Oct-2023 , 07-Jan-2024 , 09-Feb-2024 , 07-May-2024</p> <p>Synopsis The purpose of this Funding Opportunity Announcement (FOA) is to encourage grant applications for investigator-initiated efficacy clinical trials to the National Institute of Neurological Disorders and Stroke (NINDS). The trials must address questions within the mission and research interests of the NINDS and may evaluate drugs, biologics, and devices, as well as surgical, behavioral and rehabilitation therapies. Information about the mission and research interests of the NINDS can be found at the NINDS website (https://www.ninds.nih.gov/).</p>				
103393	NINDS Faculty Development Award to Promote Diversity in Neuroscience Research (K01 Clinical Trial Required)		National Institute of Neurological Disorders and Stroke/NIH/DHHS	PAR-21-153 07-May-2022	Not Specified
	<p>Contact Name Michelle Jones-London, Ph.D.</p> <p>Contact Telephone 301-451-7966</p> <p>Contact Email jonesmiche@ninds.nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2022 , 12-Jun-2022 , 07-Sep-2022 , 12-Oct-2022 , 07-Jan-2023 , 12-Feb-2023 , 07-May-2023 , 12-Jun-2023 , 07-Sep-2023 , 12-Oct-2023 , 07-Jan-2024 , 12-Feb-2024 , 07-May-2024</p> <p>Synopsis The purpose of the NINDS Faculty Development Award to Promote Diversity in Neuroscience Research (K01) is to diversify the pool of independent neuroscience research investigators by providing junior faculty with research cost support, protected research time and career stage appropriate professional development mentorship in neuroscience research. Individuals from diverse backgrounds, including those from groups underrepresented in biomedical research are eligible for</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

support under this award if they have doctoral research degrees (Ph.D. or equivalent) and are in the first 3 years of a faculty tenure track or equivalent position at the time of application. This Funding Opportunity Announcement (FOA) is designed specifically for candidates proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary clinical trial, as part of their research and career development. Those not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must apply to companion FOA (PAR-21-152).

103724	NINDS Faculty Development Award to Promote Diversity in Neuroscience Research (K01 Independent Clinical Trial Not Allowed)	National Institute of Neurological Disorders and Stroke/NIH/DHHS	PAR-21-234	07-May-2022	Not Specified
--------	--	--	------------	-------------	---------------

Contact Name	Michelle Jones-London, Ph.D.
Contact Telephone	301-451-7966
Contact Email	jonesmiche@ninds.nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	07-May-2022 , 12-Jun-2022 , 07-Sep-2022 , 12-Oct-2022 , 07-Jan-2023 , 12-Feb-2023 , 07-May-2023 , 12-Jun-2023 , 07-Sep-2023 , 12-Oct-2023 , 07-Jan-2024 , 12-Feb-2024 , 07-May-2024
Synopsis	The purpose of the NINDS Faculty Development Award to Promote Diversity in Neuroscience Research (K01) is to diversify the pool of independent neuroscience research investigators by providing junior faculty with research cost support, protected research time and career stage appropriate professional development mentorship in neuroscience research. Individuals from diverse backgrounds, including those from groups underrepresented in biomedical research are eligible for support under this award if they have doctoral research degrees (Ph.D. or equivalent) and are in the first 3 years of a faculty tenure track or equivalent position at the time of application. This Funding Opportunity Announcement (FOA) is designed specifically for candidates proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary study to a clinical trial. Under this FOA candidates are permitted to propose a research experience in a clinical trial led by a mentor or co-mentor. Those proposing a clinical trial or an ancillary study to an ongoing clinical trial as lead investigator, should apply to the companion FOA (PAR-21-153).

100306	NINDS Ruth L. Kirschstein National Research Service Award (NRSA) for Training of Postdoctoral Fellows (F32 Clinical Trial Not Allowed)	National Institute of Neurological Disorders and Stroke/NIH/DHHS	PAR-21-032	07-May-2022	Not Specified
--------	--	--	------------	-------------	---------------

Contact Name | Stephen Korn, Ph.D.

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

Contact Telephone	301-496-4188
Contact Email	korns@ninds.nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	07-May-2022 , 08-Jun-2022 , 07-Sep-2022 , 11-Oct-2022 , 07-Jan-2023 , 09-Feb-2023 , 07-May-2023 , 08-Jun-2023 , 07-Sep-2023 , 10-Oct-2023 , 07-Jan-2024
Synopsis	<p>The purpose of this award is to support outstanding scientific training of highly promising postdoctoral candidates with outstanding mentors. Candidates are eligible to apply for support from this program from ~12 months prior to the start of the proposed postdoctoral position to within 12 months after starting in the proposed postdoctoral position. This NINDS F32 seeks to foster early, goal-directed planning and to encourage applications for bold and/or innovative projects by the candidate that have the potential for significant impact. Inclusion of preliminary data is strongly discouraged; rather, this F32 seeks innovative research ideas and thoughtful plans for training and mentorship that will facilitate the development of the postdoctoral fellow into an outstanding scientist. Applications are expected to incorporate strong training in quantitative reasoning and the quantitative principles of experimental design and analysis. Support by this program is limited to the first 4 years of a candidate's activity in a specific laboratory or research environment, so as to further encourage early, thoughtful planning and timely completion of “mentored training” within a particular lab or environment. This Funding Opportunity Announcement (FOA) does not allow applicants to propose to lead an independent clinical trial, but does allow applicants to propose research experience in a clinical trial led by a sponsor or co-sponsor. This Funding Opportunity Announcement (FOA) does not allow applicants to propose to lead an independent clinical trial, but does allow applicants to propose research experience in a clinical trial led by a sponsor or co-sponsor.</p>

100819	Clinical Validation of a Candidate Biomarker for Neurological or Neuromuscular Disorders (U44 Clinical Trial Optional)	National Institute of Neurological Disorders and Stroke/NIH/DHHS	PAR-21-059	07-May-2022	Not Specified
--------	--	--	------------	-------------	---------------

Contact Name	Mary Ann Pellemounter, PhD
Contact Telephone	301-496-1779
Contact Email	mary.pellemounter@nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	07-May-2022 , 22-Jun-2022 , 07-Sep-2022 , 22-Feb-2023 , 07-May-2023 , 22-Jun-2023 , 07-Sep-2023

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Synopsis	The purpose of this Program Announcement (PAR) is to enable clinical validation of strong candidate biomarkers for neurological and neuromuscular disorders and conditions. Specifically, the goal of this PAR is to enable the rigorous clinical validation of biomarker measurements within the clinical population of interest to establish the clinical sensitivity and specificity of the biomarker consistent with FDA guidelines. This PAR assumes that 1) a candidate biomarker has already been identified, 2) detection method technology has already been developed and analytically validated, and 3) the research and/or clinical need and potential context of use has been identified.			
100817	Analytical Validation of a Candidate Biomarker for Neurological or Neuromuscular Disorders (U44 Clinical Trial Optional)	National Institute of Neurological Disorders and Stroke/NIH/DHHS	PAR-21-057	07-May-2022	Not Specified
	Contact Name	Mary Ann Pellemounter, PhD			
	Contact Telephone	301-496-1779			
	Contact Email	mary.pellemounter@nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	07-May-2022 , 22-Jun-2022 , 07-Sep-2022 , 22-Feb-2023 , 07-May-2023 , 22-Jun-2023 , 07-Sep-2023			
	Synopsis	The purpose of this Program Announcement (PAR) is to enable analytical validation of strong candidate biomarkers for neurological and neuromuscular disorders and conditions. Specifically, the goal of this PAR is to enable the rigorous validation of analytical methods for biomarker measurements, which should include evaluation of the detection method, its performance characteristics, and the optimal conditions that will generate reproducibility and accuracy consistent with FDA guidelines. This PAR assumes that 1) a candidate biomarker has already been identified, 2) detection method technology has already been developed, and 3) the research and/or clinical need and potential context of use has been identified.			
100818	Clinical Validation of a Candidate Biomarker for Neurological or Neuromuscular Disorders (U01 Clinical Trial Optional)	National Institute of Neurological Disorders and Stroke/NIH/DHHS	PAR-21-058	07-May-2022	Not Specified
	Contact Name	Mary Ann Pellemounter, PhD			
	Contact Telephone	301-496-1779			
	Contact Email	mary.pellemounter@nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Deadline Dates (ALL) 07-May-2022 , 22-Jun-2022 , 07-Sep-2022 , 22-Feb-2023 , 07-May-2023 , 22-Jun-2023 , 07-Sep-2023</p> <p>Synopsis The purpose of this Program Announcement (PAR) is to enable clinical validation of strong candidate biomarkers for neurological and neuromuscular disorders and conditions. Specifically, the goal of this PAR is to enable the rigorous clinical validation of biomarker measurements within the clinical population of interest to establish the clinical sensitivity and specificity of the biomarker consistent with FDA guidelines. This PAR assumes that 1) a candidate biomarker has already been identified, 2) detection method technology has already been developed and analytically validated, and 3) the research and/or clinical need and potential context of use has been identified.</p>				
100816	Analytical Validation of a Candidate Biomarker for Neurological or Neuromuscular Disorders (U01 Clinical Trial Optional)	National Institute of Neurological Disorders and Stroke/NIH/DHHS	PAR-21-056	07-May-2022	Not Specified
	<p>Contact Name Mary Ann Pellemounter, PhD</p> <p>Contact Telephone 301-496-1779</p> <p>Contact Email mary.pellemounter@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2022 , 22-Jun-2022 , 07-Sep-2022 , 22-Feb-2023 , 07-May-2023 , 22-Jun-2023 , 07-Sep-2023</p> <p>Synopsis The purpose of this Program Announcement (PAR) is to enable analytical validation of strong candidate biomarkers for neurological and neuromuscular disorders and conditions. Specifically, the goal of this PAR is to enable the rigorous validation of analytical methods for biomarker measurements, which should include evaluation of the detection method, its performance characteristics, and the optimal conditions that will generate reproducibility and accuracy consistent with FDA guidelines. This PAR assumes that 1) a candidate biomarker has already been identified, 2) detection method technology has already been developed, and 3) the research and/or clinical need and potential context of use has been identified.</p>				
106730	Notice of Special Interest (NOSI): Biomarker Discover and Validation in Functional Neurological Disorders	National Institute of Neurological Disorders and Stroke/NIH/DHHS	NOT-NS-22-010	07-May-2022	Not Specified
	<p>Contact Name Codrin Lungu, MD</p> <p>Contact Telephone 301-496-9135</p> <p>Contact Email lunguci@ninds.nih.gov</p> <p>Sponsor Website </p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2022 , 22-Jun-2022 , 22-Feb-2023 , 07-May-2023 , 22-Jun-2023 , 07-Sep-2023</p> <p>Synopsis NINDS is issuing this Notice of Special Interest to encourage the submission of applications focused on the development and validation of biomarkers for functional neurological disorders (FND).</p>				
086929	NINDS Postdoctoral Mentored Career Development Award (K01 - No Independent Clinical Trial Allowed)	National Institute of Neurological Disorders and Stroke/NIH/DHHS	PAR-20-049	07-May-2022	Not Specified
	<p>Contact Name Stephen Korn, PhD</p> <p>Contact Telephone</p> <p>Contact Email korns@mail.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2022 , 12-Jun-2022 , 07-Sep-2022 , 12-Oct-2022 , 07-Jan-2023</p> <p>Synopsis The purpose of the NINDS Postdoctoral Mentored Career Development Award is to support the ability of outstanding, mentored postdoctoral researchers to develop a potentially impactful research project with a comprehensive career development plan that will enable them to launch an independent research program. Candidates are encouraged to apply for support from this NINDS K01 any time between the second through fourth year of cumulative mentored postdoctoral research experience, and may be supported by this NINDS K01 within the first 6 years of cumulative postdoctoral research experience. Because the completion of a strong, well-planned, thorough career development plan, in addition to development of an impactful research project, is a critical aspect of this K01, applications are strongly encouraged early in the postdoctoral eligibility window. By the end of the proposed K01 award period, the candidate should be poised to begin an independent research career with a well-developed, impactful research project and the expertise required to become a leader in the field. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing research that does not involve leading an independent small clinical trial. Applicants to this FOA are permitted to propose research experience in a clinical trial led by a mentor or co-mentor. Applicants proposing an independent small clinical trial as lead investigator, should apply to the companion FOA (PAR-20-050).</p>				
103957	NeuroNEXT Clinical Trials (U01 Clinical Trial Optional)	National Institute of Neurological Disorders and Stroke/NIH/DHHS	PAR-21-223	05-Jun-2022	Not Specified

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Name Codrin Lungu, MD</p> <p>Contact Telephone 301-496-9135</p> <p>Contact Email lunguci@ninds.nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 05-Jun-2022 , 05-Oct-2022 , 05-Feb-2023 , 05-Jun-2023 , 05-Oct-2023 , 05-Feb-2024</p> <p>Synopsis This FOA encourages applications for exploratory clinical trials of investigational agents (drugs, biologics, surgical therapies or devices) that may contribute to the justification for and provide the data required for designing a future trial, for biomarker validation studies, or for proof of mechanism clinical studies. Diseases chosen for study should be based on the NINDS' strategic plan and clinical research interests (www.ninds.nih.gov/funding/areas/index.htm). Successful applicants will be given access to the NeuroNEXT infrastructure. Following peer review, NINDS will prioritize and order trials that are given access to the NeuroNEXT infrastructure. The NeuroNEXT Clinical Coordinating Center (CCC) will work with the successful applicant to efficiently implement the proposed study. The NeuroNEXT Data Coordinating Center (DCC) will provide statistical and data management support. The NeuroNEXT clinical sites will provide recruitment/retention support as well as on-site implementation of the clinical protocol. Applicants do not need to be part of the existing NeuroNEXT infrastructure.</p>				
107186	Clinical Trial Readiness for Functional Neurological Disorders (U01 Clinical Trial Optional)	National Institute of Neurological Disorders and Stroke/NIH/DHHS	PAR-22-053	05-Jun-2022	Not Specified
	<p>Contact Name Codrin Lungu, MD</p> <p>Contact Telephone 301-496-9135</p> <p>Contact Email lunguci@ninds.nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 05-Jun-2022 , 05-Oct-2022 , 05-Feb-2023 , 05-Jun-2023 , 05-Oct-2023 , 05-Feb-2024 , 05-Jun-2024 , 05-Oct-2024</p> <p>Synopsis Functional Neurological Disorders (FNDs) are characterized by symptoms of altered voluntary motor or sensory function with clinical findings providing evidence of incompatibility between the symptoms and recognized neurological or medical conditions. FNDs are highly prevalent and associated with significant morbidity, health care costs, and even mortality. In some respects, this group of conditions sits at the intersection of neurology and psychiatry, but the majority of cases first come to the attention of neurologists. Management is complex and requires interdisciplinary approaches. Given the</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

disability caused by the symptoms, and the high cost in healthcare utilization and loss of productivity, FNDs amount to a significant missed opportunity for therapeutic intervention and therefore, a healthcare crisis. Diagnosis and management of FNDs remain very challenging. Diagnostic criteria have been proposed but they are not universally agreed upon. Diagnosis is based on positive clinical findings, and can be supported by laboratory or ancillary investigation findings. Certain FND subtypes are more difficult to correctly diagnose than others. More importantly, laboratory-supported diagnosis is possible, and biomarkers can be developed, but significantly more research is needed in these areas to advance clinical management of FNDs. Therapies exist and have been studied in select populations but gathering high-level evidence through clinical trials is hampered by limitations in available outcome measures. Differential responses to treatments have been recorded, and thus, prediction of aggregate treatment response has been difficult. This FOA invites researchers to submit prospective clinical projects that address critical needs for clinical trial readiness in FNDs. Projects appropriate for this FOA include the validation of biomarkers, endpoints and clinical outcome assessments (COA) that are fit-for-purpose and have a defined context of use for clinical trials. Projects involving biomarker discovery or early validation should apply to the relevant FOAs (PAR-19-315, PAR-21-056, PAR-21-057, PAR-21-058, PAR-21-059). The initiative will promote partnerships among academic investigators, industry, and patient groups, and will encourage interactions with the Food and Drug Administration (FDA).

109312	RFA-RM-22-009 -- Somatic Mosaicism across Human Tissues (SMaHT) Program: Organizational Center (U24 Clinical Trial Not Allowed)	National Institute of Neurological Disorders and Stroke/NIH/DHHS	RFA-RM-22-009	08-Jun-2022	Not Specified
--------	---	--	---------------	-------------	---------------

Contact Name | Jill Morris, Ph.D.
 Contact Telephone | 301-496-5745
 Contact Email | SMaHT@mail.nih.gov
 Sponsor Website |
 Program URL | [Link to program URL](#)
 Deadline Dates (ALL) | 08-Jun-2022 , 08-Jul-2022

Synopsis | This Funding Opportunity Announcement (FOA) invites applications to establish the Organizational Center for the Somatic Mosaicism across Human Tissues (SMaHT) Network. The purpose of the SMaHT Network is to enable discovery of new biology and disease mechanisms mediated by genomic variation in somatic tissues. The Organizational Center will coordinate meetings, communication, outreach, and other organizational activities within the Network and be the main conduit for collaboration with related programs and the wider research community. This Funding Opportunity Announcement (FOA) is developed as a Common Fund initiative (<http://commonfund.nih.gov/>) through the NIH Office of the NIH Director, Office of Strategic Coordination (<https://dpcpsi.nih.gov/>). All NIH Institutes and Centers participate in Common

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
Fund initiatives. The FOA will be administered by the National Institute of Neurological Diseases and Stroke (NINDS) on behalf of the NIH.					
109325	RFA-RM-22-011 -- Somatic Mosaicism across Human Tissues (SMaHT) Program: Tool Development Projects (UG3/UH3 Clinical Trial Not Allowed)	National Institute of Neurological Disorders and Stroke/NIH/DHHS	RFA-RM-22-011	08-Jun-2022 [Optional][LOI/Pre-App]	1,700,000 USD
	<p>Contact Name Jill Morris, Ph.D.</p> <p>Contact Telephone 301-496-5754</p> <p>Contact Email SMaHT@mail.nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 08-Jun-2022 [Optional][LOI/Pre-App], 08-Jul-2022</p> <p>Synopsis This Funding Opportunity Announcement (FOA) invites applications for development of tools and technologies to enhance understanding of somatic variants as part of the Somatic Mosaicism across Human Tissues (SMaHT) Network. The purpose of the SMaHT Network is to enable discovery of new biology and disease mechanisms mediated by genomic variation in somatic tissues. Technology and Tool Development Projects will develop the next generation of technologies that will enhance our ability to detect and characterize somatic variants in human tissues. This Funding Opportunity Announcement (FOA) is developed as a Common Fund initiative (http://commonfund.nih.gov/) through the NIH Office of the NIH Director, Office of Strategic Coordination (https://dpcpsi.nih.gov/). All NIH Institutes and Centers participate in Common Fund initiatives. The FOA will be administered by the National Institute of Neurological Diseases and Stroke (NINDS) on behalf of the NIH.</p>				
107322	Translational Efforts to Advance Gene-based Therapies for Ultra-Rare Neurological and Neuromuscular Disorders (U01 - Clinical Trial Optional)	National Institute of Neurological Disorders and Stroke/NIH/DHHS	PAR-22-030	09-Jun-2022	Not Specified
	<p>Contact Name Ann-Marie Broome, PhD, MBA</p> <p>Contact Telephone 301-496-1779</p> <p>Contact Email ann-marie.broome@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 09-Jun-2022 , 08-Oct-2022 , 09-Feb-2023 , 09-Jun-2023 , 10-Oct-2023 , 08-Feb-2024 , 07-Jun-2024</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Synopsis	The Ultra-Rare Gene-Based Therapy (URGenT) network supports Investigational New Drug (IND)-enabling studies and planning activities for First-in-Human (FIH) clinical testing of gene-based or transcript-directed therapeutics, such as oligonucleotides and viral-based gene therapies, for ultra-rare neurological or neuromuscular disorders. The goal of this funding opportunity announcement (FOA) is to accelerate the development of a promising clinical candidate with robust biological rationale and demonstrated proof of concept (POC) data for the intended approach in a model system relevant to a specified patient population towards an IND filing and the initiation of a clinical trial.			
106359	Career Transition Award for NINDS Intramural Clinician-Scientists (K22 Clinical Trial Required)	National Institute of Neurological Disorders and Stroke/NIH/DHHS	PAR-21-327	12-Jun-2022	Not Specified
	Contact Name	Stephen Korn, Ph.D.			
	Contact Telephone				
	Contact Email	korns@ninds.nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	12-Jun-2022 , 12-Oct-2022 , 12-Feb-2023 , 12-Jun-2023 , 12-Oct-2023 , 12-Feb-2024 , 12-Jun-2024			
	Synopsis	This NINDS K22 is specifically designed to facilitate the transition of NINDS intramural neurologist- and neurosurgeon-scientists to independent, academic faculty positions that support clinician-scientists to engage in independently funded scientific research as well as clinical activities. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary study to an existing trial, as part of their research and career development. Applicants not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must apply to companion FOA PAR-21-328.			
106361	Career Transition Award for NINDS Intramural Clinician-Scientists (K22 Clinical Trial Not Allowed)	National Institute of Neurological Disorders and Stroke/NIH/DHHS	PAR-21-328	12-Jun-2022	Not Specified
	Contact Name	Stephen Korn, Ph.D.			
	Contact Telephone				
	Contact Email	korns@ninds.nih.gov			
	Sponsor Website				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 12-Jun-2022 , 12-Oct-2022 , 12-Feb-2023 , 12-Jun-2023 , 12-Oct-2023 , 12-Feb-2024 , 12-Jun-2024</p> <p>Synopsis This NINDS K22 is specifically designed to facilitate the transition of NINDS intramural neurologist- and neurosurgeon-scientists to independent, academic faculty positions that support clinician-scientists to engage in independently funded scientific research as well as clinical activities. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary study to a clinical trial. Applicants to this FOA are permitted to propose research experience in a clinical trial led by a mentor or co-mentor. Applicants proposing a clinical trial or an ancillary study to an ongoing clinical trial as lead investigator, should apply to the companion FOA PAR-21-327.</p>				
109940	Prospective Observational Comparative Effectiveness Research in Clinical Neurosciences (UG3/UH3 Clinical Trial Not Allowed)	National Institute of Neurological Disorders and Stroke/NIH/DHHS	PAR-22-076	17-Jun-2022	Not Specified
	<p>Contact Name Adam L. Hartman, MD</p> <p>Contact Telephone 301-496-9135</p> <p>Contact Email adam.hartman@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 17-Jun-2022 , 07-Sep-2022 , 18-Oct-2022 , 07-Jan-2023 , 17-Feb-2023 , 07-May-2023 , 19-Jun-2023 , 07-Sep-2023 , 18-Oct-2023 , 07-Jan-2024 , 20-Feb-2024 , 07-May-2024 , 16-Jun-2024 , 07-Sep-2024 , 18-Oct-2024 , 07-Jan-2025 , 19-Feb-2025 , 07-May-2025</p> <p>Synopsis The purpose of this Funding Opportunity Announcement (FOA) is to encourage grant applications for investigator-initiated prospective observational comparative effectiveness research (CER) to the National Institute of Neurological Disorders and Stroke (NINDS) (note: only prospective observational studies will be considered). The study must address questions within the mission and research interests of the NINDS and may evaluate preventive strategies, diagnostic approaches, or interventions including drugs, biologics, and devices, or surgical, behavioral, and rehabilitation therapies. NINDS is particularly interested in pragmatic study designs that utilize a cost-effective means of prospectively collecting observational data important to current clinical practice.</p>				
097476	NIH StrokeNet Clinical Trials and Biomarker Studies for Stroke Treatment, Recovery, and Prevention (UG3/UH3 Clinical Trial Optional)	National Institute of Neurological Disorders and Stroke/NIH/DHHS	PAR-20-285	20-Jun-2022	Not Specified

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

Contact Name Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL)	Claudia Scala Moy, PhD 301-496-9135 moyc@ninds.nih.gov Link to program URL 20-Jun-2022 , 18-Oct-2022 , 14-Feb-2023 , 14-Jun-2023 Synopsis <p>This FOA encourages applications for multi-site exploratory and confirmatory clinical trials focused on promising interventions; biomarker or outcome measure validation studies that are immediately preparatory to trials in stroke prevention, treatment, and recovery; and ancillary studies designed to add scientific aims to active studies being conducted within StrokeNet. Successful applicants will collaborate and conduct the study within the NIH StrokeNet. Following peer review, NINDS will prioritize studies among the highest scoring to be conducted in the NIH StrokeNet infrastructure. The NIH StrokeNet National Coordinating Center (NCC) will work with the successful applicant to implement the proposed study efficiently and the National Data Management Center (NDMC) will provide statistical and data management support. The NIH StrokeNet Regional Coordinating Centers (RCCs) and their affiliated clinical sites will provide recruitment/retention support as well as on-site implementation of the clinical protocol. The NIH StrokeNet network will also be uniquely poised to collaborate with other US and international consortia necessary to conduct larger, definitive trials of promising interventions for stroke treatment, prevention, and recovery. NINDS intends that all multi-center clinical trials in stroke treatment, recovery, or prevention supported by NINDS will be conducted in the NIH StrokeNet and that only in exceptional circumstances will NINDS consider funding multi-site stroke clinical trials outside of this program. Applicants do not need to be part of the existing NIH StrokeNet infrastructure to apply under this FOA. This FOA uses the bi-phasic, milestone driven UG3/UH3 cooperative agreement mechanism. Awards made under this FOA will initially support a one-year milestone-driven planning and start-up phase, with possible transition to an implementation (UH3) phase of up to 6 additional years. Only UG3 projects that meet the scientific milestones and award requirements of the UG3 phase may transition to the UH3 phase. Applications submitted in response to this FOA must address both the UG3 and UH3 phases and are expected to include plans for project management and performance milestones for each phase.</p>
--	---

103821	RFA-NS-21-022 -- Translational Neural Devices (U44 Clinical Trial Optional)	National Institute of Neurological Disorders and Stroke/NIH/DHHS	RFA-NS-21-022	20-Jun-2022	Not Specified
--------	---	--	---------------	-------------	---------------

Contact Name Contact Telephone	Nick Langhals, PhD 301-496-1779
-----------------------------------	------------------------------------

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

Contact Email	NINDS-Devices@nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	20-Jun-2022 , 18-Oct-2022 , 21-Feb-2023 , 19-Jun-2023 , 18-Oct-2023 , 20-Feb-2024
Synopsis	<p>The purpose of this Funding Opportunity Announcement (FOA) is to encourage applications from Small Business Concerns (SBCs) to pursue translational activities and small clinical studies to advance the development of therapeutic and diagnostic devices for disorders that affect the nervous or neuromuscular systems. Activities supported in this program include implementation of clinical prototype devices, non-clinical safety and efficacy testing, design verification and validation activities leading to submission of an Investigational Device Exemption (IDE) to the U.S. Food and Drug Administration (FDA) or Institutional Review Board (IRB) application for a Non-Significant Risk (NSR) study. The clinical study is expected to provide information about the device function or final design that cannot be practically obtained through additional non-clinical assessments (e.g., bench top or animal studies) due to the novelty of the device or its intended use. This FOA is a milestone-driven cooperative agreement program and will involve participation of NIH program staff in negotiating the final project plan before award and monitoring of research progress.</p>

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
103817	RFA-NS-21-021 -- Translational Neural Devices (UG3/UH3 - Clinical Trial Optional)	National Institute of Neurological Disorders and Stroke/NIH/DHHS	RFA-NS-21-021	20-Jun-2022	Not Specified

Contact Name	Nick Langhals, PhD
Contact Telephone	301-496-1779
Contact Email	NINDS-Devices@nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	20-Jun-2022 , 18-Oct-2022 , 21-Feb-2023 , 19-Jun-2023 , 18-Oct-2023 , 20-Feb-2024
Synopsis	<p>The purpose of this Funding Opportunity Announcement (FOA) is to encourage investigators to pursue translational activities and small clinical studies to advance the development of therapeutic, and diagnostic devices for disorders that affect the nervous or neuromuscular systems. Activities supported in this program include implementation of clinical prototype devices, non-clinical safety and efficacy testing, design verification and validation activities, obtaining an</p>

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
<p>Investigational Device Exemption (IDE) for a Significant Risk (SR) study or Institutional Review Board (IRB) approval for a Non-Significant Risk (NSR) study, as well as a subsequent small clinical study. The clinical study is expected to provide information about the device function or final design that cannot be practically obtained through additional non-clinical assessments (e.g., bench top or animal studies) due to the novelty of the device or its intended use. This FOA is a milestone-driven cooperative agreement program and will involve participation of NIH program staff in negotiating the final project plan before award and monitoring of research progress.</p>					
102747	Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Neurotherapeutic Agent Characterization and In vivo Efficacy Studies (R61/R33 Clinical Trial Not Allowed)	National Institute of Neurological Disorders and Stroke/NIH/DHHS	PAR-21-122	21-Jun-2022	750,000 USD
	<p>Contact Name Becky Roof, PhD</p> <p>Contact Telephone 301-496-1779</p> <p>Contact Email rebecca.roof@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 21-Jun-2022 , 18-Oct-2022 , 21-Feb-2023 , 20-Jun-2023 , 20-Oct-2023 , 20-Feb-2024</p> <p>Synopsis This funding opportunity announcement (FOA) provides funding to conduct pharmacodynamic, pharmacokinetic, and in vivo efficacy studies to demonstrate that proposed therapeutic agent(s) have sufficient biological activity to warrant further development to treat neurological or neuromuscular disorders that fall under the NINDS mission. Therapeutic agents include small molecules, biologics or biotechnology-derived products. This FOA is part of a suite of Innovation Grants to Nurture Initial Translational Efforts (IGNITE) to advance projects to the point where they can meet the entry criteria for the Blueprint Neurotherapeutics Network or other translational programs.</p>				
102739	Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Development and Validation of Model Systems to Facilitate Neurotherapeutic Discovery (R61/R33 Clinical Trial Not Allowed)	National Institute of Neurological Disorders and Stroke/NIH/DHHS	PAR-21-123	21-Jun-2022	750,000 USD
	<p>Contact Name Becky Roof, PhD</p> <p>Contact Telephone 301-496-1779</p> <p>Contact Email rebecca.roof@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Deadline Dates (ALL) 21-Jun-2022 , 18-Oct-2022 , 21-Feb-2023 , 20-Jun-2023 , 20-Oct-2023 , 20-Feb-2024</p> <p>Synopsis This funding opportunity announcement (FOA) encourages the development and validation of animal models and human/animal tissue ex vivo systems that recapitulate the phenotypic and physiologic characteristics of a defined neurological or neuromuscular disorder. The goal of this FOA is to promote a significant improvement in the translational relevance of animal models or ex vivo systems that will be utilized to facilitate future development of neurotherapeutics. Ideally, models proposed for this FOA would have the potential to provide feasible and meaningful assessments of efficacy following therapeutic intervention that would be applicable in both preclinical and clinical settings. This FOA is part of a suite of Innovation Grants to Nurture Initial Translational Efforts (IGNITE) Program focused on enabling the exploratory and early stages of drug discovery.</p>				
109299	Development of Biomarkers or Biomarker Signatures for Neurological and Neuromuscular Disorders (R61/R33 Clinical Trial Optional)	National Institute of Neurological Disorders and Stroke/NIH/DHHS	PAR-22-089	22-Jun-2022	Not Specified
	<p>Contact Name Carol Taylor-Burds Ph.D</p> <p>Contact Telephone 301-496-1779</p> <p>Contact Email carol.taylor-burds@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 22-Jun-2022 , 07-Sep-2022 , 22-Feb-2023 , 07-May-2023 , 22-Jun-2023 , 07-Sep-2023 , 22-Feb-2024 , 07-May-2024 , 22-Jun-2024 , 07-Sep-2024 , 21-Feb-2025 , 07-May-2025</p> <p>Synopsis The purpose of this Funding Opportunity Announcement (FOA) is to promote the development of fit-for-purpose candidate biomarkers and biomarker signatures that enable more efficient clinical trials to advance therapeutic development or be used in clinical practice to help guide clinical care decisions. Specifically, the goal of this phased funding mechanism is to first identify or confirm candidate biomarkers or biomarker signatures using human samples and/or data, followed by an independent retrospective or prospective clinical study to conduct initial clinical validation of the biomarker/signature's clinical utility for a defined Context of Use(s). In the first phase, applicants are expected to demonstrate that the biomarker acceptably identifies or predicts the concept of interest and may include optimization of the detection method using carefully standardized human samples or datasets. The overarching purpose of this initiative is to deliver candidate biomarkers or biomarker signatures that are ready for definitive analytical and clinical validation studies.</p>				
102700	Notice of Special Interest (NOSI): NINR Priority Areas for Training and Career Development Awards	National Institute of Nursing Research/NIH/DHHS	NOT-NR-21-001	08-Apr-2022	Not Specified
	Contact Name				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Telephone</p> <p>Contact Email</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 08-Apr-2022 , 07-May-2022 , 25-May-2022 , 12-Jun-2022 , 08-Aug-2022 , 07-Sep-2022 , 25-Sep-2022 , 12-Oct-2022 , 08-Dec-2022 , 07-Jan-2023 , 25-Jan-2023 , 12-Feb-2023 , 08-Apr-2023 , 07-May-2023 , 25-May-2023 , 12-Jun-2023 , 08-Aug-2023 , 07-Sep-2023</p> <p>Synopsis The National Institute of Nursing Research (NINR) is committed to training the next generation of nurse scientists at all levels of education and encouraging training in important new areas of nursing research.</p>				
084549	Palliative Care in Home and Community Settings (R01 Clinical Trial Optional)	National Institute of Nursing Research/NIH/DHHS	PAR-19-321	07-May-2022	Not Specified
	<p>Contact Name Karen A. Kehl, PhD, RN, FPCN</p> <p>Contact Telephone 301-594-8010</p> <p>Contact Email karen.kehl@mail.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2022 , 05-Jun-2022 , 07-Sep-2022</p> <p>Synopsis The purpose of this funding opportunity is to stimulate research aimed at determining needs and best practices for the integration of palliative care into home and community settings. Home and community in this FOA refer to the place where an individual resides or lives. Home- and community-based palliative care programs ensure those with serious, advanced illness who do not require hospitalization but are not appropriate for hospice have access to high quality end-of-life and palliative care.</p>				
085700	Omics-guided Biobehavioral Interventions for Improved Health Outcomes: A Step Forward in Translation (R01 Clinical Trial Optional)	National Institute of Nursing Research/NIH/DHHS	PAR-19-377	07-May-2022	Not Specified
	<p>Contact Name Lois A. Tully, PhD</p> <p>Contact Telephone 301-594-5968</p> <p>Contact Email tullyla@mail.nih.gov</p> <p>Sponsor Website</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2022 , 05-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 07-Jan-2023</p> <p>Synopsis The purpose of this funding opportunity announcement (FOA) is to stimulate clinical research that harnesses the wealth of advances in the fields of genomics and other omics (e.g., metabolomics, microbiomics, proteomics, transcriptomics, epigenomics, etc.) to incorporate these advances into translatable, personalized biobehavioral interventions for improved health outcomes.</p>				
085882	Patient Activation for Self-Management of Chronic Conditions (R01 Clinical Trial Optional)	National Institute of Nursing Research/NIH/DHHS	PAR-19-381	07-May-2022	Not Specified
	<p>Contact Name Karen Huss, PhD, RN, APRN-BC, FAAN, FAAAAI</p> <p>Contact Telephone 301-594-5970</p> <p>Contact Email hussk@mail.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2022 , 05-Jun-2022 , 05-Jul-2022 , 07-Sep-2022 , 05-Feb-2023 , 05-Mar-2023 , 07-May-2023</p> <p>Synopsis The purpose of this Funding Opportunity Announcement is to encourage grant applications that address the influence of patient activation on self-management of chronic conditions.</p>				
085884	Patient Activation for Self-Management of Chronic Conditions (R21 Clinical Trial Optional)	National Institute of Nursing Research/NIH/DHHS	PAR-19-382	07-May-2022	400,000 USD
	<p>Contact Name Karen Huss, PhD, RN, APRN-BC, FAAN, FAAAAI</p> <p>Contact Telephone 301-594-5970</p> <p>Contact Email hussk@mail.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2022 , 16-Jun-2022 , 16-Jul-2022 , 07-Sep-2022 , 16-Feb-2023 , 16-Mar-2023 , 07-May-2023</p> <p>Synopsis The purpose of this Funding Opportunity Announcement is to encourage grant applications that address the influence of patient activation on self-management of chronic conditions.</p>				
084550	Palliative Care in Home and Community Settings (R21 Clinical Trial Optional)	National Institute of Nursing Research/NIH/DHHS	PAR-19-320	07-May-2022	275,000 USD

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Name Karen A. Kehl, PhD, RN, FPCN</p> <p>Contact Telephone 301-594-8010</p> <p>Contact Email karen.kehl@mail.nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2022 , 16-Jun-2022 , 07-Sep-2022</p> <p>Synopsis The purpose of this funding opportunity is to stimulate research aimed at determining needs and best practices for the integration of palliative care into home and community settings. Home and community in this FOA refer to the place where an individual resides or lives. Home- and community-based palliative care programs ensure those with serious, advanced illness who do not require hospitalization but are not appropriate for hospice have access to high quality end-of-life and palliative care.</p>				
108054	Notice of Special Interest (NOSI): Research on Pain, Pain Management, and Opioids in Aging	National Institute on Aging/NIH/DHHS	NOT-AG-22-004	05-Apr-2022	Not Specified
	<p>Contact Name Devon Oskvig, Ph.D.</p> <p>Contact Telephone 301-827-5899</p> <p>Contact Email devon.oskvig@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 05-Apr-2022 , 12-Apr-2022 , 25-Apr-2022 , 07-May-2022 , 25-May-2022 , 05-Jun-2022 , 12-Jun-2022 , 16-Jun-2022 , 25-Jun-2022 , 08-Aug-2022 , 12-Aug-2022 , 05-Sep-2022 , 07-Sep-2022 , 25-Sep-2022 , 05-Oct-2022 , 12-Oct-2022 , 16-Oct-2022 , 25-Oct-2022 , 08-Dec-2022 , 12-Dec-2022 , 05-Jan-2023 , 07-Jan-2023 , 25-Jan-2023 , 05-Feb-2023 , 12-Feb-2023 , 16-Feb-2023 , 25-Feb-2023 , 05-Apr-2023 , 08-Apr-2023 , 12-Apr-2023 , 25-Apr-2023 , 07-May-2023 , 25-May-2023 , 05-Jun-2023 , 12-Jun-2023 , 16-Jun-2023 , 25-Jun-2023 , 08-Aug-2023 , 12-Aug-2023 , 05-Sep-2023 , 07-Sep-2023 , 25-Sep-2023 , 05-Oct-2023 , 12-Oct-2023 , 16-Oct-2023 , 25-Oct-2023 , 08-Dec-2023 , 12-Dec-2023 , 05-Jan-2024 , 07-Jan-2024 , 25-Jan-2024 , 05-Feb-2024 , 12-Feb-2024 , 16-Feb-2024 , 25-Feb-2024 , 05-Apr-2024 , 08-Apr-2024 , 07-May-2024 , 25-May-2024 , 05-Jun-2024 , 12-Jun-2024 , 16-Jun-2024 , 25-Jun-2024 , 08-Aug-2024 , 05-Sep-2024 , 07-Sep-2024 , 25-Sep-2024 , 12-Oct-2024 , 25-Oct-2024 , 05-Jan-2025 , 08-Dec-2025</p> <p>Synopsis The purpose of this Notice of Special Interest (NOSI) is to highlight that the National Institute on Aging (NIA) is interested in receiving grant applications focused on pain, pain management, and opioids related to aging or older adults and within NIA's</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		<p>mission areas. This NOSI invites research applications that focus on improving the understanding of mechanisms underlying pain experience with aging; enhancing assessment, prevention, and management strategies for pain in older adults; and improving health equity of aging populations suffering with pain. New applications, resubmissions, competing renewals, and competing revisions to existing awards are all encouraged through this NOSI. For administrative supplements focused on pain, pain management, and opioids related to aging or older adults and within NIA's mission areas, please see NOT-AG-22-005.</p>			
108233	RFA-AG-23-008 -- Pharmacokinetic and Pharmacodynamic (PK/PD) Studies of mTOR Inhibitors on Aging-Related Indications (U01 Clinical Trial Required)	National Institute on Aging/NIH/DHHS	RFA-AG-23-008	14-Apr-2022 [Optional][LOI/Pre-App]	Not Specified
	<p>Contact Name: Irina Sazonova, Ph.D. Contact Telephone: 301-435-3048 Contact Email: irina.sazonova@nih.gov Sponsor Website: Program URL: Link to program URL Deadline Dates (ALL): 14-Apr-2022 [Optional][LOI/Pre-App], 15-Jun-2022 Synopsis: This Funding Opportunity Announcement (FOA) invites applications for pharmacokinetic and pharmacodynamic (PK/PD) studies of mTOR inhibitors in populations living with different aging-related diseases or in relatively healthy older adult populations at risk for a variety of aging conditions. The studies will be funded by individual awards but will be required to interact as a network to exchange information, possibly develop harmonized measures, and pool data to facilitate broader assessment of the effects on multiple aging-related outcomes and mechanisms affected by mTOR modulation.</p>				
107099	RFA-RM-22-003 -- Cellular Senescence Network: Murine Tissue Mapping Centers (U54 - Clinical Trial Not Allowed)	National Institute on Aging/NIH/DHHS	RFA-RM-22-003	07-May-2022	Not Specified
	<p>Contact Name: Viviana Perez, Ph.D. Contact Telephone: 240-328-7301 Contact Email: viviana.perezmontes@nih.gov Sponsor Website: Program URL: Link to program URL Deadline Dates (ALL): 07-May-2022 , 05-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 07-May-2023 , 05-Jun-2023 , 07-Sep-2023 , 05-Oct-2023 , 07-Jan-2024 , 05-Feb-2024 , 07-May-2024 , 05-Jun-2024 , 07-Sep-2024 , 05-Oct-2024 , 07-Jan-2025</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

Synopsis The purpose of this Funding Opportunity Announcement (FOA) is to establish state-of-the-art Tissue Mapping Centers (TMCs) within the Cellular Senescence Network (SenNet) to build an atlas of cellular senescence in mice. The overarching goal of the SenNet consortium is to identify and functionally characterize, at single-cell resolution, the heterogeneity of senescent cells across multiple human tissues in health and lifespan. A previous FOA (RFA-RM-21-008) established the TMCs to generate data and build maps in humans. The purpose of this FOA is to solicit applications that complement the human effort by generating an atlas of cell senescence in mice that will help inform the ongoing effort in humans and serve as a blueprint for future translational research performed in mice. Through collaborative efforts, the murine component of the consortium will generate a multimodal, multidimensional atlas of senescent cells in various murine tissues (tissue choices will be predominantly dictated by the corresponding human tissues already in use within the SenNet consortium); develop innovative tools and technologies to identify and characterize senescent cells; and aggregate data across the Network into a searchable atlas of murine Cellular Senescence. The TMCs solicited through this RFA will create high-resolution, high-content, multiscale biomarkers and maps of cellular senescence across the murine lifespan, to generate a murine-specific companion to the human Senescence atlas. The mouse component of the SenNet consortium will initially focus on healthy murine tissues (modified disease models are not allowed) derived from both inbred and outbred mouse strains that are commonly used and have demonstrated value in pre-clinical research. TMCs will be expected to integrate and optimize all parts of the data generation pipeline, from tissue collection and preservation through analyses at organ-, tissue- and single-cell- level using omics, imaging and other approaches, to data integration, analysis and interpretation. This Funding Opportunity Announcement (FOA) is developed as a Common Fund initiative (<http://commonfund.nih.gov/>) through the NIH Office of the NIH Director, Office of Strategic Coordination (<https://dpcpsi.nih.gov/>). All NIH Institutes and Centers participate in Common Fund initiatives. The FOA will be administered by the National Institute on Aging (NIA) (<https://www.nia.nih.gov>) on behalf of the NIH.

102443	Notice of Special Interest (NOSI): Neurological and Neurocognitive Sequelae from SARS-CoV-2 Infection and COVID-19 in Aging and Age-Related Neurodegeneration	National Institute on Aging/NIH/DHHS	NOT-AG-21-016	07-May-2022	Not Specified
--------	---	--------------------------------------	---------------	-------------	---------------

Contact Name	Mirosław Mackiewicz, Ph.D.
Contact Telephone	301-496-9350
Contact Email	miroslaw.mackiewicz@nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	07-May-2022 , 05-Jun-2022 , 16-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 16-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 16-Feb-2023 , 07-May-2023

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Synopsis	The purpose of this Notice of Special Interest (NOSI) is to inform applicants to the National Institute on Aging (NIA) of NIA's interest in basic and clinical mechanistic research on neurological and neurocognitive sequelae originating from Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection and Coronavirus Disease 2019 (COVID-19) in aging and age-related neurodegeneration.			
101790	NIA Academic Leadership Career Award (K07 Independent Clinical Trial Not Allowed)	National Institute on Aging/NIH/DHHS	PAR-21-106	07-May-2022	Not Specified
	Contact Name				
	Contact Telephone				
	Contact Email	NIAttraining@nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	07-May-2022 , 12-Jun-2022 , 07-Sep-2022 , 12-Oct-2022 , 07-Jan-2023 , 12-Feb-2023 , 07-May-2023 , 12-Jun-2023 , 07-Sep-2023 , 12-Oct-2023 , 07-Jan-2024 , 12-Feb-2024 , 07-May-2024			
	Synopsis	The objective of the NIA Academic Leadership Career Award (K07) is to provide support for senior investigators who have the expertise and leadership skills to enhance aging and geriatric research capacity within their academic institution. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary clinical trial. Applicants to this FOA are permitted to propose research experience in a clinical trial led by another investigator.			
100297	Notice of Special Interest (NOSI): Integrative Studies of Neural Mechanisms Underlying Fundamental Affective Processes in Aging	National Institute on Aging/NIH/DHHS	NOT-AG-21-012	07-May-2022	Not Specified
	Contact Name	Luci Roberts, Ph.D.			
	Contact Telephone				
	Contact Email	roberlu@mail.nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	07-May-2022 , 05-Jun-2022 , 16-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 16-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 16-Feb-2023 , 07-May-2023 , 05-Jun-2023 , 16-Jun-2023 , 07-Sep-2023 , 05-Oct-2023 , 16-Oct-2023 , 07-Jan-2024			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Synopsis	The purpose of this Notice of Special Interest (NOSI) is to inform applicants of NIA’s interest in research on the neural mechanisms underlying fundamental affective processes in aging. Grant applications are encouraged to 1) extend research on neural mechanisms underlying affective processes into aging models; and/or 2) seek to “reverse translate” clinical research results on affective processes in aging into model systems that support elucidation of fundamental neural mechanisms. NIA also wishes to encourage collaboration among cognitive and affective neuroscientists and/or investigators working at different levels of neurobiological and behavioral analysis.			
086469	Aging Research Dissertation Awards to Increase Diversity (R36 Clinical Trial Not Allowed)	National Institute on Aging/NIH/DHHS	PAR-19-394	07-May-2022	Not Specified
	Contact Name	Shahrooz Vahedi, Ph.D.			
	Contact Telephone	301-496-9322			
	Contact Email	shahrooz.vahedi@nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	07-May-2022 , 16-Jun-2022 , 07-Sep-2022 , 16-Oct-2022 , 07-Jan-2023			
	Synopsis	The purpose of this Funding Opportunity Announcement (FOA) is to provide dissertation awards in all areas of research within NIA’s strategic priorities to increase the diversity of the scientific research workforce engaged in research on aging and aging-related health conditions.			
108346	Notice of Special Interest (NOSI): Analyses of CALERIE Datasets and Biospecimens to Elucidate the Biological Effects and the Behavioral and Psychological Aspects of Sustained Caloric Restriction in Humans	National Institute on Aging/NIH/DHHS	NOT-AG-21-028	07-May-2022	Not Specified
	Contact Name	Chhanda Dutta, Ph.D.			
	Contact Telephone	301-496-4161			
	Contact Email	Chhanda.Dutta@nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	07-May-2022 , 05-Jun-2022 , 16-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 16-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 16-Feb-2023 , 07-May-2023			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Synopsis	The National Institute on Aging (NIA) is issuing this Notice of Special Interest (NOSI) to encourage analyses of the unique research resources generated by the CALERIE (Comprehensive Assessment of Long-term Effects of Reducing Intake of Energy) trial to improve our understanding of the effects of sustained caloric restriction (CR) in humans and its underlying mechanisms.			
108112	RFA-AG-23-009 -- Lipids in Brain Aging and Alzheimer's Disease (AD) and its Related Dementias (ADRD) (R01 Clinical Trial Not Allowed)	National Institute on Aging/NIH/DHHS	RFA-AG-23-009	15-May-2022 [Optional][LOI/Pre-App]	2,500,000 USD
	Contact Name	Amanda DiBattista, Ph.D.			
	Contact Telephone	301-827-3342			
	Contact Email	amanda.dibattista@nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	15-May-2022 [Optional][LOI/Pre-App], 14-Jun-2022			
	Synopsis	The goal of this Funding Opportunity Announcement (FOA) is to support research addressing critical knowledge gaps in our understanding of how lipids contribute to vulnerability and resilience to brain aging and Alzheimer's disease (AD) and its related dementias (ADRD), including research addressing how: 1) lipid droplets affect brain aging and AD, including whether their accumulation is pathological or protective; (2) the periphery interacts with lipids in the aging brain, including whether these could be targets for future biomarkers; (3) APOE and lipid-mediated signaling influence brain aging and AD/ADRD progression; and (4) myelin lipids and their signaling contribute to brain aging and AD/ADRD.			
109174	RFA-AG-23-005 -- Health Equity and the Cost of Novel Treatments for Alzheimer's Disease and Related Dementias (R61/R33 Clinical Trial Not Allowed)	National Institute on Aging/NIH/DHHS	RFA-AG-23-005	01-Jun-2022 [Optional][LOI/Pre-App]	Not Specified
	Contact Name	Priscilla Novak, Ph.D., MPH			
	Contact Telephone	301-401-3136			
	Contact Email	NIANovelTreatmentsRFA@nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	01-Jun-2022 [Optional][LOI/Pre-App], 01-Jul-2022			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Synopsis	<p>This Funding Opportunity Announcement (FOA) invites R61/R33 applications to address health equity, drug costs, and access to new therapeutics or repurposed drugs for Alzheimer's disease (AD) and Alzheimer's disease-related dementias (ADRD). Successful applications will seek to identify preferences for pharmacological treatment among racial and ethnic minority people living with AD/ADRD, assess whether cost barriers to pharmacological care exist for racial and ethnic minority people living with AD/ADRD, and quantify expenditures and health-related quality of life (HRQoL) among people interested in receiving novel or repurposed drugs for AD/ADRD. This FOA supports a study development phase (R61) to conduct rigorous stakeholder engagement with racial and ethnic minority groups to identify, measure, and assess the demand for new and repurposed drugs. If successful, grantees will transition to an R33 phase for implementation of rigorous modeling of costs and health-related quality of life and dissemination of model findings.</p>			
109243	RFA-AG-23-014 -- Mechanisms of Brain Hypoperfusion in AD/ADRD (R01 Clinical Trial Not Allowed)	National Institute on Aging/NIH/DHHS	RFA-AG-23-014	01-Jun-2022 [Optional][LOI/Pre-App]	Not Specified
	Contact Name	Miroslaw 'Mack' Mackiewicz, Ph.D.			
	Contact Telephone	301-594-7636			
	Contact Email	miroslaw.mackiewicz@nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	01-Jun-2022 [Optional][LOI/Pre-App], 01-Jul-2022			
	Synopsis	<p>This Funding Opportunity Announcement (FOA) solicits applications for projects designed to understand molecular and cellular mechanisms underlying cerebral blood flow reduction in Alzheimer's disease (AD) and Alzheimer's disease-related dementias (ADRD).</p>			
107991	RFA-AG-23-003 -- Resources to Promote Coordination and Collaboration across Deeply Phenotyped Longitudinal Behavioral and Social Studies of Aging (U24 Clinical Trial Not Allowed)	National Institute on Aging/NIH/DHHS	RFA-AG-23-003	01-Jun-2022 [Optional][LOI/Pre-App]	1,600,000 USD
	Contact Name	Janine Simmons, M.D., Ph.D.			
	Contact Telephone	301-529-7254			
	Contact Email	janine.simmons@nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Deadline Dates (ALL) 01-Jun-2022 [Optional][LOI/Pre-App], 01-Jul-2022</p> <p>Synopsis This Funding Opportunity Announcement (FOA) invites applications to establish a Resource Development Network focused on the infrastructure needed to promote and support coordination, collaboration, and innovation across deeply phenotyped longitudinal behavioral and social studies of aging that are rich in psychological, behavioral, and biobehavioral content. This FOA calls for investigator teams to design an innovative network that will serve the field at large and advance collaboration and coordination among studies. Network activities are expected to include: Outreach to investigators and support for meetings that will stimulate innovation and collaboration. Creation of a publicly available meta-data catalogue on a web-based platform that will identify and describe existing deeply phenotyped behavioral and social datasets characterized by rich psychological, behavioral, and biobehavioral content; identify studies with overlapping measures or compatible designs; and support cross-project co-analysis. Methodological consultation services for investigators. Pilot support for collaborative teams to leverage existing deeply phenotyped longitudinal studies to answer new questions of relevance to aging and the adult lifespan, including the influence of social and behavioral factors on healthspan and biological aging; address replication and generalizability issues; and provide educational opportunities for the next generation of investigators.</p>				
082123	Cognitive Systems Analysis of Alzheimer's Disease Genetic and Phenotypic Data (U01 Clinical Trial Not Allowed)	National Institute on Aging/NIH/DHHS	PAR-19-269	05-Jun-2022	Not Specified
	<p>Contact Name Marilyn Miller, Ph.D.</p> <p>Contact Telephone 301-496-9350</p> <p>Contact Email millerm@nia.nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 05-Jun-2022</p> <p>Synopsis This Funding Opportunity Announcement (FOA) invites applications that propose Artificial Intelligence (AI), Machine Learning (ML), and/or Deep Learning (DL) approaches, collectively referred to here as "cognitive systems," that lead to the identification of gene mutations/variants that cause or contribute to the risk of or protection against the development of Alzheimer's disease (AD) and Alzheimer's disease related dementias (ADRD) via analysis of a variety of genetic, genomic, and biomarker data that are currently available to the research community.</p>				
083316	Non-Invasive Neurostimulation in AD/ADRD (R01 Clinical Trial Optional)	National Institute on Aging/NIH/DHHS	PAR-19-298	05-Jun-2022	Not Specified
	Contact Name Kristina McLinden				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Telephone 301-827-2563</p> <p>Contact Email kristina.mclinden@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 05-Jun-2022</p> <p>Synopsis The goal of this Funding Opportunity Announcement (FOA) is to encourage applications for studies using non-invasive neurostimulation/neuromodulation in the treatment of Alzheimer's disease (AD) or Alzheimer's disease-related dementias (ADRD). The goal of this FOA is to establish initial efficacy of neurostimulation/neuromodulation in the treatment of AD/ADRD or to refine these interventions for AD/ADRD patients. Multimodal or combination interventions are allowed, provided the focus and innovative component is neurostimulation. Applications that seek to develop devices, tools, or invasive techniques are outside the scope of this FOA.</p>				
083523	NIA Multi-site Clinical Trial Implementation Grant (R01 Clinical Trial Required)	National Institute on Aging/NIH/DHHS	PAR-19-302	05-Jun-2022	Not Specified
	<p>Contact Name Sergei Romashkan, M.D., Ph.D.</p> <p>Contact Telephone 301-435-3047</p> <p>Contact Email romashks@mail.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 05-Jun-2022</p> <p>Synopsis This Funding Opportunity Announcement (FOA) invites applications for implementation of investigator-initiated multi-site interventional clinical trials (all phases). The trials should be hypothesis-driven, milestone-defined, and related to NIA's research mission. Information about NIA's mission can be found on the NIA website.</p>				
084767	Limited Competition: Renewals of, and Revisions and Resubmissions to, the Longitudinal Early-onset Alzheimer's Disease Study (LEADS) Cooperative Agreement (U01 Clinical Trial Not Allowed)	National Institute on Aging/NIH/DHHS	PAR-19-338	05-Jun-2022	Not Specified
	<p>Contact Name John K. Hsiao, M.D.</p> <p>Contact Telephone 301-496-9350</p> <p>Contact Email jhsiao@mail.nih.gov</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 05-Jun-2022</p> <p>Synopsis This FOA invites revision, resubmission, or renewal applications to the Longitudinal Early-onset Alzheimer’s Disease Study (LEADS) Cooperative Agreement. Revision applications may not request funding beyond the project end date of the Parent award.</p>				
100902	Alzheimer's Clinical Trials Consortium (ACTC) Clinical Trials (R01 Clinical Trial Required)	National Institute on Aging/NIH/DHHS	PAR-20-309	05-Jun-2022	Not Specified
	<p>Contact Name Laurie Ryan, Ph.D.</p> <p>Contact Telephone 301-496-9350</p> <p>Contact Email ryanl@mail.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 05-Jun-2022 , 05-Oct-2022 , 05-Feb-2023 , 05-Jun-2023 , 05-Oct-2023</p> <p>Synopsis This Funding Opportunity Announcement (FOA) invites applications to develop and implement Phase Ib to III clinical trials of promising pharmacological and non-pharmacological interventions that may prevent, delay, or treat the symptoms of Alzheimer's disease (AD) and other age-related dementias using the Alzheimer's disease Clinical Trials Consortium (ACTC) trial coordination and management infrastructure.</p>				
081010	Pragmatic Clinical Trial on Efficacy of Managing Reduced Iron Stores on Risk of Clinically Important Events in Older Adults with Heart Failure and Anemia (U01 Clinical Trial Required)	National Institute on Aging/NIH/DHHS	PA-19-230	05-Jun-2022	Not Specified
	<p>Contact Name Sergei Romashkan, MD, Ph.D.</p> <p>Contact Telephone 301-435-3047</p> <p>Contact Email romashks@nia.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 05-Jun-2022</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Synopsis	This FOA invites applications for a pragmatic clinical trial to establish efficacy of managing reduced iron stores on risk of clinically important events in older adults with heart failure and anemia.			
091505	Translational Bioinformatics Approaches to Advance Drug Repositioning and Combination Therapy Development for Alzheimer's Disease (R01 Clinical Trial Optional)	National Institute on Aging/NIH/DHHS	PAR-20-156	05-Jun-2022	Not Specified
	Contact Name	Jean Yuan, Ph.D.			
	Contact Telephone	301-496-9350			
	Contact Email	yuanx4@mail.nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	05-Jun-2022 , 05-Oct-2022 , 05-Feb-2023			
	Synopsis	This Funding Opportunity Announcement (FOA) enables data-driven drug repositioning and combination therapy for Alzheimer's disease and Alzheimer's disease-related dementias (AD/ADRD) by developing computational methods and data resources and/or integrating computational approaches with proof-of-concept efficacy studies in cell-based models, animal models, and/or humans.			
107419	Alzheimer's Drug-Development Program (U01 Clinical Trial Optional)	National Institute on Aging/NIH/DHHS	PAR-22-047	05-Jun-2022	5,000,000 USD
	Contact Name	Lorenzo M. Refolo, Ph.D.			
	Contact Telephone	301-594-7576			
	Contact Email	refolol@nia.nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	05-Jun-2022 , 05-Oct-2022 , 05-Feb-2023 , 05-Jun-2023 , 05-Oct-2023 , 05-Feb-2024 , 05-Jun-2024 , 05-Oct-2024			
	Synopsis	The goal of this Funding Opportunity Announcement (FOA) is to provide funding support for the pre-clinical and early stage clinical (Phase I) development of novel small-molecule and biologic drug candidates that prevent Alzheimer's disease (AD), slow its progression, or treat its cognitive and behavioral symptoms. Participants in this program will receive funding for therapy development activities such as medicinal chemistry; pharmacokinetics (PK); Absorption, Distribution, Metabolism, Excretion, Toxicology (ADMET); efficacy in animal models; formulation development; chemical synthesis under Good			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		<p>Manufacturing Practices (GMP); Investigational New Drug (IND) enabling studies; and initial Phase I clinical testing. Applications not responsive to this FOA include: research on basic mechanisms of disease or mechanisms of drug action; development of biomarkers, devices, non-pharmacological interventions (e.g., exercise, diet, cognitive training), repurposed drugs and combinations therapies; discovery activities such as high-throughput screening and hit optimization; and stand-alone clinical trials.</p>			
108328	Early and Late Stage Clinical Trials for the Spectrum of Alzheimer’s Disease/Alzheimer’s Related Dementias and Age-Related Cognitive Decline (R01 Clinical Trial Optional)	National Institute on Aging/NIH/DHHS	PAR-18-878	05-Jun-2022	Not Specified
	<p>Contact Name Laurie Ryan Contact Telephone 301-496-9350 Contact Email ryanl@mail.nih.gov Sponsor Website Program URL Link to program URL Deadline Dates (ALL) 05-Jun-2022 , 05-Oct-2022 , 05-Feb-2023 , 05-Jun-2023 , 05-Oct-2023 , 05-Feb-2024 , 05-Jun-2024 , 05-Oct-2024 Synopsis The purpose of this Funding Opportunity Announcement (FOA) is to 1) invite applications that propose to develop and implement early to late stage clinical trials of promising pharmacological and non-pharmacological interventions for cognitive and neuropsychiatric changes associated with age-related cognitive decline and Alzheimer's disease (AD) and Alzheimer's disease-related Dementias (ADRD) across the spectrum from pre-symptomatic to more severe stages of disease, and 2) stimulate studies to enhance trial design and methods.</p>				
102978	Limited Competition: Alzheimer’s Disease Sequencing Project Follow-Up Study 2.0 (ADSP FUS 2.0): The Diverse Population Initiative (U01 Clinical Trial Not Allowed)	National Institute on Aging/NIH/DHHS	PAR-21-212	05-Jun-2022	Not Specified
	<p>Contact Name Marilyn Miller, Ph.D. Contact Telephone 301-496-9350 Contact Email millerm@nia.nih.gov Sponsor Website Program URL Link to program URL Deadline Dates (ALL) 05-Jun-2022 , 05-Oct-2022 , 05-Feb-2023 , 05-Jun-2023 , 05-Oct-2023 , 05-Feb-2024</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Synopsis	This Funding Opportunity Announcement (FOA) invites applications specific to sample acquisition, genome wide association studies, whole genome sequencing, quality control checking, variant calling, data calling, data sharing, data harmonization, and analysis that will support the generation of data from multi-ethnic cohorts for the Alzheimer's Disease Sequencing Project Follow-Up Study 2.0: The Diverse Population Initiative (ADSP FUS 2.0).			
109301	RFA-AG-23-007 -- Screening for Cognitive Impairment: Decision-Making (U24 Clinical Trial Optional)	National Institute on Aging/NIH/DHHS	RFA-AG-23-007	11-Jun-2022 [Optional][LOI/Pre-App]	10,720,000 USD
	Contact Name	Jonathan W. King, Ph.D.			
	Contact Telephone	301-496-3136			
	Contact Email	NIAScreeningDMFOA@nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	11-Jun-2022 [Optional][LOI/Pre-App], 11-Jul-2022			
	Synopsis	This Funding Opportunity Announcement (FOA) invites research to develop, validate, and disseminate measurement tools that could be used to screen for deficits related to decision-making, planning, and other important higher order functional outcomes in older adults. In particular, we are interested in instruments that can track changes in decision-making capacity that could be useful in the context of future screening for cognitive impairment and the development of interventions targeting functional outcomes in persons living with cognitive impairment and/or quality of life outcomes of their care partners/caregivers. The goal of this FOA is to support a research network whose goals would be to review and assess the dimensions of higher cognitive abilities and functional capacities already believed to support higher order planning and decision-making; to develop valid and reliable measures of those abilities; and to provide support for pilot efforts during the instrument development and validation in a racially, ethnically, geographically, and diagnostically diverse set of participants, as well as a set of enduring resources. Enduring resources include the measurement instruments, documentation, and normative data that will enable other, future projects to incorporate the new measurements into studies.			
106670	NIA Career Transition Award (K22 Independent Clinical Trial Not Allowed)	National Institute on Aging/NIH/DHHS	PAR-21-351	12-Jun-2022	Not Specified
	Contact Name	Saroj Regmi, Ph.D.			
	Contact Telephone	301-480-8964			
	Contact Email	saroj.regmi@nih.gov			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 12-Jun-2022 , 12-Oct-2022 , 12-Feb-2023 , 12-Jun-2023 , 12-Oct-2023 , 12-Feb-2024 , 12-Jun-2024 , 12-Oct-2024</p> <p>Synopsis The purpose of the NIA Career Transition Award (CTA) is to facilitate the transition of mentored researchers to tenure-track faculty positions conducting research that advances the mission of NIA. This award will provide three years of protected time through salary and research support to conduct biomedical research at an extramural sponsoring institution/organization to which the individual has been recruited, been offered, and has accepted a tenure-track full-time assistant professor position (or equivalent). This Funding Opportunity Announcement (FOA) is designed specifically for candidates proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary clinical trial.</p>				
104436	<p>NIA Advanced Postdoctoral Career Transition Awards to Promote Diversity in Translational Research for AD/ADRD (K99/R00 Clinical Trial Not Allowed)</p>	National Institute on Aging/NIH/DHHS	PAR-21-220	12-Jun-2022	Not Specified
	<p>Contact Name Yuan Luo, Ph.D.</p> <p>Contact Telephone 301-496-9350</p> <p>Contact Email yuan.luo@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 12-Jun-2022 , 12-Oct-2022 , 12-Feb-2023 , 12-Jun-2023 , 12-Oct-2023 , 12-Feb-2024 , 12-Jun-2024</p> <p>Synopsis The purpose of this Funding Opportunity Announcement (FOA) is to promote diversity in the translational research workforce for Alzheimer's disease and Alzheimer's disease-related dementias (AD/ADRD). This pathway to independence award will emphasize the development of skills in data science and drug discovery, and their application to various aspects of AD/ADRD research (from populations studies to research that can lead to new treatments and diagnostics, including all aspects of behavioral and social research). This award will support early career investigators from diverse backgrounds to gain critical translational skills in data science and drug discovery and transition to research independence.. The long-term goal of this program is to develop a diverse translational research workforce that can effectively participate in and/or lead a team-science, precision medicine approach to studies of AD/ADRD treatment, prevention, early detection, and disease management and care. This Funding Opportunity Announcement (FOA) is designed for candidates proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary clinical trial. Under this FOA candidates are permitted to propose a research experience in a clinical trial led by a mentor or co-mentor.</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
109431	RFA-AG-23-010 -- Noncoding RNAs in Alzheimer's Disease and Related Dementias (R01 Clinical Trial Not Allowed)	National Institute on Aging/NIH/DHHS	RFA-AG-23-010	15-Jun-2022 [Optional][LOI/Pre-App]	2,500,000 USD
	<p>Contact Name Alison Yao, Ph.D.</p> <p>Contact Telephone 301-827-7264</p> <p>Contact Email yaoal@nia.nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 15-Jun-2022 [Optional][LOI/Pre-App], 15-Jul-2022</p> <p>Synopsis The goal of this Funding Opportunity Announcement (FOA) is to stimulate research in noncoding RNAs (ncRNAs) to investigate the causality, directionality, mechanisms, and therapeutic potential of ncRNAs in Alzheimer's disease and Alzheimer's disease-related dementias (AD/ADRD). This FOA supports applications seeking to discover novel mechanisms mediated by ncRNAs and to elucidate molecular and cellular functions involved in the pathogenesis and progression of AD/ADRD.</p>				
109432	RFA-AG-23-011 -- Noncoding RNAs in Alzheimer's Disease and Related Dementias (R21 Clinical Trial Not Allowed)	National Institute on Aging/NIH/DHHS	RFA-AG-23-011	15-Jun-2022 [Optional][LOI/Pre-App]	275,000 USD
	<p>Contact Name Alison Yao, Ph.D.</p> <p>Contact Telephone 301-827-7264</p> <p>Contact Email yaoal@nia.nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 15-Jun-2022 [Optional][LOI/Pre-App], 15-Jul-2022</p> <p>Synopsis The goal of this Funding Opportunity Announcement (FOA) is to stimulate research in noncoding RNAs (ncRNAs) to investigate the causality, directionality, mechanisms, and therapeutic potential of ncRNAs implicated in Alzheimer's disease and Alzheimer's disease-related dementias (AD/ADRD). This FOA supports exploratory and developmental grant (R21) applications seeking to discover functional roles of ncRNAs and underlying mechanisms involved in the pathogenesis and progression of AD/ADRD. Proposed studies should focus on functional characterization and mechanistic investigation of previously identified ncRNAs.</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
083550	Early-Stage T1 Translational Aging Research (Bench to Bedside) for the Development of Novel Therapeutics (R33 Clinical Trial Optional)	National Institute on Aging/NIH/DHHS	PAR-19-304	16-Jun-2022	1,500,000 USD
	<p>Contact Name Chhanda Dutta, Ph.D.</p> <p>Contact Telephone 301-496-4161</p> <p>Contact Email duttac@nia.nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 16-Jun-2022</p> <p>Synopsis This Funding Opportunity Announcement (FOA) encourages Exploratory/Developmental Phase II (R33) grant applications to facilitate early-stage T1 translation (bench-to-bedside) of discoveries from basic and applied research in aging into novel therapeutics for the prevention and treatment of clinical conditions related to aging or multiple chronic conditions in older people (e.g., sarcopenia, heart failure with preserved ejection fraction (HFpEF), immunosenescence, pulmonary fibrosis, metabolic syndrome, chronic kidney disease). This includes the development of pharmacological strategies such as new classes of compounds (e.g., senolytics, anti-inflammatory agents, modulators of proteostasis and autophagy), natural products (or their derivatives, mimics, and synthetic equivalents), biologics, stem/progenitor cell-based therapies, and the repurposing of Food and Drug Administration (FDA)-approved drugs. Applications submitted in response to this FOA may involve novel treatment targets and/or innovative approaches for engaging known targets. The R33 mechanism is intended to provide milestone-driven support (up to 5 years) for innovative exploratory and developmental research activities originally initiated under the R21 mechanism. Awardees from NIA's R21 T1 translational aging research program are encouraged to apply to this FOA to expand upon the translation of their candidate pharmacological interventions from prior studies. Other applicants with sufficient and strong preliminary/proof-of-concept data (equivalent to that achievable under a R21) for a novel drug target, new compound(s), or for a potential new clinical indication for an FDA-approved drug for age-related conditions are also eligible to apply to this FOA. The scope of early-stage T1 translational research activities to be conducted under the R33 is expected to vary with the stage of translation of the candidate therapeutic. Nevertheless, the R33 support should advance the experimental intervention closer to human testing (if warranted). The development of non-pharmacological interventions is considered outside the scope of this FOA. Applications that focus on Alzheimer's disease or its related dementias are outside the scope of this announcement.</p>				
083551	Early-Stage T1 Translational Aging Research (Bench to Bedside) for the Development of Novel Therapeutics (R21/R33 Clinical Trial Optional)	National Institute on Aging/NIH/DHHS	PAR-19-305	16-Jun-2022	Not Specified
	<p>Contact Name Chhanda Dutta, Ph.D.</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Telephone 301-496-4161</p> <p>Contact Email duttac@nia.nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 16-Jun-2022</p> <p>Synopsis This Funding Opportunity Announcement (FOA) encourages Exploratory/Developmental Phased Innovation (R21/R33) grant applications to facilitate early-stage T1 translation (bench-to-bedside) of discoveries from basic and applied research in aging into novel therapeutics for the prevention and treatment of clinical conditions related to aging and/or multiple chronic conditions in older people (e.g., sarcopenia, heart failure with preserved ejection fraction (HFpEF), immunosenescence, metabolic syndrome, chronic kidney disease). This includes the development of pharmacological strategies such as new classes of compounds (e.g., senolytics, anti-inflammatory agents, modulators of proteostasis and autophagy), natural products (or their derivatives, mimics, and synthetic equivalents), biologics, stem/progenitor cell-based therapies, and the repurposing of Food and Drug Administration (FDA)-approved drugs. This FOA provides support for up to two years (R21, milestone-driven exploratory phase) for preliminary, proof-of-concept studies, which is followed by up to three years of support (R33 phase) for further/expanded preclinical development of the candidate therapeutic. Applicants may request funds for the development of assays and other methodologies required for translational studies in the project budget for the R21 and/or R33 phases. Funding for the R33 phase will be contingent on successful completion of established milestones in the R21 phase. The development of non-pharmacological interventions is considered outside the scope of this FOA. Applications that focus on Alzheimer's disease or its related dementias are outside the scope of this announcement. Applications using only the R21 mechanism will not be accepted under this FOA.</p>				
086244	<p>Small Research Grant Program for the Next Generation of Researchers in AD/ADRD Research: Area of Focus Archiving and Leveraging Existing Data Sets for Analyses (R03 Clinical Trial Not Allowed)</p>	National Institute on Aging/NIH/DHHS	PAS-19-391	16-Jun-2022	200,000 USD
	<p>Contact Name Partha Bhattacharyya, Ph.D.</p> <p>Contact Telephone 301-496-3136</p> <p>Contact Email bhattacharyyap@mail.nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 16-Jun-2022 , 16-Oct-2022</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Synopsis This Small Research Grant (R03) will support important and innovative projects to provide needed scientific insight to improve the prevention, diagnosis, treatment, and/or care for individuals with Alzheimer's disease and Alzheimer's disease-related dementias (AD/ADRD). Specifically, this FOA will support archiving and leveraging existing data sets for analyses of projects covering a wide array of topics relating to AD/ADRD. The overall goal of this FOA is (i) to encourage the next generation of U.S. researchers to pursue research and academic careers in neuroscience, AD/ADRD, and healthy brain aging and (ii) to stimulate established researchers who are not currently doing AD/ADRD research to perform pilot studies developing new, innovative AD/ADRD research programs that leverage and build upon their existing expertise. Individuals from underrepresented racial and ethnic groups, as well as individuals with disabilities, are always encouraged to apply for NIH support.</p>				
086248	Small Research Grant Program for the Next Generation of Researchers in AD/ADRD Research: Area of Focus Basic Science (R03 Clinical Trials Not Allowed)	National Institute on Aging/NIH/DHHS	PAS-19-392	16-Jun-2022	200,000 USD
	<p>Contact Name Lisa Opanashuk, Ph.D. Contact Telephone 301-807-5422 Contact Email lisa.opanashuk@nih.gov Sponsor Website Program URL Link to program URL Deadline Dates (ALL) 16-Jun-2022 , 16-Oct-2022</p> <p>Synopsis This Small Research Grant (R03) will support important and innovative projects focused on basic science approaches to elucidate neurodegenerative mechanisms/pathways of Alzheimer's disease and Alzheimer's disease-related dementias (AD/ADRD). Proposed projects should ultimately aim to improve the prevention, diagnosis, treatment, and/or care for individuals with AD/ADRD. The program seeks (i) to facilitate the next generation of researchers in the United States to pursue research and academic careers in neuroscience, AD/ADRD, and healthy brain aging and (ii) to stimulate established researchers who are not currently doing AD/ADRD research to perform pilot studies toward developing new, innovative AD/ADRD research programs that leverage and build upon their existing expertise. Individuals from underrepresented racial and ethnic groups, as well as individuals with disabilities, are always encouraged to apply for NIH support.</p>				
086252	Small Research Grant Program for the Next Generation of Researchers in AD/ADRD Research: Area of Focus Systems Biology (R03 Clinical Trial Not Allowed)	National Institute on Aging/NIH/DHHS	PAS-19-393	16-Jun-2022	200,000 USD
	<p>Contact Name Alison Yao, Ph.D.</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Telephone 301-496-9350</p> <p>Contact Email alison.yao@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 16-Jun-2022 , 16-Oct-2022</p> <p>Synopsis This Small Research Grant Program (R03) will support important and innovative system biology projects in which more scientific insight is needed to improve the prevention, diagnosis, treatment, and care for individuals with Alzheimer's disease and Alzheimer's disease-related dementias (AD/ADRD). The overall goal of this R03 program is (i) to facilitate the next generation of researchers in the United States to pursue research and academic careers in neuroscience, AD/ADRD, and healthy brain aging and (ii) to stimulate established researchers who are not currently doing AD/ADRD research to perform pilot studies toward developing new, innovative AD/ADRD research programs that leverage and build upon their existing expertise. Individuals from underrepresented racial and ethnic groups, as well as individuals with disabilities, are always encouraged to apply for NIH support.</p>				
108329	Pilot Studies for the Spectrum of Alzheimer's Disease/Alzheimer's Disease-Related Dementias and Age-Related Cognitive Decline (R61 Clinical Trial Optional)	National Institute on Aging/NIH/DHHS	PAR-21-360	17-Jun-2022	650,000 USD
	<p>Contact Name Laurie Ryan</p> <p>Contact Telephone 301-496-9350</p> <p>Contact Email ryanl@mail.nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 17-Jun-2022 , 18-Oct-2022 , 17-Feb-2023 , 19-Jun-2023 , 18-Oct-2023 , 20-Feb-2024 , 18-Jun-2024 , 18-Oct-2024</p> <p>Synopsis The purpose of this Funding Opportunity Announcement (FOA) is to 1) invite research grant applications that enable the collection of pilot data to support early stage testing of promising pharmacological and non-pharmacological interventions for cognitive and neuropsychiatric changes associated with age-related cognitive decline and Alzheimer's disease (AD) and Alzheimer's disease-related dementias (ADRD) across the spectrum from pre-symptomatic to more severe stages of disease, and 2) stimulate studies to enhance trial design and methods.</p>				
101458	Notice of Special Interest (NOSI): Alcohol-induced Tissue-specific and Organ System Diseases (R01/R21/R03)	National Institute on Alcohol Abuse and Alcoholism/NIH/DHHS	NOT-AA-20-024	07-May-2022	Not Specified

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Name Li Lin</p> <p>Contact Telephone 301-827-7749</p> <p>Contact Email linli@mail.nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2022 , 05-Jun-2022 , 16-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 16-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 16-Feb-2023 , 07-May-2023 , 05-Jun-2023 , 16-Jun-2023 , 07-Sep-2023 , 05-Oct-2023 , 16-Oct-2023 , 07-Jan-2024 , 05-Feb-2024 , 16-Feb-2024 , 07-May-2024</p> <p>Synopsis The purpose of this Notice is to inform potential applicants of the NIAAA's special interest in research project applications studying the harmful effects of alcohol on the body's tissues, organs, and systems in diverse populations across the lifespan.</p>				
098270	Notice of Special Interest (NOSI): Alcohol and Aging	National Institute on Alcohol Abuse and Alcoholism/NIH/DHHS	NOT-AA-20-019	07-May-2022	Not Specified
	<p>Contact Name Andras Orosz, Ph.D.</p> <p>Contact Telephone 301-443-2193</p> <p>Contact Email orosza@mail.nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2022 , 05-Jun-2022 , 16-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 16-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 16-Feb-2023 , 07-May-2023 , 05-Jun-2023 , 16-Jun-2023 , 07-Sep-2023</p> <p>Synopsis The purpose of this Notice of Special Interest (NOSI) is to promote research to improve our understanding of the effects of alcohol consumption on aging across different levels of biological organization including the molecular, cellular, tissue, organ, organism, and societal levels. The following broad research areas will be encouraged: 1) Basic and clinical research defining the effects of alcohol consumption on lifespan, health span, and age-related diseases depending on level of alcohol consumption, drinking pattern, and duration of drinking; 2) Research to inform evidence-based guidance for identifying risk for alcohol use disorder (AUD) among older adults as well as prevention, diagnosis, and treatment of AUD in this population; and 3) Research to extend the health span of older adults who drink and decrease the health care burden of age-related diseases associated with alcohol use.</p>				
097916	Notice of Special Interest (NOSI): Secondary Analyses of Existing Alcohol Research Data	National Institute on Alcohol Abuse and Alcoholism/NIH/DHHS	NOT-AA-20-018	07-May-2022	Not Specified

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Name Wenxing Zha, Ph.D.</p> <p>Contact Telephone 301-443-0633</p> <p>Contact Email zhaw@mail.nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2022 , 05-Jun-2022 , 05-Jun-2022 , 16-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 16-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 16-Feb-2023 , 07-May-2023 , 16-Jun-2023</p> <p>Synopsis The purpose of this Notice of Special Interest (NOSI) is to solicit applications to support the secondary analyses of existing data sets with the goal of enhancing our understanding of the following: 1) the patterns and trajectories of alcohol consumption, 2) the epidemiology and etiology, including genetics, of alcohol-related problems and disorders, and 3) alcohol-related health services and health systems, including access, quality, and efficiency. This Notice encourages applications proposing innovative analyses of existing alcohol research data, answering novel research hypotheses and questions, and developing and testing advanced analytical methodologies applicable to alcohol related epidemiological, behavioral and genetics research.</p>				
100945	Notice of Special Interest (NOSI): Advances in Research for the Treatment, Services, and Recovery of Alcohol Use Disorder	National Institute on Alcohol Abuse and Alcoholism/NIH/DHHS	NOT-AA-20-022	07-May-2022	Not Specified
	<p>Contact Name Brett T. Hagman, Ph.D.</p> <p>Contact Telephone 301-443-0638</p> <p>Contact Email brett.hagman@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2022 , 05-Jun-2022 , 16-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 16-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 16-Feb-2023 , 07-May-2023 , 05-Jun-2023 , 16-Jun-2023 , 07-Sep-2023</p> <p>Synopsis The purpose of this Notice of Special Interest (NOSI) is to advance research on various topics that fall within NIAAA's Division of Treatment and Recovery Research (DTRR). DTRR's research interests are wide-ranging and encompass broad categories such as health services, behavioral therapies and mechanisms of behavioral change (MOBC), recovery, translational research, and innovative methods and technologies for alcohol use disorder (AUD) treatment and sustaining recovery. Other areas of interest include topics focusing on special-emphasis and underserved populations, including NIH-designated U.S. health disparity populations, as well as those with co-occurring disorders; and fetal alcohol spectrum disorders (FASD). In all</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

studies, at all levels from FASD to elderly, efforts will be made to include participants that reflect the diversity of the population at large.

105028	Notice of Special Interest (NOSI): Genetics of Alcohol Sensitivity and Tolerance	National Institute on Alcohol Abuse and Alcoholism/NIH/DHHS	NOT-AA-21-029	07-May-2022	Not Specified
--------	--	---	---------------	-------------	---------------

Contact Name	Hemin Chin, PhD
Contact Telephone	301-443-1282
Contact Email	hemin.chin@nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	07-May-2022 , 05-Jun-2022 , 16-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 16-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 16-Feb-2023 , 07-May-2023 , 05-Jun-2023 , 16-Jun-2023 , 07-Sep-2023 , 05-Oct-2023 , 16-Oct-2023 , 07-Jan-2024 , 05-Feb-2024 , 16-Feb-2024 , 07-May-2024 , 05-Jun-2024
Synopsis	The purpose of this notice of special interest (NOSI) is to provide enhanced understanding of genetic, genomic, and epigenetic factors contributing to biological processes for individual variation in sensitivity, the development of tolerance, and progression to AUD. NIAAA is interested in projects that will develop innovative strategies integrating both experimental and bioinformatics approaches to establish causality for candidate genes from GWAS and linkage studies and to provide insights into genetic mechanisms of alcohol sensitivity and the development of tolerance through investigation of genomic, epigenetic, or transcriptional variation, and gene network and pathway analyses. Applicants are encouraged to consider model systems in which these complex relationships can be better studied under defined genetic backgrounds and well-controlled environmental conditions.

107782	Notice of Special Interest (NOSI): Epidemiology and Prevention of Alcohol Misuse in Understudied Young Adult Populations; Military, Workforce, and Community College	National Institute on Alcohol Abuse and Alcoholism/NIH/DHHS	NOT-AA-22-001	05-Jun-2022	Not Specified
--------	--	---	---------------	-------------	---------------

Contact Name	Bradley Kerridge, Ph.D.
Contact Telephone	301-827-7493
Contact Email	bradley.kerridge@nih.gov
Sponsor Website	
Program URL	Link to program URL

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Deadline Dates (ALL) 05-Jun-2022 , 16-Jun-2022 , 05-Sep-2022 , 07-Sep-2022 , 27-Sep-2022 , 05-Oct-2022 , 16-Oct-2022 , 05-Jan-2023 , 07-Jan-2023 , 26-Jan-2023 , 05-Feb-2023 , 16-Feb-2023 , 05-Apr-2023 , 07-May-2023 , 26-May-2023 , 05-Jun-2023 , 16-Jun-2023 , 05-Sep-2023 , 07-Sep-2023 , 26-Sep-2023 , 05-Oct-2023 , 16-Oct-2023 , 05-Jan-2024 , 07-Jan-2024 , 05-Feb-2024 , 16-Feb-2024 , 05-Apr-2024 , 07-May-2024 , 05-Jun-2024 , 16-Jun-2024 , 05-Sep-2024 , 07-Sep-2024 , 05-Oct-2024 , 16-Oct-2024 , 05-Jan-2025 , 07-Jan-2025 , 05-Feb-2025 , 16-Feb-2025 , 05-Apr-2025 , 07-May-2025 , 05-Jun-2025 , 16-Jun-2025 , 05-Sep-2025 , 07-Sep-2025</p> <p>Synopsis The purpose of this future grant application solicitation is to balance the NIAAA research portfolio by supporting research on alcohol misuse among persons aged 18 to 29 who are not enrolled in four-year colleges or universities. These persons are commonly in the military, workforce, or community college populations, which are understudied relative to their age peers in four-year colleges. Research on epidemiology, prevention, and screening centered on these understudied populations are all encouraged.</p>				
104867	Mechanisms of Alcohol Tolerance (R21/R33 Clinical Trial Optional)	National Institute on Alcohol Abuse and Alcoholism/NIH/DHHS	PAR-21-250	16-Jun-2022	1,775,000 USD
	<p>Contact Name Elizabeth M Powell, PhD</p> <p>Contact Telephone 301-443-0786</p> <p>Contact Email elizabeth.powell3@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 16-Jun-2022 , 16-Oct-2022 , 16-Feb-2023 , 16-Jun-2023 , 16-Oct-2023 , 16-Feb-2024 , 16-Jun-2024</p> <p>Synopsis This funding opportunity announcement (FOA) focuses on sensitivity and tolerance mechanisms underlying the development of alcohol use disorder. The intent of this FOA is to: (1) develop hypotheses about cellular, molecular or network mechanisms that regulate sensitivity and tolerance to alcohol, and (2) develop quantitative models to predict the development of tolerance and the progression to alcohol use disorder. These objectives will be accomplished with a Phased Innovation (R21/R33) mechanism, clinical trial optional, in which secondary data analysis or pilot studies can occur during the R21 phase, and research testing the hypotheses can be expanded in the R33 phase. The transition to the R33 phase will be determined by NIAAA program staff after evaluation of the achievement of specific milestones set for the R21 phase.</p>				
101159	Prevention and Intervention Approaches for Fetal Alcohol Spectrum Disorders (R34 Clinical Trial Optional)	National Institute on Alcohol Abuse and Alcoholism/NIH/DHHS	PAR-21-097	17-Jun-2022	450,000 USD
	<p>Contact Name William Dunty, PhD</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Telephone 301-443-7351</p> <p>Contact Email duntyw@mail.nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 17-Jun-2022 , 18-Oct-2022 , 17-Feb-2023 , 19-Jun-2023 , 17-Oct-2023</p> <p>Synopsis This Funding Opportunity Announcement (FOA) for R34 planning grant applications focuses on prevention and intervention strategies for fetal alcohol spectrum disorders (FASD) throughout the lifespan. The intent of this FOA is to support research that advances (1) prevention approaches to reduce prenatal alcohol exposure and incidence of FASD and (2) interventions for FASD. It is expected that research conducted via this mechanism will consist of studies that are a pre-requisite for preparing and submitting subsequent applications for larger scale FASD prevention or intervention studies. Applicants interested in exploratory phased projects may consider FOA (PAR-21-098, the R61/R33 option).</p>				
101160	Prevention and Intervention Approaches for Fetal Alcohol Spectrum Disorders (R61/R33 Clinical Trial Optional)	National Institute on Alcohol Abuse and Alcoholism/NIH/DHHS	PAR-21-098	17-Jun-2022	Not Specified
	<p>Contact Name William Dunty, PhD</p> <p>Contact Telephone 301-443-7351</p> <p>Contact Email duntyw@mail.nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 17-Jun-2022 , 18-Oct-2022 , 17-Feb-2023 , 19-Jun-2023 , 17-Oct-2023</p> <p>Synopsis This Funding Opportunity Announcement (FOA) focuses on prevention and intervention strategies for fetal alcohol spectrum disorders (FASD) throughout the lifespan. The intent of this FOA is to support research that advances (1) prevention approaches to reduce prenatal alcohol exposure and the incidence of FASD and (2) interventions for FASD. These objectives will be accomplished with the Exploratory/Developmental Phased Award (R61/R33) mechanism, clinical trial optional. The R61 phase will support pilot studies or secondary data analysis for hypothesis development and feasibility, and research testing the hypotheses can be expanded in the R33 phase. The transition to the R33 phase will be determined by NIAAA program staff after evaluation of the achievement of specific milestones set for the R61 phase. Highest priority will be given to applications with clinical trials. Applicants interested in planning clinical trials or adding to current projects may also consider FOA (PAR-21-097, the R34 option).</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
102240	Notice of Special Interest (NOSI): Hearing Healthcare for Adults: Improving Access and Affordability	National Institute on Deafness and Other Communication Disorders/NIH/DHHS	NOT-DC-21-001	05-Apr-2022	Not Specified
	<p>Contact Name Kelly King, Au.D, Ph.D.</p> <p>Contact Telephone 301-402-3458</p> <p>Contact Email kingke@nidcd.nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 05-Apr-2022 , 07-May-2022 , 05-Jun-2022 , 16-Jun-2022 , 05-Sep-2022 , 07-Sep-2022 , 05-Oct-2022 , 16-Oct-2022 , 05-Jan-2023 , 07-Jan-2023 , 05-Feb-2023 , 16-Feb-2023 , 05-Apr-2023 , 07-May-2023 , 05-Jun-2023 , 16-Jun-2023 , 05-Sep-2023 , 07-Sep-2023 , 05-Oct-2023 , 16-Oct-2023 , 05-Jan-2024 , 07-Jan-2024 , 05-Feb-2024 , 16-Feb-2024 , 07-May-2024 , 05-Jun-2024 , 16-Jun-2024 , 07-Sep-2024</p> <p>Synopsis The purpose of this Notice of Special Interest (NOSI) is to encourage applications for research on hearing health care in adults in support of improving access and affordability. Further research is needed to strengthen the evidence base with a goal of delivering better hearing health care outcomes in adults.</p>				
104661	Notice of Special Interest (NOSI): NIDCD Health Disparities and Inequities Research	National Institute on Deafness and Other Communication Disorders/NIH/DHHS	NOT-DC-21-003	08-Apr-2022	Not Specified
	<p>Contact Name Kelly King, Au.D, Ph.D.</p> <p>Contact Telephone 301-402-3458</p> <p>Contact Email kingke@nidcd.nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 08-Apr-2022 , 07-May-2022 , 05-Jun-2022 , 12-Jun-2022 , 16-Jun-2022 , 08-Aug-2022 , 07-Sep-2022 , 05-Oct-2022 , 12-Oct-2022 , 16-Oct-2022 , 08-Dec-2022 , 07-Jan-2023 , 05-Feb-2023 , 12-Feb-2023 , 16-Feb-2023 , 08-Apr-2023 , 07-May-2023 , 05-Jun-2023 , 12-Jun-2023 , 16-Jun-2023 , 08-Aug-2023 , 07-Sep-2023 , 05-Oct-2023 , 12-Oct-2023 , 16-Oct-2023 , 08-Dec-2023 , 07-Jan-2024 , 05-Feb-2024 , 12-Feb-2024 , 16-Feb-2024 , 08-Apr-2024 , 07-May-2024</p> <p>Synopsis This Notice of Special Interest (NOSI) encourages applications that advance the understanding or reduce the impact of health disparities and inequities in communication disorders among racial/ethnic minority and other underrepresented</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
<p>populations. Applications that address the influence or reduction of racism or discrimination in causing or sustaining health disparities and inequities are also encouraged. The research must address one or more of the NIDCD mission areas of hearing, balance, taste, smell, voice, speech, and language.</p>					
101155	NIDCD Low Risk Clinical Trials in Communication Disorders (R01 Clinical Trial Required)	National Institute on Deafness and Other Communication Disorders/NIH/DHHS	PAR-21-063	07-May-2022	2,499,995 USD
	<p>Contact Name Trinh T. Ly, M.D.</p> <p>Contact Telephone 301-435-4085</p> <p>Contact Email trinh.ly@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2022 , 05-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 07-May-2023 , 05-Jun-2023 , 07-Sep-2023 , 05-Oct-2023 , 07-Jan-2024</p> <p>Synopsis The NIDCD is committed to identifying effective interventions for the diagnosis, prevention, or treatment of communication disorders by supporting well-designed and well-executed clinical trials. This funding opportunity announcement (FOA) supports investigator initiated low risk clinical trials addressing the mission and research interests of NIDCD. Clinical trials must meet ALL the following criteria: meet the budget limits of this FOA, not require FDA oversight, are not intended to formally establish efficacy and have low risks to potentially cause physical or psychological harm. This FOA also supports low risk trials determined to be Basic Science Experimental Studies involving Humans (BESH). These studies fall within the NIH definition of a clinical trial and also meet the definition of basic research. It is advisable that only one clinical trial be proposed in each NIDCD Clinical Trials in Communication Disorders R01 application. High risk clinical trials not meeting all the criteria above are referred companion U01 FOA PAR-21-064, NIDCD Cooperative Agreement for Clinical Trials in Communication Disorders.</p>				
101085	NIDCD Mentored Career Development Award for Postdoctorate Au.D./Ph.D. Audiologists (K01 Independent Basic Experimental Studies with Humans Required)	National Institute on Deafness and Other Communication Disorders/NIH/DHHS	PAR-21-087	07-May-2022	315,000 USD
	<p>Contact Name Alberto L. Rivera-Rentas, Ph.D.</p> <p>Contact Telephone 301-496-1804</p> <p>Contact Email riverara@nidcd.nih.gov</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2022 , 14-Jun-2022 , 07-Sep-2022 , 13-Oct-2022 , 07-Jan-2023 , 14-Feb-2023 , 07-May-2023 , 13-Jun-2023 , 07-Sep-2023 , 13-Oct-2023 , 07-Jan-2024</p> <p>Synopsis The purpose of the NIDCD Mentored Career Development Award for Postdoctorate Au.D./Ph.D. Audiologists (K01) is to support comprehensive and rigorous postdoctoral research and career development experiences in the biomedical, behavioral, or clinical sciences of promising Au.D./Ph.D. audiologists who have the potential to become productive, independent investigators in scientific health-related research fields relevant to NIDCD's mission. This Mentored Career Development Award for Postdoctorate Au.D./Ph.D. Audiologists Funding Opportunity Announcement is for basic science experimental studies involving humans, referred to in NOT-OD-18-212 as "prospective basic science studies involving human participants." These studies fall within the NIH definition of a clinical trial and also meet the definition of basic research. Types of studies that should submit under this FOA include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental aspects of phenomena without specific application towards processes or products in mind. Studies conducted with specific applications toward processes or products in mind should submit under the appropriate 'Independent Clinical Trial Required' (PAR-21-085). Applicants not planning an independent clinical trial, or proposing to gain research in a clinical trial led by another investigator must apply to the companion 'Independent Clinical Trial Not Allowed' (PAR-21-086) FOA.</p>				
101080	NIDCD Mentored Career Development Award for Postdoctorate Au.D./Ph.D. Audiologists (K01 No Independent Clinical Trials)	National Institute on Deafness and Other Communication Disorders/NIH/DHHS	PAR-21-086	07-May-2022	315,000 USD
	<p>Contact Name Alberto L. Rivera-Rentas, Ph.D.</p> <p>Contact Telephone 301-496-1804</p> <p>Contact Email riverara@nidcd.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2022 , 14-Jun-2022 , 07-Sep-2022 , 13-Oct-2022 , 07-Jan-2023 , 14-Feb-2023 , 07-May-2023 , 13-Jun-2023 , 07-Sep-2023 , 13-Oct-2023 , 07-Jan-2024</p> <p>Synopsis The purpose of the NIDCD Mentored Career Development Award for Postdoctorate Au.D./Ph.D. Audiologists (K01) is to support comprehensive and rigorous postdoctoral research and career development experiences in the biomedical,</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		<p>behavioral, or clinical sciences of promising Au.D./Ph.D. audiologists who have the potential to become productive, independent investigators in scientific health-related research fields relevant to NIDCD's mission. This Funding Opportunity Announcement (FOA) is designed specifically for candidates proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary study to a clinical trial. Under this FOA candidates are permitted to propose a research experience in a clinical trial led by a mentor or co-mentor. Those proposing a clinical trial or an ancillary study to an ongoing clinical trial as lead investigator, should apply to the companion FOA PAR-21-085 for Clinical Trial Required or for PAR-21-087 for Independent Basic Experimental Studies with Humans Required..</p>			
101078	NIDCD Mentored Career Development Award for Postdoctorate Au.D./Ph.D. Audiologists (K01 Clinical Trial Required)	National Institute on Deafness and Other Communication Disorders/NIH/DHHS	PAR-21-085	07-May-2022	315,000 USD
	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email</p> <p>Sponsor Website</p> <p>Program URL</p> <p>Deadline Dates (ALL)</p> <p>Synopsis</p>	<p>Alberto L. Rivera-Rentas, Ph.D.</p> <p>301-496-1804</p> <p>riverara@nidcd.nih.gov</p> <p></p> <p>Link to program URL</p> <p>07-May-2022 , 14-Jun-2022 , 07-Sep-2022 , 13-Oct-2022 , 07-Jan-2023 , 14-Feb-2023 , 07-May-2023 , 13-Jun-2023 , 07-Sep-2023 , 13-Oct-2023 , 07-Jan-2024</p> <p>The purpose of the NIDCD Mentored Career Development Award for Postdoctorate Au.D./Ph.D. Audiologists (K01) is to support comprehensive and rigorous postdoctoral research and career development experiences in the biomedical, behavioral, or clinical sciences of promising Au.D./Ph.D. audiologists who have the potential to become productive, independent investigators in scientific health-related research fields relevant to NIDCD's mission. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary study to an existing trial, as part of their research and career development. Applicants not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must apply to companion FOA (PAR-21-086). Observational Studies involving humans should submit under PAR-21-087 - NIDCD Mentored Career Development Award for Postdoctorate Au.D./Ph.D. Audiologists (K01 Independent Basic Experimental Studies with Humans Required).</p>			
101736	NIDCD Research Career Enhancement Award for Established Investigators (K18 Independent Basic Experimental Studies with Humans Required)	National Institute on Deafness and Other Communication Disorders/NIH/DHHS	PAR-21-096	07-May-2022	Not Specified

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

Contact Name Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL) Synopsis	Alberto L. Rivera-Rentas, Ph.D. 301-496-1804 riverara@nidcd.nih.gov Link to program URL 07-May-2022 , 07-Jun-2022 , 07-Sep-2022 , 07-Oct-2022 , 07-Jan-2023 , 06-Feb-2023 , 07-May-2023 , 08-Jun-2023 , 07-Sep-2023 , 10-Oct-2023 , 07-Jan-2024 The purpose of the NIDCD Research Career Enhancement Award for Established Investigators (K18) program is to enable established, proven investigators to augment or redirect their research programs through the acquisition of new research skills to answer questions relevant to the hearing, balance, smell, taste, voice, speech and language sciences. This Funding Opportunity Announcement is for basic science experimental studies involving humans, referred to in NOT-OD-18-212 as “prospective basic science studies involving human participants.” These studies fall within the NIH definition of a clinical trial and also meet the definition of basic research. Types of studies that should submit under this FOA include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental aspects of phenomena without specific application towards processes or products in mind. Studies conducted with specific applications toward processes or products in mind should submit under PAR-21-094 "NIDCD Research Career Enhancement Award for Established Investigators (K18 Clinical Trial Required)" Applicants not planning an independent clinical trial or basic experimental study with humans, or proposing to gain research experience in a clinical trial or basic experimental study with humans led by another investigator, must apply to companion FOA PAR-21-095 "NIDCD Research Career Enhancement Award for Established Investigators (K18Independent Clinical Trial Not Allowed)" .
--	---

101734	NIDCD Research Career Enhancement Award for Established Investigators (K18 Independent Clinical Trial Not Allowed)	National Institute on Deafness and Other Communication Disorders/NIH/DHHS	PAR-21-095	07-May-2022	Not Specified
--------	--	---	------------	-------------	---------------

Contact Name Contact Telephone Contact Email Sponsor Website Program URL	Alberto L. Rivera-Rentas, Ph.D. 301-496-1804 riverara@nidcd.nih.gov Link to program URL
--	--

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Deadline Dates (ALL) 07-May-2022 , 07-Jun-2022 , 07-Sep-2022 , 07-Oct-2022 , 07-Jan-2023 , 06-Feb-2023 , 07-May-2023 , 08-Jun-2023 , 07-Sep-2023 , 10-Oct-2023 , 07-Jan-2024</p> <p>Synopsis The purpose of the NIDCD Research Career Enhancement Award for Established Investigators (K18) program is to enable established, proven investigators to augment or redirect their research programs through the acquisition of new research skills to answer questions relevant to the hearing, balance, smell, taste, voice, speech and language sciences. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study or an ancillary study to a clinical trial. proposing to serve as the lead investigator of an independent clinical trial, as part of their research and career development. Those planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must apply to companion FOA PAR-21-094 or for PAR-21-096 for Independent Basic Experimental Studies with Humans Required.</p>				
101733	NIDCD Research Career Enhancement Award for Established Investigators (K18 Clinical Trial Required)	National Institute on Deafness and Other Communication Disorders/NIH/DHHS	PAR-21-094	07-May-2022	Not Specified

Contact Name	Alberto L. Rivera-Rentas, Ph.D.
Contact Telephone	301-496-1804
Contact Email	riverara@nidcd.nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	07-May-2022 , 07-Jun-2022 , 07-Sep-2022 , 07-Oct-2022 , 07-Jan-2023 , 06-Feb-2023 , 07-May-2023 , 08-Jun-2023 , 07-Sep-2023 , 10-Oct-2023 , 07-Jan-2024
Synopsis	The purpose of the NIDCD Research Career Enhancement Award for Established Investigators (K18) program is to enable established, proven investigators to augment or redirect their research programs through the acquisition of new research skills to answer questions relevant to the hearing, balance, smell, taste, voice, speech and language sciences. This Funding Opportunity Announcement (FOA) is designed specifically for candidates proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary clinical trial, as part of their research and career development. Those not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must apply to companion FOA (PAR-21-095). Applicants not planning an independent clinical trial, but planning a basic experimental study with humans, must apply to companion FOA PAR-21-096 - NIDCD Research Career Enhancement Award for Established Investigators (K18 Independent Basic Experimental Studies with Humans Required)

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
105011	RFA-DC-22-001 -- NIDCD Research Grants for Translating Basic Research into Clinical Tools (R01 Clinical Trial Optional)	National Institute on Deafness and Other Communication Disorders/NIH/DHHS	RFA-DC-22-001	21-May-2022 [Optional][LOI/Pre-App]	Not Specified
	<p>Contact Name Roger L. Miller, Ph.D.</p> <p>Contact Telephone 301-402-3458</p> <p>Contact Email millerr@nidcd.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 21-May-2022 [Optional][LOI/Pre-App], 20-Jun-2022 , 23-Jan-2023 [Optional][LOI/Pre-App], 22-Feb-2023 , 18-Sep-2023 [Optional][LOI/Pre-App], 18-Oct-2023 , 21-May-2024 [Optional][LOI/Pre-App], 20-Jun-2024</p> <p>Synopsis This Funding Opportunity Announcement (FOA) is intended to provide an avenue for basic scientists, clinicians and clinical scientists to jointly initiate and conduct translational research projects which translate basic research findings into clinical tools for better human health. The scope of this FOA includes a range of activities to encourage translation of basic research findings which will impact the diagnosis, treatment and prevention of communication disorders. Connection to the clinical condition must be clearly established and the outcomes of the grant must have practical clinical impact.</p>				
106846	NIDCD Clinical Research Center Grant (P50 Clinical Trial Optional)	National Institute on Deafness and Other Communication Disorders/NIH/DHHS	PAR-22-025	07-Jun-2022	7,500,000 USD
	<p>Contact Name Lana Shekim, Ph.D.</p> <p>Contact Telephone 301-496-5061</p> <p>Contact Email shekiml@nidcd.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-Jun-2022 , 06-Oct-2022 , 07-Feb-2023 , 06-Jun-2023 , 06-Oct-2023 , 06-Feb-2024 , 06-Jun-2024 , 09-Oct-2024</p> <p>Synopsis The National Institute on Deafness and Other Communication Disorders (NIDCD) invites applications for Clinical Research Center Grants designed to advance the diagnosis, prevention, treatment, and amelioration of human communication disorders. For this announcement, Clinical Research is defined as research involving individuals with communication disorders or data/tissues from individuals with a communication disorder. Examples of such research include but are not limited to, studies of the prevention, pathogenesis, pathophysiology, diagnosis, treatment, management or epidemiology of</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		a disease or disorder of hearing, balance, smell, taste, voice, speech, or language. Applications may propose a low risk clinical trial but are not required to (optional).			
101157	NIDCD Cooperative Agreement for Clinical Trials in Communication Disorders (U01 - Clinical Trial Required)	National Institute on Deafness and Other Communication Disorders/NIH/DHHS	PAR-21-064	10-Jun-2022	Not Specified
	<p>Contact Name Trinh T. Ly, M.D.</p> <p>Contact Telephone 301-435-4085</p> <p>Contact Email trinh.ly@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 10-Jun-2022 , 11-Oct-2022 , 10-Feb-2023 , 09-Jun-2023 , 10-Oct-2023</p> <p>Synopsis The NIDCD is committed to identifying effective interventions for the treatment or prevention of communication disorders by supporting well- designed and well- executed clinical trials. This funding opportunity announcement (FOA) supports a cooperative agreement between an NIDCD Project Scientist and an investigator to support a clinical trial that meets ANY of the following criteria: requires FDA oversight, is intended to formally establish efficacy, or has a higher risk to potentially cause physical or psychological harm. Clinical trial applications exceeding the annual direct costs of \$700,000 or more, in certain cases, may also be a criterion for this FOA. These investigator-initiated clinical trials are perceived to benefit from close interaction, oversight, and guidance resulting from a cooperative agreement. Only one clinical trial may be proposed in each NIDCD Clinical Trials in Communication Disorders U01 application. Low risk clinical trials not meeting any of the criteria above are referred to the companion NIDCD Low Risk Clinical Trials in Communication Disorders (R01-Clinical Trial Required) PAR-21-063.</p>				
101297	NIDCD Early Career Research(ECR) Award (R21 Clinical Trial Optional)	National Institute on Deafness and Other Communication Disorders/NIH/DHHS	PAR-21-107	23-Jun-2022	375,000 USD
	<p>Contact Name Bracie Watson, Jr.</p> <p>Contact Telephone 301-402-3458</p> <p>Contact Email watsonb@nidcd.nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Deadline Dates (ALL) 23-Jun-2022 , 27-Oct-2022 , 23-Feb-2023 , 29-Jun-2023 , 26-Oct-2023</p> <p>Synopsis The NIDCD Early Career Research (ECR) Award (R21) is intended to support both basic and clinical research from scientists who are beginning to establish an independent research career. It cannot be used for thesis or dissertation research. The research must be focused on one or more of the areas within the biomedical and behavioral scientific mission of the NIDCD: hearing, balance, smell, taste, voice, speech, or language. The NIDCD ECR Award R21 grant mechanism supports different types of projects including secondary analysis of existing data; small, self-contained research projects; development of research methodology; translational research; outcomes research; and development of new research technology. Irrespective of the type of project, the intent of the NIDCD ECR Award R21 is for the Program Director(s)/Principal Investigator(s) (PD(s)/PI(s)) to obtain sufficient preliminary data for a subsequent R01 application.</p>				
106339	Notice of Special Interest (NOSI): Evaluation of Sex Differences on HIV-Associated Comorbidities in the Context of Stimulant Use	National Institute on Drug Abuse/NIH/DHHS	NOT-DA-21-020	07-May-2022	Not Specified
	<p>Contact Name Da-Yu Wu, PhD</p> <p>Contact Telephone 301-435-4649</p> <p>Contact Email wudy@nida.nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2022 , 05-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 07-May-2023 , 05-Jun-2023 , 07-Sep-2023 , 05-Oct-2023 , 07-Jan-2024 , 05-Feb-2024 , 07-May-2024</p> <p>Synopsis The goal of this Notice is to encourage applications focusing on the understanding of the biological basis of sex differences in HIV neuropathogenesis and the comorbidity of HIV with misuse of stimulants, including amphetamine, methamphetamine, cocaine, and nicotine. Studies at single cell and CNS circuits levels and in live behaving animals are encouraged.</p>				
101989	Notice of Special Interest (NOSI): Long-Term Neurocognitive Consequences of COVID-19 in Individuals Living with HIV and Substance Use Disorders	National Institute on Drug Abuse/NIH/DHHS	NOT-DA-21-018	07-May-2022	Not Specified
	<p>Contact Name Raul Mandler, MD</p> <p>Contact Telephone 301-480-2541</p> <p>Contact Email mandlerr@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Deadline Dates (ALL)	07-May-2022 , 05-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 07-May-2023 , 05-Jun-2023 , 07-Sep-2023 , 05-Oct-2023 , 07-Jan-2024 , 05-Feb-2024 , 07-May-2024 , 05-Jun-2024 , 07-Sep-2024			
	Synopsis	NIDA is interested in receiving research applications focusing on studying the long-term neurocognitive consequences of the COVID-19/HIV/SUDs syndemic.			
102988	Notice of Special Interest (NOSI): Basic Research on Fentanyl and Synthetic Fentanyl Analogs: Signaling, Neurobiology, and Pharmacology	National Institute on Drug Abuse/NIH/DHHS	NOT-DA-21-033	07-May-2022	Not Specified
	Contact Name	Pamela G. Fleming			
	Contact Telephone	301-480-1159			
	Contact Email	pfleming@nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	07-May-2022 , 05-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 07-May-2023 , 05-Jun-2023 , 07-Sep-2023 , 05-Oct-2023 , 07-Jan-2024 , 05-Feb-2024 , 07-May-2024 , 05-Jun-2024 , 07-Sep-2024			
	Synopsis	This Notice informs potential applicants to the National Institute on Drug Abuse (NIDA) about a special interest in basic research on fentanyl and synthetic fentanyl analogs. Of particular interest is research that is focused on elucidating chemical, cellular, signaling, and neurobiological mechanisms underlying abuse potential, physical dependence, addiction liability and deaths due to overdose of fentanyl and fentanyl analogs.			
103015	Notice of Special Interest (NOSI): Synthetic Psychoactive Drugs and Strategic Approaches to Counteract Their Deleterious Effects	National Institute on Drug Abuse/NIH/DHHS	NOT-DA-21-028	07-May-2022	Not Specified
	Contact Name	Pamela G. Fleming			
	Contact Telephone	301-480-1159			
	Contact Email	pfleming@nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	07-May-2022 , 05-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 07-May-2023 , 05-Jun-2023 , 07-Sep-2023 , 05-Oct-2023 , 07-Jan-2024 , 05-Feb-2024 , 07-May-2024 , 05-Jun-2024 , 07-Sep-2024			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Synopsis	This Notice informs potential applicants to the National Institute on Drug Abuse (NIDA) about a special interest in research on chemistry, pharmacology, biological targets and biochemical mechanisms that contribute to the effects of synthetic psychoactive substances.			
101618	Pilot and Feasibility Studies in Preparation for Substance Use Prevention Trials (R34 Clinical Trial Optional)	National Institute on Drug Abuse/NIH/DHHS	PA-21-110	07-May-2022	450,000 USD
	Contact Name	Amy B. Goldstein, PhD			
	Contact Telephone	301-827-4124			
	Contact Email	amy.goldstein@nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	07-May-2022 , 16-Jun-2022 , 07-Sep-2022 , 16-Oct-2022 , 07-Jan-2023 , 16-Feb-2023 , 07-May-2023 , 16-Jun-2023 , 07-Sep-2023 , 16-Oct-2023 , 07-Jan-2024			
	Synopsis	The purpose of this Funding Opportunity Announcement (FOA) is to encourage theoretically-driven pilot and/or feasibility research in the following areas: 1) the development and pilot testing of new or adapted interventions to prevent or delay the initiation of substance use and/or the progression from use to misuse or disorder and 2) services research examining questions specific to the prevention of substance use. The latter may include pilot studies of strategies or approaches to intervention, and/or other service system-based research to address areas such as economics, funding, service quality and engagement. In addition to the prevention of substance use, misuse and disorder, other outcomes of interest for the research supported through this FOA include a reduction in negative sequelae such as deaths related to impaired driving, suicidal behavior (e.g., nonfatal and fatal attempts), and substance-related acquisition or transmission of HIV infection and viral hepatitis among diverse populations and settings.			
104182	Notice of Special Interest (NOSI): Advanced Computational Approaches to Elucidate Disease Pathology and Identify Novel Therapeutics for Addiction	National Institute on Drug Abuse/NIH/DHHS	NOT-DA-21-004	07-May-2022	Not Specified
	Contact Name	Susan Wright, Ph.D.			
	Contact Telephone	301-402-6683			
	Contact Email	susan.wright@nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Deadline Dates (ALL)	07-May-2022 , 05-Jun-2022 , 16-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 16-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 16-Feb-2023 , 07-May-2023 , 05-Jun-2023 , 16-Jun-2023 , 07-Sep-2023 , 05-Oct-2023 , 16-Oct-2023 , 07-Jan-2024 , 05-Feb-2024 , 16-Feb-2024 , 07-May-2024 , 05-Jun-2024 , 16-Jun-2024 , 07-Sep-2024 , 05-Oct-2024 , 16-Oct-2024 , 07-Jan-2025			
	Synopsis	The purpose of this Notice is to inform potential applicants to the National Institute on Drug Abuse (NIDA) of NIDA's interest in grant applications that will develop or utilize advanced computational approaches to describe complex drug-disease relationships in ways that will rapidly advance the development of new treatments, allow for targeted funding of substance use disorder (SUD) drug discovery and improve health care. NIDA has a particular interest in applications that include approaches in one or more of the following categories: 1) artificial intelligence, including machine learning and deep learning, 2) supercomputing/parallel computing, and/or 3) quantum computing.			
102446	Notice of Special Interest (NOSI): Using Data to Advance HIV Epidemic Knowledge and Program Planning	National Institute on Drug Abuse/NIH/DHHS	NOT-DA-21-007	07-May-2022	Not Specified
	Contact Name	Richard A. Jenkins PhD			
	Contact Telephone	301-443-1923			
	Contact Email	jenkinsri@mail.nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	07-May-2022 , 05-Jun-2022 , 16-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 16-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 16-Feb-2023 , 07-May-2023 , 05-Jun-2023 , 16-Jun-2023 , 07-Sep-2023 , 05-Oct-2023 , 16-Oct-2023 , 07-Jan-2024 , 05-Feb-2024 , 16-Feb-2024 , 07-May-2024 , 05-Jun-2024 , 16-Jun-2024 , 07-Sep-2024			
	Synopsis	The purpose of this Notice is to encourage grant applications proposing research that makes use of available, large data sets with the objective of improving HIV epidemic modeling and service planning, with greater attention to the role of substance use. Data may be from NIDA-funded or co-funded projects as well as from other sources. This Notice is expected to increase the utilization of existing data including epidemiologic and clinic cohorts, longitudinal follow-up studies of interventions, as well as other publicly available data including those provided by government bodies, data warehouses and commercial data sources. Existing data may include data from completed projects as well as those that are ongoing. Results from studies supported by this NOSI are expected to generate knowledge that can be used to answer significant questions about HIV epidemics, promote efficient provision of services, and address limitations of existing models that have guided public policy. NIDA is particularly interested in research that integrates substance use considerations into program planning and policy to increase the quality of HIV services and their responsiveness to substance using populations.			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
107619	Notice of Special Interest (NOSI): Research in the Chemistry and Pharmacology of Addictive Drugs	National Institute on Drug Abuse/NIH/DHHS	NOT-DA-23-002	07-May-2022	Not Specified
	<p>Contact Name Kiran Vemuri, Ph.D.</p> <p>Contact Telephone 301-435-4446</p> <p>Contact Email kiran.vemuri@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2022 , 05-Jun-2022 , 12-Jun-2022 , 16-Jun-2022 , 10-Aug-2022 , 07-Sep-2022 , 05-Oct-2022 , 12-Oct-2022 , 16-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 12-Feb-2023 , 16-Feb-2023 , 08-Mar-2023 , 07-May-2023 , 05-Jun-2023 , 16-Jun-2023 , 10-Aug-2023 , 07-Sep-2023 , 05-Oct-2023 , 16-Oct-2023 , 07-Jan-2024 , 05-Feb-2024 , 16-Feb-2024 , 08-Mar-2024 , 07-May-2024 , 05-Jun-2024 , 16-Jun-2024 , 07-Sep-2024 , 12-Feb-2025</p> <p>Synopsis The mission of the Division of Neuroscience and Behavior of NIDA is to discover, facilitate and promote outstanding basic animal and human research aimed at identifying the causes and consequences of drug addiction across the lifespan and to guide treatment strategies. As a component of the Division, the Chemistry and Pharmacology Branch supports research on all aspects of the chemistry and pharmacology of addictive drugs. The Branch develops and oversees a broad portfolio encompassing research on substance use disorders (SUD) and overdose designed to: 1) elucidate mechanisms of action, synthetic and biosynthetic methodologies, structure-activity relationships, pharmacology and toxicity of addictive drugs, and determination of 3D structures of ligands bound to biological targets, 2) develop new receptor type and subtype specific agents, and 3) discover and advance the pre-clinical development of new pharmacotherapies for the treatment of SUD and overdose, emphasizing the pre-clinical stages of target identification through hit-to-lead.</p>				
101829	Notice of Special Interest (NOSI): Effects of Smoking and Vaping on the Risk and Outcome of COVID-19 Infection	National Institute on Drug Abuse/NIH/DHHS	NOT-DA-21-011	07-May-2022	Not Specified
	<p>Contact Name Raul Mandler, MD; FAAN; FANA</p> <p>Contact Telephone 301-480-2541</p> <p>Contact Email mandlerr@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Deadline Dates (ALL)	07-May-2022 , 05-Jun-2022 , 16-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 16-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 16-Feb-2023 , 07-May-2023 , 05-Jun-2023 , 16-Jun-2023 , 07-Sep-2023 , 05-Oct-2023 , 16-Oct-2023 , 07-Jan-2024 , 05-Feb-2024 , 16-Feb-2024 , 07-May-2024 , 05-Jun-2024 , 16-Jun-2024 , 07-Sep-2024			
	Synopsis	The purpose of this notice is to communicate NIDA's interest in supporting research on the effects of smoking or vaping tobacco or marijuana on the risk of acquiring COVID-19 and the clinical course of the infection. This Notice is a reissuance of NOT-DA-20-084.			
102120	Notice of Special Interest (NOSI): Telehealth Strategies for Individuals with HIV and Substance Use Disorders	National Institute on Drug Abuse/NIH/DHHS	NOT-DA-21-019	07-May-2022	Not Specified
	Contact Name	Raul Mandler, MD			
	Contact Telephone	301-480-2541			
	Contact Email	mandlerr@nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	07-May-2022 , 05-Jun-2022 , 16-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 16-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 16-Feb-2023 , 07-May-2023 , 05-Jun-2023 , 16-Jun-2023 , 07-Sep-2023 , 05-Oct-2023 , 16-Oct-2023 , 07-Jan-2024 , 05-Feb-2024 , 16-Feb-2024 , 07-May-2024 , 05-Jun-2024 , 16-Jun-2024 , 07-Sep-2024			
	Synopsis	The National Institute on Drug Abuse (NIDA) is issuing this Notice of Special Interest (NOSI) inviting research applications to explore and develop telehealth methods and strategies for diagnosis, prevention, treatment, and population analysis in individuals living with HIV and Substance Use Disorder (SUD).			
094123	Substance Use/Substance Use Disorder Dissertation Research Award (R36 - Clinical Trials Optional)	National Institute on Drug Abuse/NIH/DHHS	PA-20-208	07-May-2022	100,000 USD
	Contact Name	Aria Crump, Sc.D.			
	Contact Telephone	301-435-0881			
	Contact Email	acrump@nida.nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	07-May-2022 , 16-Jun-2022 , 07-Sep-2022 , 16-Oct-2022 , 07-Jan-2023 , 16-Feb-2023 , 07-May-2023			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

Synopsis | The goal of this FOA is to support doctoral candidates from a variety of academic disciplines for up to two years for the completion of the doctoral dissertation research project. Research projects should align with NIDA funding priorities detailed here (<https://www.drugabuse.gov/funding/funding-priorities>) or within the NIDA Strategic Plan (<https://www.drugabuse.gov/about-nida/2016-2020-nida-strategic-plan>). This award will facilitate the entry of promising new investigators into the field of substance use/substance use disorder (SU(D) research, enhancing the pool of highly talented SU(D) researchers. Applications are particularly encouraged from those who can contribute to diversifying the research workforce as described in the Notice of NIH's Interest in Diversity (NOT-OD-20-031).

090993	NIDA Small Research Grant Program (R03 Clinical Trial Required)	National Institute on Drug Abuse/NIH/DHHS	PA-20-146	07-May-2022	100,000 USD
--------	---	---	-----------	-------------	-------------

Contact Name	Katrina L Foster, PhD
Contact Telephone	301-827-5815
Contact Email	fosterkl@nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	07-May-2022 , 16-Jun-2022 , 07-Sep-2022 , 16-Oct-2022 , 07-Jan-2023 , 16-Feb-2023 , 07-May-2023
Synopsis	The NIDA Small Research Grant Program supports small clinical trials that can be carried out in a short period of time with limited resources. This program supports different types of projects including pilot, feasibility, or small clinical trials with medications, behavioral interventions, immunotherapies, therapeutic devices, therapeutic digital applications, health services, prevention interventions, biomarkers, and development of research methodology. This Funding Opportunity Announcement requires that a clinical trial be proposed. The proposed project must be related to the programmatic interests of NIDA.

102016	Notice of Special Interest (NOSI): Medical Consequences of Smoking and Vaping Drugs of Abuse in Individuals with HIV and COVID-19	National Institute on Drug Abuse/NIH/DHHS	NOT-DA-21-017	07-May-2022	Not Specified
--------	---	---	---------------	-------------	---------------

Contact Name	Raul Mandler, MD
Contact Telephone	301-480-2541
Contact Email	mandlerr@nih.gov
Sponsor Website	
Program URL	Link to program URL

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Deadline Dates (ALL)	07-May-2022 , 05-Jun-2022 , 16-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 16-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 16-Feb-2023 , 07-May-2023 , 05-Jun-2023 , 16-Jun-2023 , 07-Sep-2023 , 05-Oct-2023 , 16-Oct-2023 , 07-Jan-2024 , 05-Feb-2024 , 16-Feb-2024 , 07-May-2024 , 05-Jun-2024 , 16-Jun-2024 , 07-Sep-2024			
	Synopsis	NIDA is interested in receiving research applications focusing on individuals with HIV who smoke or vape marijuana, tobacco, cocaine and/or methamphetamine to determine the long-term effects of their use among individuals with HIV and COVID-19.			
103071	Notice of Special Interest (NOSI): Deciphering the Mosaic of Glia in the Addicted Brain	National Institute on Drug Abuse/NIH/DHHS	NOT-DA-21-001	07-May-2022	Not Specified
	Contact Name	Shang-Yi Anne Tsai, Ph.D			
	Contact Telephone	301-827-5842			
	Contact Email	stsai@nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	07-May-2022 , 05-Jun-2022 , 16-Jun-2022 , 25-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 16-Oct-2022 , 25-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 16-Feb-2023 , 25-Feb-2023 , 07-May-2023 , 05-Jun-2023 , 16-Jun-2023 , 25-Jun-2023 , 07-Sep-2023 , 05-Oct-2023 , 16-Oct-2023 , 25-Oct-2023 , 07-Jan-2024 , 05-Feb-2024 , 16-Feb-2024 , 25-Feb-2024 , 07-May-2024 , 05-Jun-2024 , 16-Jun-2024 , 25-Jun-2024 , 07-Sep-2024			
	Synopsis	National Institute on Drug Abuse (NIDA) is issuing this Notice of Special Interest (NOSI) to inform potential applicants of its interest in research project grant submissions that examine the effects of drug use on the structural and functional diversity and plasticity of glia and non-neuronal cells on nervous system process in the context of drug misuse and substance use disorders (SUD). Glial and other non-neuronal cells include astrocytes, microglia, oligodendrocytes and ependymal cells.			
100294	Notice of Special Interest (NOSI): Neuroimmune Signaling and Function in Substance Use Disorders	National Institute on Drug Abuse/NIH/DHHS	NOT-DA-20-046	07-May-2022	Not Specified
	Contact Name	Roger G Sorensen, Ph.D., MPA			
	Contact Telephone	301-443-3205			
	Contact Email	rsorensen@nida.nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Deadline Dates (ALL) 07-May-2022 , 05-Jun-2022 , 16-Jun-2022 , 25-Jun-2022 , 01-Sep-2022 , 05-Oct-2022 , 16-Oct-2022 , 25-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 16-Feb-2023 , 25-Feb-2023 , 07-May-2023 , 05-Jun-2023 , 16-Jun-2023 , 25-Jun-2023 , 07-Sep-2023</p> <p>Synopsis The purpose of this notice is to encourage research project submissions examining the role of neuroimmune signaling in the CNS in relation to: the trajectory (i.e. initiation, escalation, and maintenance) of drug misuse; consequences of chronic exposure to misused drugs; abstinence and withdrawal from prolonged use; and relapse or reinstatement of drug taking at molecular, cellular, circuit, or behavioral levels.</p>				
103874	<p>Notice of Special Interest (NOSI): Leveraging Transformative Connectome Resources in Model Organisms to Elucidate the Neurobiology of Substance Abuse Disorders</p>	National Institute on Drug Abuse/NIH/DHHS	NOT-DA-21-006	07-May-2022	Not Specified
	<p>Contact Name Olivier Berton, Ph.D.</p> <p>Contact Telephone 301-827-7771</p> <p>Contact Email olivier.berton@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2022 , 05-Jun-2022 , 16-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 16-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 16-Feb-2023 , 07-May-2023 , 05-Jun-2023 , 16-Jun-2023 , 07-Sep-2023 , 05-Oct-2023 , 16-Oct-2023 , 07-Jan-2024 , 05-Feb-2024 , 16-Feb-2024 , 07-May-2024 , 05-Jun-2024 , 16-Jun-2024 , 07-Sep-2024</p> <p>Synopsis The purpose of this notice is to encourage research project submissions that leverage whole-brain or large connectome resources in genetically tractable model organisms to investigate the role of distributed neuronal circuits in behaviors relevant to substance use disorders (SUD).</p>				
103870	<p>Notice of Special Interest (NOSI): Leveraging Longitudinal Studies in Animal Models to Identify Neural Mechanisms of Vulnerability and Resilience to Substance Use Disorder</p>	National Institute on Drug Abuse/NIH/DHHS	NOT-DA-21-003	07-May-2022	Not Specified
	<p>Contact Name Holly Moore</p> <p>Contact Telephone 301-827-7376</p> <p>Contact Email Holly.Moore@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Deadline Dates (ALL) 07-May-2022 , 05-Jun-2022 , 16-Jun-2022 , 25-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 16-Oct-2022 , 25-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 16-Feb-2023 , 25-Feb-2023 , 07-May-2023 , 05-Jun-2023 , 16-Jun-2023 , 25-Jun-2023 , 07-Sep-2023 , 05-Oct-2023 , 16-Oct-2023 , 25-Oct-2023 , 07-Jan-2024 , 05-Feb-2024 , 16-Feb-2024 , 25-Feb-2024 , 07-May-2024 , 05-Jun-2024 , 16-Jun-2024 , 25-Jun-2024 , 07-Sep-2024</p> <p>Synopsis NIDA seeks to stimulate research in non-human species aimed at modeling environmental and/or biological risk factors for SUD to elucidate neural and cognitive developmental mechanisms that may mediate, moderate, or predict the effects of these factors on subsequent emergence of SUD-related behaviors. Use of longitudinal designs and developmental-stage-appropriate paradigms are strongly encouraged.</p>				
105778	Imaging - Science Track Award for Research Transition (I/START) (R03-Basic Experimental Studies with Humans Required)	National Institute on Drug Abuse/NIH/DHHS	PAR-21-309	07-May-2022	150,000 USD
	<p>Contact Name John Fedota, PhD</p> <p>Contact Telephone 301-402-0812</p> <p>Contact Email john.fedota@mail.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2022 , 16-Jun-2022 , 07-Sep-2022 , 16-Oct-2022 , 07-Jan-2023 , 16-Feb-2023 , 07-May-2023 , 16-Jun-2023 , 07-Sep-2023 , 16-Oct-2023 , 07-Jan-2024 , 16-Feb-2024 , 07-May-2024 , 16-Jun-2024 , 07-Sep-2024</p> <p>Synopsis This Funding Opportunity Announcement (FOA) encourages Small Research Grant (R03) applications to facilitate the entry of investigators to the area of neuroimaging, including both newly independent investigators and established investigators seeking to adopt neuroimaging methodologies in their research programs, to enable the conduct of small "proof of concept" studies. The R03 is intended to support research projects that can be carried out in a short period of time with limited resources.</p>				
105780	Imaging - Science Track Award for Research Transition (I/START) (R03-Clinical Trial Optional)	National Institute on Drug Abuse/NIH/DHHS	PAR-21-310	07-May-2022	150,000 USD
	<p>Contact Name John Fedota, PhD</p> <p>Contact Telephone 301-402-0812</p> <p>Contact Email john.fedota@mail.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Deadline Dates (ALL) 07-May-2022 , 16-Jun-2022 , 07-Sep-2022 , 16-Oct-2022 , 07-Jan-2023 , 16-Feb-2023 , 07-May-2023 , 16-Jun-2023 , 07-Sep-2023 , 16-Oct-2023 , 07-Jan-2024 , 16-Feb-2024 , 07-May-2024 , 16-Jun-2024 , 07-Sep-2024</p> <p>Synopsis This Funding Opportunity Announcement (FOA) encourages Small Research Grant (R03) applications to facilitate the entry of investigators to the area of neuroimaging, including both newly independent investigators and established investigators seeking to adopt neuroimaging methodologies in their research programs, to enable the conduct of small "proof of concept" studies. The R03 is intended to support research projects that can be carried out in a short period of time with limited resources.</p>				
104862	Notice of Special Interest (NOSI): Advancing HIV/AIDS Research through Computational Neuroscience	National Institute on Drug Abuse/NIH/DHHS	NOT-DA-21-030	07-May-2022	Not Specified
	<p>Contact Name Yu (Woody) Lin</p> <p>Contact Telephone 301-435-1318</p> <p>Contact Email ylin1@mail.nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2022 , 25-May-2022 , 05-Jun-2022 , 12-Jun-2022 , 16-Jun-2022 , 25-Jun-2022 , 15-Aug-2022 , 07-Sep-2022 , 25-Sep-2022 , 05-Oct-2022 , 12-Oct-2022 , 16-Oct-2022 , 25-Oct-2022 , 07-Jan-2023 , 25-Jan-2023 , 05-Feb-2023 , 12-Feb-2023 , 16-Feb-2023 , 25-Feb-2023 , 07-May-2023 , 25-May-2023 , 05-Jun-2023 , 12-Jun-2023 , 16-Jun-2023 , 25-Jun-2023 , 07-Sep-2023 , 25-Sep-2023 , 05-Oct-2023 , 12-Oct-2023 , 16-Oct-2023 , 25-Oct-2023 , 07-Jan-2024 , 25-Jan-2024 , 05-Feb-2024 , 12-Feb-2024 , 16-Feb-2024 , 25-Feb-2024 , 07-May-2024 , 25-May-2024 , 05-Jun-2024 , 12-Jun-2024 , 16-Jun-2024 , 25-Jun-2024 , 07-Sep-2024 , 25-Sep-2024 , 12-Oct-2024 , 25-Oct-2024 , 07-Jan-2025</p> <p>Synopsis This Notice of Special Interest [NOSI] is to support computational HIV/AIDS research as it relates to NIDA's mission through collaborative research between investigators with experimental expertise related to HIV/AIDS and those with computational proficiency, including scientists from statistics, physics, mathematics, engineering, and computer science. The NOSI will support meritorious and innovative research built on well-established computational strategies (theory, models, and methods) to investigate HIV-related neurocognitive deficits and neuropathogenesis in the context of substance use or substance use disorder (SUD). Investigators are expected to have complementary and integrated expertise in their field(s), but an ongoing collaboration or record of co-authorship is not required.</p>				
106007	Notice of Special Interest (NOSI): International Research Collaboration on Drug Abuse and Addiction Research	National Institute on Drug Abuse/NIH/DHHS	NOT-DA-21-064	07-May-2022	Not Specified
	<p>Contact Name Steve Gust, Ph.D.</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Telephone 301-402-1118</p> <p>Contact Email sgust@nida.nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2022 , 05-Jun-2022 , 16-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 16-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 16-Feb-2023 , 07-May-2023 , 05-Jun-2023 , 16-Jun-2023 , 07-Sep-2023 , 05-Oct-2023 , 16-Oct-2023 , 07-Jan-2024 , 05-Feb-2024 , 16-Feb-2024 , 07-May-2024 , 05-Jun-2024 , 16-Jun-2024 , 07-Sep-2024</p> <p>Synopsis The purpose of this notice is to encourage collaborative research applications that take advantage of opportunities outside of the United States. Applications examining all areas of NIDA-supported research addressing the causes, consequences, treatment, recovery, and prevention of drug use, misuse, and addiction are encouraged. Projects may be conducted through newly formed or well-established partnerships between investigators in a U.S.-based institution and scientists working in another country. All NIH grant applications for research to be conducted outside the United States must establish that the proposal takes advantage of unique research opportunities in other countries, speeds scientific discovery, and advances U.S. health science.</p>				
109268	Notice of Special Interest (NOSI): Epidemiology of Drug Abuse	National Institute on Drug Abuse/NIH/DHHS	NOT-DA-22-004	05-Jun-2022	Not Specified
	<p>Contact Name Marsha Lopez, PhD, MHS</p> <p>Contact Telephone 301-443-6504</p> <p>Contact Email Marsha.Lopez@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 05-Jun-2022 , 16-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 16-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 16-Feb-2023 , 07-May-2023 , 05-Jun-2023 , 16-Jun-2023 , 07-Sep-2023 , 05-Oct-2023 , 16-Oct-2023 , 07-Jan-2024 , 05-Feb-2024 , 16-Feb-2024 , 07-May-2024 , 05-Jun-2024 , 16-Jun-2024 , 07-Sep-2024 , 05-Oct-2024 , 16-Oct-2024 , 07-Jan-2025 , 05-Feb-2025 , 16-Feb-2025 , 07-May-2025 , 05-Jun-2025 , 16-Jun-2025 , 07-Sep-2025</p> <p>Synopsis The purpose of this Notice is to encourage the submission of research project applications that enhance our understanding of the nature, extent, distribution, etiology, comorbidities, and consequences of drug use, misuse, and addiction across individuals, families, communities, and diverse population groups. Of interest are applications that address multiple levels of risk, resilience, and causation across scientific disciplines, and that apply novel methods to advance knowledge of the interplay among genetic, environmental, neurobiological, and developmental factors and associated health and disease</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>outcomes. Priority will be given to research with a well described path towards translation and/or public health impact. In addition to novel data collection, approaches are encouraged that build on the research investments of NIH and sister HHS agencies to harness existing data on the epidemiology and etiology of drug misuse to improve public health prevention and treatment programs. The research areas noted below should be considered in the context of topics such as health disparities or inequities, familial/genetic liability, and physical, psychiatric, and polysubstance comorbidities and interactions.</p>				
109484	Notice of Special Interest (NOSI): Leveraging Data Science to Bring Actionable Insights for Substance use Prevention and Treatment	National Institute on Drug Abuse/NIH/DHHS	NOT-DA-23-006	05-Jun-2022	Not Specified
	Contact Name	Janet Kuramoto-Crawford, PhD			
	Contact Telephone	301-443-8856			
	Contact Email	janet.kuramoto-crawford@nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	05-Jun-2022 , 16-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 16-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 16-Feb-2023 , 07-May-2023 , 05-Jun-2023 , 16-Jun-2023 , 07-Sep-2023 , 05-Oct-2023 , 16-Oct-2023 , 07-Jan-2024 , 05-Feb-2024 , 16-Feb-2024 , 07-May-2024 , 05-Jun-2024 , 16-Jun-2024 , 07-Sep-2024 , 05-Oct-2024 , 16-Oct-2024 , 07-Jan-2025 , 05-Feb-2025 , 16-Feb-2025 , 07-May-2025 , 05-Jun-2025 , 16-Jun-2025 , 07-Sep-2025			
	Synopsis	This Notice encourages research projects that 1) leverage data science to provide actionable insights for substance use prevention and treatment 2) shorten the time between data capture and data availability so that data are available real-time or near real-time, and 3) explore methods and tools that may allow for faster or better localized responses for substance use treatment and prevention. Priority will be given to projects that emphasize the use of existing data streams (e.g., electronic health records, syndromic surveillance, claims data, registry data, pharmacy dispensing, social media, and mortality records).			
109316	RFA-RM-22-010 -- Somatic Mosaicism across Human Tissues (SMaHT) Program: Data Analysis Center (UM1 Clinical Trial Not Allowed)	National Institute on Drug Abuse/NIH/DHHS	RFA-RM-22-010	08-Jun-2022 [Optional][LOI/Pre-App]	Not Specified
	Contact Name	Amy C. Lossie, Ph.D.			
	Contact Telephone	301-827-6092			
	Contact Email	SMaHT@mail.nih.gov			
	Sponsor Website				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 08-Jun-2022 [Optional][LOI/Pre-App], 08-Jul-2022</p> <p>Synopsis This Funding Opportunity Announcement (FOA) invites applications to establish the Data Analysis Center (DAC) for the Somatic Mosaicism across Human Tissues (SMAHT) Network. The purpose of the SMAHT Network is to enable discovery of new biology and disease mechanisms mediated by genomic variation in somatic tissues. The Data Analysis Center will be responsible for the following areas: 1. Managing all data on behalf of the Network, including ingestion, uniform processing, and standardized annotation, and archiving of data; 2. Developing new computational methods and bioinformatics tools and deploying them as part of an accessible data workbench; 3. Building a data portal for the Network, including the SMAHT Variant Catalog and variant browser, and 4. Harmonizing SMAHT resources with related programs. This Funding Opportunity Announcement (FOA) is developed as a Common Fund initiative (http://commonfund.nih.gov/) through the NIH Office of the NIH Director, Office of Strategic Coordination (https://dpcpsi.nih.gov/). All NIH Institutes and Centers participate in Common Fund initiatives. The FOA will be administered by the National Institute of Drug Abuse (NIDA) on behalf of the NIH.</p>				
091370	NIMHD Exploratory/Developmental Research Grant Program (R21 - Clinical Trial Optional)	National Institute on Minority Health and Health Disparities/NIH/DHHS	PAR-20-150	07-May-2022	275,000 USD
	<p>Contact Name</p> <p>Contact Telephone 301-402-1366</p> <p>Contact Email GrantsInfo@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2022 , 16-Jun-2022 , 07-Sep-2022 , 16-Oct-2022 , 07-Jan-2023 , 16-Feb-2023 , 07-May-2023</p> <p>Synopsis NIMHD invites applications to support short-term exploratory or developmental research projects that have the potential to break new ground in the fields of minority health and/or health disparities or extend previous discoveries toward new directions or applications that can directly contribute to improving minority health and/or reducing health disparities in the U.S.</p>				
108660	Notice of Special Interest (NOSI): Validation of Digital Health and Artificial Intelligence Tools for Improved Assessment in Epidemiological, Clinical, and Intervention Research	National Institutes of Health/DHHS	NOT-CA-22-037	05-Apr-2022	Not Specified
	Contact Name Dana Wolff-Hughes, PhD				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Telephone 240-620-0673</p> <p>Contact Email dana.wolff@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 05-Apr-2022 , 07-May-2022 , 26-May-2022 , 05-Jun-2022 , 07-Jun-2022 , 08-Jun-2022 , 15-Jun-2022 , 16-Jun-2022 , 24-Jun-2022 , 11-Jul-2022 , 05-Sep-2022 , 07-Sep-2022 , 05-Oct-2022 , 07-Oct-2022 , 14-Oct-2022 , 16-Oct-2022 , 20-Oct-2022 , 01-Nov-2022 , 08-Nov-2022 , 14-Nov-2022 , 28-Dec-2022 , 05-Jan-2023 , 07-Jan-2023 , 05-Feb-2023 , 15-Feb-2023 , 16-Feb-2023 , 07-Mar-2023 , 10-Mar-2023 , 10-Mar-2023 , 05-Apr-2023 , 26-Apr-2023 , 07-May-2023 , 05-Jun-2023 , 07-Jun-2023 , 16-Jun-2023 , 10-Jul-2023 , 26-Aug-2023 , 05-Sep-2023 , 07-Sep-2023 , 05-Oct-2023 , 09-Oct-2023 , 16-Oct-2023 , 17-Oct-2023 , 01-Nov-2023 , 05-Nov-2023 , 13-Nov-2023 , 28-Dec-2023 , 05-Jan-2024 , 07-Jan-2024 , 05-Feb-2024 , 15-Feb-2024 , 16-Feb-2024 , 07-Mar-2024</p> <p>Synopsis The purpose of this Notice of Special Interest (NOSI) is to encourage grant applications to support the evaluation of the utility and validity of digital health and artificial intelligence (AI) tools and technologies in epidemiological, clinical, and intervention research. The intent is to support the addition of new measurement modalities to evaluate existing and recently developed but not yet validated digital health and AI tools such as sensor technologies, smartphone applications, software as a medical device (SaMD), and AI algorithms.</p>				
108347	<p>Notice of Special Interest (NOSI): Advancing NEI AGI Research on newly Identified Factors Into Models of Visual System Regeneration</p>	National Institutes of Health/DHHS	NOT-EY-22-002	05-Apr-2022	Not Specified
	<p>Contact Name </p> <p>Contact Telephone </p> <p>Contact Email </p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 05-Apr-2022 , 07-May-2022 , 05-Jun-2022 , 16-Jun-2022 , 25-Jun-2022 , 05-Sep-2022 , 07-Sep-2022 , 05-Oct-2022 , 16-Oct-2022 , 25-Oct-2022 , 05-Jan-2023 , 07-Jan-2023 , 05-Feb-2023 , 09-Feb-2023 , 16-Feb-2023 , 25-Feb-2023 , 05-Apr-2023 , 07-May-2023 , 05-Jun-2023 , 16-Jun-2023 , 25-Jun-2023 , 05-Sep-2023 , 07-Sep-2023 , 05-Oct-2023 , 16-Oct-2023 , 25-Oct-2023 , 05-Jan-2024 , 07-Jan-2024 , 05-Feb-2024 , 16-Feb-2024 , 25-Feb-2024 , 05-Apr-2024 , 07-May-2024 , 05-Jun-2024 , 16-Jun-2024 , 05-Sep-2024 , 07-Sep-2024 , 05-Oct-2024 , 16-Oct-2024</p> <p>Synopsis The National Eye Institute (NEI) is issuing this Notice of Special Interest (NOSI) to encourage novel research that incorporates newly identified factors into new or existing models of visual system regeneration. These factors were identified by a</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

consortium of research teams as part of the Audacious Goal Initiative (AGI) and are being shared broadly with the research community. Applicants beyond the original consortium are strongly encouraged to apply.

104784	Notice of Special Interest (NOSI): HIV Drug Resistance Assays and Actionable Data Dissemination Strategies	National Institutes of Health/DHHS	NOT-AI-21-056	05-Apr-2022	Not Specified
--------	--	------------------------------------	---------------	-------------	---------------

Contact Name	Usha Sharma, PhD
Contact Telephone	240-292-4809
Contact Email	usharma@niaid.nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	05-Apr-2022 , 07-May-2022 , 05-Jun-2022 , 16-Jun-2022 , 01-Jul-2022 , 05-Sep-2022 , 07-Sep-2022 , 05-Oct-2022 , 16-Oct-2022 , 05-Jan-2023 , 07-Jan-2023 , 05-Feb-2023 , 16-Feb-2023 , 17-Feb-2023 , 05-Apr-2023 , 07-May-2023 , 05-Jun-2023 , 16-Jun-2023 , 06-Jul-2023 , 05-Sep-2023 , 07-Sep-2023 , 05-Oct-2023 , 16-Oct-2023 , 05-Jan-2024 , 07-Jan-2024 , 05-Feb-2024 , 16-Feb-2024 , 05-Apr-2024 , 07-May-2024 , 05-Jun-2024 , 16-Jun-2024 , 07-Sep-2024
Synopsis	This Notice of Special Interest (NOSI) is to inform potential applicants of NIAID's interest in the development and optimization of next generation methodologies for HIV-1 drug resistance (DR) mutation detection and reporting. This is needed to improve the guidance available to treatment and prevention programs for both individuals and populations. Research responsive to this NOSI could include the development of: (i) highly sensitive mutation detection technologies that can be integrated into multiplex assay systems capable of simultaneous assessment of large numbers of potential mutations (ii) point of care (POC) DR assays, or (iii) strategies for rapid acquisition, curation and analysis of these HIV DR data and timely dissemination to healthcare providers and public health decision makers. Strategies applicable to low and middle income countries as defined by the World Bank are especially encouraged.

105957	Time-Sensitive Obesity Policy and Program Evaluation (R01 Clinical Trial Not Allowed)	National Institutes of Health/DHHS	PAR-21-305	11-Apr-2022	Not Specified
--------	---	------------------------------------	------------	-------------	---------------

Contact Name	Mary Evans, Ph.D.
Contact Telephone	301-594-4578
Contact Email	evansmary@mail.nih.gov
Sponsor Website	
Program URL	Link to program URL

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Deadline Dates (ALL)</p> <p>Synopsis</p>	<p>11-Apr-2022 , 10-May-2022 , 09-Jun-2022 , 11-Jul-2022 , 09-Aug-2022 , 09-Sep-2022 , 07-Oct-2022 , 09-Nov-2022 , 09-Dec-2022 , 10-Jan-2023 , 09-Feb-2023 , 09-Mar-2023 , 11-Apr-2023 , 09-May-2023 , 09-Jun-2023 , 11-Jul-2023 , 09-Aug-2023 , 08-Sep-2023 , 09-Oct-2023 , 10-Oct-2023 , 11-Dec-2023 , 09-Jan-2024 , 09-Feb-2024 , 08-Mar-2024 , 09-Apr-2024 , 08-May-2024 , 10-Jun-2024 , 09-Aug-2024 , 10-Sep-2024</p> <p>This Funding Opportunity Announcement (FOA) establishes an accelerated review/award process to support time-sensitive research to evaluate a new policy or program that is likely to influence obesity related behaviors (e.g., dietary intake, physical activity, sedentary behavior, and/or sleep) and/or weight outcomes in an effort to prevent or reduce obesity. This FOA is intended to support research where opportunities for empirical study are, by their very nature, only available through expedited review and funding. All applications submitted to this FOA must demonstrate that the evaluation of an obesity-related policy or program offers an uncommon and scientifically-compelling research opportunity that will only be available if the research is initiated with minimum delay. For these reasons, applications submitted to this time-sensitive FOA are not eligible for re-submission. It is intended that eligible applications selected for funding will be awarded within 4 months of the application due date; however, administrative requirements and other unforeseen circumstances may delay issuance dates beyond that timeline.</p>			
097189	<p>Assay Development and Screening for Discovery of Chemical Probes, Drugs or Immunomodulators (R01)</p>	National Institutes of Health/DHHS	PAR-20-271	05-May-2022 [Optional][LOI/Pre-App]	Not Specified
	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email</p> <p>Sponsor Website</p> <p>Program URL</p> <p>Deadline Dates (ALL)</p> <p>Synopsis</p>	<p>Suzanne Forry, Ph.D.</p> <p>240-276-5922</p> <p>forryscs@mail.nih.gov</p> <p></p> <p>Link to program URL</p> <p>05-May-2022 [Optional][LOI/Pre-App], 07-May-2022 , 05-Jun-2022 , 05-Sep-2022 [Optional][LOI/Pre-App], 05-Oct-2022 , 07-Jan-2023</p> <p>Through this funding opportunity announcement (FOA), NCI wishes to stimulate research in discovery and development of novel, small molecules for their potential use in studying disease treatment relevant to the missions of the participating NIH Institutes (NIDCD, NIMH); and to generate new insight into the biology of relevant diseases and processes that have yet to be validated as important drug targets. Stages of discovery research covered by this FOA include: 1) assay development; 2) primary screen implementation to identify initial screening hits (high throughput target-focused screens, or moderate throughput screens); 3) hit validation using a series of assays and initial medicinal chemistry inspection to prioritize the hit set; and 4) hit-to-lead optimization.</p>			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount														
101814	Notice of Special Interest (NOSI): Leveraging Real-World Imaging Data for Artificial Intelligence-based Modeling and Early Detection of Abdominal Cancers	National Institutes of Health/DHHS	NOT-CA-21-028	07-May-2022	Not Specified														
	<table border="0" style="width: 100%;"> <tr> <td style="width: 20%; vertical-align: top;">Contact Name</td> <td>Natalie Abrams, PhD</td> </tr> <tr> <td style="vertical-align: top;">Contact Telephone</td> <td>240-474-7336</td> </tr> <tr> <td style="vertical-align: top;">Contact Email</td> <td>natalie.abrams@nih.gov</td> </tr> <tr> <td style="vertical-align: top;">Sponsor Website</td> <td></td> </tr> <tr> <td style="vertical-align: top;">Program URL</td> <td>Link to program URL</td> </tr> <tr> <td style="vertical-align: top;">Deadline Dates (ALL)</td> <td>07-May-2022 , 05-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 07-May-2023 , 05-Jun-2023 , 07-Sep-2023 , 05-Oct-2023 , 07-Jan-2024</td> </tr> <tr> <td style="vertical-align: top;">Synopsis</td> <td>The purpose of this Notice of Special Interest (NOSI) is to solicit applications to support the secondary use of real-world data for Artificial Intelligence (AI)-based predictive modeling with the ultimate goal of improving early detection and risk assessment for abdominal cancers. This Notice encourages applications proposing multi-institutional collaborative AI development approaches such as federated learning, which distributes the models to data-owners and aggregates the results without sharing the actual data.</td> </tr> </table>					Contact Name	Natalie Abrams, PhD	Contact Telephone	240-474-7336	Contact Email	natalie.abrams@nih.gov	Sponsor Website		Program URL	Link to program URL	Deadline Dates (ALL)	07-May-2022 , 05-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 07-May-2023 , 05-Jun-2023 , 07-Sep-2023 , 05-Oct-2023 , 07-Jan-2024	Synopsis	The purpose of this Notice of Special Interest (NOSI) is to solicit applications to support the secondary use of real-world data for Artificial Intelligence (AI)-based predictive modeling with the ultimate goal of improving early detection and risk assessment for abdominal cancers. This Notice encourages applications proposing multi-institutional collaborative AI development approaches such as federated learning, which distributes the models to data-owners and aggregates the results without sharing the actual data.
Contact Name	Natalie Abrams, PhD																		
Contact Telephone	240-474-7336																		
Contact Email	natalie.abrams@nih.gov																		
Sponsor Website																			
Program URL	Link to program URL																		
Deadline Dates (ALL)	07-May-2022 , 05-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 07-May-2023 , 05-Jun-2023 , 07-Sep-2023 , 05-Oct-2023 , 07-Jan-2024																		
Synopsis	The purpose of this Notice of Special Interest (NOSI) is to solicit applications to support the secondary use of real-world data for Artificial Intelligence (AI)-based predictive modeling with the ultimate goal of improving early detection and risk assessment for abdominal cancers. This Notice encourages applications proposing multi-institutional collaborative AI development approaches such as federated learning, which distributes the models to data-owners and aggregates the results without sharing the actual data.																		
105617	Effectiveness of School-Based Health Centers to Advance Health Equity (R01 Clinical Trial Optional)	National Institutes of Health/DHHS	PAR-21-287	07-May-2022	Not Specified														
	<table border="0" style="width: 100%;"> <tr> <td style="width: 20%; vertical-align: top;">Contact Name</td> <td></td> </tr> <tr> <td style="vertical-align: top;">Contact Telephone</td> <td></td> </tr> <tr> <td style="vertical-align: top;">Contact Email</td> <td>GrantsInfo@nih.gov</td> </tr> <tr> <td style="vertical-align: top;">Sponsor Website</td> <td></td> </tr> <tr> <td style="vertical-align: top;">Program URL</td> <td>Link to program URL</td> </tr> <tr> <td style="vertical-align: top;">Deadline Dates (ALL)</td> <td>07-May-2022 , 05-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 07-May-2023 , 05-Jun-2023 , 07-Sep-2023 , 07-Jan-2024 , 05-Feb-2024 , 07-May-2024 , 05-Jun-2024 , 07-Sep-2024 , 05-Oct-2024 , 07-Jan-2025</td> </tr> <tr> <td style="vertical-align: top;">Synopsis</td> <td>The purpose of this Funding Opportunity Announcement is to support research that investigates the effectiveness of school-based health centers (SBHCs) as a health services care delivery model to address the needs of school-aged children from populations with health disparities (hence, underserved youth). The goals of this FOA are to support multidisciplinary research that investigates the effectiveness of SBHCs as a health services care delivery model to detect, manage, and prevent chronic illnesses that disproportionately burden underserved youth. The mechanisms of impact by which SBHCs</td> </tr> </table>					Contact Name		Contact Telephone		Contact Email	GrantsInfo@nih.gov	Sponsor Website		Program URL	Link to program URL	Deadline Dates (ALL)	07-May-2022 , 05-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 07-May-2023 , 05-Jun-2023 , 07-Sep-2023 , 07-Jan-2024 , 05-Feb-2024 , 07-May-2024 , 05-Jun-2024 , 07-Sep-2024 , 05-Oct-2024 , 07-Jan-2025	Synopsis	The purpose of this Funding Opportunity Announcement is to support research that investigates the effectiveness of school-based health centers (SBHCs) as a health services care delivery model to address the needs of school-aged children from populations with health disparities (hence, underserved youth). The goals of this FOA are to support multidisciplinary research that investigates the effectiveness of SBHCs as a health services care delivery model to detect, manage, and prevent chronic illnesses that disproportionately burden underserved youth. The mechanisms of impact by which SBHCs
Contact Name																			
Contact Telephone																			
Contact Email	GrantsInfo@nih.gov																		
Sponsor Website																			
Program URL	Link to program URL																		
Deadline Dates (ALL)	07-May-2022 , 05-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 07-May-2023 , 05-Jun-2023 , 07-Sep-2023 , 07-Jan-2024 , 05-Feb-2024 , 07-May-2024 , 05-Jun-2024 , 07-Sep-2024 , 05-Oct-2024 , 07-Jan-2025																		
Synopsis	The purpose of this Funding Opportunity Announcement is to support research that investigates the effectiveness of school-based health centers (SBHCs) as a health services care delivery model to address the needs of school-aged children from populations with health disparities (hence, underserved youth). The goals of this FOA are to support multidisciplinary research that investigates the effectiveness of SBHCs as a health services care delivery model to detect, manage, and prevent chronic illnesses that disproportionately burden underserved youth. The mechanisms of impact by which SBHCs																		

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

improve the health of at-risk populations such as sexual and gender minority youth, immigrant youth, and youth who reside in rural areas are also a relevant focus for understanding effective models of SBHCs. Applications are expected to provide a conceptual model that describes hypothesized causal pathways by which SBHCs engage underserved youth to improve health outcomes and how SBHCs may complement (or reduce) the use of other services. Lessons learned through this initiative can help determine whether SBHCs can be adopted as a best practice care model to address the health services needs of underserved youth and if so, whether SBHCs given their accessibility to students can be an effective site of intervention to address disparities in chronic conditions, and behavioral, oral, and reproductive health of youth from underserved communities who lack access to health care.

094015	Mentored Research Scientist Development Award (Parent K01 - Independent Clinical Trial Required)	National Institutes of Health/DHHS	PA-20-176	07-May-2022	Not Specified
--------	--	------------------------------------	-----------	-------------	---------------

Contact Name	
Contact Telephone	
Contact Email	grantsinfo@nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	07-May-2022 , 12-Jun-2022 , 07-Sep-2022 , 12-Oct-2022 , 07-Jan-2023 , 12-Feb-2023 , 07-May-2023
Synopsis	<p>The purpose of the NIH Mentored Research Scientist Development Award (K01) is to provide support and “protected time” (three to five years) for an intensive, supervised career development experience in the biomedical, behavioral, or clinical sciences leading to research independence. Although all of the participating NIH Institutes and Centers (ICs) use this support mechanism to support career development experiences that lead to research independence, some ICs use the K01 award for individuals who propose to train in a new field or for individuals who have had a hiatus in their research career because of illness or pressing family circumstances.. This Funding Opportunity Announcement (FOA) is designed specifically for candidates proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary clinical trial, as part of their research and career development. Those not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must apply to companion FOA (PA-20-190). Special Note: Not all NIH Institutes and Centers participate in Parent Announcements. Applicants should carefully note which ICs participate in this announcement and view their respective areas of research interest and requirements at the Table of IC-Specific Information, Requirements and Staff Contacts website. ICs that do not participate in this announcement will not consider applications for funding. Consultation with NIH staff before submitting an application is strongly encouraged.</p>

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
094020	Mentored Research Scientist Development Award (Parent K01 - Independent Clinical Trial Not Allowed)	National Institutes of Health/DHHS	PA-20-190	07-May-2022	Not Specified
	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email grantsinfo@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2022 , 12-Jun-2022 , 07-Sep-2022 , 12-Oct-2022 , 07-Jan-2023 , 12-Feb-2023 , 07-May-2023</p> <p>Synopsis The purpose of the NIH Mentored Research Scientist Development Award (K01) is to provide support and “protected time” (three to five years) for an intensive, supervised career development experience in the biomedical, behavioral, or clinical sciences leading to research independence. Although all of the participating NIH Institutes and Centers (ICs) use this support mechanism to support career development experiences that lead to research independence, some ICs use the K01 award for individuals who propose to train in a new field or for individuals who have had a hiatus in their research career because of illness or pressing family circumstances.. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or a separate ancillary clinical trial. Applicants to this FOA are permitted to propose research experience in a clinical trial led by a mentor or co-mentor. Applicants proposing a clinical trial or an ancillary clinical trial as lead investigator, should apply to the companion FOA. Special Note: Not all NIH Institutes and Centers participate in Parent Announcements. Applicants should carefully note which ICs participate in this announcement and view their respective areas of research interest and requirements at the Table of IC-Specific Information, Requirements and Staff Contacts website. ICs that do not participate in this announcement will not consider applications for funding. Consultation with NIH staff before submitting an application is strongly encouraged.</p>				
106062	Maximizing Opportunities for Scientific and Academic Independent Careers (MOSAIC) Postdoctoral Career Transition Award to Promote Diversity (K99/R00 Independent Clinical Trial Not Allowed)	National Institutes of Health/DHHS	PAR-21-271	07-May-2022	Not Specified
	<p>Contact Name Kenneth D. Gibbs, Jr., Ph.D.</p> <p>Contact Telephone</p> <p>Contact Email kenneth.gibbs@nih.gov</p> <p>Sponsor Website</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

Program URL	Link to program URL
Deadline Dates (ALL)	07-May-2022 , 12-Jun-2022 , 07-Sep-2022 , 12-Oct-2022 , 07-Jan-2023 , 12-Feb-2023 , 07-May-2023 , 12-Jun-2023 , 07-Sep-2023 , 12-Oct-2023 , 07-Jan-2024 , 12-Feb-2024 , 07-May-2024 , 12-Jun-2024 , 07-Sep-2024
Synopsis	<p>The purpose of the Maximizing Opportunities for Scientific and Academic Independent Careers (MOSAIC) Postdoctoral Career Transition Award to Promote Diversity (K99/R00) program is to support a cohort of early career, independent investigators from diverse backgrounds conducting research in NIH mission areas. The long-term goal of this program is to enhance diversity in the biomedical research workforce. The MOSAIC K99/R00 program is designed to facilitate a timely transition of promising postdoctoral researchers from diverse backgrounds (e.g., see Notice of NIH's Interest in Diversity) from their mentored, postdoctoral research positions to independent, tenure-track or equivalent research-intensive faculty positions. The MOSAIC K99/R00 program will provide independent NIH research support before and after this transition to help awardees launch successful, independent research careers. Additionally, MOSAIC K99/R00 scholars will be part of organized scientific cohorts and will be expected to participate in mentoring, networking, and professional development activities coordinated by MOSAIC Institutionally-Focused Research Education Award to Promote Diversity (UE5) grantees. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary clinical trial. Applicants to this FOA are permitted to propose research experience in a clinical trial led by a mentor or co-mentor. Applicants proposing a clinical trial or an ancillary clinical trial as lead investigator, should apply to the companion FOA PAR-21-272.</p>

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
108832	Notice of Special Interest (NOSI): Addressing Cancer-Related Financial Hardship to Improve Patient Outcomes	National Institutes of Health/DHHS	NOT-CA-22-045	07-May-2022	Not Specified

Contact Name	Kathleen Castro, RN, MS, AOCN
Contact Telephone	240-276-6834
Contact Email	kathleen.castro@mail.nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	07-May-2022 , 25-May-2022 , 05-Jun-2022 , 07-Jun-2022 , 16-Jun-2022 , 24-Jun-2022 , 07-Sep-2022 , 25-Sep-2022 , 05-Oct-2022 , 07-Oct-2022 , 16-Oct-2022 , 20-Oct-2022 , 08-Nov-2022 , 07-Jan-2023 , 25-Jan-2023 , 05-Feb-2023 , 16-Feb-2023 , 07-

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount	
				Mar-2023 , 25-May-2023 , 05-Jun-2023 , 07-Jun-2023 , 16-Jun-2023 , 25-Sep-2023 , 05-Oct-2023 , 07-Oct-2023 , 07-Oct-2023 , 16-Oct-2023 , 16-Oct-2023 , 05-Nov-2023 , 25-Jan-2024 , 05-Feb-2024 , 16-Feb-2024		
	Synopsis	The purpose of this Notice of Special Interest (NOSI) is to promote intervention research through investigator-initiated applications that aim to study ways to mitigate financial hardship for individuals impacted by a cancer diagnosis, including patients receiving cancer treatment, survivors, and caregivers.				
097158	Notice of Special Interest (NOSI): Stimulating Intervention Research to Reduce Cardiopulmonary Impacts of Particulate Matter in Air Pollution among High-Risk Populations	National Institutes of Health/DHHS	NOT-HL-20-788	07-May-2022	Not Specified	
	Contact Name	Lawrence J. Fine, MD, DrPH				
	Contact Telephone	301-435-0305				
	Contact Email	Lawrence.Fine@NIH.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	07-May-2022 , 05-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 07-May-2023 , 05-Jun-2023 , 07-Sep-2023				
	Synopsis	The purpose of this trans-NIH Notice of Special Interest (NOSI) is to inform potential applicants that the National Heart, Lung, and Blood Institute (NHLBI) and the National Institute of Environmental Health Sciences (NIEHS) have special interest in applications aiming to investigate the impact of personal interventions to reduce exposure to particulate matter (PM) in air pollution on cardiovascular and pulmonary (cardiopulmonary) outcomes. This notice specifically encourages intervention studies or clinical trials that examine the efficacy of personal air pollution interventions to reduce the adverse cardiopulmonary effects of Particulate Matter (PM) <2.5 µm in diameter (PM2.5) in high risk or vulnerable participants.				
102694	Notice of Special Interest (NOSI): Using Systems Science Methodologies to Protect and Improve Child and Reproductive Population Health	National Institutes of Health/DHHS	NOT-HD-20-032	07-May-2022	Not Specified	
	Contact Name	Regina M. Bures, Ph.D.				
	Contact Telephone	301-496-9485				
	Contact Email	regina.bures@nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Deadline Dates (ALL)	07-May-2022 , 05-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 07-May-2023 , 05-Jun-2023 , 07-Sep-2023 , 05-Oct-2023 , 07-Jan-2024 , 05-Feb-2024 , 07-May-2024			
	Synopsis	The purpose of this Notice of Special Interest (NOSI) is to solicit applications to support multi-disciplinary scientific teams proposing research using systems science approaches to address persistent public health challenges. Systems science refers to multi-level methodologies addressing complex behavioral and social phenomena. This initiative encourages applications for both basic and applied research, including methodological and measurement development, with a focus on human behavioral and/or social science. This initiative also seeks to promote interdisciplinary collaboration among health researchers and experts in mathematical modelling.			
108369	RFA-AR-22-009 -- HEAL Initiative: Restoring Joint Health and Function to Reduce Pain Consortium (RE-JOIN) (UC2 Clinical Trial Not Allowed)	National Institutes of Health/DHHS	RFA-AR-22-009	07-May-2022	8,000,000 USD
	Contact Name	Leslie K. Derr, PhD			
	Contact Telephone	301-594-8174			
	Contact Email	leslie.derr@nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	07-May-2022 , 05-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 07-May-2023 , 05-Jun-2023 , 07-Sep-2023 , 05-Oct-2023 , 07-Jan-2024 , 05-Feb-2024 , 07-May-2024 , 05-Jun-2024 , 07-Sep-2024 , 05-Oct-2024 , 07-Jan-2025 , 05-Feb-2025 , 07-May-2025			
	Synopsis	The purpose of this Funding Opportunity Announcement is to solicit cooperative agreement applications from interdisciplinary teams that will cooperatively form the Restoring Joint Health and Function to Reduce Pain Consortium (RE-JOIN). The goal of RE-JOIN will be to define the innervation of the different articular and peri-articular tissues that collectively form the joint (including bone, cartilage, synovium, joint capsule, ligament, tendon, fascia and muscle), by sensory neurons that mediate the sensation of pain. Knowledge about the types and distribution of neurites in joint tissues will facilitate the identification of key receptors and mediators that induce pain by activating specific sensory neurons. These mediators and their receptors will provide novel targets for reducing pain. Each Research Team will conduct a research project to map the sensory innervation of the joint tissues in animal models, human tissues, or both. Research Teams projects must focus on at least one of the high priority joint types listed in the FOA and are encouraged to include a description of specific plans to extend the project to other joints and, if the primary focus is animal models, to human tissue. This FOA also provides the opportunity to further adapt or develop technologies that would improve the ability to map neurons in joint tissues. Data harmonization, integration and visualization will require extensive coordination between teams. The goal will be to integrate data from the different teams to produce models of innervation in different joints.			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
103908	Notice of Special Interest (NOSI): NIH Research Project Grant (R01) Applications from Individuals from Diverse Backgrounds, Including Under-Represented Minorities	National Institutes of Health/DHHS	NOT-NS-21-049	07-May-2022	Not Specified
	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2022 , 05-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 07-May-2023</p> <p>Synopsis The National Institute of Neurological Disorders and Stroke seeks to promote diversity in all of its research programs and to increase the participation of underrepresented groups. As the US population becomes increasingly diverse, reflection of that diversity among the biomedical research workforce is vital to our science enterprise and the NIH research mission (See NOT-OD-20-031). NIH is committed to implementing approaches to address the funding gap for researchers from diverse backgrounds and “committed to instituting new ways to support diversity, equity, and inclusion, and identifying and dismantling any policies and practices that may harm our workforce and our science”. This Notice is being issued to highlight interest in receiving research project applications submitted by investigators from diverse backgrounds.</p>				
094038	Mentored Quantitative Research Development Award (Parent K25 Independent Clinical Trial Required)	National Institutes of Health/DHHS	PA-20-197	07-May-2022	Not Specified
	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email grantinfo@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2022 , 12-Jun-2022 , 07-Sep-2022 , 12-Oct-2022 , 07-Jan-2023 , 12-Feb-2023 , 07-May-2023</p> <p>Synopsis The purpose of the Mentored Quantitative Research Career Development Award (K25) is to attract to NIH-relevant research those investigators whose quantitative science and engineering research has thus far not been focused primarily on questions of health and disease. The K25 award will provide support and "protected time" for a period of supervised study and research for productive professionals with quantitative (e.g., mathematics, statistics, economics, computer science, imaging science, informatics, physics, chemistry) and engineering backgrounds to integrate their expertise with NIH-relevant research. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing to serve as the</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary clinical trial, as part of their research and career development. Applicants not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must apply to companion FOA. Special Note: Not all NIH Institutes and Centers participate in Parent Announcements. Applicants should carefully note which ICs participate in this announcement and view their respective areas of research interest and requirements at the Table of IC-Specific Information, Requirements and Staff Contacts website. ICs that do not participate in this announcement will not consider applications for funding. Consultation with NIH staff before submitting an application is strongly encouraged.</p>				
094234	Mentored Clinical Scientist Research Career Development Award (Parent K08 Independent Clinical Trial Required)	National Institutes of Health/DHHS	PA-20-202	07-May-2022	Not Specified
	<p>Contact Name</p> <p>Contact Telephone 301-496-8580</p> <p>Contact Email grantinfo@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2022 , 12-Jun-2022 , 07-Sep-2022 , 12-Oct-2022 , 07-Jan-2023 , 12-Feb-2023 , 07-May-2023</p> <p>Synopsis The primary purpose of the NIH Mentored Clinical Scientist Research Career Development Awards (K08) program is to prepare qualified individuals for careers that have a significant impact on the health-related research needs of the Nation. This program represents the continuation of a long-standing NIH program that provides support and "protected time" to individuals with a clinical doctoral degree for an intensive, supervised research career development experience in the fields of biomedical and behavioral research, including translational research. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary clinical trial, as part of their research and career development. Applicants not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must apply to companion FOA. Special Note: Not all NIH Institutes and Centers participate in Parent Announcements. Applicants should carefully note which ICs participate in this announcement and view their respective areas of research interest and requirements at the Table of IC-Specific Information, Requirements and Staff Contacts website. ICs that do not participate in this announcement will not consider applications for funding. Consultation with NIH staff before submitting an application is strongly encouraged.</p>				
094040	Mentored Quantitative Research Development Award (Parent K25 Independent Basic Experimental Studies with Humans Required)	National Institutes of Health/DHHS	PA-20-198	07-May-2022	Not Specified

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

	Contact Name Contact Telephone Contact Email Sponsor Website Program URL Link to program URL				
	Deadline Dates (ALL) 07-May-2022 , 12-Jun-2022 , 07-Sep-2022 , 12-Oct-2022 , 07-Jan-2023 , 12-Feb-2023 , 07-May-2023				
	Synopsis	The purpose of the Mentored Quantitative Research Career Development Award (K25) is to attract to NIH-relevant research those investigators whose quantitative science and engineering research has thus far not been focused primarily on questions of health and disease. The K25 award will provide support and "protected time" for a period of supervised study and research for productive professionals with quantitative (e.g., mathematics, statistics, economics, computer science, imaging science, informatics, physics, chemistry) and engineering backgrounds to integrate their expertise with NIH-relevant research. This Parent Funding Opportunity Announcement is for basic science experimental studies involving humans, referred to in NOT-OD-18-212 as "prospective basic science studies involving human participants." These studies fall within the NIH definition of a clinical trial and also meet the definition of basic research. Types of studies that should be submitted under this FOA include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental aspects of phenomena without specific application towards processes or products in mind. Applicants not planning an independent clinical trial or basic experimental study with humans, or proposing to gain research experience in a clinical trial or basic experimental study with humans led by another investigator, must apply to the 'Independent Clinical Trial Not Allowed' companion FOA. The proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) based on their scientific missions. Special Note: Not all NIH Institutes and Centers participate in Parent Announcements. Applicants should carefully note which ICs participate in this announcement and view their respective areas of research interest and requirements at the Table of IC-Specific Information, Requirements and Staff Contacts website. ICs that do not participate in this announcement will not consider applications for funding. Consultation with NIH staff before submitting an application is strongly encouraged.			

094235	Mentored Clinical Scientist Research Career Development Award (Parent K08 Independent Clinical Trial Not Allowed)	National Institutes of Health/DHHS	PA-20-203	07-May-2022	Not Specified
--------	---	------------------------------------	-----------	-------------	---------------

Contact Name	
Contact Telephone	301-496-8580
Contact Email	grantinfo@nih.gov

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2022 , 12-Jun-2022 , 07-Sep-2022 , 12-Oct-2022 , 07-Jan-2023 , 12-Feb-2023 , 07-May-2023</p> <p>Synopsis The primary purpose of the NIH Mentored Clinical Scientist Research Career Development Awards (K08) program is to prepare qualified individuals for careers that have a significant impact on the health-related research needs of the Nation. This program represents the continuation of a long-standing NIH program that provides support and "protected time" to individuals with a clinical doctoral degree for an intensive, supervised research career development experience in the fields of biomedical and behavioral research, including translational research. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary clinical trial. Applicants to this FOA are permitted to propose research experience in a clinical trial led by a mentor or co-mentor. Applicants proposing a clinical trial or an ancillary clinical trial as lead investigator, should apply to the companion FOA. Special Note: Not all NIH Institutes and Centers participate in Parent Announcements. Applicants should carefully note which ICs participate in this announcement and view their respective areas of research interest and requirements at the website. ICs that do not participate in this announcement will not consider applications for funding. Consultation with NIH staff before submitting an application is strongly encouraged.</p>				
094233	<p>Mentored Clinical Scientist Research Career Development Award (Parent K08 Independent Basic Experimental Studies with Humans Required)</p>	National Institutes of Health/DHHS	PA-20-201	07-May-2022	Not Specified
	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2022 , 12-Jun-2022 , 07-Sep-2022 , 12-Oct-2022 , 07-Jan-2023 , 12-Feb-2023 , 07-May-2023</p> <p>Synopsis The primary purpose of the NIH Mentored Clinical Scientist Research Career Development Awards (K08) program is to prepare qualified individuals for careers that have a significant impact on the health-related research needs of the Nation. This program represents the continuation of a long-standing NIH program that provides support and "protected time" to individuals with a clinical doctoral degree for an intensive, supervised research career development experience in the fields of biomedical and behavioral research, including translational research. This Parent Funding Opportunity Announcement is for basic science experimental studies involving humans, referred to in NOT-OD-18-212 as "prospective basic science studies involving human participants." These studies fall within the NIH definition of a clinical trial and also meet the definition of</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

basic research. Types of studies that should be submitted under this FOA include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental aspects of phenomena without specific application towards processes or products in mind. Applicants not planning an independent clinical trial or basic experimental study with humans, or proposing to gain research experience in a clinical trial or basic experimental study with humans led by another investigator, must apply to the 'Independent Clinical Trial Not Allowed' companion FOA. The proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) based on their scientific missions. Special Note: Not all NIH Institutes and Centers participate in Parent Announcements. Applicants should carefully note which ICs participate in this announcement and view their respective areas of research interest and requirements at the Table of IC-Specific Information, Requirements and Staff Contacts website. ICs that do not participate in this announcement will not consider applications for funding. Consultation with NIH staff before submitting an application is strongly encouraged.

094044	Mentored Quantitative Research Development Award (Parent K25 Independent Clinical Trial Not Allowed)	National Institutes of Health/DHHS	PA-20-199	07-May-2022	Not Specified
--------	--	------------------------------------	-----------	-------------	---------------

Contact Name	
Contact Telephone	
Contact Email	grantinfo@nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	07-May-2022 , 12-Jun-2022 , 07-Sep-2022 , 12-Oct-2022 , 07-Jan-2023 , 12-Feb-2023 , 07-May-2023
Synopsis	<p>The purpose of the Mentored Quantitative Research Career Development Award (K25) is to attract to NIH-relevant research those investigators whose quantitative science and engineering research has thus far not been focused primarily on questions of health and disease. The K25 award will provide support and "protected time" for a period of supervised study and research for productive professionals with quantitative (e.g., mathematics, statistics, economics, computer science, imaging science, informatics, physics, chemistry) and engineering backgrounds to integrate their expertise with NIH-relevant research. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary clinical trial. Applicants to this FOA are permitted to propose research experience in a clinical trial led by a mentor or co-mentor. Applicants proposing a clinical trial or an ancillary clinical trial as lead investigator, should apply to the companion FOA (PA-20-197). Special Note: Not all NIH Institutes and Centers participate in Parent Announcements. Applicants should carefully note which ICs participate in this announcement and view their respective areas of research interest and requirements at the Table of IC-</p>

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

Specific Information, Requirements and Staff Contacts website. ICs that do not participate in this announcement will not consider applications for funding. Consultation with NIH staff before submitting an application is strongly encouraged.

094026	Mentored Research Scientist Development Award (Parent K01 Independent Basic Experimental Studies with Humans Required)	National Institutes of Health/DHHS	PA-20-191	07-May-2022	Not Specified
--------	--	------------------------------------	-----------	-------------	---------------

<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email</p> <p>Sponsor Website</p> <p>Program URL</p> <p>Deadline Dates (ALL)</p>	<p>Link to program URL</p> <p>07-May-2022 , 12-Jun-2022 , 07-Sep-2022 , 12-Oct-2022 , 07-Jan-2023 , 12-Feb-2023 , 07-May-2023</p>
<p>Synopsis</p>	<p>The purpose of the NIH Mentored Research Scientist Development Award (K01) is to provide support and “protected time” (three to five years) for an intensive, supervised career development experience in the biomedical, behavioral, or clinical sciences leading to research independence. Although all of the participating NIH Institutes and Centers (ICs) use this support mechanism to support career development experiences that lead to research independence, some ICs use the K01 award for individuals who propose to train in a new field or for individuals who have had a hiatus in their research career because of illness or pressing family circumstances. This Parent Funding Opportunity Announcement is for basic science experimental studies involving humans, referred to in NOT-OD-18-212 as “prospective basic science studies involving human participants.” These studies fall within the NIH definition of a clinical trial and also meet the definition of basic research. Types of studies that should be submitted under this FOA include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental aspects of phenomena without specific application towards processes or products in mind. Applicants not planning an independent clinical trial or basic experimental study with humans, or proposing to gain research experience in a clinical trial or basic experimental study with humans led by another investigator, must apply to the 'Independent Clinical Trial Not Allowed' companion FOA. The proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) based on their scientific missions. Special Note: Not all NIH Institutes and Centers participate in Parent Announcements. Applicants should carefully note which ICs participate in this announcement and view their respective areas of research interest and requirements at the Table of IC-Specific Information, Requirements and Staff Contacts website. ICs that do not participate in this announcement will not consider applications for funding. Consultation with NIH staff before submitting an application is strongly encouraged.</p>

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
103220	Notice of Special Interest (NOSI): COVID-19 Related School Disruptions Impact on Mental Health, Cognitive, Social, and Emotional Development of Children	National Institutes of Health/DHHS	NOT-MH-21-225	07-May-2022	Not Specified
	<p>Contact Name Susan Borja, PhD</p> <p>Contact Telephone 301-443-1252</p> <p>Contact Email susan.borja@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2022 , 05-Jun-2022 , 07-Sep-2022</p> <p>Synopsis NIMH is issuing this Notice of Special Interest (NOSI) to highlight interest in research to understand the mental health impact of the Coronavirus Disease 2019 (COVID-19) pandemic on school-aged children, specifically ages 3 - 12. Particularly, we are interested in the potential impact of primary instruction settings disruptions (e.g., pre-school, elementary school) on the mental health, cognitive, social, and emotional development of children. Empirical data would aid in balancing health risks for various public health mitigation strategies affecting children in the current pandemic as well as inform how to both be prepared and respond to future public health emergencies, including pandemics and disaster scenarios.</p>				
108001	Notice of Special Interest (NOSI): Epidemiologic studies in Asian Americans, Native Hawaiians, and Pacific Islanders (Parent R01 Clinical Trial Not Allowed)	National Institutes of Health/DHHS	NOT-HL-23-001	07-May-2022	Not Specified
	<p>Contact Name Robb Rowley, MD</p> <p>Contact Telephone 301-827-9126</p> <p>Contact Email Robb.Rowley@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2022 , 05-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 07-May-2023 , 05-Jun-2023 , 07-Sep-2023 , 05-Oct-2023 , 07-Jan-2024 , 05-Feb-2024 , 07-May-2024 , 05-Jun-2024 , 07-Sep-2024 , 05-Oct-2024</p> <p>Synopsis The purpose of this Notice of Special Interest (NOSI) is to stimulate novel epidemiological research to address key knowledge gaps within and between subpopulations of Asian Americans, Native Hawaiians, and Pacific Islanders. These populations are frequently aggregated in research, potentially masking important social and health differences. Given clear heterogeneity in ancestry, culture, immigration patterns among Asian Americans, socioeconomic position, and acculturation into American life, a critical need exists for epidemiological research to enhance our understanding of the interplay of environmental</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		exposures, lifestyle, behavioral, genomics, social, neighborhood, and biological factors that impact the health of Asian American, Native Hawaiian, and Pacific Islander subpopulations.			
104359	Comprehensive Care for Adults with Type 2 Diabetes Mellitus from Populations with Health Disparities (R01 Clinical Trial Optional)	National Institutes of Health/DHHS	PA-21-232	07-May-2022	2,500,000 USD
	Contact Name	Larissa Aviles-Santa, MD, MPH			
	Contact Telephone	301-827-6924			
	Contact Email	avilessantal@mail.nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	07-May-2022 , 05-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 07-May-2023 , 05-Jun-2023 , 07-Sep-2023 , 07-Jan-2024 , 05-Feb-2024 , 07-May-2024 , 05-Jun-2024 , 07-Sep-2024			
	Synopsis	This initiative will support innovative research to develop, test and evaluate multi-level/multi-component strategies (including models of health care) to effectively adapt and implement comprehensive clinical care for individuals with Type 2 diabetes mellitus from populations with health disparities concordant with recommended and evidence-based guidelines.			
104854	Notice of Special Interest (NOSI): Harnessing Big Data to Halt HIV	National Institutes of Health/DHHS	NOT-AI-21-054	07-May-2022	Not Specified
	Contact Name	Rosemary McKaig, M.P.H, Ph.D.			
	Contact Telephone	240-627-3214			
	Contact Email	rm434n@nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	07-May-2022 , 05-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 07-May-2023 , 05-Jun-2023 , 07-Sep-2023 , 05-Oct-2023 , 07-Jan-2024 , 05-Feb-2024 , 07-May-2024			
	Synopsis	The purpose of this Notice of Special Interest (NOSI) is to promote and support innovative methods in Big Data Science (BDS) to identify unappreciated biomedical, behavioral, social patterns and other social determinants that shed light on HIV acquisition, transmission, the development of comorbidities, and long-term viral control as in the HIV treatment continuum. BDS approaches can bring together data to evaluate the complex interplay between individual, contextual, and structural factors influencing the epidemiology of risk and care. Further, because this field can reveal unexpected associations through			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>analysis of diverse data, BDS approaches may reveal events that are unseen or transient in traditional analysis of datasets. Discovery of these events will considerably advance research on HIV networks of transmission and the care continuum. This NOSI will support the establishment of BDS standards, bioinformatics data tools, machine-learning algorithms, mathematical modeling, advanced epidemiology and statistical analytic methods, and consideration and application of privacy and ethical issues in the use of public and personal data in the context of HIV research.</p>				
104500	Notice of Special Interest (NOSI): Behavioral Economics for Implementation Research (BEIR) to Improve Use of Evidence-Based Practices for HLBS Conditions	National Institutes of Health/DHHS	NOT-HL-21-010	07-May-2022	Not Specified
	<p>Contact Name: Rebecca A. Roper, MS, MPH Contact Telephone: 301-496-1051 Contact Email: Rebecca.Roper@nih.gov Sponsor Website: Program URL: Link to program URL Deadline Dates (ALL): 07-May-2022 , 05-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 07-May-2023 , 05-Jun-2023 , 07-Sep-2023 , 05-Oct-2023 , 07-Jan-2024 , 05-Feb-2024 , 07-May-2024 , 05-Jun-2024 , 07-Sep-2024 Synopsis: This Notice of Special Interest (NOSI) is intended to stimulate the use of behavioral economics strategies for implementation research (BEIR) in order to develop more effective strategies for implementation of evidence-based practices (EBP) to address heart, lung, blood, and sleep (HLBS) conditions. NHLBI encourages applications that recognize the importance of cultural context, patterns of behavior change, and motivators for change across decision-making levels, including individuals (e.g., patients, parents, clinicians, others), groups, healthcare systems and/or communities. Applications that focus on the use of behavioral economics to develop implementation strategies for user-driven, sustainable interventions that may be simplified and minimally disruptive when possible are encouraged. Applications may propose either a clinical trial or non-clinical trial design, as appropriate to the research objectives.</p>				
106925	Notice of Special Interest (NOSI): Promoting Research To Understand Vascular Contributions to Cognitive Impairment and Dementia (VCID)	National Institutes of Health/DHHS	NOT-HL-23-002	07-May-2022	Not Specified
	<p>Contact Name: Jue Chen, Ph.D. Contact Telephone: 301-435-0550 Contact Email: jue.chen@nih.gov Sponsor Website: Program URL: Link to program URL</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Deadline Dates (ALL)	07-May-2022 , 05-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 07-May-2023 , 05-Jun-2023 , 07-Sep-2023 , 05-Oct-2023 , 07-Jan-2024 , 05-Feb-2024 , 07-May-2024 , 05-Jun-2024 , 07-Sep-2024 , 05-Oct-2024 , 07-Jan-2025 , 05-Feb-2025 , 07-May-2025			
	Synopsis	The purpose of this Notice is to inform potential applicants about an area of special interest to NHLBI, NINDS and NIA in research to understand mechanisms of vascular contributions to cognitive impairment and dementia (VCID) and to develop new approaches for the treatment of VCID.			
093932	NIH Pathway to Independence Award (Parent K99/R00 Independent Clinical Trial Not Allowed)	National Institutes of Health/DHHS	PA-20-188	07-May-2022	Not Specified

	Contact Name				
	Contact Telephone				
	Contact Email	grantinfo@nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	07-May-2022 , 12-Jun-2022 , 07-Sep-2022 , 12-Oct-2022 , 07-Jan-2023 , 12-Feb-2023 , 07-May-2023			
	Synopsis	The purpose of the NIH Pathway to Independence Award (K99/R00) program is to facilitate a timely transition of outstanding postdoctoral researchers with a research and/or clinical doctorate degree from mentored, postdoctoral research positions to independent, tenure-track or equivalent faculty positions. The program will provide independent NIH research support during this transition in order to help awardees to launch competitive, independent research careers. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary clinical trial. Applicants to this FOA are permitted to propose research experience in a clinical trial led by a mentor or co-mentor. Applicants proposing a clinical trial or an ancillary clinical trial as lead investigator, should apply to the companion FOA. Special Note: Not all NIH Institutes and Centers participate in Parent Announcements. Applicants should carefully note which ICs participate in this announcement and view their respective areas of research interest and requirements at the Table of IC-Specific Information, Requirements and Staff Contacts website. ICs that do not participate in this announcement will not consider applications for funding. Consultation with NIH staff before submitting an application is strongly encouraged.			

093935	NIH Pathway to Independence Award (Parent K99/R00 Independent Basic Experimental Studies with Humans Required)	National Institutes of Health/DHHS	PA-20-189	07-May-2022	Not Specified
--------	--	------------------------------------	-----------	-------------	---------------

Contact Name

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Telephone</p> <p>Contact Email</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2022 , 12-Jun-2022 , 07-Sep-2022 , 12-Oct-2022 , 07-Jan-2023 , 12-Feb-2023 , 07-May-2023</p> <p>Synopsis</p> <p>The purpose of the NIH Pathway to Independence Award (K99/R00) program is to facilitate a timely transition of outstanding postdoctoral researchers with a research and/or clinical doctorate degree from mentored, postdoctoral research positions to independent, tenure-track or equivalent faculty positions. The program will provide independent NIH research support during this transition in order to help awardees to launch competitive, independent research careers. This Parent Funding Opportunity Announcement is for basic science experimental studies involving humans, referred to in NOT-OD-18-212 as “prospective basic science studies involving human participants.” These studies fall within the NIH definition of a clinical trial and also meet the definition of basic research. Types of studies that should be submitted under this FOA include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental aspects of phenomena without specific application towards processes or products in mind. Applicants not planning an independent clinical trial or basic experimental study with humans, or proposing to gain research experience in a clinical trial or basic experimental study with humans led by another investigator, must apply to the 'Independent Clinical Trial Not Allowed' companion FOA. The proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) based on their scientific missions. Special Note: Not all NIH Institutes and Centers participate in Parent Announcements. Applicants should carefully note which ICs participate in this announcement and view their respective areas of research interest and requirements at the Table of IC-Specific Information, Requirements and Staff Contacts website. ICs that do not participate in this announcement will not consider applications for funding. Consultation with NIH staff before submitting an application is strongly encouraged.</p>				
093931	NIH Pathway to Independence Award (Parent K99/R00 Independent Clinical Trial Required)	National Institutes of Health/DHHS	PA-20-187	07-May-2022	Not Specified
	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email grantinfo@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Deadline Dates (ALL) 07-May-2022 , 12-Jun-2022 , 07-Sep-2022 , 12-Oct-2022 , 07-Jan-2023 , 12-Feb-2023 , 07-May-2023</p> <p>Synopsis The purpose of the NIH Pathway to Independence Award (K99/R00) program is to facilitate a timely transition of outstanding postdoctoral researchers with a research and/or clinical doctorate degree from mentored, postdoctoral research positions to independent, tenure-track or equivalent faculty positions. The program will provide independent NIH research support during this transition in order to help awardees to launch competitive, independent research careers. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary clinical trial, as part of their research and career development. Applicants not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must apply to companion FOA.</p>				
093955	Midcareer Investigator Award in Patient-Oriented Research (Parent K24 Independent Clinical Trial Required)	National Institutes of Health/DHHS	PA-20-193	07-May-2022	Not Specified
	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email grantinfo@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2022 , 12-Jun-2022 , 07-Sep-2022 , 12-Oct-2022 , 07-Jan-2023 , 12-Feb-2023 , 07-May-2023</p> <p>Synopsis The purpose of the NIH Midcareer Investigator Award in Patient-Oriented Research (K24) is to provide support to mid-career health-professional doctorates for protected time to devote to patient-oriented research (POR) and to act as research mentors for junior clinical investigators pursuing POR research, such as clinical residents.. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary clinical trial, as part of their research and career development. Applicants not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must apply to companion FOA. Special Note: Not all NIH Institutes and Centers participate in Parent Announcements. Applicants should carefully note which ICs participate in this announcement and view their respective areas of research interest and requirements at the Table of IC-Specific Information, Requirements and Staff Contacts website. ICs that do not participate in this announcement will not consider applications for funding. Consultation with NIH staff before submitting an application is strongly encouraged.</p>				
093953	Midcareer Investigator Award in Patient-Oriented Research (Parent K24 Independent Clinical Trial Not Allowed)	National Institutes of Health/DHHS	PA-20-186	07-May-2022	Not Specified

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email grantinfo@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2022 , 12-Jun-2022 , 07-Sep-2022 , 12-Oct-2022 , 07-Jan-2023 , 12-Feb-2023 , 07-May-2023</p> <p>Synopsis The purpose of the NIH Midcareer Investigator Award in Patient-Oriented Research (K24) is to provide support to mid-career health-professional doctorates for protected time to devote to patient-oriented research (POR) and to act as research mentors for junior clinical investigators pursuing POR research, such as clinical residents and/or junior clinical faculty. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary clinical trial. Applicants to this FOA are permitted to propose research experience in a clinical trial led by another investigator. Applicants proposing a clinical trial or an ancillary clinical trial as lead investigator, should apply to the companion FOA. Special Note: Not all NIH Institutes and Centers participate in Parent Announcements. Applicants should carefully note which ICs participate in this announcement and view their respective areas of research interest and requirements at the Table of IC-Specific Information, Requirements and Staff Contacts website. ICs that do not participate in this announcement will not consider applications for funding. Consultation with NIH staff before submitting an application is strongly encouraged.</p>				
093954	Midcareer Investigator Award in Patient-Oriented Research (Parent K24 Independent Basic Experimental Studies with Humans Required)	National Institutes of Health/DHHS	PA-20-192	07-May-2022	Not Specified
	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2022 , 12-Jun-2022 , 07-Sep-2022 , 12-Oct-2022 , 07-Jan-2023 , 12-Feb-2023 , 07-May-2023</p> <p>Synopsis The purpose of the NIH Midcareer Investigator Award in Patient-Oriented Research (K24) is to provide support to mid-career health-professional doctorates for protected time to devote to patient-oriented research (POR) and to act as research mentors for junior clinical investigators pursuing POR research, such as clinical residents and junior clinical faculty. This Parent Funding Opportunity Announcement is for basic science experimental studies involving humans, referred to in NOT-</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

OD-18-212 as “prospective basic science studies involving human participants.” These studies fall within the NIH definition of a clinical trial and also meet the definition of basic research. Types of studies that should be submitted under this FOA include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental aspects of phenomena without specific application towards processes or products in mind. Applicants not planning an independent clinical trial or basic experimental study with humans, or proposing to gain research experience in a clinical trial or basic experimental study with humans led by another investigator, must apply to the 'Independent Clinical Trial Not Allowed' companion FOA. The proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) based on their scientific missions. Special Note: Not all NIH Institutes and Centers participate in Parent Announcements. Applicants should carefully note which ICs participate in this announcement and view their respective areas of research interest and requirements at the Table of IC-Specific Information, Requirements and Staff Contacts website. ICs that do not participate in this announcement will not consider applications for funding. Consultation with NIH staff before submitting an application is strongly encouraged.

093214	Independent Scientist Award (Parent K02 Independent Basic Experimental Studies with Humans Required)	National Institutes of Health/DHHS	PA-20-173	07-May-2022	Not Specified
--------	--	------------------------------------	-----------	-------------	---------------

Contact Name	
Contact Telephone	
Contact Email	grantinfo@nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	07-May-2022 , 12-Jun-2022 , 07-Sep-2022 , 12-Oct-2022 , 07-Jan-2023 , 12-Feb-2023 , 07-May-2023
Synopsis	<p>The purpose of the NIH Independent Scientist Award (K02) is to foster the development of outstanding scientists and enable them to expand their potential to make significant contributions to their field of research. The K02 award provides three to five years of salary support and "protected time" for newly independent scientists who can demonstrate the need for a period of intensive research focus as a means of enhancing their research careers. Each independent scientist career award program must be tailored to meet the individual needs of the candidate. This Parent Funding Opportunity Announcement is for basic science experimental studies involving humans, referred to in NOT-OD-18-212 as “prospective basic science studies involving human participants.” These studies fall within the NIH definition of a clinical trial and also meet the definition of basic research. Types of studies that should be submitted under this FOA include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental aspects of phenomena without specific application</p>

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

towards processes or products in mind. Applicants not planning an independent clinical trial or basic experimental study with humans, or proposing to gain research experience in a clinical trial or basic experimental study with humans led by another investigator, must apply to the 'Independent Clinical Trial Not Allowed' companion FOA. The proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) based on their scientific missions.

093210	Independent Scientist Award (Parent K02 - Independent Clinical Trial Required)	National Institutes of Health/DHHS	PA-20-171	07-May-2022	Not Specified
--------	--	------------------------------------	-----------	-------------	---------------

Contact Name	
Contact Telephone	
Contact Email	grantinfo@nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	07-May-2022 , 12-Jun-2022 , 07-Sep-2022 , 12-Oct-2022 , 07-Jan-2023 , 12-Feb-2023 , 07-May-2023
Synopsis	The purpose of the NIH Independent Scientist Award (K02) is to foster the development of outstanding scientists and enable them to expand their potential to make significant contributions to their field of research. The K02 award provides three to five years of salary support and "protected time" for newly independent scientists who can demonstrate the need for a period of intensive research focus as a means of enhancing their research careers. Each independent scientist career award program must be tailored to meet the individual needs of the candidate. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary clinical trial, as part of their research and career development. Applicants not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must apply to companion FOA.

093225	Independent Scientist Award (Parent K02 - Independent Clinical Trial Not Allowed)	National Institutes of Health/DHHS	PA-20-174	07-May-2022	Not Specified
--------	---	------------------------------------	-----------	-------------	---------------

Contact Name	
Contact Telephone	
Contact Email	grantinfo@nih.gov
Sponsor Website	
Program URL	Link to program URL

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

Deadline Dates (ALL) 07-May-2022 , 12-Jun-2022 , 07-Sep-2022 , 12-Oct-2022 , 07-Jan-2023 , 12-Feb-2023 , 07-May-2023

Synopsis The purpose of the NIH Independent Scientist Award (K02) is to foster the development of outstanding scientists and enable them to expand their potential to make significant contributions to their field of research. The K02 award provides three to five years of salary support and "protected time" for newly independent scientists who can demonstrate the need for a period of intensive research focus as a means of enhancing their research careers. Each independent scientist career award program must be tailored to meet the individual needs of the candidate. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or a separate ancillary clinical trial. Applicants to this FOA are permitted to propose research experience in a clinical trial led by another investigator. Applicants proposing a clinical trial or an ancillary clinical trial as lead investigator, should apply to the companion FOA.

100769	Addressing the Etiology of Health Disparities and Health Advantages Among Immigrant Populations (R01 Clinical Trial Not Allowed)	National Institutes of Health/DHHS	PAR-21-080	07-May-2022	Not Specified
--------	--	------------------------------------	------------	-------------	---------------

Contact Name Deborah Linares, Ph.D.
 Contact Telephone 301-402-2516
 Contact Email deborah.linares@nih.gov
 Sponsor Website
 Program URL [Link to program URL](#)
 Deadline Dates (ALL) 07-May-2022 , 05-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 07-Jan-2023
 Synopsis The purpose of this Funding Opportunity Announcement (FOA) is to support innovative research to understand factors uniquely associated with the immigration experience that contribute to health disparities or health advantages among U.S. immigrant populations.

100780	Addressing Health Disparities among Immigrant Populations through Effective Interventions (R01 Clinical Trial Optional)	National Institutes of Health/DHHS	PAR-21-081	07-May-2022	Not Specified
--------	---	------------------------------------	------------	-------------	---------------

Contact Name Deborah Linares, Ph.D.
 Contact Telephone 301-402-2516
 Contact Email deborah.linares@nih.gov
 Sponsor Website
 Program URL [Link to program URL](#)

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
Deadline Dates (ALL) 07-May-2022 , 05-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 07-Jan-2023 Synopsis The purpose of this initiative is to support research to design and implement effective interventions to enhance health advantages and reduce the health disparities among US immigrant populations.					
100289	Discovery of in vivo Chemical Probes for the Nervous System (R01 Clinical Trial Not Allowed)	National Institutes of Health/DHHS	PAR-21-029	07-May-2022	Not Specified
Contact Name Enrique L. Michelotti, Ph.D. Contact Telephone 301-443 5415 Contact Email michelottiel@mail.nih.gov Sponsor Website Program URL Link to program URL					
Deadline Dates (ALL) 07-May-2022 , 05-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 07-May-2023 , 05-Jun-2023 , 07-Sep-2023 , 05-Oct-2023 , 07-Jan-2024 Synopsis The purpose of this Funding Opportunity Announcement (FOA) is to support investigators who have interest and capability to join efforts for the discovery of in vivo chemical probes for novel brain targets. It is expected that applicants will have, in hand, the starting compounds (“validated hits”) for chemical optimization and bioassays for testing new analog compounds. Through this FOA, NIH wishes to stimulate research in 1) discovery and development of novel, small molecules for their potential use in understanding biological processes relevant to the missions of NIMH, NIDA, NEI, and/or NIA and 2) discovery and/or validation of novel, biological targets that will inform studies of brain disease mechanisms. Emphasis will be placed on projects that provide new insight into important disease-related biological targets and biological processes. The main emphasis of projects submitted under this FOA should be the discovery of in vivo chemical probes. Applicants interested in developing cell-based chemical probes may wish to apply using the companion R21 mechanism, (PAR-21-028).					
105002	The Role of Work in Health Disparities in the U.S. (R01 Clinical Trials Optional)	National Institutes of Health/DHHS	PAR-21-275	07-May-2022	Not Specified
Contact Name Rada K. Dagher, PhD, MPH Contact Telephone 301-451-2187 Contact Email rada.dagher@nih.gov Sponsor Website Program URL Link to program URL					

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Deadline Dates (ALL) 07-May-2022 , 05-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 07-May-2023 , 05-Jun-2023 , 07-Sep-2023 , 07-Jan-2024 , 05-Feb-2024 , 07-May-2024 , 05-Jun-2024 , 07-Sep-2024</p> <p>Synopsis The purpose of this Funding Opportunity Announcement (FOA) is to support innovative population-based research that can contribute to identifying and characterizing pathways and mechanisms through which work or occupation influences health outcomes and health status among populations with health and/or health care disparities, and how work functions as a social determinant of health.</p>				
093908	NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed)	National Institutes of Health/DHHS	PA-20-185	07-May-2022	Not Specified
	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email grantsinfo@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2022 , 05-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 05-Feb-2023</p> <p>Synopsis The NIH Research Project Grant supports a discrete, specified, circumscribed project in areas representing the specific interests and competencies of the investigator(s). The proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) based on their scientific missions. This Funding Opportunity Announcement does not accept applications proposing clinical trial(s). Note: Not all NIH Institutes and Centers (ICs) participate in Parent Announcements. Applicants should carefully note which ICs participate in this announcement and view their respective areas of research interest at the R01 IC-Specific Scientific Interests and Contact website. ICs that do not participate in this announcement will not consider applications for funding.</p>				
093638	Identifying Innovative Mechanisms or Interventions that Target Multimorbidity and Its Consequences (R01 Clinical Trial Optional)	National Institutes of Health/DHHS	PAR-20-180	07-May-2022	Not Specified
	<p>Contact Name David L. Tilley, MPH, MS, CPH</p> <p>Contact Telephone 301-827-6014</p> <p>Contact Email david.tilley@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount	
	<p>Deadline Dates (ALL) 07-May-2022 , 05-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 07-May-2023 , 05-Jun-2023 , 07-Sep-2023</p> <p>Synopsis This Funding Opportunity Announcement (FOA) invites applications that seek to support the identification of shared mechanisms and development of innovative interventions to address multimorbidity or multiple chronic conditions (MCCs) and its consequences. Intervention research supported by this initiative should be designed to study: (1) mechanisms or pathways that prevent MCCs, including the identification of early biomarkers, behavioral pathways, and individual and contextual risk factors and interactions that contribute to the development of common MCCs; (2) targeted therapies and management, including self-management, of MCCs to delay progression and prevent onset of new diseases; and (3) innovative health care partnership models for managing or treating MCCs. Studies may include shared mechanisms, and assessments of interactions between risk factors and interventions that address MCCs at different periods of the lifespan in diverse populations. Use of innovative technologies to assess and intervene on risk factors and pathways are encouraged. Studies may also include those that make use of existing data and/or data linkages to explore new research questions that may be helpful in understanding the impact of mechanisms in isolation or in combination. Of particular interest are interventions that target prevention and treatment of multiple chronic health conditions, including study designs that address therapeutic targets for preventing co-occurring MCCs. Prospective applicants whose research interests relate to developing improved measures and methods for understanding multimorbidity, including but not limited to measures/tools to support basic mechanistic discovery of shared MCC pathways and identification and initial evaluation of MCC shared signatures, should see PAR-20-179.</p>					
093636	Advancing Research to Develop Improved Measures and Methods for Understanding Multimorbidity (R01 Clinical Trial Optional)		National Institutes of Health/DHHS	PAR-20-179	07-May-2022	Not Specified
	<p>Contact Name David L. Tilley, MPH, MS, CPH</p> <p>Contact Telephone 301-827-6014</p> <p>Contact Email david.tilley@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2022 , 05-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 07-May-2023 , 05-Jun-2023 , 07-Sep-2023</p> <p>Synopsis This Funding Opportunity Announcement (FOA) invites applications that seek to improve the availability, quality, and utility of data and measures that capture multimorbidity or multiple chronic conditions (MCCs) and the methods for analyzing multimorbidity data. Research supported by this initiative should be designed to discover, develop, and/or evaluate MCC measures/tools that reflect the longitudinality and life course diversity of multimorbidity. This includes but is not limited to</p>					

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

measures/tools to support basic mechanistic discovery of shared MCC pathways using animal models of MCCs, and identification and initial biological, analytical, and clinical evaluation of MCC shared signatures. Also sought are patient-focused studies that capture patient reports and related constructs such as functional limitations and quality of life; analytic approaches best suited for use with multimorbidity data and matched to target populations; and approaches that fully harness the wealth of multimorbidity data available in EHR systems. Studies may make use of existing data and data linkages to explore new research questions related to co-occurring MCCs. Prospective applicants whose research interests relate to studies that identify shared mechanisms or development of innovative interventions to address MCCs should see PAR-20-180.

093907	Research Project Grant (Parent R01 Basic Experimental Studies with Humans Required)	National Institutes of Health/DHHS	PA-20-184	07-May-2022	Not Specified
--------	---	------------------------------------	-----------	-------------	---------------

Contact Name	
Contact Telephone	301-496-4000
Contact Email	grantsinfo@od.nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	07-May-2022 , 05-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 07-May-2023
Synopsis	<p>The NIH Research Project Grant supports a discrete, specified, circumscribed project in areas representing the specific interests and competencies of the investigator(s). This Parent Funding Opportunity Announcement is for basic science experimental studies involving humans, referred to in NOT-OD-18-212 as “prospective basic science studies involving human participants.” These studies fall within the NIH definition of a clinical trial and also meet the definition of basic research. Types of studies that should submit under this FOA include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental aspects of phenomena without specific application towards processes or products in mind. Studies conducted with specific applications toward processes or products in mind should submit under the appropriate ‘Clinical Trials Required’ or ‘Clinical Trial Optional’ FOA. The proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) based on their scientific missions. Note: Not all NIH Institutes and Centers (ICs) participate in Parent Announcements. Applicants should carefully note which ICs participate in this announcement and view their respective areas of research interest at the R01 IC-Specific Scientific Interests and Contact website. ICs that do not participate in this announcement will not consider applications for funding.</p>

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount														
093035	Long-Term Effects of Disasters on Health Care Systems Serving Health Disparity Populations (R01-Clinical Trial Optional)	National Institutes of Health/DHHS	PA-20-172	07-May-2022	Not Specified														
	<table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 20%; padding: 5px;">Contact Name</td> <td style="padding: 5px;">Larissa Avilés-Santa, MD, MPH</td> </tr> <tr> <td style="padding: 5px;">Contact Telephone</td> <td style="padding: 5px;">301-827-6924</td> </tr> <tr> <td style="padding: 5px;">Contact Email</td> <td style="padding: 5px;">avilessantal@nih.gov</td> </tr> <tr> <td style="padding: 5px;">Sponsor Website</td> <td style="padding: 5px;"></td> </tr> <tr> <td style="padding: 5px;">Program URL</td> <td style="padding: 5px;">Link to program URL</td> </tr> <tr> <td style="padding: 5px;">Deadline Dates (ALL)</td> <td style="padding: 5px;">07-May-2022 , 05-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 07-May-2023 , 05-Jun-2023 , 07-Sep-2023</td> </tr> <tr> <td style="padding: 5px;">Synopsis</td> <td style="padding: 5px;">The purpose of this Funding Opportunity Announcement (FOA) is to support investigative and collaborative research focused on understanding the long-term effects of natural and/or human-made disasters on health care systems serving health disparity populations in communities in the U.S., including the U.S. territories. NIH-designated health disparity populations include racial and ethnic minorities (Blacks/African Americans, Hispanics/Latinos, American Indians/Alaska Natives, Asians, Native Hawaiians and other Pacific Islanders), sexual and gender minorities, socioeconomically disadvantaged populations, and underserved rural populations.</td> </tr> </table>					Contact Name	Larissa Avilés-Santa, MD, MPH	Contact Telephone	301-827-6924	Contact Email	avilessantal@nih.gov	Sponsor Website		Program URL	Link to program URL	Deadline Dates (ALL)	07-May-2022 , 05-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 07-May-2023 , 05-Jun-2023 , 07-Sep-2023	Synopsis	The purpose of this Funding Opportunity Announcement (FOA) is to support investigative and collaborative research focused on understanding the long-term effects of natural and/or human-made disasters on health care systems serving health disparity populations in communities in the U.S., including the U.S. territories. NIH-designated health disparity populations include racial and ethnic minorities (Blacks/African Americans, Hispanics/Latinos, American Indians/Alaska Natives, Asians, Native Hawaiians and other Pacific Islanders), sexual and gender minorities, socioeconomically disadvantaged populations, and underserved rural populations.
Contact Name	Larissa Avilés-Santa, MD, MPH																		
Contact Telephone	301-827-6924																		
Contact Email	avilessantal@nih.gov																		
Sponsor Website																			
Program URL	Link to program URL																		
Deadline Dates (ALL)	07-May-2022 , 05-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 07-May-2023 , 05-Jun-2023 , 07-Sep-2023																		
Synopsis	The purpose of this Funding Opportunity Announcement (FOA) is to support investigative and collaborative research focused on understanding the long-term effects of natural and/or human-made disasters on health care systems serving health disparity populations in communities in the U.S., including the U.S. territories. NIH-designated health disparity populations include racial and ethnic minorities (Blacks/African Americans, Hispanics/Latinos, American Indians/Alaska Natives, Asians, Native Hawaiians and other Pacific Islanders), sexual and gender minorities, socioeconomically disadvantaged populations, and underserved rural populations.																		
099859	Notice of Special Interest (NOSI): The Influence of Host Resilience on Heterogeneity of Acute Respiratory Distress Syndrome/Acute Lung Injury (ARDS/ALI)	National Institutes of Health/DHHS	NOT-HL-20-814	07-May-2022	Not Specified														
	<table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 20%; padding: 5px;">Contact Name</td> <td style="padding: 5px;">Guofei Zhou, PhD</td> </tr> <tr> <td style="padding: 5px;">Contact Telephone</td> <td style="padding: 5px;">301-827-7825</td> </tr> <tr> <td style="padding: 5px;">Contact Email</td> <td style="padding: 5px;">guofei.zhou@nih.gov</td> </tr> <tr> <td style="padding: 5px;">Sponsor Website</td> <td style="padding: 5px;"></td> </tr> <tr> <td style="padding: 5px;">Program URL</td> <td style="padding: 5px;">Link to program URL</td> </tr> <tr> <td style="padding: 5px;">Deadline Dates (ALL)</td> <td style="padding: 5px;">07-May-2022 , 05-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 07-May-2023 , 05-Jun-2023 , 07-Sep-2023 , 05-Oct-2023 , 07-Jan-2024 , 05-Feb-2024 , 07-May-2024 , 05-Jun-2024</td> </tr> <tr> <td style="padding: 5px;">Synopsis</td> <td style="padding: 5px;">The purpose of this Notice of Special Interest (NOSI) is to inform potential applicants of the special interest of NHLBI in research to understand host resilience as a critical determinant of outcomes in acute respiratory distress syndrome (ARDS) /acute lung injury (ALI).</td> </tr> </table>					Contact Name	Guofei Zhou, PhD	Contact Telephone	301-827-7825	Contact Email	guofei.zhou@nih.gov	Sponsor Website		Program URL	Link to program URL	Deadline Dates (ALL)	07-May-2022 , 05-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 07-May-2023 , 05-Jun-2023 , 07-Sep-2023 , 05-Oct-2023 , 07-Jan-2024 , 05-Feb-2024 , 07-May-2024 , 05-Jun-2024	Synopsis	The purpose of this Notice of Special Interest (NOSI) is to inform potential applicants of the special interest of NHLBI in research to understand host resilience as a critical determinant of outcomes in acute respiratory distress syndrome (ARDS) /acute lung injury (ALI).
Contact Name	Guofei Zhou, PhD																		
Contact Telephone	301-827-7825																		
Contact Email	guofei.zhou@nih.gov																		
Sponsor Website																			
Program URL	Link to program URL																		
Deadline Dates (ALL)	07-May-2022 , 05-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 07-May-2023 , 05-Jun-2023 , 07-Sep-2023 , 05-Oct-2023 , 07-Jan-2024 , 05-Feb-2024 , 07-May-2024 , 05-Jun-2024																		
Synopsis	The purpose of this Notice of Special Interest (NOSI) is to inform potential applicants of the special interest of NHLBI in research to understand host resilience as a critical determinant of outcomes in acute respiratory distress syndrome (ARDS) /acute lung injury (ALI).																		
103050	Notice of Special Interest (NOSI): Stimulate Research on the Diagnosis, Treatment, and Mechanistic Understanding of Postural Orthostatic Tachycardia Syndrome (POTS)	National Institutes of Health/DHHS	NOT-HL-21-008	07-May-2022	Not Specified														

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount	
	<p>Contact Name Denis Buxton, PhD</p> <p>Contact Telephone 301-435-0515</p> <p>Contact Email buxtond@nhlbi.nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2022 , 05-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 07-May-2023 , 05-Jun-2023 , 07-Sep-2023 , 05-Oct-2023 , 07-Jan-2024 , 05-Feb-2024 , 07-May-2024</p> <p>Synopsis Postural Orthostatic Tachycardia Syndrome (POTS) can be a debilitating condition that affects routine activities such as working or attending school. POTS primarily affects women of child-bearing age, with most studies reporting 80-90% female predominance. The peak incidence is at age 14 years, but half of all individuals with POTS develop it in adulthood. While there are no precise data on the prevalence of POTS, it is estimated to affect 0.2-1% of the U.S. population. There is thus a compelling need to stimulate research to understand the causes of POTS in order to inform the development of treatments. Improving the diagnosis of POTS through the development of biomarkers or improved diagnostic tools represents another major need. Translational studies and mechanistic clinical trials to guide the development of better treatments are also important goals. This NOSI signals interest in this important area with the goal of stimulating research applications to address these critical needs.</p>					
106732	<p>Notice of Special Interest (NOSI): Dietary, Physical Activity, Sedentary Behavior and Sleep Assessment Methodologies Among Infants and Young Children (Birth to 5 years) through Adults</p>		National Institutes of Health/DHHS	NOT-CA-21-108	07-May-2022	Not Specified
	<p>Contact Name Kirsten Herrick, PhD, MSc</p> <p>Contact Telephone 240-276-5734</p> <p>Contact Email kirsten.herrick@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2022 , 05-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 07-May-2023</p> <p>Synopsis The purpose of this NOSI is to invite investigator-initiated applications addressing approaches that improve the measurement of diet, physical activity, sedentary behavior, and sleep and their environmental influences through the development of improved methods (e.g., device-based, self-report, or other innovations). Such instruments should be based on innovative technologies (including advanced statistical and computational and/or analytical approaches), and/or integration of measurements across multiple behaviors (e.g., consumption, sleep, sedentary and active time). Applications</p>					

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

that explore and optimize innovative combinations of instruments across these behaviors are encouraged, as are efforts to develop combined measures of perceived and objective or physical features of the physical environments in which they occur. Studies addressing infants and young children (birth to 5 years) and individuals from underserved subgroups are especially encouraged, although all populations are eligible for study under this notice.

106715	Role of Astrocytes in Degeneration of the Neurovascular Unit in AD/ADRDs (R01 Clinical Trial Not Allowed)	National Institutes of Health/DHHS	PAR-22-037	07-May-2022	2,500,000 USD
--------	---	------------------------------------	------------	-------------	---------------

Contact Name	
Contact Telephone	
Contact Email	
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	07-May-2022 , 05-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 07-May-2023 , 05-Jun-2023 , 07-Sep-2023 , 07-Jan-2024 , 05-Feb-2024 , 07-May-2024 , 05-Jun-2024 , 07-Sep-2024 , 05-Oct-2024 , 07-Jan-2025
Synopsis	This funding opportunity announcement (FOA) invites basic disease-related research to address a gap in the basic research on the mechanisms of reactive astrogliosis in degeneration of the neurovascular unit that contributes to cognitive impairment and dementia. The neurovascular unit involves multiple pathways that contribute to neurodegeneration. Astrocytes, due to their overlapping roles regulating the blood brain barrier, neuronal health and response to degenerating cells, are uniquely positioned to be therapeutic targets for the AD/ADRDs.

093897	Research Project Grant (Parent R01 Clinical Trial Required)	National Institutes of Health/DHHS	PA-20-183	07-May-2022	Not Specified
--------	---	------------------------------------	-----------	-------------	---------------

Contact Name	
Contact Telephone	
Contact Email	grantsinfo@nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	07-May-2022 , 05-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 07-May-2023
Synopsis	The NIH Research Project Grant supports a discrete, specified, circumscribed project in areas representing the specific interests and competencies of the investigator(s). This Parent Funding Opportunity Announcement requires that at least 1

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>clinical trial be proposed. The proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) based on their scientific missions. NOTE: The following Institutes/Centers only accept mechanistic studies that meet NIH's definition of a clinical trial. National Heart, Lung, and Blood Institute (NHLBI) National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) National Institute of Neurological Disorders and Stroke (NINDS) National Center for Complementary and Integrative Health (NCCIH) National Institute of Mental Health (NIMH)</p>				
088091	Development and Application of PET and SPECT Imaging Ligands as Biomarkers for Drug Discovery and for Pathophysiological Studies of CNS Disorders (R01 Clinical Trial Optional)	National Institutes of Health/DHHS	PAR-20-038	07-May-2022	Not Specified
	<p>Contact Name Enrique Michelotti, Ph.D. Contact Telephone 301-443-5415 Contact Email michelottiel@mail.nih.gov Sponsor Website Program URL Link to program URL Deadline Dates (ALL) 07-May-2022 , 05-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 07-Jan-2023 Synopsis This Funding Opportunity Announcement (FOA) invites research grant applications that propose the development and evaluation of novel radioligands for positron emission tomography (PET) or single photon emission computed tomography (SPECT) imaging in human brain and the incorporation of pilot or clinical feasibility evaluation from previously collected data in pre-clinical studies. These studies are expected to provide the requisite data needed to advance promising PET ligands for use in clinical research. Projects proposing only preclinical animal studies should consider the companion FOA PAR-20-037 .</p>				
098640	Mentored Career Development Program (K01) for Early Stage Investigators Using Nonhuman Primate Research Models (K01 Independent Clinical Trial Not Allowed)	National Institutes of Health/DHHS	PAR-20-258	07-May-2022	Not Specified
	<p>Contact Name Deborah Philp, Ph.D. Contact Telephone 301-761-7766 Contact Email deborah.philp@nih.gov Sponsor Website Program URL Link to program URL Deadline Dates (ALL) 07-May-2022 , 12-Jun-2022 , 07-Sep-2022 , 12-Oct-2022 , 07-Jan-2023</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

Synopsis The purpose of this Funding Opportunity Announcement (FOA) is to provide early-stage investigators with support and “protected time” (up to five years) for intensive, research-focused career development program activities under the guidance of an experienced mentorship team with expertise in both the preclinical application of nonhuman primate (NHP) models and in translation of the results from such studies to clinical application. The focus of this program is to increase the number of highly skilled scientists using NHP models to address complex translational biomedical research designed to foster translation of outcomes into the clinic. The expectation is that through this sustained period of research career development and training, awardees will launch independent research careers and become competitive for new research project grant (e.g., R01) funding. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary study to a clinical trial. Applicants to this FOA are permitted to propose research experience in a clinical trial led by a mentor or co-mentor.

094250	Mentored Patient-Oriented Research Career Development Award (Parent K23 Independent Clinical Trial Required)	National Institutes of Health/DHHS	PA-20-206	07-May-2022	Not Specified
--------	--	------------------------------------	-----------	-------------	---------------

Contact Name	
Contact Telephone	
Contact Email	grantinfo@nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	07-May-2022 , 12-Jun-2022 , 07-Sep-2022 , 12-Oct-2022 , 07-Jan-2023 , 12-Feb-2023 , 07-May-2023
Synopsis	The purpose of the NIH Mentored Patient-Oriented Research Career Development Award (K23) is to support the career development of individuals with a clinical doctoral degree who have made a commitment to focus their research endeavors on patient-oriented research. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary clinical trial, as part of their research and career development. Applicants not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must apply to companion FOA Special Note: Not all NIH Institutes and Centers participate in Parent Announcements. Applicants should carefully note which ICs participate in this announcement and view their respective areas of research interest and requirements at the Table of IC-Specific Information, Requirements and Staff Contacts website. ICs that do not participate in this announcement will not consider applications for funding. Consultation with NIH staff before submitting an application is strongly encouraged.

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount														
094248	Mentored Patient-Oriented Research Career Development Award (Parent K23 Independent Clinical Trial Not Allowed)	National Institutes of Health/DHHS	PA-20-205	07-May-2022	Not Specified														
	<table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 20%; padding: 5px;">Contact Name</td> <td></td> </tr> <tr> <td style="padding: 5px;">Contact Telephone</td> <td></td> </tr> <tr> <td style="padding: 5px;">Contact Email</td> <td>grantinfo@nih.gov</td> </tr> <tr> <td style="padding: 5px;">Sponsor Website</td> <td></td> </tr> <tr> <td style="padding: 5px;">Program URL</td> <td>Link to program URL</td> </tr> <tr> <td style="padding: 5px;">Deadline Dates (ALL)</td> <td>07-May-2022 , 12-Jun-2022 , 07-Sep-2022 , 12-Oct-2022 , 07-Jan-2023 , 12-Feb-2023 , 07-May-2023</td> </tr> <tr> <td style="padding: 5px;">Synopsis</td> <td>The purpose of the NIH Mentored Patient-Oriented Research Career Development Award (K23) is to support the career development of individuals with a clinical doctoral degree who have made a commitment to focus their research endeavors on patient-oriented research. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or a separate ancillary clinical trial. Applicants to this FOA are permitted to propose research experience in a clinical trial led by a mentor or co-mentor. Applicants proposing a clinical trial or an ancillary clinical trial as lead investigator, should apply to the companion FOA Special Note: Not all NIH Institutes and Centers participate in Parent Announcements. Applicants should carefully note which ICs participate in this announcement and view their respective areas of research interest and requirements at the Table of IC-Specific Information, Requirements and Staff Contacts website. ICs that do not participate in this announcement will not consider applications for funding. Consultation with NIH staff before submitting an application is strongly encouraged.</td> </tr> </table>					Contact Name		Contact Telephone		Contact Email	grantinfo@nih.gov	Sponsor Website		Program URL	Link to program URL	Deadline Dates (ALL)	07-May-2022 , 12-Jun-2022 , 07-Sep-2022 , 12-Oct-2022 , 07-Jan-2023 , 12-Feb-2023 , 07-May-2023	Synopsis	The purpose of the NIH Mentored Patient-Oriented Research Career Development Award (K23) is to support the career development of individuals with a clinical doctoral degree who have made a commitment to focus their research endeavors on patient-oriented research. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or a separate ancillary clinical trial. Applicants to this FOA are permitted to propose research experience in a clinical trial led by a mentor or co-mentor. Applicants proposing a clinical trial or an ancillary clinical trial as lead investigator, should apply to the companion FOA Special Note: Not all NIH Institutes and Centers participate in Parent Announcements. Applicants should carefully note which ICs participate in this announcement and view their respective areas of research interest and requirements at the Table of IC-Specific Information, Requirements and Staff Contacts website. ICs that do not participate in this announcement will not consider applications for funding. Consultation with NIH staff before submitting an application is strongly encouraged.
Contact Name																			
Contact Telephone																			
Contact Email	grantinfo@nih.gov																		
Sponsor Website																			
Program URL	Link to program URL																		
Deadline Dates (ALL)	07-May-2022 , 12-Jun-2022 , 07-Sep-2022 , 12-Oct-2022 , 07-Jan-2023 , 12-Feb-2023 , 07-May-2023																		
Synopsis	The purpose of the NIH Mentored Patient-Oriented Research Career Development Award (K23) is to support the career development of individuals with a clinical doctoral degree who have made a commitment to focus their research endeavors on patient-oriented research. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or a separate ancillary clinical trial. Applicants to this FOA are permitted to propose research experience in a clinical trial led by a mentor or co-mentor. Applicants proposing a clinical trial or an ancillary clinical trial as lead investigator, should apply to the companion FOA Special Note: Not all NIH Institutes and Centers participate in Parent Announcements. Applicants should carefully note which ICs participate in this announcement and view their respective areas of research interest and requirements at the Table of IC-Specific Information, Requirements and Staff Contacts website. ICs that do not participate in this announcement will not consider applications for funding. Consultation with NIH staff before submitting an application is strongly encouraged.																		
094244	Mentored Patient-Oriented Research Career Development Award (Parent K23 Independent Basic Experimental Studies with Humans Required)	National Institutes of Health/DHHS	PA-20-204	07-May-2022	Not Specified														
	<table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 20%; padding: 5px;">Contact Name</td> <td></td> </tr> <tr> <td style="padding: 5px;">Contact Telephone</td> <td></td> </tr> <tr> <td style="padding: 5px;">Contact Email</td> <td></td> </tr> <tr> <td style="padding: 5px;">Sponsor Website</td> <td></td> </tr> <tr> <td style="padding: 5px;">Program URL</td> <td>Link to program URL</td> </tr> <tr> <td style="padding: 5px;">Deadline Dates (ALL)</td> <td>07-May-2022 , 12-Jun-2022 , 07-Sep-2022 , 12-Oct-2022 , 07-Jan-2023 , 12-Feb-2023 , 07-May-2023</td> </tr> <tr> <td style="padding: 5px;">Synopsis</td> <td>The purpose of the NIH Mentored Patient-Oriented Research Career Development Award (K23) is to support the career development of individuals with a clinical doctoral degree who have made a commitment to focus their research endeavors</td> </tr> </table>					Contact Name		Contact Telephone		Contact Email		Sponsor Website		Program URL	Link to program URL	Deadline Dates (ALL)	07-May-2022 , 12-Jun-2022 , 07-Sep-2022 , 12-Oct-2022 , 07-Jan-2023 , 12-Feb-2023 , 07-May-2023	Synopsis	The purpose of the NIH Mentored Patient-Oriented Research Career Development Award (K23) is to support the career development of individuals with a clinical doctoral degree who have made a commitment to focus their research endeavors
Contact Name																			
Contact Telephone																			
Contact Email																			
Sponsor Website																			
Program URL	Link to program URL																		
Deadline Dates (ALL)	07-May-2022 , 12-Jun-2022 , 07-Sep-2022 , 12-Oct-2022 , 07-Jan-2023 , 12-Feb-2023 , 07-May-2023																		
Synopsis	The purpose of the NIH Mentored Patient-Oriented Research Career Development Award (K23) is to support the career development of individuals with a clinical doctoral degree who have made a commitment to focus their research endeavors																		

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

on patient-oriented research. This Parent Funding Opportunity Announcement is for basic science experimental studies involving humans, referred to in NOT-OD-18-212 as “prospective basic science studies involving human participants.” These studies fall within the NIH definition of a clinical trial and also meet the definition of basic research. Types of studies that should be submitted under this FOA include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental aspects of phenomena without specific application towards processes or products in mind. Applicants not planning an independent clinical trial or basic experimental study with humans, or proposing to gain research experience in a clinical trial or basic experimental study with humans led by another investigator, must apply to the 'Independent Clinical Trial Not Allowed' companion FOA. The proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) based on their scientific missions. Special Note: Not all NIH Institutes and Centers participate in Parent Announcements. Applicants should carefully note which ICs participate in this announcement and view their respective areas of research interest and requirements at the Table of IC-Specific Information, Requirements and Staff Contacts website. ICs that do not participate in this announcement will not consider applications for funding. Consultation with NIH staff before submitting an application is strongly encouraged.

099392	Notice of Special Interest (NOSI): Optimizing Precision Treatment of Gynecologic, Reproductive and Obstetrical Outcomes in Adolescents and Adults with PCOS and Associated Comorbid Conditions (Clinical Trial Optional)	National Institutes of Health/DHHS	NOT-HD-20-026	07-May-2022	Not Specified
--------	--	------------------------------------	---------------	-------------	---------------

Contact Name	Esther Eisenberg, MD MPH
Contact Telephone	301-496-6516
Contact Email	esther.eisenberg@nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	07-May-2022 , 05-Jun-2022 , 16-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 16-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 16-Feb-2023 , 07-May-2023 , 05-Jun-2023 , 16-Jun-2023 , 07-Sep-2023
Synopsis	The National Institute of Child Health and Human Development (NICHD) is issuing this Notice of Special Interest (NOSI) to announce the opportunity for investigators to apply for funding to optimize treatments of comorbid conditions in adolescents and reproductive age women with a diagnosis of Polycystic Ovary Syndrome (PCOS). The goals of this initiative are to stimulate interdisciplinary scientific collaboration between gynecologists/reproductive endocrinologists/obstetricians and subspecialists in diverse medical fields, including cardiologists, endocrinologists, gastroenterologists, psychiatrists, mental health professionals, pulmonologists, among others, to: 1) advance individualized treatments consistent with gynecologic, reproductive and obstetrical needs and desires; 2) promote translational and clinical research to

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

increase knowledge and understanding of interaction of various therapies on gynecologic, reproductive and obstetric outcomes; and 3) discover and develop novel safe and more effective therapies for adolescents and women with PCOS with underlying comorbid conditions. Ultimately, this research would advance precision therapeutics for adolescents and adults with PCOS who have concomitant medical conditions.

104245	Academic Research Enhancement Award for Undergraduate-Focused Institutions (R15 Clinical Trial Not Allowed)	National Institutes of Health/DHHS	PAR-21-155	07-May-2022	300,000 USD
--------	---	------------------------------------	------------	-------------	-------------

Contact Name	Alexandra M. Ainsztein, Ph.D.
Contact Telephone	
Contact Email	alexandra.ainsztein@nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	07-May-2022 , 25-Jun-2022 , 07-Sep-2022 , 25-Oct-2022 , 07-Jan-2023 , 25-Feb-2023 , 07-May-2023 , 25-Jun-2023 , 07-Sep-2023 , 25-Oct-2023 , 07-Jan-2024 , 25-Feb-2024 , 07-May-2024
Synopsis	The purpose of this Academic Research Enhancement Award (AREA) for Undergraduate-Focused Institutions is to support small scale research grants at institutions that do not receive substantial funding from the NIH, with an emphasis on providing biomedical research experiences primarily for undergraduate students, and enhancing the research environment at applicant institutions. Eligible institutions must award baccalaureate science degrees and have received no more than \$6 million dollars per year of NIH support (in both direct and F&A/indirect costs) in 4 of the last 7 fiscal years. For institutions composed of multiple schools and colleges, the \$6 million funding limit is based on the amount of NIH funding received by all the non-health professional schools and colleges within the institution as a whole. Help determining the Organization Funding Level can be found here.

104244	Academic Research Enhancement Award for Undergraduate-Focused Institutions (R15 Clinical Trial Required)	National Institutes of Health/DHHS	PAR-21-154	07-May-2022	300,000 USD
--------	--	------------------------------------	------------	-------------	-------------

Contact Name	Minna Liang, Ph.D.
Contact Telephone	301-827-5708
Contact Email	liangm@nida.nih.gov
Sponsor Website	
Program URL	Link to program URL

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Deadline Dates (ALL) 07-May-2022 , 25-Jun-2022 , 07-Sep-2022 , 25-Oct-2022 , 07-Jan-2023 , 25-Feb-2023 , 07-May-2023 , 25-Jun-2023 , 07-Sep-2023 , 25-Oct-2023 , 07-Jan-2024 , 25-Feb-2024 , 07-May-2024</p> <p>Synopsis The purpose of this Academic Research Enhancement Award (AREA) for Undergraduate-Focused Institutions is to support small scale research grants at institutions that do not receive substantial funding from the NIH, with an emphasis on providing biomedical research experiences primarily for undergraduate students, and enhancing the research environment at applicant institutions. Eligible institutions must award baccalaureate science degrees and have received no more than \$6 million per year of NIH support (in both direct and F&A/indirect costs) in 4 of the last 7 fiscal years. For institutions composed of multiple schools and colleges, the \$6 million funding limit is based on the amount of NIH funding received by all the non-health professional schools and colleges within the institution as a whole. Help determining the Organization Funding Level can be found here.</p>				
104076	Pilot Health Services and Economic Research on the Treatment of Drug, Alcohol, and Tobacco Use Disorders (R34 - Clinical Trial Optional)	National Institutes of Health/DHHS	PA-21-180	07-May-2022	450,000 USD
	<p>Contact Name Keisher Highsmith, DrPH</p> <p>Contact Telephone </p> <p>Contact Email duffys@nida.nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2022 , 16-Jun-2022 , 07-Sep-2022 , 16-Oct-2022 , 07-Jan-2023 , 16-Feb-2023 , 07-May-2023 , 16-Jun-2023 , 07-Sep-2023 , 16-Oct-2023 , 07-Jan-2024 , 16-Feb-2024 , 07-May-2024</p> <p>Synopsis This Funding Opportunity Announcement (FOA) encourages pilot and preliminary research in preparation for larger-scale services research effectiveness trials. Relevant trials may test a wide range of approaches, including interventions, practices, and policies designed to optimize access to, and the quality, effectiveness, affordability and utilization of drug, tobacco, or alcohol use disorder treatments and related services, as well as services for comorbid medical and mental disorder conditions. Relevant approaches may include both those that are novel, and those that are commonly used in practice but lack an evidence base. This FOA provides resources for assessing the feasibility, acceptability, and utility of these approaches, in addition to usual trial preparation activities.</p>				
107543	Notice of Special Interest (NOSI): Accelerating Progress in Celiac Disease Research	National Institutes of Health/DHHS	NOT-AI-22-004	07-May-2022	Not Specified
	Contact Name Annette L. Rothermel, Ph.D.				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

Contact Telephone	240-627-3477
Contact Email	arothermel@niaid.nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	07-May-2022 , 13-May-2022 , 25-May-2022 , 01-Jun-2022 , 05-Jun-2022 , 16-Jun-2022 , 24-Jun-2022 , 07-Sep-2022 , 13-Sep-2022 , 14-Sep-2022 , 25-Sep-2022 , 05-Oct-2022 , 16-Oct-2022 , 20-Oct-2022 , 07-Jan-2023 , 13-Jan-2023 , 25-Jan-2023 , 01-Feb-2023 , 05-Feb-2023 , 16-Feb-2023 , 07-May-2023 , 12-May-2023 , 13-May-2023 , 25-May-2023 , 05-Jun-2023 , 16-Jun-2023 , 07-Sep-2023 , 14-Sep-2023 , 25-Sep-2023 , 05-Oct-2023 , 16-Oct-2023 , 07-Jan-2024 , 13-Jan-2024 , 25-Jan-2024 , 05-Feb-2024 , 16-Feb-2024 , 07-May-2024 , 25-May-2024 , 05-Jun-2024 , 16-Jun-2024 , 07-Sep-2024 , 25-Sep-2024
Synopsis	The purpose of this Notice of Special Interest (NOSI) is to inform potential applicants to the National Institutes of Health (NIH) of special interest in research on the etiology and pathogenesis of celiac disease, identification of therapeutic targets, and development of preventative or disease ameliorating therapies/strategies.

107545	Notice of Special Interest (NOSI): Expanding the Otitis Media Research Workforce: Focus on Early Stage Investigators	National Institutes of Health/DHHS	NOT-DC-22-001	07-May-2022	Not Specified
--------	--	------------------------------------	---------------	-------------	---------------

Contact Name	Bracie Watson, Jr., Ph.D.
Contact Telephone	301-402-3458
Contact Email	watsonb@nidcd.nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	07-May-2022 , 05-Jun-2022 , 10-Jun-2022 , 16-Jun-2022 , 20-Jun-2022 , 23-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 11-Oct-2022 , 16-Oct-2022 , 27-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 10-Feb-2023 , 16-Feb-2023 , 22-Feb-2023 , 23-Feb-2023 , 07-May-2023 , 05-Jun-2023 , 09-Jun-2023 , 16-Jun-2023 , 29-Jun-2023 , 07-Sep-2023 , 05-Oct-2023 , 10-Oct-2023 , 16-Oct-2023 , 18-Oct-2023 , 26-Oct-2023 , 07-Jan-2024 , 05-Feb-2024 , 16-Feb-2024 , 07-May-2024 , 05-Jun-2024 , 16-Jun-2024 , 20-Jun-2024 , 07-Sep-2024 , 05-Oct-2024 , 16-Oct-2024 , 07-Jan-2025 , 05-Feb-2025 , 16-Feb-2025 , 07-May-2025 , 05-Jun-2025 , 16-Jun-2025 , 07-Sep-2025
Synopsis	The National Institute on Deafness and Other Communication Disorderse (NIDCD) is interested in expanding the cadre of basic and clinical scientists who conduct research on otitis media (OM). The purpose of this Notice of Special Interest (NOSI) is to invite Early Stage Investigators (ESIs), as defined by the NIH https://grants.nih.gov/grants/new_investigators/index.htm#earlystage , to submit research applications that focus on

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>OM—commonly known as ear infections. There is a critical need for focused, novel, creative and innovative research approaches that accelerate the development of effective ways to prevent and treat OM.</p>				
100050	Notice of Special Interest (NOSI): Research on Rehabilitation Needs Associated with the COVID-19	National Institutes of Health/DHHS	NOT-HD-20-031	07-May-2022	Not Specified
	<p>Contact Name Theresa Cruz, PhD. Contact Telephone 301-496-9233 Contact Email cruzth@mail.nih.gov Sponsor Website Program URL Link to program URL Deadline Dates (ALL) 07-May-2022 , 05-Jun-2022 , 16-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 16-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 16-Feb-2023 , 07-May-2023 Synopsis The purpose of this Notice of Special Interest is to encourage applications in three areas related to the intersection of COVID-19, the associated mitigation actions, and rehabilitation: Encourage research to address the rehabilitation needs of survivors of COVID-19 Understand the impact of disruptions to rehabilitation services caused by the COVID-19 pandemic and associated mitigation actions Understand the social, behavioral, economic, and health impact of the COVID-19 pandemic and the associated mitigation actions on people with physical disabilities Research applications addressing these topics are considered responsive; not all topics are expected within the same application. Applications will be directed to the National Center for Medical Rehabilitation Research (NCMRR) at NICHD.</p>				
094033	NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Not Allowed)	National Institutes of Health/DHHS	PA-20-195	07-May-2022	275,000 USD
	<p>Contact Name Contact Telephone Contact Email grantsinfo@nih.gov Sponsor Website Program URL Link to program URL Deadline Dates (ALL) 07-May-2022 , 16-Jun-2022 , 07-Sep-2022 , 16-Oct-2022 , 07-Jan-2023 , 16-Feb-2023 , 07-May-2023 Synopsis The NIH Exploratory/Developmental Grant supports exploratory and developmental research projects by providing support for the early and conceptual stages of these projects. These studies may involve considerable risk but may lead to a</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

breakthrough in a particular area, or to the development of novel techniques, agents, methodologies, models, or applications that could have a major impact on a field of biomedical, behavioral, or clinical research. Note: Not all NIH Institutes and Centers (ICs) participate in Parent Announcements. Applicants should carefully note which ICs participate in this announcement and view their respective areas of research interest at the R21 IC-Specific Scientific Interests and Contact website. ICs that do not participate in this announcement will not consider applications for funding.

094032	NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Required)	National Institutes of Health/DHHS	PA-20-194	07-May-2022	275,000 USD
--------	---	------------------------------------	-----------	-------------	-------------

Contact Name	
Contact Telephone	
Contact Email	grantsinfo@nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	07-May-2022 , 16-Jun-2022 , 07-Sep-2022 , 16-Oct-2022 , 07-Jan-2023 , 16-Feb-2023 , 07-May-2023
Synopsis	<p>The NIH Exploratory/Developmental Grant supports exploratory and developmental research projects by providing support for the early and conceptual stages of these projects. These studies may involve considerable risk but may lead to a breakthrough in a particular area, or to the development of novel techniques, agents, methodologies, models, or applications that could have a major impact on a field of biomedical, behavioral, or clinical research. This Parent Funding Opportunity Announcement requires that at least 1 clinical trial be proposed. The proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) based on their scientific missions. Applicants should note that some ICs (see Related Notices) only accept applications proposing mechanistic studies that meet NIH's definition of a clinical trial through this funding opportunity announcement. The following Institutes/Centers only accept mechanistic studies that meet NIH's definition of a clinical trial. See Related Notices section below. National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) National Institute of Mental Health (NIMH) Note: Not all NIH Institutes and Centers (ICs) participate in Parent Announcements. Applicants should carefully note which ICs participate in this announcement and view their respective areas of research interest at the R21 Basic Experimental Studies with Humans Required IC-Specific Scientific Interests and Contact website. ICs that do not participate in this announcement will not consider applications for funding.</p>

094034	NIH Exploratory/Developmental Research Grant Program (Parent R21 Basic Experimental Studies with Humans Required)	National Institutes of Health/DHHS	PA-20-196	07-May-2022	275,000 USD
--------	---	------------------------------------	-----------	-------------	-------------

Contact Name

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Telephone 301-496-4000</p> <p>Contact Email grantsinfo@od.nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2022 , 16-Jun-2022 , 07-Sep-2022 , 16-Oct-2022 , 07-Jan-2023 , 16-Feb-2023 , 07-May-2023</p> <p>Synopsis The NIH Exploratory/Developmental Grant supports exploratory and developmental research projects by providing support for the early and conceptual stages of these projects. These studies may involve considerable risk but may lead to a breakthrough in a particular area, or to the development of novel techniques, agents, methodologies, models, or applications that could have a major impact on a field of biomedical, behavioral, or clinical research. This Parent Funding Opportunity Announcement is for basic science experimental studies involving humans, referred to in NOT-OD-18-212as "prospective basic science studies involving human participants." These studies fall within the NIH definition of a clinical trial and also meet the definition of basic research. Types of studies that should submit under this FOA include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental aspects of phenomena without specific application towards processes or products in mind. Studies conducted with specific applications toward processes or products in mind should submit under the appropriate 'Clinical Trials Required' or 'Clinical Trial Optional' FOA. The proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) based on their scientific missions. Note: Not all NIH Institutes and Centers (ICs) participate in Parent Announcements. Applicants should carefully note which ICs participate in this announcement and view their respective areas of research interest at the R21 Basic Experimental Studies with Humans Required IC-Specific Scientific Interests and Contact website. ICs that do not participate in this announcement will not consider applications for funding.</p>				
101780	Notice of Special Interest (NOSI): Promoting Research on Interoception and Its Impact on Health and Disease	National Institutes of Health/DHHS	NOT-AT-21-002	07-May-2022	Not Specified
	<p>Contact Name Wen G. Chen, M.MSc, Ph.D.</p> <p>Contact Telephone 301-451-3989</p> <p>Contact Email chenw@mail.nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Deadline Dates (ALL) 07-May-2022 , 05-Jun-2022 , 16-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 16-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 16-Feb-2023 , 07-May-2023 , 05-Jun-2023 , 16-Jun-2023 , 07-Sep-2023 , 05-Oct-2023 , 16-Oct-2023 , 07-Jan-2024 , 05-Feb-2024 , 16-Feb-2024 , 07-May-2024</p> <p>Synopsis The purpose of this NOSI is to promote innovative and rigorous research on interoception and its impact on health and disease. This initiative is broadly supported by many participating NIH institutes, centers, and offices (ICOs). For this NOSI, interoception includes the processes by which an organism senses, interprets, integrates, and regulates signals originating from within itself and represents its internal states. This NOSI encourages basic and clinical research projects that 1) combine diverse expertise; 2) develop and use innovative technologies and approaches to delineate interoceptive mechanisms at the molecular, cellular, circuit, functional, and/or behavioral levels; 3) assess pathophysiological processes of interoception in the context of diseases and disorders; 4) determine the impact of interventions and therapies to manipulate interoceptive processes on health and/or disease; and 5) develop and validate predictive biomarkers, computational models, or artificial intelligence models relevant to interoception and its impact on health and disease.</p>				
105478	<p>Notice of Special Interest (NOSI): Advancing Research in Gastrointestinal Dysfunction in People with Neurodevelopmental Disorders</p> <p>Contact Name Adam L. Hartman, MD</p> <p>Contact Telephone 301-496-9135</p> <p>Contact Email adam.hartman@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2022 , 05-Jun-2022 , 16-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 16-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 16-Feb-2023 , 07-May-2023 , 05-Jun-2023 , 16-Jun-2023 , 07-Sep-2023 , 05-Oct-2023 , 16-Oct-2023 , 07-Jan-2024 , 05-Feb-2024 , 16-Feb-2024 , 07-May-2024 , 05-Jun-2024 , 16-Jun-2024</p> <p>Synopsis The National Institute of Neurological Disorders and Stroke is issuing this Notice to highlight interest in receiving grant applications focused in the following area(s) to support basic, translational, and/or clinical research on the causes, diagnosis, prevention, or treatment of gastrointestinal dysfunction in people with neurodevelopmental disorders.</p>	National Institutes of Health/DHHS	NOT-NS-22-003	07-May-2022	Not Specified
107483	<p>Notice of Special Interest (NOSI): Mechanistic Studies on the Impact of Substance Use in Sex and Gender Differences in HIV-Associated Neurocognitive Disorders</p> <p>Contact Name</p> <p>Contact Telephone</p>	National Institutes of Health/DHHS	NOT-DA-22-047	07-May-2022	Not Specified

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Email</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2022 , 05-Jun-2022 , 16-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 16-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 16-Feb-2023 , 07-May-2023 , 05-Jun-2023 , 16-Jun-2023 , 07-Sep-2023 , 05-Oct-2023 , 16-Oct-2023 , 07-Jan-2024 , 05-Feb-2024 , 16-Feb-2024 , 07-May-2024 , 05-Jun-2024 , 16-Jun-2024 , 07-Sep-2024 , 05-Oct-2024 , 16-Oct-2024 , 07-Jan-2025</p> <p>Synopsis Compared to men, women are often more likely to develop HIV-associated neurocognitive impairments. The purpose of this notice is to inform potential applicants of NIDA's special interest in understanding the neurobiological bases for sex or gender-specific differences in HIV-associated neurocognitive disorders. This information can be used for targeted therapeutics and optimization of treatment options in HIV positive individuals with substance use disorders.</p>				
107484	Notice of Special Interest (NOSI): The Functional Oral Microbiome	National Institutes of Health/DHHS	NOT-DE-21-015	07-May-2022	Not Specified
	<p>Contact Name Tamara McNealy, PhD.</p> <p>Contact Telephone 202-430-1474</p> <p>Contact Email tamara.mcnealy@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2022 , 05-Jun-2022 , 16-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 16-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 16-Feb-2023 , 07-May-2023 , 05-Jun-2023 , 16-Jun-2023 , 07-Sep-2023 , 05-Oct-2023 , 16-Oct-2023 , 07-Jan-2024 , 05-Feb-2024 , 16-Feb-2024 , 07-May-2024 , 05-Jun-2024 , 16-Jun-2024 , 07-Sep-2024 , 05-Oct-2024 , 16-Oct-2024 , 07-Jan-2025 , 05-Feb-2025 , 16-Feb-2025 , 07-May-2025 , 05-Jun-2025 , 16-Jun-2025 , 07-Sep-2025</p> <p>Synopsis The National Institute of Dental and Craniofacial Research (NIDCR) is issuing this Notice of Special Interest (NOSI) to encourage research studies that focus beyond the bacteria to the multispecies communities making up the oral microbiome.</p>				
099801	Notice of Special Interest (NOSI): Mechanisms of Mycobacterial-Induced Immunity in HIV-Infected and/or Uninfected Individuals to Inform Innovative Tuberculosis Vaccine Design Notice Number:	National Institutes of Health/DHHS	NOT-AI-20-071	07-May-2022	Not Specified
	<p>Contact Name Que Dang, PhD</p> <p>Contact Telephone 240-292-6181</p> <p>Contact Email que.dang@nih.gov</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2022 , 05-Jun-2022 , 16-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 16-Oct-2022 , 07-Jan-2023</p> <p>Synopsis The purpose of this Notice of Special Interest (NOSI) is to stimulate innovative studies to identify and understand the immune responses that mediate protection from Mycobacterium tuberculosis (Mtb) infection or progression to active tuberculosis (TB) disease. Studies may focus on any stage of mycobacterial infection or following vaccination with Bacillus Calmette-Guérin (BCG) or investigational TB vaccines and may include HIV-infected or uninfected individuals. Research supported under this NOSI should go beyond descriptive information currently known about Mtb infection, immune responses to TB vaccines, or immune modulation by non-tuberculous mycobacterial (NTM) infection, or by HIV/AIDS. Applications that include characterization of the timing, anatomical location, and contribution to disease outcome, of mucosal and/or systemic immune responses to mycobacterial infection and/or vaccination are sought. This research is expected to advance understanding of immune mechanisms in Mtb infection/vaccination and contribute to the advancement of new TB vaccines, including in populations also infected with HIV.</p>				
108065	Notice of Special Interest (NOSI): Pediatric COVID-19 and Respiratory Viral Co-infection	National Institutes of Health/DHHS	NOT-HL-22-004	07-May-2022	Not Specified
	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2022 , 05-Jun-2022 , 16-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 16-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 16-Feb-2023 , 07-May-2023 , 05-Jun-2023 , 16-Jun-2023 , 07-Sep-2023 , 05-Oct-2023 , 16-Oct-2023 , 07-Jan-2024 , 05-Feb-2024 , 16-Feb-2024 , 16-Feb-2024 , 07-May-2024 , 05-Jun-2024 , 16-Jun-2024 , 16-Jun-2024 , 07-Sep-2024 , 05-Oct-2024 , 16-Oct-2024 , 07-Jan-2025 , 05-Feb-2025 , 07-May-2025 , 05-Jun-2025 , 07-Sep-2025</p> <p>Synopsis This NOSI is intended to support projects that will employ existing and new clinical trial cohorts/observational cohorts to screen for co-infection, phenotype and collect biospecimens to answer some of these questions and to encourage investigator-initiated applications for basic, translational and human subject research (not clinical trials) in this space.</p>				
104057	Joint NINDS/NIMH Exploratory Neuroscience Research Grant (R21 Clinical Trial Optional)	National Institutes of Health/DHHS	PA-21-219	07-May-2022	275,000 USD

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount	
	<p>Contact Name Karrah Benson</p> <p>Contact Telephone 301-496-0838</p> <p>Contact Email Karrah.benson@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2022 , 16-Jun-2022 , 07-Sep-2022 , 16-Oct-2022 , 07-Jan-2023 , 16-Feb-2023 , 07-May-2023 , 16-Jun-2023 , 07-Sep-2023 , 16-Oct-2023 , 07-Jan-2024 , 16-Feb-2024 , 07-May-2024</p> <p>Synopsis The Joint NINDS/NIMH Exploratory Neuroscience Research Grant program supports exploratory and innovative research projects, which fall within the missions of the NINDS and NIMH. Awards will provide support for the early and conceptual stages of projects. These studies often assess the feasibility of a novel avenue of investigation and involve considerable risk, but have the potential to bring about breakthroughs in the understanding of important areas of neuroscience, or to the development of novel techniques, agents, methodologies, or models, of high value to the neuroscience community. While this funding opportunity also accepts clinical trials, only applications proposing “mechanistic clinical trials or studies” (studying pathophysiology or mechanism of action of an intervention, but not safety or efficacy) or basic experimental studies with humans (BESH) will be supported. For information on NIH clinical trial definitions and the types of clinical trials that are within scope of this funding opportunity announcement refer to the NIH Definition of a Clinical Trial page and the Funding Opportunity Description, below, respectively.</p>					
104053	Notice of Special Interest (NOSI): Biology of Lung and Head and Neck Preneoplasia		National Institutes of Health/DHHS	NOT-CA-21-057	07-May-2022	Not Specified
	<p>Contact Name Ron Johnson, Ph.D.</p> <p>Contact Telephone 240-276-6250</p> <p>Contact Email rjohnso2@mail.nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2022 , 05-Jun-2022 , 16-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 16-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 16-Feb-2023 , 07-May-2023</p> <p>Synopsis This Notice of Special Interest (NOSI) seeks applications investigating mechanistic and biological aspects of preneoplasia leading to invasive lung and head and neck (HN) cancers. Despite having better molecular understanding of lung and HN cancers and improved therapies for affected patients, these tumors remain a major health problem in the United States (US)</p>					

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

and globally. While molecular markers of early injury of the aerodigestive epithelial field have been found, relatively little is known about the molecular mechanisms that initiate these preneoplasias and drive their progression to invasive cancer. In addition, growing evidence highlights the importance of the interaction between the immune system and cancer development. In recent years, immune-based therapies (especially, checkpoint inhibitors) have come to the forefront of standard therapies for many malignancies including lung and HN cancers. However, little is known about the immune regulation of premalignancy, including lung and HN preneoplasias. A functional understanding of the key molecular and cellular changes involved in the formation and advancement of lung and HN preneoplasias will enhance our knowledge of oncogenic progression and accelerate development of effective, rationally designed, preventive and therapeutic strategies.

103983	Notice of Special Interest (NOSI): Public Policy Effects on Alcohol-, Cannabis-, Tobacco-, and Other Drug-Related Behaviors and Outcomes	National Institutes of Health/DHHS	NOT-AA-21-028	07-May-2022	Not Specified
--------	--	------------------------------------	---------------	-------------	---------------

Contact Name	Gregory Bloss, M.A., M.P.P.
Contact Telephone	
Contact Email	Gregory.Bloss@nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	07-May-2022 , 05-Jun-2022 , 16-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 16-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 16-Feb-2023 , 07-May-2023 , 05-Jun-2023 , 16-Jun-2023 , 07-Sep-2023 , 05-Oct-2023 , 16-Oct-2023 , 07-Jan-2024 , 05-Feb-2024 , 16-Feb-2024 , 07-May-2024 , 05-Jun-2024 , 16-Jun-2024 , 07-Sep-2024
Synopsis	<p>This announcement encourages applications to conduct research on the effects of public policies on health-related behaviors and outcomes associated with alcohol, cannabis, tobacco, prescription drugs, and other substances. The purpose of the Notice is to advance understanding of how public policy may serve as a tool for improving public health and welfare through its effects on behaviors and outcomes pertaining to alcohol and other drugs. This Notice is intended to support innovative research to examine policy effects that have the potential to lead to meaningful changes in public health.</p> <p>Research projects that may be supported include, but are not necessarily limited to: causal analyses of the effects of one or multiple public policies; evaluations of the effectiveness of specific public policies as tools for improving public health through their effects on alcohol-, cannabis-, tobacco-, and other substance-related behaviors and outcomes; studies of disparities in policy effects and the role of policy in exacerbating or potentially reducing health disparities; and research to advance methods and measurement used in studying relationships between public policies and alcohol-, cannabis-, tobacco-, and other substance-related behaviors and outcomes.</p>

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
103986	Notice of Special Interest (NOSI): Early-life Factors and Cancer Development Later in Life	National Institutes of Health/DHHS	NOT-CA-21-074	07-May-2022	Not Specified
	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2022 , 05-Jun-2022 , 16-Jun-2022 , 24-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 16-Oct-2022 , 20-Oct-2022 , 08-Nov-2022 , 07-Jan-2023 , 05-Feb-2023 , 16-Feb-2023 , 07-Mar-2023 , 07-May-2023 , 05-Jun-2023 , 16-Jun-2023 , 07-Sep-2023 , 05-Oct-2023 , 16-Oct-2023 , 05-Nov-2023 , 07-Jan-2024 , 05-Feb-2024 , 16-Feb-2024 , 07-Mar-2024</p> <p>Synopsis The purpose of this Notice of Special Interest (NOSI) is to stimulate research focused on the roles of early-life factors (maternal-paternal, in utero, birth and infancy, puberty, adolescence, and young adult years) in cancer development later in life.</p>				
108483	Notice of Special Interest (NOSI): COVID-19 Pandemic Mental Health Research	National Institutes of Health/DHHS	NOT-MH-22-100	07-May-2022	Not Specified
	<p>Contact Name Pim Brouwers, Ph.D.</p> <p>Contact Telephone 240-627-3863</p> <p>Contact Email ebrouwer@mail.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2022 , 05-Jun-2022 , 15-Jun-2022 , 16-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 14-Oct-2022 , 16-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 15-Feb-2023 , 16-Feb-2023 , 07-May-2023 , 05-Jun-2023 , 15-Jun-2023 , 16-Jun-2023 , 07-Sep-2023 , 05-Oct-2023 , 16-Oct-2023 , 17-Oct-2023 , 07-Jan-2024 , 05-Feb-2024 , 15-Feb-2024 , 16-Feb-2024 , 07-May-2024 , 05-Jun-2024 , 16-Jun-2024 , 07-Sep-2024 , 05-Oct-2024 , 16-Oct-2024 , 07-Jan-2025</p> <p>Synopsis NIMH is issuing this Notice of Special Interest (NOSI) to highlight interest in basic, translational, intervention and services research relevant to the COVID-19 pandemic. NIMH is especially interested in research to provide an evidence base to understand how mental illness contributes to COVID-19 risk and mortality, how incident mental illness develops with COVID-19, and the development of scalable interventions to meet the public mental health needs during and resulting from the pandemic both specifically related to the virus but also at a broader population level that is impacted by stress,</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

disruptions, and loss of lives in the pandemic. Research addressing the intersection of COVID-19, mental health, and HIV treatment and prevention are also of interest to NIMH. Research is anticipated to focus on particularly vulnerable populations based on existing evidence of increased mental health symptoms and illness and preexisting and worsening health disparities.

099505	Notice of Special Interest (NOSI): Advancing the Science of Geriatric Palliative Care	National Institutes of Health/DHHS	NOT-AG-20-041	07-May-2022	Not Specified
--------	---	------------------------------------	---------------	-------------	---------------

Contact Name	Basil Eldadah, M.D., Ph.D.
Contact Telephone	301-496-6761
Contact Email	eldadahb@nia.nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	07-May-2022 , 05-Jun-2022 , 16-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 16-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 16-Feb-2023 , 07-May-2023 , 05-Jun-2023 , 16-Jun-2023 , 07-Sep-2023
Synopsis	This Notice of Special Interest (NOSI) encourages research grant applications focused on palliative care in geriatric populations. This NOSI covers studies in a variety of settings including hospitals (and specific sites within hospitals including specialty medical or surgical wards, intensive care units, and emergency departments), post-acute care settings, outpatient clinics and doctors' offices, patients' homes and other residential settings, long-term care facilities, hospices, and other healthcare or community settings. This NOSI encourages both prospective studies and analyses of existing datasets, health and medical records, claims data, or other sources. Leveraging ongoing cohorts, intervention studies, networks, data and specimen repositories, and other existing research resources and infrastructure is encouraged. Study designs may include observational approaches, quasi-experimental designs, and interventional studies.

105890	Notice of Special Interest (NOSI): Precision Imaging of Oral Lesions	National Institutes of Health/DHHS	NOT-DE-21-010	07-May-2022	Not Specified
--------	--	------------------------------------	---------------	-------------	---------------

Contact Name	Zhong Chen, MD, PhD
Contact Telephone	301-529-7083
Contact Email	zhong.chen@nih.gov
Sponsor Website	
Program URL	Link to program URL

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Deadline Dates (ALL) 07-May-2022 , 05-Jun-2022 , 16-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 16-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 16-Feb-2023 , 07-May-2023 , 05-Jun-2023 , 16-Jun-2023 , 07-Sep-2023 , 05-Oct-2023 , 16-Oct-2023 , 07-Jan-2024 , 05-Feb-2024 , 16-Feb-2024 , 07-May-2024 , 05-Jun-2024 , 16-Jun-2024 , 07-Sep-2024</p> <p>Synopsis Diagnosing and treating lesions of the oral cavity and oropharynx are challenging due to reliance on subjective analyses of clinical features and histopathological diagnostic criteria. High resolution and quantitative tools are needed to enhance the precision of diagnostic approaches for oral pathologies to guide options for treatment. This Notice of Special Interest (NOSI) is to encourage research projects that develop, adapt, optimize, and validate imaging-based applications and data analysis tools to enhance oral disease detection, diagnosis, and treatment. The long-term goal is to facilitate translation of research findings into clinical practice, paving the way for personalized health care through objective measures that promote accurate and timely diagnosis, targeted therapies, and improved patient survival and quality of life.</p>				
106848	Notice of Special Interest (NOSI): Biologic Factors Underlying Dental, Oral, and Craniofacial Health Disparities	National Institutes of Health/DHHS	NOT-DE-21-013	07-May-2022	Not Specified
	<p>Contact Name Hiroko Iida, DDS, MPH</p> <p>Contact Telephone 301-594-7404</p> <p>Contact Email hiroko.iida@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2022 , 05-Jun-2022 , 16-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 16-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 16-Feb-2023 , 07-May-2023 , 05-Jun-2023 , 16-Jun-2023 , 07-Sep-2023 , 05-Oct-2023 , 16-Oct-2023 , 07-Jan-2024 , 05-Feb-2024 , 16-Feb-2024 , 07-May-2024 , 05-Jun-2024 , 16-Jun-2024 , 07-Sep-2024 , 05-Oct-2024 , 16-Oct-2024 , 07-Jan-2025</p> <p>Synopsis The National Institute of Dental and Craniofacial Research (NIDCR) is issuing this Notice of Special Interest (NOSI) to encourage research studies designed to identify and understand the mechanisms by which biologic factors (microbial, immune, genetic) contribute to disparities in dental, oral, and craniofacial disease onset, progression, and persistence.</p>				
094050	NIH Small Research Grant Program (Parent R03 Clinical Trial Not Allowed)	National Institutes of Health/DHHS	PA-20-200	07-May-2022	100,000 USD
	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email grantsinfo@nih.gov</p> <p>Sponsor Website</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2022 , 16-Jun-2022 , 07-Sep-2022 , 16-Oct-2022 , 07-Jan-2023 , 16-Feb-2023 , 07-May-2023</p> <p>Synopsis The NIH Small Research Grant Program supports small research projects that can be carried out in a short period of time with limited resources. This program supports different types of projects including pilot and feasibility studies; secondary analysis of existing data; small, self-contained research projects; development of research methodology; and development of new research technology. This Funding Opportunity Announcement does not accept applications proposing clinical trial(s). Note: Not all NIH Institutes and Centers (ICs) participate in Parent Announcements. Applicants should carefully note which ICs participate in this announcement and view their respective areas of research interest at the R01 IC-Specific Scientific Interests and Contact website. ICs that do not participate in this announcement will not consider applications for funding.</p>				
103541	Notice of Special Interest (NOSI): Research on Strategies to Enhance Mental Health Interventions and Services within Employment and Job Training Settings	National Institutes of Health/DHHS	NOT-MH-21-230	07-May-2022	Not Specified
	<p>Contact Name Stephen O'Connor, Ph.D.</p> <p>Contact Telephone 301-480-8366</p> <p>Contact Email stephen.o'connor2@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2022 , 05-Jun-2022 , 15-Jun-2022 , 16-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 14-Oct-2022 , 16-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 15-Feb-2023 , 16-Feb-2023 , 07-May-2023 , 05-Jun-2023 , 15-Jun-2023 , 16-Jun-2023 , 07-Sep-2023</p> <p>Synopsis The purpose of this Notice of Special Interest (NOSI) is to encourage research focused on detection and intervention to prevent or treat mental health concerns, symptoms or disorders including drug-related conditions among unemployed and underemployed people participating in employment programs and job training settings (referred to here as "employment service customers" or "customers"). Considering the COVID-19 pandemic, the sharp rise and potentially long duration of unemployment raises concerns about the development and worsening of mental health symptoms and disorders, drug use behaviors, and suicide risk and necessitates further research to confirm the efficacy or demonstrate effectiveness of strategies in this area.</p>				
103732	Notice of Special Interest (NOSI): Women and Sex/Gender Differences in Drug and Alcohol Abuse/Dependence	National Institutes of Health/DHHS	NOT-DA-21-012	07-May-2022	Not Specified
	Contact Name Keisher Highsmith, DrPH				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Telephone</p> <p>Contact Email highsmithks@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2022 , 05-Jun-2022 , 16-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 16-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 16-Feb-2023 , 07-May-2023 , 05-Jun-2023 , 16-Jun-2023 , 07-Sep-2023 , 05-Oct-2023 , 16-Oct-2023 , 07-Jan-2024 , 05-Feb-2024 , 16-Feb-2024 , 07-May-2024 , 05-Jun-2024 , 16-Jun-2024 , 07-Sep-2024</p> <p>Synopsis The purpose of this Notice is to inform potential applicants of the National Institute on Drug Abuse (NIDA) special interest in grant applications to conduct rigorous basic, translational and/or clinical research to: (1) advance identification of sex and/or gender differences in risk for substance use disorders or the response or medical consequences of alcohol or substance misuse to uncover the mechanisms of those differences, and to conduct translational research on those differences, and (2) advance research specific to women or highly relevant to women. Both preclinical and clinical studies are sought across all areas of drug and alcohol research.</p>				
105365	Notice of Special Interest (NOSI): Research to Improve the Interpretation of Patient-Reported Outcomes at the Individual Patient Level for Use in Clinical Practice	National Institutes of Health/DHHS	NOT-OD-20-079	07-May-2022	Not Specified
	<p>Contact Name Ashley Wilder-Smith, Ph.D., MPH</p> <p>Contact Telephone 240-276-6714</p> <p>Contact Email smithas@mail.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2022 , 05-Jun-2022 , 16-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 16-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 16-Feb-2023 , 07-May-2023</p> <p>Synopsis A patient-reported outcome (PRO) is defined as any report of a person’s health status including symptoms, function and well-being, that is gathered directly from a patient, without interpretation of that report by a clinician, observer, or anyone else. PROs are critical for the support of patient-centered care, as they provide information from the patient’s perspective, and offer important information to improve patient-clinician communication, decision-making, and care delivery. PROs are increasingly being used by clinical stakeholders (e.g., providers, care delivery systems, payers and regulators) to characterize individual patients’ symptoms and functional status and the change in outcomes over time. Thus, PROs are becoming an important piece of information for clinical decision-making, including shared decision-making. The purpose of this Notice of</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		Special Interest (NOSI) is to stimulate research that contributes to the evidence base for precise and accurate PRO score interpretation at the individual patient level for use in clinical practice.			
105363	Notice of Special Interest (NOSI): Integration of Individual Residential Histories in Cancer Research	National Institutes of Health/DHHS	NOT-CA-21-092	07-May-2022	Not Specified
	Contact Name	Zaria Tatalovich, Ph.D.			
	Contact Telephone	240-276-6976			
	Contact Email	tatalovichzp@mail.nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	07-May-2022 , 05-Jun-2022 , 16-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 16-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 16-Feb-2023 , 07-May-2023 , 05-Jun-2023 , 16-Jun-2023 , 07-Sep-2023 , 05-Oct-2023 , 16-Oct-2023 , 07-Jan-2024 , 05-Feb-2024 , 16-Feb-2024 , 07-May-2024			
	Synopsis	This Notice of Special Interest (NOSI) seeks to highlight the interest of NCI's Division of Cancer Control and Population Sciences to support investigation of the role of individual Residential Histories - a record of an individual's places of residence over the life course - relative to cancer risk, etiology, prevention, treatment, and outcomes.			
088092	NIBIB Trailblazer Award for New and Early Stage Investigators (R21 Clinical Trial Optional)	National Institutes of Health/DHHS	PAR-20-084	07-May-2022	400,000 USD
	Contact Name	Randy King, Ph.D.			
	Contact Telephone	301-451-0707			
	Contact Email	Randy.King@nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	07-May-2022 , 16-Jun-2022 , 07-Sep-2022 , 16-Oct-2022 , 07-Jan-2023			
	Synopsis	This Trailblazer Award is an opportunity for NIH-defined New and Early Stage Investigators (https://grants.nih.gov/policy/early-investigators/index.htm) to pursue research programs of high interest to the NIBIB that integrate engineering and the physical sciences with the life and/or biomedical sciences. A Trailblazer project may be exploratory, developmental, proof of concept, or high risk-high impact, and may be technology design-directed, discovery-driven, or hypothesis-driven. Importantly, applicants must propose research approaches for which there are minimal or no			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>preliminary data. A distinct feature for this FOA is that no preliminary data are required, expected, or encouraged. However, if available, minimal preliminary data are allowed. Preliminary data are defined as material which the applicant has independently produced and not yet published in a peer-reviewed journal. All preliminary data should be clearly marked and limited to one-half page, which may include one figure. Applications including data more than one-half page or more than one figure will be considered noncompliant with the FOA instructions and will not go forward to review.</p>				
103419	Notice of Special Interest (NOSI): Improving Patient Adherence to Treatment and Prevention Regimens to Promote Health	National Institutes of Health/DHHS	NOT-OD-21-100	07-May-2022	Not Specified
	<p>Contact Name Wendy Nelson, PhD, MPH Contact Telephone 240-276-6971 Contact Email nelsonw@mail.nih.gov Sponsor Website Program URL Link to program URL Deadline Dates (ALL) 07-May-2022 , 05-Jun-2022 , 15-Jun-2022 , 16-Jun-2022 , 10-Aug-2022 , 07-Sep-2022 , 05-Oct-2022 , 14-Oct-2022 , 16-Oct-2022 , 14-Dec-2022 , 07-Jan-2023 , 05-Feb-2023 , 15-Feb-2023 , 16-Feb-2023 , 07-May-2023 , 05-Jun-2023 , 15-Jun-2023 , 16-Jun-2023 , 10-Aug-2023 , 07-Sep-2023 , 05-Oct-2023 , 16-Oct-2023 , 17-Oct-2023 , 07-Jan-2024 , 05-Feb-2024 , 15-Feb-2024 , 16-Feb-2024 , 07-May-2024 , 05-Jun-2024 Synopsis This Notice of Special Interest (NOSI) is being issued by the NIH Adherence Network through the Office of Behavioral and Social Sciences Research (OBSSR) with participation from multiple NIH Institutes, Centers, and Offices. This NOSI calls for research grant applications that address patient adherence to treatment and prevention regimens to promote health outcomes. Applications may address healthcare regimen initiation, implementation, and/or persistence by patients. Descriptive and intervention research may address adherence determinants at one or more levels of ecologic influence, including the patient, caregiver/family, provider, healthcare system, and community levels. The specific research interests of participating NIH Institutes and Centers are detailed within.</p>				
103312	Notice of Special Interest (NOSI): Developing and Testing Multilevel Physical Activity Interventions to Improve Health and Well-Being	National Institutes of Health/DHHS	NOT-OD-21-087	07-May-2022	Not Specified
	<p>Contact Name Bramaramba Kowtha MS, RDN, LDN Contact Telephone 301-435-8052 Contact Email bramaramba.kowtha@nih.gov Sponsor Website </p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2022 , 05-Jun-2022 , 16-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 16-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 16-Feb-2023 , 07-May-2023 , 05-Jun-2023 , 16-Jun-2023 , 07-Sep-2023 , 05-Oct-2023 , 16-Oct-2023 , 07-Jan-2024 , 05-Feb-2024 , 16-Feb-2024</p> <p>Synopsis The Office of Disease Prevention and participating ICOs are issuing this Notice to highlight our interest in encouraging highly innovative and promising translational research to improve our understanding of how to increase and maintain health-enhancing physical activity using multi-level interventions in a wide range of population groups across the lifespan (e.g., including racial and ethnic minorities, children, older adults, persons with medical/behavioral health conditions, and persons with disabilities). This includes efficacy, effectiveness and dissemination and implementation studies. It also includes support for pilot, exploratory, or developmental work in preparation for full-scale, fully powered efficacy studies, preliminary feasibility studies, as well as expanded feasibility work for a discrete, specified, circumscribed project that is based on well-established theory, existing data and evidence-based interventions.</p>				
103244	<p>Notice of Special Interest (NOSI): Research to Advance the Understanding and Management of the Multiple Organ Dysfunction Syndrome in Children (R01, R21)</p>	National Institutes of Health/DHHS	NOT-HD-21-024	07-May-2022	Not Specified
	<p>Contact Name Robert Tamburro, MD, MSc</p> <p>Contact Telephone 301-451-4295</p> <p>Contact Email robert.tamburro@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2022 , 05-Jun-2022 , 16-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 16-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 06-Feb-2023 , 07-May-2023</p> <p>Synopsis The purpose of this Notice of Scientific Interest (NOSI) is to continue a program of research to advance the understanding, prevention and treatment of pediatric multiple organ dysfunction syndrome (MODS). MODS is a clinical condition commonly encountered in the pediatric intensive care unit that is associated with significant morbidity and mortality. It is characterized by the failure or dysfunction of a consistent group of body organs or organ systems. It is triggered by a wide range of disease processes and clinical insults, most notably sepsis and trauma, and is frequently associated with uncontrolled inflammation. Despite its high prevalence and unfavorable outcomes, this clinical entity remains poorly understood. First described over 40 years ago, it still can only be described as a “syndrome,” a constellation of symptoms, rather than as a specific pathologic entity with a distinguishable cause. The current lack of understanding underscores the need for more basic, exploratory and longitudinal research. Applications may include any appropriate study design ranging from basic science and animal models</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

through prospective randomized controlled trials. It is hoped that as a result of research solicited through this NOSI, outcomes will improve both in terms of the prevention and treatment of MODS in children. Applicants planning to submit an application in response to this NOSI are strongly encouraged to contact the NICHD scientific/programmatic contact(s) listed on this NOSI in advance of the application due date.

100292	Discovery of Cell-based Chemical Probes for Novel Brain Targets (R21 Clinical Trial Not Allowed)	National Institutes of Health/DHHS	PAR-21-028	07-May-2022	275,000 USD
--------	--	------------------------------------	------------	-------------	-------------

Contact Name	Enrique L. Michelotti, Ph.D.
Contact Telephone	301-443 5415
Contact Email	michelottiel@mail.nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	07-May-2022 , 16-Jun-2022 , 07-Sep-2022 , 16-Oct-2022 , 07-Jan-2023 , 16-Feb-2023 , 07-May-2023 , 16-Jun-2023 , 07-Sep-2023 , 16-Oct-2023 , 07-Jan-2024
Synopsis	The purpose of this Funding Opportunity Announcement (FOA) is to support investigators who have interest and capability to join efforts for the discovery of cell-based chemical probes for novel brain targets. It is expected that applicants will have, in hand, the starting compounds (“validated hits”) for chemical optimization and bioassays for testing new analog compounds. Through this FOA, NIH wishes to stimulate research in: 1) discovery and development of novel, small molecules for their potential use in understanding biological processes relevant to the missions of NIMH, NIDA, NEI and/or NIA; and 2) discovery and/or validation of novel, biological targets that will inform studies of brain disease mechanisms. Emphasis will be placed on projects that provide new insight into important disease-related biological targets and biological processes. The main emphasis of projects submitted under this FOA should be the discovery of cell-based chemical probes. Applicants interested in developing in vivo chemical probes may wish to apply using the companion R01 mechanism, (PAR-21-029).

105732	Notice of Special Interest (NOSI): Immune Responses to Arthropod Feeding on Vertebrate Hosts	National Institutes of Health/DHHS	NOT-AI-21-059	07-May-2022	Not Specified
--------	--	------------------------------------	---------------	-------------	---------------

Contact Name	Qian “Joy” Liu, M.D., MSc.
Contact Telephone	301-761-6621
Contact Email	liujoy@niaid.nih.gov
Sponsor Website	
Program URL	Link to program URL

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Deadline Dates (ALL)	07-May-2022 , 05-Jun-2022 , 16-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 16-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 16-Feb-2023 , 07-May-2023 , 05-Jun-2023 , 16-Jun-2023 , 07-Sep-2023 , 05-Oct-2023 , 16-Oct-2023 , 07-Jan-2024 , 05-Feb-2024 , 16-Feb-2024 , 07-May-2024 , 05-Jun-2024 , 16-Jun-2024 , 07-Sep-2024			
	Synopsis	This Notice of Special Interest (NOSI) solicits transdisciplinary research projects to understand the immunologic events in the vertebrate host that occur at the bite site (skin) and systemically during and after feeding by hematophagous and ectoparasitic arthropods. Exploratory research on arthropod blood feeding was formerly supported by NIAID through the expired FOA, PAR-18-860, "Immune Response to Arthropod Blood Feeding (R21 Clinical Trial Not Allowed). The intent of this NOSI is to indicate continued NIAID support for research in this area as described below through applications to the parent R01 and R21 FOAs.			
108327	Research Enhancement Award Program (REAP) for Health Professional Schools and Graduate Schools (R15 Clinical Trial Required)	National Institutes of Health/DHHS	PAR-21-357	07-May-2022	300,000 USD
	Contact Name	Mahua Mukhopadhyay, Ph.D.			
	Contact Telephone	301-435-6886			
	Contact Email	mukhopam@mail.nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	07-May-2022 , 25-Jun-2022 , 07-Sep-2022 , 25-Oct-2022 , 07-Jan-2023 , 25-Feb-2023 , 07-May-2023 , 25-Jun-2023 , 07-Sep-2023 , 25-Oct-2023 , 07-Jan-2024 , 25-Feb-2024 , 07-May-2024 , 25-Jun-2024 , 07-Sep-2024 , 25-Oct-2024 , 07-Jan-2025			
	Synopsis	The purpose of the Research Enhancement Award Program (REAP) for Health Professional Schools and Graduate Schools is to support small scale research grants at institutions that do not receive substantial funding from the NIH, with an emphasis on providing biomedical research experiences primarily for health professional, undergraduate and graduate students and enhancing the research environment at applicant institutions. Eligible institutions must award baccalaureate or advanced science degrees and have received no more than \$6 million dollars per year of NIH support (in both direct and F&A/indirect costs) in 4 of the last 7 fiscal years. For institutions composed of multiple schools and colleges, the \$6 million funding limit is based on the amount of NIH funding received by all the schools and colleges within the institution as a whole. Help determining the Organization Funding Level can be found here or https://grants.nih.gov/grants/funding/r15.htm . This REAP funding opportunity announcement (FOA) supports investigator-initiated mechanistic and/or minimal risk clinical trials addressing the mission and research interests of the participating NIH institutes. For purposes of this FOA, minimal risk clinical trials are defined as those that do not require FDA oversight, do not intend to formally establish efficacy, and have low risks to potentially cause physical or psychological harm.			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
102638	New Directions in Hematology Research (SHINE-II) (R01 Clinical Trial Optional)	National Institutes of Health/DHHS	PAS-21-150	07-May-2022	600,000 USD
	<p>Contact Name: Shilpa Hattangadi, M.D.</p> <p>Contact Telephone: 301-594-7726</p> <p>Contact Email: shilpam.hattangadi@nih.gov</p> <p>Sponsor Website:</p> <p>Program URL: Link to program URL</p> <p>Deadline Dates (ALL): 07-May-2022 , 05-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 07-May-2023 , 05-Jun-2023 , 07-Sep-2023 , 05-Oct-2023 , 07-Jan-2024 , 05-Feb-2024 , 07-May-2024</p> <p>Synopsis: This Funding Opportunity Announcement (FOA) seeks innovative grant applications in nonmalignant hematology research that will steer the field in new directions. Applications to this FOA should propose proof of principle research that is tightly focused into one specific aim, which can be accomplished within a 1-3 year project period, and is directed at validating novel concepts and approaches that promise to open new pathways for discovery.</p>				
105050	Notice of Special Interest (NOSI): Use of Digital Technology and Mobile Health (mHealth) to Improve Diagnosis, Assessments, Interventions, Management and Outcomes for Individuals with Down Syndrome Across the Lifespan (R21 Clinical Trial Not Allowed)	National Institutes of Health/DHHS	NOT-OD-21-092	07-May-2022	Not Specified
	<p>Contact Name: Sujata Bardhan, Ph.D.</p> <p>Contact Telephone: 301-435-0471</p> <p>Contact Email: sujata.bardhan@nih.gov</p> <p>Sponsor Website:</p> <p>Program URL: Link to program URL</p> <p>Deadline Dates (ALL): 07-May-2022 , 16-Jun-2022 , 07-Sep-2022 , 16-Oct-2022 , 07-Jan-2023 , 16-Feb-2023 , 07-May-2023 , 16-Jun-2023 , 07-Sep-2023 , 16-Oct-2023</p> <p>Synopsis: This Notice invites applications specifically aimed at developing or building upon existing technological tools to improve diagnosis, assessments, interventions, management, and outcomes for infants, children, adolescents and adults with Down Syndrome.</p>				
106126	Notice of Special Interest (NOSI): Social, Behavioral, and Economic Impact of COVID-19 in Underserved and Vulnerable Populations	National Institutes of Health/DHHS	NOT-MH-21-330	07-May-2022	Not Specified

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Name Adam Haim, Ph.D.</p> <p>Contact Telephone </p> <p>Contact Email haima@mail.nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2022 , 05-Jun-2022 , 07-Jun-2022 , 15-Jun-2022 , 16-Jun-2022 , 07-Sep-2022 , 04-Oct-2022 , 05-Oct-2022 , 14-Oct-2022 , 16-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 07-Feb-2023 , 15-Feb-2023 , 16-Feb-2023 , 07-May-2023 , 05-Jun-2023 , 06-Jun-2023 , 15-Jun-2023 , 16-Jun-2023 , 07-Sep-2023 , 03-Oct-2023 , 05-Oct-2023 , 16-Oct-2023 , 17-Oct-2023 , 07-Jan-2024 , 05-Feb-2024 , 06-Feb-2024 , 15-Feb-2024 , 16-Feb-2024 , 07-May-2024 , 05-Jun-2024 , 16-Jun-2024 , 07-Sep-2024</p> <p>Synopsis NIH Institutes, Centers, and Offices participating in the Social, Behavioral, and Economic Impacts of COVID-19 in Vulnerable and Health Disparity Populations initiative are issuing this Notice of Special Interest (NOSI) to highlight interest in research to strengthen the understanding and response to the Coronavirus Disease 2019 (COVID-19) pandemic and help us prepare more effectively for future public health emergencies. While research related to the direct clinical effects of COVID-19 are supported by other funding opportunities, there are additional urgent public health needs, particularly in populations who experience health disparities and in vulnerable populations. The purpose of this Notice is to 1) emphasize the roles and impacts of interventions, particularly those under the umbrella of digital health, as well as community-engaged and multi-level interventions in healthcare settings to address access, reach, delivery, engagement, effectiveness, scalability, and sustainability of services that are utilized during and following the pandemic, and 2) encourage the leveraging of existing large-scale data sources with broad population coverage to improve prediction of various mitigation efforts (including vaccinations, masking, and physical distancing to inform the public health response) on transmission reduction and on social and economic impacts, and assess the downstream health and healthcare access effects, with an emphasis on underserved and vulnerable populations. Additionally, the use of large-scale data sources to study the indirect health impacts of the pandemic and subsequent social and economic changes is needed to understand the costs and benefits of various COVID-19 mitigation strategies.</p>				
106119	Small Grants for New Investigators to Promote Diversity in Health-Related Research (R21 Clinical Trial Optional)	National Institutes of Health/DHHS	PAR-21-313	07-May-2022	375,000 USD
	<p>Contact Name Katrina J. Serrano, Ph.D.</p> <p>Contact Telephone 301-480-7855</p> <p>Contact Email katrina.serrano@nih.gov</p> <p>Sponsor Website </p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2022 , 16-Jun-2022 , 07-Sep-2022 , 16-Oct-2022 , 07-Jan-2023 , 16-Feb-2023 , 07-May-2023 , 16-Jun-2023 , 07-Sep-2023 , 16-Oct-2023 , 07-Jan-2024 , 16-Feb-2024 , 07-May-2024 , 16-Jun-2024 , 07-Sep-2024</p> <p>Synopsis The purpose of this Funding Opportunity Announcement (FOA) is to provide support for new investigators from diverse backgrounds, including from groups nationally underrepresented in biomedical, clinical, behavioral and social sciences research, to conduct small research projects in the scientific mission areas of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), the National Human Genome Research Institute (NHGRI) or the National Institute of Biomedical Imaging and Bioengineering (NIBIB). New investigators at the time of award under this FOA will have had less than \$125,000 direct costs of combined research funding (excluding NIH training and NIH career awards). This R21 will support small research projects that can be carried out in a short period of time with limited resources and seeks to facilitate transition to research independence. The R21 grant mechanism supports different types of projects including pilot and feasibility studies; secondary analysis of existing data; small, self-contained research projects; development of research methodology; and development of new research technology.</p>				
106131	<p>Notice of Special Interest (NOSI): Maximizing the Scientific Value of Secondary Analyses of Existing Cohorts and Datasets in Order to Address Research Gaps and Foster Additional Opportunities in Aging Research</p>	National Institutes of Health/DHHS	NOT-AG-21-020	07-May-2022	Not Specified
	<p>Contact Name Rosaly Correa-de-Araujo, MD, MSc, Ph.D.</p> <p>Contact Telephone 301-496-6762</p> <p>Contact Email rosaly.correa-de-Araujo@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2022 , 05-Jun-2022 , 16-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 16-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 16-Feb-2023 , 07-May-2023</p> <p>Synopsis The goal of this Notice of Special Interest (NOSI) is to encourage the use of existing cohorts and datasets for well-focused secondary analyses to investigate novel scientific ideas and/or address clinically related issues on: (1) aging changes influencing health across the lifespan (e.g., Alzheimer’s disease and Alzheimer’s disease-related dementias (AD/ADRD)), (2) diseases and disabilities in older persons, and/or (3) the changes in basic biology of aging that underlie these impacts on health (the hallmarks of aging). Activities of high priority include those addressing specific hypotheses in basic biological research, clinical aging research, behavioral or social research, and/or translational geroscience to inform: the design and implementation of future epidemiologic or human intervention studies; interventions in animal models of aging;</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

research on behavioral and social factors over the life course that influence health (e.g., early life adversity); current geriatric practice in maintenance of health, disease management, and prevention of disability; or research testing of possible causal relationships between rates of aging and findings extracted by secondary analysis of the existing data. Existing datasets may also be used to develop and test new mathematical modeling and statistical analytical approaches. Analyses of sex and/or gender differences across health disparity groups (e.g., racial and ethnic groups, socioeconomic status, and sexual and gender minorities) are of high relevance. Use of cohorts that are linked to electronic health record systems and/or Centers for Medicare and Medicaid Services (CMS) administrative data are especially welcome. Applicants responding to this NOSI are strongly encouraged to describe plans for rapid sharing of data and results as well as innovative data analytics approaches (see Goal 3, NIH Strategic Plan For Data Science). Please note that applications proposing exploratory or developmental projects should consider using PA-20-195, whereas projects that already have sufficient preliminary data or a very strong and well-developed scientific premise should use PA-20-185.

106966	Notice of Special Interest (NOSI): Somatic Cell Gene Editing Therapies To Improve Transplantation Outcomes	National Institutes of Health/DHHS	NOT-AI-21-080	07-May-2022	Not Specified
--------	--	------------------------------------	---------------	-------------	---------------

Contact Name	Nasrin Nabavi, Ph.D.
Contact Telephone	240-627-3538
Contact Email	nnabavi@mail.nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	07-May-2022 , 05-Jun-2022 , 16-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 16-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 16-Feb-2023 , 07-May-2023 , 05-Jun-2023 , 16-Jun-2023 , 07-Sep-2023 , 05-Oct-2023 , 16-Oct-2023 , 07-Jan-2024 , 05-Feb-2024 , 16-Feb-2024 , 07-May-2024 , 05-Jun-2024 , 16-Jun-2024 , 07-Sep-2024 , 05-Oct-2024 , 16-Oct-2024 , 07-Jan-2025
Synopsis	The National Institute of Allergy and Infectious Diseases (NIAID) is interested in supporting research that applies somatic cell gene editing (SCGE) approaches to improve graft survival and outcomes for recipients of allogenic solid organ, pancreatic islet, or vascularized composite allograft (VCA) transplants in animal models or human tissues or organs excluded from clinical use.

107787	Notice of Special Interest (NOSI): Electronic Nicotine Delivery Systems (ENDS) and Alternative Nicotine and Tobacco Delivery Systems: Basic Mechanisms of Health Effects	National Institutes of Health/DHHS	NOT-OD-22-022	07-May-2022	Not Specified
--------	--	------------------------------------	---------------	-------------	---------------

Contact Name	Ron Johnson, Ph.D.
Contact Telephone	240-276-6250

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Email rjohnso2@mail.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2022 , 05-Jun-2022 , 16-Jun-2022 , 24-Jun-2022 , 11-Jul-2022 , 07-Sep-2022 , 05-Oct-2022 , 16-Oct-2022 , 20-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 16-Feb-2023 , 10-Mar-2023 , 07-May-2023</p> <p>Synopsis The Office of Disease Prevention and participating ICOs are issuing this Notice to communicate our interest in research examining how electronic nicotine delivery systems (ENDS) affect normal and disease states relevant to human cells, tissues, organs, and behaviors. Research on alternative nicotine and tobacco delivery systems [e.g., heated tobacco products (also called heat-not-burn)] will also be considered. Studies exclusively examining smokeless tobacco or combustible tobacco products (e.g., cigarettes, cigars) will be considered non-responsive.</p>				
108008	<p>Notice of Special Interest (NOSI): Research to Address Vaccine Hesitancy, Uptake, and Implementation among Populations that Experience Health Disparities</p>	National Institutes of Health/DHHS	NOT-MD-22-006	07-May-2022	Not Specified
	<p>Contact Name Deborah E. Linares, Ph.D., M.A.</p> <p>Contact Telephone 301-402-2516</p> <p>Contact Email deborah.linares@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2022 , 05-Jun-2022 , 08-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 08-Nov-2022 , 07-Jan-2023</p> <p>Synopsis This Notice of Special Interest (NOSI) highlights the need for research on strategies, and interventions to address vaccine hesitancy, uptake, and implementation among populations who experience health disparities in the US and its territories. Research is needed to understand and address misinformation, distrust, and hesitancy regarding uptake of vaccines (e.g., SARS-CoV-2, pneumococcal, influenza, hepatitis B, human papilloma virus (HPV)) among adults in the United States and territories, especially in populations at increased risk for morbidity and mortality due to long-standing systemic health and social inequities and chronic medical conditions. This NOSI is focused on adults 18 years and older except for SARS-CoV-2 and HPV-related vaccine topics, which may include eligible children and adolescents. The purpose of this NOSI is to solicit research to: 1) evaluate community-engaged interventions (e.g., expand reach, increase access, address psychosocial barriers) to facilitate vaccination uptake in clinical and community contexts; 2) evaluate organizational, local, state, and federal policies and initiatives that mitigate or exacerbate disparities in vaccine access, uptake, and series completion, and 3) understand and address barriers to increasing reach, access, and uptake of vaccinations among populations who experience health disparities.</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
101367	Notice of Special Interest (NOSI): Use of Human Connectome Data for Secondary Analysis	National Institutes of Health/DHHS	NOT-MH-21-175	07-May-2022	Not Specified
	<p>Contact Name Yvonne Bennett, Ph.D.</p> <p>Contact Telephone 301-222-7094</p> <p>Contact Email yvonne.bennett@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2022 , 05-Jun-2022 , 16-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 16-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 16-Feb-2023 , 07-May-2023 , 05-Jun-2023 , 16-Jun-2023 , 07-Sep-2023 , 05-Oct-2023 , 16-Oct-2023 , 07-Jan-2024 , 05-Feb-2024 , 16-Feb-2024 , 07-May-2024</p> <p>Synopsis NIMH and participating institutes/centers (ICs) listed above are issuing this Notice of Special Interest (NOSI) to encourage secondary analyses of data from the Human Connectome Project (HCP) including the multiple datasets in the Lifespan Human Connectome projects and the Human Connectomes Related to Human Disease. Applicants beyond the groups that originally collected the data are encouraged to apply. The analyses will serve to generate and evaluate hypotheses about the complex interrelationships among: brain structure, function and connectivity; cognitive, affective, sensory and motor processes; environmental factors; life event, social and psychosocial factors; genomic data, and clinical symptoms during development, aging, or disease. Details about the “Lifespan” and “Disease” Connectomes, including neuroimaging protocols and clinical and behavioral assessments, can be found at the Connectome Coordinating Facility website: https://www.humanconnectome.org/ and at the NIMH Data Archive (NDA) www.nda.nih.gov.</p>				
101300	Notice of Special Interest (NOSI): Use of Human Connectome Data for Secondary Analysis	National Institutes of Health/DHHS	NOT-MH-21-075	07-May-2022	Not Specified
	<p>Contact Name Yvonne Bennett, Ph.D.</p> <p>Contact Telephone 301-222-7094</p> <p>Contact Email yvonne.bennett@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2022 , 05-Jun-2022 , 16-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 16-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 16-Feb-2023 , 07-May-2023 , 05-Jun-2023 , 16-Jun-2023 , 07-Sep-2023 , 05-Oct-2023 , 16-Oct-2023 , 07-Jan-2024 , 05-Feb-2024 , 16-Feb-2024 , 07-May-2024</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

Synopsis NIMH and participating institutes/centers (ICs) listed above are issuing this Notice of Special Interest (NOSI) to encourage secondary analyses of data from the Human Connectome Project (HCP) including the multiple datasets in the Lifespan Human Connectome projects and the Human Connectomes Related to Human Disease. Applicants beyond the groups that originally collected the data are encouraged to apply. The analyses will serve to generate and evaluate hypotheses about the complex interrelationships among: brain structure, function and connectivity; cognitive, affective, sensory and motor processes; environmental factors; life event, social and psychosocial factors; genomic data, and clinical symptoms during development, aging, or disease. Details about the “Lifespan” and “Disease” Connectomes, including neuroimaging protocols and clinical and behavioral assessments, can be found at the Connectome Coordinating Facility website: <https://www.humanconnectome.org/> and at the NIMH Data Archive (NDA) www.nda.nih.gov.

104865	Notice of Special Interest (NOSI): Navigating Pediatric to Adult Health Care: Lost in Transition	National Institutes of Health/DHHS	NOT-HD-21-027	07-May-2022	Not Specified
--------	--	------------------------------------	---------------	-------------	---------------

Contact Name	Sonia Lee, PhD
Contact Telephone	301-594-4783
Contact Email	leesonia@mail.nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	07-May-2022 , 05-Jun-2022 , 16-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 16-Oct-2022 , 08-Nov-2022 , 07-Jan-2023 , 05-Feb-2023 , 16-Feb-2023 , 07-Mar-2023 , 07-May-2023 , 05-Jun-2023 , 16-Jun-2023 , 07-Sep-2023 , 05-Oct-2023 , 16-Oct-2023 , 05-Nov-2023 , 07-Jan-2024
Synopsis	The purpose of this Notice of Special Interest (NOSI) is to encourage applications in high-priority research areas related to pediatric health care transition for youth with chronic physical/medical conditions or intellectual/developmental disabilities. Research applications that will advance our understanding of promising practices designed to facilitate successful health care transitions (HCT) from pediatric to adult care settings as well as barriers and facilitators to such transition are encouraged. The ultimate goal is to improve care quality and patient and family outcomes during and after HCT.

107763	Notice of Special Interest (NOSI): Electronic Nicotine Delivery Systems (ENDS) and Alternative Nicotine and Tobacco Delivery Systems: Population, Clinical and Applied Prevention Mechanisms of Health Effects	National Institutes of Health/DHHS	NOT-OD-22-023	07-May-2022	Not Specified
--------	--	------------------------------------	---------------	-------------	---------------

Contact Name	Rachel Grana Mayne, PhD, MPH
Contact Telephone	240-276-5899

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Email rachel.mayne@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2022 , 05-Jun-2022 , 16-Jun-2022 , 24-Jun-2022 , 11-Jul-2022 , 07-Sep-2022 , 05-Oct-2022 , 16-Oct-2022 , 20-Oct-2022 , 08-Nov-2022 , 07-Jan-2023 , 05-Feb-2023 , 16-Feb-2023 , 07-Mar-2023 , 10-Mar-2023 , 07-May-2023 , 05-Jun-2023 , 16-Jun-2023 , 05-Oct-2023 , 16-Oct-2023 , 05-Nov-2023 , 07-Jan-2024 , 05-Feb-2024 , 16-Feb-2024 , 07-Mar-2024 , 07-May-2024</p> <p>Synopsis The Office of Disease Prevention and participating ICOs are issuing this Notice to communicate our interest in research on electronic nicotine delivery systems (ENDS). Research on alternative nicotine and tobacco delivery systems [e.g., heated tobacco products (also called heat-not-burn)] will also be considered. Research with a focus on other non-combustible nicotine and tobacco products will be considered on a case-by-case basis. Studies should examine population-based, clinical, and applied prevention of disease, including etiology and epidemiology of use, potential risks, benefits and impacts on other tobacco use behavior among different populations. Studies exclusively examining smokeless tobacco or combustible tobacco products (e.g., cigarettes, cigars) will be considered non-responsive.</p>				
107449	Notice of Special Interest (NOSI): Reducing Stigma Related to Drug Use in Human Service Settings	National Institutes of Health/DHHS	NOT-DA-21-060	07-May-2022	Not Specified
	<p>Contact Name Richard A. Jenkins PhD</p> <p>Contact Telephone 301-443-1923</p> <p>Contact Email jenkinsri@mail.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2022 , 05-Jun-2022 , 16-Jun-2022 , 11-Aug-2022 , 15-Aug-2022 , 07-Sep-2022 , 05-Oct-2022 , 16-Oct-2022 , 18-Nov-2022 , 07-Jan-2023 , 05-Feb-2023 , 16-Feb-2023 , 07-May-2023 , 05-Jun-2023 , 16-Jun-2023 , 11-Aug-2023 , 07-Sep-2023 , 05-Oct-2023 , 16-Oct-2023 , 07-Jan-2024 , 05-Feb-2024 , 16-Feb-2024 , 07-May-2024 , 05-Jun-2024 , 16-Jun-2024 , 07-Sep-2024 , 05-Oct-2024 , 16-Oct-2024 , 07-Jan-2025</p> <p>Synopsis The National Institute on Drug Abuse (NIDA) recognizes that stigma is pervasive in clinic, social service and other settings related to HIV prevention and care. Stigma contributes to a lack of attention to drug use screening, inadequate outreach to people who use drugs (PWUD) and insufficient uptake of services to prevent, treat, or mitigate HIV infection (and related consequences of drug use) among PWUD. Stigmas of interest include: internalized stigma among drug users, stigma associated with providing services to PWUD, and stigma toward PWUD by providers or service settings. Policies and</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>practices that create or augment stigma also are of interest here, as well as stigma experienced by providers who might otherwise broaden their services to PWUD. Stigma reduction interventions for HIV service settings have been developed and, in some cases, implemented on a wide scale, but generally target sexual transmission as the primary behavioral risk; however, knowledge from this work can inform stigma among PWUD. Large literatures on stigma also exist in a variety of other conditions (e.g., cancer, mental illness) which also can provide conceptual and programmatic bases to speed the development of new interventions addressing PWUD.</p>				
107248	Notice of Special Interest (NOSI): Improving Outcomes in Cancer Treatment-Related Cardiotoxicity	National Institutes of Health/DHHS	NOT-CA-22-001	07-May-2022	Not Specified
	<p>Contact Name Crystal Wolfrey Contact Telephone 240-276-6277 Contact Email wolfreyc@mail.nih.gov Sponsor Website Program URL Link to program URL Deadline Dates (ALL) 07-May-2022 , 25-May-2022 , 05-Jun-2022 , 07-Jun-2022 , 16-Jun-2022 , 21-Jun-2022 , 24-Jun-2022 , 20-Jul-2022 , 07-Sep-2022 , 25-Sep-2022 , 05-Oct-2022 , 07-Oct-2022 , 16-Oct-2022 , 24-Oct-2022 , 08-Nov-2022 , 07-Jan-2023 , 25-Jan-2023 , 05-Feb-2023 , 16-Feb-2023 , 07-Mar-2023 , 07-May-2023 , 05-Jun-2023 , 07-Jun-2023 , 16-Jun-2023 , 07-Sep-2023 , 05-Oct-2023 , 09-Oct-2023 , 16-Oct-2023 , 05-Nov-2023 , 07-Jan-2024 , 05-Feb-2024 , 16-Feb-2024 , 07-Mar-2024 , 07-May-2024 , 05-Jun-2024 , 07-Jun-2024 , 16-Jun-2024 , 07-Sep-2024 , 08-Oct-2024 Synopsis The purpose of this Notice of Special Interest (NOSI) is to encourage collaborative and innovative approaches to mitigate cardiovascular dysfunction while optimizing cancer outcomes by understanding the mechanisms of cancer treatment-related cardiotoxicity and translating the findings to improve risk stratification, early detection, prevention, and management.</p>				
106064	Maximizing Opportunities for Scientific and Academic Independent Careers (MOSAIC) Postdoctoral Career Transition Award to Promote Diversity (K99/R00 - Independent Basic Experimental Studies with Humans Required (BESH))	National Institutes of Health/DHHS	PAR-21-273	07-May-2022	Not Specified
	<p>Contact Name Lanay M. Mudd, Ph.D., FACSM Contact Telephone 301-594-9346 Contact Email lanay.mudd@nih.gov Sponsor Website Program URL Link to program URL</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Deadline Dates (ALL) 07-May-2022 , 12-Jun-2022 , 07-Sep-2022 , 12-Oct-2022 , 07-Jan-2023 , 12-Feb-2023 , 07-May-2023 , 12-Jun-2023 , 07-Sep-2023 , 12-Oct-2023 , 07-Jan-2024 , 12-Feb-2024 , 07-May-2024 , 12-Jun-2024 , 07-Sep-2024</p> <p>Synopsis The purpose of the Maximizing Opportunities for Scientific and Academic Independent Careers (MOSAIC) Postdoctoral Career Transition Award to Promote Diversity (K99/R00) program is to support a cohort of early career, independent investigators from diverse backgrounds conducting research in NIH mission areas. The long-term goal of this program is to enhance diversity in the biomedical research workforce. The MOSAIC K99/R00 program is designed to facilitate a timely transition of promising postdoctoral researchers from diverse backgrounds (e.g., see Notice of NIH's Interest in Diversity) from their mentored, postdoctoral research positions to independent, tenure-track or equivalent research-intensive faculty positions. The MOSAIC K99/R00 program will provide independent NIH research support before and after this transition to help awardees launch successful, independent research careers. Additionally, MOSAIC K99/R00 scholars will be part of organized scientific cohorts and will be expected to participate in mentoring, networking, and professional development activities coordinated by MOSAIC Institutionally-Focused Research Education Award to Promote Diversity (UE5) grantees. This Funding Opportunity Announcement is for basic science experimental studies involving humans, referred to in NOT-OD-18-212 as “prospective basic science studies involving human participants.” These studies fall within the NIH definition of a clinical trial and also meet the definition of basic research. Types of studies that should be submitted under this FOA include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental aspects of phenomena without specific application towards processes or products in mind. Applicants not planning an independent clinical trial or basic experimental study with humans, or proposing to gain research experience in a clinical trial or basic experimental study with humans led by another investigator, must apply to the 'Independent Clinical Trial Not Allowed' companion FOA. The proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) based on their scientific missions.</p>				
108357	Research Enhancement Award Program (REAP) for Health Professional Schools and Graduate Schools (R15 Clinical Trial Not Allowed)	National Institutes of Health/DHHS	PAR-22-060	07-May-2022	300,000 USD
	<p>Contact Name Lisa Chadwick</p> <p>Contact Telephone 301-435-7275</p> <p>Contact Email lisa.chadwick@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2022 , 25-Jun-2022 , 07-Sep-2022 , 25-Oct-2022 , 07-Jan-2023 , 25-Feb-2023 , 07-May-2023 , 25-Jun-2023 , 07-Sep-2023 , 25-Oct-2023 , 07-Jan-2024 , 25-Feb-2024 , 07-May-2024 , 25-Jun-2024 , 07-Sep-2024 , 25-Oct-2024 , 07-Jan-2025</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount	
	Synopsis	<p>The purpose of the Research Enhancement Award Program (REAP) for Health Professional Schools and Graduate Schools is to support small scale research grants at institutions that do not receive substantial funding from the NIH, with an emphasis on providing biomedical research experiences primarily for health professional, undergraduate and graduate students and enhancing the research environment at applicant institutions. Eligible institutions must award baccalaureate or advanced science degrees and have received no more than \$6 million dollars per year of NIH support (in both direct and F&A/indirect costs) in 4 of the last 7 fiscal years. For institutions composed of multiple schools and colleges, the \$6 million funding limit is based on the amount of NIH funding received by all the schools and colleges within the institution as a whole. Help determining the Organization Funding Level can be found here or https://grants.nih.gov/grants/funding/r15.htm.</p>				
106063		Maximizing Opportunities for Scientific and Academic Independent Careers (MOSAIC) Postdoctoral Career Transition Award to Promote Diversity (K99/R00 - Independent Clinical Trial Required)	National Institutes of Health/DHHS	PAR-21-272	07-May-2022	Not Specified
	Contact Name	Lanay M. Mudd, Ph.D., FACSM				
	Contact Telephone	301-594-9346				
	Contact Email	lanay.mudd@nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	07-May-2022 , 12-Jun-2022 , 07-Sep-2022 , 12-Oct-2022 , 07-Jan-2023 , 12-Feb-2023 , 07-May-2023 , 12-Jun-2023 , 07-Sep-2023 , 12-Oct-2023 , 07-Jan-2024 , 12-Feb-2024 , 07-May-2024 , 12-Jun-2024 , 07-Sep-2024				
	Synopsis	<p>The purpose of the Maximizing Opportunities for Scientific and Academic Independent Careers (MOSAIC) Postdoctoral Career Transition Award to Promote Diversity (K99/R00) program is to support a cohort of early career, independent investigators from diverse backgrounds conducting research in NIH mission areas. The long-term goal of this program is to enhance diversity in the biomedical research workforce. The MOSAIC K99/R00 program is designed to facilitate a timely transition of promising postdoctoral researchers from diverse backgrounds (e.g., see Notice of NIH's Interest in Diversity) from their mentored, postdoctoral research positions to independent, tenure-track or equivalent research-intensive faculty positions. The MOSAIC K99/R00 program will provide independent NIH research support before and after this transition to help awardees launch successful, independent research careers. Additionally, MOSAIC K99/R00 scholars will be part of organized scientific cohorts and will be expected to participate in mentoring, networking, and professional development activities coordinated by MOSAIC Institutionally-Focused Research Education Award to Promote Diversity (UE5) grantees. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary clinical trial, as part of their research and career development. Applicants not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must apply to companion FOA PAR-21-271.</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
108364	Health Care Models for Persons with Multiple Chronic Conditions from Populations that Experience Health Disparities: Advancing Health Care towards Health Equity (R01 - Clinical Trials Optional)	National Institutes of Health/DHHS	PAR-22-092	07-May-2022	Not Specified

Contact Name	Larissa Avilés-Santa, MD, MPH
Contact Telephone	301-827-6924
Contact Email	avilessantal@nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	07-May-2022 , 05-Jun-2022 , 07-Sep-2022 , 05-Feb-2023 , 07-May-2023 , 05-Jun-2023 , 07-Sep-2023 , 05-Feb-2024 , 07-May-2024 , 05-Jun-2024 , 07-Sep-2024
Synopsis	This initiative will support innovative, collaborative, and multi-disciplinary research designed to study the effective adaptation, integration, and implementation of recommended guidelines of care of persons with multiple chronic conditions (MCCs) from populations that experience health disparities. Projects would be expected to involve more than one component and/or more than one level of influence within existing or newly proposed health care models. The goal of this initiative is attainment of optimal treatment and health outcomes goals to advance health care towards health equity.

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
106928	RFA-AT-22-001 -- NIH Health Care Systems Research Collaboratory - Pragmatic and Implementation Trials of Embedded Interventions (UG3/UH3, Clinical Trials Optional)	National Institutes of Health/DHHS	RFA-AT-22-001	07-May-2022	4,500,000 USD

Contact Name	Wendy Weber, ND, PhD, MPH
Contact Telephone	301-402-1272
Contact Email	weberwj@mail.nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	07-May-2022 , 05-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 07-May-2023 , 05-Jun-2023 , 07-Sep-2023 , 05-Oct-2023 , 07-Jan-2024 , 05-Feb-2024 , 07-May-2024 , 05-Jun-2024 , 07-Sep-2024 , 05-Oct-2024
Synopsis	This Funding Opportunity Announcement (FOA) encourages UG3/UH3 phased cooperative research applications to conduct efficient, large-scale pragmatic or implementation trials to improve health and care delivery, with a particular focus on

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

health care systems (HCS) with less historical involvement in research studies focused on improving health outcomes for US patient populations. Awards made under this FOA will initially support a one-year milestone-driven planning phase (UG3), with possible transition to a trial conduct phase (UH3). UG3 projects that have met the scientific milestone and feasibility requirements may transition to the UH3 phase. The UG3/UH3 application must be submitted as a single application, following the instructions described in this FOA. The overall goal of this initiative is to support the "real world" assessment of health care strategies and clinical practices and procedures in health care systems (HCS) that lead to improved care for populations in a variety of healthcare contexts, with a strong focus on populations with health disparities. Results from the pragmatic studies supported by this FOA should inform policy makers, payers, doctors and patients across diverse patient care settings. This FOA requires that the intervention under study be embedded into health care delivery system, "real world" settings. Studies can propose to integrate multi-modal or multiple interventions that have demonstrated efficacy into HCS; or implement HCS changes to improve adherence to evidence-based guidelines. Trials should be conducted across three or more health care systems (HCS) that provide care to patient populations and will become part of and work with the NIH HCS Research Collaboratory. The NIH HCS Research Collaboratory Program has established a Collaboratory Coordinating Center (CCC) that is providing national leadership and technical expertise in all aspects of research with HCS. Awarded applicants will work with the HCS CCC (<https://rethinkingclinicaltrials.org/>) to facilitate further planning and refinement of the proposed study.

088011	Engineering Next-Generation Human Nervous System Microphysiological Systems (R01 Clinical Trials Not Allowed)	National Institutes of Health/DHHS	PAR-20-055	07-May-2022	Not Specified
--------	--	------------------------------------	------------	-------------	---------------

Contact Name	David M. Panchision, Ph.D.
Contact Telephone	301-443-5288
Contact Email	panchisiond@mail.nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	07-May-2022 , 05-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 07-Jan-2023
Synopsis	This Funding Opportunity Announcement (FOA) encourages research grant applications directed toward developing next-generation human cell-derived microphysiological systems (MPS) and related assays that replicate complex nervous system architectures and physiology with improved fidelity over current capabilities. Supported projects will be expected to enable future studies of complex nervous system development, function and aging in healthy and disease states. This FOA is intended to provide support for the further development of projects where preliminary data supports the feasibility of the line of investigation. Applicants without preliminary data may wish to apply to the companion R21 FOA(PAR-20-082).

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
088012	Engineering Next-Generation Human Nervous System Microphysiological Systems (R21 Clinical Trials Not Allowed)	National Institutes of Health/DHHS	PAR-20-082	07-May-2022	275,000 USD
	<p>Contact Name David M. Panchision, Ph.D.</p> <p>Contact Telephone 301-443-5288</p> <p>Contact Email panchisiond@mail.nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2022 , 16-Jun-2022 , 07-Sep-2022 , 16-Oct-2022 , 07-Jan-2023</p> <p>Synopsis This Funding Opportunity Announcement (FOA) encourages research grant applications directed toward developing next-generation human cell-derived microphysiological systems (MPS) and related assays that replicate complex nervous system architectures and physiology with improved fidelity over current capabilities. Supported projects will be expected to enable future studies of complex nervous system development, function and aging in healthy and disease states. The R21 grant mechanism is intended to encourage exploratory/developmental research by providing support for the early and conceptual stages of project development. High risk/high reward projects that lack preliminary data may be most appropriate for this FOA. Applicants with preliminary data may wish to apply to the companion R01 mechanism (PAR-20-NNN).</p>				
088090	Development and Application of PET and SPECT Imaging Ligands as Biomarkers for Drug Discovery and for Pathophysiological Studies of CNS Disorders (R01 Clinical Trial Not Allowed)	National Institutes of Health/DHHS	PAR-20-037	07-May-2022	825,000 USD
	<p>Contact Name Enrique Michelotti, Ph.D.</p> <p>Contact Telephone 301-443-5415</p> <p>Contact Email michelottiel@mail.nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2022 , 05-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 07-Jan-2023</p> <p>Synopsis This Funding Opportunity Announcement (FOA) invites research grant applications that propose the preclinical development of novel radioligands for positron emission tomography (PET) or single photon emission computed tomography (SPECT) imaging in rodent and nonhuman primate brain and incorporation of pilot or clinical feasibility evaluation in pre-clinical studies and appropriate model development. Projects proposing clinical assessments of novel radioligands should respond to FOA PAR-20-038 .</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
108950	RFA-AI-22-015 -- Biomarker Signatures of TB Infection in Young Children With and Without HIV (R01 Clinical Trial Not Allowed)	National Institutes of Health/DHHS	RFA-AI-22-015	09-May-2022 [Optional][LOI/Pre-App]	3,500,000 USD
	<p>Contact Name Tania B. Lombo, Ph.D.</p> <p>Contact Telephone 301-761-7612</p> <p>Contact Email tania.lombo@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 09-May-2022 [Optional][LOI/Pre-App], 08-Jun-2022</p> <p>Synopsis The purpose of this Funding Opportunity Announcement (FOA) is to advance research to discover and validate novel biomarkers of Tuberculosis (TB) infection and subsequent risk of progression to TB disease in young children with and without HIV.</p>				
102735	RFA-NS-21-015 -- HEAL Initiative: Team Research for Initial Translational Efforts in Non-addictive Analgesic Therapeutics Development (U19 Clinical Trial Not Allowed)	National Institutes of Health/DHHS	RFA-NS-21-015	10-May-2022 [Optional][LOI/Pre-App]	7,500,000 USD
	<p>Contact Name Michael L. Oshinsky, PhD</p> <p>Contact Telephone 301-496-9964</p> <p>Contact Email michael.oshinsky@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 10-May-2022 [Optional][LOI/Pre-App], 09-Jun-2022 , 11-Sep-2022 [Optional][LOI/Pre-App], 11-Oct-2022 , 10-May-2023 [Optional][LOI/Pre-App], 09-Jun-2023 , 10-Sep-2023 [Optional][LOI/Pre-App], 10-Oct-2023</p> <p>Synopsis This funding opportunity announcement (FOA) is part of a suite of FOAs to support the development of safe, effective, and non-addictive therapeutics to treat pain. The goal of this FOA is to support team-based research projects to develop assays, screening and early optimization work to develop a non-addictive therapeutic to treat pain. Discovery and validation of pharmacodynamic markers efficacy and pharmacokinetic/pharmacodynamic (PK/PD) studies are also responsive. The result of the project should be to advance a hit or lead to the point where they can meet the entry criteria for RFA-NS-21-010 HEAL Initiative: Non-addictive Analgesic Therapeutics Development [Small Molecules and Biologics] to Treat Pain (UG3/UH3 Clinical Trial Optional) within the 5 years of the award, there is no opportunity for renewal of this award. Applications should propose a plan that will lead to the development of analgesics with a rigorous biological rationale and scientifically sound</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

assays. If the data does not currently exist, the application must include a strong plan for developing data linking the putative therapeutic target(s) to the proposed pain indication and supporting the hypothesis that altering the target activity will produce desirable outcomes for the disease. This FOA is not specific for any one or group of pain conditions. Projects to develop therapeutics for acute pain, chronic pain, painful neuropathy, musculoskeletal pain, headache disorders, osteoarthritis, diabetic neuropathy, chemotherapy-induced neuropathy, eye pain, sickle-cell pain, post-surgical pain, cancer pain, visceral pain, post stroke pain, myofascial pain, painful disorders of the orofacial region and other conditions will be considered. Projects to develop analgesics for a combination of chronic overlapping pain conditions or for specific disease or pathological conditions will also be considered. Projects that seek to identify pain treatment targets in specific populations such as women, children, older adults, and other underrepresented groups will also be responsive to this FOA. Input from patients and caregivers on the therapeutic goals of the project is encouraged. The goal of each 5-year U19 application should be to identify candidate therapeutic(s) that will be ready to be submitted to RFA-NS-21-010 for further optimization.

104595	RFA-NS-21-029 -- HEAL Initiative: Planning Studies for Initial Analgesic Development [Small Molecules and Biologics] (R61 Clinical Trial Not Allowed)	National Institutes of Health/DHHS	RFA-NS-21-029	10-May-2022 [Optional][LOI/Pre-App]	1,000,000 USD
--------	---	------------------------------------	---------------	-------------------------------------	---------------

Contact Name	Michael L. Oshinsky, PhD
Contact Telephone	301-496-9964
Contact Email	michael.oshinsky@nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	10-May-2022 [Optional][LOI/Pre-App], 09-Jun-2022 , 11-Sep-2022 [Optional][LOI/Pre-App], 11-Oct-2022 , 10-May-2023 [Optional][LOI/Pre-App], 09-Jun-2023 , 10-Sep-2023 [Optional][LOI/Pre-App], 10-Oct-2023
Synopsis	The goal of this funding opportunity announcement (FOA) is to solicit Initial Analgesic Development R61 applications that propose 2-year exploratory/planning awards that are expected to enable a future application for RFA-NS-21-015 HEAL Initiative: Team Research - for Initial Translational Efforts in Non-addictive Analgesic Development [Small Molecules and Biologics] (U19 Clinical Trial Not Allowed). Thus, the limited scope of aims and approach of these applications are expected to establish a strong research team, feasibility, validity, or other technically qualifying results that support, enable, and/or lay the groundwork for a subsequent Team Research U19 application. These R61 awards will support the building of a research team to collect initial data and recruit additional collaborators. The application must include a plan for developing a strong research team, as well as a strategy to collect preliminary data linking putative therapeutic targets to the proposed pain indication and supporting the hypothesis that altering target activity will produce desirable outcomes for the disease.

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
109543	RFA-NS-22-028 -- BRAIN Initiative: Exploratory Team-Research BRAIN Circuit Programs - eTeamBCP (U01 Clinical Trials Optional)	National Institutes of Health/DHHS	RFA-NS-22-028	15-May-2022 [Optional][LOI/Pre-App]	Not Specified
	<p>Contact Name Karen K David, Ph.D.</p> <p>Contact Telephone 301-496-9964</p> <p>Contact Email BRAINCircuits@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 15-May-2022 [Optional][LOI/Pre-App], 14-Jun-2022 , 16-May-2023 [Optional][LOI/Pre-App], 15-Jun-2023 , 15-May-2024 [Optional][LOI/Pre-App], 14-Jun-2024</p> <p>Synopsis This funding opportunity announcement (FOA) is designed to support teams of three or more (up to six) PDs/PIs that seek to cross boundaries of interdisciplinary collaboration to elucidate the contributions of dynamic circuit activity to a specific behavioral or neural system. Applications are encouraged to propose adventurous and challenging goals that can only be tackled by a synergistic team-based approach and have the potential to be transformative and/or to enable significant advances. These studies at the exploratory stage are intended for the development of experimental capabilities and/or theoretical frameworks in preparation for a future competition for larger-scale or extended efforts, including the BRAIN TargetedBCP (R01) or the multi-component, Team-Research BRAIN Circuit Programs (U19). The overall goal of this FOA is to enable a large-scale analysis of neural systems and circuits within the context and during the simultaneous measurement of an ethologically relevant behavior. Toward this end, teams are expected to assemble and leverage multi-disciplinary expertise, and to integrate experimental with computational and theoretical approaches. Teams are expected to bridge fields by incorporating rich information on cell-types, on circuit functionality and connectivity, in conjunction with sophisticated analyses of an ethologically relevant behavior of an organism or a well-defined neural system. Teams are also expected to aim for a mechanistic understanding of the circuits of the central nervous system (CNS) by applying cutting-edge methods such as those for large-scale recording, manipulation, and analysis of neural circuits across multiple regions of the CNS.</p>				
108564	RFA-MH-22-145 -- BRAIN Initiative: Standards to Define Experiments Related to the BRAIN Initiative (R01 Clinical Trial Not Allowed)	National Institutes of Health/DHHS	RFA-MH-22-145	15-May-2022 [Optional][LOI/Pre-App]	Not Specified
	<p>Contact Name Ming Zhan, Ph.D.</p> <p>Contact Telephone 301-827-3678</p> <p>Contact Email ming.zhan@nih.gov</p> <p>Sponsor Website </p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 15-May-2022 [Optional][LOI/Pre-App], 14-Jun-2022 , 15-May-2023 [Optional][LOI/Pre-App], 14-Jun-2023 , 15-May-2024 [Optional][LOI/Pre-App], 14-Jun-2024</p> <p>Synopsis This Funding Opportunity Announcement (FOA) aims to develop standards that describe experimental protocols conducted as part of the BRAIN Initiative. It is expected that applications will solicit community input at all stages of the process. It is recommended that the first step of standard development will involve sharing data between different key groups in the experimental community in order to ensure that the developing standard will encompass the data collection efforts of those groups. The developed standard is expected to be broadly disseminated for use and widely available.</p>				
105360	<p>RFA-HG-21-001 -- Technology Development for Single-Molecule Protein Sequencing and Single-Cell Proteome Analysis (R01 Clinical Trial not allowed)</p>	National Institutes of Health/DHHS	RFA-HG-21-001	16-May-2022 [Optional][LOI/Pre-App]	275,000 USD
	<p>Contact Name Tina Gatlin, Ph.D.</p> <p>Contact Telephone 301-480-2280</p> <p>Contact Email gatlincl@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 16-May-2022 [Optional][LOI/Pre-App], 15-Jun-2022 , 16-May-2023 [Optional][LOI/Pre-App], 15-Jun-2023</p> <p>Synopsis This Funding Opportunity Announcement (FOA) solicits R21 grant applications to catalyze major advances in single-molecule protein sequencing through technology development. The goal of this initiative is to achieve technological advances over the next five years that enable generation of protein sequencing data at sufficient scale, speed, cost and accuracy to use routinely in studies of genome biology and function, and in biomedical and clinical research in general. Exploration of methods other than those currently in use is highly encouraged. High-risk/high-payoff applications are appropriate to achieve the goals of this FOA.</p>				
105362	<p>RFA-HG-21-002 -- Technology Development for Single-Molecule Protein Sequencing (R21 Clinical Trial not allowed)</p>	National Institutes of Health/DHHS	RFA-HG-21-002	16-May-2022 [Optional][LOI/Pre-App]	1,500,000 USD
	<p>Contact Name Tina Gatlin, Ph.D.</p> <p>Contact Telephone 301-480-2280</p> <p>Contact Email gatlincl@nih.gov</p> <p>Sponsor Website</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 16-May-2022 [Optional][LOI/Pre-App], 15-Jun-2022 , 16-May-2023 [Optional][LOI/Pre-App], 15-Jun-2023</p> <p>Synopsis This Funding Opportunity Announcement (FOA) solicits grant applications to catalyze major advances in single-molecule protein sequencing and single cell proteome analysis through technology development. The goal of this initiative is to achieve technological advances over the next five years that enable generation of protein sequencing data at sufficient scale, speed, cost and accuracy to use routinely in studies of genome biology and function, and in biomedical and clinical research in general.</p>				
099865	RFA-NS-21-010 -- HEAL Initiative: Non-addictive Analgesic Therapeutics Development [Small Molecules and Biologics] to Treat Pain (UG3/UH3 Clinical Trial Optional)	National Institutes of Health/DHHS	RFA-NS-21-010	16-May-2022 [Optional][LOI/Pre-App]	Not Specified
	<p>Contact Name Michael Oshinsky</p> <p>Contact Telephone 301-496-9964</p> <p>Contact Email michael.oshinsky@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 16-May-2022 [Optional][LOI/Pre-App], 15-Jun-2022 , 14-Sep-2022 [Optional][LOI/Pre-App], 14-Oct-2022 , 14-Jan-2023 [Optional][LOI/Pre-App], 14-Feb-2023 , 16-May-2023 [Optional][LOI/Pre-App], 15-Jun-2023 , 17-Sep-2023 [Optional][LOI/Pre-App], 17-Oct-2023</p> <p>Synopsis The purpose of this funding opportunity announcement (FOA) is to support preclinical optimization and development of safe, effective, and non-addictive small molecule and biologic therapeutics to treat pain. The goal of the program is to accelerate the optimization and development of promising small molecule and biologic hits/leads to Phase I clinical trials and readiness for the Early Phase Pain Investigation Clinical Network (EPPIC-Net) https://heal.nih.gov/research/clinical-research/eppic-net or other Phase II clinical studies. Applicants must have a promising biologic or small molecule hit/lead, robust biological rationale for the intended approach, and identified assays for optimization of the agent. The scope of this program includes optimization and early development activities, IND-enabling studies, development of a pharmacodynamic/target engagement biomarker, assembly and filing of an Investigational New Drug (IND) application and Phase I clinical testing. This is a milestone-driven phased cooperative agreement program involving participation of NIH program staff in the development of the project plan and monitoring of research progress.</p>				
109978	RFA-MH-22-220 -- BRAIN Initiative: Integration and Analysis of BRAIN Initiative Data (R01 Clinical Trial Not Allowed)	National Institutes of Health/DHHS	RFA-MH-22-220	16-May-2022 [Optional][LOI/Pre-App]	Not Specified

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Name Ming Zhan, Ph.D.</p> <p>Contact Telephone 301-827-3678</p> <p>Contact Email ming.zhan@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 16-May-2022 [Optional][LOI/Pre-App], 10-Jun-2022 , 14-Sep-2022 [Optional][LOI/Pre-App], 14-Oct-2022 , 10-May-2023 [Optional][LOI/Pre-App], 09-Jun-2023 , 13-Sep-2023 [Optional][LOI/Pre-App], 13-Oct-2023 , 08-May-2024 [Optional][LOI/Pre-App], 07-Jun-2024</p> <p>Synopsis This Funding Opportunity Announcement (FOA) solicits applications to develop informatics tools for analyzing, visualizing, and integrating data related to the BRAIN Initiative or to enhance our understanding of the brain. As part of programs of building the informatics infrastructure for the BRAIN Initiative, the FOA supports several different, but related activities. These include modifying existing analysis and visualization tools to deal with BRAIN Initiative data and integrating different types of BRAIN Initiative datasets. Proposing the development of new tools to deal with BRAIN Initiative data is also permitted. The tools supported under this FOA will make use of relevant data standards and will be built so that they can be integrated into the data repositories, both of which are created in awards under the other FOAs of the BRAIN initiative informatics program. The tools must be user-friendly in accessing and analyzing data from appropriate data archives, and should analyze/visualize data without requiring users to download data. The tools should also allow data to be combined for analysis/visualization from multiple locations.</p>				
108562	RFA-HL-23-001 -- ARDS, Pneumonia, and Sepsis Phenotyping Consortium Clinical Centers (U01 Clinical Trial Not Allowed)	National Institutes of Health/DHHS	RFA-HL-23-001	17-May-2022 [Optional][LOI/Pre-App]	2,075,000 USD
	<p>Contact Name Lora Reineck, MD, MS</p> <p>Contact Telephone 301-827-7845</p> <p>Contact Email lora.reineck@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 17-May-2022 [Optional][LOI/Pre-App], 17-Jun-2022</p> <p>Synopsis This funding opportunity announcement (FOA) seeks applications for Clinical Centers to form a cooperative multi-site Acute Respiratory Distress Syndrome (ARDS), Pneumonia, and Sepsis Phenotyping Consortium (APS Consortium). The APS Consortium will seek to understand the heterogeneity and underlying mechanisms of critical illness syndromes and</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

recovery, specifically in adults with ARDS, pneumonia, and/or sepsis, as well as the relationship and biological overlap among these syndromes. This will be accomplished through a prospective, longitudinal observational study with common data and biospecimen collection of 5,000 adults hospitalized in the United States with one or more of the following diagnoses: ARDS, pneumonia, or sepsis. It is expected that approximately half of the participants discharged from the hospital will have follow-up at 3, 6, and 12 months to facilitate understanding of long-term outcomes, including biological and physiological resolution of ARDS, pneumonia, and sepsis. Each of the Clinical Centers will enroll participants in a Consortium-wide longitudinal cohort, as well as utilize the data, imaging, and/or biospecimens collected Consortium-wide in a Clinical Center-specific scientific project. Throughout the program's funding period, data (including imaging data) and biospecimens collected will be made available as a resource to the broader research community as rapidly and simply as possible. The Clinical Centers will be expected to have expertise in enrolling participants in clinical studies of ARDS, pneumonia, and sepsis, such as emergency medicine, hospital medicine, and critical care clinical researchers, as well as scientific expertise for their specific projects. This FOA runs in parallel with the APS Consortium Coordinating Center (see RFA-HL-23-002).

108563	RFA-HL-23-002 -- ARDS, Pneumonia, and Sepsis Phenotyping Consortium Coordinating Center (U01 Clinical Trial Not Allowed)	National Institutes of Health/DHHS	RFA-HL-23-002	17-May-2022 [Optional][LOI/Pre-App]	Not Specified
--------	--	------------------------------------	---------------	--	---------------

Contact Name	Lora Reineck, MD, MS
Contact Telephone	301-827-7845
Contact Email	lora.reineck@nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	17-May-2022 [Optional][LOI/Pre-App], 17-Jun-2022

Synopsis
 This funding opportunity announcement (FOA) seeks applications for a Coordinating Center that will support the activities of a cooperative multi-site Acute Respiratory Distress Syndrome (ARDS), Pneumonia, and Sepsis Phenotyping Consortium (APS Consortium). The APS Consortium will seek to understand the heterogeneity and underlying mechanisms of critical illness syndromes and recovery, specifically in adults with ARDS, pneumonia, and/or sepsis, as well as the relationship and biological overlap among these syndromes. This will be accomplished through a prospective, longitudinal observational study with common data and biospecimen collection of 5,000 hospitalized adults with one or more of the following diagnoses: ARDS, pneumonia, or sepsis. It is expected that approximately half of the participants discharged from the hospital will have follow-up at 3, 6, and 12 months to facilitate understanding of long-term outcomes, including biological and physiological resolution of ARDS, pneumonia, and sepsis. Throughout the program's funding period, data (including imaging data) and biospecimens collected will be made available as a resource to the broader research community as rapidly

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

and simply as possible. The Coordinating Center will be expected to have expertise in statistics, longitudinal cohort studies, informatics, data management (including imaging data), and biospecimen management, and to have demonstrable interest in developing proactive policies for sharing. This FOA runs in parallel with the APS Consortium Clinical Centers (see RFA-HL-23-001).

104041	RFA-NS-21-023 -- BRAIN Initiative: Next-Generation Invasive Devices for Recording and Modulation in the Human Central Nervous System (UG3/UH3 Clinical Trial Optional)	National Institutes of Health/DHHS	RFA-NS-21-023	21-May-2022 [Optional][LOI/Pre-App]	Not Specified
--------	--	------------------------------------	---------------	-------------------------------------	---------------

Contact Name	Brooks Gross, PhD
Contact Telephone	301-496-1447
Contact Email	NINDS-Devices@nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	21-May-2022 [Optional][LOI/Pre-App], 20-Jun-2022 , 18-Sep-2022 [Optional][LOI/Pre-App], 18-Oct-2022 , 22-Jan-2023 [Optional][LOI/Pre-App], 21-Feb-2023 , 20-May-2023 [Optional][LOI/Pre-App], 19-Jun-2023 , 18-Sep-2023 [Optional][LOI/Pre-App], 18-Oct-2023 , 21-Jan-2024 [Optional][LOI/Pre-App], 20-Feb-2024
Synopsis	<p>The purpose of this Funding Opportunity Announcement (FOA) is to encourage investigators to pursue translational activities and small clinical studies for recording and/or stimulating devices to treat central nervous system disorders and better understand the human brain. Activities supported in this program include implementation of clinical prototype devices, non-clinical safety and efficacy testing, design verification and validation activities, obtaining an Investigational Device Exemption (IDE) for a Significant Risk (SR) study, as well as a subsequent small clinical study. Only Significant Risk (SR) clinical studies that will require an Investigational Device Exemption (IDE) from the FDA, such as chronic implants, will be supported by this FOA. The clinical study is expected to provide information about the device function or final design that cannot be practically obtained through additional non-clinical assessments (e.g., bench top or animal studies) due to the novelty of the device or its intended use. This FOA is a milestone-driven cooperative agreement program and will involve participation of NIH program staff in negotiating the final project plan before award and monitoring of research progress. Individuals, institutions, or businesses developing their own devices or that already have established collaborations with device manufacturers are welcome to apply directly to RFA-NS-21-024 or this FOA. The BRAIN PPP includes agreements with a number of device manufacturers willing to make such devices available, including devices and capabilities not yet market approved but appropriate for clinical research. In general, it is expected that the devices' existing safety and utility data will be sufficient to enable new FDA IDE and IRB approvals without need for significant additional non-clinical data. For more information on the BRAIN PPP, see https://braininitiative.nih.gov/brain-programs/public-private-partnerships</p>

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
104043	RFA-NS-21-024 -- BRAIN Initiative: Clinical Studies to Advance Next-Generation Invasive Devices for Recording and Modulation in the Human Central Nervous System (UH3 Clinical Trial Optional)	National Institutes of Health/DHHS	RFA-NS-21-024	21-May-2022 [Optional][LOI/Pre-App]	Not Specified
	<p>Contact Name Brooks Gross, PhD</p> <p>Contact Telephone 301-496-1447</p> <p>Contact Email NINDS-Devices@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 21-May-2022 [Optional][LOI/Pre-App], 20-Jun-2022 , 18-Sep-2022 [Optional][LOI/Pre-App], 18-Oct-2022 , 22-Jan-2023 [Optional][LOI/Pre-App], 21-Feb-2023 , 20-May-2023 [Optional][LOI/Pre-App], 19-Jun-2023 , 18-Sep-2023 [Optional][LOI/Pre-App], 18-Oct-2023 , 21-Jan-2024 [Optional][LOI/Pre-App], 20-Feb-2024</p> <p>Synopsis The purpose of this Funding Opportunity Announcement (FOA) is to encourage investigators to pursue first-in-human or early stage clinical studies for recording and/or stimulating devices to treat central nervous system disorders and better understand the human brain. Only Significant Risk (SR) studies that require an Investigational Device Exemption (IDE) from the FDA, such as chronic implants, will be supported by this FOA. The clinical study is expected to provide data to answer key questions about the function or final design of a device and is expected to provide information about the device function or final design that cannot be practically obtained through additional non-clinical assessments (e.g., bench top or animal studies) due to the novelty of the device or its intended use. This FOA is part of a milestone-driven cooperative agreement program and will involve participation of NIH program staff in negotiating the final project plan before award and monitoring of research progress. As part of the BRAIN Initiative, NIH has initiated a Public-Private Partnership Program (BRAIN PPP) that includes agreements (Memoranda of Understanding, MOU) with a number of device manufacturers willing to make such devices available, including devices and capabilities not yet market approved but appropriate for clinical research. In general, it is expected that the devices' existing safety and utility data will be sufficient to enable new FDA IDE and IRB approvals without need for significant additional non-clinical data. For more information on the BRAIN PPP, see https://braininitiative.nih.gov/brain-programs/public-private-partnerships Individuals, institutions, or businesses developing their own devices or that already have established collaborations with device manufacturers are welcome to apply directly to RFA-NS-21-023 or this FOA.</p>				
108952	RFA-MH-22-130 -- Integrating Mental Health Care into Health Care Systems in Low- and Middle-Income Countries (R01 Clinical Trial Optional)	National Institutes of Health/DHHS	RFA-MH-22-130	23-May-2022 [Optional][LOI/Pre-App]	Not Specified
	<p>Contact Name Andrea Horvath Marques, M.D., MPH, Ph.D.</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Telephone 301-646-7320</p> <p>Contact Email andrea.horvathmarques@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 23-May-2022 [Optional][LOI/Pre-App], 22-Jun-2022</p> <p>Synopsis This Funding Opportunity Announcement (FOA) invites implementation research applications to develop, optimize, and test innovative theory-based strategies to integrate mental and physical health care within health care systems in low-and middle-income countries (LMICs). This FOA aims to support innovative research for implementing, scaling up, and financially sustaining integrated mental health care models to ultimately increase demand and utilization, quality, access, and availability of mental health care. This FOA is also expected to contribute to the long-term goals of strengthening the sustainable research capacity in LMICs and enhancing the potential for multidirectional knowledge and the exchange of research advancements. NIMH encourages partnerships between institutions in LMICs and high-income-countries (HICs).</p>				
108901	<p>RFA-NS-22-050 -- HEAL Initiative: Discovery of Biomarkers and Biomarker Signatures to Facilitate Clinical Trials for Pain Therapeutics (UG3/UH3 Clinical Trial Optional)</p>	National Institutes of Health/DHHS	RFA-NS-22-050	24-May-2022 [Optional][LOI/Pre-App]	Not Specified
	<p>Contact Name Ram Arudchandran, PhD</p> <p>Contact Telephone 301-402-5257</p> <p>Contact Email ramachandran.arudchandran@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 24-May-2022 [Optional][LOI/Pre-App], 23-Jun-2022 , 13-Sep-2022 [Optional][LOI/Pre-App], 13-Oct-2022 , 24-Jan-2023 [Optional][LOI/Pre-App], 23-Feb-2023</p> <p>Synopsis The purpose of this Funding Opportunity Announcement (FOA) is to promote the discovery of candidate biomarkers or biomarker signatures for pain that can be used to facilitate the testing of non-opioid pain therapeutics in Phase II clinical trials. The biomarkers or biomarker signature will be developed through clinical research specifically focused on the identification of pain biomarkers or biosignatures that predict and/or monitor response to pain therapeutics. The resulting biomarkers or biomarker signatures may be focused on a single pain condition or on several pain conditions with common underlying pathophysiology. Applications to identify biomarkers or biomarker signatures that predict or monitor a therapeutic response across several related pain conditions should feature Multiple Principal Investigator (MPI)-led teams that represent each of the related pain conditions and associated clinical networks. The MPI-led teams are expected to</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

decide upon a single set of measures or biomarker modalities including, but not limited to a combination of omics, Quantitative Sensory Testing (QST), actigraphy, Electroencephalography (EEG), digital measures, etc.as components of the biosignature for all pain conditions represented in the application. Applications should feature centralized resource groups that will coordinate clinical trials and standardize all sample or data collection methods, technology development, statistical analysis and algorithm development across the pain conditions under investigation. Applications seeking to develop biomarkers or biomarker signatures that will be used to predict and/or monitor a therapeutic response for a single pain condition may also feature MPI-led teams that represent the cross functional expertise necessary for biomarker and/or signature development, along with the same types of centralized resource groups that coordinate clinical trials and standardize sample or data collection methods, technology development and statistical analysis. Studies to be supported by this FOA may include those necessary for the identification and initial biological, analytical, and clinical validation of pain biomarkers or biomarker signatures, and must include human samples and data as the source for candidate biomarkers or signatures identification and development if possible. If not, biomarkers or signatures resulting from identification in animal models must be verified in human samples at the end of the UG3 phase or during the UH3 phase. This initiative aims to deliver therapeutic response prediction and/or monitoring candidate pain biomarkers or biomarker signatures that are ready for definitive analytical and clinical validation appropriate for use in clinical trial design or decision-making in clinical practice.

109009	Notice of Special Interest (NOSI): Research Addressing Eye and Vision Health Equity/Health Disparities	National Institutes of Health/DHHS	NOT-EY-22-004	25-May-2022	Not Specified
--------	--	------------------------------------	---------------	-------------	---------------

Contact Name	Jimmy Le, Sc.D.
Contact Telephone	301-435-8160
Contact Email	Jimmy.Le@nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	25-May-2022 , 05-Jun-2022 , 16-Jun-2022 , 08-Aug-2022 , 05-Sep-2022 , 07-Sep-2022 , 25-Sep-2022 , 05-Oct-2022 , 16-Oct-2022 , 17-Nov-2022 , 08-Dec-2022 , 05-Jan-2023 , 07-Jan-2023 , 25-Jan-2023 , 05-Feb-2023 , 16-Feb-2023 , 17-Feb-2023 , 05-Apr-2023 , 08-Apr-2023 , 07-May-2023 , 25-May-2023 , 05-Jun-2023 , 16-Jun-2023 , 08-Aug-2023 , 05-Sep-2023 , 07-Sep-2023 , 25-Sep-2023 , 05-Oct-2023 , 16-Oct-2023 , 08-Dec-2023 , 05-Jan-2024 , 07-Jan-2024 , 25-Jan-2024 , 05-Feb-2024 , 16-Feb-2024 , 05-Apr-2024 , 08-Apr-2024 , 07-May-2024 , 25-May-2024 , 05-Jun-2024 , 16-Jun-2024 , 08-Aug-2024 , 05-Sep-2024 , 07-Sep-2024 , 25-Sep-2024 , 08-Dec-2024 , 05-Jan-2025 , 07-Jan-2025 , 25-Jan-2025
Synopsis	The purpose of this Notice of Special Interest (NOSI) is to highlight interest in supporting research that aims to promote health equity in the prevention, treatment, and management of eye and vision conditions. Applications that target

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	reduction of health disparities experienced by people who are visually impaired or blind are encouraged, as well as applications that investigate the impact of bias, structural racism, and discrimination in causing or sustaining eye or vision health inequities.				
108959	RFA-NS-22-027 -- BRAIN Initiative: Targeted BRAIN Circuits Planning Projects – TargetedBCPP (R34 Clinical Trials Not Allowed)	National Institutes of Health/DHHS	RFA-NS-22-027	01-Jun-2022 [Optional][LOI/Pre-App]	Not Specified
	<p>Contact Name: Karen K David, PhD</p> <p>Contact Telephone: 301-496-9964</p> <p>Contact Email: BRAINcircuits@NIH.GOV</p> <p>Sponsor Website:</p> <p>Program URL: Link to program URL</p> <p>Deadline Dates (ALL): 01-Jun-2022 [Optional][LOI/Pre-App], 01-Jul-2022 , 06-Sep-2022 [Optional][LOI/Pre-App], 06-Oct-2022 , 31-May-2023 [Optional][LOI/Pre-App], 30-Jun-2023 , 04-Sep-2023 [Optional][LOI/Pre-App], 04-Oct-2023 , 29-May-2024 [Optional][LOI/Pre-App], 28-Jun-2024 , 02-Sep-2024 [Optional][LOI/Pre-App], 02-Oct-2024</p> <p>Synopsis: This R34 FOA solicits applications that offer a limited scope of aims and an approach that will establish feasibility, validity, or other technically qualifying results that, if successful, would support, enable, and/or lay the groundwork for a potential, subsequent Targeted BRAIN Circuits Projects - TargetedBCP R01, as described in the companion FOA (RFA-NS-22-026). Applications should be adventurous, exploratory research projects that use innovative, methodologically-integrated approaches to understand how circuit activity gives rise to mental experience and behavior.</p>				
094931	NCCIH Natural Product Early Phase Clinical Trial Award (R33 Clinical Trial Required)	National Institutes of Health/DHHS	PAR-20-217	01-Jun-2022	1,050,000 USD
	<p>Contact Name: Wendy Weber, N.D., Ph.D, M.P.H.</p> <p>Contact Telephone: 301-402-1272</p> <p>Contact Email: weberwj@mail.nih.gov</p> <p>Sponsor Website:</p> <p>Program URL: Link to program URL</p> <p>Deadline Dates (ALL): 01-Jun-2022 , 07-Sep-2022 , 01-Feb-2023 , 07-May-2023</p> <p>Synopsis: This Funding Opportunity Announcement (FOA) encourages applications for investigator-initiated, early phase, clinical trials of natural products (i.e., botanicals, dietary supplements, and probiotics), which have a strong scientific premise to justify</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

further clinical testing. Under this FOA, trials must be designed so that results, whether positive or negative, will provide information of high scientific utility and will support decisions about further development or testing of the natural product. This FOA will provide up to 3 years support for studies to replicate the impact of the natural product on the biological signature(s) when used by humans and assess whether there is an association between the degree of the impact on the biological signature and functional or clinical outcomes in a patient population. Applications are encouraged to design studies to determine how to optimize the impact of the natural product on the biological signature by optimizing the delivery of the natural product by examining different doses or formulations. In addition, applications can be designed to combine the natural product with another treatment approach that is known to impact the same biological signature; or study the impact of the natural product in a target population that is more responsive. Clinical trials submitted under this FOA are expected to be hypothesis based, milestone-driven, and directly related to the research priorities and mission of NCCIH. This R33 funding mechanism is intended to accelerate the translation of emerging basic science findings about natural products into early stage clinical testing to determine whether continued clinical research is warranted. This FOA will not support efficacy or effectiveness trials, nor will it support trials to test natural products for the treatment or prevention of cancer.

108298	Limited Competition: Basic Instrumentation Grant (BIG) Program (S10 Clinical Trial Not Allowed)	National Institutes of Health/DHHS	PAR-22-081	01-Jun-2022	250,000 USD
--------	---	------------------------------------	------------	-------------	-------------

Contact Name	C. Ashley Barnes, PhD
Contact Telephone	301-435-0783
Contact Email	ashley.barnes@nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	01-Jun-2022 , 01-Jun-2023 , 03-Jun-2024
Synopsis	<p>The Basic Instrumentation Grant (BIG) Program encourages applications from groups of NIH-supported investigators to purchase a single high-priced, specialized, commercially available instrument or an integrated instrumentation system. The BIG Program is limited to institutions that have not received S10 instrumentation funding of \$250,001 or greater in any of the preceding 3 Federal fiscal years (FY). Use the following to determine applicable funding periods: for application due date of June 1, 2022, consider S10 funding in FYs 2019-2021; for application due date of June 1, 2023, consider S10 funding in FYs 2020-2022; for application due date of June 3, 2024, consider S10 funding in FYs 2021-2023. The minimum award is \$25,000. There is no maximum price limit for the instrument; however, the maximum award is \$250,000. Instruments supported include, but are not limited to, basic cell sorters, confocal microscopes, ultramicrotomes, gel imagers, or computer systems.</p>

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount														
108955	RFA-NS-22-026 -- BRAIN Initiative: Targeted BRAIN Circuits Projects- TargetedBCP (R01 Clinical Trial Not Allowed)	National Institutes of Health/DHHS	RFA-NS-22-026	01-Jun-2022 [Optional][LOI/Pre-App]	Not Specified														
	<table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 20%; padding: 5px;">Contact Name</td> <td style="padding: 5px;">Karen K David, PhD</td> </tr> <tr> <td style="padding: 5px;">Contact Telephone</td> <td style="padding: 5px;">301-496-9964</td> </tr> <tr> <td style="padding: 5px;">Contact Email</td> <td style="padding: 5px;">BRAINcircuits@NIH.GOV</td> </tr> <tr> <td style="padding: 5px;">Sponsor Website</td> <td style="padding: 5px;"></td> </tr> <tr> <td style="padding: 5px;">Program URL</td> <td style="padding: 5px;">Link to program URL</td> </tr> <tr> <td style="padding: 5px;">Deadline Dates (ALL)</td> <td style="padding: 5px;">01-Jun-2022 [Optional][LOI/Pre-App], 01-Jul-2022 , 06-Sep-2022 [Optional][LOI/Pre-App], 06-Oct-2022 , 31-May-2023 [Optional][LOI/Pre-App], 30-Jun-2023 , 04-Sep-2023 [Optional][LOI/Pre-App], 04-Oct-2023 , 29-May-2024 [Optional][LOI/Pre-App], 28-Jun-2024 , 02-Sep-2024 [Optional][LOI/Pre-App], 02-Oct-2024</td> </tr> <tr> <td style="padding: 5px;">Synopsis</td> <td style="padding: 5px;">This FOA solicits applications for research projects that seek to understand how circuit activity gives rise to mental experience and behavior using innovative, methodologically-integrated approaches. The goal is to support adventurous projects that can realize a potentially transformative outcome within 5 years. Applications are expected to address circuit function in the context of specific behaviors or neural systems, such as sensation, perception, attention, reasoning, intention, decision-making, emotion, navigation, communication, or homeostasis. Projects should link theory, data analysis, and/or computational approaches to experimental design and should produce predictive models (conceptual or quantitative). Projects should aim to improve the understanding of circuits of the central nervous system by systematically controlling stimuli and/or behavior while actively recording and/or manipulating dynamic patterns of neural activity. Diverse species or experimental systems and a cross-species/comparative approach are welcome and should be chosen based on their power to address the specific question at hand and to reveal generalizable and fundamental neuroscience principles.</td> </tr> </table>					Contact Name	Karen K David, PhD	Contact Telephone	301-496-9964	Contact Email	BRAINcircuits@NIH.GOV	Sponsor Website		Program URL	Link to program URL	Deadline Dates (ALL)	01-Jun-2022 [Optional][LOI/Pre-App], 01-Jul-2022 , 06-Sep-2022 [Optional][LOI/Pre-App], 06-Oct-2022 , 31-May-2023 [Optional][LOI/Pre-App], 30-Jun-2023 , 04-Sep-2023 [Optional][LOI/Pre-App], 04-Oct-2023 , 29-May-2024 [Optional][LOI/Pre-App], 28-Jun-2024 , 02-Sep-2024 [Optional][LOI/Pre-App], 02-Oct-2024	Synopsis	This FOA solicits applications for research projects that seek to understand how circuit activity gives rise to mental experience and behavior using innovative, methodologically-integrated approaches. The goal is to support adventurous projects that can realize a potentially transformative outcome within 5 years. Applications are expected to address circuit function in the context of specific behaviors or neural systems, such as sensation, perception, attention, reasoning, intention, decision-making, emotion, navigation, communication, or homeostasis. Projects should link theory, data analysis, and/or computational approaches to experimental design and should produce predictive models (conceptual or quantitative). Projects should aim to improve the understanding of circuits of the central nervous system by systematically controlling stimuli and/or behavior while actively recording and/or manipulating dynamic patterns of neural activity. Diverse species or experimental systems and a cross-species/comparative approach are welcome and should be chosen based on their power to address the specific question at hand and to reveal generalizable and fundamental neuroscience principles.
Contact Name	Karen K David, PhD																		
Contact Telephone	301-496-9964																		
Contact Email	BRAINcircuits@NIH.GOV																		
Sponsor Website																			
Program URL	Link to program URL																		
Deadline Dates (ALL)	01-Jun-2022 [Optional][LOI/Pre-App], 01-Jul-2022 , 06-Sep-2022 [Optional][LOI/Pre-App], 06-Oct-2022 , 31-May-2023 [Optional][LOI/Pre-App], 30-Jun-2023 , 04-Sep-2023 [Optional][LOI/Pre-App], 04-Oct-2023 , 29-May-2024 [Optional][LOI/Pre-App], 28-Jun-2024 , 02-Sep-2024 [Optional][LOI/Pre-App], 02-Oct-2024																		
Synopsis	This FOA solicits applications for research projects that seek to understand how circuit activity gives rise to mental experience and behavior using innovative, methodologically-integrated approaches. The goal is to support adventurous projects that can realize a potentially transformative outcome within 5 years. Applications are expected to address circuit function in the context of specific behaviors or neural systems, such as sensation, perception, attention, reasoning, intention, decision-making, emotion, navigation, communication, or homeostasis. Projects should link theory, data analysis, and/or computational approaches to experimental design and should produce predictive models (conceptual or quantitative). Projects should aim to improve the understanding of circuits of the central nervous system by systematically controlling stimuli and/or behavior while actively recording and/or manipulating dynamic patterns of neural activity. Diverse species or experimental systems and a cross-species/comparative approach are welcome and should be chosen based on their power to address the specific question at hand and to reveal generalizable and fundamental neuroscience principles.																		
108296	High-End Instrumentation (HEI) Grant Program (S10 Clinical Trial Not Allowed)	National Institutes of Health/DHHS	PAR-22-079	01-Jun-2022	2,000,000 USD														
	<table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 20%; padding: 5px;">Contact Name</td> <td style="padding: 5px;">Guanghu (Jeff) Wang, PhD</td> </tr> <tr> <td style="padding: 5px;">Contact Telephone</td> <td style="padding: 5px;">301-435-0772</td> </tr> <tr> <td style="padding: 5px;">Contact Email</td> <td style="padding: 5px;">HEI@mail.nih.gov</td> </tr> <tr> <td style="padding: 5px;">Sponsor Website</td> <td style="padding: 5px;"></td> </tr> <tr> <td style="padding: 5px;">Program URL</td> <td style="padding: 5px;">Link to program URL</td> </tr> <tr> <td style="padding: 5px;">Deadline Dates (ALL)</td> <td style="padding: 5px;">01-Jun-2022 , 01-Jun-2023 , 03-Jun-2024</td> </tr> </table>					Contact Name	Guanghu (Jeff) Wang, PhD	Contact Telephone	301-435-0772	Contact Email	HEI@mail.nih.gov	Sponsor Website		Program URL	Link to program URL	Deadline Dates (ALL)	01-Jun-2022 , 01-Jun-2023 , 03-Jun-2024		
Contact Name	Guanghu (Jeff) Wang, PhD																		
Contact Telephone	301-435-0772																		
Contact Email	HEI@mail.nih.gov																		
Sponsor Website																			
Program URL	Link to program URL																		
Deadline Dates (ALL)	01-Jun-2022 , 01-Jun-2023 , 03-Jun-2024																		

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

Synopsis | The High-End Instrumentation (HEI) Grant Program encourages applications from groups of NIH-supported investigators to purchase or upgrade a single item of high-end, specialized, commercially available instruments or integrated systems. The minimum award is \$600,001. There is no maximum price limit for the instrument; however, the maximum award is \$2,000,000. Instruments supported include, but are not limited to, X-ray diffractometers, high throughput robotic screening systems, mass spectrometers, nuclear magnetic resonance spectrometers, DNA and protein sequencers, biosensors, electron and light microscopes, flow cytometers, and biomedical imagers.

108297	Shared Instrumentation Grant (SIG) Program (\$10 Clinical Trial Not Allowed)	National Institutes of Health/DHHS	PAR-22-080	01-Jun-2022	600,000 USD
--------	--	------------------------------------	------------	-------------	-------------

Contact Name | Guanghu (Jeff) Wang, PhD
 Contact Telephone | 301-435-0772
 Contact Email | SIG@mail.nih.gov
 Sponsor Website |
 Program URL | [Link to program URL](#)
 Deadline Dates (ALL) | 01-Jun-2022 , 01-Jun-2022 , 03-Jun-2024

Synopsis | The Shared Instrument Grant (SIG) Program encourages applications from groups of NIH-supported investigators to purchase or upgrade a single item of high-priced, specialized, commercially available instruments or integrated instrumentation system. The minimum award is \$50,000. There is no maximum price limit for the instrument; however, the maximum award is \$600,000. Instruments supported include, but are not limited to: X-ray diffractometers, mass spectrometers, nuclear magnetic resonance spectrometers, DNA and protein sequencers, biosensors, electron and light microscopes, flow cytometers, and biomedical imagers.

094932	NCCIH Natural Product Early Phase Clinical Trial Phased Innovation Award (R61/R33 Clinical Trial Required)	National Institutes of Health/DHHS	PAR-20-218	01-Jun-2022	1,750,000 USD
--------	--	------------------------------------	------------	-------------	---------------

Contact Name | Wendy Weber, N.D., Ph.D, M.P.H.
 Contact Telephone | 301-402-1272
 Contact Email | weberwj@mail.nih.gov
 Sponsor Website |
 Program URL | [Link to program URL](#)
 Deadline Dates (ALL) | 01-Jun-2022 , 07-Sep-2022 , 01-Feb-2023 , 07-May-2023

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

Synopsis | This Funding Opportunity Announcement (FOA) encourages applications for investigator-initiated, early phase, clinical trials of natural products (i.e., botanicals, dietary supplements, and probiotics), which have a strong scientific premise to justify further clinical testing. Under this FOA, trials must be designed so that results, whether positive or negative, will provide information of high scientific utility and will support decisions about further development or testing of the natural product. This FOA will provide up to three years (R61 phase) of support for milestone-driven testing of pharmacokinetics, bioavailability, and assessment of the natural product's effect (i.e., measure of mechanism of action) when used by humans on a biological signature(s). If milestones in the R61 phase are achieved, up to 3 years of additional support (R33 phase) may be awarded to replicate the impact of the natural product on the biological signature(s) when used by humans and assess whether there is an association between the degree of the impact on the biological signature and functional or clinical outcomes in a patient population. Applications are encouraged to design R33 studies to determine how to optimize the impact of the natural product on the biological signature by optimizing the delivery of the natural product by examining different doses or formulation. In addition, applications can be designed to combine the natural product with another treatment approach that is known to impact the same biological signature; or study the impact of the natural product in a target population that is more responsive. Clinical trials submitted under this FOA are expected to be hypothesis based, milestone-driven, and directly related to the research priorities and mission of NCCIH. This R61/R33 funding mechanism is intended to accelerate the translation of emerging basic science findings about natural products into early-stage clinical testing to determine whether continued clinical research is warranted. This FOA will not support efficacy or effectiveness trials, nor will it support trials to test natural products for the treatment or prevention of cancer. A maximum of 5 years will be supported by the two phases of the R61/R33 award. Applicants are encouraged to contact the appropriate NCCIH Scientific/Research contact for the area of science for which they are planning to develop an application prior to submitting to this FOA.

097095	Promoting Research on Music and Health: Phased Innovation Award for Music Interventions (R61/R33 Clinical Trial Optional)	National Institutes of Health/DHHS	PAR-20-266	02-Jun-2022	1,750,000 USD
--------	---	------------------------------------	------------	-------------	---------------

Contact Name	Wen G. Chen, Ph.D.
Contact Telephone	301-451-3989
Contact Email	chenw@mail.nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	02-Jun-2022 , 17-Jun-2022 , 03-Oct-2022 , 19-Oct-2022 , 02-Jun-2023 , 19-Jun-2023
Synopsis	The purpose of this Funding Opportunity Announcement (FOA) is to promote innovative research on music and health with an emphasis on developing music interventions aimed at understanding their mechanisms of action and clinical applications

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

for the treatment of many diseases, disorders, and conditions. Given the emphasis on innovation, little or no preliminary data are needed to apply under this FOA. Because of the need for a multidisciplinary approach, collaborations among basic researchers, translational science researchers, music intervention experts, other clinical researchers, music health professionals, and technology development researchers are encouraged. The FOA utilizes a phased R61/R33 funding mechanism to support mechanistic research and to evaluate the clinical relevance of music interventions. The R61 phase will provide funding to either investigate the biological mechanisms or behavioral processes underlying music interventions in relevant animal models, healthy human subjects, and/or clinical populations, or can be used to develop innovative technology or approaches to enhance music intervention research. The second R33 phase will provide support for further mechanistic investigations in human subjects or animal models, intervention development, or pilot clinical studies. The pilot clinical studies may focus on intervention optimization/refinement, feasibility, adherence, and/or identification of appropriate outcome measures to inform future clinical research. Transition from the R61 to the R33 phase of the award will depend on successful completion of pre-specified milestones established in the R61.

087955	Surgical Disparities Research (R01 Clinical Trial Optional)	National Institutes of Health/DHHS	PAR-20-079	05-Jun-2022	Not Specified
--------	---	------------------------------------	------------	-------------	---------------

Contact Name | Benyam Hailu, MD, MPH
 Contact Telephone | 301-594-8696
 Contact Email | Benyam.Hailu@nih.gov
 Sponsor Website |
 Program URL | [Link to program URL](#)
 Deadline Dates (ALL) | 05-Jun-2022

Synopsis | The purpose of this Funding Opportunity Announcement (FOA) is to support investigative and collaborative research focused on understanding and addressing disparities in surgical care and outcomes, in minority and health disparity populations. While the goal is to better understand and explore effectiveness of clinical intervention approaches for addressing surgical disparities, this initiative will also seek to identify multi-level strategies at the institutional and systems level.

090374	In-Depth Phenotyping and Research Using IMPC-Generated Knockout Mouse Strains Exhibiting Embryonic or Perinatal Lethality or Subviability (R01 Clinical Trial Not Allowed)	National Institutes of Health/DHHS	PAR-20-137	05-Jun-2022	2,499,995 USD
--------	--	------------------------------------	------------	-------------	---------------

Contact Name | Mahua Mukhopadhyay, PhD
 Contact Telephone | 301-435-6886

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Email mukhopam@mail.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 05-Jun-2022 , 05-Oct-2022</p> <p>Synopsis The purpose of this Funding Opportunity Announcement (FOA) is to encourage applications to phenotype and/or perform research on embryonic lethal knockout (KO) mouse strains being generated through the International Mouse Phenotyping Consortium (IMPC) of which the NIH Knockout Mouse Phenotyping Program (KOMP2) is a member. The mission of IMPC is to generate a comprehensive catalogue of mammalian gene function that will provide the foundation for functional analyses of human genetic variation. As of November 2019, the IMPC-KOMP2 KO mouse phenotyping effort has generated mutants in 9,051 mouse genes, completed phenotypes of 7153 lines, and released data for 6255 lines corresponding to 5861 mutant genes. Overall, the IMPC hopes to achieve broad-based phenotyping of roughly 20,000 KO strains. About 30% of these strains either are expected to be embryonic or perinatal lethal, or subviable. A large portion of homozygous lethal mutations are expected to have viable heterozygous phenotypes. The scientific community has the unique opportunity to leverage these mouse strains while they are being created and bred as part of the IMPC adult mouse phenotyping effort to perform additional in-depth phenotyping and research.</p>				
105618	Molecular Imaging of Inflammation in Cancer (R01 Clinical Trial Not Allowed)	National Institutes of Health/DHHS	PAR-21-294	05-Jun-2022	Not Specified
	<p>Contact Name</p> <p>Contact Telephone 301-945-7573</p> <p>Contact Email GrantsInfo@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 05-Jun-2022 , 05-Oct-2022 , 05-Feb-2023 , 05-Jun-2023 , 05-Feb-2024 , 05-Jun-2024</p> <p>Synopsis The purpose of this Funding Opportunity Announcement (FOA) is to invite research grant applications (R01) for the development and use of current and emerging molecular imaging methods to gain fundamental insights into cancer inflammation in vivo. The motivation for this initiative is that much of current imaging research into the role of inflammation in cancer is largely based on in vitro and ex vivo methods with limited utilization of imaging approaches that could lead to significant new insights relevant to dynamic cancer and inflammation interactions. Utilization of molecular imaging probes in pre-clinical and clinical investigations for precise temporal resolution at the molecular and cellular level are valuable approaches for identification and characterization of in vivo inflammatory cellular physiology in cancers and of molecular</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

changes in response to treatment. This FOA encourages applications that focus on developing integrated imaging approaches to interrogate the role of inflammation in cancer through strong cross-field collaboration between cancer basic science researchers and imaging scientists. These collaborations are expected to advance science and understanding of cancer inflammation interactions.

109181	Notice of Special Interest (NOSI): Public Health Research on Cannabis	National Institutes of Health/DHHS	NOT-DA-22-003	05-Jun-2022	Not Specified
--------	---	------------------------------------	---------------	-------------	---------------

Contact Name	Marsha Lopez, PhD
Contact Telephone	(301) 402-1846
Contact Email	 (301) 402-1846
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	05-Jun-2022 , 16-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 16-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 16-Feb-2023 , 07-May-2023 , 05-Jun-2023 , 16-Jun-2023 , 07-Sep-2023 , 05-Oct-2023 , 16-Oct-2023 , 07-Jan-2024 , 05-Feb-2024 , 16-Feb-2024 , 07-May-2024 , 05-Jun-2024 , 16-Jun-2024 , 07-Sep-2024 , 05-Oct-2024 , 16-Oct-2024 , 07-Jan-2025 , 05-Feb-2025 , 16-Feb-2025
Synopsis	The National Institute on Drug Abuse (NIDA) is issuing this notice to encourage grant applications on the effects of changing cannabis laws and policies in the US and globally on public health.

109066	Notice of Special Interest (NOSI): Research on Drowning Prevention	National Institutes of Health/DHHS	NOT-HD-21-048	05-Jun-2022	Not Specified
--------	--	------------------------------------	---------------	-------------	---------------

Contact Name	Cinnamon A. Dixon, DO, MPH
Contact Telephone	301-827-6189
Contact Email	cinnamon.dixon@nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	05-Jun-2022 , 12-Jun-2022 , 16-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 12-Oct-2022 , 16-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 12-Feb-2023 , 16-Feb-2023 , 07-May-2023 , 05-Jun-2023 , 12-Jun-2023 , 16-Jun-2023 , 07-Sep-2023 , 05-Oct-2023 , 12-Oct-2023 , 16-Oct-2023 , 07-Jan-2024 , 05-Feb-2024 , 12-Feb-2024 , 16-Feb-2024 , 07-May-2024
Synopsis	Though epidemiologic research has helped identify drowning risk factors, little is known about what intervention strategies have the greatest efficacy to prevent drowning and/or improve outcomes after a drowning event. Thus, the goal of this NOSI

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

is to encourage and facilitate scientific discovery for drowning prevention, specifically aimed at reducing drowning risk and improving outcomes in three primary domains. Domain 1: Understanding drowning disparities and developing drowning interventions to address these disparities. Rates of drowning vary significantly. Reasons contributing to drowning risks among certain populations are multifaceted and likely related to access and exposure to water, knowledge and skills around water, and behaviors and beliefs. Research evaluating both structural and/or systemic forces which contribute to disparities in drowning risk among children, parents and communities is needed. Development of effective interventions aimed at addressing these factors as they pertain to drowning prevention is critical. Domain 2: Studying the effects of swim instruction on swim skills to prevent drowning. Swim skills, which are often obtained through swim instruction, can decrease drowning risk; however tremendous variability among types and techniques of swim instruction exists. Validated measures which consistently assess swim skill efficacy to prevent drowning at differing ages and developmental abilities are lacking. Metrics which help to identify effective, quality swim instruction to prevent drowning are needed. The development of evidence-based best practices as to when and how to instruct populations most at risk for drowning (such as children of young age, of certain races/ethnicities, with intellectual or developmental disabilities, or those with linguistic or cultural differences), is essential. Domain 3: The adoption, integration and sustainable scale-up of the drowning chain of survival. The five steps of drowning chain of survival can reduce drowning mortality. These steps include: (1) preventing drowning, (2) recognizing distress, (3) providing flotation, (4) removal from water and (5) providing care as needed. Depending on the water source, interventions which constitute these layers of drowning protection exist. Research to advance the adoption, integration and sustainable scale-up of evidence-based drowning prevention interventions and the drowning chain of survival across families and communities is needed.

109172	Microbial-based Cancer Imaging and Therapy - Bugs as Drugs (R01 Clinical Trial Not Allowed)	National Institutes of Health/DHHS	PAR-22-085	05-Jun-2022	Not Specified
--------	---	------------------------------------	------------	-------------	---------------

Contact Name	Avi Rasooly, PhD
Contact Telephone	240-276-6196
Contact Email	rasoolya@mail.nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	05-Jun-2022 , 05-Oct-2022 , 05-Feb-2023 , 05-Jun-2023 , 05-Oct-2023 , 05-Feb-2024 , 05-Jun-2024 , 05-Oct-2024 , 05-Feb-2025
Synopsis	This Funding Opportunity Announcement (FOA) solicits grant applications proposing to utilize bacteria, archaeobacteria, bacteriophages, or other non-oncolytic viruses and their natural products to study the underlying mechanisms of the complex interactions between microorganisms, tumors, and the immune system, and to explore their clinical potential for

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

cancer imaging, therapeutics or diagnostics. Projects can focus on using microorganisms as anti-tumor agents, as activators of anti-tumor immunity, or as delivery vehicles for treatment, diagnosis, or imaging, complementing or synergizing with existing tools and approaches. This FOA will support basic mechanistic and preclinical studies in cell culture and animal models. Applicants are encouraged to address both the microbial and tumor aspects of microbial tumor interactions relevant to microbial-based cancer therapy (including therapies for oral cancer), tumor imaging, tumor detection, or diagnosis. This funding opportunity is part of a broader NCI-sponsored research on microbial based cancer therapy.

107841	Risk and Protective Factors of Family Health and Family Level Interventions (R01 - Clinical Trial Optional)	National Institutes of Health/DHHS	PAR-21-358	05-Jun-2022	Not Specified
--------	---	------------------------------------	------------	-------------	---------------

Contact Name	Deborah E. Linares, PhD, MA
Contact Telephone	301-402-2516
Contact Email	Deborah.Linares@nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	05-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 07-May-2023 , 05-Jun-2023 , 07-Sep-2023 , 07-Jan-2024 , 05-Feb-2024 , 07-May-2024 , 05-Jun-2024 , 07-Sep-2024 , 05-Oct-2024 , 07-Jan-2025 , 05-Feb-2025 , 07-May-2025
Synopsis	The purpose of this initiative is to advance the science of minority health and health disparities by supporting research on family health and well-being and resilience. The NIMHD Research Framework recognizes family health, family well-being, and family resilience as critically important areas of research to decrease disparities and promote equity.

098071	Notice of Special Interest (NOSI): Simulation Modeling and Systems Science to Address Health Disparities	National Institutes of Health/DHHS	NOT-MD-20-025	05-Jun-2022	Not Specified
--------	--	------------------------------------	---------------	-------------	---------------

Contact Name	Rada Dagher, Ph.D., M.P.H.
Contact Telephone	301-451-2187
Contact Email	rada.dagher@nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	05-Jun-2022 , 05-Oct-2022 , 05-Feb-2023
Synopsis	The purpose of this Notice of Special Interest is to support investigative and collaborative research focused on developing and evaluating simulation modeling and systems science to understand and address minority health and health disparities.

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
105755	Investigator Initiated Research in Computational Genomics and Data Science (R01 Clinical Trial Not Allowed)	National Institutes of Health/DHHS	PAR-21-254	05-Jun-2022	2,500,000 USD
	<p>Contact Name Daniel Gilchrist, Ph.D.</p> <p>Contact Telephone</p> <p>Contact Email daniel.gilchrist@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 05-Jun-2022 , 05-Oct-2022 , 05-Feb-2023 , 05-Jun-2023 , 05-Oct-2023 , 05-Feb-2024 , 05-Jun-2024</p> <p>Synopsis The purpose of this funding opportunity announcement (FOA) is to invite applications for a broad range of research efforts in computational genomics, data science, statistics, and bioinformatics relevant to one or both of basic or clinical genomic science, and broadly applicable to human health and disease. This FOA supports fundamental genomics research that develops innovative analytical methodologies and approaches, early-stage development of tools and software, and refinement or hardening of software and tools of high value to the biomedical genomics community. Work supported under this FOA should be enabling for genomics and be generalizable or broadly applicable across diseases and biological systems.</p>				
107429	Patient-Clinician Relationship: Improving Health Outcomes in Populations that Experience Health Care Disparities (R01 Clinical Trial Optional)	National Institutes of Health/DHHS	PAR-22-064	05-Jun-2022	Not Specified
	<p>Contact Name Larissa Aviles-Santa, MD, MPH</p> <p>Contact Telephone 301-827-6924</p> <p>Contact Email avilessantal@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 05-Jun-2022 , 05-Oct-2022 , 05-Feb-2023 , 05-Jun-2023 , 05-Feb-2024 , 05-Jun-2024 , 05-Oct-2024</p> <p>Synopsis The purpose of this Funding Opportunity Announcement (FOA) is to support innovative multi-disciplinary and multi-level (e.g., patient, clinician, interpersonal, health care system, community) research designed to understand how optimizing patient-clinician communication and relationship affects health care outcomes in patients from populations with health care disparities. In addition, this initiative will support research to (1) gain an understanding of how the Patient-Clinician Relationship (PCR) in the primary care and chronic disease care settings affects clinical and non-clinical health outcomes in populations that experience health disparities, and (2) identify best practices and interventions that build and improve PCR leading to better health outcomes and increased health equity.</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount														
103967	Screening and Functional Validation of Human Birth Defects Genomic Variants (R01 Clinical Trial Not Allowed)	National Institutes of Health/DHHS	PAR-21-229	05-Jun-2022	2,499,995 USD														
	<table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 20%; padding-right: 10px;">Contact Name</td> <td>Mahua Mukhopadhyay, Ph.D.</td> </tr> <tr> <td style="padding-right: 10px;">Contact Telephone</td> <td>301-435-6886</td> </tr> <tr> <td style="padding-right: 10px;">Contact Email</td> <td>mukhopam@mail.nih.gov</td> </tr> <tr> <td style="padding-right: 10px;">Sponsor Website</td> <td></td> </tr> <tr> <td style="padding-right: 10px;">Program URL</td> <td>Link to program URL</td> </tr> <tr> <td style="padding-right: 10px;">Deadline Dates (ALL)</td> <td>05-Jun-2022 , 05-Feb-2023 , 05-Jun-2023 , 05-Feb-2024 , 05-Jun-2024 , 05-Feb-2025</td> </tr> <tr> <td style="padding-right: 10px;">Synopsis</td> <td>Rapid advances in genotyping and next generation sequencing technologies have led to the identification of genetic variants that are associated with a wide variety of congenital defects including structural birth defects (SBDs), intellectual developmental disabilities (IDDs) and inborn errors of metabolism (IEMs). Large quantities of genomic data collected from pediatric birth defects cohorts are available to the research community through several databases such as the Database of Genotypes and Phenotypes (dbGaP), the Gabriella Miller Kids First Data Resource Portal, the European Genome-Phenome Archive and Clinical Genome Resource (ClinGen). The purpose of this initiative is to promote the screening, functional validation and characterization of birth defects-associated genetic variants identified through public facing databases and individual efforts using in-silico tools, appropriate animal models, in vitro systems or multi-pronged approaches. This initiative addresses a challenging gap between identifying sequence variations of potential interest and recognizing which of those variations have functional effects on the phenotype of interest.</td> </tr> </table>					Contact Name	Mahua Mukhopadhyay, Ph.D.	Contact Telephone	301-435-6886	Contact Email	mukhopam@mail.nih.gov	Sponsor Website		Program URL	Link to program URL	Deadline Dates (ALL)	05-Jun-2022 , 05-Feb-2023 , 05-Jun-2023 , 05-Feb-2024 , 05-Jun-2024 , 05-Feb-2025	Synopsis	Rapid advances in genotyping and next generation sequencing technologies have led to the identification of genetic variants that are associated with a wide variety of congenital defects including structural birth defects (SBDs), intellectual developmental disabilities (IDDs) and inborn errors of metabolism (IEMs). Large quantities of genomic data collected from pediatric birth defects cohorts are available to the research community through several databases such as the Database of Genotypes and Phenotypes (dbGaP), the Gabriella Miller Kids First Data Resource Portal, the European Genome-Phenome Archive and Clinical Genome Resource (ClinGen). The purpose of this initiative is to promote the screening, functional validation and characterization of birth defects-associated genetic variants identified through public facing databases and individual efforts using in-silico tools, appropriate animal models, in vitro systems or multi-pronged approaches. This initiative addresses a challenging gap between identifying sequence variations of potential interest and recognizing which of those variations have functional effects on the phenotype of interest.
Contact Name	Mahua Mukhopadhyay, Ph.D.																		
Contact Telephone	301-435-6886																		
Contact Email	mukhopam@mail.nih.gov																		
Sponsor Website																			
Program URL	Link to program URL																		
Deadline Dates (ALL)	05-Jun-2022 , 05-Feb-2023 , 05-Jun-2023 , 05-Feb-2024 , 05-Jun-2024 , 05-Feb-2025																		
Synopsis	Rapid advances in genotyping and next generation sequencing technologies have led to the identification of genetic variants that are associated with a wide variety of congenital defects including structural birth defects (SBDs), intellectual developmental disabilities (IDDs) and inborn errors of metabolism (IEMs). Large quantities of genomic data collected from pediatric birth defects cohorts are available to the research community through several databases such as the Database of Genotypes and Phenotypes (dbGaP), the Gabriella Miller Kids First Data Resource Portal, the European Genome-Phenome Archive and Clinical Genome Resource (ClinGen). The purpose of this initiative is to promote the screening, functional validation and characterization of birth defects-associated genetic variants identified through public facing databases and individual efforts using in-silico tools, appropriate animal models, in vitro systems or multi-pronged approaches. This initiative addresses a challenging gap between identifying sequence variations of potential interest and recognizing which of those variations have functional effects on the phenotype of interest.																		
108898	Notice of Special Interest (NOSI): Priority Research Opportunities in Crisis Response Services	National Institutes of Health/DHHS	NOT-MH-22-110	05-Jun-2022	Not Specified														
	<table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 20%; padding-right: 10px;">Contact Name</td> <td>Stephen O'Connor, Ph.D.</td> </tr> <tr> <td style="padding-right: 10px;">Contact Telephone</td> <td>301-480-8366</td> </tr> <tr> <td style="padding-right: 10px;">Contact Email</td> <td>stephen.o'connor2@nih.gov</td> </tr> <tr> <td style="padding-right: 10px;">Sponsor Website</td> <td></td> </tr> <tr> <td style="padding-right: 10px;">Program URL</td> <td>Link to program URL</td> </tr> <tr> <td style="padding-right: 10px;">Deadline Dates (ALL)</td> <td>05-Jun-2022 , 15-Jun-2022 , 16-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 14-Oct-2022 , 16-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 15-Feb-2023 , 16-Feb-2023 , 07-May-2023 , 05-Jun-2023 , 15-Jun-2023 , 16-Jun-2023 , 07-Sep-2023 , 05-Oct-2023 , 16-Oct-2023 , 17-Oct-2023 , 07-Jan-2024 , 05-Feb-2024 , 15-Feb-2024 , 16-Feb-2024 , 07-May-2024 , 05-Jun-2024 , 16-Jun-2024 , 07-Sep-2024 , 05-Oct-2024 , 16-Oct-2024 , 07-Jan-2025 , 05-Feb-2025 , 16-Feb-2025 , 07-May-2025</td> </tr> </table>					Contact Name	Stephen O'Connor, Ph.D.	Contact Telephone	301-480-8366	Contact Email	stephen.o'connor2@nih.gov	Sponsor Website		Program URL	Link to program URL	Deadline Dates (ALL)	05-Jun-2022 , 15-Jun-2022 , 16-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 14-Oct-2022 , 16-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 15-Feb-2023 , 16-Feb-2023 , 07-May-2023 , 05-Jun-2023 , 15-Jun-2023 , 16-Jun-2023 , 07-Sep-2023 , 05-Oct-2023 , 16-Oct-2023 , 17-Oct-2023 , 07-Jan-2024 , 05-Feb-2024 , 15-Feb-2024 , 16-Feb-2024 , 07-May-2024 , 05-Jun-2024 , 16-Jun-2024 , 07-Sep-2024 , 05-Oct-2024 , 16-Oct-2024 , 07-Jan-2025 , 05-Feb-2025 , 16-Feb-2025 , 07-May-2025		
Contact Name	Stephen O'Connor, Ph.D.																		
Contact Telephone	301-480-8366																		
Contact Email	stephen.o'connor2@nih.gov																		
Sponsor Website																			
Program URL	Link to program URL																		
Deadline Dates (ALL)	05-Jun-2022 , 15-Jun-2022 , 16-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 14-Oct-2022 , 16-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 15-Feb-2023 , 16-Feb-2023 , 07-May-2023 , 05-Jun-2023 , 15-Jun-2023 , 16-Jun-2023 , 07-Sep-2023 , 05-Oct-2023 , 16-Oct-2023 , 17-Oct-2023 , 07-Jan-2024 , 05-Feb-2024 , 15-Feb-2024 , 16-Feb-2024 , 07-May-2024 , 05-Jun-2024 , 16-Jun-2024 , 07-Sep-2024 , 05-Oct-2024 , 16-Oct-2024 , 07-Jan-2025 , 05-Feb-2025 , 16-Feb-2025 , 07-May-2025																		

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Synopsis	The National Institutes of Health seeks research conducted in real-world settings, where a wide range of clinical presentations, psychosocial factors, age-related (e.g., youth; adult; older adult), geographic (rural/remote settings), cultural considerations, and health disparities influence the types of care that are provided. Examples of NIMH and NIDA studies that are encouraged through this Notice address the continuum of crisis service systems. Applications that include crisis services for children and under-resourced populations are encouraged. Topics of research interest span the crisis care continuum, including the effectiveness of these components: call center capabilities to address distress and coordinate care, deployed mobile crisis outreach and support, and crisis services that can diagnose and provide short term stabilization.			
107608	Drug Discovery For Nervous System Disorders (R01 Clinical Trials Not Allowed)	National Institutes of Health/DHHS	PAR-22-031	05-Jun-2022	Not Specified
	Contact Name	Enrique Michelotti, PhD			
	Contact Telephone	301-443-5415			
	Contact Email	michelottiel@mail.nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	05-Jun-2022 , 05-Oct-2022 , 05-Feb-2023 , 05-Jun-2023 , 05-Oct-2023 , 05-Feb-2024 , 05-Jun-2024 , 05-Oct-2024			
	Synopsis	This Funding Opportunity Announcement (FOA) supports the discovery of novel compounds for the prevention and treatment of nervous system disorders. Through this FOA, NIMH, NIAAA, NIDA and NIA wish to stimulate research in: 1) Identification, design, synthesis, and preclinical testing of small molecules for their potential as candidate therapeutics ; 2) Initial hit-to-lead chemistry to improve activity of compounds against the target of interest; 3) Later stage lead optimization to improve efficacy and pharmacokinetics; and 4) Initial drug metabolism and pharmacokinetic properties (DMPK). Emphasis will be placed on projects that provide novel approaches for identifying potential therapeutic agents.			
096053	Behavioral Tasks Targeting Brain Systems Relevant to Anhedonia (R01 Basic Experimental Studies with Humans Required)	National Institutes of Health/DHHS	PAR-20-235	05-Jun-2022	Not Specified
	Contact Name	Andrew Rossi			
	Contact Telephone	301-443-1576			
	Contact Email	rossia@mail.nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	05-Jun-2022 , 05-Oct-2022 , 05-Feb-2023 , 05-Jun-2023			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

Synopsis | This Funding Opportunity Announcement (FOA) encourages research to develop task-based behavioral measures that are shown to engage brain systems relevant to anhedonia using neuroimaging or other brain measures with similar spatial resolution. The goal is to identify behavioral tasks that can be used as quantitative tools in future studies of the functional constructs associated with anhedonia and in treatment development. This FOA is for basic science experimental studies involving human participants that fall within the NIH definition of a clinical trial and also meet the definition of basic research. Types of studies that should submit under this FOA include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental aspects of brain function in healthy individuals or those with disorders. These mechanistic studies are expected to be appropriate for the Basic Experimental Studies With Humans (BESH) FOAs <https://grants.nih.gov/grants/guide/notice-files/NOT-MH-19-006.html> since they are not intended to inform on the improvement of the health status of the individual or a group of individuals either by better understanding the mechanism of action of an intervention or a measurable improvement in health.

103168	Research on Autism Spectrum Disorders (R01 Clinical Trial Optional)	National Institutes of Health/DHHS	PA-21-201	05-Jun-2022	Not Specified
--------	---	------------------------------------	-----------	-------------	---------------

Contact Name | Lisa Gilotty, Ph.D.
 Contact Telephone | 301-443-3825
 Contact Email | gilottyl@mail.nih.gov
 Sponsor Website |
 Program URL | [Link to program URL](#)
 Deadline Dates (ALL) | 05-Jun-2022 , 05-Oct-2022 , 05-Feb-2023 , 05-Jun-2023 , 05-Oct-2023 , 05-Feb-2024

Synopsis | The purpose of this Funding Opportunity Announcement (FOA) is to encourage research grant applications to support research designed to elucidate the etiology, epidemiology, diagnosis, and optimal means of service delivery in relation to Autism Spectrum Disorders (ASD). The Research Project Grant (R01) mechanism supports discrete, specified projects based in scientific areas that represent the investigators' specific interests and competencies, and that fall within the mission of the participating NIH Institutes and Centers (ICs). The proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) based on their scientific missions, and preliminary data are generally expected. Applicants pursuing exploratory/developmental research to support early and conceptual stages of project development should consider the companion R21 FOA, PA-21-200. Applicants pursuing secondary analysis of existing data, and pilot or feasibility studies that can be completed with limited budgets should consider the companion R03 FOA, PA-21-199.

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount														
103023	Academic-Industrial Partnerships for Translation of Technologies for Diagnosis and Treatment (R01 - Clinical Trial Not Allowed)	National Institutes of Health/DHHS	PAR-21-166	05-Jun-2022	2,495,000 USD														
	<table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 20%; vertical-align: top;">Contact Name</td> <td>Miguel Ossandon MS</td> </tr> <tr> <td style="vertical-align: top;">Contact Telephone</td> <td>240-276-5714</td> </tr> <tr> <td style="vertical-align: top;">Contact Email</td> <td>ossandom@mail.nih.gov</td> </tr> <tr> <td style="vertical-align: top;">Sponsor Website</td> <td></td> </tr> <tr> <td style="vertical-align: top;">Program URL</td> <td>Link to program URL</td> </tr> <tr> <td style="vertical-align: top;">Deadline Dates (ALL)</td> <td>05-Jun-2022 , 05-Oct-2022 , 05-Feb-2023 , 05-Jun-2023 , 05-Oct-2023 , 05-Feb-2024</td> </tr> <tr> <td style="vertical-align: top;">Synopsis</td> <td> <p>The purpose of this Funding Opportunity Announcement (FOA) is to stimulate efforts to translate scientific discoveries and engineering developments into methods or tools that address problems in basic research to understand disease, or in applied research to assess risk, detect, prevent, diagnose, treat, and/or manage disease. The rationale is to deliver new capabilities to meet evolving requirements for technologies and methods relevant to the advance of research and delivery of care in pre-clinical, clinical and non-clinical settings, domestic or foreign, for conditions and diseases within the missions of participating institutes. This FOA specifies a partnership structure that is expected to help bridge gaps in knowledge and experience by engaging the strengths of academic, industrial, and other investigators. The partners on each application should establish an inter-disciplinary, multi-institutional research team to work in strategic alliance to implement a coherent strategy to develop and translate a solution to their chosen problem. They are expected to plan, design, and validate that the solution will be suitable for end users. Each partnership should include at least one academic and one industrial organization. Each partnership should plan to transition a technology, method, assay, device, and/or system from a demonstration of possibility to a status useful in the chosen setting. Funding may be requested to enhance, adapt, optimize, validate, and otherwise translate technologies that address problems in biology, pathology, risk assessment, diagnosis, treatment, and/or monitoring of disease status. This FOA defines "innovation" as likelihood to deliver a new capability to end users.</p> </td> </tr> </table>					Contact Name	Miguel Ossandon MS	Contact Telephone	240-276-5714	Contact Email	ossandom@mail.nih.gov	Sponsor Website		Program URL	Link to program URL	Deadline Dates (ALL)	05-Jun-2022 , 05-Oct-2022 , 05-Feb-2023 , 05-Jun-2023 , 05-Oct-2023 , 05-Feb-2024	Synopsis	<p>The purpose of this Funding Opportunity Announcement (FOA) is to stimulate efforts to translate scientific discoveries and engineering developments into methods or tools that address problems in basic research to understand disease, or in applied research to assess risk, detect, prevent, diagnose, treat, and/or manage disease. The rationale is to deliver new capabilities to meet evolving requirements for technologies and methods relevant to the advance of research and delivery of care in pre-clinical, clinical and non-clinical settings, domestic or foreign, for conditions and diseases within the missions of participating institutes. This FOA specifies a partnership structure that is expected to help bridge gaps in knowledge and experience by engaging the strengths of academic, industrial, and other investigators. The partners on each application should establish an inter-disciplinary, multi-institutional research team to work in strategic alliance to implement a coherent strategy to develop and translate a solution to their chosen problem. They are expected to plan, design, and validate that the solution will be suitable for end users. Each partnership should include at least one academic and one industrial organization. Each partnership should plan to transition a technology, method, assay, device, and/or system from a demonstration of possibility to a status useful in the chosen setting. Funding may be requested to enhance, adapt, optimize, validate, and otherwise translate technologies that address problems in biology, pathology, risk assessment, diagnosis, treatment, and/or monitoring of disease status. This FOA defines "innovation" as likelihood to deliver a new capability to end users.</p>
Contact Name	Miguel Ossandon MS																		
Contact Telephone	240-276-5714																		
Contact Email	ossandom@mail.nih.gov																		
Sponsor Website																			
Program URL	Link to program URL																		
Deadline Dates (ALL)	05-Jun-2022 , 05-Oct-2022 , 05-Feb-2023 , 05-Jun-2023 , 05-Oct-2023 , 05-Feb-2024																		
Synopsis	<p>The purpose of this Funding Opportunity Announcement (FOA) is to stimulate efforts to translate scientific discoveries and engineering developments into methods or tools that address problems in basic research to understand disease, or in applied research to assess risk, detect, prevent, diagnose, treat, and/or manage disease. The rationale is to deliver new capabilities to meet evolving requirements for technologies and methods relevant to the advance of research and delivery of care in pre-clinical, clinical and non-clinical settings, domestic or foreign, for conditions and diseases within the missions of participating institutes. This FOA specifies a partnership structure that is expected to help bridge gaps in knowledge and experience by engaging the strengths of academic, industrial, and other investigators. The partners on each application should establish an inter-disciplinary, multi-institutional research team to work in strategic alliance to implement a coherent strategy to develop and translate a solution to their chosen problem. They are expected to plan, design, and validate that the solution will be suitable for end users. Each partnership should include at least one academic and one industrial organization. Each partnership should plan to transition a technology, method, assay, device, and/or system from a demonstration of possibility to a status useful in the chosen setting. Funding may be requested to enhance, adapt, optimize, validate, and otherwise translate technologies that address problems in biology, pathology, risk assessment, diagnosis, treatment, and/or monitoring of disease status. This FOA defines "innovation" as likelihood to deliver a new capability to end users.</p>																		
092568	Research on Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) (R01 Clinical Trials Not Allowed)	National Institutes of Health/DHHS	PAR-20-165	05-Jun-2022	Not Specified														
	<table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 20%; vertical-align: top;">Contact Name</td> <td>Vicky Whittemore, PhD</td> </tr> <tr> <td style="vertical-align: top;">Contact Telephone</td> <td>301-496-1917</td> </tr> <tr> <td style="vertical-align: top;">Contact Email</td> <td>vicky.whittemore@nih.gov</td> </tr> <tr> <td style="vertical-align: top;">Sponsor Website</td> <td></td> </tr> <tr> <td style="vertical-align: top;">Program URL</td> <td>Link to program URL</td> </tr> </table>					Contact Name	Vicky Whittemore, PhD	Contact Telephone	301-496-1917	Contact Email	vicky.whittemore@nih.gov	Sponsor Website		Program URL	Link to program URL				
Contact Name	Vicky Whittemore, PhD																		
Contact Telephone	301-496-1917																		
Contact Email	vicky.whittemore@nih.gov																		
Sponsor Website																			
Program URL	Link to program URL																		

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Deadline Dates (ALL) 05-Jun-2022 , 05-Oct-2022 , 05-Feb-2023</p> <p>Synopsis This Funding Opportunity Announcement (FOA) encourages investigator(s)-initiated applications that propose to examine the etiology, diagnosis, pathophysiology and manifestations of myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) in diverse groups and across the lifespan. Applications that address gaps in the understanding of the environmental and biological risk factors, the determinants of heterogeneity among individuals with ME/CFS, and the common mechanisms influencing the multiple affected body systems in ME/CFS are encouraged. The NIH is particularly interested in funding interdisciplinary research that will enhance our knowledge of disease processes and provide evidence-based solutions to improve the diagnosis, treatment, and quality of life of all persons with ME/CFS. This interdisciplinary research may include the building of scientific teams to study and develop biomarkers and/or characterize the pathophysiological response of organ systems in individuals with ME/CFS. Applicants are encouraged to propose novel and innovative research that will break new ground or extend previous discoveries toward new directions.</p>				
091413	Academic-Industrial Partnerships (AIP) to Translate and Validate In Vivo Imaging Systems (R01 Clinical Trial Optional)	National Institutes of Health/DHHS	PAR-20-155	05-Jun-2022	Not Specified
	<p>Contact Name Christopher M. Hartshorn, Ph.D.</p> <p>Contact Telephone 240-781-3315</p> <p>Contact Email christopher.hartshorn@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 05-Jun-2022</p> <p>Synopsis The purpose of this Funding Opportunity Announcement (FOA) is to stimulate translation of scientific discoveries and engineering developments in imaging, data science and/or spectroscopic technologies into methods or tools that address contemporary problems in understanding the fundamental biology, potential risk of development, diagnosis, treatment, and/or disease status for cancer or other disease. A distinguishing feature of each application to this FOA will be formation of an academic-industrial partnership: a strategic alliance of academic and industrial investigators who work together as partners to identify and translate a technological solution for mitigation of a cancer (or other disease-related) problem. In this sense, the FOA acts more as funding mechanism for driving translational research in imaging more than for a specific scientific or clinical research area. These partnerships are expected to solidify pre-existing collaborations or new ones that would drive the field of imaging, as a whole, further than if they had not been formed. This FOA defines innovation as likelihood to deliver a new capability to end users. This FOA will support clinical trials that test functionality, or validate performance in the chosen setting. This FOA is not intended to support commercial production, basic research projects, or clinical trials that lack translation as the primary motivation.</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount														
091506	Novel Mechanism Research on Neuropsychiatric Symptoms (NPS) in Alzheimer's Dementia (R01 Clinical Trial Optional)	National Institutes of Health/DHHS	PAR-20-157	05-Jun-2022	Not Specified														
	<table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 20%; padding: 5px;">Contact Name</td> <td style="padding: 5px;">Jovier D. Evans, PhD</td> </tr> <tr> <td style="padding: 5px;">Contact Telephone</td> <td style="padding: 5px;">301-443-1369</td> </tr> <tr> <td style="padding: 5px;">Contact Email</td> <td style="padding: 5px;">jevans1@mail.nih.gov</td> </tr> <tr> <td style="padding: 5px;">Sponsor Website</td> <td style="padding: 5px;"></td> </tr> <tr> <td style="padding: 5px;">Program URL</td> <td style="padding: 5px;">Link to program URL</td> </tr> <tr> <td style="padding: 5px;">Deadline Dates (ALL)</td> <td style="padding: 5px;">05-Jun-2022 , 05-Oct-2022 , 05-Feb-2023</td> </tr> <tr> <td style="padding: 5px;">Synopsis</td> <td style="padding: 5px;"> <p>The goal of this Funding Opportunity Announcement (FOA) is to encourage applications for studies that will enhance knowledge of mechanisms associated with neuropsychiatric symptoms (NPS) in persons with Alzheimer's disease (AD) or Alzheimer's disease-related dementias (ADRD). The findings are expected to advance mechanistic understanding of both biobehavioral and neurobiological pathways leading to NPS. Findings may also provide insight into novel therapeutic targets that can be advanced into interventions to treat and prevent the development of NPS in AD and/or ADRD. This FOA uses the R01 mechanism, while the companion announcement PAR-20-159 uses the R21 mechanism. High risk/high payoff projects that lack preliminary data or utilize existing data may be most appropriate for the R21 mechanism.</p> </td> </tr> </table>					Contact Name	Jovier D. Evans, PhD	Contact Telephone	301-443-1369	Contact Email	jevans1@mail.nih.gov	Sponsor Website		Program URL	Link to program URL	Deadline Dates (ALL)	05-Jun-2022 , 05-Oct-2022 , 05-Feb-2023	Synopsis	<p>The goal of this Funding Opportunity Announcement (FOA) is to encourage applications for studies that will enhance knowledge of mechanisms associated with neuropsychiatric symptoms (NPS) in persons with Alzheimer's disease (AD) or Alzheimer's disease-related dementias (ADRD). The findings are expected to advance mechanistic understanding of both biobehavioral and neurobiological pathways leading to NPS. Findings may also provide insight into novel therapeutic targets that can be advanced into interventions to treat and prevent the development of NPS in AD and/or ADRD. This FOA uses the R01 mechanism, while the companion announcement PAR-20-159 uses the R21 mechanism. High risk/high payoff projects that lack preliminary data or utilize existing data may be most appropriate for the R21 mechanism.</p>
Contact Name	Jovier D. Evans, PhD																		
Contact Telephone	301-443-1369																		
Contact Email	jevans1@mail.nih.gov																		
Sponsor Website																			
Program URL	Link to program URL																		
Deadline Dates (ALL)	05-Jun-2022 , 05-Oct-2022 , 05-Feb-2023																		
Synopsis	<p>The goal of this Funding Opportunity Announcement (FOA) is to encourage applications for studies that will enhance knowledge of mechanisms associated with neuropsychiatric symptoms (NPS) in persons with Alzheimer's disease (AD) or Alzheimer's disease-related dementias (ADRD). The findings are expected to advance mechanistic understanding of both biobehavioral and neurobiological pathways leading to NPS. Findings may also provide insight into novel therapeutic targets that can be advanced into interventions to treat and prevent the development of NPS in AD and/or ADRD. This FOA uses the R01 mechanism, while the companion announcement PAR-20-159 uses the R21 mechanism. High risk/high payoff projects that lack preliminary data or utilize existing data may be most appropriate for the R21 mechanism.</p>																		
108571	Notice of Special Interest (NOSI): Enhancing Research on Deciphering Mechanisms of COVID-19-Associated Coagulopathy	National Institutes of Health/DHHS	NOT-HL-23-003	05-Jun-2022	Not Specified														
	<table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 20%; padding: 5px;">Contact Name</td> <td style="padding: 5px;">Anthony Agresti</td> </tr> <tr> <td style="padding: 5px;">Contact Telephone</td> <td style="padding: 5px;">301-827-8014</td> </tr> <tr> <td style="padding: 5px;">Contact Email</td> <td style="padding: 5px;">agrestia@nhlbi.nih.gov</td> </tr> <tr> <td style="padding: 5px;">Sponsor Website</td> <td style="padding: 5px;"></td> </tr> <tr> <td style="padding: 5px;">Program URL</td> <td style="padding: 5px;">Link to program URL</td> </tr> <tr> <td style="padding: 5px;">Deadline Dates (ALL)</td> <td style="padding: 5px;">05-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 07-May-2023 , 05-Jun-2023 , 07-Sep-2023 , 05-Oct-2023 , 07-Jan-2024 , 05-Feb-2024 , 07-May-2024 , 05-Jun-2024 , 07-Sep-2024 , 05-Oct-2024 , 05-Feb-2025 , 05-Jun-2025</td> </tr> <tr> <td style="padding: 5px;">Synopsis</td> <td style="padding: 5px;"> <p>This Notice of Special Interest (NOSI) aims to accelerate a comprehensive understanding of the mechanisms of COVID-19-Associated Coagulopathy (CAC) which are provoked by vascular endothelial cell injury, hyperimmune responses, and hypercoagulability at genomic, molecular, and cellular levels. Knowledge obtained from such studies may be applied to the future design of early diagnostics and effective treatment for high-risk patients as well as enable CAC research findings to be applied to on-going COVID-19 clinical trials.</p> </td> </tr> </table>					Contact Name	Anthony Agresti	Contact Telephone	301-827-8014	Contact Email	agrestia@nhlbi.nih.gov	Sponsor Website		Program URL	Link to program URL	Deadline Dates (ALL)	05-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 07-May-2023 , 05-Jun-2023 , 07-Sep-2023 , 05-Oct-2023 , 07-Jan-2024 , 05-Feb-2024 , 07-May-2024 , 05-Jun-2024 , 07-Sep-2024 , 05-Oct-2024 , 05-Feb-2025 , 05-Jun-2025	Synopsis	<p>This Notice of Special Interest (NOSI) aims to accelerate a comprehensive understanding of the mechanisms of COVID-19-Associated Coagulopathy (CAC) which are provoked by vascular endothelial cell injury, hyperimmune responses, and hypercoagulability at genomic, molecular, and cellular levels. Knowledge obtained from such studies may be applied to the future design of early diagnostics and effective treatment for high-risk patients as well as enable CAC research findings to be applied to on-going COVID-19 clinical trials.</p>
Contact Name	Anthony Agresti																		
Contact Telephone	301-827-8014																		
Contact Email	agrestia@nhlbi.nih.gov																		
Sponsor Website																			
Program URL	Link to program URL																		
Deadline Dates (ALL)	05-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 07-May-2023 , 05-Jun-2023 , 07-Sep-2023 , 05-Oct-2023 , 07-Jan-2024 , 05-Feb-2024 , 07-May-2024 , 05-Jun-2024 , 07-Sep-2024 , 05-Oct-2024 , 05-Feb-2025 , 05-Jun-2025																		
Synopsis	<p>This Notice of Special Interest (NOSI) aims to accelerate a comprehensive understanding of the mechanisms of COVID-19-Associated Coagulopathy (CAC) which are provoked by vascular endothelial cell injury, hyperimmune responses, and hypercoagulability at genomic, molecular, and cellular levels. Knowledge obtained from such studies may be applied to the future design of early diagnostics and effective treatment for high-risk patients as well as enable CAC research findings to be applied to on-going COVID-19 clinical trials.</p>																		

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount														
109791	Accelerating the Pace of Child Health Research Using Existing Data from the Adolescent Brain Cognitive Development (ABCD) Study (R01-Clinical Trial Not Allowed)	National Institutes of Health/DHHS	PAR-22-137	05-Jun-2022	1,250,000 USD														
	<table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 20%; padding: 5px;">Contact Name</td> <td style="padding: 5px;">Julia Zehr, Ph.D.</td> </tr> <tr> <td style="padding: 5px;">Contact Telephone</td> <td style="padding: 5px;">301-443-1617</td> </tr> <tr> <td style="padding: 5px;">Contact Email</td> <td style="padding: 5px;">Zehrj@mail.nih.gov</td> </tr> <tr> <td style="padding: 5px;">Sponsor Website</td> <td></td> </tr> <tr> <td style="padding: 5px;">Program URL</td> <td style="padding: 5px;">Link to program URL</td> </tr> <tr> <td style="padding: 5px;">Deadline Dates (ALL)</td> <td style="padding: 5px;">05-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 07-May-2023 , 05-Jun-2023 , 07-Sep-2023 , 05-Oct-2023 , 07-Jan-2024 , 05-Feb-2024 , 07-May-2024 , 05-Jun-2024 , 07-Sep-2024 , 05-Oct-2024 , 07-Jan-2025 , 05-Feb-2025 , 07-May-2025</td> </tr> <tr> <td style="padding: 5px;">Synopsis</td> <td style="padding: 5px;">The Adolescent Brain Cognitive Development (ABCD) Study is collecting data on health and mental health, cognitive function, substance use, cultural and environmental factors, and brain structure and function from youth starting when they are 9-10 years-old and following them longitudinally to early adulthood. These data will be made available to the scientific community through the NIMH Data Archive. The purpose of this Funding Opportunity Announcement (FOA) is to encourage applications proposing the analysis of this public use dataset to increase knowledge of adolescent health and development. More information about the ABCD Study may be found on the ABCD Study web page (www.abcdstudy.org). This FOA uses the R01 grant mechanism, whereas its companion FOA, PAR-22-138, seeks shorter, higher-risk R21 grant applications.</td> </tr> </table>					Contact Name	Julia Zehr, Ph.D.	Contact Telephone	301-443-1617	Contact Email	Zehrj@mail.nih.gov	Sponsor Website		Program URL	Link to program URL	Deadline Dates (ALL)	05-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 07-May-2023 , 05-Jun-2023 , 07-Sep-2023 , 05-Oct-2023 , 07-Jan-2024 , 05-Feb-2024 , 07-May-2024 , 05-Jun-2024 , 07-Sep-2024 , 05-Oct-2024 , 07-Jan-2025 , 05-Feb-2025 , 07-May-2025	Synopsis	The Adolescent Brain Cognitive Development (ABCD) Study is collecting data on health and mental health, cognitive function, substance use, cultural and environmental factors, and brain structure and function from youth starting when they are 9-10 years-old and following them longitudinally to early adulthood. These data will be made available to the scientific community through the NIMH Data Archive. The purpose of this Funding Opportunity Announcement (FOA) is to encourage applications proposing the analysis of this public use dataset to increase knowledge of adolescent health and development. More information about the ABCD Study may be found on the ABCD Study web page (www.abcdstudy.org). This FOA uses the R01 grant mechanism, whereas its companion FOA, PAR-22-138, seeks shorter, higher-risk R21 grant applications.
Contact Name	Julia Zehr, Ph.D.																		
Contact Telephone	301-443-1617																		
Contact Email	Zehrj@mail.nih.gov																		
Sponsor Website																			
Program URL	Link to program URL																		
Deadline Dates (ALL)	05-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 07-May-2023 , 05-Jun-2023 , 07-Sep-2023 , 05-Oct-2023 , 07-Jan-2024 , 05-Feb-2024 , 07-May-2024 , 05-Jun-2024 , 07-Sep-2024 , 05-Oct-2024 , 07-Jan-2025 , 05-Feb-2025 , 07-May-2025																		
Synopsis	The Adolescent Brain Cognitive Development (ABCD) Study is collecting data on health and mental health, cognitive function, substance use, cultural and environmental factors, and brain structure and function from youth starting when they are 9-10 years-old and following them longitudinally to early adulthood. These data will be made available to the scientific community through the NIMH Data Archive. The purpose of this Funding Opportunity Announcement (FOA) is to encourage applications proposing the analysis of this public use dataset to increase knowledge of adolescent health and development. More information about the ABCD Study may be found on the ABCD Study web page (www.abcdstudy.org). This FOA uses the R01 grant mechanism, whereas its companion FOA, PAR-22-138, seeks shorter, higher-risk R21 grant applications.																		
102069	Natural History of Disorders Screenable in the Newborn Period (R01 Clinical Trial Optional)	National Institutes of Health/DHHS	PAR-21-115	05-Jun-2022	Not Specified														
	<table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 20%; padding: 5px;">Contact Name</td> <td style="padding: 5px;">Melissa Parisi, MD, PhD</td> </tr> <tr> <td style="padding: 5px;">Contact Telephone</td> <td style="padding: 5px;">301-435-6880</td> </tr> <tr> <td style="padding: 5px;">Contact Email</td> <td style="padding: 5px;">parisima@mail.nih.gov</td> </tr> <tr> <td style="padding: 5px;">Sponsor Website</td> <td></td> </tr> <tr> <td style="padding: 5px;">Program URL</td> <td style="padding: 5px;">Link to program URL</td> </tr> <tr> <td style="padding: 5px;">Deadline Dates (ALL)</td> <td style="padding: 5px;">05-Jun-2022 , 05-Oct-2022 , 05-Feb-2023 , 05-Jun-2023 , 05-Oct-2023</td> </tr> <tr> <td style="padding: 5px;">Synopsis</td> <td style="padding: 5px;">This funding opportunity announcement (FOA) encourages applications that propose to develop studies that will lead to a broad understanding of the natural history of disorders that already do or could potentially benefit from early identification by newborn screening. A comprehensive understanding of the natural history of a disorder has been identified as a</td> </tr> </table>					Contact Name	Melissa Parisi, MD, PhD	Contact Telephone	301-435-6880	Contact Email	parisima@mail.nih.gov	Sponsor Website		Program URL	Link to program URL	Deadline Dates (ALL)	05-Jun-2022 , 05-Oct-2022 , 05-Feb-2023 , 05-Jun-2023 , 05-Oct-2023	Synopsis	This funding opportunity announcement (FOA) encourages applications that propose to develop studies that will lead to a broad understanding of the natural history of disorders that already do or could potentially benefit from early identification by newborn screening. A comprehensive understanding of the natural history of a disorder has been identified as a
Contact Name	Melissa Parisi, MD, PhD																		
Contact Telephone	301-435-6880																		
Contact Email	parisima@mail.nih.gov																		
Sponsor Website																			
Program URL	Link to program URL																		
Deadline Dates (ALL)	05-Jun-2022 , 05-Oct-2022 , 05-Feb-2023 , 05-Jun-2023 , 05-Oct-2023																		
Synopsis	This funding opportunity announcement (FOA) encourages applications that propose to develop studies that will lead to a broad understanding of the natural history of disorders that already do or could potentially benefit from early identification by newborn screening. A comprehensive understanding of the natural history of a disorder has been identified as a																		

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>necessary element to facilitate appropriate interventions for infants identified by newborn screening. By defining the sequence and timing of the onset of symptoms and complications of a disorder, a valuable resource will be developed for the field. In addition, for some disorders, specific genotype-phenotype correlations may allow prediction of the clinical course, and for other disorders, identification of modifying genetic, epigenetic, or environmental factors will enhance an understanding of the clinical outcomes for an individual with such a condition. Comprehensive data on natural history will facilitate the field's ability to: 1) accurately diagnose the disorder; 2) understand the genetic and clinical heterogeneity and phenotypic expression of the disorder; 3) identify underlying mechanisms related to basic defects; 4) potentially prevent, manage, and treat symptoms and complications of the disorder; and 5) provide children and their families with needed support and predictive information about the disorder.</p>				
110057	Notice of Special Interest (NOSI): Emerging and Existing Issues of Coronavirus Disease 2019 (COVID-19) Research Related to the Health and Well-Being of Women, Children and Individuals with Physical and/or Intellectual Disabilities	National Institutes of Health/DHHS	NOT-HD-22-002	05-Jun-2022	Not Specified
	<p>Contact Name Robert Tamburro, MD, MSc Contact Telephone 301-480-2619 Contact Email robert.tamburro@nih.gov Sponsor Website Program URL Link to program URL Deadline Dates (ALL) 05-Jun-2022 , 16-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 16-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 16-Feb-2023 , 07-May-2023 , 05-Jun-2023 , 16-Jun-2023 , 07-Sep-2023 , 05-Oct-2023 , 16-Oct-2023 , 07-Jan-2024 , 05-Feb-2024 , 16-Feb-2024 , 07-May-2024 , 05-Jun-2024 Synopsis The purpose of this funding opportunity is to provide an avenue for researchers to pursue funding to conduct research addressing these and other emerging and existing COVID-related issues among pregnant and lactating people, infants, children and adolescents, and individuals with physical and/or intellectual disabilities.</p>				
110112	Leveraging Health Information Technology (Health IT) to Address and Reduce Health Care Disparities (R01 Clinical Trial Optional)	National Institutes of Health/DHHS	PAR-22-145	05-Jun-2022	Not Specified
	<p>Contact Name Yewande A. Oladeinde, Ph.D. Contact Telephone 301-402-4307 Contact Email beda.jean-francois@nih.gov Sponsor Website </p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 05-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 07-May-2023 , 05-Jun-2023 , 07-Sep-2023 , 05-Oct-2023 , 07-Jan-2024 , 05-Feb-2024 , 07-May-2024 , 05-Jun-2024 , 07-Sep-2024 , 05-Oct-2024 , 07-Jan-2025 , 05-Feb-2025 , 07-May-2025</p> <p>Synopsis This funding opportunity announcement (FOA) seeks to support research that examines the impact of leveraging health information technology (health IT) to reduce disparities in access to and utilization of health care services, patient-clinician communication, and health outcomes for populations that experience health disparities in the U.S.</p>				
110034	<p>Notice of Special Interest (NOSI): Research Using Implementation Science To Support the Delivery of Evidence-Based Practices in Community-Based Mental or General Medical Healthcare Settings</p>	National Institutes of Health/DHHS	NOT-MH-22-170	05-Jun-2022	Not Specified
	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 05-Jun-2022 , 15-Jun-2022 , 16-Jun-2022 , 11-Aug-2022 , 07-Sep-2022 , 05-Oct-2022 , 14-Oct-2022 , 16-Oct-2022 , 18-Nov-2022 , 07-Jan-2023 , 05-Feb-2023 , 15-Feb-2023 , 16-Feb-2023 , 07-May-2023 , 05-Jun-2023 , 15-Jun-2023 , 16-Jun-2023 , 11-Aug-2023 , 07-Sep-2023 , 05-Oct-2023 , 16-Oct-2023 , 17-Oct-2023 , 07-Jan-2024 , 05-Feb-2024 , 15-Feb-2024 , 16-Feb-2024 , 07-May-2024 , 05-Jun-2024 , 16-Jun-2024 , 07-Sep-2024 , 05-Oct-2024 , 16-Oct-2024 , 07-Jan-2025 , 05-Feb-2025 , 16-Feb-2025 , 07-May-2025</p> <p>Synopsis This Notice of Special Interest (NOSI) highlights interest in mental health services and implementation science research to support the adoption and sustainability of evidence-based practices (EBPs) in community-based settings that deliver care to people with mental illness. These settings could include, but are not limited to, Certified Community Behavioral Health Clinics (CCBHCs) funded through the Substance Abuse and Mental Health Services Administration (SAMHSA) Certified Community Behavioral Health Clinic-Expansion (CCBHC-E) grant program.</p>				
110102	<p>Notice of Special Interest (NOSI): Dissemination and Implementation Research to Advance Mental, Emotional, and Behavioral Health Preventive Interventions in School Settings</p>	National Institutes of Health/DHHS	NOT-AT-22-004	05-Jun-2022	Not Specified
	Contact Name	Beda Jean-Francois, Ph.D.			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Telephone 202-313-2144</p> <p>Contact Email Bedar.Jean-Francois@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 05-Jun-2022 , 15-Jun-2022 , 16-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 14-Oct-2022 , 16-Oct-2022 , 17-Nov-2022 , 07-Jan-2023 , 05-Feb-2023 , 15-Feb-2023 , 16-Feb-2023 , 17-Feb-2023 , 07-May-2023 , 05-Jun-2023 , 15-Jun-2023 , 16-Jun-2023 , 07-Sep-2023 , 05-Oct-2023 , 16-Oct-2023 , 17-Oct-2023 , 07-Jan-2024 , 05-Feb-2024 , 15-Feb-2024 , 16-Feb-2024 , 07-May-2024 , 05-Jun-2024</p> <p>Synopsis The purpose of this Notice of Special Interest (NOSI) is to stimulate dissemination and implementation research to support innovative approaches to identifying, understanding, and developing strategies for overcoming barriers to the adoption, adaptation, integration, scale-up and sustainability of evidence-based preventive interventions to support children’s mental, emotional, and behavioral (MEB) health in school settings. This NOSI encourages applications which focus on dissemination and implementation research to deliver interventions in the school setting that will promote healthy MEB development and/or prevent MEB disorders. Applications should include a focus on one of the following: (1) primary/universal prevention MEB programs designed to promote healthy MEB development by decreasing risk factors and increasing protective factors to prevent onset of an MEB disorder; or (2) secondary/selective prevention programs designed to support screening and early identification of MEB disorders to slow progression with early intervention. Applications focused on tertiary/indicated treatment of MEB disorders will be considered non-responsive to this Notice.</p>				
109941	Focused Technology Research and Development (R01 Clinical Trial Not Allowed)	National Institutes of Health/DHHS	PAR-22-127	05-Jun-2022	Not Specified
	<p>Contact Name Fei Wang, Ph.D.</p> <p>Contact Telephone </p> <p>Contact Email wangf@mail.nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 05-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 07-May-2023 , 05-Jun-2023 , 07-Sep-2023 , 05-Oct-2023 , 07-Jan-2024 , 05-Feb-2024 , 07-May-2024 , 05-Jun-2024 , 07-Sep-2024 , 05-Oct-2024 , 07-Jan-2025 , 05-Feb-2025 , 07-May-2025</p> <p>Synopsis This Funding Opportunity Announcement (FOA) supports projects relevant to the NIGMS mission or those of other NIH institutes or Centers (ICs) participating in the FOA that focus solely on the development of technologies with the potential to</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

enable acquisition of biomedical knowledge. Projects should be justified in terms of technical innovation and utility of such technical innovation for impacting future biomedical research. Outcomes or products of the proposed project should significantly advance the current state of the art and be sufficiently characterized for application in addressing a broad range of biomedical research questions. These outcomes may include, but are not limited to: laboratory instruments and other devices, algorithms and software, chemical reagents and processes, biological molecules or systems that have been modified by human intervention to become research tools. The goal of this FOA is to support the development of technologies with demonstrated proof-of-concept that have remaining significant technical challenges to full implementation and broad utility. As such, applications should not propose to test specific biological questions. Applications proposing to test specific biological questions are not responsive to this FOA and will be administratively withdrawn without review. Applications with a focus on optimization, hardening, or obvious extrapolations of established technology will be a lower priority for funding.

109721	International Research Ethics Education and Curriculum Development Award (R25 Clinical Trial Not Allowed)	National Institutes of Health/DHHS	PAR-22-118	07-Jun-2022	1,150,000 USD
--------	---	------------------------------------	------------	-------------	---------------

Contact Name	Barbara Sina, Ph.D.
Contact Telephone	301-402-9467
Contact Email	sinab@mail.nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	07-Jun-2022 , 06-Jun-2023 , 06-Jun-2024
Synopsis	<p>The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The overarching goal of this R25 program is to support "the ethics of" educational activities that foster a better understanding of biomedical, behavioral and clinical research and its implications. (The overarching goal of this R25 program is to support educational activities that foster a better understanding of "the ethics of" biomedical, behavioral and clinical research and its implications.) To accomplish the stated over-arching goal, this FOA will support creative educational activities with a primary focus on: Courses for Skills Development Mentoring Activities Curriculum or Methods Development Research Experiences The Fogarty International Bioethics Training Program aims to increase the number of research intensive institutions in low- and middle-income countries (LMICs) that can provide advanced education in international research ethics. This FOA will support innovative LMIC master's level research ethics education programs proposing integrated activities to develop culturally appropriate foundational research ethics curriculum, research ethics career skills development courses, ethics research or practicum experiences, and effective mentoring approaches. Education programs supported by this initiative should equip scientists, health professionals and academics in these countries with in-depth knowledge of the ethical principles, processes and policies related to international research. Programs should be designed to</p>

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	strengthen the critical competencies needed to provide research ethics education, ethical review leadership and expert consultation to LMIC researchers, their academic or research institutions, governments and international health research organizations to enhance the application of research ethics principles.				
108601	RFA-MH-22-115 -- BRAIN Initiative: Development of Novel Tools to Probe Cell-Specific and Circuit-Specific Processes in Human and Non-Human Primate Brain (UG3/UH3 Clinical Trial Optional)	National Institutes of Health/DHHS	RFA-MH-22-115	07-Jun-2022	Not Specified
	<p>Contact Name Douglas S. Kim, Ph.D.</p> <p>Contact Telephone 301-827-6463</p> <p>Contact Email douglas.kim@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-Jun-2022 , 07-Jun-2023 , 07-Jun-2024</p> <p>Synopsis The purpose of this Brain Research through Advancing Innovative Neurotechnologies (BRAIN) Initiative Funding Opportunity Announcement is to encourage applications that will develop and validate novel tools to facilitate the detailed analysis and manipulation of complex circuits in large brains. Critical advances in the treatment of brain disorders in human populations are hindered by our lack of ability to monitor and manipulate circuitry in safe, minimally-invasive ways. Clinical intervention with novel cell- and circuit-specific tools will require extensive focused research designed to remove barriers for targeted circuit manipulation. In addition to identification and removal of barriers, the need to delineate dysfunctional circuitry poses additional challenges. Neuroscience has experienced an impressive influx of exciting new research tools in the past decade, especially since the launch of the BRAIN Initiative. However, the majority of these cell- and circuit-specific mapping, monitoring, and manipulating tools has been developed for use in model organisms, primarily rodents, fish and flies. These cutting-edge tools are increasingly adaptable to larger mammalian brains and, more importantly, are emerging as potential human therapeutic strategies for brain disorders. A pressing need to develop tools for use in large brains or those that are more directly relevant to the human brain is the focus of this initiative. The initiative will support initial proof of principle studies aimed at demonstrating the feasibility of using the cutting-edge approaches in humans and other mammalian species (e.g., non-human primate [NHP]/sheep/pigs).</p>				
108852	RFA-NS-22-018 -- HEAL Initiative: Discovery and Functional Evaluation of Human Pain-associated Genes & Cells (U19 Clinical Trial Not Allowed)	National Institutes of Health/DHHS	RFA-NS-22-018	07-Jun-2022 [Optional][LOI/Pre-App]	7,500,000 USD
	<p>Contact Name D.P. Mohapatra, PhD</p> <p>Contact Telephone 301-496-9964</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Email dp.mohapatra@ni.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-Jun-2022 [Optional][LOI/Pre-App], 07-Jul-2022 , 11-Sep-2022 [Optional][LOI/Pre-App], 11-Oct-2022 , 07-Feb-2023 [Optional][LOI/Pre-App], 09-Mar-2023</p> <p>Synopsis The purpose of this funding opportunity announcement is to support research that uses human tissue or cells to generate comprehensive datasets for the discovery and characterization of functional genetic elements, epigenetic signatures, and molecular/cellular pathways that underlie human pain transduction, transmission, and processing. This FOA will support concerted multidisciplinary team science efforts that apply large-scale high-throughput approaches on tissues involved in human pain processing as part of the NIH HEAL Initiative's Program to Reveal and Evaluate Cells-to-gene Information that Specify Intricacies, Origins, and the Nature of Human Pain (PRECISION Human Pain). U19 Centers will operate as a cooperative network to promote collaboration and coordination of research activities. U19 Centers will also coordinate with the U24 HEAL Initiative: Human Pain-associated Genes & Cells Data Coordination and Integration Center that will curate, harmonize, and integrate datasets generated by this U19 research program.</p>				
108853	<p>RFA-NS-22-021 -- HEAL Initiative: Human Pain-associated Genes & Cells Data Coordination and Integration Center (U24 Clinical Trial Not Allowed)</p>	National Institutes of Health/DHHS	RFA-NS-22-021	07-Jun-2022 [Optional][LOI/Pre-App]	5,000,000 USD
	<p>Contact Name D.P. Mohapatra, PhD</p> <p>Contact Telephone 301-496-9964</p> <p>Contact Email dp.mohapatra@ni.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-Jun-2022 [Optional][LOI/Pre-App], 07-Jul-2022 , 11-Sep-2022 [Optional][LOI/Pre-App], 11-Oct-2022</p> <p>Synopsis The goal of this funding opportunity announcement is to support a Human Pain-associated Genes & Cells Data Coordination and Integration Center as part of the NIH HEAL Initiative's Program to Reveal and Evaluate Cells-to-gene Information that Specify Intricacies, Origins, and the Nature of Human Pain (PRECISION Human Pain).The Data Coordination and Integration Center will curate, harmonize, and integrate comprehensive -omics and cellular function datasets generated by companion U19 Centers for Discovery and Functional Evaluation of Human Pain-associated Genes & Cells, which include the characterization of functional genetic elements, epigenetic signatures, and molecular/cellular pathways that underlie human pain signal transduction, transmission and processing. The Human Pain-associated Genes & Cells Data Coordination and Integration Center will lead efforts to establish spatial and semantic standards for managing heterogeneous human pain-</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount	
	<p>associated data types and information, collect and register multimodal human pain-associated data to common neural tissue coordinate systems, and establish a web-accessible information system that can be widely used throughout the research community. A central goal of the PRECISION Human Pain network is to generate comprehensive, integrated datasets, maps, and other resources on human genes and cellular function phenotypes underlying the heterogeneity, pathogenesis and susceptibility to specific pain conditions.</p>					
087107	RFA-NS-19-044 -- BRAIN Initiative Advanced Postdoctoral Career Transition Award to Promote Diversity (K99/R00 Independent Clinical Trial Required)	National Institutes of Health/DHHS	RFA-NS-19-044	08-Jun-2022	Not Specified	
	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email</p> <p>Sponsor Website</p> <p>Program URL</p> <p>Deadline Dates (ALL)</p> <p>Synopsis</p>	<p>Edmund (Ned) Talley, PhD</p> <p>301-496-1917</p> <p>BRAINDIVERSITYK99R00@nih.gov</p> <p></p> <p>Link to program URL</p> <p>08-Jun-2022 , 11-Oct-2022</p> <p>The purpose of the NIH BRAIN Initiative Advanced Postdoctoral Career Transition Award to Promote Diversity (K99/R00) program is to enhance workforce diversity in the neuroscience workforce and maintain a strong cohort of new and talented, NIH-supported, independent investigators from diverse backgrounds in BRAIN Initiative research areas. This program is designed to facilitate a timely transition of outstanding postdoctoral researchers with a research and/or clinical doctorate degree from mentored, postdoctoral research positions to independent, tenure-track or equivalent faculty positions. The program will provide independent NIH research support during this transition in order to help awardees to launch competitive, independent research careers. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary study to an existing trial, as part of their research and career development. Applicants not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must apply to the companion FOA (RFA-NS-19-043)</p>				
087104	RFA-NS-19-043 -- BRAIN Initiative Advanced Postdoctoral Career Transition Award to Promote Diversity (K99/R00 Independent Clinical Trial Not Allowed)	National Institutes of Health/DHHS	RFA-NS-19-043	08-Jun-2022	Not Specified	
	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email</p>	<p>Edmund (Ned) Talley, PhD</p> <p>301-496-1917</p> <p>BRAINDIVERSITYK99R00@nih.gov</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 08-Jun-2022 , 11-Oct-2022</p> <p>Synopsis The purpose of the NIH BRAIN Initiative Advanced Postdoctoral Career Transition Award to Promote Diversity (K99/R00) program is to enhance workforce diversity in the neuroscience workforce and maintain a strong cohort of new and talented, NIH-supported, independent investigators from diverse backgrounds in BRAIN Initiative research areas. This program is designed to facilitate a timely transition of outstanding postdoctoral researchers with a research and/or clinical doctorate degree from mentored, postdoctoral research positions to independent, tenure-track or equivalent faculty positions. The program will provide independent NIH research support during this transition in order to help awardees to launch competitive, independent research careers. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary study to a clinical trial. Applicants to this FOA are permitted to propose research experience in a clinical trial led by a mentor or co-mentor. Applicants proposing a clinical trial or an ancillary study to an ongoing clinical trial as lead investigator, should apply to the companion FOA RFA-NS-19-044 .</p>				
102690	<p>RFA-OD-21-004 -- Maximizing the Scientific Value of Existing Biospecimen Collections (R21 Clinical Trial Not Allowed)</p>	National Institutes of Health/DHHS	RFA-OD-21-004	09-Jun-2022 [Optional][LOI/Pre-App]	275,000 USD
	<p>Contact Name Rachel Grana Mayne, PhD</p> <p>Contact Telephone 240-276-5899</p> <p>Contact Email granar@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 09-Jun-2022 [Optional][LOI/Pre-App], 08-Aug-2022 , 07-Jan-2023 [Optional][LOI/Pre-App], 08-Mar-2023</p> <p>Synopsis The purpose of this Funding Opportunity Announcement (FOA) is to invite R21 applications to stimulate exploratory research relevant to the mission of the Food and Drug Administration (FDA) - Center for Tobacco Products (CTP) using existing (publicly available) biospecimens currently stored in repositories in the United States. This will include, but not be limited to, collections associated with the Population Assessment of Tobacco and Health (PATH) Study, the National Health and Nutrition Examination Survey (NHANES), the National Heart, Lung and Blood Institute's (NHLBI) Biologic Specimen and Data Repository Information Coordinating Center (BioLINCC), and the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial. Proposed research should seek to maximize the scientific value of these stored collections and to provide researchers with an opportunity to generate preliminary data for subsequent research proposals. Other publicly available</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

datasets would be considered, depending on analyses to be conducted. These applications need to provide justification why the data set is unique, and the research questions cannot be answered from a publicly available, nationally representative, data set. The awards under this FOA will be administered by NIH using funds that have been made available through FDA-CTP and the Family Smoking Prevention and Tobacco Control Act (P.L. 111-31). Research results from this FOA are expected to generate findings and data that are directly relevant in informing the FDA's regulation of the manufacture, distribution, and marketing of tobacco products to protect public health. Research Projects must address the research priorities related to the regulatory authority of the Food and Drug Administration (FDA) - Center for Tobacco Products (CTP).

102689	RFA-OD-21-003 -- Secondary Analyses of Existing Datasets of Tobacco Use and Health (R21 Clinical Trial Not Allowed)	National Institutes of Health/DHHS	RFA-OD-21-003	09-Jun-2022 [Optional][LOI/Pre-App]	275,000 USD
--------	---	------------------------------------	---------------	-------------------------------------	-------------

<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email</p> <p>Sponsor Website</p> <p>Program URL</p> <p>Deadline Dates (ALL)</p> <p>Synopsis</p>	<p>Rachel Grana Mayne, PhD</p> <p>240-276-5899</p> <p>granar@nih.gov</p> <p></p> <p>Link to program URL</p> <p>09-Jun-2022 [Optional][LOI/Pre-App], 08-Aug-2022 , 07-Jan-2023 [Optional][LOI/Pre-App], 08-Mar-2023</p> <p>The purpose of this Funding Opportunity Announcement (FOA) is to invite R21 applications proposing the innovative analysis of existing (publicly available) nationally representative U.S. cross-sectional and longitudinal data, to investigate novel scientific ideas and/or to generate new models, systems, tools, methods, or technologies that have the potential for significant impact on biomedical or biobehavioral research in areas relevant to the Food and Drug Administration (FDA) - Center for Tobacco Products (CTP). Other publicly available data sets would be considered depending on the analyses to be conducted; however, nationally representative analyses will receive priority. Applications not using nationally representative data sets will need to provide justification why the data set is unique, and why the research questions cannot be answered from a (publicly available) nationally representative data set. This FOA encourages the analyses of public use datasets that may inform tobacco regulatory actions in the United States (U.S.). The awards under this FOA will be administered by NIH using funds that have been made available through FDA-CTP and the Family Smoking Prevention and Tobacco Control Act (P.L. 111-31). Research results from this FOA are expected to generate findings and data that are directly relevant in informing the FDA's regulation of the manufacture, distribution, and marketing of tobacco products to protect public health. Research Projects must address the research priorities related to the regulatory authority of the Food and Drug Administration (FDA) - Center for Tobacco Products (CTP).</p>
---	--

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount														
103396	RFA-MH-21-180 --BRAIN Initiative: Reagent Resources for Brain Cell Type-Specific Access and Manipulation to Broaden Distribution of Enabling Technologies for Neuroscience (U24 Clinical Trial Not Allowed)	National Institutes of Health/DHHS	RFA-MH-21-180	12-Jun-2022 [Optional][LOI/Pre-App]	Not Specified														
	<table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 20%; padding-right: 5px;">Contact Name</td> <td>Douglas S. Kim, Ph.D.</td> </tr> <tr> <td style="padding-right: 5px;">Contact Telephone</td> <td>301-827-6463</td> </tr> <tr> <td style="padding-right: 5px;">Contact Email</td> <td>douglas.kim@nih.gov</td> </tr> <tr> <td style="padding-right: 5px;">Sponsor Website</td> <td></td> </tr> <tr> <td style="padding-right: 5px;">Program URL</td> <td>Link to program URL</td> </tr> <tr> <td style="padding-right: 5px;">Deadline Dates (ALL)</td> <td>12-Jun-2022 [Optional][LOI/Pre-App], 12-Jul-2022</td> </tr> <tr> <td style="padding-right: 5px;">Synopsis</td> <td> <p>This Funding Opportunity Announcement (FOA) from the NIH Brain Research through Advancing Innovative Neurotechnologies® (BRAIN) Initiative is intended to support the establishment of facilities at minority-serving institutions (MSIs) and Institutional Development Award (IDeA)-eligible institutions for scaled production and distribution of brain cell type-specific access and manipulation reagents. Reagents will be initially developed in pilot resource projects for brain cell type-specific access and manipulation across vertebrate species from the BRAIN Initiative Armamentarium project. Awardees under this FOA will work with the other Armamentarium awardees to manufacture and distribute the resources for use throughout the neuroscience community. It is envisioned that the awardees will work both with the Armamentarium community as well as with the neuroscience research community to optimize the new reagents. The types of reagents to be produced and distributed could include but are not limited to viral vectors, nucleic acid constructs, and nanoparticles designed for selective access to and manipulation of brain cell types. Such reagents will enable neuroscientists to probe circuit function with high precision in experimental animals and ex vivo human tissue and cells. Facilities are needed to contribute to the production and distribution of BRAIN Initiative Armamentarium project reagents broadly to neuroscience users.</p> </td> </tr> </table>					Contact Name	Douglas S. Kim, Ph.D.	Contact Telephone	301-827-6463	Contact Email	douglas.kim@nih.gov	Sponsor Website		Program URL	Link to program URL	Deadline Dates (ALL)	12-Jun-2022 [Optional][LOI/Pre-App], 12-Jul-2022	Synopsis	<p>This Funding Opportunity Announcement (FOA) from the NIH Brain Research through Advancing Innovative Neurotechnologies® (BRAIN) Initiative is intended to support the establishment of facilities at minority-serving institutions (MSIs) and Institutional Development Award (IDeA)-eligible institutions for scaled production and distribution of brain cell type-specific access and manipulation reagents. Reagents will be initially developed in pilot resource projects for brain cell type-specific access and manipulation across vertebrate species from the BRAIN Initiative Armamentarium project. Awardees under this FOA will work with the other Armamentarium awardees to manufacture and distribute the resources for use throughout the neuroscience community. It is envisioned that the awardees will work both with the Armamentarium community as well as with the neuroscience research community to optimize the new reagents. The types of reagents to be produced and distributed could include but are not limited to viral vectors, nucleic acid constructs, and nanoparticles designed for selective access to and manipulation of brain cell types. Such reagents will enable neuroscientists to probe circuit function with high precision in experimental animals and ex vivo human tissue and cells. Facilities are needed to contribute to the production and distribution of BRAIN Initiative Armamentarium project reagents broadly to neuroscience users.</p>
Contact Name	Douglas S. Kim, Ph.D.																		
Contact Telephone	301-827-6463																		
Contact Email	douglas.kim@nih.gov																		
Sponsor Website																			
Program URL	Link to program URL																		
Deadline Dates (ALL)	12-Jun-2022 [Optional][LOI/Pre-App], 12-Jul-2022																		
Synopsis	<p>This Funding Opportunity Announcement (FOA) from the NIH Brain Research through Advancing Innovative Neurotechnologies® (BRAIN) Initiative is intended to support the establishment of facilities at minority-serving institutions (MSIs) and Institutional Development Award (IDeA)-eligible institutions for scaled production and distribution of brain cell type-specific access and manipulation reagents. Reagents will be initially developed in pilot resource projects for brain cell type-specific access and manipulation across vertebrate species from the BRAIN Initiative Armamentarium project. Awardees under this FOA will work with the other Armamentarium awardees to manufacture and distribute the resources for use throughout the neuroscience community. It is envisioned that the awardees will work both with the Armamentarium community as well as with the neuroscience research community to optimize the new reagents. The types of reagents to be produced and distributed could include but are not limited to viral vectors, nucleic acid constructs, and nanoparticles designed for selective access to and manipulation of brain cell types. Such reagents will enable neuroscientists to probe circuit function with high precision in experimental animals and ex vivo human tissue and cells. Facilities are needed to contribute to the production and distribution of BRAIN Initiative Armamentarium project reagents broadly to neuroscience users.</p>																		
109251	RFA-NS-22-048 -- BRAIN Initiative Connectivity across Scales (BRAIN CONNECTS): Comprehensive Centers for Mouse Brain (UM1 Clinical Trial Not Allowed)	National Institutes of Health/DHHS	RFA-NS-22-048	13-Jun-2022 [Optional][LOI/Pre-App]	Not Specified														
	<table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 20%; padding-right: 5px;">Contact Name</td> <td>Edmund Talley</td> </tr> <tr> <td style="padding-right: 5px;">Contact Telephone</td> <td>301-496-1917</td> </tr> <tr> <td style="padding-right: 5px;">Contact Email</td> <td>BRAIN-CONNECTS-Inquiries@nih.gov</td> </tr> <tr> <td style="padding-right: 5px;">Sponsor Website</td> <td></td> </tr> <tr> <td style="padding-right: 5px;">Program URL</td> <td>Link to program URL</td> </tr> </table>					Contact Name	Edmund Talley	Contact Telephone	301-496-1917	Contact Email	BRAIN-CONNECTS-Inquiries@nih.gov	Sponsor Website		Program URL	Link to program URL				
Contact Name	Edmund Talley																		
Contact Telephone	301-496-1917																		
Contact Email	BRAIN-CONNECTS-Inquiries@nih.gov																		
Sponsor Website																			
Program URL	Link to program URL																		

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Deadline Dates (ALL) 13-Jun-2022 [Optional][LOI/Pre-App], 13-Jul-2022 , 13-Jun-2023 [Optional][LOI/Pre-App], 13-Jul-2023</p> <p>Synopsis This Funding Opportunity Announcement (FOA) solicits applications for Comprehensive Centers to develop the research capacity and technical capabilities to map mouse brain connectivity, with goals of brain-wide coverage and comprehensive mapping of local and long-range cell-to-cell connectivity at the level of synaptic connections. Proposals may focus on a sub-volume of the central nervous system (CNS), provided the volume is sufficiently large to demonstrate feasibility of collecting, reconstructing, analyzing, integrating, disseminating, and interpreting synapse-level connectivity maps of entire brains. The resulting feasibility data from these awards are expected to inform NIH decisions on program continuation in a potential subsequent five-year funding period for production of brain-wide wiring diagrams. Applications may propose limited testing and optimization using additional species beyond mouse for testbed technology development, if strong scientific and cost justification is provided. Applications must address the following five required research activity elements: (1) Sample Processing and Data Acquisition, (2) Data Processing and Management, (3) Integration and Dissemination, (4) Research Discovery, and (5) Feasibility Metrics and Milestones. Successful Centers will establish and scale complete pipelines from sample collection through data integration and dissemination, using state-of-art methods. They will automate and streamline processes for sample collection and data acquisition, optimize protocols for data management, and develop solutions for highly accurate circuit reconstruction. They will incorporate toolsets and infrastructure for seamless integration with other datasets of the same and different modalities, and for easy-access dissemination to the research community for collaborative annotation and analyses. They will apply their data to address research questions of high significance for understanding the relationship between structure and function of brain circuits. Centers will be integrated into the BRAIN CONNECTS Network, consisting of projects from this FOA and its companion announcements, as a coordinated effort aimed at developing wiring diagrams that can span entire brains across multiple scales.</p>				
109253	<p>RFA-NS-22-049 -- BRAIN Initiative Connectivity across Scales (BRAIN CONNECTS): Specialized Projects for Scalable Technologies (U01 Clinical Trial Not Allowed)</p>	National Institutes of Health/DHHS	RFA-NS-22-049	13-Jun-2022 [Optional][LOI/Pre-App]	Not Specified
	<p>Contact Name Edmund Talley</p> <p>Contact Telephone 301-496-1917</p> <p>Contact Email BRAIN-CONNECTS-Inquiries@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 13-Jun-2022 [Optional][LOI/Pre-App], 13-Jul-2022 , 13-Jun-2023 [Optional][LOI/Pre-App], 13-Jul-2023 , 13-Jun-2024 [Optional][LOI/Pre-App], 13-Jul-2024</p> <p>Synopsis This Funding Opportunity Announcement (FOA) supports Specialized Projects to develop current or emerging technologies to generate comprehensive atlases of brain connectivity, with an emphasis on human, non-human primate (NHP), and</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

mouse. Projects using other species are also permitted, if their use is well justified and the goal is test and validate approaches that can be generalized across species. Applications may address any aspect(s) of data collection, reconstruction, analysis, integration, dissemination, and interpretation of brain connectivity and associated data pipelines, to enable faster, more precise, and more cost-effective generation and interpretation of brain-wide wiring diagrams. Proposals are encouraged to develop distinct capabilities and competencies that may be expected to complement Comprehensive Centers solicited by the companion FOAs, with aims of further developing and optimizing current technologies, or proposing entirely new, disruptive, and potentially risky approaches. Funded projects will be integrated into the BRAIN CONNECTS Network, consisting of other Specialized Projects from this FOA, and Comprehensive Centers from its companion announcements, as a coordinated effort aimed at developing the capabilities to generate wiring diagrams that can span entire brains across multiple scales.

109249	RFA-NS-22-047 -- BRAIN Initiative Connectivity across Scales (BRAIN CONNECTS): Comprehensive Centers for Human and Non-Human Primate Brain (UM1 Clinical Trial Not Allowed)	National Institutes of Health/DHHS	RFA-NS-22-047	13-Jun-2022 [Optional][LOI/Pre-App]	Not Specified
--------	---	------------------------------------	---------------	--	---------------

Contact Name	Edmund Talley
Contact Telephone	301-496-1917
Contact Email	BRAIN-CONNECTS-Inquiries@nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	13-Jun-2022 [Optional][LOI/Pre-App], 13-Jul-2022 , 13-Jun-2023 [Optional][LOI/Pre-App], 13-Jul-2023
Synopsis	<p>This Funding Opportunity Announcement (FOA) solicits applications for Comprehensive Centers to develop the research capacity and technical capabilities to map human and non-human primate (NHP) brain connectivity, with goals of brain-wide coverage and comprehensive mapping of region-to-region connectivity at the level of axonal projections. Proposals may focus on a sub-volume of the central nervous system (CNS), provided the volume is sufficiently large to demonstrate feasibility of collecting, reconstructing, analyzing, integrating, disseminating, and interpreting projection-level connectivity maps of entire brains. The resulting feasibility data from these awards are expected to inform NIH decisions on program continuation in a potential subsequent five-year funding period for production of brain-wide wiring diagrams. Applications may propose limited testing and optimization using additional species beyond human and NHPs for testbed technology development, if strong scientific and cost justification is provided. Applications must address the following five required research activity elements: (1) Sample Processing and Data Acquisition, (2) Data Processing and Management, (3) Integration and Dissemination, (4) Research Discovery, and (5) Feasibility Metrics and Milestones. Successful Centers will establish and scale complete pipelines from sample collection through data integration and dissemination, using state-of-art methods.</p>

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>They will automate and streamline processes for sample collection and data acquisition, optimize protocols for data management, and develop solutions for highly accurate circuit reconstruction. They will incorporate toolsets and infrastructure for seamless integration with other datasets of the same and different modalities, and for easy-access dissemination to the research community for collaborative annotation and analyses. They will apply their data to address research questions of high significance for understanding the relationship between structure and function of brain circuits. Centers will be integrated into the BRAIN CONNECTS Network, consisting of projects from this FOA and its companion announcements, as a coordinated effort aimed at developing wiring diagrams that can span entire brains across multiple scales.</p>				
097805	RFA-MH-20-600 -- BRAIN Initiative: Data Archives for the BRAIN Initiative (R24 Clinical Trial Optional)	National Institutes of Health/DHHS	RFA-MH-20-600	14-Jun-2022 [Optional][LOI/Pre-App]	Not Specified
	<p>Contact Name Ming Zhan, Ph.D. Contact Telephone 301-827-3678 Contact Email ming.zhan@nih.gov Sponsor Website Program URL Link to program URL Deadline Dates (ALL) 14-Jun-2022 [Optional][LOI/Pre-App], 14-Jul-2022 , 14-Jun-2023 [Optional][LOI/Pre-App], 14-Jul-2023 Synopsis This Funding Opportunity Announcement (FOA) solicits applications to develop web-accessible data archives to capture, store, and curate data related to BRAIN Initiative activities. The data archives teams will work with the research community to incorporate tools that allow users to analyze and visualize the data, but the creation of such tools is not part of this FOA. The data archives will use appropriate standards to describe the data, but the creation of such standards is not part of this FOA. A goal of this program is to advance research by creating a community resource data archive with appropriate standards and summary information that is broadly available and accessible to the research community for furthering research.</p>				
105415	Technology Development for Single-Molecule Protein Sequencing (R43/R44 Clinical Trial Not Allowed)	National Institutes of Health/DHHS	PAR-21-247	15-Jun-2022	Not Specified
	<p>Contact Name Tina Gatlin, Ph.D. Contact Telephone 301-480-2280 Contact Email gatlincl@nih.gov Sponsor Website </p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 15-Jun-2022 , 15-Jun-2023</p> <p>Synopsis This Funding Opportunity Announcement (FOA) solicits R43/R44 grant applications to catalyze major advances in single-molecule protein sequencing through technology development. The goal of this initiative is to achieve technological advances over the next five years that enable generation of protein sequencing data at sufficient scale, speed, cost and accuracy to use routinely in studies of genome biology and function, and in biomedical and clinical research in general. Exploration of methods other than those currently being commercialized is highly encouraged.</p>				
109173	Microbial-based Cancer Imaging and Therapy - Bugs as Drugs (R21 Clinical Trial Not Allowed)	National Institutes of Health/DHHS	PAR-22-086	16-Jun-2022	275,000 USD
	<p>Contact Name Avi Rasooly, PhD</p> <p>Contact Telephone 240-276-6196</p> <p>Contact Email rasoolya@mail.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 16-Jun-2022 , 16-Oct-2022 , 16-Feb-2023 , 16-Jun-2023 , 16-Oct-2023 , 16-Feb-2024 , 16-Jun-2024 , 16-Oct-2024 , 16-Feb-2025</p> <p>Synopsis This Funding Opportunity Announcement (FOA) solicits grant applications proposing to utilize bacteria, archaeobacteria, bacteriophages, or other non-oncolytic viruses and their natural products to study the underlying mechanisms of the complex interactions between microorganisms, tumors, and the immune system, and to explore their clinical potential for cancer imaging, therapeutics or diagnostics. Projects can focus on using microorganisms as anti-tumor agents, as activators of anti-tumor immunity, or as delivery vehicles for treatment, diagnosis, or imaging, complementing or synergizing with existing tools and approaches. This FOA will support basic mechanistic and preclinical studies in cell culture and animal models. Applicants are encouraged to address both the microbial and tumor aspects of microbial tumor interactions relevant to microbial-based cancer therapy (including therapies for oral cancer), tumor imaging, tumor detection, or diagnosis This funding opportunity is part of a broader NCI-sponsored research on microbial based cancer therapy.</p>				
104714	Limited Competition: Promoting a Basic Understanding of Chemical Threats to Skin (R34 Clinical Trial Not Allowed)	National Institutes of Health/DHHS	PAS-21-245	16-Jun-2022	450,000 USD
	<p>Contact Name Hung Tseng PhD</p> <p>Contact Telephone 301-496-0810</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Email tsengh@mail.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 16-Jun-2022 , 16-Oct-2022 , 16-Feb-2023 , 05-Jun-2023 , 16-Oct-2023 , 16-Feb-2024 , 16-Jun-2024</p> <p>Synopsis This Funding Opportunity Announcement (FOA) is to support applications to a new NIAMS initiative to encourage the skin research community to contribute to basic understanding of skin injuries caused by chemical threats to the civilian population, with an emphasis on investigating the commonalities of such injuries and identifying potential shared signaling pathways and therapeutic targets for countermeasure development.</p>				
108897	Notice of Special Interest (NOSI): Assessment of Suicide Thoughts and Behaviors among Children and Preteens	National Institutes of Health/DHHS	NOT-MH-22-086	16-Jun-2022	Not Specified
	<p>Contact Name Eric R. Murphy, PhD</p> <p>Contact Telephone 301-443-9230</p> <p>Contact Email eric.murphy@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 16-Jun-2022 , 07-Sep-2022 , 16-Oct-2022 , 07-Jan-2023 , 16-Feb-2023 , 07-May-2023 , 16-Jun-2023 , 07-Sep-2023 , 16-Oct-2023 , 07-Jan-2024 , 16-Feb-2024 , 07-May-2024</p> <p>Synopsis The purpose of this Notice of Special Interest (NOSI) is to encourage advance research that addresses outstanding questions related to the developmentally and culturally appropriate characterization and assessment of STB in children/preteens. For purposes of this NOSI, children/preteens are defined as youth 12 years old and younger. NIMH encourages applications that consider issues relevant to the assessment of diverse youth, including the acceptability and cultural relevance of the strategies for assessment among youth from minoritized backgrounds and/or sexual and gender minority youth.</p>				
092569	Research on Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) (R21 Clinical Trials Not Allowed)	National Institutes of Health/DHHS	PAR-20-168	16-Jun-2022	275,000 USD
	<p>Contact Name Vicky Whittemore, PhD</p> <p>Contact Telephone 301-496-1917</p> <p>Contact Email vicky.whittemore@nih.gov</p> <p>Sponsor Website</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 16-Jun-2022 , 16-Oct-2022 , 16-Feb-2023</p> <p>Synopsis This Funding Opportunity Announcement (FOA) encourages investigator(s)-initiated applications that propose to examine the etiology, diagnosis, pathophysiology and manifestations of myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) in diverse groups and across the lifespan. Applications that address gaps in the understanding of the environmental and biological risk factors, the determinants of heterogeneity among individuals with ME/CFS, and the common mechanisms influencing the multiple affected body systems in ME/CFS are encouraged. The NIH is particularly interested in funding interdisciplinary research that will enhance our knowledge of disease processes and provide evidence-based solutions to improve the diagnosis, treatment, and quality of life of all persons with ME/CFS. This interdisciplinary research may include the building of scientific teams to study and develop biomarkers and/or characterize the pathophysiological response of organ systems in individuals with ME/CFS. The R21 Grant mechanism is intended to support innovative, high impact research projects. Such projects would either 1) generate pilot data to assess the feasibility of a novel avenue of investigation; 2) involve high risk experiments that could lead to a breakthrough in ME/CFS; 3) demonstrate the feasibility of new technologies that could have a major impact on ME/CFS research. Applications submitted under this mechanism should be limited to those with the potential for truly ground-breaking impact.</p>				
087474	Research Infrastructure Development for Interdisciplinary Aging Studies (R21/R33 - Clinical Trial Optional)	National Institutes of Health/DHHS	PAR-20-070	16-Jun-2022	1,775,000 USD
	<p>Contact Name Winifred K. Rossi</p> <p>Contact Telephone 301-496-3836</p> <p>Contact Email rossiw@mail.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 16-Jun-2022 , 16-Oct-2022</p> <p>Synopsis This FOA invites applications that propose to develop novel research infrastructure that will advance the science of aging in specific areas requiring interdisciplinary partnerships or collaborations. This FOA will use the NIH Phased Innovation Award (R21/R33) mechanism to provide up to 2 years of R21 support for initial developmental activities and up to 3 years of R33 support for expanded activities. Through this award, investigators will develop a sustainable research infrastructure to support projects that address key interdisciplinary aging research questions.</p>				
091508	Novel Mechanism Research on Neuropsychiatric Symptoms (NPS) in Alzheimer's Dementia (R21 Clinical Trial Optional)	National Institutes of Health/DHHS	PAR-20-159	16-Jun-2022	275,000 USD

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Name Jovier D. Evans, PhD</p> <p>Contact Telephone 301-443-1369</p> <p>Contact Email jevans1@mail.nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 16-Jun-2022 , 16-Oct-2022 , 16-Feb-2023</p> <p>Synopsis The goal of this Funding Opportunity Announcement (FOA) is to encourage applications for studies that will enhance knowledge of mechanisms associated with neuropsychiatric symptoms (NPS) in persons with Alzheimer's disease (AD) or Alzheimer's disease-related dementia (ADRD). The findings are expected to advance mechanistic understanding of both biobehavioral and neurobiological pathways leading to NPS. Findings may also provide insight into novel therapeutic targets that can be advanced into interventions to treat and prevent the development of NPS in AD and/or ADRD. PAR-20-157 uses the R01 grant mechanism, while PAR-20-159 uses the R21 mechanism. High risk/high payoff projects that lack preliminary data or utilize existing data may be most appropriate for the R21 mechanism.</p>				
100734	<p>Exploring the Scientific Value of Existing or New Sepsis Human Biospecimen Collections (R21/R33 - Clinical Trial Not Allowed)</p>	National Institutes of Health/DHHS	PAR-21-077	16-Jun-2022	Not Specified
	<p>Contact Name Xiaoli Zhao, Ph.D.</p> <p>Contact Telephone </p> <p>Contact Email xiaoli.zhao@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 16-Jun-2022 , 16-Oct-2022</p> <p>Synopsis The purpose of this funding opportunity announcement (FOA) is to support efficient collection, banking, and sharing of biospecimens and associated clinical data from critically ill patients, ultimately for use in mechanistic research on sepsis. The goals of this FOA are to determine the scientific value of existing or newly collected sepsis human biospecimen sets as testbeds for studies on human sepsis and to provide guidance on the best practices for collecting, utilizing, and analyzing human biospecimens, thus maximizing their value for the entire sepsis research community. This FOA invites applicants to submit proof of concept and scale-up studies to determine the scientific value of existing or new collections of human sepsis biospecimens with associated patient health record data. The biospecimens used in this study must be linked to clinical datasets useful for sepsis endotyping/stratification and characterization of disease trajectory, and the use of contemporary</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

cutting-edge technologies in the analysis of these biospecimens is highly encouraged. Studies should focus on: 1) assessment of the utility of existing biospecimen repositories from critically ill and septic patients for future mechanistic research; or 2) development of improved methods for de novo collection and analysis of biospecimens from critically ill patients, ultimately for mechanistic studies of sepsis. The proposed studies should be information-gathering and useful for hypothesis generation; the final results should be data and approaches that can ultimately form the basis for future mechanistic studies and biospecimen collection efforts. Mechanistic studies based on testable hypotheses already formed should be submitted to other opportunities for research grants (e.g., R01 or R35 applications). Applications to solely support novel technology development should be submitted for the Technology Development program. Interventional studies that meet the NIH definition for a clinical trial, or studies including animal models of sepsis, will not be accepted. The FOA will provide support for up to two years (R21 phase) for research planning activities and feasibility studies, followed by the possible transition to up to an two additional years of scaled-up, expanded, or confirmatory research support (R33 phase). Ideally, in the R21 phase, applicants should test new methods for biospecimen acquisition and/or verify the quality of those or existing biospecimens, and identify assays useful for future mechanistic research. The R33 phase should focus on scale-up activities to generate data useable to formulate testable hypotheses of the prediction, development, complexity, and resolution of sepsis in humans. The total project period for an application may not exceed four years. This FOA requires applicant-identified measurable R21 phase milestones, which will be used to determine whether an award transitions to the R33 phase. Transition to the R33 phase is not automatic, and NIGMS anticipates that about half of the funded R21 phase awards may progress to the R33 phase award.

107609	Drug Discovery For Nervous System Disorders (R21 Clinical Trials Not Allowed)	National Institutes of Health/DHHS	PAR-22-032	16-Jun-2022	275,000 USD
--------	---	------------------------------------	------------	-------------	-------------

Contact Name	Enrique Michelotti, PhD
Contact Telephone	301-443-5415
Contact Email	michelottiel@mail.nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	16-Jun-2022 , 16-Oct-2022 , 16-Feb-2023 , 16-Jun-2023 , 16-Oct-2023 , 16-Feb-2024 , 16-Jun-2024 , 16-Oct-2024
Synopsis	This Funding Opportunity Announcement (FOA) supports the discovery of novel compounds for the prevention and treatment of nervous system disorders. Through this FOA NIMH, NIA, NIAAA and NIDA wish to stimulate research in: 1) Identification, design, synthesis, and preclinical testing of small molecules for their potential as candidate therapeutics; 2) Initial hit-to-lead chemistry to improve activity of compounds against the target of interest; 3) Later stage lead optimization to improve efficacy and pharmacokinetics; and 4) Initial drug metabolism and pharmacokinetic properties (DMPK). Emphasis

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

will be placed on projects that provide novel approaches for identifying potential therapeutic agents. This FOA will also support applications proposing preclinical discovery of biotechnology products and biologics with potential as candidate therapeutics including, but not limited to, large biologic macromolecules, (e.g., proteins, antibodies, and peptides), gene-based therapies (i.e., oligonucleotide- and viral-based), cell therapies, and novel emerging therapies (e.g., microbial and microbiome therapies).

103180	Research on Autism Spectrum Disorders (R21 Clinical Trial Optional)	National Institutes of Health/DHHS	PA-21-200	16-Jun-2022	275,000 USD
--------	---	------------------------------------	-----------	-------------	-------------

Contact Name	Lisa Gilotty, Ph.D.
Contact Telephone	301-443-3825
Contact Email	gilottyl@mail.nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	16-Jun-2022 , 16-Oct-2022 , 16-Feb-2023 , 16-Jun-2023 , 16-Oct-2023 , 16-Feb-2024
Synopsis	The purpose of this Funding Opportunity Announcement (FOA) is to encourage research grant applications to support research designed to elucidate the etiology, epidemiology, diagnosis, and optimal means of service delivery in relation to Autism Spectrum Disorders (ASD). The R21 grant mechanism is intended to encourage exploratory/developmental research by providing support for the early and conceptual stages of project development. Exploratory, novel studies that break new ground or extend previous discoveries toward new directions are appropriate for this mechanism. No preliminary data are required but may be included if available. Applicants pursuing secondary analysis of existing data, and pilot or feasibility studies that can be completed with limited budgets should consider the companion R03 FOA, PA-21-199 . Applicants pursuing larger studies in established scientific areas where preliminary data are expected should consider the companion R01 FOA, PA-21-201.

103183	Research on Autism Spectrum Disorders (R03 Clinical Trial Optional)	National Institutes of Health/DHHS	PA-21-199	16-Jun-2022	100,000 USD
--------	---	------------------------------------	-----------	-------------	-------------

Contact Name	Lisa Gilotty, Ph.D.
Contact Telephone	301-443-3825
Contact Email	gilottyl@mail.nih.gov
Sponsor Website	
Program URL	Link to program URL

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Deadline Dates (ALL) 16-Jun-2022 , 16-Oct-2022 , 16-Feb-2023 , 16-Jun-2023 , 16-Oct-2023 , 16-Feb-2024</p> <p>Synopsis The purpose of this Funding Opportunity Announcement (FOA) is to encourage research grant applications to support research designed to elucidate the etiology, epidemiology, diagnosis, and optimal means of service delivery in relation to Autism Spectrum Disorders (ASD). An R03 grant supports small, discrete, well-defined projects that can be completed in two years and that require limited resources. R03 applications may include development of new research methodologies or technology, secondary analysis of existing data, and pilot or feasibility studies. Preliminary data are not required, particularly in applications proposing pilot or feasibility studies. Applicants pursuing exploratory/developmental research to support early and conceptual stages of project development should consider the companion R21 FOA, PA-21-200. Applicants pursuing larger studies in established scientific areas where preliminary data are expected should consider the companion R01 FOA, PA-21-201.</p>				
109792	Accelerating the Pace of Child Health Research Using Existing Data from the Adolescent Brain Cognitive Development (ABCD) Study (R21-Clinical Trial Not Allowed)	National Institutes of Health/DHHS	PAR-22-138	16-Jun-2022	275,000 USD
	<p>Contact Name Julia Zehr, Ph.D.</p> <p>Contact Telephone 301-443-1617</p> <p>Contact Email Zehrj@mail.nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 16-Jun-2022 , 07-Sep-2022 , 16-Oct-2022 , 07-Jan-2023 , 16-Feb-2023 , 07-May-2023 , 16-Jun-2023 , 07-Sep-2023 , 16-Oct-2023 , 07-Jan-2024 , 16-Feb-2024 , 07-May-2024 , 16-Jun-2024 , 07-Sep-2024 , 16-Oct-2024 , 07-Jan-2025 , 16-Feb-2025 , 07-May-2025</p> <p>Synopsis The Adolescent Brain Cognitive Development (ABCD) Study is collecting data on health and mental health, cognitive function, substance use, cultural and environmental factors, and brain structure and function from youth starting when they are 9-10 years-old and following them longitudinally to early adulthood. These data will be made available to the scientific community through the NIMH Data Archive. The purpose of this Funding Opportunity Announcement (FOA) is to encourage applications proposing the analysis of this public use dataset to increase knowledge of adolescent health and development. More information about the ABCD Study may be found on the ABCD Study web page (www.abcdstudy.org). This FOA seeks shorter, higher-risk</p>				
105756	Investigator Initiated Research in Computational Genomics and Data Science (R21 Clinical Trial Not Allowed)	National Institutes of Health/DHHS	PAR-21-255	16-Jun-2022	275,000 USD

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Name Daniel Gilchrist, Ph.D.</p> <p>Contact Telephone</p> <p>Contact Email daniel.gilchrist@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 16-Jun-2022 , 16-Oct-2022 , 16-Feb-2023 , 16-Jun-2023 , 16-Oct-2023 , 16-Feb-2024 , 16-Jun-2024</p> <p>Synopsis The purpose of this funding opportunity announcement (FOA) is to invite applications for a broad range of research efforts in computational genomics, data science, statistics, and bioinformatics relevant to one or both of basic or clinical genomic science, and broadly applicable to human health and disease. This FOA supports fundamental genomics research that develops innovative analytical methodologies and approaches, early-stage development of tools and software, and refinement or hardening of software and tools of high value to the biomedical genomics community. Work supported under this FOA should be enabling for genomics and be generalizable or broadly applicable across diseases and biological systems.</p>				
108358	Exploratory/Developmental Bioengineering Research Grants (EBRG) (R21 Clinical Trial Not Allowed)	National Institutes of Health/DHHS	PAR-22-090	16-Jun-2022	275,000 USD
	<p>Contact Name Miguel R. Ossandon, Ph.D.</p> <p>Contact Telephone 240-276-5714</p> <p>Contact Email ossandom@mail.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 16-Jun-2022 , 16-Oct-2022 , 16-Feb-2023 , 16-Jun-2023 , 16-Oct-2023 , 16-Feb-2024 , 16-Jun-2024 , 16-Oct-2024</p> <p>Synopsis The purpose of this engineering-oriented funding opportunity announcement (FOA) is to encourage submissions of exploratory/developmental Bioengineering Research Grant (EBRG) applications to demonstrate feasibility and potential utility of new capabilities or improvements in quality, speed, efficacy, operability, costs, and/or accessibility of solutions to problems in basic biomedical, pre-clinical, or clinical research, clinical care delivery, or accessibility</p>				
101555	Early Stage Investigator Research Using Nonhuman Primate (NHP) Models (R21 Clinical Trial Not Allowed)	National Institutes of Health/DHHS	PAR-21-109	16-Jun-2022	400,000 USD
	<p>Contact Name Manuel Moro, DVM, Ph.D.</p> <p>Contact Telephone 301-480-1796</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Email manuel.moro@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 16-Jun-2022 , 16-Oct-2022 , 16-Feb-2023 , 16-Jun-2023 , 16-Oct-2023 , 16-Feb-2024</p> <p>Synopsis The purpose of this Funding Opportunity Announcement (FOA) is to support research using nonhuman primate (NHP) models performed by early-stage investigators who are within 10 years of their terminal degree or residency training and have at least two years of postdoctoral experience. This FOA is designed specifically for applicants proposing to develop new research directions using NHP models in basic science or translational research.</p>				
109942	<p>Technology Development Research for Establishing Feasibility and Proof of Concept (R21 - Clinical Trial Not Allowed)</p>	National Institutes of Health/DHHS	PAR-22-126	16-Jun-2022	275,000 USD
	<p>Contact Name Fei Wang, Ph.D.</p> <p>Contact Telephone</p> <p>Contact Email wangf@mail.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 16-Jun-2022 , 07-Sep-2022 , 16-Oct-2022 , 07-Jan-2023 , 16-Feb-2023 , 07-May-2023 , 16-Jun-2023 , 07-Sep-2023 , 16-Oct-2023 , 07-Jan-2024 , 16-Feb-2024 , 07-May-2024 , 16-Jun-2024 , 07-Sep-2024 , 16-Oct-2024 , 07-Jan-2025 , 16-Feb-2025 , 07-May-2025</p> <p>Synopsis This Funding Opportunity Announcement (FOA) supports exploratory research leading to the development of innovative technologies for biomedical research that is relevant to the NIGMS mission or that of other NIH Institutes or Centers (ICs) participating in this FOA. Projects should entail a high degree of risk and/or novelty, which will be offset by a high future potential impact in biomedical research. Outcomes or products of the proposed project, which should significantly advance the current state of the art, may include, but are not limited to: laboratory instruments and other devices, algorithms and software, chemical reagents and processes, biological molecules or systems that have been modified by human intervention to become research tools. The goal of this FOA is to support proof of concept, high-risk and potentially high-reward studies for feasibility and exploratory technology development. Due to the constraints that would be imposed on broad utility, this FOA does not support technology development that is narrowly focused on addressing specific biological questions. Rather, applications should propose development of innovative tools that can potentially benefit a broad spectrum of biomedical research. Moreover, feasibility of the proposed technology must not have already been established in the literature or with preliminary data. Applications that are focused on technology development to address specific biological questions and/or</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

include unpublished or published data that provide proof of concept are not responsive to this FOA and will be administratively withdrawn without review.

097436	Ethical, Legal and Social Implications (ELSI) Research (R01 Clinical Trial Optional)	National Institutes of Health/DHHS	PAR-20-254	17-Jun-2022	Not Specified
--------	--	------------------------------------	------------	-------------	---------------

Contact Name	Joy Boyer
Contact Telephone	301-402-4997
Contact Email	boyerj@mail.nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	17-Jun-2022 , 19-Oct-2022 , 17-Feb-2023 , 19-Jun-2023
Synopsis	This Funding Opportunity Announcement (FOA) invites Research Project Grant (R01) applications that propose to study the ethical, legal and social implications (ELSI) of human genome research. Applications may propose studies using either single or mixed methods. Proposed approaches may include but are not limited to data-generating qualitative and quantitative approaches, legal, economic and normative analyses, and other types of analytical and conceptual research methodologies, such as those involving the direct engagement of stakeholders.

097437	Ethical, Legal and Social Implications (ELSI) Exploratory/Developmental Research Grant (R21 Clinical Trial Optional)	National Institutes of Health/DHHS	PAR-20-255	17-Jun-2022	275,000 USD
--------	--	------------------------------------	------------	-------------	-------------

Contact Name	Joy Boyer
Contact Telephone	301-402-4997
Contact Email	boyerj@mail.nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	17-Jun-2022 , 19-Oct-2022 , 17-Feb-2023 , 19-Jun-2023
Synopsis	This Funding Opportunity Announcement (FOA) invites Exploratory/Developmental Research Grant (R21) applications that propose to study the ethical, legal and social implications (ELSI) of human genome research. These applications should propose single or mixed methods studies that break new ground, extend previous discoveries in new directions or develop preliminary data in preparation for larger studies. Of particular interest are studies that explore the implications of new or emerging genomic technologies or novel uses of genomic information.

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount														
097475	Ethical, Legal and Social Implications (ELSI) Small Research Grant (R03 Clinical Trial Optional)	National Institutes of Health/DHHS	PAR-20-257	17-Jun-2022	100,000 USD														
	<table border="0" style="width: 100%;"> <tr> <td style="width: 20%; vertical-align: top;">Contact Name</td> <td>Joy Boyer</td> </tr> <tr> <td style="vertical-align: top;">Contact Telephone</td> <td>301-402-4997</td> </tr> <tr> <td style="vertical-align: top;">Contact Email</td> <td>boyerj@mail.nih.gov</td> </tr> <tr> <td style="vertical-align: top;">Sponsor Website</td> <td></td> </tr> <tr> <td style="vertical-align: top;">Program URL</td> <td>Link to program URL</td> </tr> <tr> <td style="vertical-align: top;">Deadline Dates (ALL)</td> <td>17-Jun-2022 , 19-Oct-2022 , 17-Feb-2023 , 19-Jun-2023</td> </tr> <tr> <td style="vertical-align: top;">Synopsis</td> <td>This Funding Opportunity Announcement (FOA) invites Small Research Grant (R03) applications to study the ethical, legal and social implications (ELSI) of human genome research. These applications should be for small, self-contained research projects, such as those that involve single investigators. Of particular interest are projects that propose normative or conceptual analyses, including focused legal, economic, philosophical, anthropological, or historical analyses of new or emerging issues. This mechanism can also be used for the collection of preliminary data and the secondary analysis of existing data.</td> </tr> </table>					Contact Name	Joy Boyer	Contact Telephone	301-402-4997	Contact Email	boyerj@mail.nih.gov	Sponsor Website		Program URL	Link to program URL	Deadline Dates (ALL)	17-Jun-2022 , 19-Oct-2022 , 17-Feb-2023 , 19-Jun-2023	Synopsis	This Funding Opportunity Announcement (FOA) invites Small Research Grant (R03) applications to study the ethical, legal and social implications (ELSI) of human genome research. These applications should be for small, self-contained research projects, such as those that involve single investigators. Of particular interest are projects that propose normative or conceptual analyses, including focused legal, economic, philosophical, anthropological, or historical analyses of new or emerging issues. This mechanism can also be used for the collection of preliminary data and the secondary analysis of existing data.
Contact Name	Joy Boyer																		
Contact Telephone	301-402-4997																		
Contact Email	boyerj@mail.nih.gov																		
Sponsor Website																			
Program URL	Link to program URL																		
Deadline Dates (ALL)	17-Jun-2022 , 19-Oct-2022 , 17-Feb-2023 , 19-Jun-2023																		
Synopsis	This Funding Opportunity Announcement (FOA) invites Small Research Grant (R03) applications to study the ethical, legal and social implications (ELSI) of human genome research. These applications should be for small, self-contained research projects, such as those that involve single investigators. Of particular interest are projects that propose normative or conceptual analyses, including focused legal, economic, philosophical, anthropological, or historical analyses of new or emerging issues. This mechanism can also be used for the collection of preliminary data and the secondary analysis of existing data.																		
108288	Notice of Special Interest (NOSI): BRAIN Initiative: Translation of Groundbreaking Technologies from Early-stage Development through Early Clinical Study via Blueprint MedTech	National Institutes of Health/DHHS	NOT-NS-22-052	20-Jun-2022	Not Specified														
	<table border="0" style="width: 100%;"> <tr> <td style="width: 20%; vertical-align: top;">Contact Name</td> <td>Nick Langhals, PhD</td> </tr> <tr> <td style="vertical-align: top;">Contact Telephone</td> <td>301-496-1779</td> </tr> <tr> <td style="vertical-align: top;">Contact Email</td> <td>NINDS-Devices@nih.gov</td> </tr> <tr> <td style="vertical-align: top;">Sponsor Website</td> <td></td> </tr> <tr> <td style="vertical-align: top;">Program URL</td> <td>Link to program URL</td> </tr> <tr> <td style="vertical-align: top;">Deadline Dates (ALL)</td> <td>20-Jun-2022 , 18-Oct-2022 , 21-Feb-2023 , 19-Jun-2023 , 18-Oct-2023 , 20-Feb-2024 , 20-Jun-2024</td> </tr> <tr> <td style="vertical-align: top;">Synopsis</td> <td>This Notice of Special Interest (NOSI) encourages the translation of the novel neurotechnologies, funded through the Brain Research through Advancing Innovative Neurotechnologies® (BRAIN) Initiative and overseen by the NIH Blueprint MedTech program. Academic and Small Business Concerns (SBCs) are encouraged to submit grant applications that propose non-clinical validation for subsequent clinical feasibility studies. Applications supporting the development and translation of groundbreaking neurotechnologies that fit within the mission of the BRAIN Initiative are encouraged.</td> </tr> </table>					Contact Name	Nick Langhals, PhD	Contact Telephone	301-496-1779	Contact Email	NINDS-Devices@nih.gov	Sponsor Website		Program URL	Link to program URL	Deadline Dates (ALL)	20-Jun-2022 , 18-Oct-2022 , 21-Feb-2023 , 19-Jun-2023 , 18-Oct-2023 , 20-Feb-2024 , 20-Jun-2024	Synopsis	This Notice of Special Interest (NOSI) encourages the translation of the novel neurotechnologies, funded through the Brain Research through Advancing Innovative Neurotechnologies® (BRAIN) Initiative and overseen by the NIH Blueprint MedTech program. Academic and Small Business Concerns (SBCs) are encouraged to submit grant applications that propose non-clinical validation for subsequent clinical feasibility studies. Applications supporting the development and translation of groundbreaking neurotechnologies that fit within the mission of the BRAIN Initiative are encouraged.
Contact Name	Nick Langhals, PhD																		
Contact Telephone	301-496-1779																		
Contact Email	NINDS-Devices@nih.gov																		
Sponsor Website																			
Program URL	Link to program URL																		
Deadline Dates (ALL)	20-Jun-2022 , 18-Oct-2022 , 21-Feb-2023 , 19-Jun-2023 , 18-Oct-2023 , 20-Feb-2024 , 20-Jun-2024																		
Synopsis	This Notice of Special Interest (NOSI) encourages the translation of the novel neurotechnologies, funded through the Brain Research through Advancing Innovative Neurotechnologies® (BRAIN) Initiative and overseen by the NIH Blueprint MedTech program. Academic and Small Business Concerns (SBCs) are encouraged to submit grant applications that propose non-clinical validation for subsequent clinical feasibility studies. Applications supporting the development and translation of groundbreaking neurotechnologies that fit within the mission of the BRAIN Initiative are encouraged.																		

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount														
106107	Blueprint Medtech: Small Business Translator (U44 - Clinical Trial Optional)	National Institutes of Health/DHHS	PAR-21-282	20-Jun-2022	Not Specified														
	<table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 20%; padding-right: 10px;">Contact Name</td> <td>Leonardo Angelone, Ph.D</td> </tr> <tr> <td style="padding-right: 10px;">Contact Telephone</td> <td></td> </tr> <tr> <td style="padding-right: 10px;">Contact Email</td> <td>Blueprint-MedTech@nih.gov</td> </tr> <tr> <td style="padding-right: 10px;">Sponsor Website</td> <td></td> </tr> <tr> <td style="padding-right: 10px;">Program URL</td> <td>Link to program URL</td> </tr> <tr> <td style="padding-right: 10px;">Deadline Dates (ALL)</td> <td>20-Jun-2022 , 18-Oct-2022 , 21-Feb-2023 , 20-Jun-2023 , 18-Oct-2023 , 20-Feb-2024 , 20-Jun-2024</td> </tr> <tr> <td style="padding-right: 10px;">Synopsis</td> <td> <p>The purpose of this Funding Opportunity Announcement (FOA) is to encourage applications from Small Business Concerns (SBCs) to pursue translational activities and limited-size clinical studies to advance the development of therapeutic and diagnostic devices for disorders that affect the nervous or neuromuscular systems. Activities supported in this program include implementation of clinical prototype devices, non-clinical safety and efficacy testing, design verification and validation activities leading to submission of an Investigational Device Exemption (IDE) to the U.S. Food and Drug Administration (FDA) or Institutional Review Board (IRB) application for a Non-Significant Risk (NSR) study. The clinical study is expected to provide information about the device function or final design that cannot be practically obtained through additional non-clinical assessments (e.g., bench top or animal studies) due to the novelty of the device or its intended use.</p> <p>This FOA is a milestone-driven cooperative agreement program and will involve participation of NIH program staff in negotiating the final project plan before award and monitoring of research progress. Participants in Blueprint MedTech receive funding for all activities to be conducted in their own laboratories. In addition, applicants will collaborate with NIH-funded consultants to receive assistance with specialty areas including regulatory, reimbursement, intellectual property, commercialization, and strategic partnerships. Participants can also augment their project with NIH contract research organizations (CROs) that specialize in large animal testing, sterilization testing, biocompatibility assessment, manufacturing, and medical monitoring. SBCs developing their own devices or that already have established collaborations with device manufacturers are welcome to apply directly to this FOA or any of the companion opportunities. For more information see BP MedTech website: https://neuroscienceblueprint.nih.gov/neurotherapeutics/blueprint-medtech</p> </td> </tr> </table>					Contact Name	Leonardo Angelone, Ph.D	Contact Telephone		Contact Email	Blueprint-MedTech@nih.gov	Sponsor Website		Program URL	Link to program URL	Deadline Dates (ALL)	20-Jun-2022 , 18-Oct-2022 , 21-Feb-2023 , 20-Jun-2023 , 18-Oct-2023 , 20-Feb-2024 , 20-Jun-2024	Synopsis	<p>The purpose of this Funding Opportunity Announcement (FOA) is to encourage applications from Small Business Concerns (SBCs) to pursue translational activities and limited-size clinical studies to advance the development of therapeutic and diagnostic devices for disorders that affect the nervous or neuromuscular systems. Activities supported in this program include implementation of clinical prototype devices, non-clinical safety and efficacy testing, design verification and validation activities leading to submission of an Investigational Device Exemption (IDE) to the U.S. Food and Drug Administration (FDA) or Institutional Review Board (IRB) application for a Non-Significant Risk (NSR) study. The clinical study is expected to provide information about the device function or final design that cannot be practically obtained through additional non-clinical assessments (e.g., bench top or animal studies) due to the novelty of the device or its intended use.</p> <p>This FOA is a milestone-driven cooperative agreement program and will involve participation of NIH program staff in negotiating the final project plan before award and monitoring of research progress. Participants in Blueprint MedTech receive funding for all activities to be conducted in their own laboratories. In addition, applicants will collaborate with NIH-funded consultants to receive assistance with specialty areas including regulatory, reimbursement, intellectual property, commercialization, and strategic partnerships. Participants can also augment their project with NIH contract research organizations (CROs) that specialize in large animal testing, sterilization testing, biocompatibility assessment, manufacturing, and medical monitoring. SBCs developing their own devices or that already have established collaborations with device manufacturers are welcome to apply directly to this FOA or any of the companion opportunities. For more information see BP MedTech website: https://neuroscienceblueprint.nih.gov/neurotherapeutics/blueprint-medtech</p>
Contact Name	Leonardo Angelone, Ph.D																		
Contact Telephone																			
Contact Email	Blueprint-MedTech@nih.gov																		
Sponsor Website																			
Program URL	Link to program URL																		
Deadline Dates (ALL)	20-Jun-2022 , 18-Oct-2022 , 21-Feb-2023 , 20-Jun-2023 , 18-Oct-2023 , 20-Feb-2024 , 20-Jun-2024																		
Synopsis	<p>The purpose of this Funding Opportunity Announcement (FOA) is to encourage applications from Small Business Concerns (SBCs) to pursue translational activities and limited-size clinical studies to advance the development of therapeutic and diagnostic devices for disorders that affect the nervous or neuromuscular systems. Activities supported in this program include implementation of clinical prototype devices, non-clinical safety and efficacy testing, design verification and validation activities leading to submission of an Investigational Device Exemption (IDE) to the U.S. Food and Drug Administration (FDA) or Institutional Review Board (IRB) application for a Non-Significant Risk (NSR) study. The clinical study is expected to provide information about the device function or final design that cannot be practically obtained through additional non-clinical assessments (e.g., bench top or animal studies) due to the novelty of the device or its intended use.</p> <p>This FOA is a milestone-driven cooperative agreement program and will involve participation of NIH program staff in negotiating the final project plan before award and monitoring of research progress. Participants in Blueprint MedTech receive funding for all activities to be conducted in their own laboratories. In addition, applicants will collaborate with NIH-funded consultants to receive assistance with specialty areas including regulatory, reimbursement, intellectual property, commercialization, and strategic partnerships. Participants can also augment their project with NIH contract research organizations (CROs) that specialize in large animal testing, sterilization testing, biocompatibility assessment, manufacturing, and medical monitoring. SBCs developing their own devices or that already have established collaborations with device manufacturers are welcome to apply directly to this FOA or any of the companion opportunities. For more information see BP MedTech website: https://neuroscienceblueprint.nih.gov/neurotherapeutics/blueprint-medtech</p>																		
106116	Blueprint MedTech Translator (UG3/UH3 - Clinical Trial Optional)	National Institutes of Health/DHHS	PAR-21-315	20-Jun-2022	Not Specified														
	<table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 20%; padding-right: 10px;">Contact Name</td> <td>Nick Langhals, PhD</td> </tr> <tr> <td style="padding-right: 10px;">Contact Telephone</td> <td>301-496-1779</td> </tr> <tr> <td style="padding-right: 10px;">Contact Email</td> <td>NINDS-Devices@nih.gov</td> </tr> </table>					Contact Name	Nick Langhals, PhD	Contact Telephone	301-496-1779	Contact Email	NINDS-Devices@nih.gov								
Contact Name	Nick Langhals, PhD																		
Contact Telephone	301-496-1779																		
Contact Email	NINDS-Devices@nih.gov																		

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	20-Jun-2022 , 18-Oct-2022 , 21-Feb-2023 , 19-Jun-2023 , 18-Oct-2023 , 20-Feb-2024 , 20-Jun-2024			
	Synopsis	<p>The purpose of this Funding Opportunity Announcement (FOA) is to encourage investigators to pursue translational activities and clinical feasibility studies to advance the development of therapeutic, and diagnostic devices for disorders that affect the nervous or neuromuscular systems. Activities supported in this program include implementation of clinical prototype devices, non-clinical safety and efficacy testing, design verification and validation activities, obtaining an Investigational Device Exemption (IDE) for a Significant Risk (SR) study or Institutional Review Board (IRB) approval for a Non-Significant Risk (NSR) study, as well as a subsequent clinical feasibility study. The clinical study is expected to provide information about the device function or final design that cannot be practically obtained through additional non-clinical assessments (e.g., bench top or animal studies) due to the novelty of the device or its intended use. This FOA is a milestone-driven cooperative agreement program and will involve participation of NIH program staff in negotiating the final project plan before award and monitoring of research progress. Participants in Blueprint MedTech receive funding for all activities to be conducted in their own laboratories. In addition, applicants will collaborate with NIH-funded consultants to receive assistance with specialty areas including regulatory, reimbursement, intellectual property, commercialization, and strategic partnerships. Participants can also augment their project with NIH contract research organizations that specialize in large animal testing, sterilization testing, biocompatibility assessment, manufacturing, and medical monitoring. Individuals, institutions, or businesses developing their own devices or that already have established collaborations with device manufacturers are welcome to apply directly to this FOA or any of the companion opportunities. For more information see BP MedTech website: https://neuroscienceblueprint.nih.gov/neurotherapeutics/blueprint-medtech</p>			

106783	Research on Biopsychosocial Factors of Social Connectedness and Isolation on Health, Wellbeing, Illness, and Recovery (R01 Basic Experimental Studies with Humans Required)	National Institutes of Health/DHHS	PAR-21-349	21-Jun-2022	Not Specified
--------	---	------------------------------------	------------	-------------	---------------

	Contact Name	William Elwood, PhD			
	Contact Telephone	301-402-0116			
	Contact Email	william.elwood@nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	21-Jun-2022 , 21-Jun-2023 , 21-Jun-2024			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Synopsis	<p>This funding opportunity announcement (FOA) invites research projects that seek to explain the underlying mechanisms, processes, and trajectories of social relationships and how these factors affect outcomes in human health, illness, recovery, and overall wellbeing. Types of projects submitted under this FOA include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical and/or behavioral outcomes in humans to understand fundamental aspects of phenomena related to social connectedness and isolation. NIH considers such studies as Basic Experimental Studies with Humans (BESH) that are prospective basic science studies involving human participants that meet the NIH definition of basic research and fall within the NIH definition of clinical trials (see, e.g., NOT-OD-19-024). Applications should not propose a goal of clinical outcomes or products. Applications that propose studies including model animal research or observational studies involving humans should submit under the companion FOA, PAR-21-350 "Research on Biopsychosocial Factors of Social Connectedness and Isolation on Health, Wellbeing, Illness, and Recovery (R01 Clinical Trials Not Allowed).</p>			
106784	Research on Biopsychosocial Factors of Social Connectedness and Isolation on Health, Wellbeing, Illness, and Recovery (R01 Clinical Trials Not Allowed)	National Institutes of Health/DHHS	PAR-21-350	21-Jun-2022	Not Specified
	Contact Name	William Elwood, PhD			
	Contact Telephone	301-402-0116			
	Contact Email	william.elwood@nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	21-Jun-2022 , 21-Jun-2023 , 21-Jun-2024			
	Synopsis	<p>This funding opportunity announcement (FOA) invites research projects that seek to model the underlying mechanisms, processes, and trajectories of social relationships and how these factors affect outcomes in health, illness, recovery, and overall wellbeing. Both animal model and human subjects research projects are welcome; however, clinical trials are not allowed. Researchers proposing Basic Experimental Studies with Humans (BESH) should consider the companion FOA, PAR-21-349, "Research on Biopsychosocial Factors of Social Connectedness and Isolation on Health, Wellbeing, Illness, and Recovery (R01 Basic Experimental Studies with Humans Required)".</p>			
106790	Research on Biopsychosocial Factors of Social Connectedness and Isolation on Health, Wellbeing, Illness, and Recovery (R01 Clinical Trial Required)	National Institutes of Health/DHHS	PAR-21-352	21-Jun-2022	Not Specified
	Contact Name	William Elwood, PhD			
	Contact Telephone	301-402-0116			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Email william.elwood@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 21-Jun-2022 , 21-Jun-2023 , 21-Jun-2024</p> <p>Synopsis This funding opportunity announcement (FOA) invites research projects that seek to explain the underlying mechanisms, processes, and trajectories of social relationships and how these factors affect outcomes in human health, illness, recovery, and overall wellbeing. Types of projects submitted under this FOA include mechanistic studies that are classified as clinical trials. Mechanistic studies are defined as studies with the objective to understand the mechanism(s) of action of an intervention, a biological or behavioral process, or the pathophysiology of a disease/condition. See NOT-AT-20-001 and NOT-MH-19-006 for examples of clinical trials that are/are not considered mechanistic studies. Clinical trials that propose to influence a clinical outcome, test safety or feasibility of an intervention, demonstrate the clinical efficacy or effectiveness of an intervention, or analyze the effect size of an intervention on clinical outcomes are ineligible for this FOA. Types of studies that should submit under this FOA include clinical trials that assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental aspects of phenomena without specific application towards processes or products in mind. Researchers proposing basic science experimental studies involving human participants should consider this FOA's companion for basic experimental studies with humans, PAR-21-349, "Research on Health, Wellbeing, Illness, and Recovery (R01 Basic Experimental Studies with Humans Required)." Applications proposing studies that include, but are not limited to, model animal research or observational studies involving humans should submit under the companion FOA, PAR-21-350, "Research on Biopsychosocial Factors of Social Connectedness and Isolation on Health, Wellbeing, Illness, and Recovery (R01 Clinical Trials Not Allowed).</p>				
102740	<p>Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Assay Development and Neurotherapeutic Agent Identification (R61/R33 Clinical Trial Not Allowed)</p>	National Institutes of Health/DHHS	PAR-21-124	21-Jun-2022	750,000 USD
	<p>Contact Name Becky Roof, PhD</p> <p>Contact Telephone 301-496-1779</p> <p>Contact Email rebecca.roof@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 21-Jun-2022 , 18-Oct-2022 , 21-Feb-2023 , 20-Jun-2023 , 20-Oct-2023 , 20-Feb-2024</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

Synopsis | This funding opportunity announcement (FOA) encourages research grant applications to develop in vitro and/or ex vivo assays and conduct iterative screening efforts to identify and characterize potential therapeutic agents for neurological or neuromuscular disorders. This FOA is part of a suite of Innovation Grants to Nurture Initial Translational Efforts (IGNITE) to advance projects to the point where they can meet the entry criteria for the Blueprint Neurotherapeutics Network (BPN) or other translational programs.

105249	Identification and Characterization of Bioactive Microbial Metabolites for Advancing Research on Microbe-Diet-Host Interactions (R01 Clinical Trial Not Allowed)	National Institutes of Health/DHHS	PAR-21-253	22-Jun-2022	Not Specified
--------	--	------------------------------------	------------	-------------	---------------

Contact Name	Padma Maruvada
Contact Telephone	301-594-8884
Contact Email	maruvadp@mail.nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	22-Jun-2022 , 20-Oct-2022 , 22-Jun-2023 , 19-Oct-2023
Synopsis	The purpose of the Funding Opportunity Announcement is to invite applications to identify and characterize microbial metabolites that will establish causal associations between microbial metabolism and host health and disease. Data acquired through this initiative will be used to create a knowledgebase of microbial metabolites and associated functions that will be provided to the research community. Development of the database and knowledge portal for these awards will be supported under a separate initiative: RFA-DK-21-014, Identification and Characterization of Bioactive Microbial Metabolites for Advancing Research on Microbe-Diet-Host Interactions Knowledgebase Management Center (Clinical Trial Not Allowed).

109667	Centers of Excellence in Genomic Science (RM1 Clinical Trial Optional)	National Institutes of Health/DHHS	PAR-22-107	22-Jun-2022	7,500,000 USD
--------	--	------------------------------------	------------	-------------	---------------

Contact Name	Adam Felsenfeld, Ph.D.
Contact Telephone	301-480-2269
Contact Email	adam_felsenfeld@nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	22-Jun-2022 , 22-Jun-2023 , 21-Jun-2024

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Synopsis	<p>The Centers of Excellence in Genomic Science (CEGS) program establishes academic Centers for advanced genome research. Each CEGS award supports a multi-investigator, interdisciplinary team to develop integrated, transformative genomic approaches to address a biomedical problem. A CEGS project will address a critical issue in genomic science, genomic medicine, or computational genomics, proposing a highly innovative solution that would be a major advance. The research will entail substantial risk, balanced by outstanding scientific and management plans and very high potential payoff. A CEGS will focus on the development of novel technological or computational methods for the production or analysis of comprehensive data sets, on a genome-scale biomedical problem, or on other ways to develop and use genomic approaches for understanding biological systems or furthering the application of genomic knowledge, data, and methods towards clinical applications. Each CEGS will nurture genomics by facilitating the interaction of investigators from several disciplines. Along with its scientific goals, CEGS will also expand the pool of genomic scientists and engineers that can use and apply the novel methods, concepts, and knowledge developed by the CEGS by providing education and outreach experiences to scientists at all career levels. .</p>			
095409	Enhancing Science, Technology, EnginEering, and Math Educational Diversity (ESTEEMED) Research Education Experiences (R25)	National Institutes of Health/DHHS	PAR-20-223	24-Jun-2022	Not Specified
	Contact Name	Zeynep Erim, Ph.D.			
	Contact Telephone	301-451-4797			
	Contact Email	erimz@mail.nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	24-Jun-2022			
	Synopsis	<p>The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The overarching goal of this R25 program is to support educational activities that encourage individuals from diverse backgrounds, including those from groups underrepresented in the biomedical and behavioral sciences, to pursue further studies or careers in research To accomplish the stated over-arching goal, this FOA will support creative educational activities with a primary focus on: Courses for Skills Development Research Experiences for undergraduate freshmen and sophomores from diverse backgrounds, including those from groups underrepresented in bioengineering or STEM fields relevant to bioengineering, such as engineering or the physical/computational sciences, which play key roles in biomedical technologies and innovation. The ESTEEMED program is intended to expose students to bioengineering research early in their college careers and interest them in potentially pursuing advanced studies in bioengineering or a related field. It will prepare students to join, in their junior and senior years, an honors program, supported by federal or institutional funds, that promotes STEM and entrance into a Ph.D. program. The ultimate goal is for the participants to pursue a Ph.D. or</p>			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		M.D./Ph.D. degree and a subsequent research career integrating engineering and the physical sciences with medicine and biology in academia or industry.			
108628	Lasker Clinical Research Scholars Program (Si2/R00 Clinical Trial Optional)	National Institutes of Health/DHHS	PAR-22-078	24-Jun-2022	Not Specified
	Contact Name	Charles R. Dearolf, Ph.D.			
	Contact Telephone	301-402-1225			
	Contact Email	LaskerScholar@nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	24-Jun-2022			
	Synopsis	This FOA encourages applications for the Lasker Clinical Research Scholars Program for the purpose of supporting the research activities during the early stage careers of independent clinical researchers. The program offers the opportunity for a unique bridge between the NIH intramural and extramural research communities and contains two phases. In the first phase, Lasker Scholars will receive appointments for up to 5-7 years as tenure-track investigators within the NIH Intramural Research Program with independent research budgets. In the second phase, successful scholars will receive up to 3 years of NIH support for their research at an extramural research facility; or, the Scholar can be considered to remain as an investigator within the intramural program.			
076848	NLM Research Grants in Biomedical Informatics and Data Science (R01 Clinical Trial Optional)	National Library of Medicine/NIH/DHHS	PAR-18-896	07-May-2022	1,000,000 USD
	Contact Name	Dr. Hua-Chuan Sim			
	Contact Telephone	301-594-4882			
	Contact Email	simh@mail.nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	07-May-2022 , 05-Jun-2022 , 07-Sep-2022			
	Synopsis	National Library of Medicine (NLM) offers support for innovative research and development in biomedical informatics and data science. The scope of NLM's interest in these research domains is broad, with emphasis on new methods and approaches to foster data driven discovery in the biomedical and clinical health sciences as well as domain-independent,			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

reusable approaches to discovery, curation, analysis, organization and management of health-related digital objects. Biomedical informatics and data science draw upon many fields, including mathematics, statistics, information science, computer science and engineering, and social/behavioral sciences. Application domains include health care delivery, basic biomedical research, clinical and translational research, precision medicine, public health, biosurveillance, health information management in disasters, and similar areas. NLM defines biomedical informatics as the science of optimal representation, organization, management, integration and presentation of information relevant to human health and biology. NIH defines data science as the interdisciplinary field of inquiry in which quantitative and analytical approaches, processes, and systems are developed and used to extract knowledge and insights from increasingly large and/or complex sets of data. This FOA will use the NIH Research Project (R01) award mechanism.

099844	Computational Approaches to Curation at Scale for Biomedical Research Assets (R01 Clinical Trial Not Allowed)	National Library of Medicine/NIH/DHHS	PAR-20-304	07-May-2022	1,000,000 USD
--------	---	---------------------------------------	------------	-------------	---------------

Contact Name	Alan VanBierliet, PhD
Contact Telephone	301-594-4882
Contact Email	vanbiervlietaq@mail.nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	07-May-2022 , 05-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 07-May-2023
Synopsis	National Library of Medicine (NLM) wishes to accelerate the availability of and access to secure, complete data sets and computational models that can serve as the basis of transformative biomedical discoveries by improving the speed and scope of the curation processes.

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

102835	Development of Animal Models and Related Biological Materials for Research (R21 Clinical Trial Not Allowed)	Office of Research Infrastructure Programs/NIH/DHHS	PAR-21-167	07-May-2022	275,000 USD
--------	---	---	------------	-------------	-------------

Contact Name	Sige Zou, Ph.D.
Contact Telephone	301-435-0749
Contact Email	zous@mail.nih.gov
Sponsor Website	

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2022 , 16-Jun-2022 , 07-Sep-2022 , 16-Oct-2022 , 07-Jan-2023 , 16-Feb-2023 , 07-May-2023 , 16-Jun-2023 , 07-Sep-2023 , 16-Oct-2023 , 07-Jan-2024 , 16-Feb-2024 , 07-May-2024</p> <p>Synopsis This funding opportunity announcement (FOA) encourages innovative research to develop, characterize, and improve animal models, biological materials, and novel technologies to better understand human health and disease. This FOA also seeks projects aimed at improving the diagnosis and control of diseases that interfere with animal use for biomedical research. The proposed project must have broad application to multiple NIH Institutes or Centers (ICs) to align with the Office of Research Infrastructure Programs' (ORIP) trans-NIH mission. The proposed studies must explore multiple body systems or evaluate diseases that impact multiple body systems. Applications that develop models focused on a specific disease or area of research, or only propose studies primarily relevant to a single NIH IC, will be considered not acceptable to this FOA and will be withdrawn.</p>				
107732	<p>Notice of Special Interest (NOSI): Development of Resources and Technologies for Enhancing Rigor, Reproducibility, and Translatability of Animal Models in Biomedical Research</p>	Office of Research Infrastructure Programs/NIH/DHHS	NOT-OD-22-039	07-May-2022	Not Specified
	<p>Contact Name Sige Zou, PhD</p> <p>Contact Telephone 301-435-0749</p> <p>Contact Email zous@mail.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2022 , 16-Jun-2022 , 07-Sep-2022 , 16-Oct-2022 , 07-Jan-2023 , 16-Feb-2023 , 07-May-2023 , 16-Jun-2023 , 07-Sep-2023 , 16-Oct-2023 , 07-Jan-2024 , 16-Feb-2024 , 07-May-2024</p> <p>Synopsis With this Notice of Special Interest (NOSI), ORIP intends to support exploratory/developmental and highly innovative projects aimed at developing broadly applicable technologies, tools, and resources for validating animal models and enhancing the rigor, reproducibility, and translatability of animal research. This NOSI is for two-year projects that address key animal resource- and technology-related gaps identified in the "Validation of Animal Models and Tools for Biomedical Research" workshop organized by ORIP, NHLBI, NIA, NIDDK, NIGMS, and NINDS. Animal models of interest for this NOSI include, but are not limited to, invertebrate and vertebrate organisms ranging from C. elegans and Drosophila to zebrafish, mouse, rat, pig, and nonhuman primates.</p>				

National Science Foundation (NSF) Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount														
105980	Dear Colleague Letter: Special Guidelines for Submitting Collaborative Proposals under the National Science Foundation and Czech Science Foundation Collaborative Research Opportunities	National Science Foundation	NSF 21-111	01-Jun-2022 [LOI/Pre-App]	Not Specified														
	<table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 20%; padding: 5px;">Contact Name</td> <td></td> </tr> <tr> <td style="padding: 5px;">Contact Telephone</td> <td></td> </tr> <tr> <td style="padding: 5px;">Contact Email</td> <td>nsf-gacr@nsf.gov</td> </tr> <tr> <td style="padding: 5px;">Sponsor Website</td> <td></td> </tr> <tr> <td style="padding: 5px;">Program URL</td> <td>Link to program URL</td> </tr> <tr> <td style="padding: 5px;">Deadline Dates (ALL)</td> <td>01-Jun-2022 [LOI/Pre-App]</td> </tr> <tr> <td style="padding: 5px;">Synopsis</td> <td>The U.S. National Science Foundation (NSF) and the Czech Science Foundation (GACR) have signed a Memorandum of Understanding (MOU) on Research Cooperation. The MOU provides a framework to encourage collaboration between U.S. and Czech research communities and sets out the principles by which jointly supported activities might be developed. The MOU provides for an international collaboration arrangement whereby U.S. researchers may receive funding from NSF and Czech researchers may receive funding from GACR. Through a "lead agency model," NSF and GACR will allow proposers from both countries to collaborate to write a single proposal that will undergo a single review process at NSF. This NSF-GACR collaborative research opportunity focuses on discoveries and innovations in the areas of artificial intelligence, nanotechnology, and plasma science. Proposals will be accepted for collaborative research in these areas at the intersection of GACR's Call for Proposals and participating NSF programs. Specific participating NSF programs are listed on the NSF Office of International Research and Engineering (OISE) website at https://www.nsf.gov/od/oise/IntlCollaborations/CzechRepublic.jsp.</td> </tr> </table>					Contact Name		Contact Telephone		Contact Email	nsf-gacr@nsf.gov	Sponsor Website		Program URL	Link to program URL	Deadline Dates (ALL)	01-Jun-2022 [LOI/Pre-App]	Synopsis	The U.S. National Science Foundation (NSF) and the Czech Science Foundation (GACR) have signed a Memorandum of Understanding (MOU) on Research Cooperation. The MOU provides a framework to encourage collaboration between U.S. and Czech research communities and sets out the principles by which jointly supported activities might be developed. The MOU provides for an international collaboration arrangement whereby U.S. researchers may receive funding from NSF and Czech researchers may receive funding from GACR. Through a "lead agency model," NSF and GACR will allow proposers from both countries to collaborate to write a single proposal that will undergo a single review process at NSF. This NSF-GACR collaborative research opportunity focuses on discoveries and innovations in the areas of artificial intelligence, nanotechnology, and plasma science. Proposals will be accepted for collaborative research in these areas at the intersection of GACR's Call for Proposals and participating NSF programs. Specific participating NSF programs are listed on the NSF Office of International Research and Engineering (OISE) website at https://www.nsf.gov/od/oise/IntlCollaborations/CzechRepublic.jsp .
Contact Name																			
Contact Telephone																			
Contact Email	nsf-gacr@nsf.gov																		
Sponsor Website																			
Program URL	Link to program URL																		
Deadline Dates (ALL)	01-Jun-2022 [LOI/Pre-App]																		
Synopsis	The U.S. National Science Foundation (NSF) and the Czech Science Foundation (GACR) have signed a Memorandum of Understanding (MOU) on Research Cooperation. The MOU provides a framework to encourage collaboration between U.S. and Czech research communities and sets out the principles by which jointly supported activities might be developed. The MOU provides for an international collaboration arrangement whereby U.S. researchers may receive funding from NSF and Czech researchers may receive funding from GACR. Through a "lead agency model," NSF and GACR will allow proposers from both countries to collaborate to write a single proposal that will undergo a single review process at NSF. This NSF-GACR collaborative research opportunity focuses on discoveries and innovations in the areas of artificial intelligence, nanotechnology, and plasma science. Proposals will be accepted for collaborative research in these areas at the intersection of GACR's Call for Proposals and participating NSF programs. Specific participating NSF programs are listed on the NSF Office of International Research and Engineering (OISE) website at https://www.nsf.gov/od/oise/IntlCollaborations/CzechRepublic.jsp .																		
107542	Dear Colleague Letter: Cryogenics below 1 K - Systems, Cycle, and Materials	National Science Foundation	NSF 22-018	30-Apr-2022 [LOI/Pre-App]	Not Specified														
	<table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 20%; padding: 5px;">Contact Name</td> <td>Thomas F. Kuech</td> </tr> <tr> <td style="padding: 5px;">Contact Telephone</td> <td></td> </tr> <tr> <td style="padding: 5px;">Contact Email</td> <td>tkuech@nsf.gov</td> </tr> <tr> <td style="padding: 5px;">Sponsor Website</td> <td>Link to sponsor website</td> </tr> <tr> <td style="padding: 5px;">Program URL</td> <td></td> </tr> <tr> <td style="padding: 5px;">Deadline Dates (ALL)</td> <td>30-Apr-2022 [LOI/Pre-App], 30-Jun-2022</td> </tr> </table>					Contact Name	Thomas F. Kuech	Contact Telephone		Contact Email	tkuech@nsf.gov	Sponsor Website	Link to sponsor website	Program URL		Deadline Dates (ALL)	30-Apr-2022 [LOI/Pre-App], 30-Jun-2022		
Contact Name	Thomas F. Kuech																		
Contact Telephone																			
Contact Email	tkuech@nsf.gov																		
Sponsor Website	Link to sponsor website																		
Program URL																			
Deadline Dates (ALL)	30-Apr-2022 [LOI/Pre-App], 30-Jun-2022																		

National Science Foundation (NSF) Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p style="text-align: right; margin-right: 10px;">Synopsis</p> <p>With this Dear Colleague Letter (DCL), the National Science Foundation’s (NSF) Directorate for Engineering (ENG) and Directorate for Mathematical & Physical Sciences (MPS) invite the submission of Early-concept Grants for Exploratory Research (EAGER) proposals to focus on new approaches to refrigeration at <1K, materials needed to enable ultra-low temperature refrigeration, and new processing techniques needed to fabricate these new types of refrigeration systems.</p>				
108663	Expanding Capacity in Quantum Information Science and Engineering	National Science Foundation	22-561	06-May-2022	Not Specified
	<p style="text-align: right; margin-right: 10px;">Synopsis</p> <p>The NSF Expanding Capacity in Quantum Information Science and Engineering (ExpandQISE) program aims to increase research capacity and broaden participation in Quantum Information Science and Engineering (QISE) and related disciplines through the creation of a diversified investment portfolio in research and education that will lead to scientific and engineering breakthroughs, while securing a talent pipeline in a field where workforce needs of industry, government and academia continue to outgrow the available talent. The ExpandQISE program helps build and maintain a close connection between new efforts and existing impactful work done at the existing QISE Centers or leading QISE research Institutions, while creating and nurturing necessary critical mass at Institutions not yet fully involved in QISE. In keeping with the NSF goal of increasing the participation of all members of society in the scientific enterprise, institutions at which more than 50% of enrolled students come from groups that are currently under-represented in the sciences, e.g. minority-serving institutions (MSIs), are especially encouraged to apply.</p>	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email</p> <p>Sponsor Website</p> <p>Program URL</p> <p>Deadline Dates (ALL)</p>	<p>Tomasz Durakiewicz</p> <p>703-292-4892</p> <p>tdurakie@nsf.gov</p> <p>Link to sponsor website</p> <p>Link to program URL</p> <p>06-May-2022 , 03-Jun-2022 , 03-Feb-2023 [LOI/Pre-App], 03-Mar-2023 , 07-Apr-2023</p>		
105122	Tribal Colleges and Universities Program (TCUP)	National Science Foundation	21-595	01-Jun-2022	Not Specified
	<p style="text-align: right; margin-right: 10px;">Synopsis</p>	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email</p> <p>Sponsor Website</p>	<p>Jody Chase</p> <p>703-292-8640</p> <p>jchase@nsf.gov</p> <p>Link to sponsor website</p>		

National Science Foundation (NSF) Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 01-Jun-2022 , 01-Sep-2022</p> <p>Synopsis The Tribal Colleges and Universities Program (TCUP) provides awards to federally recognized[1] Tribal Colleges and Universities, Alaska Native-serving institutions, and Native Hawaiian-serving institutions to promote high quality science (including sociology, psychology, anthropology, linguistics, economics and bioeconomics, statistics, and other social and behavioral sciences; natural sciences; computer science, including, but not limited to, artificial intelligence, quantum information science, and cybersecurity), technology, engineering and mathematics (STEM), STEM education, research, and outreach. Support is available to TCUP-eligible institutions for transformative capacity-building or community engagement projects through Instructional Capacity Excellence in TCUP Institutions (ICE-TI), Targeted STEM Infusion Projects (TSIP),TCUP for Secondary and Elementary Teachers in STEM (TSETS), TCU Enterprise Advancement Centers (TEA Centers), Cyberinfrastructure Health, Assistance, and Improvements (CHAI), and Preparing for TCUP Implementation (Pre-TI). Collaborations led by TCUP institutions that involve non-TCUP institutions of higher education are supported through TCUP Partnerships, with the participation of other NSF programs to support the work of non-TCUP institutions. Finally, research studies that further the scholarly activity of individual faculty members are supported through Small Grants for Research (SGR). Through the opportunities highlighted above, as well as collaborations with other National Science Foundation (NSF) divisions and directorates, and other organizations, TCUP aims to increase Native individuals' participation in STEM careers, improve the quality of STEM programs at TCUP-eligible institutions, and facilitate the development of a strong STEM enterprise in TCUP institutions' service areas.</p>				
109414	Industry-University Cooperative Research Centers Program	National Science Foundation	20-570	08-Jun-2022	Not Specified
	<p>Contact Name Prakash G. Balan</p> <p>Contact Telephone 703-292-5341</p> <p>Contact Email pbalan@nsf.gov</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 08-Jun-2022 , 14-Sep-2022 [LOI/Pre-App], 14-Dec-2022</p> <p>Synopsis The IUCRC program catalyzes breakthrough pre-competitive research by enabling close and sustained engagement between industry innovators, world-class academic teams, and government agencies. IUCRCs help industry partners and government agencies connect directly and efficiently with university researchers to achieve three primary objectives: 1) Conduct high-impact research to meet shared and critical industrial needs in companies of all sizes; 2) Enhance U.S. global leadership in</p>				

National Science Foundation (NSF) Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

driving innovative technology development, and 3) Identify, mentor and develop a diverse, highly skilled science and engineering workforce.

101564	Cyber-Physical Systems (CPS)	National Science Foundation	21-551	15-Jun-2022	Not Specified
--------	--	-----------------------------	--------	-------------	---------------

Contact Name	David Corman
Contact Telephone	703-292-8754
Contact Email	dcorman@nsf.gov
Sponsor Website	Link to sponsor website
Program URL	Link to program URL
Deadline Dates (ALL)	15-Jun-2022 , 30-Dec-2022
Synopsis	<p>The CPS program aims to develop the core research needed to engineer these complex CPS, some of which may also require dependable, high-confidence, or provable behaviors. Core research areas of the program include control, data analytics, and machine learning including real-time learning for control, autonomy, design, Internet of Things (IoT), mixed initiatives including human-in- or human-on-the-loop, networking, privacy, real-time systems, safety, security, and verification. By abstracting from the particulars of specific systems and application domains, the CPS program seeks to reveal cross-cutting, fundamental scientific and engineering principles that underpin the integration of cyber and physical elements across all application domains. The program additionally supports the development of methods, tools, and hardware and software components based upon these cross-cutting principles, along with validation of the principles via prototypes and testbeds. This program also fosters a research community that is committed to advancing education and outreach in CPS and accelerating the transition of CPS research into the real world.</p>

110003	Spectrum Innovation Initiative: National Radio Dynamic Zones	National Science Foundation	22-579	20-Jun-2022	Not Specified
--------	--	-----------------------------	--------	-------------	---------------

Contact Name	John M. Chapin
Contact Telephone	703-292-8222
Contact Email	SII@nsf.gov
Sponsor Website	Link to sponsor website
Program URL	Link to program URL
Deadline Dates (ALL)	20-Jun-2022

National Science Foundation (NSF) Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

Synopsis | The electromagnetic spectrum is an essential resource for many sectors of society and the economy. Commercial applications (e.g., wireless communication, navigation, and telemetry) compete for spectrum access with scientific activities (e.g., radio astronomy, earth observation, geospace sciences, and polar research) and other vital spectrum-dependent services (e.g., air traffic control). Ongoing technological progress has created a situation where each application, activity, and service seeks additional spectrum access. Potential benefits from additional spectrum access include faster communications, new astronomical and scientific discoveries, more energy-efficient cities, increased highway capacity and safety, and more accurate weather predictions. Achieving these benefits calls for increased use of dynamic spectrum sharing – ways to enable diverse spectrum users to safely operate closer together in space or frequency or to trade spectrum access more rapidly than is possible with traditional spectrum management approaches. The goal of this Spectrum Innovation Initiative: National Radio Dynamic Zones (SII-NRDZ) program is to advance the use of dynamic spectrum sharing. The unifying concept investigated in SII-NRDZ is the radio dynamic zone: an area or volume with automatic spectrum management mechanisms that control electromagnetic energy entering, escaping, or occupying the zone. SII-NRDZ seeks to perform extended (6- to 12-month) field trials of various types of radio dynamic zone spectrum sharing at sites where the field trials will enhance spectrum access for facilities or applications. The field trials will mature understanding and capability towards wider use of spectrum sharing, and towards eventual establishment of a permanent highly capable National Radio Dynamic Zone somewhere in the USA. The National Radio Dynamic Zone is envisioned to support a facility for at-scale research and experimentation on systems that use or manage spectrum in innovative ways. SII-NRDZ is an interdisciplinary program that seeks to foster collaboration among spectrum sharing researchers; domain experts with knowledge of specific applications, scientific activities, or instruments; site or mission experts who understand the operations of specific facilities or systems; spectrum regulatory specialists; and others. The SII-NRDZ program includes two types of projects. SII-NRDZ research studies are traditional NSF grants for investigation of spectrum sharing solutions and risk analysis techniques, or for investigation of applications and sites for radio dynamic zone field trials. SII-NRDZ Engineering and Execution Lead awards are cooperative agreements for work to mature results of the research studies into robust implementations and to lead the planned extended field trials. The SII-NRDZ goal to advance the use of dynamic spectrum sharing requires the evolution of spectrum management practice. The key to spectrum management evolution is ensuring trust by stakeholders who rely on current interference prevention mechanisms and seek to protect future options. SII-NRDZ program activities are designed to help build the trust that is critical for progress.

108389	NSF Small Business Innovation Research Phase II (SBIR)/ Small Business Technology Transfer (STTR) Programs Phase II (SBIR/STTR Phase II)	National Science Foundation	NSF 22-552	30-Jun-2022	1,000,000 USD
--------	--	-----------------------------	------------	-------------	---------------

Contact Name	
Contact Telephone	703-292-8050

National Science Foundation (NSF) Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Email sbir@nsf.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 30-Jun-2022 , 26-Oct-2022</p> <p>Synopsis The NSF SBIR/STTR programs support moving scientific excellence and technological innovation from the lab to the market. By investing federal research and development funds into startups and small businesses, NSF hopes to build a strong national economy and stimulate the creation of novel products, services, and solutions in the private sector; strengthen the role of small business in meeting federal research and development needs; increase the commercial application of federally supported research results; and develop and increase the US workforce, especially by fostering and encouraging participation by socially and economically disadvantaged and women-owned small businesses. The SBIR/STTR programs at NSF solicit proposals based on groundbreaking scientific discoveries or significant engineering breakthroughs from the small businesses consistent with NSF's mission to promote the progress of science; to advance the national health, prosperity, and welfare; and to secure the national defense.</p>				
108391	<p>NSF Small Business Innovation Research (SBIR)/ Small Business Technology Transfer (STTR) Programs Phase I (SBIR/STTR Phase I)</p>	National Science Foundation	NSF 22-551	30-Jun-2022	275,000 USD
	<p>Contact Name Henry Ahn</p> <p>Contact Telephone 703-292-7069</p> <p>Contact Email hahn@nsf.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 30-Jun-2022 , 26-Oct-2022</p> <p>Synopsis The NSF SBIR/STTR programs support moving scientific excellence and technological innovation from the lab to the market. By investing federal research and development funds into startups and small businesses, NSF hopes to build a strong national economy and stimulate the creation of novel products, services, and solutions in the private sector; strengthen the role of small business in meeting federal research and development needs; increase the commercial application of federally supported research results; and develop and increase the US workforce, especially by fostering and encouraging participation by socially and economically disadvantaged and women-owned small businesses. The NSF SBIR/STTR programs solicit proposals from small businesses based on groundbreaking scientific discoveries or significant engineering breakthroughs consistent with NSF's mission to promote the progress of science; to advance the national health, prosperity, and welfare;</p>				

National Science Foundation (NSF) Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

| and to secure the national defense.

Other Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
104738	Lawrence and Isabel Barnett Drug Development Program	ALS Association		01-Jun-2022	500,000 USD
	Contact Name				
	Contact Telephone	1-800-782-4747			
	Contact Email	researchgrants@alsa-national.org			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	01-Jun-2022			
	Synopsis	The ALS Association offers the Lawrence and Isabel Barnett Drug Development Program provides support for preclinical assessment of therapeutics for ALS that have a high probability of reaching the clinic within three years. This program is open to industry and academic investigators proposing to develop novel or repositioning approaches for ALS. Awards will be limited \$500,000 total costs for the entire 2-year period of performance.			
	Applicant Types				
	Funding Limit	250,000.00 per year			
	Limited Submission	No			
042399	Research Grants	American Academy of Otolaryngic Allergy Foundation		01-Jun-2022	10,000 USD
	Contact Name	Elisabeth Herzfeld-Rice			
	Contact Telephone	202-955-5010 x 600			
	Contact Email	foundation@aoallergy.org			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	01-Jun-2022			
	Synopsis	The AAOA Foundation seeks to advance allergy research and knowledge for the treatment of otolaryngic conditions by inviting applications for grants to conduct research in the pathogenesis, pathophysiology, diagnosis, prevention, or treatment of otolaryngic allergy. Funds are available to support multiple projects each year; each project may have total direct costs of \$10,000.			
	Applicant Types				
	Funding Limit	10,000.00 maximum			

Other Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Limited Submission	No			
045882	Outstanding Investigator Award for Breast Cancer Research	American Association for Cancer Research		30-Jun-2022	Not Specified
	Contact Name	Michael J. Powell, PhD, Deputy Director of Scientific Programs			
	Contact Telephone	215-440-9373			
	Contact Email	michael.powell@aacr.org			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	30-Jun-2022			
	Synopsis	The AACR established this Award to recognize an investigator whose novel and significant work has had or may have a far-reaching impact on the etiology, detection, diagnosis, treatment, or prevention of breast cancer. Such work may involve any discipline across the continuum of biomedical research, including basic, translational, clinical, and epidemiological studies.			
	Applicant Types				
	Funding Limit	0.00 see detail			
	Limited Submission	No			
032751	Eva King Killiam Research Award	American College of Neuropsychopharmacology		23-Jun-2022	Not Specified
	Contact Name				
	Contact Telephone	615-324-2360			
	Contact Email	acnp@acnp.org			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	23-Jun-2022			
	Synopsis	The American College of Neuropsychopharmacology (ACNP) presents the Eva King Killiam Research Award to an early career researcher on the basis of outstanding translational research contributions to neuropsychopharmacology.			
	Applicant Types				
	Funding Limit	0.00 see detail			

Other Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Limited Submission	No			
103871	Barbara Fish Memorial Award	American College of Neuropsychopharmacology		23-Jun-2022	Not Specified
	Contact Name				
	Contact Telephone	615-324-2360			
	Contact Email	acnp@acnp.org			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	23-Jun-2022			
	Synopsis	The American College of Neuropsychopharmacology (ACNP) presents the Barbara Fish Memorial Award to an ACNP member who has made an outstanding contribution to basic, translational or clinical neuroscience. Award recipients will receive a monetary award and a plaque to be given at the ACNP Annual Meeting.			
	Applicant Types				
	Funding Limit	0.00 see detail			
	Limited Submission	No			
072617	Joel Elkes Research Award	American College of Neuropsychopharmacology		23-Jun-2022	Not Specified
	Contact Name				
	Contact Telephone	615-324-2360			
	Contact Email	acnp@acnp.org			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	23-Jun-2022			
	Synopsis	The American College of Neuropsychopharmacology (ACNP) presents the Joel Elkes Research Award to a young scientist in recognition of an outstanding clinical contribution to neuropsychopharmacology.			
	Applicant Types				
	Funding Limit	0.00 see detail			

Other Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Limited Submission	No			
095617	Media Award	American College of Neuropsychopharmacology		23-Jun-2022	Not Specified
	Contact Name				
	Contact Telephone	615-324-2360			
	Contact Email	acnp@acnp.org			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	23-Jun-2022			
	Synopsis	The ACNP Media Award was established to recognize major contributions to the education of the public about mental illness and substance abuse research and the positive impact of research on treatment. The Media Award consists of an expense paid trip to the ACNP Annual Meeting and a plaque to be presented at the Annual Meeting.			
	Applicant Types				
	Funding Limit	0.00 see detail			
	Limited Submission	No			
092353	Stephanie Watts Career Development Award	American Heart Association		25-May-2022	Not Specified
	Contact Name				
	Contact Telephone	214-706-1240			
	Contact Email	council.awards@heart.org			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	25-May-2022 , 01-Jun-2022 , 03-Jun-2022			
	Synopsis	This award supports early career investigators working in hypertension and cardiovascular research who show exceptional promise but may be currently unfunded or have limited access to extramural funding.			
	Applicant Types				
	Funding Limit	0.00 see detail			

Other Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Limited Submission	No			
079306	Lifestyle and Cardiometabolic Health Early Career Investigator Award	American Heart Association		09-Jun-2022	Not Specified
	Contact Name				
	Contact Telephone	214-706-1181			
	Contact Email	council.awards@heart.org			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	09-Jun-2022			
	Synopsis	The Council on Lifestyle and Cardiometabolic Health Young Investigator Award recognizes and awards early career investigator and trainee council members for their achievements and their continuing research. The award also encourages young scientists to become involved in the Council on Lifestyle and Cardiometabolic Health and to develop and maintain productive careers.			
	Applicant Types				
	Funding Limit	0.00 see detail			
	Limited Submission	Yes			
092352	Harry Goldblatt New Investigator Award	American Heart Association		01-Jun-2022	Not Specified
	Contact Name				
	Contact Telephone	214-706-1181			
	Contact Email	council.awards@heart.org			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	01-Jun-2022 , 03-Jun-2022			
	Synopsis	The Harry Goldblatt Award for New Investigators recognizes a new independent investigator working in hypertension or cardiovascular research who has significantly contributed to our understanding of the causes of hypertension and related cardiovascular disease. The awardee will be selected by the Council's Awards Committee from applicants who have submitted abstracts accepted for presentation at the Hypertension Scientific Sessions, along with other materials.			

Other Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Applicant Types Funding Limit 0.00 see detail Limited Submission No				
005950	Marvin Moser Clinical Hypertension Award	American Heart Association		03-Jun-2022	2,000 USD
	Contact Name Contact Telephone 212-696-9099 Contact Email council.awards@heart.org Sponsor Website Link to sponsor website Program URL Link to program URL Deadline Dates (ALL) 03-Jun-2022 Synopsis The Marvin Moser Clinical Hypertension Award recognizes a qualified mid-career or senior Hypertension Clinician for their dedication to the treatment and care of hypertensive patients. Applicant Types Funding Limit 2,000.00 see detail Limited Submission No				
080457	Award for Outstanding Doctoral Thesis Research in Biological Physics	American Physical Society		01-Jun-2022	Not Specified
	Contact Name Contact Telephone 301-209-3200 Contact Email honors@aps.org Sponsor Website Link to sponsor website Program URL Link to program URL Deadline Dates (ALL) 01-Jun-2022 Synopsis The Award for Outstanding Doctoral Thesis Research in Biological Physics recognizes doctoral thesis research of outstanding quality and achievement in any area of experimental, computational, engineering, or theoretical Biological Physics, broadly construed, and to encourage effective written and oral presentation of research results. Applicant Types				

Other Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Funding Limit	0.00 see detail			
	Limited Submission	Yes			
083145	APA Distinguished Scientific Awards for an Early Career Contribution to Psychology	American Psychological Association		01-Jun-2022	Not Specified
	Contact Name	Suzanne Wandersman			
	Contact Telephone	202-336-6000			
	Contact Email	swandersman@apa.org			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	01-Jun-2022			
	Synopsis	The American Psychological Association (APA) provides an award to recognize excellent psychologists who are at early stages of their research careers.			
	Applicant Types				
	Funding Limit	0.00 not provided			
	Limited Submission	No			
102829	Mitchell A. Baran Achievement Award for Clinical Excellence in Aerosol and Airway Clearance Therapies	American Respiratory Care Foundation		01-Jun-2022	2,500 USD
	Contact Name				
	Contact Telephone	972-243-2272			
	Contact Email				
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	01-Jun-2022			
	Synopsis	This award is given to recognize and honor those individuals demonstrating clinical excellence and leadership in advocating and promoting the use of evidence-based, clinically sound practices for the delivery of aerosolized medications and/or the application of non-pharmacologic airway clearance therapies.			
	Applicant Types				

Other Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Funding Limit	2,500.00 see detail			
	Limited Submission	No			
068798	Thomas L. Petty, MD Invacare Award for Excellence in Home Respiratory Care	American Respiratory Care Foundation		01-Jun-2022	Not Specified
	Contact Name	Crystal Maldonado			
	Contact Telephone	972-243-2272			
	Contact Email				
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	01-Jun-2022			
	Synopsis	This award recognizes outstanding individual achievement in home respiratory care.			
	Applicant Types				
	Funding Limit	0.00 see detail			
	Limited Submission	No			
068800	NBRC Frederic Helmholtz, Jr., MD Educational Research Fund	American Respiratory Care Foundation		01-Jun-2022	5,000 USD
	Contact Name				
	Contact Telephone	972-243-2272			
	Contact Email				
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	01-Jun-2022			
	Synopsis	The National Board for Respiratory Care/Applied Measurement Professionals, Inc. has provided an endowment to the American Respiratory Care Foundation to support up to \$5,000 for educational or credentialing research. A Master's Thesis, or Doctoral Dissertation with practical value to the respiratory care profession are acceptable submissions by a candidate.			
	Applicant Types				
	Funding Limit	5,000.00 see detail			
	Limited Submission	No			

Other Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
068786	Forrest M. Bird, MD, PhD, ScD Lifetime Scientific Achievement Award	American Respiratory Care Foundation		01-Jun-2022	Not Specified
	Contact Name Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL) Synopsis Applicant Types Funding Limit Limited Submission	Crystal Maldonado 972-243-2272 Link to sponsor website Link to program URL 01-Jun-2022 This award acknowledges outstanding individual scientific contributions in the area of respiratory care of cardiopulmonary disorders. 0.00 see detail No			
035693	ASRM/NIH/Duke Clinical Research/Reproductive Scientist Training (CREST) Program	American Society for Reproductive Medicine		01-Jun-2022	Not Specified
	Contact Name Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL) Synopsis Applicant Types Funding Limit Limited Submission	 202-863-4985 nicole.goetz@cuanschutz.edu Link to sponsor website Link to program URL 01-Jun-2022 The CREST training program is offered by the NICHD, the Clinical Research Training Program (CRTP) at Duke University, and ASRM. This 2-year program meets an existing need for physicians in private or academic clinical practice to obtain formalized academic training in the quantitative and methodological principles of clinical research in reproductive medicine. 0.00 not provided No			

Other Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
104547	Career Transition Grants	American Society of Transplantation		01-Jun-2022	50,000 USD
	Contact Name				
	Contact Telephone	856-439-9986			
	Contact Email	research@myast.org			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	01-Jun-2022			
	Synopsis	The purpose of these grants is to promote the careers of mid-career independent investigators whose research relates to the field of solid organ transplantation (and/or immunology relating to solid organ transplant). The grants support the investigator's transition to an R-series or equivalent grant.			
	Applicant Types				
	Funding Limit	50,000.00 see detail			
	Limited Submission	No			
019022	Department of Urology - Endourology Fellowship at Northwestern	American Urological Association		02-Jun-2022	Not Specified
	Contact Name	Debra Caridi, Fellowship Coordinator			
	Contact Telephone	516-520-1226			
	Contact Email	debra@endourologysociety.com			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	02-Jun-2022 , 20-Jun-2022			
	Synopsis	The Endourological Society facilitates one and two year clinical fellowships around the world. The training is focused on developing advanced knowledge, experience, and technical skills in endourologic and laparoscopic and/or robotic assisted surgery. Fellows also receive training in translational research, as an underlying goal is the training of future academicians and potential national and international leaders in their specialty.			
	Applicant Types				
	Funding Limit	0.00 not provided			

Other Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Limited Submission	No			
104556	Request for Proposals (RFP) -- Diversity, Equity and Inclusion in Cultivating a New Generation of Rheumatologists	Arthritis Foundation		06-Jun-2022	Not Specified
	Contact Name				
	Contact Telephone	1-800-283-7800			
	Contact Email	AFScience@arthritis.org			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	06-Jun-2022			
	Synopsis	<p>The Arthritis Foundation (AF) is committed to Diversity, Equity, and Inclusion (DEI) in order to support the training of a diverse generation of rheumatologists and to improve health outcomes for all patients with rheumatic diseases, especially those living with arthritis. Two complementary AF initiatives were launched in 2021 and will continue in 2022 to support AF's aspirations. The first program aims to provide seed funding to support impactful and innovative research to improve health outcomes across different racial and ethnic groups, as well as among various categories of socioeconomic status. The second program has a goal to increase diversity in the next generation of rheumatologists, for those who are physicians or physician/scientists. The ability of proposed projects to have a lasting impact and to be sustained beyond the award period, with potential for their findings to lead directly to advocacy and to reduce structural barriers, are considered important for success. Focus on arthritis research and curriculum development is preferred.</p>			
	Applicant Types				
	Funding Limit	0.00 see detail			
	Limited Submission	No			
018455	Sir Harcourt Caughey Award	Auckland Medical Research Foundation		29-Jun-2022	17,250 USD
	Contact Name	Research Programme Manager			
	Contact Telephone	+64 9 923 1701			
	Contact Email	amrf@medicalresearch.org.nz			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	29-Jun-2022			

Other Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p style="text-align: right;">Synopsis</p> <p>The Sir Harcourt Caughey Award provides funds up to \$25,000 for recipients who may: (i) be a graduate of New Zealand who, having trained in research overseas, is returning to New Zealand to a part-time appointment in Auckland and who has sufficient experience in research to deserve part-time support (or similar to a part-time Senior Research Fellowship) in such research; or (ii) be a New Zealand medical graduate in Auckland who is deserving of assistance to train in a specific field overseas and to undertake research in that area, especially where there is a local deficiency in expertise in that field; or (iii) be sufficiently prestigious in a particular field of medical knowledge and/or research to visit Auckland, normally for 3-4 weeks, to foster interest and research in that specialty. SPECIAL INSTRUCTIONS FOR 2022 ROUND 1: The Auckland Medical Research Foundation will only accept applications for this grant type if the NZ government conditions are met for safe travel to or from the destination(s) identified in the application. For information, please refer to https://covid19.govt.nz/travel/ For category 2, applicants must provide evidence from their host institution that they allow travel to the destination requested in their application. The AMRF will not be responsible for any costs associated with the recipient being stranded or having to quarantine in any situation, whether or not it was an approved destination when the application was submitted.</p> <p style="text-align: right;">Applicant Types</p> <p style="text-align: right;">Funding Limit</p> <p style="text-align: right;">Limited Submission</p>				
096334	Frontiers of Knowledge Awards	BBVA Foundation		30-Jun-2022	440,000 USD
	<p style="text-align: right;">Contact Name</p> <p style="text-align: right;">Contact Telephone</p> <p style="text-align: right;">Contact Email</p> <p style="text-align: right;">Sponsor Website</p> <p style="text-align: right;">Program URL</p> <p style="text-align: right;">Deadline Dates (ALL)</p> <p style="text-align: right;">Synopsis</p> <p style="text-align: right;">Applicant Types</p> <p style="text-align: right;">Funding Limit</p> <p style="text-align: right;">Limited Submission</p>	<p>94 487 52 52</p> <p>awards-info@fbbva.es</p> <p>Link to sponsor website</p> <p>Link to program URL</p> <p>30-Jun-2022</p> <p>The BBVA Foundation Frontiers of Knowledge Awards recognize fundamental contributions in a broad array of areas of scientific knowledge, technology, humanities and artistic creation.</p> <p>400,000.00 see detail</p> <p>No</p>			
089931	PhD Fellowships	Boehringer Ingelheim Fonds		01-Jun-2022	Not Specified

Other Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Name</p> <p>Contact Telephone +49 (0)6131 2750 80</p> <p>Contact Email secretariat@bifonds.de</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 01-Jun-2022 , 01-Oct-2022</p> <p>Synopsis The Boehringer Ingelheim Fonds (BIF) awards PhD fellowships of 2 to 3.5 years to outstanding junior scientists worldwide who wish to pursue an ambitious PhD project in basic biomedical research in an internationally leading laboratory.</p> <p>Applicant Types</p> <p>Funding Limit 0.00 see detail</p> <p>Limited Submission No</p>				
045367	<p>Partnering Opportunity for Late Stage Preclinical Projects (CLIN1)</p>	California Institute for Regenerative Medicine		29-Apr-2022	6,000,000 USD
	<p>Contact Name</p> <p>Contact Telephone 510-340-9101</p> <p>Contact Email clinical@cirm.ca.gov</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 29-Apr-2022 , 31-May-2022 , 30-Jun-2022 , 31-Jul-2022</p> <p>Synopsis The mission of California Institute for Regenerative Medicine (CIRM) is to accelerate stem cell treatments to patients with unmet medical needs. The objective of this program announcement is to create a highly competitive partnering opportunity to accelerate the completion of an IND or IDE filing with the Food and Drug Administration (FDA) and initiate clinical trial start-up with a promising stem or progenitor cell-based or gene therapy treatment that addresses an unmet medical need. CIRM expects projects under this program to advance rapidly into the clinic and to achieve the proposed IND filing within 24 months.</p> <p>Applicant Types</p> <p>Funding Limit 6,000,000.00 maximum</p> <p>Limited Submission No</p>				

Other Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
045538	Partnering Opportunity For Clinical Trial Stage Projects (CLIN2)	California Institute for Regenerative Medicine		29-Apr-2022	Not Specified
	Contact Name				
	Contact Telephone	510-340-9101			
	Contact Email	Clinical@cirm.ca.gov			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	29-Apr-2022 , 31-May-2022 , 30-Jun-2022 , 31-Jul-2022			
	Synopsis	<p>The mission of California Institute for Regenerative Medicine (CIRM) is to accelerate stem cell treatments to patients with unmet medical needs. The objective of this program announcement is to create a highly competitive partnering opportunity to accelerate the completion of a clinical trial for a promising stem or progenitor cell-based or gene therapy treatment that addresses an unmet medical need. Under this program, CIRM will act not only as a funding agency, but will also devote significant internal resources and leverage its external team of world-class subject matter experts to actively advance the project. The result of a successful application will be the formation of a true partnership that both accelerates the program and gives it the greatest opportunity for success.</p>			
	Applicant Types				
	Funding Limit	0.00 see detail			
	Limited Submission	No			
074890	Team Grant: E-Rare-6 Joint Transnational Call (2022)	Canadian Institutes of Health Research		15-Jun-2022	355,500 USD
	Contact Name				
	Contact Telephone	613-954-1968			
	Contact Email	support@cihr-irsc.gc.ca			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	15-Jun-2022			
	Synopsis	<p>CIHR-IG is pleased to be partnering with approximately 18 international funding organizations in the context of this European Joint Programme on Rare Diseases (EJP RD) call for proposals 2021. The topic of the call is Social Sciences and Humanities Research to improve health care implementation and everyday life of people living with a rare disease.</p>			

Other Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Applicant Types Funding Limit 150,000.00 per year Limited Submission No				
109754	Request for Applications: Essential Open Source Software for Science (Cycle 5)	Chan Zuckerberg Initiative		19-Apr-2022	400,000 USD
	Contact Name Contact Telephone Contact Email sciencegrants@chanzuckerberg.com Sponsor Website Link to sponsor website Program URL Link to program URL Deadline Dates (ALL) 19-Apr-2022 , 02-Jun-2022 Synopsis The Chan Zuckerberg Initiative invites applications in support of open source software projects that are essential to biomedical research. The goal of the program is to support software maintenance, growth, development, and community engagement for these critical tools. Applications can request funding between \$50,000 USD and \$200,000 USD total costs per year for two years (inclusive of up to 15% for indirect/overhead costs) for an overall amount requested between \$100,000 USD and \$400,000 USD total costs for the two-year duration of the grant. Applicant Types Funding Limit 200,000.00 per year Limited Submission No				
074665	Clinical Research Scholars Program Award	Cystic Fibrosis Foundation		01-Jun-2022	Not Specified
	Contact Name Contact Telephone 301-841-2614				

Other Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Contact Email grants@cff.org Sponsor Website Link to sponsor website Program URL Link to program URL Deadline Dates (ALL) 01-Jun-2022 Synopsis The Cystic Fibrosis Clinical Research Scholars Program (CRSP) Award is designed to enable promising early-career physician scientists to enhance their clinical research proficiency and support their development of the necessary clinical research capabilities to become independent investigators who formulate and lead multi-center, clinical research studies. Applicant Types Funding Limit 0.00 see detail Limited Submission No				
070774	Research Grants	Diabetes Research and Wellness Foundation (U.S.)		30-Jun-2022	100,000 USD
	Contact Name Valerie Jeremiah Contact Telephone 202-298-9211 Contact Email diabeteswellness@diabeteswellness.net Sponsor Website Link to sponsor website Program URL Link to program URL Deadline Dates (ALL) 30-Jun-2022 , 30-Dec-2022 Synopsis The Diabetes Research and Wellness Foundation (DRWF) accepts research applications related to finding the cause, prevention, treatment, and cure of diabetes and its complications. The maximum support of these grants is up to \$50,000 per year for up to two years. Applicant Types Funding Limit 50,000.00 per year Limited Submission No				
057992	Simulation Research Grant	Emergency Medicine Residents' Association		03-Jun-2022	500 USD
	Contact Name Contact Telephone 972-550-0920				

Other Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Contact Email awards@emra.org Sponsor Website Link to sponsor website Program URL Link to program URL Deadline Dates (ALL) 03-Jun-2022 Synopsis The purpose of the EMRA Simulation Research Grant is to provide research funding to Emergency Medicine (EM) physician-in-training interested in completing simulation-based projects during residency/medical school. Applicant Types Funding Limit 500.00 see detail Limited Submission No				
030970	Eppendorf & Science Prize for Neurobiology	Eppendorf AG		15-Jun-2022	25,000 USD
	Contact Name Selection Committee for the Eppendorf & Science Prize for Neurobiology Science Contact Telephone +1 202326 6513 Contact Email eppendorfsceinceprize@aaas.org Sponsor Website Link to sponsor website Program URL Link to program URL Deadline Dates (ALL) 15-Jun-2022 Synopsis The international Eppendorf & Science Prize for Neurobiology is awarded annually to one young scientist who is not older than 35 years for the most outstanding neurobiological research based on methods of molecular and cell biology conducted by him/her during the past three years. The prize consists of \$25,000. Applicant Types Funding Limit 25,000.00 see detail Limited Submission No				
006022	Module I – Observational Training with Experts Fellowship Grant	European Society of Gastrointestinal Endoscopy		01-Jun-2022	1,430 USD
	Contact Name Contact Telephone + 49-89-907 7936-00 Contact Email secretariat@esge.com				

Other Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 01-Jun-2022</p> <p>Synopsis The European Society of Gastrointestinal Endoscopy (ESGE) offers fellowship grants to fully-trained endoscopists wishing to undertake further training in highly specialised endoscopic techniques at officially recognised ESGE training centres. Also, through a mutual cooperation, ESGE and the Japan Gastroenterological Endoscopy Society (JGES) offer one grant, Module I, per year in an exchange programme. The selected ESGE grantee is assigned to one of the leading Japanese institutions.</p> <p>Applicant Types</p> <p>Funding Limit 1,300.00 see detail</p> <p>Limited Submission No</p>				
057307	Research Grants	Fibrolamellar Cancer Foundation		01-Jun-2022	Not Specified
	<p>Contact Name</p> <p>Contact Telephone 203-340-7800</p> <p>Contact Email grants@fibrofoundation.org</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 01-Jun-2022 , 01-Oct-2022</p> <p>Synopsis The Fibrolamellar Cancer Foundation (FCF) is accepting proposals to support innovative research leading to improved understanding and curative treatments for fibrolamellar carcinoma (FLC). FLC, also known as fibrolamellar hepatocellular carcinoma (FL-HCC), is an aggressive liver cancer that tends to strike teens and young adults. The research must focus specifically on FLC. Studies should be intended to advance knowledge relevant to the understanding, diagnosis, epidemiology, or treatment of FLC. Of particular interest are applications showing a clear path towards a novel therapy or clinical trials with the ultimate goal of achieving a cure for FLC. The Foundation will accept grant applications to support innovative and promising research projects towards the listed goals. The FCF believes that collaboration engaging the best talent across institutions, together with early sharing of data and resources, often accelerates the path to a cure for rare cancers.</p> <p>Applicant Types</p> <p>Funding Limit 0.00 see detail</p> <p>Limited Submission No</p>				

Other Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
001781	William T. Grant Scholars Program	Grant (William T.) Foundation		15-Jun-2022 [LOI/Pre-App]	350,000 USD
	<p>Contact Name</p> <p>Contact Telephone 212-752-0071</p> <p>Contact Email info@wtgrantfdn.org</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 15-Jun-2022 [LOI/Pre-App], 06-Jul-2022</p> <p>Synopsis The William T. Grant Scholars Program supports career development for promising early-career researchers. The program funds five-year research and mentoring plans that significantly expand researchers' expertise in new disciplines, methods, and content areas.</p> <p>Applicant Types</p> <p>Funding Limit 350,000.00 maximum</p> <p>Limited Submission Yes</p>				
058073	University of Toronto Integrated Neonatal-Perinatal Fellowship Training Program	Hospital for Sick Children Foundation/Sick Kids Foundation		30-Jun-2022	Not Specified
	<p>Contact Name Sonia Dos Santos, Interim Education Administrative Coordinator</p> <p>Contact Telephone 416-813-7654 x 228902</p> <p>Contact Email neonatal.fellowship@sickkids.ca</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 30-Jun-2022</p> <p>Synopsis The University of Toronto Training Program in Neonatal-Perinatal Medicine provides two years of neonatal-perinatal training to paediatricians.</p> <p>Applicant Types</p> <p>Funding Limit 0.00 not provided</p> <p>Limited Submission No</p>				

Other Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
012624	International Travel and Subsistence Grants	Houghton Trust		15-Jun-2022	Not Specified
	Contact Name	Dr. S. J. Baigent			
	Contact Telephone				
	Contact Email	sue.baigent@outlook.com			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	15-Jun-2022			
	Synopsis	Grants are awarded for the furtherance of study or research in avian diseases by attending/participating in relevant scientific meetings, visiting appropriate laboratories for discussions and learning specific techniques, or attending training courses. The scope of Avian Pathology journal defines the research areas for appropriate applications. Applicants who will give an oral/poster presentation will be considered more favourably.			
	Applicant Types				
	Funding Limit	0.00 see detail			
	Limited Submission	No			
109019	Incyte Ingenuity Awards	Incyte		24-Jun-2022	100,000 USD
	Contact Name				
	Contact Telephone				
	Contact Email	IncyteIngenuity@VOZAdvisors.com			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	24-Jun-2022			
	Synopsis	The Incyte Ingenuity Awards aim to support the graft-versus-host disease (GVHD) community by funding two novel initiatives that address challenges faced by GVHD patients, caregivers, and healthcare providers.			
	Applicant Types				
	Funding Limit	100,000.00 maximum			
	Limited Submission	Yes			

Other Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
058306	Operating Grants	International Organization For the Study of Inflammatory Bowel Disease		30-Jun-2022	275,000 USD
	Contact Name	Marischka Konings			
	Contact Telephone	+31 35 5426745			
	Contact Email	ioibd@mkproducties.nl			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	30-Jun-2022			
	Synopsis	The International Organization For the Study of Inflammatory Bowel Disease (IOIBD) offers Operating Grants of up to €250,000 for one year, preferably equally divided between Clinical and Basic Science Projects. Preference will be given to grants less than or equal to €50,000.			
	Applicant Types				
	Funding Limit	250,000.00 maximum			
	Limited Submission	Yes			
009045	Ernst H. Bárány Prize	International Society for Eye Research		01-Jun-2022	Not Specified
	Contact Name				
	Contact Telephone	415-561-8569			
	Contact Email	mail@iser.org			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	01-Jun-2022			
	Synopsis	The Ernst H. Bárány Prize is awarded to a distinguished scientist who has made outstanding contributions in research that increases our understanding of ocular pharmacology directly related to or applicable to glaucoma, diabetic retinopathy, macular degeneration, or related retinal diseases.			
	Applicant Types				
	Funding Limit	0.00 not provided			

Other Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Limited Submission	No			
061954	Asia Pacific Chapter Scholarship	International Society for Peritoneal Dialysis		30-Jun-2022	3,000 USD
	Contact Name	Professor CC Szeto			
	Contact Telephone				
	Contact Email	ccszeto@cuhk.edu.hk			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	30-Jun-2022 , 31-Dec-2022			
	Synopsis	Asia Pacific Chapter Scholarships promote PD awareness, knowledge and expertise by visiting a centre of excellence for 2-3 months. It is intended primarily for nephrologists and renal nurses in the Asia Pacific region, especially in the developing countries. The ISPD APC aims to offer up to two fellowship grants per semester. The total maximum per individual cannot exceed US\$3,000.			
	Applicant Types				
	Funding Limit	3,000.00 maximum			
	Limited Submission	No			
024383	Scholarship Program	International Team for Implantology (ITI)		30-Jun-2022	21,600 USD
	Contact Name	Anna Häuptli			
	Contact Telephone	+41 (0) 61 270 83 83			
	Contact Email	scholarship@iti.org			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	30-Jun-2022			
	Synopsis	The International Team for Implantology (ITI) offers a post-graduate program for young clinicians to gain international experience in implant dentistry. The program allows ITI Scholars to gain insight into case planning, implant surgery and prosthetic restorations and, in most ITI Scholarship Centers, also into research and teaching.			
	Applicant Types				
	Funding Limit	20,000.00 see detail			

Other Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Limited Submission	No			
110041	DOROTHY COFUND -- Develop Interdisciplinary Approaches to Health Crises Collaboratively	Irish Research Council		23-May-2022	Not Specified
	Contact Name				
	Contact Telephone				
	Contact Email	dorothy@research.ie			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	23-May-2022 , 07-Jun-2022			
	Synopsis	DOROTHY is a postdoctoral research programme open to researchers from all disciplines who wish to focus on research into public health crises. DOROTHY is open to applicants from all nationalities and disciplines, provided that their research topic relates to public health crises. Research areas will include, but will not be limited to, epidemiology, engineering of materials, health psychology, health economics, social history, medical and health humanities, and philosophy.			
	Applicant Types				
	Funding Limit	0.00 see detail			
	Limited Submission	No			
024717	Strategic Research Agreements: Multi Project	Juvenile Diabetes Research Foundation International		03-May-2022 [LOI/Pre-App]	Not Specified
	Contact Name				
	Contact Telephone	800-533-2873			
	Contact Email	preawardsupport@jdrf.org			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	03-May-2022 [LOI/Pre-App], 17-Jun-2022 [LOI/Pre-App]			
	Synopsis	JDRF's Strategic Research Agreements provide research funding for single or multiple investigators to address critical gaps and challenges and potential breakthroughs in Type 1 diabetes research. The JDRF Strategic Research Agreement for multiple projects provides a mechanism to stimulate new collaborations between clinical and basic scientists and/or between scientists from diverse backgrounds as a means to conceive and develop new approaches to major challenges, potential			

Other Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Applicant Types</p> <p>Funding Limit</p> <p>Limited Submission</p>	<p>breakthroughs, or persistent obstacles to progress along the various paths to prevent, treat or cure Type 1 diabetes and its complications.</p> <p>0.00 not provided</p> <p>No</p>			
061435	Research Grants	LEO Foundation		21-Jun-2022	Not Specified
	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email</p> <p>Sponsor Website</p> <p>Program URL</p> <p>Deadline Dates (ALL)</p> <p>Synopsis</p> <p>Applicant Types</p> <p>Funding Limit</p> <p>Limited Submission</p>	<p>+ 45 32 72 51 10</p> <p>applications@leo-foundation.org</p> <p>Link to sponsor website</p> <p>Link to program URL</p> <p>21-Jun-2022 , 04-Sep-2022</p> <p>LEO Foundation open competition grants are given to support the best dermatology research projects worldwide.</p> <p></p> <p>0.00 not provided</p> <p>No</p>			
036282	LEO Foundation Awards	LEO Foundation		21-Jun-2022	100,000 USD
	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email</p> <p>Sponsor Website</p> <p>Program URL</p> <p>Deadline Dates (ALL)</p> <p>Synopsis</p>	<p>+ 45 32 72 51 10</p> <p>applications@leo-foundation.org</p> <p>Link to sponsor website</p> <p>Link to program URL</p> <p>21-Jun-2022 , 04-Sep-2022</p> <p>The LEO Foundation Awards constitute a global recognition and are given annually to outstanding young scientists whose work represent extraordinary contributions to dermatology research. There will be three awards of 100.000 USD, one in each of the Americas, EMEA (Europe/Middle East/Africa) and Asia-Pacific regions.</p>			

Other Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Applicant Types Funding Limit 100,000.00 maximum Limited Submission No				
002595	Distinguished Innovator Award (DIA)	Lupus Research Alliance		15-Jun-2022	1,000,000 USD
	Contact Name Dr. Hoang Nguyen, Senior Scientific Program Manager Contact Telephone -646-884-6000 Contact Email hnguyen@lupusresearch.org Sponsor Website Link to sponsor website Program URL Link to program URL Deadline Dates (ALL) 15-Jun-2022 Synopsis The Distinguished Innovator Award provides outstanding scientists with substantial support to conduct highly innovative research into the fundamental causes of systemic lupus erythematosus and so provide new directions towards a cure. Applications from investigators from diverse disciplines are encouraged. The award provides \$1.0 million over four years. Applicant Types Funding Limit 250,000.00 per year Limited Submission No				
108503	New Program	Mathers (G.Harold and Leila Y.) Foundation		15-Apr-2022 [LOI/Pre-App]	Not Specified
	Contact Name Contact Telephone Contact Email support@mathersfoundation.org Sponsor Website Link to sponsor website Program URL Deadline Dates (ALL) 15-Apr-2022 [LOI/Pre-App], 30-Jun-2022 Synopsis The mission of The G. Harold and Leila Y. Mathers Foundation is to advance knowledge in the life sciences by sponsoring				

Other Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Applicant Types</p> <p>Funding Limit</p> <p>Limited Submission</p>	<p>scientific research that will benefit mankind. Basic scientific research, with potential translational application, is central to this goal, and fundamental to the Foundation's operating principles.</p> <p>0.00 not provided</p> <p>Yes</p>			
022414	Fellowship Program	Matsumae International Foundation		20-Jun-2022	Not Specified
	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email</p> <p>Sponsor Website</p> <p>Program URL</p> <p>Deadline Dates (ALL)</p> <p>Synopsis</p> <p>Applicant Types</p> <p>Funding Limit</p> <p>Limited Submission</p>	<p>contact@mif-japan.org</p> <p>Link to sponsor website</p> <p>Link to program URL</p> <p>20-Jun-2022</p> <p>The Matsumae International Foundation offers fellowships of three to six months in duration to doctorate degree holders who have never been to Japan.</p> <p>0.00 see detail</p> <p>No</p>			
067186	Pediatric Dermatology Fellowship (Minnesota)	Mayo Clinic College of Medicine and Science		30-Jun-2022	Not Specified
	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email</p> <p>Sponsor Website</p> <p>Program URL</p> <p>Deadline Dates (ALL)</p> <p>Synopsis</p>	<p>Kelly J. Ihrke</p> <p>507-284-3736</p> <p>mayodermfellows@mayo.edu</p> <p>Link to sponsor website</p> <p>Link to program URL</p> <p>30-Jun-2022</p> <p>Mayo Clinic in Rochester, Minnesota, offers a one-year Pediatric Dermatology Fellowship that focuses on advanced care of</p>			

Other Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Applicant Types	infants and children with severe skin disease. During this fellowship, fellows will work with Mayo Clinic staff members and residents in clinical, laboratory and procedural dermatology, as well as colleagues in plastic surgery, rheumatology, ophthalmology and other departments.			
	Funding Limit	0.00 see detail			
	Limited Submission	No			
061247	Merck MISP Clostridium Difficile Grant	Merck		11-Jun-2022	Not Specified
	Contact Name	Boski Patel			
	Contact Telephone	267-305-3173			
	Contact Email	boski_patel@msd.com			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	11-Jun-2022			
	Synopsis	The Investigator Studies Program aims to advance science and improve patient care by supporting, through the provision of drug/vaccine and/or total/partial funding, high-quality research that is initiated, designed, implemented and sponsored by external investigators. Results will be generated and properly disseminated in peer-reviewed publications.			
	Applicant Types				
	Funding Limit	0.00 not provided			
	Limited Submission	No			
058805	Investigator Studies Program (MISP) -- Surgery -- Anesthesia	Merck		01-May-2022 [LOI/Pre-App]	Not Specified
	Contact Name	Lisa Mount			
	Contact Telephone	267-305-1258			
	Contact Email	lisa_mount@merck.com			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			

Other Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Deadline Dates (ALL) 01-May-2022 [LOI/Pre-App], 18-Jun-2022 , 01-Sep-2022 [LOI/Pre-App], 19-Oct-2022</p> <p>Synopsis The Investigator Studies Program aims to advance science and improve patient care by supporting, through the provision of drug/vaccine and/or total/partial funding, high-quality research that is initiated, designed, implemented and sponsored by external investigators. Results will be generated and properly disseminated in peer-reviewed publications.</p> <p>Applicant Types</p> <p>Funding Limit 0.00 not provided</p> <p>Limited Submission No</p>				
109786	Request for Proposals--Study of Subvalvular Aortic Stenosis (SAS) in the Newfoundland Dog Breed	Morris Animal Foundation		03-Jun-2022	50,000 USD
	<p>Contact Name</p> <p>Contact Telephone 800-243-2345</p> <p>Contact Email grantapplications@morrisanimalfoundation.org</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 03-Jun-2022</p> <p>Synopsis The sponsor is accepting proposals for the study of subvalvular aortic stenosis (SAS) in the Newfoundland dog breed. One or more of the following areas must be addressed: Genetic studies - these may include comparison of Newfoundlands with other breeds that have high or low prevalence of this disease. Functional studies are particularly welcome. Epidemiological studies of Newfoundlands diagnosed in secondary (rather than tertiary) referral centers by board-certified cardiologists. Necropsy investigations of Newfoundlands with or without SAS lesions, that were previously examined using echocardiography.</p> <p>Applicant Types</p> <p>Funding Limit 50,000.00 maximum</p> <p>Limited Submission No</p>				
097011	Research Fellow Award	Multiple Myeloma Research Foundation		24-Jun-2022	75,000 USD
	<p>Contact Name Mark Hamilton, PhD</p> <p>Contact Telephone 203-652-0233</p> <p>Contact Email hamiltonm@themmrf.org</p>				

Other Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 24-Jun-2022</p> <p>Synopsis The Multiple Myeloma Research Foundation (MMRF) seeks proposals for the MMRF 2022 Research Fellowship Program, an initiative supporting early career researchers at the post-doctorate, medical fellow, or junior faculty levels currently active or interested in research in multiple myeloma. Investigators may request up to \$75,000 total costs, including up to 10% indirect costs, per year for a two (2) year period (total award is \$150,000).</p> <p>Applicant Types</p> <p>Funding Limit 75,000.00 maximum</p> <p>Limited Submission No</p>				
067593	Pilot Project Grants	Myositis Association		16-May-2022 [LOI/Pre-App]	100,000 USD
	<p>Contact Name Chrissy Thornton</p> <p>Contact Telephone 703-553-2631</p> <p>Contact Email chrissy@myositis.org</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 16-May-2022 [LOI/Pre-App], 30-Jun-2022</p> <p>Synopsis Pilot Grants are designed to fund new and innovative research projects in the hope that they will attract funding from other sources (such as NIH). A competitive application will clearly delineate how this pilot funding will lead to future grant support. In addition, a competitive application will clearly distinguish itself from the investigator's existing research program. Any industry partnership must be clearly disclosed and a letter of support from the industry partner must be included. Pilot grants will be awarded for one or two years and up to a maximum of \$100,000 annually, subject to satisfactory progress.</p> <p>Applicant Types</p> <p>Funding Limit 100,000.00 maximum</p> <p>Limited Submission No</p>				
067591	Research Fellowships	Myositis Association		16-May-2022 [LOI/Pre-App]	100,000 USD

Other Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Name Chrissy Thornton</p> <p>Contact Telephone 703-553-2631</p> <p>Contact Email Chrissy@myositis.org</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 16-May-2022 [LOI/Pre-App], 30-Jun-2022</p> <p>Synopsis Mentored Research Fellowships are designed to help promising junior investigators (MDs and PhDs) for a period of two years, subject to satisfactory progress, at the salary level approved by the participating institution, to a maximum received annually of \$50,000. Candidates should have completed residency or fellowship training or have received a PhD within the three years prior to commencing the Fellowship and be performing research under the supervision of an established mentor. Recipients must devote at least 50% of their time to research, but may include some study and clinical experience in allied fields. There should be limited supplementation of salary from outside sources.</p> <p>Applicant Types </p> <p>Funding Limit 50,000.00 per year</p> <p>Limited Submission No</p>				
004820	Research Grants (Temporarily Suspended)	National Headache Foundation		30-Jun-2022	Not Specified
	<p>Contact Name Dr. Timothy R. Smith, Research Committee Chair</p> <p>Contact Telephone 312-274-2650</p> <p>Contact Email tsmith@studymetrix.com</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL </p> <p>Deadline Dates (ALL) 30-Jun-2022 , 30-Sep-2022 , 31-Dec-2022</p> <p>Synopsis The National Headache Foundation supports research in the field of headache and pain as part of its mission, which also includes offering education and information to people living with migraine disease and headache disorders.</p> <p>Applicant Types </p> <p>Funding Limit 0.00 see detail</p> <p>Limited Submission No</p>				

Other Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
075992	Peter G. Pentchev Niemann-Pick Type C Research Fellowship	National Niemann-Pick Disease Foundation, Inc.		01-Jun-2022	Not Specified
	Contact Name Joslyn Crowe, NNPfD Executive Director Contact Telephone 877-287-3672 Contact Email nnpdf@nnpdf.org Sponsor Website Link to sponsor website Program URL Link to program URL Deadline Dates (ALL) 01-Jun-2022 Synopsis The National Niemann-Pick Disease Foundation (NNPDF) invites applications for research fellowships examining the biology of Niemann-Pick Type C (NPC), a lethal neuro-degenerative disease for which there are no effective therapies. Applicant Types Funding Limit 0.00 see detail Limited Submission No				
078566	Research Grants Program	National Rosacea Society		17-Jun-2022	15,000 USD
	Contact Name Contact Telephone 847-382-8971 Contact Email info@rosacea.org Sponsor Website Link to sponsor website Program URL Link to program URL Deadline Dates (ALL) 17-Jun-2022 Synopsis The National Rosacea Society awards grants of up to \$15,000, or higher in special cases, for research on rosacea. Applicant Types Funding Limit 15,000.00 see detail Limited Submission No				
045773	Predoctoral and Postdoctoral Fellowships in Spinal Cord Injury Research	New York State Department of Health	RFA # 18591	01-Jun-2022	Not Specified

Other Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Name David Googins</p> <p>Contact Telephone 518-474-7002</p> <p>Contact Email scirb@health.ny.gov</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 01-Jun-2022</p> <p>Synopsis The New York State Department of Health and the Spinal Cord Injury Research Board (SCIRB) are accepting applications from not-for-profit organizations and governmental organization in New York State. They will provide funding for predoctoral and postdoctoral fellowships. Approximately \$1.5 million will be available for this request for applications (RFA) to fund approximately six to ten training (pre- or post- doctoral) awards. Eligible organizations are invited to submit applications for predoctoral fellowships with total annual costs of up to \$51,000 per year or postdoctoral fellowships with total annual costs of up to \$80,000 per year. Each will be a two year awards.</p> <p>Applicant Types </p> <p>Funding Limit 0.00 see detail</p> <p>Limited Submission No</p>				
021106	Research Grants	Oncology Nursing Society Foundation		08-May-2022 [LOI/Pre-App]	50,000 USD
	<p>Contact Name </p> <p>Contact Telephone 866-257-4667</p> <p>Contact Email info@onfgivesback.org</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 08-May-2022 [LOI/Pre-App], 30-Jun-2022</p> <p>Synopsis Oncology Nursing Society Foundation offers General Research grants for emerging to mid-career oncology nurse researchers who have not previously received and completed at least one research study with a funding level of \$50,000 as the study PI.</p> <p>Applicant Types </p> <p>Funding Limit 50,000.00 maximum</p> <p>Limited Submission No</p>				

Other Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
083547	Collaborative Research Development Grant	Ovarian Cancer Research Alliance		07-Apr-2022 [LOI/Pre-App]	900,000 USD
	Contact Name	Sarah DeFeo			
	Contact Telephone	212-268-1002			
	Contact Email	grants@ocrf.org			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	07-Apr-2022 [LOI/Pre-App], 22-Jun-2022			
	Synopsis	Ovarian Cancer Research Alliance is requesting Letters of Intent for the 2022 Collaborative Research Development Grant. The purpose of this grantmaking program is to provide funds for ovarian cancer research projects that may involve several investigators within one institution or collaborations between groups in multiple institutions. Interdisciplinary collaborations are encouraged.			
	Applicant Types				
	Funding Limit	300,000.00 per year			
	Limited Submission	No			
078435	Early Career Investigator Grant	Ovarian Cancer Research Alliance		07-Apr-2022 [LOI/Pre-App]	450,000 USD
	Contact Name	Kristin McGowan			
	Contact Telephone	212-268-1002			
	Contact Email	grants@ocrahope.org			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	07-Apr-2022 [LOI/Pre-App], 22-Jun-2022			
	Synopsis	Ovarian Cancer Research Alliance is requesting Letters of Intent for the 2023 Early Career Investigator Grant (formerly called the Liz Tilberis Early Career Award). The Early Career Investigator Grant is for junior faculty with a strong commitment to an investigative career in the field of ovarian cancer research. The intent of these grants is to support a substantial time commitment to research and academic endeavors in ovarian cancer.			
	Applicant Types				

Other Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Funding Limit	150,000.00 per year			
	Limited Submission	No			
089503	Designated Grant Program	Pediatric Cancer Research Foundation		01-Jun-2022	Not Specified
	Contact Name				
	Contact Telephone	949-859-6312			
	Contact Email	info@pcrf-kids.org			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	01-Jun-2022			
	Synopsis	Donor Designated Grant Programs fund projects in communities or regions local to the specific donor or fundraising activity. Grants can be for any specific amount as designated by the donor or contributing organization.			
	Applicant Types				
	Funding Limit	0.00 see detail			
	Limited Submission	No			
089498	Emerging Investigator Fellowship Grant	Pediatric Cancer Research Foundation		01-Jun-2022	50,000 USD
	Contact Name				
	Contact Telephone	949-859-6312			
	Contact Email	info@pcrf-kids.org			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	01-Jun-2022			
	Synopsis	Emerging Investigator Fellowship Grants are designed to support Post-Doctoral Fellowships and Clinical Investigator training for emerging pediatric cancer researchers to pursue exciting research ideas.			
	Applicant Types				
	Funding Limit	50,000.00 per year			
	Limited Submission	No			

Other Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
089495	Basic Research Science Grant	Pediatric Cancer Research Foundation		01-Jun-2022	750,000 USD
	Contact Name				
	Contact Telephone	949-859-6312			
	Contact Email	info@pcrf-kids.org			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	01-Jun-2022			
	Synopsis	Basic Science Research Grants fund basic science, translational and/or clinical state of the art pediatric cancer research initiatives. Funding is up to \$250,000 per year, for up to 3 years.			
	Applicant Types				
	Funding Limit	250,000.00 per year			
	Limited Submission	No			
089497	Translational Research Grant	Pediatric Cancer Research Foundation		01-Jun-2022	200,000 USD
	Contact Name				
	Contact Telephone	949-859-6312			
	Contact Email	info@pcrf-kids.org			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	01-Jun-2022			
	Synopsis	Translational Research Grants fund new research protocols and therapies that hold promise for improved outcomes and accelerates cures from the laboratory bench to the bedside of children and teens with highrisk cancers. Funding is up to \$100,00 per year, for up to 2 years.			
	Applicant Types				
	Funding Limit	100,000.00 per year			
	Limited Submission	No			
109506	Competitive Grant Program: Transthyretin Cardiac Amyloidosis Fellowship - United States	Pfizer Pharmaceuticals		15-Jun-2022	80,000 USD

Other Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Name Amanda Stein, Grant Officer</p> <p>Contact Telephone </p> <p>Contact Email amanda.j.stein@pfizer.com</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 15-Jun-2022</p> <p>Synopsis Pfizer is issuing this Request for Proposals (RFP) to support institutions with fellowship programs for Cardiologists that have a strong focus on clinical practice, research, and education to further the understanding of transthyretin cardiac amyloidosis. Grant funding is available to support one fellow for up to a year at \$80,000.</p> <p>Applicant Types </p> <p>Funding Limit 80,000.00 maximum</p> <p>Limited Submission No</p>				
110048	Competitive Grant Program: Acromegaly Research- United States	Pfizer Pharmaceuticals		30-Jun-2022	100,000 USD
	<p>Contact Name Amanda Stein, Grant Officer</p> <p>Contact Telephone </p> <p>Contact Email amanda.j.stein@pfizer.com</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 30-Jun-2022</p> <p>Synopsis Pfizer is issuing this Request for Proposals (RFP) for projects involving acromegaly research in the United States. Individual projects requesting up to \$100,000 will be considered.</p> <p>Applicant Types </p> <p>Funding Limit 100,000.00 maximum</p> <p>Limited Submission No</p>				
070888	RPB Stein Innovation Awards	Research to Prevent Blindness		15-Jun-2022 [LOI/Pre-App]	300,000 USD

Other Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Name Pattie Moran</p> <p>Contact Telephone 646-892-9566</p> <p>Contact Email pmoran@rpbusa.org</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 15-Jun-2022 [LOI/Pre-App], 01-Jul-2022</p> <p>Synopsis The RPB Stein Innovation (SI) Awards provide funds to two groups of researchers, both with a common goal of understanding the visual system and the diseases that compromise its function. These SI Awards are intended to provide seed money to proposed high-risk/high-gain vision science research which is innovative, cutting-edge, and demonstrates out-of-the-box thinking.</p> <p>Applicant Types </p> <p>Funding Limit 300,000.00 maximum</p> <p>Limited Submission No</p>				
006942	Career Development Awards		Research to Prevent Blindness	15-Jun-2022 [LOI/Pre-App]	350,000 USD
	<p>Contact Name Pattie Moran, Director of Grants Administration</p> <p>Contact Telephone 646-892-9566</p> <p>Contact Email pmoran@rpbusa.org</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 15-Jun-2022 [LOI/Pre-App], 01-Jul-2022</p> <p>Synopsis The RPB Career Development Award helps RPB-supported ophthalmology chairs support promising junior ophthalmology faculty who have demonstrated their potential for independent research. The \$350,000 grant is payable for up to four years upon approval of a 20-month substantive progress report.</p> <p>Applicant Types </p> <p>Funding Limit 350,000.00 maximum</p> <p>Limited Submission No</p>				

Other Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
001730	Physician and Public Awareness Proposals	ResMed Foundation		15-Jun-2022	Not Specified
	<p>Contact Name Kristi Burlingame, Executive Director</p> <p>Contact Telephone 858-361-0755</p> <p>Contact Email kristib@resmedfoundation.org</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 15-Jun-2022 , 15-Dec-2022</p> <p>Synopsis The Foundation's goal in this funding category is to further the awareness and knowledge of the inherent dangers of untreated sleep disordered breathing, its symptoms, diagnosis and treatment with sleep specialists, primary care physicians, educators and the general public.</p> <p>Applicant Types </p> <p>Funding Limit 0.00 not provided</p> <p>Limited Submission No</p>				
002115	Investigator Award	Rheumatology Research Foundation		01-Jun-2022 [LOI/Pre-App]	375,000 USD
	<p>Contact Name </p> <p>Contact Telephone 404-365-1373</p> <p>Contact Email foundation@rheumatology.org</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 01-Jun-2022 [LOI/Pre-App], 01-Jul-2022</p> <p>Synopsis This award is intended to support junior investigators with a faculty appointment during the period that they are developing a project that will be competitive for NIH and/or equivalent funding. It is not intended to be a second postdoctoral fellowship. The purpose is to provide support for basic science, translational, and clinical investigators engaged in research relevant to the rheumatic diseases for the period between the completion of post-doctorate fellowship training and establishment as an independent investigator.</p> <p>Applicant Types </p>				

Other Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Funding Limit	375,000.00 maximum			
	Limited Submission	No			
000622	Scientist Development Award	Rheumatology Research Foundation		01-Jun-2022 [LOI/Pre-App]	Not Specified
	Contact Name				
	Contact Telephone	404-365-1373			
	Contact Email	foundation@rheumatology.org			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	01-Jun-2022 [LOI/Pre-App], 01-Jul-2022			
	Synopsis	This award is designed for individuals in the early stages of their career (typically Fellows) or those without significant prior research experience who plan to embark on careers in rheumatic diseases. The purpose of this award is to provide support for a structured research training program for rheumatologists or health professionals in the field of rheumatology.			
	Applicant Types				
	Funding Limit	0.00 see detail			
	Limited Submission	No			
095001	Innovative Research Award	Rheumatology Research Foundation		01-Jun-2022 [LOI/Pre-App]	400,000 USD
	Contact Name				
	Contact Telephone	404-365-1373			
	Contact Email	foundation@rheumatology.org			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	01-Jun-2022 [LOI/Pre-App], 01-Jul-2022			
	Synopsis	The Innovative Research Award provides essential support for innovative studies focused on generating new insights into the cause, progression, treatment, and outcomes of rheumatic and musculoskeletal diseases. The award amount is up to \$400,000 for two years (maximum \$200,000 per year).			

Other Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Applicant Types Funding Limit 400,000.00 maximum Limited Submission No				
039276	Research Professorship	Royal Society		09-Jun-2022	Not Specified
	Contact Name Contact Telephone +44 (0) 20 7451 2263 Contact Email seniorfellowships@royalsociety.org Sponsor Website Link to sponsor website Program URL Link to program URL Deadline Dates (ALL) 09-Jun-2022 Synopsis Royal Society Research Professorships provide long term support for world-class researchers of outstanding achievement and promise. The aim of this scheme is to release the best leading researchers from teaching and administration allowing them to focus on research. Applicant Types Funding Limit 0.00 see detail Limited Submission No				
027718	International Exchanges Scheme	Royal Society		15-Jun-2022	15,720 USD
	Contact Name Contact Telephone +44(0) 20 7451 2557 Contact Email international.exchanges@royalsociety.org Sponsor Website Link to sponsor website Program URL Link to program URL Deadline Dates (ALL) 15-Jun-2022 , 28-Sep-2022 Synopsis These schemes are for scientists based in the UK who want to stimulate collaborations with leading scientists overseas through either a one-off visit or bilateral travel. Applicant Types				

Other Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Funding Limit	12,000.00 maximum			
	Limited Submission	No			
071837	Research Grants	SENS Research Foundation		25-Jun-2022	Not Specified
	Contact Name				
	Contact Telephone	650-336-1780			
	Contact Email	foundation@sens.org			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	25-Jun-2022 , 23-Sep-2022 , 01-Nov-2022			
	Synopsis	SRF is uniquely focused on a damage repair approach to treating the diseases of aging. This approach has amazing potential to positively affect the human condition by giving people interventions and treatments that yield more years of healthy, productive life.			
	Applicant Types				
	Funding Limit	0.00 not provided			
	Limited Submission	No			
095262	Humanitarian Award	Society for Industrial & Organizational Psychology		01-Jun-2022	1,500 USD
	Contact Name				
	Contact Telephone	419-353-0032			
	Contact Email	SIOP@siop.org			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	01-Jun-2022			
	Synopsis	The SIOP Humanitarian Award is given for sustained, significant, and outstanding humanitarian contributions related to I-O psychology. The recipient of the award is given a plaque and a cash prize of \$1,500 (or a donation of the same amount donated to the charity/foundation of the recipient's choice).			
	Applicant Types				

Other Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Funding Limit	1,500.00 see detail			
	Limited Submission	No			
016255	SOPHE/CDC Student Fellowship in Injury Prevention	Society for Public Health Education		01-Jun-2022	2,000 USD
	Contact Name				
	Contact Telephone	202-408-9804			
	Contact Email	info@sophe.org			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	01-Jun-2022			
	Synopsis	The SOPHE/CDC Student Fellowship in Injury Prevention recognizes, assists and trains students working on research or practice-based projects in either unintentional injury prevention or violence prevention from the perspective of health education or the behavioral sciences.			
	Applicant Types				
	Funding Limit	2,000.00 see detail			
	Limited Submission	No			
040849	Research Grant	Society for the Advancement of Blood Management		01-Jun-2022	25,000 USD
	Contact Name	Steven Frank			
	Contact Telephone	928-551-6400			
	Contact Email	sfrank3@jhmi.edu			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	01-Jun-2022			
	Synopsis	The SABM Research Grant, supported by SABM and an education grant from HemoSonics LLC, is intended to advance the field of patient blood management by supporting a young investigator who intends to study methods of promoting blood conservation. This one-year grant provides starter funding to further scientific inquiry and clinical knowledge in the field of patient blood management. Preference will be given to junior faculty who will be advised by an experienced mentor. It is			

Other Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Applicant Types</p> <p>Funding Limit</p> <p>Limited Submission</p>	<p>anticipated that the funded study will generate results that can be used as pilot data or preliminary findings to support future grant applications focused on methods to improve blood management and to promote blood conservation. It is expected that all applicants will be members of SABM, or will become members of SABM for at least one year.</p> <p>25,000.00 maximum</p> <p>No</p>			
066849	Mentored Clinical Scientist Research Career Development Award (K08)	Society for Vascular Surgery		12-Jun-2022	Not Specified
	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email</p> <p>Sponsor Website</p> <p>Program URL</p> <p>Deadline Dates (ALL)</p> <p>Synopsis</p> <p>Applicant Types</p> <p>Funding Limit</p> <p>Limited Submission</p>	<p>Jane D. Scott</p> <p>301-435-0535</p> <p>scottj2@nhlbi.nih.gov</p> <p>Link to sponsor website</p> <p>Link to program URL</p> <p>12-Jun-2022 , 12-Jul-2022 , 12-Oct-2022 , 12-Nov-2022</p> <p>The SVS Foundation offers this award in partnership with the NHLBI as a means to facilitate the research career development of individuals pursuing a career in vascular research. This award provides financial support over and above that offered by the NHLBI K08 mechanism.</p> <p></p> <p>0.00 see detail</p> <p>No</p>			
096603	Vilcek Prize for Creative Promise in Biomedical Science	Vilcek Foundation		10-Jun-2022	50,000 USD
	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email</p> <p>Sponsor Website</p> <p>Program URL</p> <p>Deadline Dates (ALL)</p>	<p></p> <p>212-472-2500</p> <p>info@vilcek.org</p> <p>Link to sponsor website</p> <p>Link to program URL</p> <p>10-Jun-2022</p>			

Other Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Synopsis The Vilcek Foundation will award three Creative Promise Prizes of \$50,000 each to young foreign-born biomedical scientists who demonstrate outstanding early achievement. Eligible work may be creative, independent research in basic, applied, and/or translational biomedical science.</p> <p>Applicant Types</p> <p>Funding Limit 50,000.00 see detail</p> <p>Limited Submission No</p>				
001134	Requests for Proposals in Leukemia Research	When Everyone Survives Foundation, Inc.		01-Jun-2022	50,000 USD
	<p>Contact Name</p> <p>Contact Telephone 770-595-3573</p> <p>Contact Email grants@wesfoundation.org</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 01-Jun-2022</p> <p>Synopsis This request for proposals (RFP) is offered by the When Everyone Survives Foundation (WES Leukemia Research Foundation) to solicit innovative research in leukemia. Grants of \$50,000 for one year are offered to new and established investigators who are requesting support for laboratory, translational, or clinical research related to acute leukemia.</p> <p>Applicant Types</p> <p>Funding Limit 50,000.00 maximum</p> <p>Limited Submission No</p>				

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
083145	APA Distinguished Scientific Awards for an Early Career Contribution to Psychology	American Psychological Association		01-Jun-2022	Not Specified
	Contact Name	Suzanne Wandersman			
	Contact Telephone	202-336-6000			
	Contact Email	swandersman@apa.org			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	01-Jun-2022			
	Synopsis	The American Psychological Association (APA) provides an award to recognize excellent psychologists who are at early stages of their research careers.			
	Applicant Types				
	Funding Limit	0.00 not provided			
	Limited Submission	No			
061954	Asia Pacific Chapter Scholarship	International Society for Peritoneal Dialysis		30-Jun-2022	3,000 USD
	Contact Name	Professor CC Szeto			
	Contact Telephone				
	Contact Email	ccszeto@cuhk.edu.hk			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	30-Jun-2022 , 31-Dec-2022			
	Synopsis	Asia Pacific Chapter Scholarships promote PD awareness, knowledge and expertise by visiting a centre of excellence for 2-3 months. It is intended primarily for nephrologists and renal nurses in the Asia Pacific region, especially in the			

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Applicant Types</p> <p>Funding Limit</p> <p>Limited Submission</p>	<p>developing countries. The ISPD APC aims to offer up to two fellowship grants per semester. The total maximum per individual cannot exceed US\$3,000.</p> <p>3,000.00 maximum</p> <p>No</p>			
035693	ASRM/NIH/Duke Clinical Research/Reproductive Scientist Training (CREST) Program	American Society for Reproductive Medicine		01-Jun-2022	Not Specified
	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email</p> <p>Sponsor Website</p> <p>Program URL</p> <p>Deadline Dates (ALL)</p> <p>Synopsis</p> <p>Applicant Types</p> <p>Funding Limit</p> <p>Limited Submission</p>	<p>202-863-4985</p> <p>nicole.goetz@cuanschutz.edu</p> <p>Link to sponsor website</p> <p>Link to program URL</p> <p>01-Jun-2022</p> <p>The CREST training program is offered by the NICHD, the Clinical Research Training Program (CRTP) at Duke University, and ASRM. This 2-year program meets an existing need for physicians in private or academic clinical practice to obtain formalized academic training in the quantitative and methodological principles of clinical research in reproductive medicine.</p> <p>0.00 not provided</p> <p>No</p>			
041313	Australian Aboriginal and Torres Strait Islander Awards	National Heart Foundation of Australia		17-Jun-2022	Not Specified
	<p>Contact Name</p>				

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

Contact Telephone	(03) 9321 1581
Contact Email	research@heartfoundation.org.au
Sponsor Website	Link to sponsor website
Program URL	Link to program URL
Deadline Dates (ALL)	17-Jun-2022
Synopsis	The Aboriginal and Torres Strait Islander Award is expected to produce tangible outcomes with the potential of creating high-impact change in the Aboriginal and Torres Strait Islander cardiovascular health research community.
Applicant Types	
Funding Limit	0.00 see detail
Limited Submission	No

080457	Award for Outstanding Doctoral Thesis Research in Biological Physics	American Physical Society	01-Jun-2022	Not Specified
--------	--	---------------------------	-------------	---------------

Contact Name	
Contact Telephone	301-209-3200
Contact Email	honors@aps.org
Sponsor Website	Link to sponsor website
Program URL	Link to program URL
Deadline Dates (ALL)	01-Jun-2022
Synopsis	The Award for Outstanding Doctoral Thesis Research in Biological Physics recognizes doctoral thesis research of outstanding quality and achievement in any area of experimental, computational, engineering, or theoretical Biological Physics, broadly construed, and to encourage effective written and oral presentation of research results.
Applicant Types	
Funding Limit	0.00 see detail

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Limited Submission	Yes			
103871	Barbara Fish Memorial Award	American College of Neuropsychopharmacology		23-Jun-2022	Not Specified
	Contact Name				
	Contact Telephone	615-324-2360			
	Contact Email	acnp@acnp.org			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	23-Jun-2022			
	Synopsis	The American College of Neuropsychopharmacology (ACNP) presents the Barbara Fish Memorial Award to an ACNP member who has made an outstanding contribution to basic, translational or clinical neuroscience. Award recipients will receive a monetary award and a plaque to be given at the ACNP Annual Meeting.			
	Applicant Types				
	Funding Limit	0.00 see detail			
	Limited Submission	No			
089495	Basic Research Science Grant	Pediatric Cancer Research Foundation		01-Jun-2022	750,000 USD
	Contact Name				
	Contact Telephone	949-859-6312			
	Contact Email	info@pcrf-kids.org			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	01-Jun-2022			

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Synopsis Basic Science Research Grants fund basic science, translational and/or clinical state of the art pediatric cancer research initiatives. Funding is up to \$250,000 per year, for up to 3 years.</p> <p>Applicant Types </p> <p>Funding Limit 250,000.00 per year</p> <p>Limited Submission No</p>				
109073	Better Methods, Better Research	Medical Research Council (MRC)		15-Jun-2022	818,750 USD
	<p>Contact Name Dr Rosalind Roberts, Programme Manager</p> <p>Contact Telephone </p> <p>Contact Email rosalind.roberts@mrc.ukri.org</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 15-Jun-2022</p> <p>Synopsis Researchers based at an organisation eligible for UKRI funding can apply for funding to improve the methods used by others in biomedical and health research. Projects must focus on an area within MRC or NIHR's remit.</p> <p>Applicant Types </p> <p>Funding Limit 625,000.00 maximum</p> <p>Limited Submission No</p>				
079625	Call for Proposals for Transnational Research Projects on Cerebrovascular Diseases	ERA-NET NEURON		28-Jun-2022	Not Specified
	<p>Contact Name Dr. Waed Khalek</p> <p>Contact Telephone +49 228 3821-1191</p> <p>Contact Email NeuronCalls@agencerecherche.fr</p>				

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	28-Jun-2022			
	Synopsis	The aim of this year's call is to facilitate multinational, collaborative research projects that will address important translational questions in the areas of stroke and other cerebrovascular diseases including small vessels disease (CSVD) and the dysfunction of brain barriers.			
	Applicant Types				
	Funding Limit	0.00 see detail			
	Limited Submission	No			
006942	Career Development Awards		Research to Prevent Blindness	15-Jun-2022 [LOI/Pre-App]	350,000 USD
	Contact Name	Pattie Moran, Director of Grants Administration			
	Contact Telephone	646-892-9566			
	Contact Email	pmoran@rpbusa.org			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	15-Jun-2022 [LOI/Pre-App], 01-Jul-2022			
	Synopsis	The RPB Career Development Award helps RPB-supported ophthalmology chairs support promising junior ophthalmology faculty who have demonstrated their potential for independent research. The \$350,000 grant is payable for up to four years upon approval of a 20-month substantive progress report.			
	Applicant Types				
	Funding Limit	350,000.00 maximum			
	Limited Submission	No			

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
104547	Career Transition Grants	American Society of Transplantation		01-Jun-2022	50,000 USD
	Contact Name				
	Contact Telephone	856-439-9986			
	Contact Email	research@myast.org			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	01-Jun-2022			
	Synopsis	The purpose of these grants is to promote the careers of mid-career independent investigators whose research relates to the field of solid organ transplantation (and/or immunology relating to solid organ transplant). The grants support the investigator's transition to an R-series or equivalent grant.			
	Applicant Types				
	Funding Limit	50,000.00 see detail			
	Limited Submission	No			
074665	Clinical Research Scholars Program Award	Cystic Fibrosis Foundation		01-Jun-2022	Not Specified
	Contact Name				
	Contact Telephone	301-841-2614			
	Contact Email	grants@cff.org			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	01-Jun-2022			
	Synopsis	The Cystic Fibrosis Clinical Research Scholars Program (CRSP) Award is designed to enable promising early-career physician scientists to enhance their clinical research proficiency and support their development of the necessary			

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>clinical research capabilities to become independent investigators who formulate and lead multi-center, clinical research studies.</p> <p>Applicant Types</p> <p>Funding Limit 0.00 see detail</p> <p>Limited Submission No</p>				
014129	Clinical Trial Award	Cancer Research UK		09-Jun-2022 [LOI/Pre-App]	Not Specified
	<p>Contact Name</p> <p>Contact Telephone 0203 469 8498</p> <p>Contact Email clinicalresearch@cancer.org.uk</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 09-Jun-2022 [LOI/Pre-App]</p> <p>Synopsis Clinical Trial Awards support interventional clinical trials of cancer treatment (including systemic treatment, radiotherapy and surgery) with the aim of improving outcome.</p> <p>Applicant Types</p> <p>Funding Limit 0.00 see detail</p> <p>Limited Submission No</p>				
083547	Collaborative Research Development Grant	Ovarian Cancer Research Alliance		07-Apr-2022 [LOI/Pre-App]	900,000 USD
	<p>Contact Name Sarah DeFeo</p> <p>Contact Telephone 212-268-1002</p> <p>Contact Email grants@ocrf.org</p>				

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	07-Apr-2022 [LOI/Pre-App], 22-Jun-2022			
	Synopsis	Ovarian Cancer Research Alliance is requesting Letters of Intent for the 2022 Collaborative Research Development Grant. The purpose of this grantmaking program is to provide funds for ovarian cancer research projects that may involve several investigators within one institution or collaborations between groups in multiple institutions. Interdisciplinary collaborations are encouraged.			
	Applicant Types				
	Funding Limit	300,000.00 per year			
	Limited Submission	No			

110048	Competitive Grant Program: Acromegaly Research- United States	Pfizer Pharmaceuticals		30-Jun-2022	100,000 USD
--------	---	------------------------	--	-------------	----------------

	Contact Name	Amanda Stein, Grant Officer			
	Contact Telephone				
	Contact Email	amanda.j.stein@pfizer.com			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	30-Jun-2022			
	Synopsis	Pfizer is issuing this Request for Proposals (RFP) for projects involving acromegaly research in the United States. Individual projects requesting up to \$100,000 will be considered.			
	Applicant Types				
	Funding Limit	100,000.00 maximum			
	Limited Submission	No			

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
110047	Competitive Grant Program: Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Research in Canada	Pfizer Pharmaceuticals		07-Jun-2022	100,000 USD
	Contact Name	Amanda Stein, Grant Officer			
	Contact Telephone				
	Contact Email	amanda.j.stein@pfizer.com			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	07-Jun-2022			
	Synopsis	Pfizer Global Medical Grants (GMG) is issuing this Request for Proposals (RFP) for research involving Transthyretin Amyloid Cardiomyopathy (ATTR-CM) in Canada. Individual projects requesting up to \$100,000 will be considered.			
	Applicant Types				
	Funding Limit	100,000.00 maximum			
	Limited Submission	No			
109506	Competitive Grant Program: Transthyretin Cardiac Amyloidosis Fellowship - United States	Pfizer Pharmaceuticals		15-Jun-2022	80,000 USD
	Contact Name	Amanda Stein, Grant Officer			
	Contact Telephone				
	Contact Email	amanda.j.stein@pfizer.com			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	15-Jun-2022			

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Synopsis Pfizer is issuing this Request for Proposals (RFP) to support institutions with fellowship programs for Cardiologists that have a strong focus on clinical practice, research, and education to further the understanding of transthyretin cardiac amyloidosis. Grant funding is available to support one fellow for up to a year at \$80,000.</p> <p>Applicant Types</p> <p>Funding Limit 80,000.00 maximum</p> <p>Limited Submission No</p>				
019022	Department of Urology - Endourology Fellowship at Northwestern	American Urological Association		02-Jun-2022	Not Specified
	<p>Contact Name Debra Caridi, Fellowship Coordinator</p> <p>Contact Telephone 516-520-1226</p> <p>Contact Email debra@endourologysociety.com</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 02-Jun-2022 , 20-Jun-2022</p> <p>Synopsis The Endourological Society facilitates one and two year clinical fellowships around the world. The training is focused on developing advanced knowledge, experience, and technical skills in endourologic and laparoscopic and/or robotic assisted surgery. Fellows also receive training in translational research, as an underlying goal is the training of future academicians and potential national and international leaders in their specialty.</p> <p>Applicant Types</p> <p>Funding Limit 0.00 not provided</p> <p>Limited Submission No</p>				
089503	Designated Grant Program	Pediatric Cancer Research Foundation		01-Jun-2022	Not Specified

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Name</p> <p>Contact Telephone 949-859-6312</p> <p>Contact Email info@pcrf-kids.org</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 01-Jun-2022</p> <p>Synopsis Donor Designated Grant Programs fund projects in communities or regions local to the specific donor or fundraising activity. Grants can be for any specific amount as designated by the donor or contributing organization.</p> <p>Applicant Types</p> <p>Funding Limit 0.00 see detail</p> <p>Limited Submission No</p>				

002595	Distinguished Innovator Award (DIA)	Lupus Research Alliance		15-Jun-2022	1,000,000 USD
--------	---	-------------------------	--	-------------	------------------

	<p>Contact Name Dr. Hoang Nguyen, Senior Scientific Program Manager</p> <p>Contact Telephone -646-884-6000</p> <p>Contact Email hnguyen@lupusresearch.org</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 15-Jun-2022</p> <p>Synopsis The Distinguished Innovator Award provides outstanding scientists with substantial support to conduct highly innovative research into the fundamental causes of systemic lupus erythematosus and so provide new directions towards a cure. Applications from investigators from diverse disciplines are encouraged. The award provides \$1.0 million over four years.</p>				
--	--	--	--	--	--

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Applicant Types Funding Limit 250,000.00 per year Limited Submission No				
110041	DOROTHY COFUND -- Develop Interdisciplinary Approaches to Health Crises Collaboratively	Irish Research Council		23-May-2022	Not Specified
	Contact Name Contact Telephone Contact Email dorothy@research.ie Sponsor Website Link to sponsor website Program URL Link to program URL Deadline Dates (ALL) 23-May-2022 , 07-Jun-2022 Synopsis DOROTHY is a postdoctoral research programme open to researchers from all disciplines who wish to focus on research into public health crises. DOROTHY is open to applicants from all nationalities and disciplines, provided that their research topic relates to public health crises. Research areas will include, but will not be limited to, epidemiology, engineering of materials, health psychology, health economics, social history, medical and health humanities, and philosophy. Applicant Types Funding Limit 0.00 see detail Limited Submission No				
110085	Early Career Fellowships	Multiple Sclerosis Society of G.B. and N. Ireland		07-Jun-2022	327,500 USD
	Contact Name Contact Telephone 020-8438-0822				

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Email researchnetwork@mssociety.org.uk</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-Jun-2022</p> <p>Synopsis Early Career Fellowships aim to attract and retain talented postdoctoral researchers who want to build a successful career in Multiple Sclerosis research. These grants provide a staged career structure and the opportunity to progress towards higher level appointments. Funding is up to £250,000.</p> <p>Applicant Types</p> <p>Funding Limit 250,000.00 maximum</p> <p>Limited Submission No</p>				
078435	Early Career Investigator Grant	Ovarian Cancer Research Alliance		07-Apr-2022 [LOI/Pre-App]	450,000 USD
	<p>Contact Name Kristin McGowan</p> <p>Contact Telephone 212-268-1002</p> <p>Contact Email grants@ocrahope.org</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-Apr-2022 [LOI/Pre-App], 22-Jun-2022</p> <p>Synopsis Ovarian Cancer Research Alliance is requesting Letters of Intent for the 2023 Early Career Investigator Grant (formerly called the Liz Tilberis Early Career Award). The Early Career Investigator Grant is for junior faculty with a strong commitment to an investigative career in the field of ovarian cancer research. The intent of these grants is to support a substantial time commitment to research and academic endeavors in ovarian cancer.</p> <p>Applicant Types</p> <p>Funding Limit 150,000.00 per year</p>				

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Limited Submission	No			
029516	Early Career Researcher Partnership Award	Diabetes Canada		17-Jun-2022	Not Specified
	Contact Name				
	Contact Telephone	416-363-3373			
	Contact Email	research@diabetes.ca			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	17-Jun-2022			
	Synopsis	Diabetes Canada established the Early Career Researcher Award (previously Young Scientist Award) in 1987 for the purpose of encouraging, by appropriate recognition, outstanding research conducted in Canada by young scientists in the field of diabetes. This award continues today with the support of research funding from Diabetes Canada and CIHR-INMD. The significance of the award and the distinguished recipient is recognized by a special lecture.			
	Applicant Types				
	Funding Limit	0.00 not provided			
	Limited Submission	No			
089498	Emerging Investigator Fellowship Grant	Pediatric Cancer Research Foundation		01-Jun-2022	50,000 USD
	Contact Name				
	Contact Telephone	949-859-6312			
	Contact Email	info@pcrf-kids.org			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	01-Jun-2022			

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Synopsis Emerging Investigator Fellowship Grants are designed to support Post-Doctoral Fellowships and Clinical Investigator training for emerging pediatric cancer researchers to pursue exciting research ideas.</p> <p>Applicant Types</p> <p>Funding Limit 50,000.00 per year</p> <p>Limited Submission No</p>				
063826	Endometriosis Millennium Fund	Royal College of Obstetricians and Gynaecologists		17-Jun-2022	6,550 USD
	<p>Contact Name</p> <p>Contact Telephone +44 20 7772 6200</p> <p>Contact Email awards@rcog.org.uk</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 17-Jun-2022</p> <p>Synopsis Available to RCOG Members and Trainees working in the British Isles, the RCOG is able to offer up to £5,000 in order to stimulate and encourage research (clinical or laboratory based) in the field of endometriosis.</p> <p>Applicant Types</p> <p>Funding Limit 5,000.00 maximum</p> <p>Limited Submission No</p>				
108209	Environmental Sustainability in Life Sciences and Medical Practice	Medical Research Council (MRC)		28-Jun-2022	131,000 USD
	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email</p>				

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	28-Jun-2022			
	Synopsis	Researchers can apply for funding to research environmental sustainability in life science and medical practice. Applications should: show how net zero carbon aspirations will be supported seek to improve MRC's understanding or provide practical solutions. MRC will fund 80% of the full economic cost up to £100,000. Projects will be funded for up to 12 months.			
	Applicant Types				
	Funding Limit	100,000.00 maximum			
	Limited Submission	No			
030970	Eppendorf & Science Prize for Neurobiology	Eppendorf AG		15-Jun-2022	25,000 USD
	Contact Name	Selection Committee for the Eppendorf & Science Prize for Neurobiology Science			
	Contact Telephone	+1 202326 6513			
	Contact Email	eppendorfsceinceprize@aaas.org			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	15-Jun-2022			
	Synopsis	The international Eppendorf & Science Prize for Neurobiology is awarded annually to one young scientist who is not older than 35 years for the most outstanding neurobiological research based on methods of molecular and cell biology conducted by him/her during the past three years. The prize consists of \$25,000.			
	Applicant Types				
	Funding Limit	25,000.00 see detail			
	Limited Submission	No			

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
009045	Ernst H. Bárány Prize	International Society for Eye Research		01-Jun-2022	Not Specified
	Contact Name Contact Telephone 415-561-8569 Contact Email mail@iser.org Sponsor Website Link to sponsor website Program URL Link to program URL Deadline Dates (ALL) 01-Jun-2022 Synopsis The Ernst H. Bárány Prize is awarded to a distinguished scientist who has made outstanding contributions in research that increases our understanding of ocular pharmacology directly related to or applicable to glaucoma, diabetic retinopathy, macular degeneration, or related retinal diseases. Applicant Types Funding Limit 0.00 not provided Limited Submission No				
032751	Eva King Killiam Research Award	American College of Neuropsychopharmacology		23-Jun-2022	Not Specified
	Contact Name Contact Telephone 615-324-2360 Contact Email acnp@acnp.org Sponsor Website Link to sponsor website Program URL Link to program URL Deadline Dates (ALL) 23-Jun-2022				

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Synopsis The American College of Neuropsychopharmacology (ACNP) presents the Eva King Killam Research Award to an early career researcher on the basis of outstanding translational research contributions to neuropsychopharmacology.</p> <p>Applicant Types </p> <p>Funding Limit 0.00 see detail</p> <p>Limited Submission No</p>				
068786	Forrest M. Bird, MD, PhD, ScD Lifetime Scientific Achievement Award	American Respiratory Care Foundation		01-Jun-2022	Not Specified
	<p>Contact Name Crystal Maldonado</p> <p>Contact Telephone 972-243-2272</p> <p>Contact Email </p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 01-Jun-2022</p> <p>Synopsis This award acknowledges outstanding individual scientific contributions in the area of respiratory care of cardiopulmonary disorders.</p> <p>Applicant Types </p> <p>Funding Limit 0.00 see detail</p> <p>Limited Submission No</p>				
096334	Frontiers of Knowledge Awards	BBVA Foundation		30-Jun-2022	440,000 USD
	<p>Contact Name </p> <p>Contact Telephone 94 487 52 52</p> <p>Contact Email awards-info@fbbva.es</p>				

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

Sponsor Website	Link to sponsor website
Program URL	Link to program URL
Deadline Dates (ALL)	30-Jun-2022
Synopsis	The BBVA Foundation Frontiers of Knowledge Awards recognize fundamental contributions in a broad array of areas of scientific knowledge, technology, humanities and artistic creation.
Applicant Types	
Funding Limit	400,000.00 see detail
Limited Submission	No

020223	Gavin and Ann Kellaway Medical Research Fellowship	Auckland Medical Research Foundation		29-Jun-2022	41,400 USD
--------	--	--------------------------------------	--	-------------	------------

Contact Name	
Contact Telephone	+64 9 923 1701
Contact Email	amrf@medicalresearch.org.nz
Sponsor Website	Link to sponsor website
Program URL	Link to program URL
Deadline Dates (ALL)	29-Jun-2022
Synopsis	The Gavin and Ann Kellaway Medical Research Fellowship supports senior medically qualified, or established medical research persons, who would gain value from further study abroad, or in furthering their research expertise and knowledge at an approved overseas research institution. SPECIAL INSTRUCTIONS FOR 2022 ROUND 1: The Auckland Medical Research Foundation will only accept applications for this grant type if the NZ government conditions are met for safe travel to or from the destination(s) identified in the application. For information, please refer to https://covid19.govt.nz/travel/ For category 2, applicants must provide evidence from their host institution that they allow travel to the destination requested in their application. The AMRF will not be responsible for any costs

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Applicant Types</p> <p>Funding Limit</p> <p>Limited Submission</p>	<p>associated with the recipient being stranded or having to quarantine in any situation, whether or not it was an approved destination when the application was submitted.</p> <p>20,000.00 per month</p> <p>No</p>			

109124	Global Alliance for Chronic Diseases (GACD): A Life Course Approach to Common Non- Communicable Disease Risk Factor Prevention and Reduction Funding	National Health and Medical Research Council	GO5443	02-Jun-2022	Not Specified
--------	--	--	--------	-------------	---------------

	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email</p> <p>Sponsor Website</p> <p>Program URL</p> <p>Deadline Dates (ALL)</p> <p>Synopsis</p> <p>Applicant Types</p> <p>Funding Limit</p> <p>Limited Submission</p>	<p>help@nhmrc.gov.au</p> <p>Link to sponsor website</p> <p>Link to program URL</p> <p>02-Jun-2022</p> <p>NHMRC invites applications from Australian researchers under the GACD Common Risk Factors Call 2022. This grant opportunity will support implementation research proposals that take a life course approach to reducing the risks for non-communicable diseases (NCDs) in low- and middle-income countries (LMICs) and/or in disadvantaged populations in high-income countries (HICs).</p> <p>0.00 see detail</p> <p>No</p>			
--	---	--	--	--	--

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount																				
082337	Grants Program	Pacific Power Foundation		15-Jun-2022	Not Specified																				
<table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 25%; padding: 5px;">Contact Name</td> <td style="padding: 5px;">Tarie Hansen, Foundation Grants Administrator</td> </tr> <tr> <td style="padding: 5px;">Contact Telephone</td> <td style="padding: 5px;">503-813-7257</td> </tr> <tr> <td style="padding: 5px;">Contact Email</td> <td style="padding: 5px;">pacificorpfoundation@pacificorp.com</td> </tr> <tr> <td style="padding: 5px;">Sponsor Website</td> <td style="padding: 5px;">Link to sponsor website</td> </tr> <tr> <td style="padding: 5px;">Program URL</td> <td style="padding: 5px;">Link to program URL</td> </tr> <tr> <td style="padding: 5px;">Deadline Dates (ALL)</td> <td style="padding: 5px;">15-Jun-2022 , 15-Sep-2022 , 15-Dec-2022</td> </tr> <tr> <td style="padding: 5px;">Synopsis</td> <td style="padding: 5px;">The Pacific Power Foundation awards grants to nonprofit organizations in the categories of education/STEM; community enhancement; culture and arts; and safety and wellness.</td> </tr> <tr> <td style="padding: 5px;">Applicant Types</td> <td style="padding: 5px;"></td> </tr> <tr> <td style="padding: 5px;">Funding Limit</td> <td style="padding: 5px;">0.00 see detail</td> </tr> <tr> <td style="padding: 5px;">Limited Submission</td> <td style="padding: 5px;">No</td> </tr> </table>						Contact Name	Tarie Hansen, Foundation Grants Administrator	Contact Telephone	503-813-7257	Contact Email	pacificorpfoundation@pacificorp.com	Sponsor Website	Link to sponsor website	Program URL	Link to program URL	Deadline Dates (ALL)	15-Jun-2022 , 15-Sep-2022 , 15-Dec-2022	Synopsis	The Pacific Power Foundation awards grants to nonprofit organizations in the categories of education/STEM; community enhancement; culture and arts; and safety and wellness.	Applicant Types		Funding Limit	0.00 see detail	Limited Submission	No
Contact Name	Tarie Hansen, Foundation Grants Administrator																								
Contact Telephone	503-813-7257																								
Contact Email	pacificorpfoundation@pacificorp.com																								
Sponsor Website	Link to sponsor website																								
Program URL	Link to program URL																								
Deadline Dates (ALL)	15-Jun-2022 , 15-Sep-2022 , 15-Dec-2022																								
Synopsis	The Pacific Power Foundation awards grants to nonprofit organizations in the categories of education/STEM; community enhancement; culture and arts; and safety and wellness.																								
Applicant Types																									
Funding Limit	0.00 see detail																								
Limited Submission	No																								
056842	Grants Program	Sonora Area Foundation		01-Jun-2022	Not Specified																				
<table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 25%; padding: 5px;">Contact Name</td> <td style="padding: 5px;">Allie Lincoln, Grants Administrator</td> </tr> <tr> <td style="padding: 5px;">Contact Telephone</td> <td style="padding: 5px;">209-533-2596</td> </tr> <tr> <td style="padding: 5px;">Contact Email</td> <td style="padding: 5px;">allie@sonora-area.org</td> </tr> <tr> <td style="padding: 5px;">Sponsor Website</td> <td style="padding: 5px;">Link to sponsor website</td> </tr> <tr> <td style="padding: 5px;">Program URL</td> <td style="padding: 5px;">Link to program URL</td> </tr> <tr> <td style="padding: 5px;">Deadline Dates (ALL)</td> <td style="padding: 5px;">01-Jun-2022 , 01-Aug-2022 , 01-Oct-2022 , 01-Dec-2022</td> </tr> </table>						Contact Name	Allie Lincoln, Grants Administrator	Contact Telephone	209-533-2596	Contact Email	allie@sonora-area.org	Sponsor Website	Link to sponsor website	Program URL	Link to program URL	Deadline Dates (ALL)	01-Jun-2022 , 01-Aug-2022 , 01-Oct-2022 , 01-Dec-2022								
Contact Name	Allie Lincoln, Grants Administrator																								
Contact Telephone	209-533-2596																								
Contact Email	allie@sonora-area.org																								
Sponsor Website	Link to sponsor website																								
Program URL	Link to program URL																								
Deadline Dates (ALL)	01-Jun-2022 , 01-Aug-2022 , 01-Oct-2022 , 01-Dec-2022																								

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Synopsis The Foundation provides funding in these primary interest areas: human services; education; arts/culture/humanities; health; public/society benefit; and environment/animals. The sponsor supports pilot or demonstration projects, new or expanded programs, and capacity building.</p> <p>Applicant Types</p> <p>Funding Limit 0.00 not provided</p> <p>Limited Submission No</p>				
068718	Grants Program	Washington Square Health Foundation		01-Jun-2022	Not Specified
	<p>Contact Name Catherine Kapella</p> <p>Contact Telephone 312-664-6488</p> <p>Contact Email washington@wshf.org</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 01-Jun-2022 , 01-Dec-2022</p> <p>Synopsis The Washington Square Health Foundation, Inc. grants funds in order to promote and maintain access to adequate healthcare for all people in the Chicagoland area regardless of race, sex, creed or financial need. The Foundation meets this goal through its grants for medical and nursing education, medical research and direct healthcare services.</p> <p>Applicant Types</p> <p>Funding Limit 0.00 not provided</p> <p>Limited Submission No</p>				

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount																				
092352	Harry Goldblatt New Investigator Award	American Heart Association		01-Jun-2022	Not Specified																				
<table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 25%; border-right: 1px solid black;">Contact Name</td> <td></td> </tr> <tr> <td style="border-right: 1px solid black;">Contact Telephone</td> <td>214-706-1181</td> </tr> <tr> <td style="border-right: 1px solid black;">Contact Email</td> <td>council.awards@heart.org</td> </tr> <tr> <td style="border-right: 1px solid black;">Sponsor Website</td> <td>Link to sponsor website</td> </tr> <tr> <td style="border-right: 1px solid black;">Program URL</td> <td>Link to program URL</td> </tr> <tr> <td style="border-right: 1px solid black;">Deadline Dates (ALL)</td> <td>01-Jun-2022 , 03-Jun-2022</td> </tr> <tr> <td style="border-right: 1px solid black;">Synopsis</td> <td>The Harry Goldblatt Award for New Investigators recognizes a new independent investigator working in hypertension or cardiovascular research who has significantly contributed to our understanding of the causes of hypertension and related cardiovascular disease. The awardee will be selected by the Council's Awards Committee from applicants who have submitted abstracts accepted for presentation at the Hypertension Scientific Sessions, along with other materials.</td> </tr> <tr> <td style="border-right: 1px solid black;">Applicant Types</td> <td></td> </tr> <tr> <td style="border-right: 1px solid black;">Funding Limit</td> <td>0.00 see detail</td> </tr> <tr> <td style="border-right: 1px solid black;">Limited Submission</td> <td>No</td> </tr> </table>						Contact Name		Contact Telephone	214-706-1181	Contact Email	council.awards@heart.org	Sponsor Website	Link to sponsor website	Program URL	Link to program URL	Deadline Dates (ALL)	01-Jun-2022 , 03-Jun-2022	Synopsis	The Harry Goldblatt Award for New Investigators recognizes a new independent investigator working in hypertension or cardiovascular research who has significantly contributed to our understanding of the causes of hypertension and related cardiovascular disease. The awardee will be selected by the Council's Awards Committee from applicants who have submitted abstracts accepted for presentation at the Hypertension Scientific Sessions, along with other materials.	Applicant Types		Funding Limit	0.00 see detail	Limited Submission	No
Contact Name																									
Contact Telephone	214-706-1181																								
Contact Email	council.awards@heart.org																								
Sponsor Website	Link to sponsor website																								
Program URL	Link to program URL																								
Deadline Dates (ALL)	01-Jun-2022 , 03-Jun-2022																								
Synopsis	The Harry Goldblatt Award for New Investigators recognizes a new independent investigator working in hypertension or cardiovascular research who has significantly contributed to our understanding of the causes of hypertension and related cardiovascular disease. The awardee will be selected by the Council's Awards Committee from applicants who have submitted abstracts accepted for presentation at the Hypertension Scientific Sessions, along with other materials.																								
Applicant Types																									
Funding Limit	0.00 see detail																								
Limited Submission	No																								
095262	Humanitarian Award	Society for Industrial & Organizational Psychology		01-Jun-2022	1,500 USD																				
<table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 25%; border-right: 1px solid black;">Contact Name</td> <td></td> </tr> <tr> <td style="border-right: 1px solid black;">Contact Telephone</td> <td>419-353-0032</td> </tr> <tr> <td style="border-right: 1px solid black;">Contact Email</td> <td>SIOP@siop.org</td> </tr> <tr> <td style="border-right: 1px solid black;">Sponsor Website</td> <td>Link to sponsor website</td> </tr> <tr> <td style="border-right: 1px solid black;">Program URL</td> <td>Link to program URL</td> </tr> </table>						Contact Name		Contact Telephone	419-353-0032	Contact Email	SIOP@siop.org	Sponsor Website	Link to sponsor website	Program URL	Link to program URL										
Contact Name																									
Contact Telephone	419-353-0032																								
Contact Email	SIOP@siop.org																								
Sponsor Website	Link to sponsor website																								
Program URL	Link to program URL																								

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Deadline Dates (ALL) 01-Jun-2022</p> <p>Synopsis The SIOP Humanitarian Award is given for sustained, significant, and outstanding humanitarian contributions related to I-O psychology. The recipient of the award is given a plaque and a cash prize of \$1,500 (or a donation of the same amount donated to the charity/foundation of the recipient’s choice).</p> <p>Applicant Types</p> <p>Funding Limit 1,500.00 see detail</p> <p>Limited Submission No</p>				
109198	Ignite Innovation Grants	Arthritis Society		16-May-2022 [LOI/Pre-App]	79,000 USD
	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email research@arthritis.ca</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 16-May-2022 [LOI/Pre-App], 29-Jun-2022</p> <p>Synopsis The Innovation Grants program provides funding to support research proposals aligned with the Arthritis Society's priority focus areas. The Arthritis Society’s Strategic Plan 2020-2025: Accelerating Impact - Research Strategy aims to identify research avenues that focus on areas of highest priority to patients and achieve the highest levels of scientific excellence and rigour. Projects must be based on “high risk” ideas that have a strong potential for “high reward”. Applications must focus on innovative research efforts in the following priority areas: arthritis pain, OA, IA, childhood and work.</p> <p>Applicant Types</p> <p>Funding Limit 50,000.00 per year</p> <p>Limited Submission No</p>				

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount																				
109019	Incyte Ingenuity Awards	Incyte		24-Jun-2022	100,000 USD																				
	<table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 25%; border-right: 1px solid black;">Contact Name</td> <td></td> </tr> <tr> <td style="border-right: 1px solid black;">Contact Telephone</td> <td></td> </tr> <tr> <td style="border-right: 1px solid black;">Contact Email</td> <td>IncyteIngenuity@VOZAdvisors.com</td> </tr> <tr> <td style="border-right: 1px solid black;">Sponsor Website</td> <td>Link to sponsor website</td> </tr> <tr> <td style="border-right: 1px solid black;">Program URL</td> <td>Link to program URL</td> </tr> <tr> <td style="border-right: 1px solid black;">Deadline Dates (ALL)</td> <td>24-Jun-2022</td> </tr> <tr> <td style="border-right: 1px solid black;">Synopsis</td> <td>The Incyte Ingenuity Awards aim to support the graft-versus-host disease (GVHD) community by funding two novel initiatives that address challenges faced by GVHD patients, caregivers, and healthcare providers.</td> </tr> <tr> <td style="border-right: 1px solid black;">Applicant Types</td> <td></td> </tr> <tr> <td style="border-right: 1px solid black;">Funding Limit</td> <td>100,000.00 maximum</td> </tr> <tr> <td style="border-right: 1px solid black;">Limited Submission</td> <td>Yes</td> </tr> </table>					Contact Name		Contact Telephone		Contact Email	IncyteIngenuity@VOZAdvisors.com	Sponsor Website	Link to sponsor website	Program URL	Link to program URL	Deadline Dates (ALL)	24-Jun-2022	Synopsis	The Incyte Ingenuity Awards aim to support the graft-versus-host disease (GVHD) community by funding two novel initiatives that address challenges faced by GVHD patients, caregivers, and healthcare providers.	Applicant Types		Funding Limit	100,000.00 maximum	Limited Submission	Yes
Contact Name																									
Contact Telephone																									
Contact Email	IncyteIngenuity@VOZAdvisors.com																								
Sponsor Website	Link to sponsor website																								
Program URL	Link to program URL																								
Deadline Dates (ALL)	24-Jun-2022																								
Synopsis	The Incyte Ingenuity Awards aim to support the graft-versus-host disease (GVHD) community by funding two novel initiatives that address challenges faced by GVHD patients, caregivers, and healthcare providers.																								
Applicant Types																									
Funding Limit	100,000.00 maximum																								
Limited Submission	Yes																								
059508	Individual Investigator Research Awards	Cancer Prevention and Research Institute of Texas		08-Jun-2022	1,050,000 USD																				
	<table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 25%; border-right: 1px solid black;">Contact Name</td> <td></td> </tr> <tr> <td style="border-right: 1px solid black;">Contact Telephone</td> <td>512-463-3190</td> </tr> <tr> <td style="border-right: 1px solid black;">Contact Email</td> <td>cprit@cprit.state.tx.us</td> </tr> <tr> <td style="border-right: 1px solid black;">Sponsor Website</td> <td>Link to sponsor website</td> </tr> <tr> <td style="border-right: 1px solid black;">Program URL</td> <td>Link to program URL</td> </tr> <tr> <td style="border-right: 1px solid black;">Deadline Dates (ALL)</td> <td>08-Jun-2022</td> </tr> <tr> <td style="border-right: 1px solid black;">Synopsis</td> <td>Individual Investigator Research Awards support applications for innovative research projects addressing critically important questions that will significantly advance knowledge of the causes, prevention, and/or treatment of cancer.</td> </tr> </table>					Contact Name		Contact Telephone	512-463-3190	Contact Email	cprit@cprit.state.tx.us	Sponsor Website	Link to sponsor website	Program URL	Link to program URL	Deadline Dates (ALL)	08-Jun-2022	Synopsis	Individual Investigator Research Awards support applications for innovative research projects addressing critically important questions that will significantly advance knowledge of the causes, prevention, and/or treatment of cancer.						
Contact Name																									
Contact Telephone	512-463-3190																								
Contact Email	cprit@cprit.state.tx.us																								
Sponsor Website	Link to sponsor website																								
Program URL	Link to program URL																								
Deadline Dates (ALL)	08-Jun-2022																								
Synopsis	Individual Investigator Research Awards support applications for innovative research projects addressing critically important questions that will significantly advance knowledge of the causes, prevention, and/or treatment of cancer.																								

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Applicant Types</p> <p>Funding Limit</p> <p>Limited Submission</p>	<p>Areas of interest include laboratory research, translational studies, and/or clinical investigations. Applicants may request a maximum of \$350,000 in total costs per year for up to 3 years for research.</p> <p>350,000.00 per year</p> <p>No</p>			
088485	Individual Investigator Research Awards for Computational Systems Biology of Cancer	Cancer Prevention and Research Institute of Texas		08-Jun-2022	1,200,000 USD
	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email</p> <p>Sponsor Website</p> <p>Program URL</p> <p>Deadline Dates (ALL)</p> <p>Synopsis</p> <p>Applicant Types</p> <p>Funding Limit</p> <p>Limited Submission</p>	<p>512-463-3190</p> <p>cpvit@cpvit.state.tx.us</p> <p>Link to sponsor website</p> <p>Link to program URL</p> <p>08-Jun-2022</p> <p>The Cancer Prevention and Research Institute of Texas supports applications for innovative mathematical and/or computational research projects addressing questions that will advance current knowledge in the (a) mechanisms that tie altered gene expression and downstream molecular mechanisms to functional cancer phenotypes and/or (b) mechanisms that tie tumor morphology to functional cancer phenotypes and/or mechanisms that tie treatment sequence and combination to evolving functional cancer phenotypes (that emerge as a result of treatment selection).</p> <p>400,000.00 per year</p> <p>No</p>			
109814	Innovation in Time Resilience, Dissemination and Application – Demonstrator	Innovate UK		01-Jun-2022	1,310,000 USD

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Name</p> <p>Contact Telephone 0300 321 4357</p> <p>Contact Email support@innovateuk.gov.uk</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 01-Jun-2022</p> <p>Synopsis Innovate UK, part of UK Research and Innovation, is working with the National Physical Laboratory (NPL) to invest up to £4.7 million in innovation projects that contribute to resilient time, frequency and synchronisation (TFS) and its dissemination and application. The key areas for development are: resilience distribution trust, assurance and security integration and processing of signals The aims of this competition are to: support and enable business led innovation across the UK supply chain in resilient TFS for the development of products, services and end user applications develop a TFS ecosystem and capability for relevant industries and critical national infrastructure disrupt and create new markets, both in the UK and globally, to improve the provision of TFS The innovation in time resilience, dissemination and application competition has two strands: Strand 1: demonstrator (this strand) - for projects undertaking late stage industrial research or experimental developmental projects. Strand 2: feasibility - for projects undertaking early stage feasibility studies.</p>				
	Applicant Types				
	Funding Limit	1,000,000.00 maximum			
	Limited Submission	No			
109812	Innovation in Time Resilience, Dissemination and Application – Feasibility	Innovate UK		01-Jun-2022	327,500 USD

Contact Name

Contact Telephone 0300 321 4357

Contact Email support@innovateuk.gov.uk

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	01-Jun-2022			
	Synopsis	<p>Innovate UK, part of UK Research and Innovation, is working with the National Physical Laboratory (NPL) to invest up to £4.7 million in innovation projects that contribute to resilient time, frequency and synchronisation (TFS) and its dissemination and application. The key areas for development are: resilience distribution trust, assurance and security integration and processing of signals The aims of this competition are to: support and enable business led innovation across the UK supply chain in resilient TFS for the development of products, services and end user applications develop a TFS ecosystem and capability for relevant industries and critical national infrastructure disrupt and create new markets, both in the UK and globally, to improve the provision of TFS The innovation in time resilience, dissemination and application competition has two strands: Strand 1: demonstrator - for projects undertaking late stage industrial research or experimental developmental projects. Strand 2: feasibility (this strand) - for projects undertaking early stage feasibility studies.</p>			
	Applicant Types				
	Funding Limit	250,000.00 maximum			
	Limited Submission	No			
095001	Innovative Research Award	Rheumatology Research Foundation		01-Jun-2022 [LOI/Pre-App]	400,000 USD
	Contact Name				
	Contact Telephone	404-365-1373			
	Contact Email	foundation@rheumatology.org			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	01-Jun-2022 [LOI/Pre-App], 01-Jul-2022			

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Synopsis The Innovative Research Award provides essential support for innovative studies focused on generating new insights into the cause, progression, treatment, and outcomes of rheumatic and musculoskeletal diseases. The award amount is up to \$400,000 for two years (maximum \$200,000 per year).</p> <p>Applicant Types</p> <p>Funding Limit 400,000.00 maximum</p> <p>Limited Submission No</p>				
027718	International Exchanges Scheme	Royal Society		15-Jun-2022	15,720 USD
	<p>Contact Name</p> <p>Contact Telephone +44(0) 20 7451 2557</p> <p>Contact Email international.exchanges@royalsociety.org</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 15-Jun-2022 , 28-Sep-2022</p> <p>Synopsis These schemes are for scientists based in the UK who want to stimulate collaborations with leading scientists overseas through either a one-off visit or bilateral travel.</p> <p>Applicant Types</p> <p>Funding Limit 12,000.00 maximum</p> <p>Limited Submission No</p>				
012624	International Travel and Subsistence Grants	Houghton Trust		15-Jun-2022	Not Specified
	<p>Contact Name Dr. S. J. Baigent</p> <p>Contact Telephone</p> <p>Contact Email sue.baigent@outlook.com</p>				

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 15-Jun-2022</p> <p>Synopsis Grants are awarded for the furtherance of study or research in avian diseases by attending/participating in relevant scientific meetings, visiting appropriate laboratories for discussions and learning specific techniques, or attending training courses. The scope of Avian Pathology journal defines the research areas for appropriate applications. Applicants who will give an oral/poster presentation will be considered more favourably.</p> <p>Applicant Types</p> <p>Funding Limit 0.00 see detail</p> <p>Limited Submission No</p>				
002115	Investigator Award	Rheumatology Research Foundation		01-Jun-2022 [LOI/Pre-App]	375,000 USD
	<p>Contact Name</p> <p>Contact Telephone 404-365-1373</p> <p>Contact Email foundation@rheumatology.org</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 01-Jun-2022 [LOI/Pre-App], 01-Jul-2022</p> <p>Synopsis This award is intended to support junior investigators with a faculty appointment during the period that they are developing a project that will be competitive for NIH and/or equivalent funding. It is not intended to be a second postdoctoral fellowship. The purpose is to provide support for basic science, translational, and clinical investigators engaged in research relevant to the rheumatic diseases for the period between the completion of post-doctorate fellowship training and establishment as an independent investigator.</p> <p>Applicant Types</p>				

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Funding Limit	375,000.00 maximum			
	Limited Submission	No			
058805	Investigator Studies Program (MISP) -- Surgery -- Anesthesia	Merck		01-May-2022 [LOI/Pre-App]	Not Specified
	Contact Name	Lisa Mount			
	Contact Telephone	267-305-1258			
	Contact Email	lisa_mount@merck.com			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	01-May-2022 [LOI/Pre-App], 18-Jun-2022 , 01-Sep-2022 [LOI/Pre-App], 19-Oct-2022			
	Synopsis	The Investigator Studies Program aims to advance science and improve patient care by supporting, through the provision of drug/vaccine and/or total/partial funding, high-quality research that is initiated, designed, implemented and sponsored by external investigators. Results will be generated and properly disseminated in peer-reviewed publications.			
	Applicant Types				
	Funding Limit	0.00 not provided			
	Limited Submission	No			
017267	James Cook Research Fellowships	Royal Society of New Zealand		12-May-2022	151,800 USD
	Contact Name				
	Contact Telephone	+64 4 470 5764			
	Contact Email	james.cook@royalsociety.org.nz			
	Sponsor Website	Link to sponsor website			

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 12-May-2022 , 16-Jun-2022</p> <p>Synopsis The James Cook Research Fellowships, administered by the Royal Society Te Apārangi on behalf of the New Zealand Government, are awarded to researchers who have the requisite qualifications and experience and are able to demonstrate that they have achieved national and international recognition in their area of scientific research. The fellowships allow them to concentrate on their chosen research for two years without the additional burden of administrative and teaching duties. The funding package annually is \$100,000 plus GST and up to \$10,000 plus GST in relevant expenses.</p> <p>Applicant Types</p> <p>Funding Limit 110,000.00 per year</p> <p>Limited Submission No</p>				
072617	Joel Elkes Research Award	American College of Neuropsychopharmacology		23-Jun-2022	Not Specified
	<p>Contact Name</p> <p>Contact Telephone 615-324-2360</p> <p>Contact Email ancp@acnp.org</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 23-Jun-2022</p> <p>Synopsis The American College of Neuropsychopharmacology (ACNP) presents the Joel Elkes Research Award to a young scientist in recognition of an outstanding clinical contribution to neuropsychopharmacology.</p> <p>Applicant Types</p> <p>Funding Limit 0.00 see detail</p> <p>Limited Submission No</p>				

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
107875	Joint Translational Call (JTC) 2022	European Joint Programme on Rare Diseases (EJP-RD)		15-Jun-2022	Not Specified
	<p>Contact Name Maria Druet, Joint Call Secretariat</p> <p>Contact Telephone +34 91 822 2530</p> <p>Contact Email mdruet@isciii.es</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 15-Jun-2022 , 28-Jul-2022</p> <p>Synopsis The aim of this call is to enable scientists in different countries to build an effective collaboration on a common interdisciplinary research project based on complementarities and sharing of expertise, with expected impact to use the results in the future for benefit of patients. The EJP RD Joint Transnational Call 2022 for Rare Diseases Research Project (JTC 2022) focuses on the “Development of new analytic tools and pathways to accelerate diagnosis and facilitate diagnostic monitoring of rare diseases.”</p> <p>Applicant Types </p> <p>Funding Limit 0.00 see detail</p> <p>Limited Submission No</p>				
107672	Joint Transnational Call 2022: Prevention in Personalised Medicine	ERA PerMed		14-Jun-2022	Not Specified
	<p>Contact Name Monika Frenzel and Michael Joulie</p> <p>Contact Telephone +33 1 73 54 83 32</p> <p>Contact Email ERAPerMed@agencerecherche.fr</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p>				

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Deadline Dates (ALL) 14-Jun-2022</p> <p>Synopsis Through its fifth transnational call (non-cofunded by the EC), ERA PerMed aims to foster research on prevention in personalised medicine. Personalised prevention or targeted/tailored prevention considers both individual susceptibility to the risk of disease (e.g. depending on the genomic, environmental background or lifestyle) and its perceived value and benefit (cultural and social factors).</p> <p>Applicant Types</p> <p>Funding Limit 0.00 see detail</p> <p>Limited Submission No</p>				
097748	KTEs – Knowledge Transfer Experiments	SMART4ALL		15-Jun-2022	Not Specified
	<p>Contact Name Prof. Nikolaos Voros, Project Coordinator</p> <p>Contact Telephone +30 2610 369151</p> <p>Contact Email voros@uop.gr</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 15-Jun-2022</p> <p>Synopsis SMART4ALL is a H2020 funded project that builds capacity amongst European stakeholders via the development of self-sustained, cross-border experiments that transfer knowledge and technology between academia and industry. It targets Customised Low-Energy Computing (CLEC) for Cyber-Physical Systems (CPS) and the Internet of Things (IoT) and combines a set of unique characteristics that join together under a common vision different cultures, different policies, different geographical areas and different application domains. SMART4ALL brings a new paradigm for revealing “hidden innovation treasures” – mainly from geographical areas that are underrepresented in European funding – and helping them to find the path to market via new, innovative commercial products. As part of its strategy, the project will develop and maintain an active network of DIHs across Central, South and Eastern Europe for supporting academics, SMEs and Slightly Bigger Companies entering the digitisation era. In order to achieve this,</p>				

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>SMART4ALL will design and implement 3 types of cross-border Pathfinder Application Experiments (PAEs): 1) Knowledge Transfer Experiments (KTE) 2) Focused Technology Transfer Experiments (FTTEs) 3) Cross-domain Technology Transfer Experiments (CTTEs) These guidelines describe the SMART4ALL first Open Call for Knowledge Transfer Experiments (KTE), which comprise a novel type of internship experiments allowing smaller projects, or less mature ideas to be presented, tested and thus potentially find the fertile ground to grow and reveal its product potentials.</p> <p>Applicant Types</p> <p>Funding Limit 0.00 see detail</p> <p>Limited Submission No</p>				
019937	Large Project Grants (Temporarily Suspended)	Barts and The London Charity		10-May-2022 [LOI/Pre-App]	655,000 USD
	<p>Contact Name</p> <p>Contact Telephone 020 7618 1717</p> <p>Contact Email grants@bartscharity.org.uk</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 10-May-2022 [LOI/Pre-App], 30-Jun-2022 [LOI/Pre-App], 07-Jul-2022 , 20-Oct-2022</p> <p>Synopsis The sponsor wants to help advance research focused on health-related problems of local and international significance and which supports the delivery of safe and compassionate care to patients.</p> <p>Applicant Types</p> <p>Funding Limit 500,000.00 maximum</p> <p>Limited Submission No</p>				
104738	Lawrence and Isabel Barnett Drug Development Program	ALS Association		01-Jun-2022	500,000 USD

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Name</p> <p>Contact Telephone 1-800-782-4747</p> <p>Contact Email researchgrants@alsa-national.org</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 01-Jun-2022</p> <p>Synopsis The ALS Association offers the Lawrence and Isabel Barnett Drug Development Program provides support for preclinical assessment of therapeutics for ALS that have a high probability of reaching the clinic within three years. This program is open to industry and academic investigators proposing to develop novel or repositioning approaches for ALS. Awards will be limited \$500,000 total costs for the entire 2-year period of performance.</p> <p>Applicant Types</p> <p>Funding Limit 250,000.00 per year</p> <p>Limited Submission No</p>				

036282	LEO Foundation Awards	LEO Foundation		21-Jun-2022	100,000 USD
--------	---------------------------------------	----------------	--	-------------	-------------

	<p>Contact Name</p> <p>Contact Telephone + 45 32 72 51 10</p> <p>Contact Email applications@leo-foundation.org</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 21-Jun-2022 , 04-Sep-2022</p>				
--	---	--	--	--	--

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Synopsis</p> <p>Applicant Types</p> <p>Funding Limit</p> <p>Limited Submission</p>	<p>The LEO Foundation Awards constitute a global recognition and are given annually to outstanding young scientists whose work represent extraordinary contributions to dermatology research. There will be three awards of 100,000 USD, one in each of the Americas, EMEA (Europe/Middle East/Africa) and Asia-Pacific regions.</p> <p>100,000.00 maximum</p> <p>No</p>			
079306	Lifestyle and Cardiometabolic Health Early Career Investigator Award	American Heart Association		09-Jun-2022	Not Specified
	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email</p> <p>Sponsor Website</p> <p>Program URL</p> <p>Deadline Dates (ALL)</p> <p>Synopsis</p> <p>Applicant Types</p> <p>Funding Limit</p> <p>Limited Submission</p>	<p>214-706-1181</p> <p>council.awards@heart.org</p> <p>Link to sponsor website</p> <p>Link to program URL</p> <p>09-Jun-2022</p> <p>The Council on Lifestyle and Cardiometabolic Health Young Investigator Award recognizes and awards early career investigator and trainee council members for their achievements and their continuing research. The award also encourages young scientists to become involved in the Council on Lifestyle and Cardiometabolic Health and to develop and maintain productive careers.</p> <p>0.00 see detail</p> <p>Yes</p>			
005950	Marvin Moser Clinical Hypertension Award	American Heart Association		03-Jun-2022	2,000 USD
	<p>Contact Name</p>				

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Telephone 212-696-9099</p> <p>Contact Email council.awards@heart.org</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 03-Jun-2022</p> <p>Synopsis The Marvin Moser Clinical Hypertension Award recognizes a qualified mid-career or senior Hypertension Clinician for their dedication to the treatment and care of hypertensive patients.</p> <p>Applicant Types </p> <p>Funding Limit 2,000.00 see detail</p> <p>Limited Submission No</p>				
006412	McDonald Fellowship	Multiple Sclerosis International Federation		30-Jun-2022	78,600 USD
	<p>Contact Name </p> <p>Contact Telephone +44 (0)20 7620 1911</p> <p>Contact Email research@msif.org</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 30-Jun-2022</p> <p>Synopsis The McDonald Fellowship enables early career multiple sclerosis researchers from low- and middle-income countries to work in a research institution outside of their own country. For 2022 the sponsor is open to applications for virtual or local projects to overcome the travel restrictions imposed by COVID-19. During the visit or virtual project, participants either gain expertise or carry out parts of joint research projects.</p> <p>Applicant Types </p>				

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Funding Limit	60,000.00 see detail			
	Limited Submission	No			
095617	Media Award	American College of Neuropsychopharmacology		23-Jun-2022	Not Specified
	Contact Name				
	Contact Telephone	615-324-2360			
	Contact Email	acnp@acnp.org			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	23-Jun-2022			
	Synopsis	The ACNP Media Award was established to recognize major contributions to the education of the public about mental illness and substance abuse research and the positive impact of research on treatment. The Media Award consists of an expense paid trip to the ACNP Annual Meeting and a plaque to be presented at the Annual Meeting.			
	Applicant Types				
	Funding Limit	0.00 see detail			
	Limited Submission	No			
108036	Medical Research Future Fund – Clinical Trials Activity Grant Opportunity	National Health and Medical Research Council	GO5344	22-Jun-2022 [LOI/Pre-App]	Not Specified
	Contact Name				
	Contact Telephone	1800 500 983			
	Contact Email	help@nhmrc.gov.au			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Deadline Dates (ALL) 22-Jun-2022 [LOI/Pre-App], 06-Jul-2022</p> <p>Synopsis The Clinical Trials Activity (the Initiative) aims to: give patients across Australia more access to clinical trials show which treatments and medicines work best for patients provide researchers with more opportunities to work with international colleagues to bring international trials to Australian patients promote new approaches that support efficient and effective research The grant opportunity aims to fund research in two priority areas: • Rare cancers, rare diseases and unmet need • Effective health interventions.</p> <p>Applicant Types</p> <p>Funding Limit 0.00 see detail</p> <p>Limited Submission No</p>				
108041	Medical Research Future Fund – Preventive and Public Health Research Initiative--2021 Chronic Respiratory Conditions Grant Opportunity	National Health and Medical Research Council	GO5338	29-Jun-2022 [LOI/Pre-App]	Not Specified
	<p>Contact Name</p> <p>Contact Telephone 1800 500 983</p> <p>Contact Email Help@nhmrc.gov.au</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 29-Jun-2022 [LOI/Pre-App], 13-Jul-2022</p> <p>Synopsis The Preventive and Public Health Research Initiative (the Initiative) aims to enable or support: testing innovative public health approaches, such as through exercise and nutrition, to address the risk factors associated with the prevalence and persistence of chronic and complex diseases in Australia funding health system research to identify innovative approaches to treat and manage chronic and complex diseases generating evidence to support the translation of new preventive and public health measures into practice implementing innovative approaches to improve the quality and cost-effectiveness of preventive healthcare interventions The Medical Research Future Fund (MRFF) – Preventive and Public Health Research Initiative – 2021 Chronic Respiratory Conditions Grant Opportunity</p>				

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>will support research that: Stream 1: develop treatable trait-based precision medicine approaches for chronic respiratory disease Stream 2: clinically validate feasible technology enabled approaches to medication and therapeutic adherence and self-management of chronic respiratory diseases.</p> <p>Applicant Types</p> <p>Funding Limit 0.00 not provided</p> <p>Limited Submission No</p>				
107982	Medical Research Future Fund –Preventive and Public Health Research Initiative--2021 Consumer-Led Research Grant	National Health and Medical Research Council	G05353	29-Jun-2022 [LOI/Pre-App]	Not Specified
	<p>Contact Name</p> <p>Contact Telephone 1800 500 983</p> <p>Contact Email help@nhmrc.gov.au</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 29-Jun-2022 [LOI/Pre-App], 13-Jul-2022</p> <p>Synopsis The Preventive and Public Health Research Initiative (the Initiative) aims to enable or support research to: test innovative public health approaches, such as through exercise and nutrition, to address the risk factors associated with the prevalence and persistence of chronic and complex diseases in Australia fund health system research to identify innovative approaches to treat and manage chronic and complex diseases generate evidence to support the translation of new preventive and public health measures into practice implement innovative approaches to improve the quality and cost-effectiveness of preventive healthcare interventions Applicants to this grant opportunity are expected to describe how their proposed project aligns with the objectives and outcomes of the Preventive and Public Health Research Initiative and the Measures of Success as described in the Evaluation Strategy.</p> <p>Applicant Types</p> <p>Funding Limit 0.00 see detail</p>				

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Limited Submission	No			
108040	Medical Research Future Fund--2021 Early to Mid-Career Researchers Grant Opportunity	National Health and Medical Research Council	GO5339	29-Jun-2022 [LOI/Pre-App]	Not Specified
	Contact Name				
	Contact Telephone	1800 500 983			
	Contact Email	help@nhmrc.gov.au			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	29-Jun-2022 [LOI/Pre-App], 13-Jul-2022			
	Synopsis	<p>The MRFF, established under the Medical Research Future Fund Act 2015 (MRFF Act), provides grants of financial assistance to support health and medical research and innovation to improve the health and wellbeing of Australians. It operates as an endowment fund with the capital preserved in perpetuity. The objectives and intended outcomes of this grant opportunity are aligned with the following Australian Medical Research and Innovation Priorities 2020-2022: Consumer-Driven Research Translational Research Infrastructure The intended outcomes of the research funded by this grant opportunity is to improve the health and wellbeing of Australians by: Stream 1 (Incubator): supporting early-career researchers to develop innovative solutions for addressing significant health challenges. Stream 2 (Accelerator): supporting mid-career researchers to transform health practice and/or policy. Stream 3 (Targeted Call for Research): supporting early to mid-career researchers to translate new therapies and/or products into practice.</p>			
	Applicant Types				
	Funding Limit	0.00 see detail			
	Limited Submission	No			
042680	Medical/Dental Postgraduate Scholarship	National Health and Medical Research Council	GO3917	11-May-2022 [LOI/Pre-App]	Not Specified

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Name</p> <p>Contact Telephone 61 2 6217 9000</p> <p>Contact Email nhmrc@nhmrc.gov.au</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 11-May-2022 [LOI/Pre-App], 08-Jun-2022</p> <p>Synopsis Medical/Dental Postgraduate Scholarships are awarded to provide support to combined MBBS/PhD students, and medical or dental graduates undertaking a higher research degree involving full-time research.</p> <p>Applicant Types</p> <p>Funding Limit 0.00 see detail</p> <p>Limited Submission No</p>				
066849	Mentored Clinical Scientist Research Career Development Award (K08)	Society for Vascular Surgery		12-Jun-2022	Not Specified
	<p>Contact Name Jane D. Scott</p> <p>Contact Telephone 301-435-0535</p> <p>Contact Email scottj2@nhlbi.nih.gov</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 12-Jun-2022 , 12-Jul-2022 , 12-Oct-2022 , 12-Nov-2022</p> <p>Synopsis The SVS Foundation offers this award in partnership with the NHLBI as a means to facilitate the research career development of individuals pursuing a career in vascular research. This award provides financial support over and above that offered by the NHLBI K08 mechanism.</p> <p>Applicant Types</p>				

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Funding Limit	0.00 see detail			
	Limited Submission	No			
061247	Merck MISP Clostridium Difficile Grant	Merck		11-Jun-2022	Not Specified
	Contact Name	Boski Patel			
	Contact Telephone	267-305-3173			
	Contact Email	boski_patel@msd.com			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	11-Jun-2022			
	Synopsis	The Investigator Studies Program aims to advance science and improve patient care by supporting, through the provision of drug/vaccine and/or total/partial funding, high-quality research that is initiated, designed, implemented and sponsored by external investigators. Results will be generated and properly disseminated in peer-reviewed publications.			
	Applicant Types				
	Funding Limit	0.00 not provided			
	Limited Submission	No			
102829	Mitchell A. Baran Achievement Award for Clinical Excellence in Aerosol and Airway Clearance Therapies	American Respiratory Care Foundation		01-Jun-2022	2,500 USD
	Contact Name				
	Contact Telephone	972-243-2272			
	Contact Email				
	Sponsor Website	Link to sponsor website			

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 01-Jun-2022</p> <p>Synopsis This award is given to recognize and honor those individuals demonstrating clinical excellence and leadership in advocating and promoting the use of evidence-based, clinically sound practices for the delivery of aerosolized medications and/or the application of non-pharmacologic airway clearance therapies.</p> <p>Applicant Types</p> <p>Funding Limit 2,500.00 see detail</p> <p>Limited Submission No</p>				
006022	Module I – Observational Training with Experts Fellowship Grant	European Society of Gastrointestinal Endoscopy		01-Jun-2022	1,430 USD
	<p>Contact Name</p> <p>Contact Telephone + 49-89-907 7936-00</p> <p>Contact Email secretariat@esge.com</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 01-Jun-2022</p> <p>Synopsis The European Society of Gastrointestinal Endoscopy (ESGE) offers fellowship grants to fully-trained endoscopists wishing to undertake further training in highly specialised endoscopic techniques at officially recognised ESGE training centres. Also, through a mutual cooperation, ESGE and the Japan Gastroenterological Endoscopy Society (JGES) offer one grant, Module I, per year in an exchange programme. The selected ESGE grantee is assigned to one of the leading Japanese institutions.</p> <p>Applicant Types</p> <p>Funding Limit 1,300.00 see detail</p> <p>Limited Submission No</p>				

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount																				
106496	Momentum – Funding for Recently Tenured Professors	VolkswagenStiftung Foundation		01-Jun-2022	Not Specified																				
<table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 25%; border-right: 1px solid black;">Contact Name</td> <td>Dr. Selahattin Danisman</td> </tr> <tr> <td style="border-right: 1px solid black;">Contact Telephone</td> <td>+49 511 8381-256</td> </tr> <tr> <td style="border-right: 1px solid black;">Contact Email</td> <td>danisman@volkswagenstiftung.de</td> </tr> <tr> <td style="border-right: 1px solid black;">Sponsor Website</td> <td>Link to sponsor website</td> </tr> <tr> <td style="border-right: 1px solid black;">Program URL</td> <td>Link to program URL</td> </tr> <tr> <td style="border-right: 1px solid black;">Deadline Dates (ALL)</td> <td>01-Jun-2022</td> </tr> <tr> <td style="border-right: 1px solid black;">Synopsis</td> <td>This initiative addresses academics at an early stage following the appointment to their first tenured professorship. The goal is to open up opportunities in this phase of their career to advance the content and strategic development of their professorship.</td> </tr> <tr> <td style="border-right: 1px solid black;">Applicant Types</td> <td></td> </tr> <tr> <td style="border-right: 1px solid black;">Funding Limit</td> <td>0.00 see detail</td> </tr> <tr> <td style="border-right: 1px solid black;">Limited Submission</td> <td>No</td> </tr> </table>						Contact Name	Dr. Selahattin Danisman	Contact Telephone	+49 511 8381-256	Contact Email	danisman@volkswagenstiftung.de	Sponsor Website	Link to sponsor website	Program URL	Link to program URL	Deadline Dates (ALL)	01-Jun-2022	Synopsis	This initiative addresses academics at an early stage following the appointment to their first tenured professorship. The goal is to open up opportunities in this phase of their career to advance the content and strategic development of their professorship.	Applicant Types		Funding Limit	0.00 see detail	Limited Submission	No
Contact Name	Dr. Selahattin Danisman																								
Contact Telephone	+49 511 8381-256																								
Contact Email	danisman@volkswagenstiftung.de																								
Sponsor Website	Link to sponsor website																								
Program URL	Link to program URL																								
Deadline Dates (ALL)	01-Jun-2022																								
Synopsis	This initiative addresses academics at an early stage following the appointment to their first tenured professorship. The goal is to open up opportunities in this phase of their career to advance the content and strategic development of their professorship.																								
Applicant Types																									
Funding Limit	0.00 see detail																								
Limited Submission	No																								
068800	NBRC Frederic Helmholtz, Jr., MD Educational Research Fund	American Respiratory Care Foundation		01-Jun-2022	5,000 USD																				
<table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 25%; border-right: 1px solid black;">Contact Name</td> <td></td> </tr> <tr> <td style="border-right: 1px solid black;">Contact Telephone</td> <td>972-243-2272</td> </tr> <tr> <td style="border-right: 1px solid black;">Contact Email</td> <td></td> </tr> <tr> <td style="border-right: 1px solid black;">Sponsor Website</td> <td>Link to sponsor website</td> </tr> <tr> <td style="border-right: 1px solid black;">Program URL</td> <td>Link to program URL</td> </tr> <tr> <td style="border-right: 1px solid black;">Deadline Dates (ALL)</td> <td>01-Jun-2022</td> </tr> </table>						Contact Name		Contact Telephone	972-243-2272	Contact Email		Sponsor Website	Link to sponsor website	Program URL	Link to program URL	Deadline Dates (ALL)	01-Jun-2022								
Contact Name																									
Contact Telephone	972-243-2272																								
Contact Email																									
Sponsor Website	Link to sponsor website																								
Program URL	Link to program URL																								
Deadline Dates (ALL)	01-Jun-2022																								

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Synopsis The National Board for Respiratory Care/Applied Measurement Professionals, Inc. has provided an endowment to the American Respiratory Care Foundation to support up to \$5,000 for educational or credentialing research. A Master's Thesis, or Doctoral Dissertation with practical value to the respiratory care profession are acceptable submissions by a candidate.</p> <p>Applicant Types</p> <p>Funding Limit 5,000.00 see detail</p> <p>Limited Submission No</p>				
108503	New Program	Mathers (G.Harold and Leila Y.) Foundation		15-Apr-2022 [LOI/Pre-App]	Not Specified
	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email support@mathersfoundation.org</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL</p> <p>Deadline Dates (ALL) 15-Apr-2022 [LOI/Pre-App], 30-Jun-2022</p> <p>Synopsis The mission of The G. Harold and Leila Y. Mathers Foundation is to advance knowledge in the life sciences by sponsoring scientific research that will benefit mankind. Basic scientific research, with potential translational application, is central to this goal, and fundamental to the Foundation's operating principles.</p> <p>Applicant Types</p> <p>Funding Limit 0.00 not provided</p> <p>Limited Submission Yes</p>				
100431	Non-Drug Approaches Grants	Parkinson's UK		22-Jun-2022	262,000 USD

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

Contact Name	
Contact Telephone	
Contact Email	researchapplications@parkinsons.org.uk
Sponsor Website	Link to sponsor website
Program URL	Link to program URL
Deadline Dates (ALL)	22-Jun-2022 , 14-Sep-2022
Synopsis	Parkinson's UK is accepting applications for a grant scheme that aims to support and accelerate research to develop non-drug approaches for Parkinson's. There is no minimum value and the maximum award amount is £200,000.
Applicant Types	
Funding Limit	200,000.00 maximum
Limited Submission	No

071378	Norman Borlaug Award for Field Research and Application	World Food Prize Foundation	15-Jun-2022	10,000 USD
--------	---	-----------------------------	-------------	------------

Contact Name	Ms.Ellen Franzenburg, Director of Secretariat Operations
Contact Telephone	+1-515-245-3783
Contact Email	efranzenburg@worldfoodprize.org
Sponsor Website	Link to sponsor website
Program URL	Link to program URL
Deadline Dates (ALL)	15-Jun-2022
Synopsis	The Norman Borlaug Award for Field Research and Application is presented annually in the amount of \$10,000 to recognize exceptional, science-based achievement in international agriculture and food production by an individual under 40 who has clearly demonstrated intellectual courage, stamina, and determination in the fight to eliminate global hunger and poverty.
Applicant Types	

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Funding Limit	10,000.00 maximum			
	Limited Submission	No			
090392	Open Scheme	Pathological Society of Great Britain and Ireland		01-Jun-2022	13,100 USD
	Contact Name				
	Contact Telephone	020 7 484 8046			
	Contact Email	admin@pathsoc.org			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	01-Jun-2022 , 01-Sep-2022 , 01-Dec-2022			
	Synopsis	The Open Scheme provides support for activities not covered by another Society scheme, all of which should support the Society's mission, which is to promote the understanding of disease. The sum requested should not exceed £10,000.			
	Applicant Types				
	Funding Limit	10,000.00 maximum			
	Limited Submission	No			
058306	Operating Grants	International Organization For the Study of Inflammatory Bowel Disease		30-Jun-2022	275,000 USD
	Contact Name	Marischka Konings			
	Contact Telephone	+31 35 5426745			
	Contact Email	ioibd@mkproducties.nl			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Deadline Dates (ALL) 30-Jun-2022</p> <p>Synopsis The International Organization For the Study of Inflammatory Bowel Disease (IOIBD) offers Operating Grants of up to €250,000 for one year, preferably equally divided between Clinical and Basic Science Projects. Preference will be given to grants less than or equal to €50,000.</p> <p>Applicant Types</p> <p>Funding Limit 250,000.00 maximum</p> <p>Limited Submission Yes</p>				
104632	Orange Knowledge Programme (OKP)	Nuffic		28-Jun-2022	Not Specified
	<p>Contact Name</p> <p>Contact Telephone +31 (0)70 - 4260 260</p> <p>Contact Email</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 28-Jun-2022 , 11-Oct-2022</p> <p>Synopsis The Orange Knowledge Programme scholarships are open to mid-career professionals in specific countries to study at institutions in the Netherlands. Scholarships are available for a selection of short courses (duration 2 weeks to 12 months) or master's programmes (duration 12 to 24 months).</p> <p>Applicant Types</p> <p>Funding Limit 0.00 see detail</p> <p>Limited Submission No</p>				

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

045882	Outstanding Investigator Award for Breast Cancer Research	American Association for Cancer Research		30-Jun-2022	Not Specified
--------	---	--	--	-------------	---------------

	Contact Name	Michael J. Powell, PhD, Deputy Director of Scientific Programs			
	Contact Telephone	215-440-9373			
	Contact Email	michael.powell@aacr.org			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	30-Jun-2022			
	Synopsis	The AACR established this Award to recognize an investigator whose novel and significant work has had or may have a far-reaching impact on the etiology, detection, diagnosis, treatment, or prevention of breast cancer. Such work may involve any discipline across the continuum of biomedical research, including basic, translational, clinical, and epidemiological studies.			
	Applicant Types				
	Funding Limit	0.00 see detail			
	Limited Submission	No			

045538	Partnering Opportunity For Clinical Trial Stage Projects (CLIN2)	California Institute for Regenerative Medicine		29-Apr-2022	Not Specified
--------	--	--	--	-------------	---------------

	Contact Name				
	Contact Telephone	510-340-9101			
	Contact Email	Clinical@cirm.ca.gov			
	Sponsor Website	Link to sponsor website			

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 29-Apr-2022 , 31-May-2022 , 30-Jun-2022 , 31-Jul-2022</p> <p>Synopsis The mission of California Institute for Regenerative Medicine (CIRM) is to accelerate stem cell treatments to patients with unmet medical needs. The objective of this program announcement is to create a highly competitive partnering opportunity to accelerate the completion of a clinical trial for a promising stem or progenitor cell-based or gene therapy treatment that addresses an unmet medical need. Under this program, CIRM will act not only as a funding agency, but will also devote significant internal resources and leverage its external team of world-class subject matter experts to actively advance the project. The result of a successful application will be the formation of a true partnership that both accelerates the program and gives it the greatest opportunity for success.</p> <p>Applicant Types</p> <p>Funding Limit 0.00 see detail</p> <p>Limited Submission No</p>				
045367	Partnering Opportunity for Late Stage Preclinical Projects (CLIN1)	California Institute for Regenerative Medicine		29-Apr-2022	6,000,000 USD
	<p>Contact Name</p> <p>Contact Telephone 510-340-9101</p> <p>Contact Email clinical@cirm.ca.gov</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 29-Apr-2022 , 31-May-2022 , 30-Jun-2022 , 31-Jul-2022</p> <p>Synopsis The mission of California Institute for Regenerative Medicine (CIRM) is to accelerate stem cell treatments to patients with unmet medical needs. The objective of this program announcement is to create a highly competitive partnering opportunity to accelerate the completion of an IND or IDE filing with the Food and Drug Administration (FDA) and initiate clinical trial start-up with a promising stem or progenitor cell-based or gene therapy treatment that addresses</p>				

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>an unmet medical need. CIRM expects projects under this program to advance rapidly into the clinic and to achieve the proposed IND filing within 24 months.</p> <p>Applicant Types</p> <p>Funding Limit 6,000,000.00 maximum</p> <p>Limited Submission No</p>				
067186	Pediatric Dermatology Fellowship (Minnesota)	Mayo Clinic College of Medicine and Science		30-Jun-2022	Not Specified
	<p>Contact Name Kelly J. Ihrke</p> <p>Contact Telephone 507-284-3736</p> <p>Contact Email mayodermfellows@mayo.edu</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 30-Jun-2022</p> <p>Synopsis Mayo Clinic in Rochester, Minnesota, offers a one-year Pediatric Dermatology Fellowship that focuses on advanced care of infants and children with severe skin disease. During this fellowship, fellows will work with Mayo Clinic staff members and residents in clinical, laboratory and procedural dermatology, as well as colleagues in plastic surgery, rheumatology, ophthalmology and other departments.</p> <p>Applicant Types</p> <p>Funding Limit 0.00 see detail</p> <p>Limited Submission No</p>				
075992	Peter G. Pentchev Niemann-Pick Type C Research Fellowship	National Niemann-Pick Disease Foundation, Inc.		01-Jun-2022	Not Specified
	Contact Name Joslyn Crowe, NNPDF Executive Director				

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Telephone 877-287-3672</p> <p>Contact Email nnpdf@nnpdf.org</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 01-Jun-2022</p> <p>Synopsis The National Niemann-Pick Disease Foundation (NNPDF) invites applications for research fellowships examining the biology of Niemann-Pick Type C (NPC), a lethal neuro-degenerative disease for which there are no effective therapies.</p> <p>Applicant Types </p> <p>Funding Limit 0.00 see detail</p> <p>Limited Submission No</p>				
089931	PhD Fellowships	Boehringer Ingelheim Fonds		01-Jun-2022	Not Specified
	<p>Contact Name </p> <p>Contact Telephone +49 (0)6131 2750 80</p> <p>Contact Email secretariat@bifonds.de</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 01-Jun-2022 , 01-Oct-2022</p> <p>Synopsis The Boehringer Ingelheim Fonds (BIF) awards PhD fellowships of 2 to 3.5 years to outstanding junior scientists worldwide who wish to pursue an ambitious PhD project in basic biomedical research in an internationally leading laboratory.</p> <p>Applicant Types </p> <p>Funding Limit 0.00 see detail</p>				

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Limited Submission	No			
046432	PhD Fellowships	Multiple Sclerosis Society of G.B. and N. Ireland		07-Jun-2022	Not Specified
	Contact Name				
	Contact Telephone	020-8438-0822			
	Contact Email	researchnetwork@mssociety.org.uk			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	07-Jun-2022			
	Synopsis	PhD Fellowships are designed to encourage the best science graduates to embark on a research career in Multiple Sclerosis.			
	Applicant Types				
	Funding Limit	0.00 see detail			
	Limited Submission	No			
061875	PhD Studentships	International Spinal Research Trust		06-Jun-2022	Not Specified
	Contact Name				
	Contact Telephone	+44 (0)207 653 8937			
	Contact Email	research@spinal-research.org			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	06-Jun-2022			

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount	
	Synopsis Applicant Types Funding Limit Limited Submission	International Spinal Research Trust offers PhD Studentships aimed at encouraging the development of talented, highly-motivated young scientists in the field of spinal cord repair, in both clinical and basic science research environments. 0.00 see detail No				
001730	Physician and Public Awareness Proposals	ResMed Foundation		15-Jun-2022	Not Specified	
	Contact Name Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL) Synopsis Applicant Types Funding Limit Limited Submission	Kristi Burlingame, Executive Director 858-361-0755 kristib@resmedfoundation.org Link to sponsor website Link to program URL 15-Jun-2022 , 15-Dec-2022 The Foundation's goal in this funding category is to further the awareness and knowledge of the inherent dangers of untreated sleep disordered breathing, its symptoms, diagnosis and treatment with sleep specialists, primary care physicians, educators and the general public. 0.00 not provided No				
067593	Pilot Project Grants	Myositis Association		16-May-2022 [LOI/Pre-App]	100,000 USD	
	Contact Name	Chrissy Thornton				

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Telephone 703-553-2631</p> <p>Contact Email chrissy@myositis.org</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 16-May-2022 [LOI/Pre-App], 30-Jun-2022</p> <p>Synopsis Pilot Grants are designed to fund new and innovative research projects in the hope that they will attract funding from other sources (such as NIH). A competitive application will clearly delineate how this pilot funding will lead to future grant support. In addition, a competitive application will clearly distinguish itself from the investigator's existing research program. Any industry partnership must be clearly disclosed and a letter of support from the industry partner must be included. Pilot grants will be awarded for one or two years and up to a maximum of \$100,000 annually, subject to satisfactory progress.</p> <p>Applicant Types</p> <p>Funding Limit 100,000.00 maximum</p> <p>Limited Submission No</p>				
020216	Postdoctoral Fellowship	Auckland Medical Research Foundation		01-Jun-2022 [LOI/Pre-App]	Not Specified
	<p>Contact Name</p> <p>Contact Telephone +64 9 923 1701</p> <p>Contact Email admin@medicalresearch.org.nz</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 01-Jun-2022 [LOI/Pre-App], 17-Aug-2022</p> <p>Synopsis The Postdoctoral Fellowship provides two years support for outstanding science or medical graduates who have recently completed a degree at doctorate level and who propose to pursue a career in medical research.</p>				

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Applicant Types Funding Limit 0.00 see detail Limited Submission No				
045773	Predoctoral and Postdoctoral Fellowships in Spinal Cord Injury Research	New York State Department of Health	RFA # 18591	01-Jun-2022	Not Specified
	Contact Name David Googins Contact Telephone 518-474-7002 Contact Email scirb@health.ny.gov Sponsor Website Link to sponsor website Program URL Link to program URL Deadline Dates (ALL) 01-Jun-2022 Synopsis The New York State Department of Health and the Spinal Cord Injury Research Board (SCIRB) are accepting applications from not-for-profit organizations and governmental organization in New York State. They will provide funding for predoctoral and postdoctoral fellowships. Approximately \$1.5 million will be available for this request for applications (RFA) to fund approximately six to ten training (pre- or post- doctoral) awards. Eligible organizations are invited to submit applications for predoctoral fellowships with total annual costs of up to \$51,000 per year or postdoctoral fellowships with total annual costs of up to \$80,000 per year. Each will be a two year awards. Applicant Types Funding Limit 0.00 see detail Limited Submission No				
095968	Prevention and Population Research Project Awards	Cancer Research UK		23-Jun-2022	Not Specified
	Contact Name Dr. Anbalakan Paramasivam				

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

Contact Telephone	+44 (0) 20 3469 8824
Contact Email	pprc@cancer.org.uk
Sponsor Website	Link to sponsor website
Program URL	Link to program URL
Deadline Dates (ALL)	23-Jun-2022
Synopsis	Prevention and Population Research Awards provide support for focused research proposals centred on key questions in prevention and population research.
Applicant Types	
Funding Limit	0.00 see detail
Limited Submission	No

071885	Regional Grant Program	Idaho Community Foundation		15-Jun-2022	25,000 USD
--------	--	----------------------------	--	-------------	------------

Contact Name	
Contact Telephone	208-342-3535
Contact Email	grants@idahocf.org
Sponsor Website	Link to sponsor website
Program URL	Link to program URL
Deadline Dates (ALL)	15-Jun-2022 , 15-Aug-2022
Synopsis	The Forever Idaho Regional Grant Program distributes general operating grants with special consideration given to organizations working in one of ICF's Areas of Impact (Family Homelessness and Basic Needs, Mental and Physical Health, Educational Opportunities, and/or Access to Services). If awarded, funds may be used for any direct or indirect costs related to the organization's activities, including payroll, rent, utilities, supplies and equipment, project costs, capital improvements, and/or programmatic needs.
Applicant Types	

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Funding Limit	25,000.00 maximum			
	Limited Submission	No			
109754	Request for Applications: Essential Open Source Software for Science (Cycle 5)	Chan Zuckerberg Initiative		19-Apr-2022	400,000 USD
	Contact Name				
	Contact Telephone				
	Contact Email	sciencegrants@chanzuckerberg.com			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	19-Apr-2022 , 02-Jun-2022			
	Synopsis	The Chan Zuckerberg Initiative invites applications in support of open source software projects that are essential to biomedical research. The goal of the program is to support software maintenance, growth, development, and community engagement for these critical tools. Applications can request funding between \$50,000 USD and \$200,000 USD total costs per year for two years (inclusive of up to 15% for indirect/overhead costs) for an overall amount requested between \$100,000 USD and \$400,000 USD total costs for the two-year duration of the grant.			
	Applicant Types				
	Funding Limit	200,000.00 per year			
	Limited Submission	No			
104556	Request for Proposals (RFP) -- Diversity, Equity and Inclusion in Cultivating a New Generation of Rheumatologists	Arthritis Foundation		06-Jun-2022	Not Specified
	Contact Name				
	Contact Telephone	1-800-283-7800			

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

Contact Email	AFScience@arthritis.org
Sponsor Website	Link to sponsor website
Program URL	Link to program URL
Deadline Dates (ALL)	06-Jun-2022
Synopsis	The Arthritis Foundation (AF) is committed to Diversity, Equity, and Inclusion (DEI) in order to support the training of a diverse generation of rheumatologists and to improve health outcomes for all patients with rheumatic diseases, especially those living with arthritis. Two complementary AF initiatives were launched in 2021 and will continue in 2022 to support AF's aspirations. The first program aims to provide seed funding to support impactful and innovative research to improve health outcomes across different racial and ethnic groups, as well as among various categories of socioeconomic status. The second program has a goal to increase diversity in the next generation of rheumatologists, for those who are physicians or physician/scientists. The ability of proposed projects to have a lasting impact and to be sustained beyond the award period, with potential for their findings to lead directly to advocacy and to reduce structural barriers, are considered important for success. Focus on arthritis research and curriculum development is preferred.
Applicant Types	
Funding Limit	0.00 see detail
Limited Submission	No

109786	Request for Proposals--Study of Subvalvular Aortic Stenosis (SAS) in the Newfoundland Dog Breed	Morris Animal Foundation		03-Jun-2022	50,000 USD
--------	---	--------------------------	--	-------------	------------

Contact Name	
Contact Telephone	800-243-2345
Contact Email	grantapplications@morrisanimalfoundation.org
Sponsor Website	
Program URL	Link to program URL

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Deadline Dates (ALL) 03-Jun-2022</p> <p>Synopsis The sponsor is accepting proposals for the study of subvalvular aortic stenosis (SAS) in the Newfoundland dog breed. One or more of the following areas must be addressed: Genetic studies - these may include comparison of Newfoundlands with other breeds that have high or low prevalence of this disease. Functional studies are particularly welcome. Epidemiological studies of Newfoundlands diagnosed in secondary (rather than tertiary) referral centers by board-certified cardiologists. Necropsy investigations of Newfoundlands with or without SAS lesions, that were previously examined using echocardiography.</p> <p>Applicant Types</p> <p>Funding Limit 50,000.00 maximum</p> <p>Limited Submission No</p>				
001134	Requests for Proposals in Leukemia Research	When Everyone Survives Foundation, Inc.		01-Jun-2022	50,000 USD
	<p>Contact Name</p> <p>Contact Telephone 770-595-3573</p> <p>Contact Email grants@wesfoundation.org</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 01-Jun-2022</p> <p>Synopsis This request for proposals (RFP) is offered by the When Everyone Survives Foundation (WES Leukemia Research Foundation) to solicit innovative research in leukemia. Grants of \$50,000 for one year are offered to new and established investigators who are requesting support for laboratory, translational, or clinical research related to acute leukemia.</p> <p>Applicant Types</p> <p>Funding Limit 50,000.00 maximum</p> <p>Limited Submission No</p>				

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
109608	Research and Innovation for Global Health Transformation - Call 5	National Institute for Health Research (NIHR)		29-Jun-2022	3,930,000 USD
	Contact Name	NIHR RIGHT Global Health team			
	Contact Telephone	+44 (0)20 8843 8843			
	Contact Email	ccf-globalhealth@nihr.ac.uk			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	29-Jun-2022			
	Synopsis	The NIHR fifth Research and Innovation for Global Health Transformation (RIGHT) call will support targeted research to strengthen health service delivery and resilience in low and middle income countries (LMICs) in the context of extreme weather events. The NIHR is seeking programmes of applied health research that can strengthen health service delivery and resilience in LMICs in the context of extreme weather events caused by the changing climate. This funding opportunity is open to lead applicants from UK or LMIC institutions. RIGHT typically awards funding of £1-3 million (maximum of £3 million) for research projects with a duration of 3-5 years.			
	Applicant Types				
	Funding Limit	3,000,000.00 maximum			
	Limited Submission	No			
097011	Research Fellow Award	Multiple Myeloma Research Foundation		24-Jun-2022	75,000 USD
	Contact Name	Mark Hamilton, PhD			
	Contact Telephone	203-652-0233			
	Contact Email	hamiltonm@themmrf.org			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Deadline Dates (ALL) 24-Jun-2022</p> <p>Synopsis The Multiple Myeloma Research Foundation (MMRF) seeks proposals for the MMRF 2022 Research Fellowship Program, an initiative supporting early career researchers at the post-doctorate, medical fellow, or junior faculty levels currently active or interested in research in multiple myeloma. Investigators may request up to \$75,000 total costs, including up to 10% indirect costs, per year for a two (2) year period (total award is \$150,000).</p> <p>Applicant Types</p> <p>Funding Limit 75,000.00 maximum</p> <p>Limited Submission No</p>				
067591	Research Fellowships	Myositis Association		16-May-2022 [LOI/Pre-App]	100,000 USD
	<p>Contact Name Chrissy Thornton</p> <p>Contact Telephone 703-553-2631</p> <p>Contact Email Chrissy@myositis.org</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 16-May-2022 [LOI/Pre-App], 30-Jun-2022</p> <p>Synopsis Mentored Research Fellowships are designed to help promising junior investigators (MDs and PhDs) for a period of two years, subject to satisfactory progress, at the salary level approved by the participating institution, to a maximum received annually of \$50,000. Candidates should have completed residency or fellowship training or have received a PhD within the three years prior to commencing the Fellowship and be performing research under the supervision of an established mentor. Recipients must devote at least 50% of their time to research, but may include some study and clinical experience in allied fields. There should be limited supplementation of salary from outside sources.</p> <p>Applicant Types</p> <p>Funding Limit 50,000.00 per year</p>				

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Limited Submission	No			
040849	Research Grant	Society for the Advancement of Blood Management		01-Jun-2022	25,000 USD
	Contact Name	Steven Frank			
	Contact Telephone	928-551-6400			
	Contact Email	sfrank3@jhmi.edu			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	01-Jun-2022			
	Synopsis	<p>The SABM Research Grant, supported by SABM and an education grant from HemoSonics LLC, is intended to advance the field of patient blood management by supporting a young investigator who intends to study methods of promoting blood conservation. This one-year grant provides starter funding to further scientific inquiry and clinical knowledge in the field of patient blood management. Preference will be given to junior faculty who will be advised by an experienced mentor. It is anticipated that the funded study will generate results that can be used as pilot data or preliminary findings to support future grant applications focused on methods to improve blood management and to promote blood conservation. It is expected that all applicants will be members of SABM, or will become members of SABM for at least one year.</p>			
	Applicant Types				
	Funding Limit	25,000.00 maximum			
	Limited Submission	No			
071837	Research Grants	SENS Research Foundation		25-Jun-2022	Not Specified
	Contact Name				
	Contact Telephone	650-336-1780			

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Email foundation@sens.org</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 25-Jun-2022 , 23-Sep-2022 , 01-Nov-2022</p> <p>Synopsis SRF is uniquely focused on a damage repair approach to treating the diseases of aging. This approach has amazing potential to positively affect the human condition by giving people interventions and treatments that yield more years of healthy, productive life.</p> <p>Applicant Types</p> <p>Funding Limit 0.00 not provided</p> <p>Limited Submission No</p>				

061435	Research Grants	LEO Foundation		21-Jun-2022	Not Specified
--------	---------------------------------	----------------	--	-------------	---------------

	<p>Contact Name</p> <p>Contact Telephone + 45 32 72 51 10</p> <p>Contact Email applications@leo-foundation.org</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 21-Jun-2022 , 04-Sep-2022</p> <p>Synopsis LEO Foundation open competition grants are given to support the best dermatology research projects worldwide.</p> <p>Applicant Types</p> <p>Funding Limit 0.00 not provided</p> <p>Limited Submission No</p>				
--	--	--	--	--	--

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount																				
021106	Research Grants	Oncology Nursing Society Foundation		08-May-2022 [LOI/Pre-App]	50,000 USD																				
<table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 25%; border-right: 1px solid black;">Contact Name</td> <td></td> </tr> <tr> <td style="border-right: 1px solid black;">Contact Telephone</td> <td>866-257-4667</td> </tr> <tr> <td style="border-right: 1px solid black;">Contact Email</td> <td>info@onfgivesback.org</td> </tr> <tr> <td style="border-right: 1px solid black;">Sponsor Website</td> <td>Link to sponsor website</td> </tr> <tr> <td style="border-right: 1px solid black;">Program URL</td> <td>Link to program URL</td> </tr> <tr> <td style="border-right: 1px solid black;">Deadline Dates (ALL)</td> <td>08-May-2022 [LOI/Pre-App], 30-Jun-2022</td> </tr> <tr> <td style="border-right: 1px solid black;">Synopsis</td> <td>Oncology Nursing Society Foundation offers General Research grants for emerging to mid-career oncology nurse researchers who have not previously received and completed at least one research study with a funding level of \$50,000 as the study PI.</td> </tr> <tr> <td style="border-right: 1px solid black;">Applicant Types</td> <td></td> </tr> <tr> <td style="border-right: 1px solid black;">Funding Limit</td> <td>50,000.00 maximum</td> </tr> <tr> <td style="border-right: 1px solid black;">Limited Submission</td> <td>No</td> </tr> </table>						Contact Name		Contact Telephone	866-257-4667	Contact Email	info@onfgivesback.org	Sponsor Website	Link to sponsor website	Program URL	Link to program URL	Deadline Dates (ALL)	08-May-2022 [LOI/Pre-App], 30-Jun-2022	Synopsis	Oncology Nursing Society Foundation offers General Research grants for emerging to mid-career oncology nurse researchers who have not previously received and completed at least one research study with a funding level of \$50,000 as the study PI.	Applicant Types		Funding Limit	50,000.00 maximum	Limited Submission	No
Contact Name																									
Contact Telephone	866-257-4667																								
Contact Email	info@onfgivesback.org																								
Sponsor Website	Link to sponsor website																								
Program URL	Link to program URL																								
Deadline Dates (ALL)	08-May-2022 [LOI/Pre-App], 30-Jun-2022																								
Synopsis	Oncology Nursing Society Foundation offers General Research grants for emerging to mid-career oncology nurse researchers who have not previously received and completed at least one research study with a funding level of \$50,000 as the study PI.																								
Applicant Types																									
Funding Limit	50,000.00 maximum																								
Limited Submission	No																								
057307	Research Grants	Fibrolamellar Cancer Foundation		01-Jun-2022	Not Specified																				
<table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 25%; border-right: 1px solid black;">Contact Name</td> <td></td> </tr> <tr> <td style="border-right: 1px solid black;">Contact Telephone</td> <td>203-340-7800</td> </tr> <tr> <td style="border-right: 1px solid black;">Contact Email</td> <td>grants@fibrofoundation.org</td> </tr> <tr> <td style="border-right: 1px solid black;">Sponsor Website</td> <td>Link to sponsor website</td> </tr> <tr> <td style="border-right: 1px solid black;">Program URL</td> <td>Link to program URL</td> </tr> <tr> <td style="border-right: 1px solid black;">Deadline Dates (ALL)</td> <td>01-Jun-2022 , 01-Oct-2022</td> </tr> </table>						Contact Name		Contact Telephone	203-340-7800	Contact Email	grants@fibrofoundation.org	Sponsor Website	Link to sponsor website	Program URL	Link to program URL	Deadline Dates (ALL)	01-Jun-2022 , 01-Oct-2022								
Contact Name																									
Contact Telephone	203-340-7800																								
Contact Email	grants@fibrofoundation.org																								
Sponsor Website	Link to sponsor website																								
Program URL	Link to program URL																								
Deadline Dates (ALL)	01-Jun-2022 , 01-Oct-2022																								

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Synopsis	<p>The Fibrolamellar Cancer Foundation (FCF) is accepting proposals to support innovative research leading to improved understanding and curative treatments for fibrolamellar carcinoma (FLC). FLC, also known as fibrolamellar hepatocellular carcinoma (FL-HCC), is an aggressive liver cancer that tends to strike teens and young adults. The research must focus specifically on FLC. Studies should be intended to advance knowledge relevant to the understanding, diagnosis, epidemiology, or treatment of FLC. Of particular interest are applications showing a clear path towards a novel therapy or clinical trials with the ultimate goal of achieving a cure for FLC. The Foundation will accept grant applications to support innovative and promising research projects towards the listed goals. The FCF believes that collaboration engaging the best talent across institutions, together with early sharing of data and resources, often accelerates the path to a cure for rare cancers.</p>			
	Applicant Types				
	Funding Limit	0.00 see detail			
	Limited Submission	No			
070774	Research Grants	Diabetes Research and Wellness Foundation (U.S.)		30-Jun-2022	100,000 USD
	Contact Name	Valerie Jeremiah			
	Contact Telephone	202-298-9211			
	Contact Email	diabeteswellness@diabeteswellness.net			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	30-Jun-2022 , 30-Dec-2022			
	Synopsis	<p>The Diabetes Research and Wellness Foundation (DRWF) accepts research applications related to finding the cause, prevention, treatment, and cure of diabetes and its complications. The maximum support of these grants is up to \$50,000 per year for up to two years.</p>			
	Applicant Types				

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Funding Limit	50,000.00 per year			
	Limited Submission	No			
042399	Research Grants	American Academy of Otolaryngic Allergy Foundation		01-Jun-2022	10,000 USD
	Contact Name	Elisabeth Herzfeld-Rice			
	Contact Telephone	202-955-5010 x 600			
	Contact Email	foundation@aaallergy.org			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	01-Jun-2022			
	Synopsis	The AAOA Foundation seeks to advance allergy research and knowledge for the treatment of otolaryngic conditions by inviting applications for grants to conduct research in the pathogenesis, pathophysiology, diagnosis, prevention, or treatment of otolaryngic allergy. Funds are available to support multiple projects each year; each project may have total direct costs of \$10,000.			
	Applicant Types				
	Funding Limit	10,000.00 maximum			
	Limited Submission	No			
004820	Research Grants (Temporarily Suspended)	National Headache Foundation		30-Jun-2022	Not Specified
	Contact Name	Dr. Timothy R. Smith, Research Committee Chair			
	Contact Telephone	312-274-2650			
	Contact Email	tsmith@studymetrix.com			
	Sponsor Website	Link to sponsor website			

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Program URL Deadline Dates (ALL) 30-Jun-2022 , 30-Sep-2022 , 31-Dec-2022 Synopsis The National Headache Foundation supports research in the field of headache and pain as part of its mission, which also includes offering education and information to people living with migraine disease and headache disorders. Applicant Types Funding Limit 0.00 see detail Limited Submission No				
078566	Research Grants Program	National Rosacea Society		17-Jun-2022	15,000 USD
	Contact Name Contact Telephone 847-382-8971 Contact Email info@rosacea.org Sponsor Website Link to sponsor website Program URL Link to program URL Deadline Dates (ALL) 17-Jun-2022 Synopsis The National Rosacea Society awards grants of up to \$15,000, or higher in special cases, for research on rosacea. Applicant Types Funding Limit 15,000.00 see detail Limited Submission No				
039276	Research Professorship	Royal Society		09-Jun-2022	Not Specified
	Contact Name Contact Telephone +44 (0) 20 7451 2263				

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Email seniorfellowships@royalsociety.org</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 09-Jun-2022</p> <p>Synopsis Royal Society Research Professorships provide long term support for world-class researchers of outstanding achievement and promise. The aim of this scheme is to release the best leading researchers from teaching and administration allowing them to focus on research.</p> <p>Applicant Types</p> <p>Funding Limit 0.00 see detail</p> <p>Limited Submission No</p>				
053972	<p>Response Mode Funding Scheme - Health Improvement, Protection and Services Research Committee Grants</p>	Chief Scientist Office - Scotland		24-Jun-2022	393,000 USD
	<p>Contact Name Dr. Tom Barlow</p> <p>Contact Telephone 0131 244 8350</p> <p>Contact Email tom.barlow@gov.scot</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 24-Jun-2022</p> <p>Synopsis The Health Improvement, Protection and Services Research Committee considers applications for research aimed at improving or protecting population health or improving the quality, safety and/or effectiveness of healthcare in Scotland.</p> <p>Applicant Types</p> <p>Funding Limit 300,000.00 maximum</p>				

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Limited Submission	No			
053968	Response Mode Funding Scheme - Translational Clinical Studies Research Committee Grants	Chief Scientist Office - Scotland		24-Jun-2022	393,000 USD
	Contact Name	Dr. Alan McNair			
	Contact Telephone	0131 244 8494			
	Contact Email	alan.mcnair@gov.scot			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	24-Jun-2022			
	Synopsis	The Translational Clinical Studies Research Committee considers applications for research aimed at improving treatments and / or diagnostic approaches for conditions of clinical importance to the population of Scotland.			
	Applicant Types				
	Funding Limit	300,000.00 maximum			
	Limited Submission	No			
070888	RPB Stein Innovation Awards	Research to Prevent Blindness		15-Jun-2022 [LOI/Pre-App]	300,000 USD
	Contact Name	Pattie Moran			
	Contact Telephone	646-892-9566			
	Contact Email	pmoran@rpbusa.org			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	15-Jun-2022 [LOI/Pre-App], 01-Jul-2022			

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Synopsis	The RPB Stein Innovation (SI) Awards provide funds to two groups of researchers, both with a common goal of understanding the visual system and the diseases that compromise its function. These SI Awards are intended to provide seed money to proposed high-risk/high-gain vision science research which is innovative, cutting-edge, and demonstrates out-of-the-box thinking.			
	Applicant Types				
	Funding Limit	300,000.00 maximum			
	Limited Submission	No			
024383	Scholarship Program	International Team for Implantology (ITI)		30-Jun-2022	21,600 USD
	Contact Name	Anna Häuptli			
	Contact Telephone	+41 (0) 61 270 83 83			
	Contact Email	scholarship@iti.org			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	30-Jun-2022			
	Synopsis	The International Team for Implantology (ITI) offers a post-graduate program for young clinicians to gain international experience in implant dentistry. The program allows ITI Scholars to gain insight into case planning, implant surgery and prosthetic restorations and, in most ITI Scholarship Centers, also into research and teaching.			
	Applicant Types				
	Funding Limit	20,000.00 see detail			
	Limited Submission	No			
061426	Scholarships for the Next Generation of Scientists	Cancer Research Society, Inc.		28-Apr-2022	94,800 USD
	Contact Name	Dajan O'Donnell			
	Contact Telephone	514 861-9227 x234			

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Email grants@src-crs.ca</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 28-Apr-2022 , 29-Jun-2022</p> <p>Synopsis The Scholarships for the Next Generation of Scientists is a Cancer Research Society funding program with the goal of supporting upcoming young cohorts of Canadian researchers. The award consists of two parts covering a period of three years, with no possibility for renewal.</p> <p>Applicant Types</p> <p>Funding Limit 120,000.00 maximum</p> <p>Limited Submission No</p>				
000622	Scientist Development Award	Rheumatology Research Foundation		01-Jun-2022 [LOI/Pre-App]	Not Specified
	<p>Contact Name</p> <p>Contact Telephone 404-365-1373</p> <p>Contact Email foundation@rheumatology.org</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 01-Jun-2022 [LOI/Pre-App], 01-Jul-2022</p> <p>Synopsis This award is designed for individuals in the early stages of their career (typically Fellows) or those without significant prior research experience who plan to embark on careers in rheumatic diseases. The purpose of this award is to provide support for a structured research training program for rheumatologists or health professionals in the field of rheumatology.</p> <p>Applicant Types</p> <p>Funding Limit 0.00 see detail</p>				

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Limited Submission	No			
089247	Second International Call: One Health Approach to Zoonoses Research and Innovation	ERA-NET Cofund on International Coordination of Research on Infectious Animal Diseases (ICRAD)		30-Jun-2022	Not Specified
	Contact Name				
	Contact Telephone				
	Contact Email	ptj-icrad-calls@fz-juelich.de			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	30-Jun-2022			
	Synopsis	The overall goal of this ICRAD call is to support cross-cutting research and innovation to better understand zoonoses focussing on the animal-human-environment interface and by developing novel vaccine and diagnostics technology platforms to improve animal health and by consequence animal welfare.			
	Applicant Types				
	Funding Limit	0.00 see detail			
	Limited Submission	No			
073896	Short Industry Fellowship	Royal Society		02-Jun-2022	1,310 USD
	Contact Name				
	Contact Telephone	+44 20 7451 2666			
	Contact Email	innovationgrants@royalsociety.org			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	02-Jun-2022 , 03-Nov-2022			

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Synopsis	This scheme, part of the Royal Society's Industry programme, enables scientists employed in industry or academia and/or their postdoctoral researcher to have shorter more dynamic engagements between academia and industry, working on a mutually beneficial and collaborative project.			
	Applicant Types				
	Funding Limit	1,000.00 see detail			
	Limited Submission	No			
057992	Simulation Research Grant	Emergency Medicine Residents' Association		03-Jun-2022	500 USD
	Contact Name				
	Contact Telephone	972-550-0920			
	Contact Email	awards@emra.org			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	03-Jun-2022			
	Synopsis	The purpose of the EMRA Simulation Research Grant is to provide research funding to Emergency Medicine (EM) physician-in-training interested in completing simulation-based projects during residency/medical school.			
	Applicant Types				
	Funding Limit	500.00 see detail			
	Limited Submission	No			
098360	Singapore International Graduate Award	Agency for Science, Technology & Research		01-Jun-2022	Not Specified
	Contact Name				
	Contact Telephone	65 6826 6111			
	Contact Email	singa_enquiries@hq.a-star.edu.sg			

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	01-Jun-2022			
	Synopsis	SINGA is an award offered to international students with excellent academic undergraduate and/or master's results, and strong interest in doing research leading to a doctorate (PhD) in Science and Engineering at a Singapore University. SINGA supports PhD studies in Biomedical Sciences, Computing and Information Sciences, Engineering and Technology, and Physical Sciences.			
	Applicant Types				
	Funding Limit	0.00 see detail			
	Limited Submission	No			

020227	Sir Douglas Robb Memorial Fund	Auckland Medical Research Foundation		29-Jun-2022	1,380 USD
--------	--	--------------------------------------	--	-------------	-----------

	Contact Name				
	Contact Telephone	+64 9 923 1701			
	Contact Email	amrf@medicalresearch.org.nz			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	29-Jun-2022			
	Synopsis	The Sir Douglas Robb Memorial Fund is for the support of small projects which would normally have a medical background, but which need not be strictly “medical research”. For example, the fund has been used to enhance medical libraries, to fund overseas speakers at medical conferences, and to assist in publication of papers relating to medical research.			
	Applicant Types				
	Funding Limit	2,000.00 maximum			

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Limited Submission	No			
018455	Sir Harcourt Caughey Award	Auckland Medical Research Foundation		29-Jun-2022	17,250 USD
	Contact Name	Research Programme Manager			
	Contact Telephone	+64 9 923 1701			
	Contact Email	amrf@medicalresearch.org.nz			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	29-Jun-2022			
	Synopsis	<p>The Sir Harcourt Caughey Award provides funds up to \$25,000 for recipients who may: (i) be a graduate of New Zealand who, having trained in research overseas, is returning to New Zealand to a part-time appointment in Auckland and who has sufficient experience in research to deserve part-time support (or similar to a part-time Senior Research Fellowship) in such research; or (ii) be a New Zealand medical graduate in Auckland who is deserving of assistance to train in a specific field overseas and to undertake research in that area, especially where there is a local deficiency in expertise in that field; or (iii) be sufficiently prestigious in a particular field of medical knowledge and/or research to visit Auckland, normally for 3-4 weeks, to foster interest and research in that specialty. SPECIAL INSTRUCTIONS FOR 2022 ROUND 1: The Auckland Medical Research Foundation will only accept applications for this grant type if the NZ government conditions are met for safe travel to or from the destination(s) identified in the application. For information, please refer to https://covid19.govt.nz/travel/ For category 2, applicants must provide evidence from their host institution that they allow travel to the destination requested in their application. The AMRF will not be responsible for any costs associated with the recipient being stranded or having to quarantine in any situation, whether or not it was an approved destination when the application was submitted.</p>			
	Applicant Types				
	Funding Limit	25,000.00 maximum			
	Limited Submission	No			

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
014087	Small Research Grant	Fisheries Society of the British Isles		01-Jun-2022	6,550 USD
	Contact Name				
	Contact Telephone	+44 (0)151 600 3362			
	Contact Email	admin@fsbi.org.uk			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	01-Jun-2022 , 01-Oct-2022			
	Synopsis	The FSBI funds a number of small research projects each year to support members of the Society to undertake novel research into any aspect of fish biology and fisheries science that is relevant to the Society's objectives. The Small Research Grant scheme is open to bids for up to £5000 per project.			
	Applicant Types				
	Funding Limit	5,000.00 maximum			
	Limited Submission	No			
016255	SOPHE/CDC Student Fellowship in Injury Prevention	Society for Public Health Education		01-Jun-2022	2,000 USD
	Contact Name				
	Contact Telephone	202-408-9804			
	Contact Email	info@sophe.org			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	01-Jun-2022			
	Synopsis	The SOPHE/CDC Student Fellowship in Injury Prevention recognizes, assists and trains students working on research or practice-based projects in either unintentional injury prevention or violence prevention from the perspective of health education or the behavioral sciences.			

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Applicant Types Funding Limit 2,000.00 see detail Limited Submission No				
067126	Sowers Club of Nebraska Foundation Grant	Sowers Club of Lincoln, Inc.		15-Jun-2022	Not Specified
	Contact Name Contact Telephone 402-438-2244 Contact Email info@thesowersclub.com Sponsor Website Link to sponsor website Program URL Link to program URL Deadline Dates (ALL) 15-Jun-2022 , 15-Sep-2022 Synopsis The Sowers Club accepts grant applications to help serve the community and those in need. Applicant Types Funding Limit 0.00 not provided Limited Submission No				
073623	Stars Career Development Award	Arthritis Society		18-May-2022	Not Specified
	Contact Name Contact Telephone 416-979-7228 x3320 Contact Email research@arthritis.ca Sponsor Website Link to sponsor website Program URL Link to program URL				

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Deadline Dates (ALL) 18-May-2022 , 29-Jun-2022</p> <p>Synopsis The Stars Career Development award was created to help firmly establish the career of early and mid-career investigators. This salary and research funding represents a three (3) year commitment by the Arthritis Society and CIHR-IMHA, together with an additional three (3) year commitment by the applicant's Host Institution. The program provides funding to support research programs aligned with the Arthritis Society's 2020-2025 Research Strategy. The Arthritis Society will be accepting applications relevant to five research priority areas: arthritis pain, OA, IA, childhood and work.</p> <p>Applicant Types</p> <p>Funding Limit 0.00 see detail</p> <p>Limited Submission No</p>				

092353	Stephanie Watts Career Development Award	American Heart Association		25-May-2022	Not Specified
--------	--	----------------------------	--	-------------	---------------

Contact Name	
Contact Telephone	214-706-1240
Contact Email	council.awards@heart.org
Sponsor Website	Link to sponsor website
Program URL	Link to program URL
Deadline Dates (ALL)	25-May-2022 , 01-Jun-2022 , 03-Jun-2022
Synopsis	This award supports early career investigators working in hypertension and cardiovascular research who show exceptional promise but may be currently unfunded or have limited access to extramural funding.
Applicant Types	
Funding Limit	0.00 see detail
Limited Submission	No

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
024717	Strategic Research Agreements: Multi Project	Juvenile Diabetes Research Foundation International		03-May-2022 [LOI/Pre-App]	Not Specified
	Contact Name Contact Telephone 800-533-2873 Contact Email preawardsupport@jdrf.org Sponsor Website Link to sponsor website Program URL Link to program URL Deadline Dates (ALL) 03-May-2022 [LOI/Pre-App], 17-Jun-2022 [LOI/Pre-App] Synopsis JDRF's Strategic Research Agreements provide research funding for single or multiple investigators to address critical gaps and challenges and potential breakthroughs in Type 1 diabetes research. The JDRF Strategic Research Agreement for multiple projects provides a mechanism to stimulate new collaborations between clinical and basic scientists and/or between scientists from diverse backgrounds as a means to conceive and develop new approaches to major challenges, potential breakthroughs, or persistent obstacles to progress along the various paths to prevent, treat or cure Type 1 diabetes and its complications. Applicant Types Funding Limit 0.00 not provided Limited Submission No				
074890	Team Grant: E-Rare-6 Joint Transnational Call (2022)	Canadian Institutes of Health Research		15-Jun-2022	355,500 USD
	Contact Name Contact Telephone 613-954-1968 Contact Email support@cihr-irsc.gc.ca Sponsor Website Program URL Link to program URL				

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Deadline Dates (ALL) 15-Jun-2022 Synopsis CIHR-IG is pleased to be partnering with approximately 18 international funding organizations in the context of this European Joint Programme on Rare Diseases (EJP RD) call for proposals 2021. The topic of the call is Social Sciences and Humanities Research to improve health care implementation and everyday life of people living with a rare disease. Applicant Types Funding Limit 150,000.00 per year Limited Submission No				
068798	Thomas L. Petty, MD Invacare Award for Excellence in Home Respiratory Care	American Respiratory Care Foundation		01-Jun-2022	Not Specified
	Contact Name Crystal Maldonado Contact Telephone 972-243-2272 Contact Email Sponsor Website Link to sponsor website Program URL Link to program URL Deadline Dates (ALL) 01-Jun-2022 Synopsis This award recognizes outstanding individual achievement in home respiratory care. Applicant Types Funding Limit 0.00 see detail Limited Submission No				
089497	Translational Research Grant	Pediatric Cancer Research Foundation		01-Jun-2022	200,000 USD
	Contact Name Contact Telephone 949-859-6312				

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Email info@pcrf-kids.org</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 01-Jun-2022</p> <p>Synopsis Translational Research Grants fund new research protocols and therapies that hold promise for improved outcomes and accelerates cures from the laboratory bench to the bedside of children and teens with highrisk cancers. Funding is up to \$100,00 per year, for up to 2 years.</p> <p>Applicant Types</p> <p>Funding Limit 100,000.00 per year</p> <p>Limited Submission No</p>				
046658	Translational Research Project Grants	Heart Research UK		01-Jun-2022	262,000 USD
	<p>Contact Name</p> <p>Contact Telephone 0113 234 7474</p> <p>Contact Email grants@heartresearch.org.uk</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 01-Jun-2022</p> <p>Synopsis Translational Research Project Grants aim to bridge the gap between laboratory-based scientific research and patient care.</p> <p>Applicant Types</p> <p>Funding Limit 200,000.00 see detail</p> <p>Limited Submission No</p>				

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
012008	TWAS-SN Bose Postgraduate Fellowship Programme	TWAS, the Academy of Sciences for the Developing World		30-Jun-2022	Not Specified
	Contact Name Contact Telephone +39 040 2240687 Contact Email fellowships@twas.org Sponsor Website Link to sponsor website Program URL Link to program URL Deadline Dates (ALL) 30-Jun-2022 Synopsis TWAS and the S.N. Bose National Centre for Basic Sciences in Kolkata, India have agreed to offer fellowships to young foreign scientists from developing countries who wish to pursue research towards a PhD in physical sciences. Applicant Types Funding Limit 0.00 see detail Limited Submission No				
109784	Two-stage Call for Proposals for Research Teams for Women RISE	International Development Research Centre (IDRC)		15-Apr-2022	Not Specified
	Contact Name Contact Telephone Contact Email women-RISE-femmes@idrc.ca Sponsor Website Link to sponsor website Program URL Link to program URL Deadline Dates (ALL) 15-Apr-2022 , 24-Jun-2022 Synopsis The Women RISE initiative will support action-oriented research on how women’s health and their work (paid or unpaid) intersect and interact in the context of preparing, responding to and recovering from COVID-19. Specifically,				

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Applicant Types</p> <p>Funding Limit</p> <p>Limited Submission</p>	<p>it will support population and public health research that addresses UN Research Roadmap for the COVID-19 Recovery Priority 3.5: “How have recent economic changes disproportionately affect women and women’s health, and how can recovery strategies be inclusive, gender transformative and health promoting for women?”</p> <p>0.00 see detail</p> <p>No</p>			
058073	University of Toronto Integrated Neonatal-Perinatal Fellowship Training Program	Hospital for Sick Children Foundation/Sick Kids Foundation		30-Jun-2022	Not Specified
	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email</p> <p>Sponsor Website</p> <p>Program URL</p> <p>Deadline Dates (ALL)</p> <p>Synopsis</p> <p>Applicant Types</p> <p>Funding Limit</p> <p>Limited Submission</p>	<p>Sonia Dos Santos, Interim Education Administrative Coordinator</p> <p>416-813-7654 x 228902</p> <p>neonatal.fellowship@sickkids.ca</p> <p>Link to sponsor website</p> <p>Link to program URL</p> <p>30-Jun-2022</p> <p>The University of Toronto Training Program in Neonatal-Perinatal Medicine provides two years of neonatal-perinatal training to paediatricians.</p> <p></p> <p>0.00 not provided</p> <p>No</p>			
022157	Victor Cohn Prize for Excellence in Medical Science Reporting	Council for the Advancement of Science Writing		30-Jun-2022	3,000 USD
	<p>Contact Name</p> <p>Contact Telephone</p>	<p>Sylvia Kantor</p> <p>206-880-0177</p>			

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Email sylviakantor@casw.org</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 30-Jun-2022</p> <p>Synopsis The Victor Cohn Prize for Excellence in Medical Science Reporting is given annually, and seeks to honor a writer for a body of work published or broadcast within the last five years which, for reasons of uncommon clarity, accuracy, breadth of coverage, enterprise, originality, insight and narrative power, has made a profound and lasting contribution to public awareness and understanding of critical advances in medical science and their impact on human health and well-being.</p> <p>Applicant Types</p> <p>Funding Limit 3,000.00 see detail</p> <p>Limited Submission No</p>				
093521	Vienna Research Groups for Young Investigators (VRG)	Vienna Science and Technology Fund (WWTF)		15-Jun-2022	1,760,000 USD
	<p>Contact Name Dr. Donia Lasinger</p> <p>Contact Telephone +43 1 402 31 43 - 16</p> <p>Contact Email donia.lasinger@wwtf.at</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 15-Jun-2022</p> <p>Synopsis The current Vienna Research Groups for Young Investigators call 2022 is issued for up to two group leader positions as part of the WWTF's Environmental Systems Research programme. It addresses Vienna-based universities and research institutions that intend to hire an excellent young researcher from abroad for setting up and managing an independent research group. Active recruitment procedures are mandatory.</p>				

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount																				
<table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 25%; border-right: 1px solid black;">Applicant Types</td> <td></td> </tr> <tr> <td style="border-right: 1px solid black;">Funding Limit</td> <td>1,600,000.00 maximum</td> </tr> <tr> <td style="border-right: 1px solid black;">Limited Submission</td> <td>No</td> </tr> </table>						Applicant Types		Funding Limit	1,600,000.00 maximum	Limited Submission	No														
Applicant Types																									
Funding Limit	1,600,000.00 maximum																								
Limited Submission	No																								
096603	Vilcek Prize for Creative Promise in Biomedical Science	Vilcek Foundation		10-Jun-2022	50,000 USD																				
<table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 25%; border-right: 1px solid black;">Contact Name</td> <td></td> </tr> <tr> <td style="border-right: 1px solid black;">Contact Telephone</td> <td>212-472-2500</td> </tr> <tr> <td style="border-right: 1px solid black;">Contact Email</td> <td>info@vilcek.org</td> </tr> <tr> <td style="border-right: 1px solid black;">Sponsor Website</td> <td>Link to sponsor website</td> </tr> <tr> <td style="border-right: 1px solid black;">Program URL</td> <td>Link to program URL</td> </tr> <tr> <td style="border-right: 1px solid black;">Deadline Dates (ALL)</td> <td>10-Jun-2022</td> </tr> <tr> <td style="border-right: 1px solid black;">Synopsis</td> <td>The Vilcek Foundation will award three Creative Promise Prizes of \$50,000 each to young foreign-born biomedical scientists who demonstrate outstanding early achievement. Eligible work may be creative, independent research in basic, applied, and/or translational biomedical science.</td> </tr> <tr> <td style="border-right: 1px solid black;">Applicant Types</td> <td></td> </tr> <tr> <td style="border-right: 1px solid black;">Funding Limit</td> <td>50,000.00 see detail</td> </tr> <tr> <td style="border-right: 1px solid black;">Limited Submission</td> <td>No</td> </tr> </table>						Contact Name		Contact Telephone	212-472-2500	Contact Email	info@vilcek.org	Sponsor Website	Link to sponsor website	Program URL	Link to program URL	Deadline Dates (ALL)	10-Jun-2022	Synopsis	The Vilcek Foundation will award three Creative Promise Prizes of \$50,000 each to young foreign-born biomedical scientists who demonstrate outstanding early achievement. Eligible work may be creative, independent research in basic, applied, and/or translational biomedical science.	Applicant Types		Funding Limit	50,000.00 see detail	Limited Submission	No
Contact Name																									
Contact Telephone	212-472-2500																								
Contact Email	info@vilcek.org																								
Sponsor Website	Link to sponsor website																								
Program URL	Link to program URL																								
Deadline Dates (ALL)	10-Jun-2022																								
Synopsis	The Vilcek Foundation will award three Creative Promise Prizes of \$50,000 each to young foreign-born biomedical scientists who demonstrate outstanding early achievement. Eligible work may be creative, independent research in basic, applied, and/or translational biomedical science.																								
Applicant Types																									
Funding Limit	50,000.00 see detail																								
Limited Submission	No																								
001781	William T. Grant Scholars Program	Grant (William T.) Foundation		15-Jun-2022 [LOI/Pre-App]	350,000 USD																				
<table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 25%; border-right: 1px solid black;">Contact Name</td> <td></td> </tr> <tr> <td style="border-right: 1px solid black;">Contact Telephone</td> <td>212-752-0071</td> </tr> <tr> <td style="border-right: 1px solid black;">Contact Email</td> <td>info@wtgrantfdn.org</td> </tr> <tr> <td style="border-right: 1px solid black;">Sponsor Website</td> <td>Link to sponsor website</td> </tr> </table>						Contact Name		Contact Telephone	212-752-0071	Contact Email	info@wtgrantfdn.org	Sponsor Website	Link to sponsor website												
Contact Name																									
Contact Telephone	212-752-0071																								
Contact Email	info@wtgrantfdn.org																								
Sponsor Website	Link to sponsor website																								

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 15-Jun-2022 [LOI/Pre-App], 06-Jul-2022</p> <p>Synopsis The William T. Grant Scholars Program supports career development for promising early-career researchers. The program funds five-year research and mentoring plans that significantly expand researchers' expertise in new disciplines, methods, and content areas.</p> <p>Applicant Types</p> <p>Funding Limit 350,000.00 maximum</p> <p>Limited Submission Yes</p>				
015485	Wynn Kent Public Communication Award	Actuarial Foundation		01-Jun-2022	1,000 USD
	<p>Contact Name</p> <p>Contact Telephone 847-706-3535</p> <p>Contact Email conference@ccactuaries.org</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 01-Jun-2022</p> <p>Synopsis The Wynn Kent Public Communication Award recognizes an actuary who has contributed to the public awareness of financial risk and the work product of the actuarial profession to the public in the fields of life, health, casualty, pension, and/or in other related areas.</p> <p>Applicant Types</p> <p>Funding Limit 1,000.00 see detail</p> <p>Limited Submission No</p>				
019729	Young Investigator Prize	Lundbeck Foundation		28-Jun-2022	140,000 USD
	Contact Name				

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Contact Telephone +4539128001 Contact Email application@lundbeckfonden.com Sponsor Website Link to sponsor website Program URL Link to program URL Deadline Dates (ALL) 28-Jun-2022 Synopsis The LF Young Investigator prize is awarded to a particularly promising scientist under the age of 40, who has conducted outstanding research within biomedical sciences. Applicant Types Funding Limit 1,000,000.00 see detail Limited Submission No				
103440	Young Talents in Clinical Research	Swiss Academy of Medical Sciences		30-Jun-2022	Not Specified
	Contact Name Dr. Myriam Tapernoux Contact Telephone +41 31 306 92 70 Contact Email m.tapernoux@samw.ch Sponsor Website Link to sponsor website Program URL Link to program URL Deadline Dates (ALL) 30-Jun-2022 Synopsis Medical doctors engaged in clinical research are faced with many challenges, including the lack of time, particularly during medical training, and the scarcity of funding for research projects. There is currently no system-inherent support in Switzerland for young doctors starting out in clinical research: they must acquire the necessary theoretical and practical skills mostly on their own. By funding protected time for research and project grants, Young Talents in Clinical Research contributes to improving the quality of clinical research in Switzerland and to implementing the				

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

	Roadmap for developing the next generation of clinical researchers of the Federal Office of Public Health. The research supported must take place in Switzerland.
Applicant Types	
Funding Limit	0.00 see detail
Limited Submission	No